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The cohesiveness of the proposed syndrome of alcohol dependence, and the
evolution of symptoms over time, was validated in a clinical sample. In healthy
individuals and in clinical samples, biological markers showed early signs of the
syndrome in healthy men. A comparison of Lothian general population data with
Edinburgh hospital admission data showed that heavier alcohol consumption predicted
admission to a general hospital bed. Analysis of national centrally collected data showed
that the burden on Scottish hospitals due to alcohol problems rose in the last 40 years.
A randomized controlled trial showed the value of intervening at an early stage in
the career of a problem drinker.
To treat more severe alcohol dependence, withdrawal symptoms must be
controlled. When randomly allocated to either a longer-acting or a shorter-acting
benzodiazepine, the former showed an advantage.
To help prevent relapse, 'extended' treatment emerged as only very marginally
more effective than one session of firm advice to the patient to abstain. The medications
disulfiram and naltrexone, if compliance was enhanced, were found to reduce relapse.
Acamprosate appeared to be effective too, when results from many studies were pooled.
A selective serotonin re-uptake inhibitor (SSRI), fluvoxamine, was associated with
increased likelihood of relapse in early-onset alcohol dependence, a surprising finding,
which speculatively might be mediated through increased impulsivity in some patients.
Analysis of data on treatment of depression in the General Practice Research Database
confirmed other emerging concerns regarding the safety of the SSRI group of drugs in
young people.
Abstinence was accompanied by improvement in brain magnetic resonance
parameters and cognitive testing.
Analysis of outcomes in placebo-controlled treatment studies for alcohol
dependence, set alongside the costs to the Health Service of treating the complications of
alcohol dependence, showed that the costs of failure to help patients attain abstinence are
much greater than the costs ofproviding effective treatments.
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SYNOPSIS
The numbering refers to the Table ofPublications
The syndrome of alcohol dependence I commenced this contribution to research
on alcohol dependence in 1976. At that time, there was debate about how alcohol
consumption and 'alcohol problems' were related, and the part played by some putative
psychobiological process meriting the term 'syndrome' or even 'disease'. Having
attempted to distill items of proven reliability, I tested the cohesiveness of the
components of the proposed syndrome of alcohol dependence, and their evolution in
time, in a clinical sample (1, 2, 3). I also studied the interaction of these symptoms with
self-reported consumption, and problems, in non-clinical samples where heavy drinkers
were to be found - namely brewery and distillery manual workers and (at the other end of
the socioeconomic spectrum) members of the Institute of Directors and Chamber of
Commerce.
The concept of a dependence syndrome could be justified in terms of a dominant single
factor, with elements forming a scale of severity. Early features were indicators of
impaired control of drinking and growing tolerance e.g. 'needing more than companions';
later features were those of physiological withdrawal such as morning tremor and relief
drinking.
Early detection The survey of working men sponsored by the Medical Research
Council (1977-9) was my opportunity to refine ways of obtaining self-report and
objective data about alcohol consumption patterns and problems, and examine reliability
(4, 6). The experience of measuring these parameters in mainly healthy men, alerted me
to the possibility of early intervention, to detect and treat a condition which was, at least
potentially, reversible. (Having trained in psychiatry and neurology, it was clear to me
that we were seeing many illnesses which, at least with present knowledge, were not
reversible!).
I tested various emerging biological markers, and developed a brief questionnaire, to aid
in early detection. Tests were carried out in healthy populations of working men and in
clinical samples. Mean cell volume of the red blood cell was more likely to be raised in
smokers, and in frequent drinkers ('tipplers') rather than episodic drinkers: two novel
findings. But only two-thirds of heavy drinkers (over 4 pints of beer per day or
equivalent) had an elevation of either MCV or gamma-glutamyl transferase (GGT) (6). I
investigated the accuracy of an amino-acid anomaly (whose analysis proved too complex
to introduce more widely) (7) and that of serum ferritin (8). However, the use of
carbohydrate deficient transferrin (CDT) as a marker of excessive drinking was being
developed by commercial interests. Its widening use led me to wonder whether the
slightly different time-frame of its response to drinking alcohol, as well as its apparent
freedom from confounding by drug therapies, would make it a useful clinical tool in
advance detection of when an alcoholic patient in treatment had a relapse. We discovered
that CDT might 'herald' relapse to drinking - in the sense that sometimes the CDT would
rise above the abstinent baseline level - before the patient declared a relapse which later
he/she would admit, or be clinically evident in terms of deterioration in health, liver
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enzymes or social circumstances. The CDT test can be helpful is this way, although there
is still some 'noise', or unreliability, around this test (9, 10).
In the general medical wards, comparison of hospital case records with results of
screening interview by a nurse showed that routine admission procedures underestimated
consumption, adverse consequences and dependence. Laboratory markers were not
sufficient to be used as a screening test on their own (12) The dependence syndrome was
by no means a universal feature of men admitted to medical wards with alcohol related
problems. (13) This has subsequently been noted, sometimes with surprise, in studies of
patients admitted to hospital with alcoholic liver cirrhosis. It was also found when we
studied 100 case records of patients who had received a liver transplant for alcoholic liver
disease (although a diagnosis of alcohol dependence pre-transplant turned out to be a
predictor of relapse to harmful drinking during the follow-up years) (39).
Early intervention We compared the drinking patterns of patients admitted to medical
wards to those of the general population documented in a drinking survey conducted in
the Lothians at the same period. As might be expected, the risk of admission for liver
disease was increased 8-fold in those drinking over 50 units (400gm ethanol) per week,
and three fold for upper gastrointestinal disorders, respiratory disorders and myocardial
infarction, compared light drinkers. (14)
Thus, medical wards were able to provide a sample in which to test, in a randomized
controlled trial, the value of intervening at an early stage in the career of a problem
drinker (This study was funded by the Scottish Health Department). We tested an
intervention by a nurse: a non-judgmental dialogue of the concerning the pros and cons
of the patient's drinking (in his/her view), and a discussion aimed at helping the patient
modify some social behaviours and some beliefs and attitudes. The one-year follow-up
was conducted by another nurse who was blind to the original treatment group, and who
obtained in many cases a serum specimen to test for markers of heavy drinking. We
concluded that the nurse's intervention, while the patient had been in a medical ward, had
tweaked some patients into changing their drinking to a less harmful pattern, beyond
what may have been effected by the medical service's and physician's input (i.e. beyond
what had been achieved in the 'no intervention' control).
The resulting paper (BMJ, 1985) (19) affirmed a role for specially trained nurses in the
general hospital. The design and method were replicated in several large trials in primary
care in UK and by the World Health Organization. The Edinburgh Royal Infirmary
alcohol liaison nurse service developed after two further feasibility studies in the 1990s
funded by the Scottish NHS, and a further prevalence survey, this time in the orthopedic
service (15). The study is still influencing the development of services for alcohol
problems in acute general hospitals in a number of countries.
I studied the data-bases held by several of the Centres d'Hygiene Alimentaire. These
health centres had been instituted in France in the 1960's to assess and treat drink-drive
offenders, and workers referred through managers and occupational physicians due to
alcohol-related work problems (20). I was able to show that these centres tended to see
people at an early stage of their drinking problem (compared to the psychiatric and
general hospital services), and recorded some good outcomes with fairly minimal medical
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and nursing intervention - minimal, that is, compared to the 6-12 week residential
programmes being offered widely in the Western countries in the 1970's.
Other Prevalence Studies
General
I reviewed UK data on prevalence of alcohol problems and dependence in 1982, which
in 2007 is of course out-of date, but nevertheless shows the principles and limitations in
this area of study(l 1).
The demand in primary care for management of alcohol problems needed to be
quantified. Locally, we experimented with an inexpensive method of estimating the
demand in one primary care locality using a combination of data already held on practice
records, interviews with key people in the community (not only health workers), hospital
discharge by address of the patients and other local area statistics which were already
available on alcohol-related problems (17).
Hospital discharge data, though a more precise measure, will almost always
underestimate the total population prevalence of a condition. However, because trends in
our own clinical work load suggested a rising prevalence, I examined trends in the
Scottish NHS hospital data base. This showed that there was, indeed, a striking rise in
alcohol-related disorders throughout Scotland (18). Sadly the trend noted in 1997 has
continued to date.
- Special groups
Throughout the 1950's - 1970's analysis of morbidity by occupation groupings, alcohol
problems were seen to occur among the medical profession more commonly than would
be expected by chance. It had been hoped, however, that just as happened with smoking
and lung cancer in the 1950's-1960's, doctors in the UK might show an example to the
population and reduce their incidence of alcohol-related illness. The data collected by
Scottish psychiatric hospitals allowed an analysis of discharge data by diagnosis and by
occupation. We found that although there was indeed still an excess of doctors compared
to other Social Class 1 groups, this might be accounted for by a cohort of heavy drinkers
over the age of 45(16). Perhaps the trend of an excess in the medical profession would
disappear. A possible avenue for this change might be a greater willingness by the
profession itself to identify earlier, and manage more successfully doctors with
impending alcohol problems.
The treatment of doctors, with psychiatric or addiction illnesses, had not always been
well conducted. I was asked to make a distillation of the literature, and therapists'
experience, on how to assist doctors, including those whose professional practice was
deemed impaired. (42) It is important for clinicians to realize that doctors might evade
admitting their problems; objective and constructive approaches are necessary ingredients
of successful therapy, including objective monitoring of the drinking and drugs use, and
work performance.
Management of Harmful Drinking and Alcohol Dependence in Primary Care
Evidence of the value of early intervention for alcohol problems led to a successful bid to
the commissioning committee of SIGN (Scottish Intercollegiate Guidelines Network) to
fund a systematic review of the detection and management of alcohol problems in
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primary care. I brought together a team which I chaired, with technical support from
SIGN. 1 oversaw the review and the grading of evidence, leading to Guidelines for The
Management of Harmful Drinking and Alcohol Dependence in Primary Care. This was
peer reviewed, and the final product was published by SIGN www.sign.ac.uk/pdf/sign74.pdf)
As well as being distributed by NHS Scotland, the document has served as a model for a
number of other national alcohol guidelines. (41)
Treatments for alcohol dependence
Managing alcohol withdrawal: This step in the treatment of alcohol dependence seldom
presented major clinical problems, if cases were promptly identified and protocols were
followed. Benzodiazepines seemed safe and effective. However, there were concerns that
benzodiazepines with a long half-life might accumulate and impair cognitive recovery,
and thus retard the patient's learning and practising the skills for sobriety. We tested a
short-acting versus a long-acting benzodiazepine. However, we found no major
differences in cognitive functioning, and since the only seizure occurred with the shorter
acting lorazepam, it remains our practice today to use one of the longer acting
compounds (25).
Treatment for alcohol problems: Preventing relapse
The more severely dependent drinkers seemed to require more than one brief motivating
dialogue. We conducted another randomized controlled study funded by the Scottish
Health Department to investigate the efficacy of the treatments that the NHS services
typically provided at that time (1980's) - in-patient detoxification and group work, and/or
the opportunity for regular out-patient supportive counselling and an invitation to join an
out-patient support group. However, compared to just one session of firm advice to the
patient to abstain, 'extended' treatment emerged as marginally more effective only in
terms of reduction of social problems. (One caveat in interpreting that result was that, for
ethical reasons, a safety net was in place in which patients' families were being seen
monthly by a worker gathering outcome data. This could have had a therapeutic effect on
the family and thereby influenced the problem drinker) (27).
This study obtained follow-up data at 2 years on over 80% of the sample. Our early
intervention study quoted above had follow-up data at 1 year on 85%. Other studies
being published in the field had lower follow-up rates, and the effect of this on the value
of the study required attention, to know best how to deal, in the analysis, with loss of
data. For example, should all those lost to follow-up be regarded as failures? In fact,
published work giving baseline data and other information on those harder to follow-up
seemed to support such a view (4).
It was important to look for other treatments. Disulfiram ('Antabuse') had been in use
for over 20 years, but there was only limited evidence of its efficacy, and no trials had
been conducted in the UK.
The literature revealed that the only studies showing efficacy had set up a supervision
system to help ensure that the patient was seen to swallow the medication. This was
needed in any further test of the medication. I also decided that the correct test of the drug
must be 'single blind' i.e. where the clinician and patients knew whether or not the
patient was taking an active deterrent tablet, because knowing you are on this drug is part
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of the treatment. The research assessor was kept blind to the treatment allocation. This
study showed that, in patients who were prepared to volunteer for a trial of disulfiram,
those allocated to disulfiram supervised by a partner, an employer or by the clinic, drank
much less than patients taking supervised Vitamin C. (Vitamin C tablets were chosen as
the 'control' because it is one of the vitamins which has been shown to be deficient in
many alcoholic patients, and thus we could ethically advise subjects that taking a Vitamin
C tablet regularly might help their recovery)(28). The paper led to a renewed interest by
centres in Finland, India and Germany to conduct trials into the use of supervised
disulfiram. This has been accompanied by a wider and more effective use of the drug by
clinicians in the UK and a number of other countries.
Recently, we have looked further at the issue of compliance with this drug, by testing the
efficiency of a breath analyzer (invented by a collaborating chemist) to detect metabolites
of disulfiram (30).
Unwanted effects of disulfiram including neuropathy, and liver damage, have long been a
concern of the use of disulfiram. I conducted a literature search to attempt to quantify the
risks (29).
More recent pharmacotherapies By 1980, animal models had revealed certain
neuronal pathways and receptor sites which were implicated in liking for alcohol (i.e.
exhibiting preference for ethanol over sucrose solution), alcohol-seeking behaviour, and
emergence of signs and behaviours resembling human alcohol dependence.
Animal research had shown that animals with reduced cerebral serotonin receptor
transmission drank more alcohol. The first SSRI (selective serotonin enhancing drug)
licensed for human use in the UK was fluvoxamine. I approached the manufacturer for
assistance to test this as a method of reducing relapse over one year in alcohol dependent
patients, including depressed and non-depressed subjects. An overall negative result
proved to be due mainly to a subgroup (defined a priori as 'early onset' and characterized
by novelty-seeking and impulsivity) who consumed more alcohol, not less, when
randomized to this medication (34). Later, a similar result was found by US research
teams for two other SSRIs. It is clinically an important finding, because of the
widespread use of SSRIs in primary care today.
This same pattern was found in USA with fluoxetine, and with sertraline. The SSRIs have
proven helpful in freeing patients from inhibiting obsessional anxiety. But some
alcoholics do not benefit from 'freeing' from their inhibitions. Rather, they need to
improve their self-control!
We can speculate that this might be related to an increase in impulsivity due to SSRI
treatment. This possibility has since emerged in another area. I contributed to the
conception, design and interpretation of two epidemiological studies into another
potential unwanted effect of SSRIs, related to impulsivity, namely deliberate self-harm.
We examined whether the risk of deliberate self-harm was greater when an SSRI had
been prescribed compared to when a tricyclic, or other type of antidepressant, had been
prescribed for depression. The general practice research data-base study showed that
although there was no greater risk demonstrable of completed suicide, there was indeed a
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greater risk of non-fatal self-harm associated with the SSRIs in those aged 18 and under
(35). (One manufacturer subsequently admitted that the previously analyzed data showed
an increase risk up to the age of 25.)
Another opportunity to gather insight into the connection between SSRIs and self-harm
was to compare the prescription of antidepressants in the Edinburgh area according to the
Lothian prescribing data base, and the frequency of admission for self-poisoning to the
Edinburgh Royal Infirmary. This did not reveal an excess of admissions related to the
SSRIs but did highlight an excess with two other antidepressants, venlafaxine and
mirtazapine (36). (As discussed in the paper, confounding by severity of depression could
have accounted for the excess related to these medications, since they tended at the time
of the study to be prescribed as second -line after failure to respond to an SSRI.)
These and related studies will hopefully increase the caution with which antidepressant
drugs are prescribed, including in alcohol dependent people.
Animals consuming ethanol, or being exposed to ethanol vapour for long periods,
develop withdrawal symptoms when ethanol is withdrawn. In a number of laboratory
models, the animals have been observed to return quite rapidly to consumption of
alcohol, once it is made available again. In the 1980's a compound was described which
reduced the animals' rapid return to ethanol-seeking behaviour during the withdrawal
period. This appeared to be due to partial inhibition of an over-sensitive GABA (gamma
amino butyric acid) -glutamate receptor system. The drug was not addictive itself. I
contacted the firm and requested that we conduct a multicentre study in the UK to test
whether this drug helped to prevent rapid return to drinking. The company was already
mounting a series of controlled studies in other European countries. Our UK study did
not show a statistically significant advantage of acamprosate over placebo in terms of
abstinence (32). However, because of the 13 positive studies that were conducted
elsewhere in mid- and south- Europe, I remained interested, and I suggested to the
manufacturers a post hoc analysis to test whether the drug could help patients limit their
drinking once they started. The combined multi-site data base was large enough to permit
such an analysis. A small effect in the predicted direction was found, as well as a
confirmation in the meta-analysis of its effectiveness in sustaining complete abstinence
(33).
A third neural receptor system implicated in alcohol dependence concerns what is
thought to underlie the rewarding, positive, experience of alcohol particularly for some
genetically predisposed people - the endogenous opioid transmitter system. Previous
trials of medications in alcohol dependent patients conducted by ourselves and many
others had shown how, without supervision, compliance with medication was poor. In
our protocol for the study of the opioid antagonist, naltrexone, I included a priori that we
should look at naltrexone efficacy separately in compliant and non-compliant patients. In
the event, the drug was only shown to reduce relapse in the compliant sub-group. (31) In
conjunction with a Finnish pharmaceutical company, I was the lead clinician in planning
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and conducting a multicentre UK study of another opioid antagonist, nalmefene,
recruiting and treating patients largely in primary care. A trend emerged favouring
nalmefene over placebo in preventing relapse (in preparation, not cited in publications
listed below; two Finnish studies have found more convincing evidence of efficacy,
whereas a study in USA, reported at scientific meetings, found a high recovery rate in the
placebo group too, and failed to show an advantage of nalmefene over placebo).
Brain damage in alcohol dependence, and treatment
It is a tautology to state that alcohol dependent patients repeat their mistakes. It is the
hallmark of the syndrome. Our aim in treatment is to prevent relapse and, if it occurs, to
help minimize adverse consequences for the drinker and family.
The dimensions of cognitive impairment were fairly well delineated by 1980-90.
However, the installation in the 1980s in the Edinburgh Royal Infirmary of one of the
first magnetic coils to measure resonance of water components in body tissues including
brain provided an opportunity to find anatomical and physiological markers of these
cognitive deficits. Magnetic resonance imaging (MRI), as it came to be called, showed
that nearly half of our patients had abnormalities compared to controls. (21, 22, 23) The
extent of these was related (though weakly) to impairment in flexibility of thinking and
planning as well as, in more deteriorated patients, in the ability to learn new material
(24). (This was one of the first to use MRI to study brain damage in alcoholics. The paper
is the lead citation in a 2005 New England Journal ofMedicine review paper on
cognition and alcohol by Stampfer et al., Vol 352:245) This clearly was relevant to
treatment, which till then depended mainly on discussion of how the patient might change
thinking and behaviour, and learn new ways of coping with problems, and social cues to
drinking. If learning was impaired till the brain recovered (if it was going to recover),
which might require months of abstinence, these treatments would have limitations.
Abstinence was indeed shown to be associated with improvement in MRI and cognitive
testing.
The growing pool of research into cognitive impairment in heavy drinkers has influenced
psychological treatment programmes. We have lowered our expectation of how rapidly
patients can change engrained attitudes and patterns of behaviour, and amplified the role
of pharmacotherapies, particularly in the early months of abstinence.
A tool for clinical services to measure outcome of treatment for alcohol dependence
From my experience of rating scales for alcohol dependence and problems, I developed a
brief tool for clinic use to measure outcome. This 11 item scale, the Alcohol Related
Problems Questionnaire (ARPQ), administered at follow-up was a proxy for both the
patient's previous 6 month's scores on quality of life and the utilization of health service
resources in that period. (26) The costing of health service usage proved an important
exercise and was a forerunner of the national exercise undertaken later (see below).
Cost effectiveness of treatments for alcohol dependence
There is skepticism about the value to society of offering treatment for alcohol
dependence. This is perhaps due to the visibility of those patients who repeatedly relapse
and deteriorate in their physical health and social functioning. We followed a sample of
patients treated at our service to see how costs continued to accrue for those patients who
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relapsed - and we examined costs of helping those who succeeded in remaining
abstinent. (38)
An extended approach to this was studied in the coming years. In the 1990's, the Scottish
Executive created the Health Technology Board Scotland (HTBS), tasked with evaluating
the efficacy, and cost effectiveness, of treatments offered by NHS Scotland. I helped
prepare a proposal, that the Board should examine the cost effectiveness of treatments to
prevent relapse in alcohol dependence.
A systematic review was conducted of published studies, and also included unpublished
studies where these were discovered and the raw data could be obtained. A review to
assess scientific quality was conducted. Studies using behavioral measures and in which
the family and/or significant others were involved in the treatment, were grouped
together ( e.g. behavioral marital therapy; community reinforcement therapy) . The
following treatments were found to be effective in quality studies: Psychosocial
treatments: relapse prevention/ coping skills training, motivational interviewing,
behavioral family therapy/ community reinforcement therapy; Pharmacotherapy:
acamprosate, naltrexone, and supervised disulfiram. Meta-analysis was conducted to give
a composite outcome effect size for each treatment.
The cost ofproviding a course of each treatment was calculated.
Also, the cost to NHS Scotland offailed treatment was calculated, based on the known
rates of medical complications which ensue in the drinking alcohol dependent individual,
and the costs to NHS Scotland of treating these complications (e.g. the cost of managing
alcoholic liver disease, alcohol-related trauma, alcohol chronic pancreatitis etc.,
including GP consultation and hospital admission costs).
In the health-economic model used, the assumption was made that cases who recovered
(went without a relapse for the study duration) remained well after that treatment, which
permitted an estimate of the cost advantages over time of that treatment compared to our
previous standard outcome ( from early UK studies) of a 15% recovery rate. Table 1
summarizes the surprising estimates obtained, and published in the Health Technology
Assessment Report (38). For the effective psychosocial treatments, there is actually a
negative cost i.e. a cost saving overall arising because while only some patients recover
completely, others offered the treatments improve and reduce their use of health service
resources.
The review also found evidence that helping patients to link with Alcoholics Anonymous
was an effective part of treatment, and noted that AA groups placed no financial burden
on the Health Service. Although I have not conducted research, other than literature
reviews, of the AA method, its value to hundreds of our patients over these 30 years has
been immense.
A complex treatment sometimes needed to save the life of an alcohol dependent patient is
liver transplant. In a project with colleagues in the liver transplant service in Sydney,
Australia, I assessed outcomes over up to 17 years in 100 patients who had received a
liver transplant for alcoholic cirrhosis. Relapse after a costly procedure as transplantation
generates much concern. This project revealed that relapse was related to baseline
severity of dependence and psychiatric illness (39). The implication is that monitoring
and treatment by psychiatric or alcohol services might prevent some relapses to harmful
drinking in transplant patients.
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CONCLUSIONS
During the period of this research, Scotland saw an increase in the prevalence of alcohol
dependence. The research submitted for this thesis does not attend to the causes of that
change. Cultural and economic changes have probably been the main contributing
factors. However, there have been advances in the recognition of people who develop
alcohol dependence, and in how they can be helped.
TABLE 1
Costs, calculated over 20 years, for 1000 patients with alcohol
dependence offered specific effective treatments, compared with
'standard' support (Health Technology Board of Scotland, 2003)
(negative cost = health cost saving)
(In this Thesis, see published paper No. 38)
www. docs, scottishmedicines.org/
docs/pdf/Alcohol%20Report.pdf
Additional Cost per additional
recovered recovery
patients
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Alcohol Dependence: Methodological Issues in its
Measurement; Reliability of the Criteria
Jonathan Chick
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Royal Edinburgh Hospital, Edinburgh 10
Summary
Instruments measuring alcohol dependence have seldom been presented with evidence of their reliability.
There are a number of difficulties in designing such instruments which contribute to unreliability. The
items in a standard interview, The Edinburgh Alcohol Dependence Schedule, are shown in this paper to
have acceptable inter-rater reliability, although difficulties in operationalising'impaired control' remain.
Introduction *
Operational criteria of alcohol dependence
Operational definitions of alcohol dependence based on traditional criteria include
items from conceptually distinct domains. A recent example is that of Hilton and
Lokare [1]. Out of 34 items 5 referred to a subject's reasons for drinking (e.g. 'drink
because of loneliness'); 6 to his attitudes to his drinking (e.g. 'felt ashamed of your
drinking'); 2 to the attitudes ofothers to his drinking (e.g. 'been advised to cut down
on your drinking'); 8 to consequences (mainly adverse) of drinking other than
'dependence'/>«r se (e.g.'. . . been violent after drinking'). Of the remaining 13items,
4 were about short-term withdrawal symptoms; 4 were about frequency of'salience'
(e.g. '. . . drink whenever you have a chance'); 1 was about being a drink ahead of
one's companions; and 2 perhaps reflected intensity ofneed (e.g. 'does it bother you if
there is no drink available?').
These criteria are derived from the definition ofjellinek [2] which led to Glatt's
instrument [3], to the ALCADD and MAST screening tests and the 'criteria' of the
National Council on Alcoholism [4], A more restricted definition would omit those
aspects which can be viewed as consequences of drinking or the effects of the
interaction of the drinker and his social environment. It would thus be conceptually
more homogenous and would reflect the finding ofgeneral population studies (rather
than studies of help-seeking populations) that there is only partial overlap between
scores on heavy consumption itself, reasons for drinking, adverse consequences of
drinking and items denoting withdrawal phenomena and the subjective experiences
of intense desire and impaired control [5-9].
Edwards and Gross [10] provided such a circumscribed definition of alcohol
dependence listing seven elements: narrowing of the drinking repertoire; salience of
drink-seeking behaviour; increased tolerance to alcohol; repeated withdrawal
symptoms; relief or avoidance of withdrawal symptoms by further drinking;
subjective awareness of compulsion to drink; the tendency for the syndrome to be
176 Chick
reinstated after a period of abstinence. This paper presents an assessment of the
reliability of the criteria offered in this definition. However, first a comment will be
made on the literature on reliability studies in this area followed by a discussion of
some of the pertinent methodological difficulties.
The Reliability of 'alcoholism' criteria
An important step in evaluating a proposed syndrome is to establish the reliability of
the criteria which were used in its provisional description, that is, to establish that
measurements of the criteria can be made and repeated without significant error.
In the literature, the issue of the reliability of'alcoholism' criteria is frequently
sidestepped. Mulford [11] in his paper on an Alcoholic Stages Index stated that ifan
instrument has validity 'that should also dispose of the reliability issue'. The
argument is that if an instrument does the job it is predicted to do, its error must be
insignificant. The applicability of this argument to measures of alcohol dependence
depends on the validation criteria being appropriate. The demonstration that an
instrument said to measure dependence distinguishes between patients attending an
alcoholism treatment unit and a general population sample (as, for example, Hilton
and Lokare [1] provided) is not an absolute demonstration that the items are valid
measures ofalcohol dependence. The finding might occur in part because a hospital
sample are 'people with problems', or 'people who are worried about their drinking
and seek help', or they have a different response set to the instrument since they
identify themselves as alcoholics [12, 13].
When the reliability issue is not sidestepped, but investigated, the results are
perturbing. Gillies et al. [ 14] devised a questionnaire containing 30 items (or 35 items
in another version) about 'alcohol involvement'. The list contained most of the
commonly asked alcoholism questions, excluding those about adverse social or
medical consequences. Reliability was assessed by test-retest. Amongst individuals
who were neither heavy drinkers nor alcoholics, test-retest correlation was good
(.87), though this is not strong evidence since in such a population very few items
would be acknowledged. In contrast, in 30 alcoholic in-patients the rank order of
subjects produced by the second administration after a varying period while still
in-patients was statistically speaking unrelated to the rank order on the first test. On
the scale from 0 to 140 points the 95 per cent confidence limits of the score derived
from the test-retest study was ± 30 points. The authors suggest that the in-patient
experience affected the subjects' evaluations of their own drinking behaviour, but do
not indicate whether this is a consistent trend in one direction (e.g. to acknowledging
more items reflecting perhaps a more self-critical attitude) or a random effect. The
importance of these data on reliability would depend on the use to which the
questionnaire was to be put. However, the result raises doubts about whether any
questionnaire items on alcoholism can be sufficiently unambiguous, to elicit
responses unaffected by the subject's self-evaluation.
A self-completed questionnaire is unlikely ever to provide the clauses and
qualifications necessary to define precisely complex experiences such as comprise
alcohol dependence. A standardised interview in which items are fated by an
individual trained in the definitions being used, with guide notes to refer to, provides
greater hope of reliability.
Caetano et al. [15] presented preliminary data on a standardised alcoholism
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interview. Some of the interview was about background factors, and physical and
mental consequences of drinking, but there was a section on recent drinking
behaviour, which is of interest to this discussion. The interview was conducted with
ten patients, by one interviewer, and tape-recorded. Four other raters also rated the
tapes. Weighted Kappa, a coefficient of between-rater agreements which takes
account both ofchance agreements and the degree ofdisagreement, yielded values of
from 0.37 to 0.91 on eight items concerned with symptoms and consumption on 'a
typical heavy drinking day'. The authors did not report on the distribution of scores
obtained from individual items. (Studies of inter-rater agreement are most
informative when the cases represent the whole range of possible scores on the
items.) The use of tapes and several raters make for a stringent test of reliability.
Unfortunately the published series has not as yet been extended to include more
cases.
An examination of test-retest reliability of a semi-structured drinking history
interview was reported by Summers [16]. Twenty-eight male voluntary patients in
an alcoholism treatment unit were interviewed on admission, and the 15 who stayed
for two weeks or more were reinterviewed on about the 14th day, with respect to the
same period of time. It was stated that inter-rater reliability between two
interviewers was high, but it was not specified whether the second interview was
conducted by the same or a different interviewer. However, test-retest correlation
was low.
Though few instruments assessing alcohol dependence have been presented
with evidence of their reliability, there are hints that items in common use in such
instruments are ambiguous and subject to varied interpretations. For example,
Glatt [3] usedJellinek's questionnaire to study the drinking experiences ofalcoholic
in-patients. He also gave nine of the items to a sample of 'moderate drinkers'
(mainly doctors and nurses, representing the same social class distribution as the
alcoholics) who were 'not showing at the present time any evidence that drinking
over a period ofseveral years had affected their work or health'. Of the 80 men in the
'moderate' sample, 7.5% reported early morning drinking, 8.8% reported 'needing
more drink to get same effect', and 16.3% reported 'decrease in tolerance'. Clearly
the 'moderate drinkers' may have included some extreme drinkers who had
remained free ofsocial or medical consequences. However, it is surprising that early
morning drinking had apparently occurred first at a mean age of 24.7 years in the
moderate drinkers but at a mean age of 35.3 years in the alcoholics. 'Needing more
for same effect' and 'decreased tolerance' if it was acknowledged by the moderate
drinkers also apparently occurred earlier than in the alcoholics. However, the
groups had not differed significantly in the age at which they started drinking. One
explanation, and perhaps the most likely one, is that the moderate drinkers were
using a lower threshold for reporting these items. That is, these items, as defined,
were unreliable.
This cursory review is sufficient to show that the reliability of alcohol
dependence criteria is an issue that deserves to be investigated rather than evaded.
Methodological difficulties
Three issues in designing a reliable instrument to measure alcohol dependence will
be discussed and illustrated from the literature.
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Specifying the Items. Of the elements ofalcohol dependence described by Edwards and
Gross [10] perhaps the most difficult to operationalise are 'subjective awareness of
compulsion to drink' and 'reinstatement after abstinence'.
Stockwell et al. [17] tackled the first of these in a cautious manner using two
questionnaire items on intensity of subjective disposition to drink in the morning
during a heavy drinking period. They only specified the morning perhaps because
they appear to have tried to avoid eliciting experiences cued by stimuli external to
the individual. The experience of morning craving is arguably more dependent on
stimuli arising within the individual, for example those associated with falling blood
alcohol. However, the element of subjective compulsion to drink suggested in the
Edwards and Gross description is more general than merely morning craving.
Also included in that element is the subjective experience of impaired control of
drinking. Stockwell et al. do not attempt, in the limited format of a questionnaire, to
assess this.
They tackled 'reinstatement after abstinence' as follows: they devised an item
'Imagine the following situation: (1) You have been completely off drink for a few
weeks, (2) you then drink very heavily for two days. How would you feel the morning
after those two days of heavy drinking?' The reliability of Imagine-the-following-
situation-questions requires special attention. The authors have not commented on
the reliability of the individual items in their questionnaire.
Specifying the timeperiod and allowingforfluctuating severity. The time period to which the
respondent should refer is a crucial specification. From longitudinal general
population studies it is known that individuals move into and out of dependence on
alcohol (e.g. [5]). Classical bout drinkers could certainly be said at times in their lives
to move frequently into and out of the 'physiological', if not the 'psychological',
elements of the syndrome. A study of the drinking habits of'alcoholics' at large in the
general population [18] amongst whom very few were classical bout alcoholics,
showed that for many subjects 'alcoholic drinking' was interspersed within the same
year by periods during which they could be said to drink like other people.
In questionnaires, often no time period is specified. Instead the present tense is
used (e.g. Mulford, [11], 'Would you say these things about your drinking: without
realising it, I end up drinking more than I had planned to?. . . etc.'). Such vagueness
probably makes for unreliability."
One alternative is to ask the subject to make a judgement about a 'typical'
drinking period. Stockwell et al. [17] asked the subject to 'recall a recent month . . .
when you were drinking heavily in a way which, for you, was, fairly typical ofa heavy
drinking period'. (The instrument used was a questionnaire. ) Caetano et al. [15]
asked the subject to judge his own 'typical drinking day'.. The interviewer was
directed to identify the period with some objectivity to which the patient"referred.
This approach sidesteps astutely the difficulty that some symptoms fluctuate in
severity. The chiefsnag is that the term 'typical' is subject to interpretation. To some
it implies 'average'; to the self-critical respondent it may imply a 'typically bad'
period; to the equivocating respondent it may define a period when nothing striking
took place; to the committed alcoholic it may define a period when he was
experiencing the 'typical' that is, 'textbook', symptoms of alcoholism.
Another objection to using the 'typical drinking day' at least in the Scottish
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setting where the present author works is that a significant proportion ofpatients are
mainly weekend drinkers, whose drinking increases from Thursday to Saturday and
then subsides on Sunday and Monday. They are unable to offer a 'typical drinking
day', and would probably find it hard to answer questiorfs about a typical heavy
drinking period. .Shift workers, who have less access to alcohol in a country with
restricted licensing hours during the week when they are on evening ('back') shift,
present a further problem.
The third alternative is to specify a recent time period in terms of weeks or
months. Ahlstrom-Laakso [18] found that the past 12 months was too long a period
for subjects to recall accurately and this is borne out in clinical experience.
Furthermore marked fluctuation may have occurred during such a long period.
Ideally, current degree of dependence would refer to the respondent's state on
the day of the interview, which is experience immediately available to him, without
memory intervening. However, if an instrument is to have a use in populations
attending agencies, who have perhaps been 'detoxified' in the week or so prior to
interview, this definition of current will be inappropriate.
The reference period for determining recent, or current dependence, needs to be
long enough to avoid immediately recent detoxification and to catch recent heavy
periods for those whose drinking fluctuates markedly, but no so long as to be hazy in
the memory. The past three months might be a convenient period to specify.
However, the difficulty remains that some symptoms, for example morning tremor,
will in many subjects fluctuate in severity and/or frequency even during that
relatively brief period. One is forced back to asking the subject to specify for the
three-month period either a usual or average severity/frequency (e.g. 'tremor three
days per week on average'), a typical severity/frequency (with the reservations
mentioned above) or, severity/frequency 'when at its worst' or 'when at its most
frequent'.
Is there a place for cumulative measure? This subsection quoted the view that
individuals move into and out of dependence dn alcohol. The early instruments,
such as the Grapevine questionnaire [2], and most of the widely used 'screening'
instruments phrase many items in the form 'Have you ever . . .?'. Such items yield a
cumulative lifetime score. An individual who had a long history, but recently had
been drinking little, could have a low score on 'recent' severity of dependence but a
high cumulative score. The cumulative score would be of little relevance to research
on, say, short-term physiological correlates of dependence. However, it might be
relevant to genetic research, or outcome research.
Aim of the Present Study
The aim of this study was to assess the inter-rater reliability of a set of criteria of
alcohol dependence, loosely based on the description of Edwards and Gross [10].
The pilot phase was to improve definitions of items and to test various ways of
specifying reference periods.
Method
The pilot phase - developing the instrument
A standardized interview seemed to be more likely than a self-completed
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questionnaire to avoid the vagueness and ambiguity which besets instruments in this
field. Items were based on the elements of the syndrome as described by Edwards
and Gross [10] and were brutal simplifications, being preformed precoded items, of
the complexifies portrayed by these authors. Considerable effort was put into the
detailed wording of the items, some ofwhich went through as many as four versions
during pilotting on 25 male patients in psychiatric and general hospitals who were
regular drinkers. Guide notes evolved.
No item on reinstatement after abstinence was included because of the difficulty
found in operafionalizing it. (With hindsight these may not have been insuperable.
However, since many respondents in this sample had never been abstinent, many
'not applicables' would have been rated.)
'The past three months' emerged as a time base for measuring 'current'
dependence which caught the last heavy drinking period of the few classical bout
drinkers in the pilot sample, but which was not too long for respondents to recall. An
attempt to provide a different format for bout drinkers was abandoned in the pilot
phase because the overlap between bout and non-bout drinking made the distinction
difficult to operationalize.
The final instrument
The final schedule ('The Edinburgh Alcohol Dependence Schedule', available from
the author) dealt with 26 'symptoms', with sub-items dealing with 'recent' (past
three months) severity and frequency, yielding 44 items in all. These are listed,
abbreviated, in Table 1. For reasons which no longer seem pertinent four items only
had a rating in the 'ever' form, and a 'recent' rating was not included. These were
two items on changes in tolerance, 14,41, one item tentatively deemed to represent
tolerance relative to one's drinking companions, 15, and the item on 'true' alcoholic
amnesia, 44. Two items on Narrowing of Repertoire, 1, 2, had a rating only in the
'recent' form because it was found in the pilot phase that answers to this question in
the 'ever' form were difficult to rate.
(Items on diminished tolerance and amnesias, 41—44, were included for
historical reasons. Traditionally they are regarded as symptoms of alcoholism and
their relation to dependence was to be tested using this instrument. However, they
do not appear in the Edwards and Gross conception of alcohol dependence.
Diminished tolerance and amnesias are each end-experiences of several differing
psychophysiological paths. This obvious fact makes them poor candidates for
inclusion in the syndrome.)
A response bias towards permitting acknowledgement of socially deviant
behaviour and experience was sought, using the preamble: 'This interview is about
your pattern of drinking and about certain experiences that are common in regular
drinkers. The questions take about 25 minutes. It is not connected with your
treatment and it is confidential. It is to help us understand more about the different
varieties of drinking patterns.'
The guide notes specified that interviewers were to use the exact wording
provided, and ask each question, regardless ofwhether the respondent had already
discussed the experience involved in earlier replies. Specific occasions were to be
recalled and described by the respondent wherever either the interviewer or the
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Table 1
Scale Uneven Could not Disagreement Remaining K % agreement
Points Distribution be rated over cases of total cases
of responses by one or Applicability
other rater
m m n« on nj (nt + m + m)
cases
Narrowing of Repertoire
1 Day' 2 - 0 0 41 .85 93
2 Mood* 2 - 1 0 40 .87 95
Salience
3 Spending more time
drinking 2 - 0 0 41 .90 98
4 Giving up interests 2 - 0 2 39 .95 93
6 Missing meals 2 - 0 0 41 .88 95
7 Frequency 3 - 0 0 41 ,.96 98
Need
8 Restless without 2 - 0 1 40 .95 95
9 Severity* 4 - 3 0 23" .75 77
10 Think4 ' 2 - 0 0 41 .94 98
11 Frequency 4 - 1 0 40 .96 95
12 Organise day* 2 - 1 0 40 1.00 98
13 Frequency 3 - 1 0 40 .91 93
Tolerance
14 Increased tolerance 2 'absent' in
only 4
0 1 40 .77 93
15 More than
companions' 2 — 0 0 41 .93 98
Impaired control
16 Limit' 2 - 0 3 38 .95 90
17 Frequency 4 - 2 3 36 .89 85
18 Drunk* 2 - 0 3 38 .94 90
19 Frequency 4 - I 3 37 .91 88
20 Passing out* 2 - 1 0 40 .88 93
21 Frequency 4 - 1 0 40 .95 95
22 Difficulty cutting 3 - 0 0 41 .83 90
down
Withdrawal
23 Tremor 2 - 0 0 41 .90 98
24 Frequency 4
no ratings
0 0 41 .89 93
25 Severity 5 of points
1 and 3
0 0 26" .78 90
26 Morning drink 2 - 0 0 41 1.0 100
27 Frequency 4 - 1 0 40 .87 90
28 Timing 4 - 0 0 41 .91 95
29 Retching 2 - 0 0 41 1.0 100
30 Frequency 4 - 0 0 41 1.0 100
31 Sweat 2 - 0 0 41 1.0 100
32 Frequency 4 - 0 0 41 .86 90
33 Tense'" 2 - 1 3 37 .89 85
34 Frequency 4 - 1 3 37 .92 85
35 Panic 2 - 0 0 41 .90 95
36 Frequency 4
'present'
1 0 40 .89 93
37 Fit 2 only in
3 cases
0 0 41 1.0 100
38 Frequency 3 - 0 0 41 1.0 100
39 Hallucinations 2 - 0 0 41 1.0 100
40 Frequency 3 - 0 0 41 1.0 100
(iContinued overleaf)
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Symptoms not conceptually part of dependence
41 Diminished tolerance 2 - 1 0 40 .93 95
42 Amnesia11 2 - 0 0 41 .93 98
43 Frequency 4
'present'
0 0 41 1.0 100
44 'True' amnesia" 2 only in 2 0 24" .78 88
2 cases
I Change from drinking less on a weekday to drinking same or more nowadays.
* Change from drinking according to mood, to not drinking according to mood nowdays.
' Certain situations or times of the day when regularly restless or irritable without a drink.
Applies = Scores 1 point. Score a further point for either 'restless when interferes with what you're doing' or
'others notice you feeling restless'.
4 At times can't think of anything but how to get a drink.
5 Organize day beforehand to ensure you can obtain a drink at times you think you'll need one.
* Going for a drink between rounds or getting a start on companions.
' Set a limit but felt completely unable to keep to it.
* Had difficulty preventing yourself getting, what you would call, drunk.
* Passing out while drinking, in a public place.
10 Wake up tense after drinking the day before, even though no obvious problems ahead that day.
II Completely unable to remember things you did while drinking (the events of 5 mins. or more).
11 As II,'... when you did not have a good drink in you, were not drunk (and other people, if they had seen you,
would not have thought that you were drunk)'.
" Item amended at mid-point of study; therefore only coded on last 26 cases.
respondent were in doubt about a response. Contained in the guide notes were
expanded definitions of the items, permitted probes, and criteria for inclusion and
exclusion.
The items about the frequency of certain experiences were either of the form
'How many times has that happened in the past three months?' (e.g. 'passing out',
'hallucinations'); or 'How many times per week has that happened during the past
three months?', qualified by 'at its most frequent' for tremor and morning drinking
to allow for fluctuating frequency. Individuals who stated that the frequency of their
other symptoms fluctuated (e.g. sweats, tenseness, etc.) were to be rated according to
the frequency of the symptom 'at its most frequent'.
'Severity' in the past three months as well as or instead of'frequency' was rated
for certain items (tremor, restlessness without alcohol, morning drinking). Thus
severity of tremor was graded according to whether in the past three months tremor
had ever been severe enough to make it 'difficult to hold a cup or glass', or had caused
'legs or body to shake', etc.
Recent severity of'restlessness', 9, and recent frequency of tremor, 25, together
with 'true amnesia', 44, were only included in the schedule midway during the
study, and thus only for 26 subjects.
The sample
For the present study, 41 male admissions to the Edinburgh Unit for Treatment of
Alcoholism were interviewed. They comprised two cohorts of approximately
consecutive male admissions under 65 years. A patient was not approached for his
co-operation if he was known to the ward staff to be demented or to have memory
impairment. In addition, two patients on whom an interview was commenced were
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not included because ofdementia on simple clinical criteria evident to the research
interviewers.
The 41 men ranged in age from 21 to 61 years, mean 41.1 years. They
represented the following occupational categories:
professional (2); technical/managerial (11); other non-manual (8); skilled manual
(11); non-skilled manual (9).
The raters
Two raters were present at each interview, the author plus one of five colleagues,
selected to represent a range ofexperience. None of these six was on the ward staffor
had prior knowledge of the patients to be seen. The colleagues comprised two
psychiatrists, with special experience of alcoholism (who rated five and seven
interviews respectively) a psychiatrist without special experience (10 interviews); a
trainee psychiatric nurse (7 interviews) and a psychology graduate (12 interviews),
both without special experience. Only the psychology graduate had practice with
the schedule before the study (he had never interviewed an alcoholic before).
Otherwise raters only read the guide notes and discussed the schedule in detail with
the author before seeing their first subject.
The procedure
The subject was asked ifhe would be interviewed in confidence 'as part ofa research
project about patterns of drinking'. None refused. One rater conducted the
interview, the other was present but silent. Rating was completed independently.
Seventeen of the interviews were conducted by the author, 24 by the other rater, the
author conducting a similar proportion of each rater's set of interviews.
Analysis
For each rating, the numbers of the possible types of disagreement and agreement
were counted and Cohen's Kappa (K) calculated, a coefficient of agreement which
takes account of chance agreement [19]. Its significance was calculated by the
method suggested by Cohen. For some items, where three or more possible levels
would be rated, weighted kappa (a modification allowing for some disagreements
being less serious than others), would have been an appropriate coefficient.
However, such high levels ofsignificance were obtained using unweighted kappa for
these items that there was nothing to be gained by complicating the analysis.
Results
Table 1 lists the items. Where an item is followed by a rating of 'frequency',
'severity', or 'timing', that item refers to lifetime occurrence, the sub-items to the past
three months.
The first column gives the number of scale points on which an item could be
rated.
The second column notes instances where the distribution of responses was
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markedly uneven. This factor limits the use which can be made of percentage
agreement as an index of agreement, but is reflected in kappa and its confidence
limits.
The third column records the number of cases where one or both of the raters
failed to rate the item. These instances appeared to be due to lack of precise enough
information rather than careless omission. This indicates deficiency either in the
definition and guide notes, the probes, or the rating scale. Severity (in the past three
months) of being 'regularly restless or irritable without a drink in certain situations
or at certain times of the day' could be 'present' (score 1) or could be 'noticeable by
others' (add one point) and/or 'interfere with what you are doing' (add one point).
This item was introduced after 15 cases had been interviewed and had not been
properly pilotted. In three of the 26 interviews where this item was used, the author
could not make a rating from the information elicited by the interviewing co-rater,
though the converse never occurred. (The guide notes and probes were presumably
not specific enough, given the wording of the question, and are being revised.)
The fourth column records where one rater felt an item to be 'absent' or 'present'
while the other specified 'not applicable'. This highlights particularly an
unreliability in two items about impaired control. This will be discussed later.
Kappa is shown in the sixth column. It was calculated on the number of cases
shown in column five, which omitted cases (m and na) where the anomalies noted
above had occurred. To give an impression of reliability throughout the whole
sample column seven defines these anomalies as disagreements and presents as a
percentage the ratio of the total number of agreements to total number of cases.
With four exceptions, every item yielded a kappa which was significant at the
level p< 0.001. The exceptions were 'increased tolerance', (k= .77, p< 0.005); fit
(k= 1.0, p<0.01); recent fit (k= 1.0, p<.02); 'true' alcoholic amnesia (k=.78,
p< .05).
Discussion
In the context in which they have been examined these items yield high inter-rater
agreement. The results compare favourably with those obtained in alcohol
dependence by Caetano et al. [15] and for symptoms ofanxiety and depression [20].
This was achieved without extensive practice with the schedule or training, but the
cost was that on some items inadequate information was elicited by the unpractised
interviewer (see discussion above of severity of'restlessness').
The acid test of inter-rater reliability has yet to be conducted namely between
pairs of raters not including the author. However, probably most items and their
specifications are robust enough to withstand this test, with the following
reservations.
The two items which subjects found most difficult to answer (in the author's
memory) and which raters reported finding difficult in their debriefing, were 16/17
'Have there been occasions when you set yourself a limit on how much you'd have,
but found yourselfcompletely unable to keep to a limit?' (inability to keep to a limit
which could confidently be ascribed to social pressure, the too generous host etc. was
not included); and 18/19 'Different people mean different things by "getting
drunk". Have there ever been occasions when you found it difficult to stop yourself
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from getting, whatjoa would call, drunk?'. The snag was deciding whether or not the
subject did on occasions intend to keep to a limit, or not get drunk. And, if he did so,
but continued to drink, whether that intention was overcome by forces from within
him 'beyond his control' or whether he simply changed his mind. This obscure area
and the findings in this sample will be the subject ofa subsequent paper. Suffice it to
say, for the present, that obtaining a response was difficult, and these were the items
where, more than in others, there was disagreement over applicability (usually over
whether the subject had or had not tried on occasions to limit his drinking); and
where there were instances where one rater felt unable to make a rating. Several
versions of these items were pilotted, along with items on impaired control used by
previous workers. Depending as it must on the language of intention, impaired
control as couched in these two items is conceptually too nebulous for inclusion in a
schedule where more than 90 per cent agreement between raters is expected. It
might however be worth trying a more direct item, such as, 'Have you felt an
irresistible compulsion to continue drinking once your start?'
Three other items failed to yield 90 per cent or more agreement between raters:
9, recent severity of'restless without a drink', where the snag was a combination of
inadequately defined scale points and difficulty in deciding whether a subject had
ever been 'without', giving a rating 'not applicable'.
33/34, 'tense after drinking the day before, even though no obvious problems ahead
that day'; the caveat about 'obvious problems' is required because it is common for
people in a treatment unit to have pressing problems (impending separation from
wife, or loss ofjob) which fill the mind on waking. However, if this item were to be
retained further delineation of 'obvious problems' would be necessary.
44, ' true' alcoholic amnesia: this was defined using Jellinek's understanding of the
alcoholic 'blackout', being a memory lapse occurring after moderate drinking ('not
more than 50 or 60g of absolute alcohol' inJellinek's definition) unaccompanied by
signs of intoxication. The raters agreed on its presence only in one out of26 subjects,
disagreed once, and in two subjects a rating was not made by one rater because the
caveat 'when you were not drunk and the people would not have thought you were
drunk' was not sufficiently explored. This item, it has already been mentioned, is not
part of the Edwards and Gross [10] description of dependence.
Conclusions
Of four items lacking the very high degree of reliability obtainable by the majority,
two can be improved fairly simply and hopefully made fully reliable:
Tense in the morning following drinking
Degrees of severity of restless without a drink.
The other two items failing this criteria are inherently difficult to operationalize and
it is unlikely they can be made more reliable:
Inability to keep to a limit
Difficulty preventing getting drunk.
The level of reliability of all the items seems, however, sufficient for data
gathered using the instrument to be used for further analysis. The hypothesis that
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Is There a Unidimensional Alcohol Dependence
Syndrome?
Jonathan Chick
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Department of Psychiatry, Royal Edinburgh Hospital, Edinburgh
Summary
The elements of the provisional description of the Alcohol Dependence Syndrome were operationalised
into a structured interview given to 109 men attending an alcoholism treatment unit. A single underly¬
ing dimension could not be demonstrated. The main dimension comprised Subjective Need, With¬
drawal, and aspects of Salience. Narrowing of Repertoire and Impaired Control formed separate
dimensions.
In their attempt to supercede the conglomerate concept of alcoholism, the WHO
Group of Investigators on Criteria for Identifying and Classifying Disabilities
related to Alcohol Consumption decided to set apart 'one important disability
requiring definition and clarification . . . the alcohol dependence syndrome'. 'The
reality and significance of this syndrome seemed to be well supported by a review
of present evidence' [1].
As proposed initially, the syndrome of alcohol dependence was to be seen as a
'clustering', but one which would yield a 'range of severity' [2], It is suggested
that, despite variety of manifestation, it is to be seen as a unitary phenomenon:
'Symptoms (are) ranged upon a continuum of severity. . . . The syndrome of
alcohol dependence is given expression and, in various ways, both facilitated and
hindered by an individual's personality and general circumstances, but remains,
nevertheless, a unitary syndrome' [3]. One type of evidence for the syndrome
being 'a psychobiological reality not an arbitrary social label' was to be, there¬
fore, its unidimensionality.
If the notion of an alcohol dependence syndrome is upheld there are implica¬
tions in many areas. In research, it suggests that physiological, genetic and learn¬
ing theory approaches to aetiology deserve support. In planning treatment ser¬
vices, the implication is that some drinkers require help from specialists and that
parts of treatment programmes from one culture may be transportable to other
cultures since there is universal core component to the condition. With a view to
prevention, the implications may be those drawn by, for example, the British
Royal College of Psychiatrists: 'The tactics for remedying the situation are not
(therefore) simply commonsense . . .'. 'Any person who drinks should be aware
that he is using a drug which can induce dependence' [4].
Illustrative Review of Empirical Studies on the Unitariness of Alcohol
Dependence
Two commonly used methods of investigating whether a set of data lie on a
continuum are factor analysis and Guttman scaling.
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Factor analysis gives rise to several criteria against which to test a hypothesis
of unitariness. Different authors in the alcohol literature have used different
criteria but the common feature is a demonstration that the major factor accounts
for a very substantial part of the variance.
Guttman scaling provides a more stringent test of the unitariness of a set of
items. If items meet the requirements of Guttman scaling it implies that they are
cumulative (in terms of severity, not natural history) as well as unidimensional.
(If items form a perfect Guttman scale then individuals at a given point on the
scale will, by definition, have that item and also every item on the scale below
that one, but none above it.*)
Factor Analytic Studies
Horn and Wanberg [5] analysed questionnaire responses from 2,300 patients
admitted to an alcoholism treatment facility. The 41 items were about style and
quantity of drinking, consequences, attitudes of self and others to one's drinking,
reasons for drinking and withdrawal symptoms. Principal component analysis
yielded 13 factors with eigenvalues greater than unity. The proportion of the
variance accounted for by the first factor was not reported. These 13 factors
tended to correlate positively but weakly with each other. From this the authors
concluded that 'alcoholism', if it was a unitary attribute, was an attribute made
of poorly associated components.
In contrast are factor analytic studies which demonstrate a reasonable degree
of unitariness. With one exception, however, which will be described, these have
not shed light on the concept of alcohol dependence as defined by Edwards and
Gross [2], To illustrate, two such studies will be mentioned.
Overall and Patrick [6] gave a questionnaire containing 135 items concerned
with alcohol abuse and related behaviours to 160 psychiatric in-patients 'with a
wide range of alcohol use'. The factor analysis they performed yielded a first
factor which accounted for 27.2% of the variance. The other factors to emerge
each only accounted for between 1.9% and 3.5% of the variance. The 42 items
most highly related to the primary 'alcohol abuse' factor were about adverse
consequences of drinking (six), reasons for drinking (four), amount of alcohol
(four), drunken periods (two), attitudes to one's own drinking (six), other people's
attitudes to one's drinking (two), the remaining 18 about 'dependence' as
described by Edwards and Gross. The correlation matrix of these 42 items
yielded a major factor with an eigenvalue of 18.2 which was more than nine times
the root of the next most important factor. The authors reasonably concluded
that they had demonstrated that the set of 42 items defined a unidimensional
factor domain. Did their main factor look like a core syndrome of'alcohol depen¬
dence'?
The items which loaded most heavily on it were in order (1) Do you feel that
drinking is a real problem for you? (2) Do you frequently skip meals when you aj
drinking? (3) Are you now an alcoholic? (4) Do you drink more than most of your
friends? (5) When you get drunk do you sometimes stay that way for two to three
* Guttman scaling can generate scales which are conceptually meaningless. As with factor analysis a judgement
must be made as to the practical sense of a revealed dimension.
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days or longer? (6) Do you frequently take a drink to calm your nerves? This does
not look like the Edwards and Gross description of dependence. In a sample of
patients, especially of voluntary in-patients, if items about self-identification as an
alcoholic or problem drinker are included it is perhaps not surprising that the
main factor to emerge is influenced by perceiving alcohol as a problem. This will
be the feature which, above all, alcoholic in-patients will have in common.
Hilton and Lokare [7] derived a general factor which, though they called it
'alcohol dependence' might also more aptly have been given another name, for
example 'problematic drinking experiences' factor. It was a dimension which
depended heavily on adverse consequences and other items best conceived of as
properties of the interaction of the individual and his social environment. (This
study is commented on in [8]).
These sort of results, then, will not do as evidence for a unitary alcohol
dependence syndrome as proposed by Edwards and Gross.
Stockwell et al. [3] designed a questionnaire specifically to measure alcohol
dependence as defined by Edwards and Gross. In 104 patients of an alcoholism
service, 19 already refined questionnaire items defining four aspects of the syn¬
drome were factor analysed 'to determine whether one major factor would
account for a majority of the variance to comply with the concept of a single
syndrome of alcohol dependence'. A general factor emerged accounting for 53 per
cent of the total variance, strongly suggesting that the aspects of the syndrome
studied reflected a single phenomenon. The aspects measured were physical
withdrawal symptoms, affective withdrawal symptoms, withdrawal relief drink¬
ing, morning craving and reinstatement after abstinence. 'Salience of drinking-
seeking behaviour', some features of the proposed 'subjective awareness of com¬
pulsion to drink' and 'narrowing of the drinking repertoire' are elements of the
Edwards and Gross description that were not included. Thus the unitariness of
the whole of the Edwards and Gross conception was not tested.
It also remains to be seen whether such a clearly unitary picture emerges in
samples of alcohol dependent individuals which span the whole range of severity
which the syndrome is supposed to show. In the study of Stockwell et al., clinical
ratings of severity were made in 75 of the subjects. This included only 4%
deemed to have minimal dependence, 24% with mild to moderate dependence,
with a preponderance (68%) being in the moderate or severe category. It is not
stated whether the range of scores of these 75 was similar to the whole sample of
104, but if it was, then one may conclude that their factor analyses were per¬
formed on responses from a sample somewhat weighted towards the severe end.
Guttman Scaling Studies
The searcher after unidimensionality of alcohol dependence via Guttman scaling
is somewhat deterred by Cahalan and Room's conclusion that symptom scales in
alcoholism 'have never fulfilled traditional standards for Guttman scales' [9].
True, Jackson [10] in populations of identified alcoholics from various sources
produced the scales of'Preoccupation with Alcohol' and 'Psychological Involve¬
ment' (whose items bear some resemblance to the Edwards and Gross descrip¬
tion) which did meet Guttman criteria. However, this was only achieved when
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contrived items were used, that is scale points composed conjunctively or disjunc¬
tively of two or three of the individual questionnaire items.
Descendents of these scales had considerable use in prevalence studies but
were mysteriously inefficient at identifying 'known alcoholics' in survey popula¬
tions [11, 12]. This fact was one of several influences on Mulford's most recent
attempts to design instruments in this area [13]. Out of step with fashion, he
retained the notion of alcoholism (though stridently a social rather than a biologi¬
cal phenomenon) but stated his intention to 'avoid a unitary perspective'. The
index he has produced does not illuminate the question that is central to this
paper - namely, within the conglomerate of 'alcoholism' is there a unidimen-
sional core syndrome of alcohol dependence. Apart from Stockwell et al. [3]
whose answer, while clear, is not complete, there is no definite help from the
client literature or the survey literature. The present study hopes to go further
towards providing an answer.
Aims and Design
The present study tests the hypothesis that there exists a core syndrome which is
unidimensional. An experimental approach to this question in humans cannot,
pace Isbell, today be contemplated. One is constrained to gathering data from
self-reports*,t. The sample should be ideologically uncontaminated subjects, that
is from a population rather than an agency sample, but a yield of 100 definitely
alcohol dependent individuals could only be obtained in a population survey of,
say, 40 times that number. In the present study, feasibility dictated that subjects
attending an agency were studied, and the hypothesis tested on their self-reports.
To increase the homogeneity of the sample, only men were chosen.
How can the comforting palingenesis which dogs self-report research in agency
samples be avoided? First, one must obtain a sample which represents a range of
previous exposure to ideologies ofalcoholism, and ofself-identification as alcoholics,
in order that the effect of each on the self-report instrument can be quantified.
Second, the instrument must be robust, without room for ambiguity, to minimize
bias to response set: in short, ofproven reliability. Each of these steps with respect to
the present paper is reported on separately [8, 14],
Further, subjects should be interviewed as close as possible to the time of their




The Edinburgh Alcohol Dependence Schedule is described in [8] together with
evidence of the reliability of its items. These items dealt with 'recent' and 'lifetime'
* The criteria of the National Council on Alcoholism, in contrast, comprise physical signs and blood abnor¬
malities as well as self-report items but these are direct indicators of heavy consumption and only indirect
indicators of 'dependence' as defined by Edwards and Gross
t Withdrawal phenomena (e.g. amplitude of tremor) can of course be measured objectively but only give infor¬
mation on severity of withdrawal on a given occasion. Severity of dependence fluctuates and a measure that
summarizes a recent period is more appropriate to the hypothesis being tested here. This can only be achieved
by asking the subject to recall that period.
A Unidimensional Alcohol Dependence Syndrome? 269
occurrence of 24 symptoms which were operational attempts to define the concepts
in the Edwards and Gross [2] provisional description of the alcohol dependence
syndrome, excepting the element of reinstatement after abstinence. Twenty-one of
these symptoms were deemed to reflect 'recent' dependence.
Two indices of consumption were derived. The subject was asked to recall in
detail his consumption during the seven days prior to the interview or, if he was an
in-patient, prior to his admission. The total he consumed (in grams of absolute
alcohol) in those seven days was called 'last week's consumption'. Degree of prior
exposure to beliefs about alcoholism; and self-identification as having 'no', 'slight',
or 'definite' alcohol problem, or 'alcoholism', were also recorded.
The subjects
The sample of 109 men attending the Royal Edinburgh Hospital alcoholism
treatment unit consisted of two sets of consecutive male admissions plus 17
unsystematically sampled male out-patients. Men over 65 years old were excluded
and also those in whom there was clinical evidence of brain damage or memory
impairment. Their mean age was 41.1 years.
Information about previous exposure to beliefs about alcoholism was
unavailable for 12 subjects, all in-patients. Of the remaining 97, 22 per cent stated
they have never sought advice about their drinking previously, and had never read a
pamphlet or seen television films about alcoholism. At the other extreme, 56 per cent
had had previous psychiatric consultation, or had attended two or more AA
meetings, or read a pamphlet on alcoholism or obtained advice at a voluntary
agency.
Information about self-identification was unavailable in the same 12 subjects. Of
the remaining 97, 67 % stated they would describe themselves as alcoholics, 14% as
having a definite alcohol problem, 9% as having a slight problem and 7 % as not
having a problem.
Their occupational categories were: professional (14%), technical /managerial
(21%), other non-manual (11%), skilled manual (28 %), non-skilled manual (26 %).
Their consumption during the 'past 7 days' varied between over 1,600 gm absolute
alcohol (approximately 7 bottles of 40% spirits) (40.4%), to less than 800 gm
(28.3%) and their 'maximum day's consumption' between over 400 gm (28.5%) to
less than 160 gm (30.2 %). Sixty-one per cent regarded that segment ofconsumption
as 'typical', 14% regarded it as more than 14% as less than 'typical', and 11 % said
they did not recognize such a thing as a 'typical week'.
The approach made to the subjects and the preambles to the interview were
described in [8], The interviewer was either the author, a co-rater (see [8]) in which
case the author's ratings were submitted for analysis, or a psychologist trained in the
use of the schedule. Out-patients were interviewed on the day of their first visit, prior
to their intake interview. In-patients were interviewed as soon after admission as
their medical condition permitted, which was always within seven days.
Analysis
The analysis was conducted in three parts:
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An attempt to validate the items by analysing the subsets of items deemed to represent the
elements described by Edwards and Gross. Guttman scaling analysis was applied to
these subsets to determine whether they met the criteria of unidimensionality and
cumulativeness (coefficient of reproducibility CR>0.90, coefficient of scalability
CS > 0.60 [15]). Subsets that fell short of the criteria had items added or subtracted
and the points varied as suggested by scale-item correlations, in the hope of
generating scales. When this failed, the subsets were factor analysed as a less
stringent test of unidimensionality. If items in a subset met one test of
unidimensionality, that was taken to indicate at least that they shared some
meaning, though could not constitute a test of validity.
A search for a Guttman scale that would cross subsets of items was then conducted.
Contrived items, derived from the subsets, were scaled, and also individual items,
according to an ad hoc procedure, depending on familiarity with the data and the
scalability of the subsets, and hunch. This part was concluded before factor analysis
was begun.
A search for a main factor suggesting a unitary dimension was then conducted.
1. A principal components analysis of the correlation matrix of the 'Edwards
and Gross' items was made.
2. The principal factors so derived were also rotated orthogonally (by Varimax
rotation) and obliquely with Kaiser normalisation through a range of degrees of
obliqueness, with the object of specifying the simplest factor structure, according to
the guidelines summarised by Harman [16]. (These are 'rules of thumb' only and
suggest the pattern of 'zeros' in the columns and rows of the factor matrix which
accompany the simplest solution. Restated in geometric terms the rules imply that
(a) many points will lie near the final factor axes and (b) only a small number of
points will remain removed from both axes.)
By this stage in the analysis it was clear that amongst 'cumulative' items
unidimensionality was far harder to demonstrate than amongst 'recent' items. So for
brevity, only the findings for the factor analysis on 'recent' items will be described.
The factor analysis was not performed on the correlation matrix ofall the 'recent'
symptoms, because there were instances of logical dependency between variables.
Factoring intercorrelations among these variables raises the communalities and
factor coefficients spuriously.
Two items are 'logically dependent' if response to one imposes a logical
constraint on response to the other. In this study, 'timing of a morning drink' could
only be rated above zero for an individual who had already scored on the item
'frequency of morning drinking' since zero on that latter item would have meant the
individual had not taken a morning drink in the three-month period to which the
'timing' question referred.
'Quantity of morning drinking'; was logically dependent on 'timing', and
'frequency of morning drinking'; and severity of tremor was logically dependent on
frequency of tremor.
An ad'hoc decision was made as to which variables of logically dependent sets to
retain in the factor analysis. From the sets of items on tremor and morning drinking
only the 'frequency' items of each set were retained.
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3. A third step was to enter a further set of items of theoretical interest: age,
occupation, in-patient/out-patient status; consumption; and two symptoms not part
of the Edwards and Gross description: diminished tolerance and amnesias.
Results
Internal structure of the subsets of items representing the proposed elements of the syndrome.
Seven symptoms were deemed to represent the element of Withdrawal: tremor
frequency and severity (degree of functional impairment), tension, night or morning
sweats, night or morning panic, hallucinations and fits. In their 'recent' form, a scale
emerged which closely approached the criteria, but only when the items were
restricted to frequency of tremor, retching, tension, sweating and panic (CR 0.89, CS
0.66, n = 98*). These five items plus severity of tremor yielded a principal factor
which accounted for 52.5 per cent of their total variance, though they also yielded
one secondary factor on which panic and tension were loaded.
The element of Salience was deemed to be reflected in the items 'spending more
time drinking', 'missing meals', 'organising the day' ('to ensure you could obtain a
drink at times you thought you would need one'), 'giving up interests' ('because
spending more time drinking instead'). This subset were far from meeting the
scaling criteria either in the 'cumulative' or 'recent' forms. The four items
comprising Salience were intercorrelated and the matrix factor analysed. Two
factors with eigenvalues greater than unity were derived, accounting for 39.9 per
cent and 26.6 per cent of the total variance respectively. This indicates that these
four items do not reflect a single dimension.
The element ofReliefDrinking, comprised in the items on frequency, timing and
quantity of morning relief drinking scaled very clearly (CR .99, CS .97, n=62t).
The element of Subjective Awareness of Compulsion to Drink was operationalized
using two sets of items, Intensity ofFelt Need, and Impaired Control. 'A feeling that
you can't think of anything else', 'organising the day' and 'restless without' (the
Need items) in their 'recent' form but not their cumulative form comprised a scale
(CR 0.92, CS 0.70, n = 45: higher ratings of 'restless' were amended partway
through the study, thus data were only available on the last 45 cases).
Items on Impaired Control included 'difficulty preventing getting drunk', and
'completely unable to keep to a limit' (both of which yielded many ratings of'not
applicable' since intention to control drinking was foreign to many subjects).
Amongst those to whom both these items were applicable, a scale including 'passing
out in a public place' could be generated in both 'cumulative' and 'recent' forms
(CR 0.91, CS 0.67, n = 52 and CR 0.93, CS 0.77, n = 57). 'Difficulty cutting down'
which was couched only in the 'ever' form did not scale with all or with any two of the
other three items.
The Edwards and Gross element Narrowing of the Drinking Repertoire was only
represented by two items and thus could not be examined for its tendency to scale
* A case is omitted from the analysis if one or more of the items being scaled was rated 'not applicable in that
subject'. Thus, n varies.
t Quantity of morning drinking was only obtained in the first 62 cases interviewed, at which point a shortened
schedule was printed, omitting this item in the cause of brevity.
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Table 2 also shows the frequency with which items were acknowledged (in any
degree). Elements dominating the 1st factor are Withdrawal (excepting hallucina¬
tions and fits); Relief Drinking; and the Need sub-element. The Salience item
'missing meals' had a moderately high loading. The 2nd factor is dominated by
the Impaired Control sub-element; the 3rd by Narrowing of Repertoire; the 4th
by the severe (or perhaps more idiosyncratic) symptoms of withdrawal - fits and
hallucinations (fits, it should be noted, were a rare symptom making this an unre¬
liable item in a factor analysis); the 5th by the Salience items 'Spending more
time drinking' and 'giving up interests' and the 6th by the two items deemed to
represent Increased Tolerance.
The 'simplest' solution, as defined above, was obtained by rotating these fac¬
tors, with Kaiser normalization to produce a fairly oblique solution (delta = 0,
[15]). The structure of this solution is shown in Table 3. There are no major
differences between this and the principal components solution though the 1st
factor is now dominated slightly more clearly by Withdrawal than by Need and
Relief Drinking.
Table 3 Factor structure (after oblique rotation) of the 21 dependence symptoms
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 Factor 7
Narrowed repertoire: Day .05 -.04 .82 .05 .05 -.09 .09
Narrowed repertoire: Mood -.01 .03 .64 .10 -.31 .16 -.45
Spending more time drinking .35 .30 .27 -.00 .52 .18 -.37
Giving up interests .17 .21 .01 .09 .11 .21 -.84
Need more for same effect .16 .02 .02 .11 .12 .65 -.09
More than companions .05 .42 .18 .14 -.29 .54 -.23
Missing meals .51 .17 .48 .25 .16 .30 -.04
Restless without .31 .19 -.01 .12 .13 .72 -.08
Can't think ofanything else .55 .14 .15 .28 -.09 .59 -.19
Organise day .54 .31 .02 .23 .06 .58 .29
Can't keep to limit .20 .86 -.01 -.01 -.01 .15 -.17
Difficult to avoid get drunk -.02 .83 .04 .26 -.12 .07 -.13
Passing out .49 .27 .07 .52 -.34 .05 -.13
Frequency of tremor .84 .03 .10 .09 .26 .36 .08
Frequency ofa.m. drink .59 -.07 .18 .20 -.09 .68 -.02
Retching .73 .17 .10 .32 .09 .26 -.16
Sweating .65 .11 .16 .17 -.11 .29 -.10
Morning tension .60 .31 -.00 .46 -.02 .16 -.40
Panic .25 .21 .28 .82 -.11 .26 -.16
Fits -.02 -.18 -.11 .29 .73 .08 .03
Hallucinations .23 .06 .01 .77 .24 .14 .01
n = 109
Table 4 shows the correlations between these factors. In general, these are
positive but low.
In the next stage, to the correlation matrix were added the symptoms of
diminished tolerance and amnesia; last week's consumption; age; occupation; and
in-patient/out-patient status. The effect of this was not to alter the explanatory
power of the first factor which again accounted for only one-quarter (22.3 per
cent) of the variance. The inclusion of the consumption variable was responsible
for 'passing out' appearing more clearly on the first factor on which consumption
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Table 4 Factor correlations: oblique solution, the 21 dependence symptoms
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Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6
Factor 1
Factor2 .16
Factor 3 .12 .05
Factor 4 .25 .13 .07
Factor 5 .05 -.08 -.06 -.01
Factor 6 .31 .14 .10 .15 .02
Factor 7 -.08 -.18 -.11 -.08 -.04
itself also loaded highly. Other loadings remained very similar. (Frequency of
amnesia loaded highly on this 1st factor.) The relative loadings of the individual
dependence symptoms on the remaining factors resembled their loadings on the
factors produced in the analysis of dependence symptoms alone, though it is of
note that consumption loaded negatively (— 0.327) on Factor 2 ('Impaired Con¬
trol'), until an oblique rotation was performed when Factor 2 had just positive
consumption loading (0.126). Frequency of amnesia loaded equally on Factor 1
and Factor 2 (0.470), (0.482). Table 5 shows the loadings on the first seven factors
after oblique rotation (Kaiser normalization; delta = 0).
Table 5 Factor structure (after oblique rotation) of the enlarged set ofitems
Factor 1 Factor 2 Factor 3 Factor 4 Factor 5 Factor 6 Factor
Age .12 -.08 .07 -.04 .08 -.03 -.03
Occupation .02 .10 .02 .11 .06 .77 .22
In-patient/Out-patient -.16 -.03 .09 .05 .72 .17 .06
Narrowed repertoire: Day .08 -.12 .67 .05 .16 .12 .15
Narrowed repertoire: Mood -.01 .13 .75 .02 .06 -.20 -.07
Spending more time drinking .22 .27 .12 .16 .26 -.07 .77
Giving up interests .09 ' .29 .12 .11 .06 -.65 .30
Need more for same effect .14 .06 .02 .13 -.11 .01 .13
More than companions .27 .41 .17 -.01 .43 -.16 -.30
Diminished tolerance* .21 .23 -.09 .32 -.60 .20 .05
Missing meals .45 .10 .39 .18 -.11 .12 .41
Restless without .41 .24 -.06 .20 .33 .01 .04
Can't think ofanything else .59 .27 .24 .29 -.11 .04 .06
Organise day .66 .28 -.09 .21 -.07 .21 .00
Can't keep to limit .16 .80 -.03 -.07 -.05 -.12 .15
Difficult avoid get drunk .02 .82 .08 .18 .06 -.02 -.10
Passing out .50 .25 .20 .27 -.02 .06 -.05
Frequency of tremor .75 .00 .03 .17 -.11 .06 .46
Frequency ofa.m. drink .64 .03 .25 .21 -.10 -.06 -.05
Retching .73 .23 .13 .40 -.04 -.16 .20
Sweating .67 .15 .21 .16 .06 -.13 .05
Morning tension .49 .39 .15 .48 -.06 -.30 .20
Panic .26 .24 .38 .68 .04 .01
Fits .01 -.27 -.32 .49 .21 -.13 .32
Hallucinations .21 .11 .04 .81 -.09 .07 .07
Frequency ofamnesiast .47 .48 .17 .45 -.15 .17 .27
Last week's consumption .76 .12 -.05 .18 .26 .14 .00
n = 109
* acknowledged by 33 %
t acknowledged by 77 %
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Discussion
The 'aims' section of this paper is a lie. The original chief intention had been to
construct a scale of severity of alcohol dependence, somewhat taking for granted
the Edwards and Gross provisional description. Therefore, the four main findings
of this paper arose in a context which was relatively free of personal bias against
a unidimensional syndrome. Indeed, if anything the bias may have been towards
finding a single dimension, since then a nice, publishable scale would have arisen.
It is important to state this since the procedures employed (scavenging for scales
and fishing for factors) give room for subjectivity.
The main findings are summarised below. The discussion will deal first with
points arising from the nature of the data; second with more conceptual matters.
1. Only a very limited range of items could be coaxed into a Guttman scale
which crossed boundaries between elements of the syndrome. Since the scale
obtained was based on data from only half the subjects ('restless without' was
modified half-way through the study) replication here is specially required.
2. The items studied did not yield a single factor which could be said to account
for 'a very substantial proportion of the total variance'. Nor did the main
factors 'intercorrelate highly'.*
3. Turning to the individual elements, Withdrawal, Need, some aspects of Sali¬
ence, and Relief Drinking form the core of the syndrome, according to the
factor analysis. That Relief Drinking did not belong on the 'core' Guttman
scale is slightly puzzling, though it was significantly related to it (p = .0001).
The other symptoms in that scale were those that might have been predicted
from the factor analysis had it been conducted first.
Impaired control, at least the truly subjective aspects of this sub-element
of the element Subjective Awareness of Compulsion to Drink, formed a dimen¬
sion in its own right. (Passing Out loaded on the first factor rather than the
second and while being an objective index of impaired control — assuming no
subjects like passing out in public — does not strictly reflect Subjective Awareness
of Compulsion to Drink).
Narrowing of Repertoire formed a separate dimension.t
4. It is the Core dimension that is most clearly related to high alcohol consump¬
tion.
* A more prominent first factor might emerge in a more heterogeneous sample (e.g. drawn from the general
population). However Stockwell et al. [3] found a first factor accounting for over 50 per cent of the total variance
demonstrating that, depending on the choice of symptoms, a clear major dimension can be revealed by the
method of principal components analysis even in a sample as homogeneous as patients attending alcoholism
units.
t The separateness of the elements of Impaired Control and Narrowing of Repertoire from the core of the
syndrome was perforce also demonstrated by their lack of association with the 'core' Guttman scale (measuring
degree of severity). 'Core' Guttman scale score against: Unable to keep to a limit \2 = 16.2, 18df, ns. Difficulty
avoid getting drunk: \2 ~ 10.0, 18df, ns; Narrowing of repertoire (day of week) xI = 5.5, 6df, ns; Narrowing of
repertoire (mood): x2 = 9.0, 6df, ns. Also in support of the view that separate dimensions are present are the low
correlations between these four items individually and the individual items loading on the main factor. The
highest for the Narrowing of Repertoire element was between Narrowing of Repertoire (mood) and Missing
Meals (0.22); for the Impaired Control element, between Unable to keep to a limit and Organizing the Day
(0.25).
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Points arising from the nature of the data
What artifacts could have led the Impaired Control items and the Narrowing of
Repertoire items to appear as distinct dimensions?
First, the snare of logical dependence between items, already referred to: At first
glance it seems likely that 'difficulty preventing getting drunk' must be a conse¬
quence of being 'unable to keep to a limit', i.e. logically dependent on inability to
keep to a limit. If this was the case one should find not only a high intercorrela-
tion (which was so, 0.57) but also a paucity of cases where 'difficulty preventing
getting drunk' was acknowledged in the absence of 'inability to keep to a limit'.
This was not the case: 15 out of 45 subjects acknowledged the item 'difficulty
preventing getting drunk' who did not acknowledge 'inability to keep to a limit'.
The Narrowing of Repertoire items could not be perceived as logically dependent:
the 'Day' item was a change from 'drinking more on a day off or weekend than a
weekday' to drinking the same or mpre on a weekday; the 'Mood' item was a
change from having at one time drunk according to mood ('happy, depressed
etc.') to not drinking according to mood.
Second, the problem of Not Applicable (N/A) ratings: For 'unable to keep to a
limit' and 'difficulty preventing getting drunk' N/A (in the past three months)
was rated respectively in 48 per cent and 30 per cent of subjects. Many subjects
said they never set limits and never consciously made a decision to avoid getting
drunk. At one extreme were those who didn't because they knew it was pointless;
and at the other those who didn't because they never perceived any need. This
potential distinction was unfortunately so difficult to pursue in the majority of
those rated N/A that attempts to modify the rating in order to make better sense
of the data were unreliable (between pairs of rater) and therefore abandoned. In
the factor analysis 'N/A' on these two Impaired Control items was entered as
'absent'. Would the analysis have produced a different result if conducted only in
those subjects to whom the questions were strictly applicable (those who had on
occasions in the past three months 'set a limit' or 'tried to avoid getting drunk')?
This proved not to be the case: even amongst these cases, claiming impaired
control did not load on the main factor and again appeared separately. (The
number of cases (48) was however insufficiently large in proportion to the number
of variables (21) for confidence to be laid on this result.)
The same argument does not apply to the two items on Narrowing of Reper¬
toire. Here the proportion of N/A codings was too small to have appreciably
biased the result (7 per cent and 9 per cent respectively).
Third, the problem of operationalising the element of Increased Tolerance requires
separate mention, since the form of the two Increased Tolerance items may have
diminished their loading on the 1st factor. Increased tolerance is not an event,
like 'passing out' or 'experiencing tremor' whose frequency can be counted.lt is a
process of which the individual gradually becomes aware. Subjects were not
asked whether their tolerance had increased by an increment in the past three
months, which was the time period for the other items on the 'recent' analysis. The
items were rated positively if they had ever remarked on their tolerance increasing
or their 'needing' more than their companions. Thus it was possible for a subject
to score on both these items even though his symptomatology in the recent past
had been mild or absent. Indeed, score on the 'core' Guttman scale of recent
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severity was unrelated to either of the Increased Tolerance items
(X2 = 5.5, 6 df, ns; x2 ~ 6.9, 6 df, ns, respectively; n = 36).
No definite conclusions about the place of Increased Tolerance in the range of
items studied here can therefore be drawn from this study, because the items
were not properly measured.
Fourth, the lack of association of Consumption with Impaired Control: was this an
artefact of basing the measurement of consumption on the seven days prior to
interview (or hospital admission)? Perhaps a systematic bias towards associating
consumption with the Core dimension (Factor 1) rather than for example
Impaired Control (Factor 2) might have been introduced if, say, those who
experienced Impaired Control tended to drink atypically little immediately prior
to their first out-patient visit or their admission to hospital. However there was no
relation between the two main items about impaired control, and whether or not
the week of drinking rated was seen by the respondent as 'typical' (including
'more than typical') or not ('less than typical' or 'no such thing as a typical
week'). ('Typical' by 'can't keep to limit': x2 = 1-29 3 df, ns; 'typical' by 'difficult
prevent get drunk:' x2 ~ 1-70 3 df, ns).
Conceptual issues and points arising from the nature of the sample
There are already examples in the alcoholism literature of how easy it is to
demolish your own straw man. Is the unidimensional alcohol dependence syn¬
drome another figment of the quarrelsome imagination of jostling alcohol re¬
searchers? It is beyond doubt that Edwards and Gross foresaw the complexities of
the picture they drew. In defining their use of the term syndrome they stated:
'Not all the elements need always be present, nor always present with the same
intensity' and 'The syndrome must be viewed as subtle and plastic. . . .' [12].
Inconsistent with this version are hints, several times repeated by Edwards
and Gross, and Stockwell et al. [3], of a hypothesis of unidimensionality: 'Each
part of this syndrome relates in some way to each other part'; plus references to 'a
coherent whole' [2]. Indeed Edwards and Gross suggest that 'when the elements
within a story do not add up to a coherent whole most often the doctor has not
taken a sufficiently careful history or the patient is withholding some element of
the syndrome'. Taken too literally that statement would put the Edwards and
Gross description into the realm of the unfalsifiable like certain versions of
psychoanalytic thought whereby uncongenial or missing data are explained away
either as lack of sophistication in the investigator or denial and repression in the
subject.
The Edwards and Gross description does not belong in the realm of the
unfalsifiable and it is legitimate to ask of the present study: did the doctor take a
sufficiently careful history? (were the elements adequately operationalised?) and/
or was the patient withholding something? (were the subjects minimising or
lying?)
It remains for the proponents to decide the first, and if necessary do better;
there is no doubt that certain concepts are awkward to operationalise, in particu¬
lar impaired control and narrowed repertoire, the two elements which most
clearly did not fit. For impaired control this is probably mostly due to the difficul-
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ties of operationalising a concept which has recourse to the realm of intention and
the will.
If subjects minimised or lied, they did not lie in a way that is consistent with
prevailing notions of alcoholic denial. That is, of the two elements that most
clearly did not fit, one is not commonly regarded by the lay population as a
symptom of alcoholism (narrowed repertoire - in terms of day of week and mood)
[14], The other (impaired control) is part of the folk beliefs about alcoholics [14]
and therefore, on the alcoholic denial theory should be acknowledged more read¬
ily by those who have agreed to define themselves as alcoholics than by those who
have not. Thus, at a given level of severity, impaired control items should be
more frequently acknowledged by those who self-identified as alcoholics. This was
not the case for this sample [14].
Another possible reason for the separateness of the Impaired Control element
is that only the subject who had on at least one occasion done something about
his drinking would have had the intention to exert control over his intake, and
that also such individuals would have recently been drinking and experiencing
symptoms in an atypical way - on and off. The data do not support this view:
acknowledging impaired control did not relate to degree of previous contact with
agencies etc., whether individuals to whom these items did not apply were
deemed not to have the item or were excluded from the analysis. ('Previous
exposure' by 'can't keep to limit' (N/A ='Absent') x2 ~ 5.9, 9df, ns, n = 97;
(N/A excluded) x2 = 7.2, 9 df, ns, n = 47; 'Previous exposure' by 'difficult avoid
get drunk' (N/A = 'absemt') x2 = 15.2, 9 df, ns, n = 97; (N/A excluded) x2 — 9.6, 9
df, ns, n = 65.)
Conclusions
The activities of the Society for the Prevention of Cruelty to Dead Horses are
secret. Members of the Society claim that the old doctrines of their disciplines
(such as 'classic Marxism' or 'pure behaviourism' or 'the disease of alcoholism')
are dead. They request us to refrain from flogging poor dead animals, but surrep¬
titiously re-erect the doctrine in a new guise. Is this why Impaired Control is to
be found in the reformulated alcohol dependence syndrome, so that the condition
may remain in the realm of disease (by virtue of being 'beyond the will') and the
preserve of a chauvinist medical profession? That debate grows tedious. But here
is a study which finds that if a unidimensional syndrome exists, it comprises
Withdrawal; Subjective Need; aspects of Salience; and probably Relief Drinking
and Increased Tolerance; — at least, among the patients at a Scottish alcoholism
treatment unit. This finding is compatible with that of Stockwell et al. [3].
The argument is not that Impaired Control* is not experienced by some
'problem' drinkers (and some 'normal' drinkers too [17]), but that it is not part of
the core of the syndrome. That two elements form separtae dimensions away
from the core dimension is not evidence against the syndrome per se. This finding
* For some individuals, impaired control may best be understood as a post hoc explanation for problematic
drinking, part of the 'search after meaning'. This would account for the findings of reliable investigations of
temporal ordering of symptoms in non-ideologically biased samples: namely that Impaired Control items tend to
be placed at the beginning of a patient's sequence, if indeed he has chosen to acknowledge those items [16].
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does however suggest a need to adjust the description of the syndrome. It also has
implications for its measurment, particularly the measurement of its severity.
This is the subject of a further paper [18].
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Application to the alcohol dependence
syndrome of a method of determining the sequential
development of symptoms
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Edinburgh, and the Department ofStatistics, University of Edinburgh
synopsis Temporal ordering of core items in the alcohol dependence syndrome was investigated
in 38 men admitted to an alcoholism treatment unit. An analysis of rank sums yielded a modal
sequence which resembled classical descriptions of alcoholism, though Toss of control' appeared
very early.
INTRODUCTION
A recent WHO report has drawn a theoretical
distinction between an alcohol dependence syn¬
drome and disabilities related to alcohol con¬
sumption (Edwards et al. 1977). Classical descrip¬
tions of alcoholism, for example by Jellinek
(1952), had included a wide range of items which
referred to social consequences, symptoms of
mental disorders, self-concepts, and attitudes to
drinking and seeking treatment. The departure
in the WHO report from this classical description
has empirical as well as theoretical support. In
population surveys (e.g. Knupfer, 1967) and in
samples of alcoholics (Chandler et al. 1971)
social damage from alcohol and dependence on
alcohol are not inevitably associated. When the
sequential development of symptoms in alco¬
holics was analysed by Orford & Hawker (1974)
it was found that items related to social damage
did not occur predictably at any stage of the
process. Some degree of order emerged, however,
when items related more closely to dependence
were examined.
An account of alcohol dependence is needed
which is less encumbered by the conceptually
distinct area of social consequences and personal
attitudes. Edwards & Gross (1976) provided 'a
provisional description' of the syndrome, point-
1 Address for correspondence: Dr J. Chick, MRC Unit for
Epidemiological Studies in Psychiatry, University Depart¬
ment of Psychiatry, Royal Edinburgh Hospital, Edinburgh
EH10 5HF.
ing out that, among other types of elaboration,
studies of its natural history were required.
The present paper concerns an analysis of the
temporal relationship of 23 items, loosely based
on the Edwards & Gross description of alcohol
dependence. (A subsequent paper will report on
the scalability of this set of items.) There could be
practical benefits in demonstrating a typical se¬
quence of development of symptoms of alcohol
dependence, for example to health educators or
to epidemiologists wishing to identify 'early
cases'. In alcoholism research, a demonstration
of an orderly sequence of symptoms has also
been sought for a theoretical purpose: to bolster
the proposition that alcoholism is a tangible
phenomenon rather than a social label.
The work of Trice & Wahl (1958), Park (1973),
Park & Whitehead (1973) and Orford & Hawker
(1974) on the developmental ordering of symp¬
toms has, on the whole, supported Jellinek's
original claim that there was an order, though
small discrepancies were found in all the studies,
for example, in the relative position in the order
of 'morning drinks' and 'amnesias'. Park and
Orford & Hawker imply that, if items related to
a core syndrome were studied, then a more defi¬
nite process might emerge. Our study has tried to
restrict itself to studying core items.
The aims of the study were first to determine
whether there were systematic deviations from
randomness in the orderings of the items pro¬
duced by alcoholics, and secondly to derive a
0033-2917/79/2828-3930 $01.00 © 1979 Cambridge University Press
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typical sequence capable of describing these
deviations.
METHOD
The sample was 38 consecutive male admissions
to an alcoholism treatment unit who were aged
65 or below and who one week after admission
exhibited no clinical evidence of memory impair¬
ment or dementia. Their ages ranged from 21 to
65 years. Twenty-seven (71 %) claimed they
would describe themselves as alcoholics, and they
all had been diagnosed to be alcohol dependent.
As a rough indication of their exposure to beliefs
about alcoholism they were asked about their
reading and their contact with agencies. For
about a quarter, it was their second admission.
A further 40 % had had at least one appointment
as an out-patient or with their family doctor to
discuss their drinking. Of these, a few had read
books or pamphlets on alcoholism; 2 had had
sporadic contact with Alcoholics Anonymous
and 3 had at one time attended A.A. regularly.
Fourteen men (37 %) could be regarded as
'unexposed to beliefs about alcoholism'.
A structured interview1 was administered ap¬
proximately one week after admission by a psy¬
chiatrist not involved in their treatment and
without previous knowledge of them. The 23
items had evolved through extensive pilot work
and were closely defined in guide notes to avoid
the ambiguity and vagueness which line the well-
trodden paths of alcoholism questionnaires.
Wherever possible before a respondent scored on
an item he was asked to recall an example. The
items are listed in Table 1.
Eliciting the sequence
Previous investigations of sequencing (Jellinek,
1946; Trice & Wahl, 1958; Glatt, 1961; Park,
1973; Orford & Hawker, 1974) required re¬
spondents to recall their age when the item began
to happen (Orford & Hawker were more specific
in asking for 'age of first occurrence'). None of
these papers report on the reliability of this
method. Subjects in our own pilot studies found
it very difficult to recall age but found it easier to
offer an ordering of items. Another objection to
the method used in the 4 earliest studies quoted
1 Available from the authors.
was that the items were presented on a list given
to the subject. The ordering on the list was
plainly not random and may have suggested a
sequence to the respondent.
Our method was to hand the subject at the end
of the structured interview a pile of cards each
naming an item he had acknowledged. The pile
was shuffled so that he received the cards in a
random order. He was told:
We are interested in the way people's drinking
changes over the years and in which experiences tend
to come before others. On these cards are some of the
things you mentioned had happened to you. Put them
in order so that the things which happened earliest
are at the top and so on. Do it according to when the
particular item first happened. If two or more items
seemed to happen at the same time so that you can¬
not separate them in your memoiy, place them side
by side.
Subjects found this task easy. The interviewer
only intervened if a respondent asked or seemed




An assessment was made of the degree of agree¬
ment between 2 clinicians interviewing con¬
jointly but rating independently. The clinicians
had to decide whether each item was present or
absent or, in the case of some items, not applic¬
able. ('Not applicable' was treated as 'absent'
for the analysis of reliability.) Twenty-six sub¬
jects were interviewed conjointly. Five clinicians
took part in the exercise.
(b) Of eliciting the sequence
Seventeen subjects were re-interviewed after an
interval ofone week. They were presented with the
subset of items they had ordered a week pre¬
viously and asked to place the items in order on
the same basis as the first occasion. They were
told that this was a check on the method, not on
their memory.
Analysis
As will be seen later, the results of the reliability
study of the items themselves were so unequivocal
as not to require analysis. The test-retest relia-
Alcohol dependence syndrome
Table 1. 23 items comprising a structured interview into alcohol dependence
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Change to drinking same on a work day as a day off
Change from drinking according to mood to not drinking according to mood
Giving up interests because drinking interferes
Missing main meals regularly because of drinking
Spending more time drinking
Restless without a drink
Times when can't think of anything else but getting a drink
Organizing day to ensure supply
Needing more than companions (getting a start on them or going for a drink
between rounds)
Completely unable to keep to a limit
Difficulty preventing getting drunk
Difficulty cutting down
Passing out while drinking in public
Trembling after drinking the day before
Morning drink
Morning retching or vomiting
Wakening up panicking or frightened




(Drinking related experiences not central to the alcohol dependence syndrome)
bility of the method of eliciting the sequence was
examined by calculating Spearman's coefficient
of rank correlation within each subject on the
rankings of the items on the 2 occasions.
The analysis of the full set of patient responses
proceeded by a test of the hypothesis of random¬
ness. Had each patient ordered all the items,
Kendell's coefficient of concordance would have
provided a satisfactory method of analysis and
an ordering could have been obtained from the
rank sums associated with each item. However,
in view of the missing data resulting from patients
not experiencing all the items, a modification of
this method was used (Bernard & van Elteren,
1953). This test uses the information in the data
set as a whole and takes account of missing
values and ties. There is, however, no description
of an ordering method in the work of Bernard &
van Elteren, but their procedure suggested such a
technique which is now briefly described.
The rank of each item in a patient's sequence
was calculated, the earliest item experienced
being given a rank of 1. Then the average rank of
the items within that patient's sequence was sub¬
tracted from that of each item in the same se¬
quence to give a reduced rank. These were then
summed for each item over all patients, and the
resulting sums were divided by their null hypo¬
thesis standard deviation given by Bernard & van
Elteren. This gave the 'criterion value' for each
item. The rank order of these values was the
'modal ordering'.
There is an element of arbitrariness in this
procedure, as will be discussed later. It was
therefore thought desirable to reanalyse the data
by a modification of the same method due to
Prentice (1977) for purposes of comparison.
Essentially this method involves scaling the re¬
duced ranks of a subject in proportion to the
total number of items ordered by that subject and
proceeding as before, although the variance of
the sums of scaled reduced ranks is rather differ¬
ent. While this method has improved statistical
properties, its chief attraction is the intuitive
appeal of scaling the reduced ranks.
Finally, Spearman rank correlations of the
sequences obtained from each of the subjects,
with the ranks of the items in the modal order
(obtained by the method of Bernard & van
Elteren), were calculated.
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RESULTS
Reliability of items
All of the 23 items were assessed as present in
some of the subjects. Table 2 expresses the relia¬
bility of the assessment of presence/absence in
each of the items in terms of amount of agree¬
ment attained between the 2 raters.
Reliability of patients' assessments of sequence
Seventeen Spearman rank correlation coefficients
(corrected for ties) were calculated, one for each
of the subjects. These ranged in value from 0-34
(Ni = 10) to 1-0 (A) = 4) with median value
0-75 (Ni = 8). All but three of these were signifi¬
cantly different from zero at or beyond the 5 %
level. The number of items (Aj) in the sequences
of the subjects ranged from 2 to 16.
Tests of randomness
(a) The method of Bernard & van Elteren
(1953) gave a value of the test statistic of 81-2
which, assuming the asymptotic distribution
applies, is a realization of a x2 variable with
22 degrees of freedom. This result is extremely
significant (P <^0-01).
(b) Applying the modification due to Prentice
(1977) yielded a test statistic value of 75-4 which
again, assuming the x222 distribution, is ex-
temely significant.
Orderings
The modal orderings obtained by the 2 methods
are displayed in Table 3. The frequencies with
which individual items were rated present are
shown, along with their criterion values. The
Spearman coefficient of rank correlation between
the 2 orderings is 0-98.
'Post hoc' correlation study: between individuals'
sequences and the modal ordering
These correlations ranged in value from —0-56
to 1 00. Eight of the 38 coefficients were negative.
The median value of the set of correlations was
0-50.
DISCUSSION
The reliability of the findings will be discussed
first, followed by the discussion of the main
study. Before commenting on the interpretation
of the results, there will be a brief explanation of
the factors governing the choice of methods of
statistical analysis.
(a) Reliability
Inter-rater agreement on presence/absence of
items was so high as to render statistical analysis
superfluous. The limitation placed on assessing
the statistical significance of the within-patient
tesi-retest study of ordering was that the number
of items ordered by the subjects varied between
subjects.
All 17 test-retest correlation coefficients were
positive, and all but 3 of these were significantly
different from zero. Since these are rank corre¬
lations and often calculated on small numbers, it
is not surprising that a few of the coefficients
Table 2. Inter-rater reliability (expressed as %
agreement) for 23 items in 26 subjects
Item % agreement
B, G, /, M, K, L, U, V 100
c, E, F, H, J, N, S, Q, X, Y 96
A, D, P, T, R 92
Table 3. Typical ordering of 23 symptoms ob¬
tained by 2 methods of analysis in 38 male
admissions to an alcoholism unit
Bernard & van Elteren Prentice modification
Symptom Frequency Criterion Symptom Criterion
/ 18 -3-34 / - 3-18
H 22 -317 H -3-07
J 17 -2-24 J -2-20
Y 15 - 1 -76 D — 1-71
D 26 - 1-72 X — 1 -41
X 35 - 1-53 Y -1 -28
K 12 - 1-35 K - 1-03
C 17 -0-87 C -0-78
E 14 -0 82 E -0-70
A 8 - 0-21 T -0-22
G 21 019 P 0-36
B 3 0 24 G 0-38
T 25 0-37 B 0-38
P 10 0 53 A 0-47
L 32 103 L 0-77
F 25 103 F 0-88
N 28 1 -44 N 0 99
S 21 1 -45 S 1-26
u 1 1 -60 u 1-60
M 30 207 M 2 11
Q 11 2-50 Q 2-67
R 9 2-89 R 2-94
V 8 3-91 V 3-81
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were not large. In summary, the method appears
tolerably reliable.
(b) The ordering of items
The main analysis of the item orderings was
determined by the nature of the data and the
alternative hypothesis, that is, the null hypo¬
thesis of randomness. In the present study, the
null hypothesis of randomness was initially to be
tested against the general alternative (i.e. un¬
specified 'non-randomness') whereas Park (1973)
explicitly tested against the alternative of specified
order, that being the ordering due to Jellinek
(1952). Orford & Hawker (1974) performed a
number of trinomial tests for sequencing deter¬
mined by their data on mean age of occurrence.
One limitation of the tests used by Park (1973)
and Orford & Hawker (1974) is precisely their
plurality, giving rise to many statistics and as¬
sociated significance levels with consequent
difficulties in their overall interpretation. Further,
these writers considered items in pairs, whereas,
of course, items do not arise naturally in pairs in
the data. There is a degree of arbitrariness in such
assessment, for in general one could consider
items in sets of any size, the mathematical theory
being given by Wormleighton (1959). An as¬
sociated difficulty in examining items in pairs is
that the ordering relationships established are
not necessarily transitive. That is, for example,
that for 3 items A, B and C ordered by 10 subjects
it might be that A precedes B in 6 subjects, B
precedes C in 6 subjects but C precedes A in 8
subjects as follows:
ABC ABC BCA BCA BCA BCA
CAB CAB CAB CAB.
'Missing' data in the sense that not all subjects
order the same number of items can only aggra¬
vate the difficulties already mentioned.
The unmodified method of testing the null
hypothesis in this study circumvents difficulties
of interpretation by giving rise to only one test
statistic and being designed for the analysis of
incomplete data sets. Despite the distribution of
the statistic depending on an asymptotic argu¬
ment requiring the number of subjects to be
'large', it is clear that the high values observed
are extremely significant (even if the exact-small-
sample distribution is rather different from that
given by the asymptotic approximation).
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The ordering method used is an ' ad hoc' pro¬
cedure (as, indeed, are those of earlier writers on
the same topic). It was adopted, as mentioned
earlier, because it arose naturally from the
Bernard & van Elteren test, and it is reasonable
to assume that some of the advantages of the test
apply also to the ordering procedure, in particu¬
lar the inbuilt capacity to take account of missing
values. There are methods in existence for ob¬
taining orderings based on maximizing 'objec¬
tive' criteria which are capable of more detailed
specification than the present criterion; for ex¬
ample, Tate (1961) gives one such method which
was used in the analysis of the sequence of bone
development in the foetal foot. However, the
appropriateness of any particular criterion, no
matter how clearly it may be defined, will always
be a subject for argument. In the present case,
the adjustment of Tate's criterion to take account
of missing values would necessarily be arbitrary.
Even if such adjustment were made, the only way
to establish which ordering of symptoms was
most satisfactory would be to consider all pos¬
sible orderings and select the one which yielded
the maximum value, a Herculean task, involving
considering 23! orderings.
It can be seen, therefore, that our method of
analysing ordering is far from unique, and it
would thus be wrong to draw conclusions too
firmly, especially about the relative ordering of
items with similar criterion values - e.g. C,
'giving up interests', and E, 'restless without a
drink'. However, it seems unequivocal, particu¬
larly on comparing the results of the modified and
unmodified analysis, that there does exist an
ordering and that items could be said to fall into
early, middle and late categories. The sequences
obtained by the 2 methods are very similar, with
the major differences occurring in the central
part of the sequence where, in any case, the
differences between values of the criteria are
small.
We turn now to the form of the modal ordering
itself, generated by this analysis. This ordering is
not to be interpreted as the sequence of symp¬
toms that most alcoholics follow, because not all
alcoholics will experience all symptoms. Nor
does it imply that later symptoms inevitably fol¬
low if early symptoms have been experienced
(which the downward gradient of the well known
'Glatt chart' symbolizes). Our modal sequence
states only that, if a man experiences symptoms
PSM 9
318 J. Chick and J. C. Duffy
x, y and z, they will tend to occur in the order
suggested by the sequence.
Two 'loss of control' items, / and J, appear
early. Other early symptoms are features of
'salience' (Y, 'spending more time drinking',
and D, 'miss main meals regularly because of
drinking'), and 'needing more than companions'
(//). Late symptoms are predominantly features
of physiological withdrawal: trembling, morning
nausea, sweats, morning drinks, panics and
hallucinations.
In the classic description of alcoholism based
on the self-selected Alcoholics Anonymous mem¬
bers studied by Jellinek (1946), loss of control,
while still preceding symptoms of physical addic¬
tion was a middle-stage experience. Indeed, it
came to be seen as the hallmark of the fully
developed disease (Keller, 1972). In the present
study, 'being sometimes completely unable to
keep to a limit' (/), which was acknowledged by
about half the sample, typically preceded the
first experience of amnesia (X) and anticipatory
drinking (H).
Our result is closer to that of Orford &
Hawker (1974) who found that the item
'when you started drinking you found you
couldn't stop' clustered with early items which
they grouped as representing 'psychological
dependence'.
There is, however, a Toss ofcontrol' symptom,
P (' passing out while drinking in a public place'),
which was a middle-stage experience. The find¬
ings support the view of Storm & Cutler (1975)
that there are degrees of impaired control. While
it may be extremely difficult for certain alco¬
holics to keep to their intentions regarding their
drinking by the time they have developed physi¬
cal dependence, a degree of'difficulty' will have
been experienced for much longer.
It could be argued that our subjects' recall of
their earlier experiences was markedly influenced
by 'search after meaning'-the tendency to re¬
construct past events to help explain subsequent
experience. Then it would be understandable that
those individuals who saw themselves as being
unable to control their drinking would have
placed this at the beginning of theirhistories,asan
explanation of all that followed. This is possible,
though each subject was encouraged to lay out
his sequence by recalling specific incidents.
Secondly, if this process is an important influence
on recall, it is strange that it could not be detected
also in the earlier work on sequencing by
Jellinek, Glatt, Trice & Wahl and Park.
Attention to the position of certain individual
items should not obscure the overall similarity
between these results and the classical descrip¬
tions of alcoholism. Physiological dependence as
indicated by the 'withdrawal' items tends to fol¬
low a period in which alcohol is becoming more
salient in the individual's life, a sense of increas¬
ing need is noticed, and for some, a loss of flexi¬
bility in the pattern of drinking has occurred.
This study has replicated, using more reliable
methods of data collection and simpler, more
appropriate, analyses, much of the findings of
previous workers.
The overall similarity with previous findings
cannot be attributed to sampling, like Jellinek,
members of Alcoholics Anonymous (a self-
selected group possibly conforming to a stereo¬
typed view of their condition). The present
sample of 38 contained only 3 regular A.A.
attenders plus 2 who had attended occasionally.
The purpose of the post-hoc correlation study
was to assess the degree to which the modal
sequence generated by the method resembled the
sequences provided by the subjects. As would be
expected, because the data demonstrate a syste¬
matic tendency to ordering, most of the correla¬
tions were positive and half were above 0-5. That
some of the correlations were low or negative is
important. Two possible explanations for this are
as follows.
First, perhaps not all of the 23 items possess a
tendency to ordering. Those that did not would
be 'noisy' and subjects who had experienced
many of them might well show low or negative
correlations with the modal ordering. (Unfor¬
tunately we do not yet know which items, if any,
are these 'noisy' items.)
Secondly, perhaps not all individuals share the
syndrome which has been assumed common to
all; or they might have a variant of the syndrome.
Examination of the drinking histories and social
characteristics of the 8 patients with negative
correlations (the patients with 'atypical' se¬
quences) did not show any obvious common
characteristic. Three of the 8 had been classified
as 'restrained' drinkers (did not acknowledge /,
unable to keep to a limit; J, difficulty preventing
getting drunk; or P, passing out); there was only
one other patient in the sample of 38 who was a
'restrained' drinker. Thus, 'restrained' drinkers,
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uncommon in the sample as a whole, were over-
represented in the group with atypical sequences.
However, the remaining 5 with atypical se¬
quences acknowledged a wide range of items and
no common thread linked their drinking his¬
tories. Occupational status and living group did
not distinguish the atypical patients, nor did
failing to self-identify as an alcoholic or lack of
previous exposure to beliefs about alcoholism.
Edwards & Gross (1976) suggest that the syn¬
drome of alcohol dependence 'must be pictured
as subtle and plastic'. Perhaps it should be ex¬
pected that there would be some patients who
show considerable, idiosyncratic, variation from
the modal sequence.
CONCLUSIONS
A reliable method of eliciting the developmental
sequencing of a set of items believed to refer to
the core alcohol dependence syndrome yielded a
sequence which was not random. A modal order
of items was generated. Among men admitted to
a Scottish Alcoholism Unit, the early items in the
modal order refer to impaired control on single
drinking occasions, feelings of need for alcohol
and increasing salience. The late items, as ex¬
pected from earlier work and clinical experience,
refer to withdrawal symptoms. This study says
nothing about the inevitability or otherwise with
which the sequence is followed in a given indi¬
vidual once the early items have been experi¬
enced. Some individuals deviate from the modal
sequence and possible reasons for this are
explored.
We wish to thank the patients and staff at the Unit
for the Treatment of Alcoholism at the Royal Edin¬
burgh Hospital for their kind cooperation and Dr
N. Kreitman, Dr M. Malone, Dr J. Dyer and Dr L.
Whalley for their help at various stages in the study.
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Summary
Thirty-one per cent of survey respondents asked about their last week's
drinking claimed it was atypical. They are shown, by examining their levels
on two blood tests (mean cell volume and gamma-glutamyl transpeptidase)
and by a comparison of their consumption on a recent social occasion with
that of their companions, to be reporting a trivial difference between their
last week and their typical week and appear to be attempting to deny heavy
habitual consumption.
Key words:
Some workers use as a measure of consumption self-reported drinking
during a recent fixed period — past seven days as in several British surveys, or
past month as in some Scandinavian surveys. A proportion of respondents
report that this period was not typical, and Dight [1], in a Scottish
population survey, found that the number of people reporting last week's
consumption was more than usual is greater than the number reporting it
was less than usual. She had avoided interviewing near to festivals and
concluded that some of those who claimed last week's drinking was more
than usual were people who wished to play down their consumption or were
evasive, and were wrong in saying it had been "more than usual".
This conclusion allowed Dight, and has allowed others, conveniently to
ignore the possibility that for some survey respondents the past week's
drinking is an unreliable indicator of recent, or "usual", consumption. Those
who claimed last week's drinking was more than usual reported higher
weekly totals than the average respondent, and Dight tentatively concluded
that such respondents were drawn disproportionately from among the heavy
♦Presented at the 10th ICAA Institute on Prevention and Treatment of Drug Depen¬
dence, Cardiff, Wales, Gt. Britain, 1980.
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consumers. It is, of course, the heavy consumers that surveyors are usually
most interested in. The validity of interview data on alcohol consumption is
a matter of the utmost concern to survey methodology.
In this paper, two blood measures are used as tests of the validity of the
claim that last week's drinking was "atypical". These are MCV (mean cell
volume) and serum gamma-GT (gamma-glutamyl transpeptidase), established
indicators of consumption in the general population [2 - 4]. Drinking
alcohol (0.75 g/kg body weight) on as few as three consecutive evenings may
produce a short-term rise in gamma—GT in some individuals. The elevation is
slight, however, unless drinking is repeated at weekly intervals for 3 - 4
weeks [5]. To the authors' knowledge, such short-term elevations of MCV
have not been reported. That elevations from short periods of drinking are
trivial is suggested by the finding that in alcoholic patients the length of a
current drinking bout is strongly related to elevation of gamma-GT, inde¬
pendent of blood alcohol concentration at admission, with bouts of less than
2 weeks' duration being associated with a mean gamma-GT within the
normal range [6]. The substantial elevations in these tests found in habitual
heavy drinkers take 2 - 6 weeks to return to normal, depending on the extent
of the elevation, and probably are slower for MCV than gamma-GT [7 - 9].
Hypotheses
(1) If the difference between "usual" and "last week's" drinking is real
and important, then the following predictions can be made:
(a) Respondents who claim that last week's drinking was more than
usual should more often than respondents who say that week was "typical"
have a gamma-GT and/or MCV lower than their last week's consumption
would have predicted had it been their habitual level. This follows from
assuming that the blood tests chiefly reflect consumption in the preceding
2 - 6 weeks. If the past 7 days had truly been unusually heavy this is unlikely
to have yet expressed itself significantly in the blood tests. The converse of
this prediction should hold in those who claim that last week's drinking was
less than usual.
(b) Since there is a strong tendency for people to drink the same on an
occasion as their companions drink (see for example, refs. 1 and 10) then
those who said they drank more than their usual in the last 7 days might be
expected to have drunk more than their companions at the social gathering
they most recently attended. (This prediction assumes that on the whole the
last social gathering was typical for them, whereas perhaps the explanation
of their recent atypical drinking was their unexpected immersion in a heavy
drinking set — a possibility that will be explored.)
(2) If claiming last week's drinking was more than usual represents
evasiveness, such respondents might be expected to refuse a blood sample at
a survey interview more often than others and to have been regarded by the
survey interviewer as uncooperative.
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Method
The subjects were manual workers drawn from pay-rolls of breweries
and a distillery (sampling described in ref 31) and senior company
executives drawn from lists of names in local directories. Completed
interviews were obtained from 79% of the combined samples: 318 manual
workers and 298 executives.
The interview was a 40-minute standardised enquiry into work, life¬
style and health. No interviewing was conducted near to festivals. A self-
completed "personality" form was administered*. At the end of the
interview, the rater recorded whether the subject had been "cooperative" or
not.
Eliciting consumption
The past 7 days' consumption was obtained as part of a description of
work and social events in that week. All subjects were asked to say if that
week's consumption was typical, and, if not, whether it was more or less
than usual. They could, however, be coded as saying they had "no typical
week". Information was elicited about the last social occasion when they
met socially (i.e. not for business or at work) with two or more other adults.
A blood samples was requested at the end of the interview; 92.4% of
the alcohol production workers and 89.1% of the directors interviewed
agreed to the blood test. The correlation in the whole sample of past week's
consumption with gamma-GT was 0.35 (n = 507) and with MCV 0.34 (n =
498, controlling for age). (MCV was measured by Coulter Counter and
gamma-GT by the method of Rosalki and Rau [12].)
Analysis
To test hypothesis la the regression of the past week's consumption on
each of the blood tests was computed. Subjects who had provided a blood
sample were divided according to whether their blood test was above or
below the regression line. Subjects who claimed they had no "typical week"
amounted to 4.6% of those from whom a blood sample was obtained. They
are excluded from all tables and analysis. Also excluded are subjects who
were taking drugs such as anticonvulsants or had a physical illness which
might have caused abnormality in either of the blood tests. There is a slight
discrepancy in the number of analyses between the gamma-GT and the MCV
computations because some MCV analyses were not performed owing to
leaking tubes or delay reaching laboratory.
Of the alcohol production workers 246 were manual workers from two
firms where a high response rate had been obtained. The remainder were
♦This consisted of 14 items with high face validity designed to measure the
dimensions of rebelliousness, extraversion, impulsiveness, rigidity and "personal care".
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either non-manual workers or were from two low-response-rate firms. Except
on the analyses of blood test data the analyses will be presented separately
for directors and for alcohol production workers, the latter including only
those manual workers from high-response-rate firms, to improve the homo¬
geneity of the samples.
Results
i
As Dight found, those who claim last week's drinking was more than
usual tend to report a week that was heavier than other respondents (Table
1).
TABLE 1
Self-reported consumption in past week by typicality of past week
Consumption is expressed in units [1 unit = 8 grams of alcohol (1 cl)]
Last week Last week Last week
"more than usual" "typical" "less than usual"
Alcohol production workers
0 0 (-) 18 (10%) 2
1 - 10 2 ( 6%) 34 (18%) 3
11 -40 20 (62%) 76 (41%) 9 61%
41 + 10 (31%) 58 (31%) 4
32 186 18
Mean consumption 42.5 37.9 28.9
Directors
0 0 14 ( 8%) 5 (19%)
1 - 10 17 (20%) 41 (24%) 6 (22%)
11 - 40 44 (52%) 76 (50%) 11 (41%)
41 + 23 (27%) 38 (22%) 5 (19%)
84 169 26
Mean consumption 34.3 30.2 23.3
TABLE 2
Distribution about the regression line of gamma-GT on consumption by typicality of past
week's drinking
Gamma-GT Gamma-GT
below regression line above regression line
Last week "typical" 290 (69%) 131 (31%) Raw X2 c
Last week "more than usual" 95 (73%) 35 (27%) 0.83 n.s.
Last week "less than usual" 37 (69%) 17 (31%)
For the whole table:
raw x2 = 0.87 n.s.
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TABLE 3
Distribution about the regression line of MCV on consumption by typicality of past
week's drinking
Last week "typical"
Last week "more than usual"
Last week "less than usual"
For whole table:
raw x2 = 2.13 n.s.
MCV MCV
below regression line above regression line
257 (61%) 164 (39%) Raw X2 =
70 (54%) 60 (46%) 2.13 n.s.
32 (58%) ( 22 (42%)
TABLE 4
Consumption relative to male companions at last social occasion by typicality of past
week
Last week Last week Last week Total
"more than usual" "typical" "less than usual"
Alcohol production
workers
Drank more than 2 ( 6%) 14 ( 8%) 1 - 17 ( 7%)
companions
Same 24 (77%) 116 (64%) 11 (61%) 151 (66%)
Less 5 (16%) 50 (27%) 6 (33%) 61 (27%)
31 180 18 229
Directors
Drank more than 8 (10%) 5 ( 3%) 1 ( 2%) 14 ( 5%)
companions
Same 58 (70%) 110 (70%) 13 (48%) 181 (67%)
Less 17 (20%) 47 (29%) 13 (48%) 77 (28%)
83 162 27 272
Hypothesis la
Tables 2 and 3 show that those who claimed last week's drinking was
more than usual did not tend to have blood tests below what would have
been expected on the basis of their report of the past 7 days' drinking; nor
was the converse true for those who claimed their last week's drinking was
less than usual.
Hypothesis lb
Table 4 refers to consumption at the last social occasion. Subjects were
asked whether they drank the same, more, or less than the mean of their
male companions. Usually this necessitated recalling the consumption of
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each of their companions and calculating the mean, and comparing it with
their own consumption on that occasion.
Table 4 shows that whereas few drank more than their companions
many claimed to have drunk less! There was, however, only a slight trend for
those who reported last week was "more than usual" to have drunk more
than their companions, and this occurred only in the directors (10% of the
"more than usual" group as opposed to 5% for the whole directors sample).
It was not the case that this subgroup of directors had on that occasion
been unusually immersed in a heavy drinking environment. Table 5 shows no
trend for "last-week-more-than-usual" directors to have described that most
recent social occasion as a session at which the average drunk by male
companions was especially high.
TABLE 5
Average consumption of male companions at last social occasion by typicality of past
week
Values are companions' average units [1 unit = 8 grams of alcohol (1 cl) ]
Last week Last week Last week
"more than usual" "typical" "less than usual'
Alcohol production
workers
<6 8 (28%) 41 (23%) 5 (28%)
7 - 11 11 (35%) 72 (41%) 7 (39%)
12 + 12 (39%) 64 (36%) 6 (33%)
31 177 18
Companions' mean 7.2 6.9 6.8
consumption
Directors
<6 46 (58%) 106 (64%) 12 44%
7 - 11 29 (36%) 46 (28%) 13 (48%)
12 + 5 ( 6%) 14 ( 8%) 2 ( 7%)
80 166 27
Companions' mean 5.15 4.9 5.6
consumption
Hypothesis 2
Of those who claimed that their last week's drinking was more than
usual, 9.2% refused the blood sample, whereas the proportion of those who
said last week's drinking was typical was 8.1% a trivial difference. There were
20 subjects rated as "uncooperative". They did not fall disproportionately
among the group who claimed their last week's drinking was more than
usual (x2 = 0.79 n.s).
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Conclusions
The blood tests are rough indicators of consumption. The blood test
analysis, taken together with the finding that those who claimed to have
drunk more than usual in the last week did not in general drink more than
their companions at the last social occasion, point to one of two
conclusions: either (1) these people are truthful in reporting taht their last
week's consumption had been atypical, but the difference between that and
their habitual consumption is trivial, or (2) they wish to deny being habitual
"heavy" drinkers because of embarrassment. (It is embarrassment rather
than evasiveness: they are not so blatant as to refuse the blood sample or be
uncooperative.)
It is interesting that the proportion of the directors who claimed last
week's drinking was more than usual was significantly greater than the
proportion in this catagory amongst the production workers (30% as
opposed to 14%, p < 0.001). We know from our other work that when an
individual's past week's reported consumption is "corrected" according to
his blood tests, the necessary adjustment is greater for directors than for
production workers [13]. It appears that it is more important for the
directors than the production workers to give a favourable impression.
None of the self-ratings of "personality" was related to typicality of
the past week's drinking.
This study should not be interpreted to mean that our sample has been
shown to be accurate in their self-reports. Our regression lines of
consumption against blood tests was obtained from within the sample, not
using an external criterion; thus self-report cannot be validated absolutely.
Rather our study shows that it is permissible to ignore in aggregate analyses
claims that last week's drinking was atypical. Widespread underreporting,
one of the thorns in the alcohol surveyor's flesh, is possibly still present in
our spmple.
The reasons why some individuals claim their recent drinking was
atypical when perhaps it was not, remains to be investigated. It is probably
a way of "saving face", so as not to appear an habitual drinker, and appears
to be more frequently used by those of relatively higher social status.
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Alcoholism Treatment Evaluation:
the Drop out Dilemma*
Jonathan Chick
Key words: alcoholism, treatment, evaluation; drop out; lifetime analysis; in¬
tention to treat principle
Summary
Patients requesting help for alcohol problems often do not follow the allocated
treatment. This occurs frequently also even in the studies where consent to partici¬
pate has been given. Also, in the studies they may be withdrawn from the treatment
because their condition is not improving or worsening, or because of the adverse
effects thought to be due to the treatment, or patients cease attending and the
contact may be lost.
Outcome data may be available however on 'drop-outs' of either type, selected
systematically or through other channels. The researcher has a dilemma: whether
or not to include those patients in the analysis of outcome. If they are omitted,
some of the advantages gained by random allocation to different treatment groups
may be lost, as happened in a recent rendomized controlled trial of tiapride in
alcoholism, when amongst study completers the groups were no longer matched
on the important social parameters. If they are included, is it unfair to the treat¬
ments) being tested because some patients have had little if any of the treatment?
This could be especially important with a treatment that only begins to show its
therapeutic effect after, say, a month.
Life table analysis permits data on patients to be included for as long as data are
available, up to an agreed point (take a drink/relapse into problem drinking/with¬
drawal from the study, etc.). But, clinical experience is that patients taking a
treatment may slip and hesitate, stop and resume, while still overall gaining from
the treatment in the long term. 'Intention to treat' includes all patients entered
into the study however much or little treatment they actually received, thus avoid¬
ing that objection. Matching is retained. What is being assessed is a package that
* Presented at the Conference »New Trends in the Treatment of Alcoholism« sponsored by the Plinius Major Society,
Trieste, Italy, May 31 to June 2,1993.
Address for reprints: Dr. Jonathan Chick, Royal Edinburgh Hospital, Alcohol Problem Clinic, 35. Morningside Park,
Edinburgh EH10 5HD, Scotland, UK.
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the patient has been offered (disulfiram evaluations illustrate this point). It is close
to actual clinical practice. But, it is necessary to select data through the follow-up
period, maintaining contact. The methods shown to increase patient's compliance
in alcoholism treatment, such as empathy and reducing barriers, must be employed.
It cannot be assumed that all out of contact are failures.
One way in which alcoholism is unlike most illnesses is that, at times, patients seem
not to want to get better. In treatment outcome studies large numbers of subjects drop
out:
- some are lost, and there is no data on outcome;
- some are lost, but data is available if the patient's permission had been obtained at
the outset, from the family or the work place, or from public records, or the general
practitioner;
- some may remain in contact but do not follow treatment, or request to stop the
treatment, or are withdrawn by the investigator (for these, data can easily continue
to be collected).
The matching of samples that was aimed for in the randomisation may however be
lost. A recently submitted report on tiapride, a selective D2 antagonist, in alcoholism
treatment met this. In the whole sample of 50 patients in each group (placebo,
tiapride), the groups were adequately matched on two variables which previous re¬
search has shown to be relevant to outcome: living arrangements, and whether married
or cohabiting. But in those patients who took the study drug for a minimum of one
month (study completers), there was a bias in the tiapride group towards better social
stability at entry: in the »study completers« taking tiapride only 4% were in the »living
alone« category compared to 43% in the placebo study completers; 67% of tiapride
study completers were married or cohabiting compared to 43% of placebo study
completers.1
When analyses are made of study completers only, attempts can be made to partial
out the effect of variables on which the groups are no longer matched, as was done in
the tiapride study mentioned. However it is not possible to know all the ways in which
matching may be lost due to drop outs, and there may be important predictors of
outcome in alcoholism treatment which are not yet known to us. »Motivation« may be
highly predictive though difficult to measure. If the experimental treatment is more
demanding to adhere to for some reason that the control treatment, then less moti¬
vated patients may drop out more frequently from the experimental group, creating a
bias towards more motivated patients.
To avoid randomisation error, no more than 5% of patients should be excluded from
the outcome analysis.2 Drop out rates in alcoholism evaluation research are often
much higher than this.
This paper discusses methods for avoiding loss of data, or worse, erroneous results,
when studies are conducted with high drop out.
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LIFE-TABLE (SURVIVAL CURVE) ANALYSIS
Gordis et al? followed by Fuller and Williford4 were the first to publish an alcoholism
treatment outcome study using life-table analysis, a method that has now become
widely used. In Fuller and Williford's study of disulfiram efficacy, a single outcome
measure was used, complete abstinence (confirmed by relative's reports, absence of
progressive alcohol-related physical illness or blood tests, and all blood ethanol tests
negative) throughout the 1 year follow-up. Information in this thorough study was
available on all 128 men. Though 23% of the disulfiram groups and only 12% of the
placebo group remained abstinent, this finding was not significant (chi-square) at the
p<.05 level. However, the cumulative abstinence over the 12 months achieved by the
disulfiram groups was significantly greater than control when analysed by life-table
methods (p=0.022; and p=.016).
This powerful method follows response to treatment over time rather than at a single
end point, and patients are counted for as long as they are followed.
The life-table method, as Fuller and Williford point out, has a limitation in that it
ignores events after failure (in their analysis, taking the first drink). A useful treatment
for alcoholism might help, for example, not in preventing taking the first drink but
preventing consumption escalating (e.g. Luintre et al.,5 1990), or reinstatement of
dependence, or the return of mental, social or physical problems.
More recent studies have used life-table analysis, and applied several end-points. For
example O'Malley et al.6, a 3 month study, found that a group given naltrexone did
better than a control group in surviving to time of first drink, and to time of first relapse
(drinking five or more drinks per occasion, four for women). This study does not report
its drop out rate, except for the number of those who did not complete the first week's
medication, but states that an attempt was made to consider potential biases due to
differential attrition between groups.
The drop-out rate (non-completion of the protocol) in the 3 month naltrexone
study by Volpicelli et al.1 was 36% (25/70), in line with reports of other alcohol
treatment evaluations. This study also used an end-point analysis method, including
drop-outs up to the point at which the last data were obtained. With »relapse« as
end point, a significant advantage to naltrexone was found on survival curve analy¬
sis (p<.01).
Are drop-outs failures?
As already stated, the problem with survival curve analysis (and other end-point
analyses when end-point is the last assessment made while the protocol is still being
followed or at termination) is that it implies the drop-out is a failure. Data after the
endpoint is ignored or not collected. Whether this is an appropriate assumption can




Paredes et al.8 found that difficulty in follow-up, as indicated by lack of a phone number,
and by number of attempts necessary to interview, did not predict abstinence status at
6 months.
O'Donnell,9 in a follow-up study principally of drug addicts, found that the hard to find
were more often abstinent than easy to find (reflecting the clinical impression that
some drinkers and drug users stay in contact with clinics because they are needing
help).
LaPorte et al.,10 again for substance abusers, found that the number of attempts to
complete 142 follow-up interviews 6 month after admission to a one month programme
was not related to outcome status.
Nordstrom and Berglundu over a twenty year post-hospital period found that in alco¬
holics believed to be well adjusted socially, in that recent records showed them to have
had little time on sickness benefit and benefit given indicated a fairly high income, the
loss to follow-up was 14%. In a poorly adjusted group (many days sick, low level of
benefit) the loss to follow-up was 9%. In the good adjustment group, difficulty to
achieve follow-up was related to worse outcome, though this was not the case in the
low adjustment subsample.
The following studies, however, favour the assumption that for alcoholics drop out is
likely to reflect worse outcome:
Ruggels et aid2 following up over 18 months clients of selected alcoholism treatment
centres found that non-contacts had been more severe cases at entry to the centre.
Wolff and Holland13 showed that 94 patients who did not respond to a follow-up
questionnaire were less likely, according to information obtained later, to be abstinent
than 135 who had responded, but there was no difference in employment status
between the responders and non-responders.
Moos and Blissu found that effort taken to achieve follow-up at 6 months was related
to poor outcome on 2 of 7 criteria (and they controlled for the length of time between
discharge from the clinic and the follow-up interview).
Moos et al.15 in their 2 year outcome study found that in those for whom no persuasion
was necessary to make the interview, 34% were abstinent, compared to only 15% in
those where two or more persuasive efforts were needed.
In the Rand 4 year follow-up16 subjects not located had been of lower socioeconomic
status and lower social stability, and had been more severe cases at entry to the study.
Subjects not contactable or who refused at 18 months but were located and interviewed
at the 4 year point were less likely to have been abstinent for the past year or more
than those who had been seen at 18 months (14% v. 22%).
However, a regression model of drinking status at 4 years found the effort spent
locating a case was not a predictor of outcome.
In the German multi-centre study17 of in-patient treatment programmes offering
between 6 weeks and 6 month programmes, at 18 mont follow-up, those who had
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dropped out of treatment (17% of 1,410 patients) were doing less well than those who
had not (30% abstinent versus 58%).
While it seems, therefore, that to assume a drop out is a treatment failure rather than
a success, will more often be correct than incorrect, it still does not seem satisfactory
scientifically to make this assumption when as many as a third of subjects are in this
category. Patients may stop and start, relapse, and return to treatment, eventually to
gain.
THE INTENTION TO TREAT PRINCIPLE; USE OF CUMULATIVE
DATA DURING THE FOLLOW-UP
One solution to the drop-out problem lies in the fact that most drop-outs are patients
who cease medication or are protocol violators rather than subjects who have disap¬
peared completely: in the Volpicelli study quoted, out of the 26 dropouts there were
only 5 who were »unavailable for follow-up«. Studies could, obeying the intention-to-
-treat principle (11 1), continue collecting data even though medication or other treat¬
ment is no longer being taken, or a relapse has occurred and perhaps detoxification
has been required. (A practical definition of ITT is »all patients randomised who took
at least one dose of treatment and who provided any follow-up data for one or more
key variables«2). Only if the subject is spending long periods of the follow-up in prison
or other residential facility with no access to alcohol would on-going data be meaning¬
less. Thus, a cumulative picture of outcome in the ITT sample can be obtained for the
whole period, for example, total number of days drinking, estimated total alcohol
consumed, accumulated alcohol-related harm (e.g.Addiction Severity Index in the way
O'Malley et al.6 used it; or an alcohol-related problems score, e. g. Chick et al.18,19); or
blood test results.
It is relevant that, for example, in very thorough NIMH Treatment of Depression
Colaborative Research Program20 differences between treatment groups were clearer
in the intent-to-treat sample than in the study completers.
The objection
Some clinicians object that it is unfair to a treatment to evaluate it in patients some of
whom have not taken more than an initial dose. As well as the ITT analysis, analysis
can still be done stratified for compliance with treatment, so that good compliers with
treatment A can be compared with good compliers with control. The Fawcett et al.21
lithium study appeared to show that good compliers with lithium had a good outcome:
when those patients in the lithium group who had maintained a serum lithium level of
0.5 umol/L of more were included (63% still abstinent at one year compared with 19%
in those who did not maintain that level of serum lithium or who admitted not taking
their tablets for at least half the time). However, it was possible to compare them with
the compliers in the placebo group. Fuller et al.22 in a very large study of disulfiram
were able to measure compliance on the placebo group using riboflavin-labeling of
tablets, and urine checks. Good compliers were defined as those submitting at least
15 of a possible 39 urine specimens positive for riboflavin. There was a highly signifi-
83
Alcoholism
cant relationship between compliance with a drug regime and abstinence, regardless
of whether it was disulfiram 250 mg, 1 mg or placebo (43% abstinent for one year
versus 8%). However, when good compliers were compared across groups, no differ¬
ence between groups was found, and neither was a difference between groups seen for
poor compliers. The snag here is that even in this large study, the numbers begin to be
small.*
Including an analysis with stratification for compliance permits at least a separate view
of those patients disposed to follow the treatment.
Alcoholism treatment research is well suited to using cumulative data, such as total
drinking days or accumulated problems, because the condition is marked by events (a
day of drinking, losing a job, having a drunken argument etc.) unlike some other
conditions like depressive illness or hypertension which have to be monitored by
measures made at the interview. If a contact visit is missed, much of the data can be
collected retrospectively at a later point, or collected from an informant.
Analysis by ITT using cumulative data fits with clinical common sense: we are comparing
the outcome of a group of patients offered treatment A with a group offered treatment
B. The acceptability of the treatment, and the ease with which it is followed, are relevant
ingredients if extrapolation to the routine clinical situation is to be possible.
Above all, it meets with clinical experience in that patients taking a treatment may slip
and hesitate, stop and resume, while still overall gaining from the treatment.
The value of this, however, depends on getting complete follow-up data. Fuller et a/.4
had data on all 128 patients. Many studies have managed 90% follow-up. This requires
gaining permission at intake to contact relatives to obtain a follow-up address and
preferably also information on the patient's drinking; at intake to record auxiliary
addresses and phone numbers for the patient: use of phone contact as soon as the
patient misses an appointment;23,24 barriers at the clinic to patient contact must be
removed, and investigators and therapists employed who are warm and empathic.
Permission to see the patient at home should be requested and resources provided to
fund home follow-up interviews.
CONCLUSION
Analysing data only to the point of termination of protocol adherence, or to an
endpoint such as first drink or relapse has its place, particularly when the power of
life-table methods are used. Clinicians, however, see much advantage to continuing to
collect data on all patients throughout the whole study period to permit an analysis of
the intention-to-treat sample. If numbers permit, the value of the treatment, rather
than the package including its acceptability, can be estimated by stratification by
compliance.
* In Fuller et al. if compliance was judged according to contact with the clinic, then a result in favour of disulfiram did
emerge: among patients who were not completely abstinent for the year but who were compliant in the sense that they gave
all 7 follow-up interviews, those on 250 mg disulfiram reported a mean of49 drinking days, those on 1 mg disulfiram reported
a mean of 75 and those on no disulfiram reported a mean of 86 (p=0.05).
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Sazetak
VREDNOVANJE LIJECENJA ALKOHOLIZMA: DILEMA U VEZI
S OTPALIMAIZ PROCESA LIJECENJA
Bolesnici koji traze pomoc zbog problema vezanih uz alkohol cesto ne slijede
predvideni proces lije&nja. Ovo se cesto pojavljuje i u studijama gdje je dana su-
glasnost za sudjelovanje u procesu. Takoder, u studijama mogu biti povu&ni iz
analize, jer se njihovo stanje ili ne poboljsava ili se pogorsava, ili zbog nepozeljnih
ucinaka za koje se smatra da su posljedica lijecenja, ili pacijenti prestaju dolaziti i
izgubi se tako kontakt s njima.
Podaci o ishodu mogu biti na raspolaganju bez obzira na otpale iz procesa lijecenja iz
bilo kojeg razloga, selektirani sustavno ili na neke druge nacine. Istrazivac je u sljedecoj
dilemi: ukljuciti ili ne ukljuciti takve pacijente u analizu uspjesnosti lije&nja. Ako budu
izostavljeni, neke prednosti dobivene slucajnom distribucijom razlicito lije&nih
skupina bivaju izgubljene, kao sto se vidjelo u nedavnom randomiziranom kontrolira-
nom ispitivanju tiaprida u alkoholicara, kada medu ispitanicima koji su zavrsili studiju
nije vise bilo uskladenosti prema vaznim socijalnim parametrima. Ako ih se ukljuci u
analize, to nije sasvim pravedno prema primijenjenom lije&nju, jernekipacijenti imaju
malo (ako bilo sto) od lijecenja. Ovo bi moglo biti od posebne vaznosti za lije&nja koja
pocinju pokazivati terapeutske ucinke tek nakon npr. mjesec dana.
Podaci iz analiza vitalnih statistika omogucavaju da se ukljuce svi raspolozivi podaci
o pacijentima do ugovorenog stupnja (popiti pi&/recidivirati/izostati iz studije,
itd.). Ali, klinicka iskustva govore da pacijenti na lijecenju mogu iskliznuti ili biti
neodlucni, stati i razmisliti, dok se ukupni rezultat lije&nja vidi tek u du2em
razdoblju. »Namjera za lije&nja« ukljucuje sve pacijente uklju&ne u ispitivanje,
bez obzira na to koliko su od tog lijecenja primili, cime se izbjegava ovaj moguci
prigovor. Uskladivanje skupina je odrzano. Ono sto se utvrduje jest vrijednost
paketa ponudenog pacijentu (vrednovanje disulfirama ilustrira to pitanje). Blisko
je trenutnoj klinickoj praksi. No, nuzno je izabrati podatke tijekom duljegrazdoblja
pra&nja, odrzavajuci kontakt. Metode koje pokazuju bolje pacijentovo podnosenje
lije&nja alkoholizma, kao sto je empatija i redukcija prepreka, moraju biti koristene.
Ne smije se pretpostaviti da svi ispitanici s kojima kontakt nije odrzan nisu uspjeli u
lije&nju.
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MEAN CELL VOLUME AND GAMMA-
GLUTAMYL-TRANSPEPTIDASE AS MARKERS
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Summary The usefulness of serum-gamma-glutamyl-
transpeptidase (y-GT) and mean cell
volume (MCV) as markers of alcohol consumption was
assessed in men in employment (266 company directors and
222 manual workers in alcohol-production firms) and in 34
male alcoholic patients. The correlations of admitted
consumption with y-GT were 0-307 (directors) and 0-418
(manual workers) and with MCV 0-439 (directors) and 0 • 360
(manual workers). A man with an MCV of over 98 fl and a
y-GT level above 50 i.u./l had a 62% chance of admitting to
drinking over 450 g alcohol per week. Although the
probability of being a heavy drinker increases progressively
with elevation in both these tests, as screening tests they lack
power, though false positives may be explained in part by
inaccurate self-reports by both survey subjects and patients.
For clinical purposes, however, the tests have a use in
supplementing self-report and in following problem drinkers
in outpatient treatment.
group, suggesting that interview might be more reliable than
questionnaire.
The London study was alone in concluding that serum-y-
GT is only a weak indicator of consumption: even in the
interviewed group a correlation ofonly 0-139 was found. As
with most of the other studies cited here, no attempt was
made in the analysis to exclude obvious "false positives" (for
example, people taking anticonvulsants, a cause of elevation
of both MCV and y-GT). Finally, men attending "routine
health examination" at a private clinic—the setting of the
London study—have often been encouraged to attend by
their companies and may underreport heavy consumption
fearing, despite reassurance, that information is not
confidential.
The present study is of two populations of men in
employment, chosen because of their known high risk of
alcohol-related problems. It attempts to overcome some ofthe
limitations in the above studies and provide firmer data on the
practical value of these two tests.
The chief difficulty in specifying the relation between
blood tests and alcohol consumption is obtaining valid data
on consumption. Self-reports have been thought in many
studies to be less than valid, with a tendency to under¬
reporting.15 Experiments could avoid this, but the heaviest
experimental exposure yet reported in relation to either of
these blood tests was 0 • 75 g ofethanol per kg body weight for
2 days repeated weekly for 4 weeks, in only 8 subjects (7
showed a rise, greatest on average at the third and fourth
exposure).16
In the present study consumption data depend on self-
report, but the utmost care was taken to ensure reliability:
clinically experienced interviewers were used, and recall of
consumption was tied in detail to activities ofthe immediately
preceding week.
introduction
DOCTORS must be weary ofbeing told that they often fail to
recognise alcohol-related problems. However, alcoholism
continues to masquerade as other conditions, patients still
tend to minimise their alcohol consumption, and there is now
a movement to intervene earlier in problem drinking, before
the patient's social supports have been lost. This had led to a
search for biochemical markers of alcohol intake.
Alcoholics, even without chronic liver disease, tend to have
raised serum-gamma-glutamyl-transpeptidase (y-GT)
levels1,2 and an elevated mean cell volume (MCV).3"6 Health-
screening studies have shown a relationship of varying
strength between self-reported alcohol intake and both
serum-y-GT7'11 and MCV.7'8'12'14
Interpretation of these studies is subject to a number of
limitations. In some the base population is unspecified, the
subjects having been self-selected attenders at a screening
centre.7"9'11 The number of heaviest drinkers has either been
very small8,9 or unspecified (and probably small).7,10,12'14
The reported relationships between serum-y-GT and age and
weight,10 and between MCV and age and smoking12,13 have
sometimes been ignored. Consumption data have been of
uncertain quality, elicited only by questionnaire, except in
health-screening studies in London," Malmo,9 and Paris.12
The London study found that mean reported consumption
was higher in the half of the sample who were interviewed
than in the half who answered the same questions in
questionnaire form. Moreover, the correlation between
consumption and serum-y-GT was higher in the interviewed
methods
Data were obtained from two subgroups of men living and
working in Edinburgh and the surrounding Lothian region. First,
all 312 manual workers at two alcohol-production firms were
approached, yielding 247 completed interviews—a response of
79-2%, of whom 92% provided a blood sample. Secondly 369
company directors and senior executives appearing in either of two
professional lists were approached by letter and 298 agreed to be
interviewed—a response of 81 %, of whom 92% provided a blood
sample.
To exclude from the study subjects with known causes ofelevated
MCV and serum-y-GT other than alcohol, several precautions were
taken. Subjects were asked about current medication, current and
recent illnesses, and in the event ofan abnormal result on either test
the general practitioner was asked if he knew of any medication or
illness which might explain the abnormality. In addition, in all
subjects who had an MCV above 102 fl, serum vitamin-B^ and
folate were measured to exclude subjects with other causes of
macrocytosis. 6 manual workers but no directors were excluded at
this point, leaving a final sample of 266 directors and 222 manual
workers.
We also report on 34 patients selected from a consecutive series of
men newly admitted to an alcoholism treatment unit for whom the
past week's drinking had been typical of their recent drinking.
The measure of alcohol consumption reported on here was total
intake (coverted to grams ofabsolute alcohol, a half-pint of3% lager
or a single measure of spirits containing about 8 g alcohol) in the 7
days preceding interview. The male interviewer asked the subject to
recall in detail his activities, both work and leisure, during these
days and what beverages in what amounts he drank. Themean total
.fflL-fiiCJliaiiual Jitorkers was 271 g, SD 374, and the directors
214 g, SD 184.
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20% of the manual workers and 39% of the directors said that the
past week was not typical for them. We have argued elsewhere that
at the aggregate level discrepancies between habitual drinking and £
the past week's drinking are likely to be trivial^'C U'lt/t t* I^SliE
Serum-y-GT was measured by the method ofRosalki1 and MCV c
with a Coulter counter. Subjects were asked their current weight (or £
were weighed ifthey could not give this) and were asked about their ^
weekly tobacco consumption. |
RESULTS , |
Data are presented in three forms: (1) as intercorrelations to |
describe the linear relationships between variables; (2) as M
graphs showing the probability of reporting heavy
consumption at increasing blood-test scores; and (3) as
sensitivity/specificity tables to assess the screening power of
the tests when "upper limits of normal" are used as cut-off
points.
10 20 30 40 50 60
-GT (i.u./U
70 80 90 100
Fig. 1—Relationship between probability of reporting weekly alcohol
consumption of 450 g or more and y-GT.
Serum-y- GT
The directors has a mean serum-y-GT of47 • 2 i.u./l (range
9-700, SD 63 • 6); the manual workers had a mean of 43 ■ 0
i.u./l (range 9-699, SD 67 ■ 7).
Serum-y-GT correlated significantly (p<0-001) with
frequency and amount ofconsumption in both directors and
manual workers (table l). Only in the manual workers was
TABLE I—INTERCORRELATIONS OF y-GT, ALCOHOL CONSUMPTION,





Amount per week 0-418 0-680 0-148
Age 0-041 -0-119 -0-182 166
Weight 0-129 0-000 0-048 0-067
If a correlation is 0-146 or over, p<0-01.
there a weak relationship to weight (r=0 ■ 129, p = 0 • 027). Its
relation to frequency ofdrinking disappeared when amount,
weight, and age were controlled for (r = 0-08, manual
workers; -0-07, directors).
Fig. 1 refers to all survey subjects and patients and is
derived as follows: serum-y-GT scores were grouped into
eight categories, and for each group the proportion of men
saying that they had drunk 450 g ofalcohol or more in the past
week (equivalent to 4 pints of lager per day) was plotted. The
likelihood of an individual drinking at that level increases
with rising serum-y-GT but does not reach 50% until y-GT
reaches 59 i.u./l.
If50 i.u./l is taken as the cut-offpoint, serum-y-GT is not a
very powerful screening test, mainly because of "false
positives", though it performed better among the manual
workers than among the directors and patients (table II).
MCV
The directors had a mean MCV of 91 • 4 fl (range 78-118,
SD 5 • 3), and the manual workers a mean of 90 • 0 fl (range
80-104, SD 4-6).
MCV correlated significantly (p<0-001) with frequency
and amount ofconsumption in directors and manual workers
(table III). Amount of consumption had an independent
relationship to MCV in both groups after controlling for
frequency, age, and smoking (partial r=0-29, directors;
0-14, manual workers). In the manual workers only,
frequency of drinking, smoking, and age correlated
significantly (0-25) with MCV. (Smoking had an
independent relationship with MCV in both groups: after
controlling for frequency, amount, and age, its correlation
with smoking was 0-240 in the directors and 0-376 in the
manual workers.)
Fig. 2 is derived for increasing MCV categories in a way
analogous to fig. 1. The probability ofstating a consumption
TABLE II—SENSITIVITY AND SPECIFICITY OF BLOOD TESTS AS




— (n = 222) (n = 266) (n = 34)
Report >450 g/wk 47 30 30
y-GT>50 i.u./L'
n 45 65 20
Sensitivity}" 53-2% 50-0% 60%
False positives:}: 11-4% 21-9% 50%
MCV >98fI:
n 17 23 12
Sensitivity 22-9% 32-1% 40%
False positives 3-6% 6-2% 0%
MCV >98fl and y-GT >50 i.u./l:
n 11 10 8
Sensitivity 17-7% 16-6% 26-6%
False positives 1-7% 2-2% 0%
MCV >98fl or y-GT >50 i.u./l:
n 51 78 24
Sensitivity 53-2% 63-3% 73-3%
False positives 14-8% 25-8% 50%
* Equivalent to 28 pints of 3% alcohol by volume lager, or about 2 bottles of
spirits per week.
■f* Proportion of "heavy" drinkers who had high scores.
Proportion of "non-heavy" drinkers who had high scores.
TABLE III—INTERCORRELATIONS OF MCV, ALCOHOL CONSUMPTION,






per week Age Smoking
MCV 0-340 0-439 0-216 0-267
Frequency of
drinking 0-432 ^0-669 0-142 0-068
Amount per week 0-360 0-679 0-044 0-159
Age 0-156 -0-118 -0-166 -0-038
Smoking 0-413 0-200 0-140 o-ooT^
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Fig. 2—Relationship between probability ofreporting weekly alcohol
consumption of 450 g or more and MCV.
of 450 g/week or more increases progressively with rising
MCV throughout the range and reaches 66% when MCV is
over 98 fl.
Table II shows that MCV (using a cut-offof 98 fl) is a poor
screening test for heavy drinking, in that it has a low
sensitivity—i.e., it misses many cases.
MCV and y-GT Combined
Table II shows that when the criterion is serum-y-GT 50
i.u./l or over and MCV 98 fl or over, few false positives are
detected, though sensitivity is low, the opposite being true
when either MCV or y-GT is raised.
DISCUSSION
In the manual workers alcohol-induced macrocytosis is
related not only to total amount ofalcohol drunk per week but
also to a pattern of sustained moderate exposure to alcohol
rather than intermittent intense exposure. This was not the
case for y-GT. Perhaps the putative direct toxic action of
alcohol on the developing erythroblast3 is compensated for
during lulls between binges.
Our method has produced larger correlations between
admitted consumption and these two blood tests than
obtained in previous studies. The graphs in figs. 1 and 2 show
that at the higher range ofeach test there is a high probability
that an individual has admitted to "heavy" drinking. For
screening, however, these tests appear to lack power—for
example, using 50 i.u./l (an often-quoted "upper limit of
normal") as the cut-off for y-GT an unacceptable high false-
positive rate was found (21-9% in directors, 11-4% in
manual workers). The high false-positive rate in terms of
admittedconsumption may be attributed partly to evasiveness
about drinking on the part of some respondents. This
possibility is supported by there being a higher false positive
rate among the directors and the patients than among the
manual workers. With respect to the directors, it has been
shown that known alcoholics more often go undetected in
self-report surveys if they are of high rather than low social
class.18 As for the clinic patients, it is widely found that some
alcoholics underreport their drinking even when they have
come for treatment.
Nevertheless, table II shows that a man with both tests
elevated has a 2-in-3 chance ofbeing a heavy drinker; and the
graphs of probability indicate that a high MCV or serum-y-
GT in a man who does not present as a heavy drinker may be a
reason to question him or a relative more closely about
alcohol intake. In surveys, aggregate analyses may justify
reallocating respondents with elevated tests to higher
consumption categories.
Other biochemical tests correlate with alcohol intake,19 and
abnormal heterogeneity of transferrin seems to be relatively
powerful.20 However, MCV and serum-y-GT aie widely
available and inexpensive and at present can be
recommended for use in clinical practice as markers of
alcohol intake, subject to the limitations discussed. It should
be emphasised that tests should not be a substitute for a
detailed non-judgemental inquiry into drinking (perhaps best
tied to an account ofwork and leisure activities). One study of
hospital case-notes revealed that only 36% contained even a
barely adequate note ofalcohol consumption.21
In those patients in whom there is an alcohol-induced
elevation of one of these tests, cessation or reduction of
drinking leads to a fall in the next 3-6 weeks, which provides
the clinician with a useful indication of treatment
progress.2'4'22 Patients whose goal is reduction of drinking
rather than abstinence find serial test results an aid to
monitoring their consumption.
Requests for reprints should be addressed to J. C., Royal Edinburgh
Hospital, Edinburgh EH 10 5HF.
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Plasma a-Amino-rc-Butyric Acid : Leucine Ratio
and Alcohol Consumption in Working Men
and in Alcoholics
Jonathan Chick,1 Margaret Longstaff,2 Norman Kreitman1
Martin Plant,3 David Thatcher2 and Jonathan Waite4
Summary. The ratio of plasma a-amino-n-butyric acid to leucine is higher in alcoholics,
especially those who have drunk heavily recently, than in light drinkers. The ratio is of no
value by itself as a screening test.
Alcoholics sometimes minimize or deny their drinking and undetected
alcoholism masquerades as a variety of medical conditions. This has led to
a search for a biochemical marker. Shaw et al. (1) reported that the ratio
of plasma a-amino-n-butyric acid (aanb) to leucine (A : L ratio) might be
a marker for alcoholism. A subsequent study (2) comparing 130 alcoholics,
100 controls and 31 subjects with liver disease unrelated to alcohol
confirmed that alcoholics had a high A: L ratio. Liver disease without
alcoholism did not elevate the ratio.
Other workers (3-5) have either failed to find differences between the
mean A : L ratios of controls and alcoholics or have found differences
which could be accounted for by liver disease alone. However, different
definitions of "alcoholic" may have been used, and none of these reports
gave sufficient detail about either amount or recency of consumption.
Another explanation for discrepant findings is that the measurement of the
A: L ratio might be unreliable because aanb is present only in small
quantities in plasma. With one exception (5) reliability has not been
thoroughly discussed. Moderate drinkers have been found to show greater
variation in their A : L ratio than nondrinkers, though in the small sample
studied the tendency for moderate drinkers to have a higher ratio did not
reach significance (6).
The aim of the present study was to illuminate these contradictory
findings by studying the reliability of the biochemical procedure and
refining consumption data. We studied individuals drawn not from
general hospitals, as was the case in all but one of the above studies, but
from groups of relatively healthy drinkers.
1 Medical Research Council Unit for Epidemiological Studies in Psychiatry, University
Department of Psychiatry, Royal Edinburgh Hospital, Edinburgh 10, Scotland.
2 Department of Molecular Biology, University of Edinburgh, Edinburgh, Scotland.
5 Alcohol Research Croup, University Department of Psychiatry, Royal Edinburgh
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Method
We report on two separate samples: alcoholic patients and a survey sample that
was obtained from groups known to contain heavy drinkers but that were of
contrasting social background.
First, three alcohol production companies were approached. In two firms the
total manual work force (312 men) was contacted and interviews and blood
samples were obtained from 222. From a third firm volunteers only were
requested and 40 subjects were obtained. Second, 369 company directors (senior
executives) whose names appeared in two professional lists were approached bv
letter and interviews and blood samples were obtained from 208.
The patients were 48 consecutive admissions to a psychiatric unit for alcoholics.
They represented a wide range of socioeconomic groups according to most recent
occupation: professional-executive 22%, other nonmanual 24%, skilled manual
22%, unskilled manual 32%. (On some analyses N is reduced because of loss or
leaking of sample, delay reaching laboratory, or insufficient blood for analysis.)
In a 40-minute interview, subjects were asked to describe in detail their alcohol
consumption in the seven days preceding the interview, facilitated by an account
of social and work activities in that week. Sixty-seven percent of survey subjects
said that it had been a "typical" week. In community samples there is evidence
that the preceding week's drinking provides a reasonable estimate, for aggregate
analyses, of usual consumption (7). Estimates of alcoholic patients' recent
consumption are notoriously difficult to make but for uniformity consumption in
the preceding week was also used for them. In the survey, a question on sporadic
heavy consumption was also asked—how many times in the past 2 years had more
than 130 g (4.2 oz) or more than 260 g (8.4 oz) of absolute alcohol been drunk in a
day.
Blood w as obtained by venepuncture at the time of the interview. Subjects were
not fasting; for survey subjects the time of day varied. Samples taken in the
evening were stored overnight at 4°C; for the biochemical tests they were spun
and plasma was stored within 3 hr of venepuncture; and for the hematological
analysis they were put into sequestrene tubes and analyzed the same day. Plasma
for amino acid analysis was stored at — 20°C, thawed and deproteinized with
trichloracetic acid. Amino acid measurements were made by automated cation
exchange chromatography on a Rank-Hilger J182 Chromaspek amino acid
analyzer using a ninhydrin detection system. Although this analyzer uses a high
pressure and a microbore column, full physiological fluid analyses have at least a
3-hr duration. The pH gradient elution system is very flexible, and a program
which resolved aanb and leucine in 90 min was developed. The analyzer was
interfaced with a Digico M16V minicomputer and asr33 teletype input-output
peripheral. In order to obtain maximum accuracy in both peak recognition and
quantitation the integrator was standardized every fourth sample. Standard
solutions contained 100 nmol/ml Sigma amino acid standards with 100 nmol/ml
aanb and 100 nmol/ml norleucine in pH 2.2 acidic analyzer buffer. Amino acid
recovery was also estimated by direct comparison of peak heights with those of
standard analyses and by manual integration of the peaks by triangulation. Mean
cell volume (mcv) was measured by Coulter Counter. Gamma glutamyl transpep¬
tidase activity (gamma-gt) was analyzed in plasma stored at 4°C by the method
described by Rosalki and Rau (8).
Results and Discussion
Reliability. Three estimates of the reliability of the procedure were
made. First, using standard samples the percentage of standard deviation
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in the ratio of the two amino acids was found to be 10.6 (based on 23
samples). Second, 74 specimens were analyzed and the plasma frozen,
stored and reanalyzed after 2-20 weeks. The Pearson Product Moment
Correlation between the ratios calculated on the two occasions was .93
(p < .001) and the Spearman Rank Correlation was .90 (p < .007). Third,
9 specimens were analyzed on separate aliquots, on the same day, but on a
different run of the analyzer. The Pearson Product Moment Correlation of
the ratios calculated from these two analyses was .98 (p < .0001), and the
Spearman Rank Correlation was .99 (p < .001). This level of reliability
would appear to be satisfactory.
A: L Ratio and Reported Consumption. The median consumption
reported by the directors was 168 g (5.4 oz) of absolute alcohol per week
(range 0-904 g) and that by the manual workers was 200 g (6.4 oz) per
week (range 0-1904 g). Of the directors 9% reported 578 g (18.6 oz) per
week or more, equivalent to 4 "large" measures of whisky per day and of
the manual workers 16% were drinking in this range. Among the patients
only 35 had been drinking amounts typical of their recent past in the week
preceding the blood sample and their median consumption was 1074 g
(34.5 oz) (range 24-3500 g): 83% had drunk over 578 g (18.6 oz). The
other 19 had either detoxified themselves before admission or had been in
the hospital for more than 7 days before the interview and blood sample.
In the survey sample, the preceding week's reported consumption
correlated with an A : L ratio of .06 (N = 470). There might be objections
that there was a lack of correlation between the A: L ratio and reported
consumption in the survey sample because nonalcoholics lie unsystemati-
cally about their consumption. However, controlling for age, fairly high
correlations of reported consumption with mcv (r = .34) and gamma-gt
(r = .35), more established indicators of consumption (9), argue against
this. Furthermore, the correlation between consumption and the A: L
ratio increased only slightly when those with "atypical" consumption in
the preceding week were excluded: r = .11 (iV = 335). There was no
relationship between the A: L ratio and sporadic heavy consumption
(r = .07).
We cannot exclude the possibility that inconsistency in sample collec¬
tion (e.g., some subjects had eaten recently, not all samples were stored
overnight before being frozen) added error to the study and obscured
emerging relationships.
Discriminating Power of the A : L Ratio. The patients had a mean ( ±
sd) A : L ratio of .15 ± .07, significantly higher (p < .001) than that of the
manual workers (.11 ± .05) and "light drinkers" (.11 ± .06) in the survey
sample. "Light drinkers" (IV = 173) were those who said that they had
drunk less than 120 g (3.9 oz) of alcohol in the previous week and include
abstainers. The directors had an intermediate A : L ratio of . 13 ± .06. The
mean A : L ratio of 14 patients who had consumed more than 1280 g (41.2
oz) of alcohol in the week preceding admission was . 19 ± .08 and that of
patients who were not "recent heavy drinkers" was .14, a difference that
nearly reached significance (p = .056).
Age and weight are possible contaminants of the relationship between
the ratio and alcohol consumption but neither correlated with the A : L
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ratio. A ratio of .2 or above (an arbitrary cut-off) was found in 11 % of the
173 light drinkers, 23% of all patients and 43% of "recent heavy-
drinking" patients. None of the light drinkers w ith a ratio of .2 or above
had an elevated mcv or gamma-ct and thus were relatively unlikely to be
very heavy drinkers.
Thus, alcoholics whose consumption was both recent and heavy tended
to have a high A: L ratio. An elevated ratio is a moderately specific
indicator of this group because only 11 % of light drinkers had a ratio of at
least .2. However, it lacks sensitivity, since only 43% of such patients had
a ratio at or above that level.
A : L Ratio and Liver Disorder. In the patients, data were available on
serum aminotransferase (mean, 52 ± 26 i.u./l), serum alkaline phospha¬
tase (mean, 187 ± 63 i.u./l), serum gamma-ct (mean, 124 ± 152 i.u./l)
and serum bilirubin (mean, 13.5 ± 10 mol/1). The only significant
correlate of the A:L ratio was the serum bilirubin (r = .25, N = 48,
(p = .05). The mean A: L ratio of the 14 patients with elevated serum
bilirubin was .18 ± .07. "Recent heavy drinkers" were not disproportion¬
ately represented in this group (5 out of 14, or 36% as compared with
33% of the total patient sample), indicating an independent relationship
of the A: L ratio with elevated serum bilirubin. However, simply taking
any two elevated liver function tests as a criterion of liver disease did not
reveal a relationship to the A: L ratio. In the survey sample there was no
relationship between serum gamma-gt (mean, 47 ± 64 i.u./l) and the
A : L ratio (r = .02, N = 466).
Though the frequency and severity of liver disease in these samples were
not great, the indication is that serum bilirubin (but not serum hepatic
enzyme concentration) is related to the A : L ratio. This relationship could
not be accounted for by recent heavy consumption.
Conclusions
It is possible that there was lack of support for Shaw et al. (1, 2) in the
literature because other workers have not studied alcoholics whose
drinking was both heavy and recent. However, the present study does not
provide evidence that the A : L ratio is a useful marker by itself of heavy
alcohol consumption, though it would presumably be useful in combina¬
tion with other tests. Given the different drinking and nutritional patterns
of alcoholics, the range of biochemical systems affected by alcohol, and
the likely genetic variability in susceptibility of those various systems, it is
unlikely that a single powerful biochemical marker of alcoholism will be
found.
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Abstract — For 576 working men the relationship between reported recent alcohol consumption,
serum ferritin, mean cell volume, and gamma glutamyl transferase was studied. Serum ferritin
was significantly increased in heavy drinkers, but as a screening test it failed to yield a useful
advantage over a combination of mean cell volume and gamma glutamyl transferase.
INTRODUCTION
Ferritin is the major storage form of iron in the
body. It is found particularly in liver, spleen
and bone marrow. Elevated serum levels are
found in hepatic diseases where there is liver
cell death, and some malignancies, without
elevation of total body iron stores (Reeves and
Haurani, 1980; Lundin et al., 1981). Alcoholics
tend to have elevated values. These elevations
recede after about two weeks' abstinence and it
seems to be dysfunction in liver rather than
erythropoiesis that is important in determining
serum ferritin changes in these patients (Lun¬
din et al., 1981).
Kristenson et al. (1981) found that serum
ferritin was elevated in 67% of men identified
in the general population to be heavy drinkers
with increased serum gamma glutamyl trans¬
ferase (GGT), but found only one elevated
value in 39 teetotal males. The following report
is also based on healthy males — a population
of men working in occupations in which drink¬
ing is common. We examine the value of serum
ferritin as a marker of heavy drinking.
SAMPLE AND METHODS
From 269 manual workers employed in
Scottish alcohol manufacturing industries, and
207 senior executives in a range of commercial
concerns, information on recent consumption
was elicited, a blood sample taken, and results
obtained on mean cell volume (MCV), serum
GGT and serum ferritin. No subject was
included if his current medication or current or
recent illnesses might have explained an eleva¬
tion of MCV or serum GGT. The fieldwork
was conducted in 1978/79. We also report here
on 30 patients selected from a consecutive
series of men newly admitted to the Alcohol
Problems Clinic in Edinburgh who reported
that their past week's drinking had been typical
of their recent drinking, and from whom the
three blood test results were obtained.
The measure of alcohol consumption re¬
ported here was total intake (converted to
grams of absolute alcohol, a half-pint of 3%
lager or a single measure of wine or spirits
containing about 8 g alcohol) in the seven days
preceding interview. The male interviewer
asked the subject to recall in detail his activi¬
ties, both work and leisure, during these days
and what beverages, in what amounts, he
drank.
Twenty per cent of the manual workers and
39% of the directors said that the past week
was not typical for them. We have argued
elsewhere that at the aggregate level discrepan¬
cies between habitual drinking and the past
week's drinking are likely to be trivial (Chick et
al., 1981a).
Serum GGT was measured by the method of
Rosalki et al. (1971) and MCV with a Coulter
counter. Subjects were asked their current
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weight (or were weighed if they could not give
this) and were asked about their weekly tobac¬
co consumption.
Ferritin was assayed using an immuno-
radiometric method (Miles et al., 1974). The
specimens had been frozen and then thawed.
The coefficient of variation of the assay was
10.4% at the upper value of the reference
interval. Amongst Finnish normal men, the
range of values obtained is 23-175 mg/1, mean
78 mg/1.
RESULTS
The mean values of serum ferritin obtained
were: manual workers 106 mg/1, S.D. 94, range
8-666; executives 151 mg/1, S.D. 96, range 10-
500; patients 269 mg/1, S.D. 247, range 8-980.
It should be noted that these are slightly
skewed distributions, and the statistics to be
quoted should be interpreted in that light.
The product moment correlations between
serum ferritin and alcohol consumption in the
past week were +0.255 (P < 0.0001) (manual
workers) and +0.296 (P < 0.0001) (execu¬
tives). Serum ferritin had a relationship to
serum GGT independently of consumption,
partial correlations, controlling for consump¬
tion, being +0.410 (P < 0.0001) (manual
workers) and +0.213 (P < 0.0001) (executives).
Serum ferritin had no relationship with MCV
independent of consumption.
A cut-off point of 250 mg/1 gave the best
discrimination between light and heavy drink¬
ing. As in our earlier paper (Chick et al.,
1981b), we used 98 fl as the cut-off for MCV
and 50 IU/I for serum GGT.
Table 1 shows that serum ferritin does not
add any power to the discrimination between
heavy and light drinkers which can be achieved
using MCV and serum GGT. Even though the
sensitivity of the discrimination can be raised
slightly (from 51 to 55% among the manual
workers and from 64 to 72% among the
executives), this occurs at the expense of
specificity, i.e. the proportion of false positives
(light drinkers with a positive test) also in¬
creases.
DISCUSSION
In our earlier report about MCV and serum
GGT as screening tests for heavy alcohol
consumption (Chick et al., 1981b), we dis¬
cussed the contribution made to the false
positive rate of evasiveness about drinking.
However, when using these tests, the clinician
can make a positive result a reason for ques¬
tioning a patient more closely about his drink¬
ing, or obtaining a history from a relative.
If elevated, they also provide a means of
monitoring rises and falls in a patient's con¬
sumption. Valimaki et al. (1983) show that
serum ferritin would likewise be useful in
Table 1. Effect of adding serum ferritin assay to the sensitivity and specificity of a
combination of MCV and serum GGT as indicating admitted alcohol consumption of over
450 g per week
Elevation of Elevation of MCV
MCV or serum GGT serum GGT or ferritin
O/ O//o /o
Manual workers
Less than 450 g/week, N = 209 18 21
More than 450 g/week, N = 47 51 55
Executives
Less than 450 g/week, N = 177 28 33
More than 450 g/week, N = 25 64 72
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monitoring rises and falls in consumption in a
given patient including some of those in whom
serum GGT was not elevated. However, the
differences in serum ferritin levels between
individuals are due to many influences other
than alcohol alone. A correlation of 0.29
indicates that only 9% of the variation in
ferritin levels can be accounted for by varia¬
tions in alcohol consumption. The high level of
significance of the correlation is due to our use
of a large sample.
We have confirmed the observations of
Lundin et al. (1981) that the rise in serum
ferritin in the heavy drinker is related to liver
rather than erythropoietic changes. Serum fer¬
ritin assay, though kits are now commercially
available, does not, in our view, have a
practical role as a screening test for heavy
drinking, except perhaps in the situation where
the subject is taking an anticonvulsant or other
enzyme-inducing drug. Our reasoning is that
the elevation of serum ferritin may reflect only
'hepatocellular damage', whereas serum GGT
and other liver enzyme elevations can also be
brought about by enzyme induction (Rosalki et
al., 1971). (However, a specific study of serum
ferritin in patients taking anticonvulsants has
not yet been reported.)
While one or two readily conducted tests
with an accepted cut-off point — such as serum
GGT and MCV — are useful to today's
clinician, discriminant functions derived from a
battery of tests may prove more powerful in
future. Ryback et al. (1982) derived such a
function in a hospitalised population, although
to date an assessment of its power in other
patient samples, or the general population, has
not been published. However, when discrimi¬
nant functions have been derived from a
battery of tests in a general population sample,
the function's ability to distinguish heavy from
occasional drinkers, even within the popula¬
tion from which they have been derived, has,
unfortunately, been limited (Whitfield et al.,
1981; Shaper et al., 1985).
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Abstract
Patients' reports together with findings at clinical examination and information from an informant such as a relative were used
to categorise patients as relapsed or not relapsed during a 6 month period of out-patient treatment at an alcohol problems clinic.
At each fortnightly visit, blood was taken for measurement of serum y-glutamyl transferase and carbohydrate deficient transferrin
(Pharmacia method). A total of 53 patients attended for at least one follow-up visit. Mean CDT differentiated relapsers from
non-relapsers at seven of the 11 visits (P < 0.05), but at no visit did mean GGT differentiate. CDT tended to become elevated after
a relapse more quickly than GGT. However, whether using upper limit of normal (ULN), or defining a 'positive test' as > last
test and either > 20% above lowest previous test or > ULN, specificity (averaged over the 11 visits) was greater for GGT than
CDT. Some of the false positive results for CDT were in patients who, shortly after having a positive test, relapsed, suggesting
that a rising CDT can herald a relapse admitted by the patient. This could not be shown for false positive GGT results. Inspection
of individual trajectories of alcohol consumption and blood test results shows that for some patients GGT is the more effective
marker of relapse, whilst for others CDT operates better. © 1997 Elsevier Science Ireland Ltd.
Keywords: Alcohol dependence; Relapse; Carbohydrate deficient transferrin; y-Glutamyl transferase
1. Introduction
As a result of ambivalence about their drinking,
problem drinkers are sometimes not frank about their
current consumption, which can impede medical deci¬
sions and divert therapy. If a medical examination is
being conducted for an employment issue or renewal of
the driving licence, there are extra inhibitions to frank¬
ness. Breath or urine tests for ethanol only reflect very
recent drinking. Keso and Salaspuro (1990) categorised
73% of patients followed up for 8 months as achieving
controlled drinking. However, only 52% had two nor¬
mal values for two recognised markers of excessive
* Corresponding author. Present address: 35 Morningside Park,
Edinburgh EH10 5HF, UK. Tel.: +44 131 5376442; fax: +44 131
5376866; e-mail: jchick@compuserve.com
consumption, y-glutamyl transferase and mean erythro¬
cyte cell volume, which shed doubt on how 'controlled'
some patients' drinking had been.
A review of studies of blood test screening for heavy
drinking (Litten et al., 1995) concluded that serum
carbohydrate deficient transferrin (CDT) has a similar
sensitivity in many populations to serum y-glutamyl
transferase (GGT), but that its specificity was greater.
The relation of sensitivity to specificity depends on the
cut-off chosen for an abnormal result as well as the
population in which the test is studied. Some recent
reports in populations with liver disease (e.g. Ouyaha et
ah, 1995) have found sensitivity of CDT as a marker of
drinking to be lower than that of GGT, although its
specificity is greater because it is normal in many
non-drinking patients with non-alcoholic liver disease.
However, it may be elevated in non-drinkers with some
0376-8716/97/$ 17.00 © 1997 Elsevier Science Ireland Ltd. All rights reserved.
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uncommon conditions such as primary biliary cirrhosis
(Bean et al., 1995). Its specificity has been shown to be
valuable in the detection of alcohol misuse in 59 men
and 19 women with acute pancreatitis. At a cut-off of
> 17 U/L, the specificity of CDT was 100% and sensi¬
tivity 75%, whereas GGT could not distinguish alco¬
holic from non-alcoholic pancreatitis (Jaakkola et al.,
1994).
GGT may be influenced by factors such as body mass
index, coffee consumption, the hour of the day and
physical activity (Schiele et al., 1977; Robinson and
Whitehead, 1989; Nilssen et al., 1990). None of these
factors are yet known to influence CDT.
The GGT is currently used in some clinics and in
research as a marker of relapse in alcohol dependent
patients in out-patient treatment. The value of rising
CDT in detecting relapse has been demonstrated by
Borg et al. (1995) and Helander et al. (1996) who
examined individual trajectories for each patient. Ros-
man et al. (1995) found that CDT detected relapse with
a specificity of 79% plus a sensitivity of 76% when
applying a cut-off of > 20 U/L, and a specificity of 90%
plus a sensitivity of 55% when applying a cut-off of
> 25 U/L. However, currently a CDT test is more
expensive and labour intensive than a GGT test and it
has not entered routine practice in most centres. The
present study examines whether CDT offers an advan¬
tage over GGT as a marker of relapse in the follow-up
of a wide range patients at a routine alcohol problems
out-patient clinic.
2. Materials and method
A total of 60 patients diagnosed as alcohol dependent
(American Psychiatric Association, 1987) agreed to fort¬
nightly blood tests and named an informant such as a
spouse or relative to give additional information about
the drinking or any signs of relapse.
CDT is not yet known to be an efficient marker in
those aged over 65, and does not distinguish alcohol
abuse in primary biliary cirrhosis, chronic active hepati¬
tis or drug induced hepatopathy: these were therefore
exclusions. Also excluded were patients in whom the
clinician would need access to liver function tests for
legal reasons, or because there was significant liver
disease (defined for this study as bilirubin > 25 /zmol/1).
On a fortnightly basis for 6 months, the clinician
estimated the previous 2 weeks' consumption and alco¬
hol problems using the self-report time-line follow back
method (Sobell and Sobell, 1992) and informants' re¬
ports, using physical signs, breath alcohol test and
clinical experience to hone up the self report. For most
subjects, the same clinician performed all the assess¬
ments. The clinician and subject may have been of the
same or opposite gender.
Venepuncture was performed at each visit and serum
sent for assay. Results were stored at the laboratory.
The clinician was kept blind to all blood test results. All
patients who attended more than the intake appoint¬
ment were to be kept in the study, to approximate to the
clinical situation where out-patients cease attending
without warning, but may reappear weeks or months
later.
The plasma CDT assay used a commercially available
kit (CDTect, Pharmacia Diagnostics, Uppsala, Sweden)
based on the separation of transferrin isoforms on an
anion-exchange chromatography microcolumn followed
by a double antibody radioimmunoassay. We took
normal values to be: males below 21 U/L, females below
26 U/L. The analytical coefficient of variation (CV) in
our hands was 10%.
Plasma GGT activity was assayed by SYS 3 BM/Hi-
tachi 747/737 method (Boehringer Mannheim, Lewes,
E. Sussex) reference ranges being males: 10-55 U/L,
females: 5-35 U/L. For the GGT assay the analytical
CV determined in our department was 4%.
2.1. Definition of a 'positive test' for relapse
In order to reflect the way in which a clinician might
use test results as they emerge in a patient being
followed up on a regular basis, a 'positive test' was
defined as a result greater than or equal to the test result
at the last visit, and either > 20% above the lowest
recorded up to that point, or > upper limit of normal
(ULN). We believe that clinicians use variation of
alcohol-sensitive blood tests within the 'normal' range,
and within the range outside the normal, when they are
checking self-reported consumption, and this was why
we chose as cut-offs a percentage change in the test
results.
(A cut-off of + 2.5% specified in the study protocol
was abandoned when analysis of results commenced in
favour of + 20%, based on an analytic CV of 10% for
CDT in our hands. When composite CV (analytical plus
biological CV) was calculated (see Section 3) we realised
that even + 20% was rather low (see Section 4)).
2.2. Definition of relapse
A relapse was defined in two ways: (1) In the past 14
days, weekly consumption of > 56 units of alcohol/
week (80 g/day) for at least 7 days, chosen because we
had used this in our previous work on markers (Chick
et al., 1981) and because it represents a clinically signifi¬
cant relapse, beyond 'controlled drinking'. (2) A 'clini¬
cian's definition': at least one problem in the preceding
14 days from the Alcohol Related Problems Question¬
naire (Patience et al., 1997) comprising 11 social and
medical harms related to alcohol (the subject may or
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may not have been recorded as drinking > 56 units/
week).
2.3. Ethical considerations
Subjects had at least 24 h to decide to participate. If
during the study clinicians believed that for the pa¬
tient's safety blood test results should be examined,
laboratory results could be requested and the subject
withdrawn. In addition the laboratory informed the
consultant (J.C.) if a patient developed a serum biliru¬
bin > 25 /rmol/1 or liver enzymes > 5 times the upper
limit of normal, and a clinical decision about with¬
drawal from the study was made. The study was ap¬
proved by the Ethics of Research Committee. Patients
gave written informed consent.
3. Results
3.1. Characteristics of the patients and retention in the
study
One subject was withdrawn from the study because
of an elevated bilirubin. A total of six patients attended
only for the intake visit. The remaining 53 patients (43
male, ten female) were white, aged 30-59 years.
Pattern of drinking was continuous in 65%, episodic
or 'bout' in 35%. Mean age of onset of heavy drinking
was 25 years (S.D. = 8.1). Their alcohol dependence
was rated as moderate in 30%, severe in 70%. In the
month prior to entry, 19% were abstinent. Some had
been abstinent for very much longer (maximum 465
days), but were still in regular contact with the clinic to
sustain their resistance to relapse. Of those drinking in
the past month, 14% were drinking up to 80 g/day of
ethanol, and the remainder more than 80 g/day. At
entry to the study six patients had a positive breath
alcohol reading and four had severe tremor (mild
tremor in 25). Two-thirds regularly smoked tobacco.
Patients frequently missed appointments but returned
subsequently. Thus for the 11 follow-up visits, the
number of patients with data available on a specific
visit varied from 43 to 19. There were 41 patients with
at least 12 weeks continuous observations and at least
one relapse (32 males, nine females) and these we
termed 'per protocol patients'.
A 'relevant medical or surgical history or concomi¬
tant disease' was documented in 34 patients. A new
physical disorder arising during the study was docu¬
mented in 27 patients. Medication of some type was
being taken at the beginning or was commenced during
the study in 49 patients. (These patients were not
omitted from the study nor from the analysis, because
we wished to test the markers' performance in the worst
possible clinical situation, in which full data on con¬
comitant illness or medications is not available, e.g.
unconscious patient and unreliable patient).
3.2. Marker reliabilities
The mean composite CV (analytical + biological) cal¬
culated in nine non-drinking patients in the study sam¬
ple (six male, three female) assessed at fortnightly visits
(8-12 visits per patient) was 15.3% for CDT and 30.6%
for GGT, presumably reflecting the greater biological
variation in GGT.
3.3. Comparison of relapsers versus non-relapsers
3.3.1. Sensitivities and specificities of a positive test
Sensitivity was defined as the rate at which individu¬
als who relapsed were correctly identified by the test
(i.e. the true positive rate), and specificity as the rate at
which individuals who had not relapsed were correctly
identified (i.e. the true-negative rate). The sensitivity
and specificity of each marker, at each time point, was
calculated using either 'above ULN' as a positive test
or the definition of a 'positive test' given above. Table
1 shows the means over all time points, for the two
definitions of relapse. The specificity of CDT in indicat¬
ing relapse (either definition) appears to be less than
that for GGT. Instances of false positive results were
examined separately—see below.
(When the above analyses were performed in the 'per
protocol' subsample, only very minimal alterations oc-
Table 1
Sensitivities and specificities of blood tests as markers of two defini¬
tions of relapse
Clinical relapseb Sensitivity Specificity
CDT above ULNa 0.75 0.68
GGT above ULN 0.50 0.70
CDT 'positive'd 0.54 0.60
GGT 'positive'11 0.47 0.80
> 56 units/week (mean of 80 g
ethanol/day)c
CDT above ULN 0.90 0.60
GGT above ULN 0.59 0.73
CDT 'positive'd 0.69 0.60
GGT 'positive'"1 0.64 0.76
Mean over 11 follow-up visits, n varies from 43 to 19 over different
visits.
Sensitivity, true positives/(true positives + false negatives); Specificity,
true negatives/(true negatives + false positives).
a Upper limit of normal. GGT, males 55 U/L; females, 35 U/L. CDT,
males 21 U/L; females 26 U/L.
b 'Clinical relapse' (at least one problem from the Alcohol Related
Problems Questionnaire in the past 14 days).
c 'Consumption relapse' (in the past 14 days, weekly consumption of
>56 units of alcohol/week (80 g/day) for at least 7 days).
d Positive test, >test result at last visit and either >20% above lowest
recorded up to that point, or >ULN.
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CDT and GGT (with S.D.) in relapsers and non-relapsers ('clinical relapse') at each visit
No relapse Relapse
n Mean S.D. n Mean S.D. P
U/L)
24 35 28 19 136 331 0.057
19 38 43 13 97 173 0.251
19 50 67 10 365 731 0.125
16 186 596 13 79 79 0.794
17 160 443 12 82 89 0.947
11 33 15 10 64 59 0.219
11 167 451 17 80 69 0.223
11 151 319 8 96 77 0.355
19 51 51 4 49 29 0.749
13 92 209 6 83 70 0.415
19 42 33 6 69 77 0.801
U/L)
23 22.7 19.5 18 31.1 14.8 0.014
19 18.4 8.3 11 30.2 11.6 0.005
19 17.3 10.8 10 29.1 21.7 0.021
16 21.2 113.2 13 29.8 17.6 0.102
17 20.8 13.2 12 45.1 38.2 0.007
11 20.9 7.7 10 44.8 34.4 0.011
11 28.4 23.3 17 35.6 21.5 0.162
11 29.7 23.4 8 29.1 12.1 0.516
19 24.4 14.4 4 43.8 18.1 0.110
13 19.4 9.6 6 41.8 27.5 0.034
19 21.4 16.1 6 32.0 6.8 0.007
lificance of difference between relapsers and non-relapsers,
on rank-sum test.
i in the sensitivities and specificities shown in
1).
Mean test scores
an CDT differentiated clinical relapsers from clin-
on-relapsers at seven of the 11 visits (Wilcoxon
sum test, P < 0.05), but at no visit did mean GGT
;ntiate between the groups (Table 2). For relapse
d as excessive consumption, Fig. 1 shows that
who had consumed 56 units/week (i.e. an average
g/day) or more, for at least 7 days, tended to have
cantly higher CDT than those who had not drunk
it range (statistically significant (P < 0.05) at six
points), while GGT did not differentiate signifi-
' at any time point between those drinking below
bove that level.
ause there was such wide dispersion of the GGT
s, the analysis was repeated using logarithmically
ormed blood test results. Mean log CDT discrim-
1 significantly (P < 0.05) at five time points, but
log GGT failed to discriminate at any points.
7ming of test elevation
>m the drinking record, there were 33 subjects
tiad at least 1 week when they consumed > 56
units/week (i.e. an average of 80 g/day) for 7 days. The
first visit at which this was recorded was noted, and
corresponding and subsequent blood tests results exam¬
ined. GGT and CDT rose simultaneously at seven
of these instances; in three instances, neither rose;
GGT rose before CDT in five instances and CDT
before GGT in 17. (In one subject blood tests at
the time of the drinking were incomplete). Thus, it can
be concluded that CDT tends to react more briskly
than GGT.
3.5. Test relationships to quantity consumed
At each time point, correlations were calculated be¬
tween the test and the previous 2 weeks' consumption.
There were no significant correlations between GGT and
past 2 weeks consumption (range — 0.4- + 0.26), while
at three time points correlations between CDT and
previous two weeks' consumption were significant at the
level F<0.05 (range +0.10 to +0.66). Because of the
wide dispersal of the GGT results, this was repeated
using log GGT and log CDT. No correlations were
significant for GGT (range — 0.02 to + 0.29), and four
were significant at the level P < 0.05 for CDT (range
+ 0.28 to + 0.60).
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4. Discussion
In its heterogeneity, this sample was probably typical
of attenders at an alcohol clinic linked to medical or
psychiatric services. More than 1/2 had another medical
condition, and almost all took medication of some kind
during the study. More medical disorders and drugs
have been shown to affect GGT than CDT. Examina¬
tion of individual trajectories revealed one example
where a GGT 'false positive' had been due to a drug
(lofepramine), but there may have been others. The
clinician will often prefer a marker which is less suscep¬
tible to confounding influences.
Unfortunately, the great number of missing values
has prevented a more appropriate analysis such as a
multivariate repeated measures analysis. In presenting
data at each time point as in Fig. 1, Table 1 and Table
2, an apparent trend may be inflated, because some of
the same individuals appear in each analysis. To answer
the questions posed by this study, the required popula¬
tion is of patients who are prepared to be seen regularly
and frequently, and who are likely to relapse. Unfortu¬
nately, relapsers miss appointments. It is therefore in¬
herently a difficult study to conduct.
The comparison of the mean scores at the different
time points (Table 2,Fig. 1) suggests that overall CDT
appears to be an earlier indicator of relapse than GGT.
Table 1, however, reveals that when our definition of a
'positive' test is used, there appear to be on average
more false positives with CDT than GGT. This may be
in part because CDT 'heralds' relapse—as explained
above. Rosman et al. (1995), like ourselves, reported
that a rise in CDT sometimes occurred before the
relapse was admitted or obvious. Borg et al. (1995),
basing their conclusions on daily urine 5-hydroxy tryp-
tophol as a marker of recent drinking, found that
alcohol-dependent out-patients frequently drank in a
way that was initially not obvious and was only re¬
vealed later.
Another factor contributing to false positives was a
cut-off (20% above lowest recorded at that point for
that patient) that was only just at the upper limit of the
composite coefficient of variation, and thus 'positives'
for both markers are (statistically) likely to occur with¬
out drinking alcohol.
4.1. Studies suggesting CDT may be more 'responsive'
than GGT
The half-life of CDT in newly abstinent alcoholics
was 16 + 5 days in the study of Behrens et al. (1988),
and the review by Allen et al. (1994), put it at about 15
days, while for GGT it has been found to vary between
14 and 26 days (Litten et al., 1995). CDT can thus be
said to be a slightly more responsive indicator.
Behrens et al. (1988) suggest that the CDT test has
increased sensitivity in abstinent alcoholics given a new
alcohol challenge. They found that serum CDT in¬
creased within a few days of starting drinking. Stibler et
al. (1986) suggested that less than the 10 days was
necessary for an elevation in non-alcoholics taking a
daily alcohol consumption of 60 g/day. They found that
in the six patients who drank after discharge and in
whom CDT level soon rose again, GGT and transami¬
nases remained normal in all but one. Our results
support this sensitisation hypothesis.
(It should be noted that there is currently some
confusion about how much alcohol needs to be con¬
sumed by non-heavy drinkers, and for how long, to
elevate CDT above normal. Stibler et al. (1986) sug¬
gested that at least 60 g/day for at least 3 weeks was
required. Salmela et al. (1994) found that 60 g/day for
3 weeks caused CDT (Pharmacia method) to rise above
cut-off (UFN) in only two out of ten volunteers, but an
elevation was found in nine out of ten. Lesch et al.
(1996) failed to show consistent elevations (Axis %
method) in 51 healthy men drinking either 60 or 80
g/day.)
4.2. Limitations of CDT as a relapse marker
The apparent high false positive rate at the cut-offs
we used may, of course, also reflect a weakness in the
test. There are various methods for assessing CDT and
there is currently debate about whether tri-sialo-trans-
ferrins should be included when calculating CDT (Heg-
gli et al., 1996). There are limitations on the absolute
meaning of a single positive CDT test.
4.3. Clinical application of CDT in detecting relapse
Ideally patients who are receiving treatment for alco¬
hol dependence are frank with their therapists about
resumption of drinking. However, even the most em-
pathic therapist may not achieve such a completely
open relationship. When resumption of drinking may
escalate to a relapse with very serious medical or social
consequences, aids to the recognition of return to
drinking have an important clinical role. This study
shows that, if repeated tests are being done at relatively
short intervals, in some patients CDT will perform
better than GGT as an objective early marker of re¬
sumed drinking.
In patients taking antidepressants or anticonvulsants,
a drug-related false positive test is less likely with CDT
than with GGT. In patients taking disulfiram, there is
no specific advantage of CDT over GGT, because
neither test appears to be elevated by this drug (He-
lander and Carlsson, 1996; for GGT, Chick et al.,
1992).
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When a patient requests assistance in reassuring an
employer or a professional licensing body, or in the
case of child protection procedures a social work panel,
or reports are requested for the court when an offender
has a deferred sentence pending following treatment for
alcohol dependence, then CDT is a helpful aid to the
clinician monitoring response to treatment.
We would agree with Helander et al. (1996) that the
two markers should be regarded as complimentary. In
the individual case, by following changes in the tests
during alcohol withdrawal, the most sensitive marker
for that individual can be determined.
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LIMITATIONS OF CDT AND GGT IN DETECTING RELAPSES IN PATIENTS
ATTENDING AN ALCOHOL PROBLEMS CLINIC
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Abstract: Biochemical markers ofalcohol consumption are usefulfor the detection and monitoring ofproblem
drinking. Blood samples from 37 patients attending an alcohol treatment clinic were analysed for GGT and
%CDT, and results were compared with self-reported periods of abstinence and alcohol consumption. Poor
correlation was obtained between GGT and %CDT, and between these assays and self-reported alcohol use. The
apparent sensitivity and specificity ofGGT (57%, 63%) and %>CDT (43%o, 88%), were considerably lower than
those reported by other workers.
Keywords: Alcohol dependence, carbohydrate deficient tranferrin, gamma glutamyl tranferase, biochemical markers
of alcohol consumption.
Alcohol (ethanol) abuse is a serious problem for theindividuals concern d nd ha serious social
consequences for the user's relationships in the family and the
workplace, and also for society at large.
Alcohol is a CNS depressant which leads to loss of
concentration, impaired judgement and vision, slower reaction,
over estimation of personal ability, dizziness, nausea and
disturbances of balance and co-ordination.1 Elevated
concentrations of alcohol in the blood can have an adverse
effect on driving ability and give rise to errors and accidents.
Driving ability can also be affected by sensory and mental
defects occurring in chronic alcohol abuse. In the workplace,
alcohol abuse can lead to a deterioration in the standard of
workmanship particularly in occupations requiring high levels
of concentration and skill, rapid reactions, and visual acuity. In
addition there is a greater risk of accidents and injury, and an
increase in absenteeism from work. As a result, alcohol abuse
has serious financial implications for employers and for the
national economy.
Measurement of the concentration of alcohol in plasma or
blood is used routinely in the investigation of road traffic
accidents but is of limited value in detecting possible alcohol
abuse because of the rapid rate of metabolism of alcohol in
blood (about 120 mg/kg per hour). Measurement of mean cell
volume (MCV) has been used as a marker of drinking but is of
limited value.2
Self-reporting of alcohol use is notoriously unreliable but it
is still considered to be important in the management ofalcohol
abusers and forms the basis of many evaluations of analytical
procedures.3"8 The accuracy of information obtained can be
improved considerably by the use ofcollateral reporting which
involves not only the patient but a spouse or relative and/or a
working colleague.
Measurement of serum gamma glutamyl transferase (GGT)
together with other liver function tests is widely used for the
investigation ofpossible alcohol abuse and for the management
ofpatients with alcohol problems.2"910 In the UK, it is also used
for processing applications for renewal of driving licences.
Despite its wide use, several reports have drawn attention to
the diagnostic inaccuracy of GGT for these purposes.9"11
It has been suggested that carbohydrate deficient transferrin
Correspondence to: Dr Jonathan Chick, Alcohol Problems Clinic, 35
Morningside Park, Edinburgh EH 10 5HD.
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(CDT)12 has a greater sensitivity and/or specificity than GGT in
detecting alcohol dependence.913 There have, however, been
only a few studies ofnon dependent hazardous drinkers.10 The
half-life of CDT, about 15 days, is probably slightly shorter
than that of GGT (14-26 days), and hence CDT may be
considered to be a slightly more responsive indicator.8-912'13 In
addition, GGT may be influenced by factors such as body mass
index, coffee consumption, the hour of the day and physical
activity.1416 None ofthese factors are yet known to affect CDT.
Carbohydrate deficient transferrin
Serum transferrin contains two complex carbohydrate chains
consisting of four different carbohydrates (N-
acetylglucosamine, mannose, galactose, sialic acid) but the exact
content varies considerably.12 The terminal sialic acid is the
only charged carbohydrate in serum transferrin.
Regular high alcohol consumption results in the appearance
of isoforms of serum transferrin, which are deficient in their
carbohydrate content. These isotransferrins have a decreased
sialic acid content and are less negatively charged and have
higher isoelectric points than normal transferrins. The isoforms
can, therefore, be separated by methods based on charge.
Daily alcohol intake ofmore than 60g ethanol (about 45 units/
week) for at least one week usually results in elevated
concentrations of CDT. During alcohol abstinence,
concentrations are reported to return to normal levels with a
mean half-life of 12-17 days.8 912-13 CDT is a potentially useful
marker of drinking 2-3 weeks previous to a blood test.
Heggli et al17 investigated the sensitivity and accuracy of
using relative concentrations of the different isotransferrins in
serum for the diagnosis ofchronically elevated elevated alcohol
consumption. They found that including the tri-sialo-transferrin
fraction into the definition of %CDT resulted in an increased
accuracy in the detection ofchronically elevated alcohol intake.
A commercial kit for the measurement of serum CDT is
marketed by Pharmacia Diagnostics (Uppsala, Sweden). The
CDTect™ assay is based on the separation of transferrin
isoforms on a microcolumn followed by a double antibody
radioimmunoassay. A fluorimetric immunoassay version ofthe
kit is also available.
More recently, Axis Biochemicals ASA (Grunerlokka, Oslo,
Norway) developed a commercial turbidimetric immunoassay
which measures the percentage of the CDT isoforms (a-, mono,
di-, and trisialotransferrin) relative to total transferrin in serum.
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Predicting relapse in problem drinkers
Ideally patients who are receiving treatment for alcohol
dependence are frank with their therapists about resumption of
drinking. However, even the most empathic therapist may not
achieve such a completely open relationship. When resumption
of drinking may escalate with very serious medical or social
consequences, aids to the recognition of a return to drinking at
an early stage have an important clinical role.18
Conventional markers, including serum GGT, have been used
to detect increased consumption ofalcohol, but by the time it is
detected, people are frequently already dependent on alcohol
and suffer from major complications caused by their
consumption.19 For early identification of heavy drinking and
monitoring during treatment ofout-patients, markers with higher
sensitivity and specificity are needed.
Serum CDT is reported to be an accurate biochemical marker
for the detection of recent excessive alcohol consumption, with
a greater sensitivity and/or specificity than GGT. There have
also been several reports of the use of CDT in the detection of
relapses in alcohol-dependent patients.7,12'19
We describe here a study in which blood samples from
patients attending an alcohol treatment clinic were analysed
for %CDT, GGT and liver function tests and results were
compared with reported periods of abstinence and alcohol
consumption.
Subjects and methods
Thirty seven patients (29 males, 8 females) attending a Scottish
alcohol treatment clinic volunteered to give a venous blood
sample. They were mainly out-patients attending for follow-up,
and the remainder were in-patients admitted within the past 10
days. The interval since their last drink ofany alcoholic beverage
was recorded and using the Timeline follow-back method22 their
consumption in units of alcohol in the preceding 14 days was
totalled (one unit is equivalent to about lOg ethanol).
Abstinence from alcohol for less than 14 days and alcohol
consumption during this period greater than the "safe limit"
(Royal Colleges of Physicians, Psychiatrists and General
Practitioners, 1994) ie greater than a mean of20 units per week,
were taken as an indication of relapse. Definitions of relapse
and possible relapse, are given in Table I.
The plasma GGT activity was measured by the SYS 3 BM/
Hitachi 747/737 method (Boehringer Mannheim, Lewes, E.
Sussex). Reference ranges of 10-55 u/L for males and 5-35 u/L
for females were used. The coefficient of variation (CV) of the
method is 4%.
Percentage CDT was measured by the Axis turbidimetric
immunoassay. Serum transferrin in the sample was saturated
with Fe3+ and the isoforms separated on an ion-exchange
microcolumn.
The eluted CDT isoforms form immune complexes with
antitransferrin antibodies and the CDT content was determined
by a turbidimetric assay on a Cobas Mira analyser (Roche
Diagnostics, Welwyn City, UK). The total transferrin content
of the samples was determined separately using the same anti¬
transferrin complexes. Measurements were evaluated using a
calibration curve and the %C DT value calculated according to
the manufacturer's instructions. 23
Daily intake of alcohol exceeding 60g ethanol for periods
longer than two weeks, may result in %CDT values higher than
6%. The %CDT range for total abstainers is found to be 0-5%.23
Results
There was a low correlation between %CDT and GGT
(correlation coefficient, 0.370). Percentage CDT also showed a
low correlation with self reported days ofabstinence (correlation
coefficient, -0.151) and only a moderate correlation with self
reported alcohol consumption in the preceding 14 days
(correlation coefficient, 0.302); the corresponding correlation
coefficients for GGT were -0.222 and 0.283, respectively.
A summary of the findings for samples from the 37 patients
investigated is given in Table I. Ofthe 23 samples from patients
with a reported abstinence time of less than 14 days, and
consumption greater than 40 units in the preceding 14 days,
GGT and %CDT were above the reference ranges for 13 (57%)
and 10 (43%), respectively. Of these patients, seven (30%)
showed neither GGT nor %CDT outside the reference ranges.
For eight patients with a reported duration of abstinence of 14
or more days, five (63%) ofthe GGT results and seven (88%) of
the %CDT results were within reference limits. Using a higher
cutoff (90 units in the preceding 14 days), the %CDT was greater
than 6% in six of20 patients.
The sensitivity and specificity of the %CDT assay in
detecting relapse based on self reporting were 43% and 88%
respectively; the corresponding values for GGT were 57% and
63%, respectively.
Efficiency (the proportion of the total number of patients
correctly classified using the test) was 58% for GGT and 55%
for CDT.
Discussion
A comparison ofthe use ofGGT and CDT as biological markers
of heavy alcohol consumption has been reported in a large
number of publications.9 Although the findings differ widely
depending on the investigative procedures employed and the
populations studied, GGT is considered to have equal sensitivity
but to be less specific than CDT. Behrens et al13 report that
CDT proved to be a more sensitive marker than GGT for chronic
alcoholism whereas GGT was more useful only in patients with
normal CDT levels before alcohol withdrawal.
In our study the sensitivity and specificity ofGGT and %CDT
were considerably lower than those reported by other
workers.911 There was also relatively poor correlation between
these markers and self reported time since last alcoholic drink
and alcohol consumption over the preceding 14 days. This
may in part be because some others make a comparison between
newly admitted alcoholic patients in a general hospital and non¬
alcoholic admissions to that hospital, while we have attempted
Table I
Summary of performance of GGT and %CDT assays compared












Number of GGT and %CDT Results
Number Above Reference Ranges [1]
of








GGT (males) 10-55u/L; GGT (females) 5-35u/L
[2] Relapsed Abstinent days: <14 days, and Consumption
(14 days): >40 units
[3] Possible Relapse Abstinent days: <14 days, and Consumption
(14 days): <40 units
[4] Abstinent Abstinent days: >14 days
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to examine drinking within a sample of alcoholics. Some other
studies have used wholly in-patients in detoxification units, eg
Stowell et al," when estimates of time since last alcoholic drink
and recent total alcohol consumption are likely to be more
reliable than in our sample comprising mainly out-patients.
Nevertheless, a previous study from our clinic ofnewly admitted
in patients,24 like our present study, also found a very poor
correlation between GGT and self-reported alcohol
consumption. The results from our relatively small study do,
however, support the previously reported finding that CDT is
more specific but less sensitive than GGT for the detection of
alcohol abuse.9
Combined use of CDT and GGT is reported to increase the
sensitivity of detecting alcohol abuse in patients admitted to
hospital to 95% and proved to be useful in the evaluation of
treatment.13 In our study, measurement of CDT in addition to
GGT gaveonly a limited improvement in the detection ofrelapse.
Our definition of relapse (see Table I) was lower than the cut¬
offof 60g per day for at least two weeks (le about 45 units per
week) at which the %CDT can be expected to exceed 6%. This
might seem to explain the lower sensitivity of%CDT reported
here. However, even when we use 90 units per two weeks as
cut-off, the %CDT was greater than 6% in only six out of 20
patients (30%).
Assays for GGT can be performed on automated analysers,
are inexpensive, and are readily available in most clinical
biochemistry laboratories. In contrast, CDT is a highly labour
intensive assay requiring specialist equipment, reagent costs
are high, and the shelf-life of RIA kits is short (about one
month). A CDTect™ fluorimetric immunoassay has been
introduced but the assay is still labour intensive and reagents
are expensive although the shelf-like of kits is considerably
longer (6-9 months). The Axis turbidimetric immunoassay for
%CDT involves a preliminary separation stage similar to that of
the CDTect™ method and hence this stage is labour intensive.
The Axis assay can, however, be performed using analytical
equipment which is readily available in most clinical
biochemistry laboratories, eg Roche Cobas Mira/Fara and IL
900/1800, but the calculation has to be done manually.
Allen et al8 have drawn attention to the need for further
research to establish more precisely the period of abstinence
necessary for CDT levels to return to the normal range and to
determine the extent to which duration ofCDT elevation might
reflect the initial level of the marker, typical drinking pattern,
age and gender, as well as type of laboratory test, and which is
the optimum CDT quantitation method to use. In addition, there
is a dearth of information on subsequent CDT levels should
drinking moderate but not cease.
Conclusions
Current markers of alcohol use have obvious limitations, and it
seems unlikely that for clinical purposes, laboratory tests will
completely replace a physician's judgement in the diagnosis of
hazardous alcohol intake or dependence.10,25 A serious problem
with the introduction of new markers is unreliability of self-
reported periods of abstinence and quantity of alcohol
consumed which are used as criteria for the evaluation of
analytical methods. If however, their limitations are clearly
understood, laboratory tests provide useful aids in detection
and objective monitoring of hazardous alcohol consumption
and many of its pathological sequelae.10,25
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I Prevalence Estimates of Alcohol-Related Disorders
The vagaries of recording cause of death and the variation in
different epochs and between regions in referral policies and
hospital admission policies conspire against the use of official
statistics as prevalence estimates. In the epidemiology of
alcohol-related disorders the alternative method, the direct
survey, is handicapped because of the reticence of the heavy
drinker and, indeed, the difficulty the door-to-door interviewer
has finding him at home. Figure 1 shows trends in England and
Wales in some of the "indirect indices of alcoholism".
FIG. 1. Deaths from alcoholism and cirrhosis, of¬
fences of drunkenness and consumption of al¬
cohol in England and Wales, 1860-1978
(Reprinted, with permission, from Taylor, 1981)
Deaths are expressed per million, drunkenness offences as rate per
10000 population, and per caput alcohol consumption as litres of
absolute alcohol
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Cirrhosis. The death rate in the UK has risen since 1950,
though it is still appreciably lower than it was in 1900. From a
rate of 23/million in 1950 it rose by 3% a year to 44/million in
1979. Standardized mortality rates show that the trend is not
accounted for by slight changes in the age structure of the
population (Registrar General's annual reports). Figure 2
shows that this increase cannot be accounted for merely by a
shift in doctors' preference for the term "cirrhosis" as against
other categories of liver disease.
Hospital admissions. Admissions for alcoholism have also
risen in most developed countries during the past 20 years. For
example, in Scotland, in 1906, many years before the 1960s
movement to provide specialized in-patient treatment for
alcoholics, the typical mental hospital recorded alcoholism as
one of the three major causes of admission. By 1957 it was
relegated to a position of minor importance, accounting for only
a total of 840 admissions. By 1974 total admissions for
alcoholism and alcoholic psychosis had reached 5417 and in
1978 were still 5222, despite a growing interest in out-patient
and "community" care. First admissions, a somewhat more
accurate indicator of inception, rose as shown in Table I. The
work load contributed to by alcoholism also increased during
this period, discharges from general hospitals with the diagnosis
of alcoholism or alcoholic psychosis nearly quadrupling in the
decade 1968-78.
Survey estimates. There are two main precautions in
obtaining direct estimates of prevalence of alcohol-related dis¬
abilities from community surveys. First, surveys are known to
under-estimate the number of heavy drinkers (Pernanen, 1974).
Second, prevalence rates in surveys are very sensitive to altera¬
tions in the definition of a "case". In a North American survey
analysed by Clark (1966) changing the definition with respect to
severity yielded a variation in rates from 3/1000 to 62/1000.
When he made the criteria lax enough to include past as well as
present alcohol-related problems a figure of 272/1000 was
reached. Clearly, the epidemiologist is not looking at a fixed
condition, "alcoholism", which is either present or absent, and
where a case remains a case, but at a range of alcohol-related
problems which are reported by members of the community in
different degrees and which may be either past or present.
FIG. 2. Deaths from cirrhosis and other liver disease,
England and Wales, 1946-79
(Data from Registrar General's annual reports)
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TABLE I. Scotland: first admissions to psychiatric
hospitals with a diagnosis of alcoholism and
alcoholic psychosis
(Data from Scottish Home and Health Department)
1965 1967 1969 1971 1973 1975 1977 1979
Males 960 1000 966 1120 1509 1647 1621 1532
Females 194 182 213 301 379 434 497 558
2 Patterns of Alcohol Consumption
i National Variations
National data on consumption patterns are as subject to
important errors as those on prevalence of problems (Kreitman,
1977). Government revenue statistics are the usual source of
information on over-all consumption in nations.
Grape growing is, of course, associated with high con¬
sumption, with France, Portugal, Spain and Italy having the
highest per caput consumption in Europe. The relation between
agriculture, gastronomic customs, symbolic meanings of alcohol
and national styles of drinking has to date only been the subject
of discursive papers. In the UK, revenue on beer and spirits has
been collected since the 17th century. Spring & Buss (1977)
note that beer consumption was at its maximum in 1689 and
spirits in the early 1870s. The lowest point in per caput
consumption of all forms of alcohol for three centuries was
reached after the Second World War. The next two decades
have seen a steady rise. The trend until 1978, shown in fig. 1, is
still present (Brewers' Society, 1980).
The causes of temporal fluctuations in national consumption
are incompletely understood. Number of outlets and to a less
extent price and advertising can be demonstrated by econo¬
metric analysis to have some effect (McGuinness, 1980).
"Formal controls" comprise laws on drinking and driving, and
drunkenness, and taxation and licensing laws. A recent change
in legislation in Scotland provided an opportunity for studying
the effect of an extension of licensing laws. "Before" and
"after" surveys were conducted (Knight & Wilson, 1980) and
showed that, during this period, though there was a reduction in
average speed of drinking, over-all consumption increased in
women and in men aged <45 years. Changes in prevailing
customs and attitudes to drinking—"informal controls"—are
probably equally if not more important, but their effects are even
less well understood.
ii Trends amongst Women
In the past decade, in several countries, the long-standing gap
between men's and women's consumption appeared to be
diminishing. Comparisons between successive surveys provide
the only direct means of testing this impression. For example, a
World Health Organization survey in 1978 in the Lothian region
of Scotland repeated measures already available for that area
from a survey in 1972 (Dight, 1976). While not finding an
increase in the proportion of male drinkers who fell into the
higher-consumption categories, the WHO survey found that
now 11% of women admit to consuming 11 or more units1 a
week, whereas previously only 4% of women drinkers fell into
1 1 "unit" is designated as equivalent to 10ml or 8 g of alcohol, i.e. \ pint beer, a single
measure of spirits (40% by volume), 4 oz of table wine, and so on
that category. The increase was accounted for chiefly by
younger, single women (World Health Organization, in
preparation).
Some possible causes of these changes in women's drinking
are discussed by Shaw (1980): greater female employment and
higher earnings; the recent increased availability of alcohol in
supermarkets; advertising aimed specifically at women; the
growing numbers of women employed in public houses and
clubs; blurring of the traditional sex differences in both leisure
and work activities.
iii Influence ofAge
The increase in consumption which took place after the
Second World War in most developed countries was accom¬
panied by more frequent drinking amongst 14-18 year olds. In
the USA and Finland where survey data over successive years
are available the trend was not continued into the 1970s:
Ahlstrom (19792) in Finland and Rachal et al. (19803) in the
USA found a slight decrease in regular drinking and a slight
increase in abstaining. In the UK, the rate of offences for
drunkenness amongst this age-group also reached a plateau in
the 1970s. In all surveys in the UK and Scandinavia in the past
15 years, men in their early twenties are the heaviest consumers.
In Scotland, high consumption amongst young men appears to
continue for longer than in England and Wales and Northern
Ireland (Wilson, 1980a).
iv Regional Variations within the UK
Edwards et al. (1972) found that London survey respondents
who were Scottish and Irish reported heavier consumption than
respondents born in England. Wilson (1980a) compared results
of similar surveys conducted in 1978, in England, Wales,
Scotland and Northern Ireland. Reported abstention rates,
mean consumption and proportion of heavy drinkers were the
same in Scotland and in England and Wales, but Northern
Ireland had a greater proportion of abstainers and lower
consumption amongst those who drank. Drinking was concen¬
trated into fewer days in Scotland, so that 40% of all adult male
drinkers in Scotland had drunk 8 units or more on one day,
compared with 27% of English adult male drinkers.
v Occupation, Social Class and Leisure
Plant (1979) discussed the various reasons for the as¬
sociation of heavy drinking and certain occupations: availability
of alcohol at work; social pressure; separation from normal
social and sexual relationships (e.g. seamen, servicemen);
freedom from supervision (which has been proposed as a
contributing factor to the heavy drinking of doctors, lawyers
and company directors). In the 1978 England and Wales
survey, workers from the construction industry had the highest
proportion of men drinking over 50 units/week (19% as
opposed to 6% for the whole male population). Men from the
drinks industry had the highest average per person consumption,
18% drinking over 50 units/week. In Scotland (Chick et al.
1981a) 25% of manual workers in an alcohol production firm
admitted to drinking over 50 units/week. In that study it was
also found that 15% of company directors and senior executives
from a wide range of companies admitted to drinking in that
1 Ahlstrom S (1979) Paper presented at the meeting of the Epidemiology Section,
International Council on Alcoholism and Addiction, Tours
3 Rachal V, Maisto S, Guess L & Hubbard R (1980) Paper presented at the meeting of
the Epidemiology Section, International Council on Alcoholism and Addiction, Cardiff
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range. A comparison of reported consumption with data from
blood tests suggested that the directors minimized their reports
more than the manual workers. In fact, the directors had a
higher mean y-glutamyltransferase (y-GT) value. Drinking
during the working day was as common in the work setting of
the directors as that of the distillery workers.
By following through for two years new recruits to a brewery
and, as a control, a biscuit factory, Plant demonstrated that
brewery work attracts men who are already heavy drinkers as
well as leading to an increased consumption amongst new
recruits.
Earlier surveys found fewer heavy drinkers in the upper social
classes than did recent surveys. By 1978, Wilson (1980b) found
the same proportion of heavy drinkers in social class II
(managerial and junior professional) as amongst manual
workers. Drinking in the lower social classes is more concen¬
trated. "Going out for a drink" is the commonest evening
leisure activity of both men and women nowadays (Wilson,
1980b).
vi The Relation between per Caput Consumption and Number
ofHeavy Drinkers
A controversial issue is whether a social or economic
influence which produces a rise in the average consumption in a
population tends to increase the proportion of heavy drinkers
(see Bruun et al. 1975). Clearly there is no necessary reason
why this should be so. For example, if retailing forces were
directed at a hitherto predominantly abstinent group and caused
many to become light drinkers a rise in per caput consumption
at national level would result without more individuals be¬
coming heavy drinkers. One cannot predict statistically from
per caput consumption to numbers of heavy drinkers, only
empirically.
Where successive surveys in the same population are made
against a background of increasing consumption the link
between per caput consumption and prevalence of heavy
consumption can be tested. Comparable surveys of national
samples in the USA were conducted in 1964, 1966, 1969, 1970
and 1971, a period when per caput consumption was increasing
at the rate of 30%/decade. The proportion of abstainers in the
population did not change. The shift was towards somewhat
heavier drinking by those already drinking and a greater number
of individuals drinking, at least occasionally, at levels where they
might be intoxicated (Room, 1974).
Between two surveys, in 1969 and 1976, Finland experienced
a 67% rise in per caput consumption. There was a trivial rise in
the proportion of the population drinking in the highest
consumption category, but a greater proportion of drinking
occurred on occasions when blood alcohol was likely to have
exceeded lOOmg/lOOml (Simpura, 1978).
Cartwright et al. (1978) compared surveys carried out in
south London in 1965 and 1974. The mean admitted
consumption of respondents in the second survey was 47%
greater than in the first. The proportion of individuals drinking
over 50 units/week increased from 1-3% to 4%. However, the
number of individual subjects in this category in 1974, because
of the small size of the survey, was merely 10. Furthermore,
different sampling frames were used in the two surveys.
In Scotland it is assumed that consumption has been rising
throughout the 1960s and 1970s, though separate customs and
excise figures are not available. In the UK as a whole,
consumption rose continually throughout this period (Brewers'
Society, 1980), and it is assumed that this applied to Scotland
too. Nevertheless, Scottish surveys found the prevalence of
those admitting to over 50 units/week to be unchanged: 7% in
1972 (Dight, 1976) and 6% in 1978 (Wilson, 1980a).
The survey is a blunt instrument, which leaves particularly
ragged edges at the heavy end of the consumption distribution.
A possible link between rising per caput consumption and
proportion of heavy users cannot be regarded as proved or
disproved by the above examples. General population survey
data about heavy consumers are too unreliable. It would in any
case be dangerous to extrapolate from the results of surveys in
one culture to conditions in another culture. A more pressing
question is whether or not there is a link between trends in
availability and attitudes to drinking in a nation, as reflected in
per caput consumption, and rates of harm from alcohol (see
section 6).
3 The Relation Between Alcohol Consumption and Adverse
Consequences
i Collation Studies
Correlation of per caput consumption with age-specific
mortality rates across a number of countries or regions suggests
a link between alcohol and cirrhosis (e.g. Schmidt, 1977a) and
alcohol and cancer of the gastrointestinal tract (e.g. Knox,
1977). The method has also demonstrated a link between
alcohol and deaths from road accidents and a negative link
between wine consumption and death from ischaemic heart
disease (St Leger et al. 1979).
ii Health Hazards in the Individual Heavy Drinker
Schmidt & Popham (1976) have reviewed the extensive
international literature on morbidity and mortality of alcoholics.
In the UK, Adelstein & White (1976) found a sample of
alcoholics known to mental hospitals to have an over-all excess
mortality of 2-2 to 1. As well as cirrhosis, suicide and
accidental death, other conditions also contribute. Cancer,
pancreatic and gastrointestinal disease and circulatory dis¬
orders are discussed elsewhere in this number. The raised
mortality from bronchitis and pneumonia is thought to be due to
the smoking habits and social decline of some alcoholics in
hospital-identified populations. The raised rate of stroke death
is mediated by high blood pressure (e.g. Kozarevic et al. 1980).
Rates of disease obtained from a "clinic" population may be
fallacious if applied generally, as they are biased by the factors
that led to the patient attending hospital and so being identified.
For example, the increased risk of suicide (Ritson, 1977)
in alcoholics known to a psychiatric hospital reflects the fact
that the initial presentation may have been emotional distress or
depression. Alcoholics driven to attend clinics have usually
suffered many reverses.
However, other factors probably also contribute to the
relation between alcoholism and suicide. Young alcoholics tend
to abuse other drugs. An underlying "depressive constitution"
may contribute in some instances. Alcohol may cause
depression pharmacologically (Whitlock & Evans, 1978).
Recently it has become clear that alcohol and depression are
related, not only in psychiatric clinic samples, but also in the
general population (Weissman et al. 1980).
Factors such as social disruption and lower social class,
which lead to referral to some types of clinic, may be why some
and not all clinic samples of alcoholics have a raised prevalence
of peptic ulcer. Community surveys do not show links between
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heavy drinking and peptic ulcer. However, they are limited in
that they usually detect few if any subjects admitting to drinking
in the alcoholic range. In a review of 14 studies in this area and
from a survey of relatively heavy-drinking distillery workers and
company directors, I have concluded that on balance it is
unlikely that alcohol causes peptic ulcers (Chick, in
preparation).
Nevertheless, heavy drinkers identified in community surveys
do also have an excess mortality. Among white male employees
of the Chicago Western Electric Company, consumption
(admitted) of 6 or more drinks a day was associated with a
trebling of mortality. An excess mortality was still demon¬
strable after allowing for cigarette consumption and this applied
to death from cancer and cardiovascular disease too (Dyer et al.
1980). These authors review mortality studies in other
community-based cohorts, and note agreement with their own
findings.
Peterson et al. (1980) invited a group of 48-49-year-old men
from the general population to a screening clinic. Of the 41 who
died in the initial 1-4 year follow-up, 16 were "heavy drinkers"
confirmed by a raised y-GT value that was unlikely to have been
due to another cause (my analysis).
iii Level ofDrinking and Adverse Consequences
A man who drinks 50 units/week (80g/day), but concen¬
trates it all into Friday and Saturday evenings, is clearly more at
risk of injury or accidental death from drunkenness than if he
spreads his drinking through the week. There is no evidence
that this pattern puts him more or less at risk of damaging his
liver (Schmidt, 1977b). However, it is controversial whether at
that level of consumption he is "significantly" at risk of
contracting cirrhosis.
The most important study of the quantity drunk by patients
with alcoholic liver disease is that of Lelbach (1974). In 417
male alcoholics with reliable consumption data, he showed that
quantity of alcohol consumed was related to severity of liver
damage as determined by biopsy. All patients with cirrhosis
reported drinking over 196g/day. In two studies on defined
populations in France (Bouches du Rhone and Ille et Vilaine),
patients with ascitic cirrhosis were interviewed about their
consumption (Pequignot & Tuyns, 1976; Pequignot et al. 1978).
The same interview was given to a general population sample
drawn from the electoral roll. Whereas 74% and 72% of the
cirrhotics admitted to drinking over 80g/day, only 20% and
14% of the general population did so. The relative risk (an
index of "observed" to "expected" cases) is already 6 times
greater at 40-60g/day than at 0-20g/day. At 60-80g/day it is
14 times greater. Lelbach had no cases where consumption was
<196g/day: perhaps some cirrhotics who might have fallen into
the lower-consumption category were excluded as "not provid¬
ing reliable consumption data". One would expect in a
population attending an alcohol clinic only to find heavy
drinkers. On the other hand, perhaps Pequignot's estimates of
his subjects' consumption were considerably minimized, a
possibility he freely admits. Furthermore, as in most general
population studies, the heavy drinkers not in hospital with
cirrhosis may have been missed: in the Ille et Vilaine study, for
example, the non-contact rate (males) was 18% and in the
Bouches du Rhone study it was 34% (whole sample). Exces¬
sive drinkers, particularly, may not only refuse to be interviewed
but also tend to be socially unstable and difficult to contact. A
final caveat to interpreting Pequignot's finding that nearly a
third of the male cirrhotics admitted to drinking <80g/day is
that "cryptogenic" cases were deliberately included: some of
these may have had a non-alcoholic cause.
Saunders et al. (1981) reviewed the evidence that women
develop alcoholic liver disease after a shorter and lighter
exposure to alcohol than men. Pequignot's Ille et Vilaine study
(though not the Bouches du Rhone study) shows a significantly
greater proportion of women than men cirrhotics in the
21 40g/day consumption category (my analysis). However,
perhaps a sample of female cirrhotics contains a higher
proportion of cases of non-alcoholic aetiology than does a
sample of male cirrhotics.
iv Other Mediators of the Relationship between Consumption
and Consequences
Cultural forces are an important influence on whether or not
at a given consumption an individual has problems from his
drinking. Within nations, higher social class has been shown to
protect an individual from adverse social consequences. Be¬
tween cultures, the meaning of drinking, the comportment
expected of the drinker by his peers and the permissiveness or
otherwise of the orthodox culture towards drunken behaviour
influence the rate and type of social problems (Makela, 1978).
Surveys find only limited overlap between high consumption
and problems from drinking. Not all "problem drinkers" are
heavy consumers and vice versa. Style of drinking has some
bearing: a measure of consumption in terms of amount drunk on
each occasion improves predictions of who will have social
problems, but by no means completely (Cartwright et al. 1978).
Amongst "alcoholics" social problems accrue more readily
amongst those with few resources (lower social economic
groups). Death from liver disease is commoner in those from
higher-status occupations, perhaps because they are not subject
to the criticism, for example from employers, which intermit
tently or permanently puts a brake on the drinker in a less
privileged position (Edwards et al. 1974).
Type of beverage is of little relevance for adverse health
consequences, though it seems likely that spirits are important in
the link between alcohol and cancer of the oral cavity and
oesophagus (Wynder & Mabuchi, 1972).
Certain personality traits are predictive of harm from
drinking. When cohorts of young men have been followed into
adult life those who were impulsive, gregarious and rebellious as
teenagers are more likely to have subsequent problems from
drinking. Amongst working men, impulsivity, rebelliousness
and carelessness predict problems even when consumption is
held constant, as do early separations from mother or father
(Chick, in preparation).
4 Alcohol and Longevity
Two recent papers describing prospective studies designed to
examine risk factors in heart disease report that light drinkers
(consuming <4 drinks/day) have a lower total mortality than
abstainers (Blackwelder et al. 1980; Marmot et al. 1981).
The difficulties in interpreting these data are as follows. First,
if heavy drinkers deny their drinking they will inflate the
mortality of the non-drinkers. However, there is no evidence
that very heavy drinkers are more likely to totally deny their
drinking rather than just minimize it. Secondly, those who were
already fatally ill might have become abstainers, because of their
illness. Marmot et al. showed that this was unlikely to have
introduced much of a bias in their sample, but Day (1978) in a
longitudinal study of mortality found that the increased
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mortality associated with abstention was confined to those who
had become abstainers and was not found in lifetime abstainers.
A major difficulty is in the inference that not drinking is the
cause of the slightly greater mortality in the abstainers. Person¬
ality characteristics, believed to be relevant to death from heart
disease, have not been studied in abstainers: for example
abstainers might contain a greater proportion of those driving,
ambitious individuals prone to coronary disease than light
drinkers.
More important is that (i) the effect noted by Marmot el at. is
very small (the relative risk of abstainers is only 1-6 that of light
drinkers); (ii) it apparently occurs with reported drinking as low
as 1 unit (half a pint of beer) a week to 1 unit a day, which is a
small dose if a direct pharmacological action is hypothesized;
(iii) it disappears at fairly low levels of drinking (4 units/day);
(iv) it is not demonstrable in the 40-49 year olds, only in the
50—64 year olds; (v) a similar effect is not demonstrable in the
study already described of Dyer et al. (data analysed by me).
Further specifically designed studies are now required.
5 Natural History of Problem Drinking
Epidemiologists have demonstrated that the problem drinker
is not an individual irredeemably condemned but rather that
people move into and out of problem drinking. Surveys record
low rates of drinking problems after age 50. Drew (1968),
examining the ages of alcoholics known to agencies, concluded
that the prevalence of alcoholism in the population diminishes
more rapidly with age than can be accounted for by mortality
and successful treatment. One-half to one-third of respondents
in two large US surveys who reported a given "problem" no
longer reported that problem when re-interviewed 4 years later.
Though some accrue a different alcohol-related problem in the
meantime it is by no means inevitable (Clark & Cahalan, 1976).
Ojesjo (1981) re-interviewed after a 15 year interval a general
population cohort and found that of the 96 alcoholics identified
originally 29 were now inactive or "much improved"; (25 had
died). Work in this area has shown that, of the external
influences, changes in social circumstances such as job and
personal relationships are important.
6 Per Caput Consumption and Prevalence of Harm
A most pressing question is whether influences on mean
consumption, such as availability of alcoholic beverages and
prevailing attitudes to drinking, affect the prevalence of harmful
consequences of drinking. Although this is related to the issue
discussed above, of whether rises in mean consumption are
linked with rises in proportion of heavy consumers, it is clearer
to discuss each issue separately. It is, of course, the prevalence
of harmful consequences that is practically more important than
the numbers of heavy drinkers. Falling real price, increasing
sales outlets and greater advertising, as already mentioned, may
have had a role in increasing consumption since 1945. These
factors are unlikely, however, to be sufficient explanations for
the rise in prevalence of harm in this period. Other relevant
changes in society include: increasing secularization, continuing
weakening of the extended family and the blurring of sex roles,
to name but a few.
Nevertheless, comparisons between nations and regions
undoubtedly show covariation between per caput consumption
and cirrhosis mortality. Furthermore, there is considerable
evidence that within regions there is covariation over time
between consumption and indices of harm (Bruun et al. 1975;
Skog, 1980), though there is no example where a sudden
decrease in per caput consumption has occurred that was not in
wartime. This correlation is not seen so clearly in a recent
report by de Lint (1981) of changes in the Netherlands in the
period 1950-75.
Two of the examples cited above (section 2(vi)) of successive
surveys in the same population provide data on changes in
problem rates. In the Finnish study (Simpura, 1978), where per
caput consumption increased by 67% from 1969 to 1976, an
increase in the percentage of drinkers reporting problems also
occurred: "Worrying about controlling my drinking" was
reported by 15% of men in 1969 and 29% in 1976 (women, 4%
and 14%); "social problems" were reported by 22% of men in
1969 and 32% in 1976 (women, 3% and 7%). However, the
proportion having problems rose at every consumption level,
meaning that either a certain amount of alcohol caused more
problems in 1976 than in 1969 or, more likely, the threshold at
which people admitted a problem had fallen.
The London comparison between 1965 and 1974 (Cart-
wright et al. 1978) also does not provide strong evidence.
Although the authors found that an increase in admitted
problems had accompanied the 47% rise in per caput con¬
sumption, 3 of the 5 problem items were rather trivial. Because
of the small sample size in the 1974 study, only 2 individuals
were identified who had had 4 items and none who had had 5.
It is not going beyond the current evidence to state that a
change in per caput consumption is a marker of change in
problem rates and, indeed, that recent trends (in particular
increased availability) have made a contribution to rise in the
indices of harm. What is not known is whether this association
can be put into reverse, though it is widely advocated as the
most expedient solution given the magnitude of the alternative
task of educating whole populations to drink safely.
APPENDIX: SCREENING METHODS
i Screening for Problems
Questionnaires such as the Michigan Alcoholism Screening
Test (MAST) (Selzer, 1971) and the Severity of Alcohol
Dependence Questionnaire (SADQ) (Stockwell et al. 1979)
have shown that a variety of populations will admit, in a pencil
and paper exercise, to a range of alcohol-related problems and
symptoms. Some of the MAST items are rather trivial. The
SADQ restricts itself to "dependence" items. Where skilled
personnel are available reliability can be improved by direct
interviewing (Chick, 1980). Decisions about cut-off points in
terms of number and severity of problems are an arbitrary
matter. The time-frame in such instruments is also arbitrary.
Many of the MAST questions are phrased in the form "Have
you ever ...?", thus identifying "cases" who may now be "in
remission".
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ii Screeningfor Heavy Consumption
As in survey work, consumption is best elicited by taking a
very recent period and asking the subject in detail about each
drinking occasion during that period. He should be asked to
recall his leisure activities and his daily routine for each day, to
jog his memory. In countries where drinking tends to be
relatively infrequent such as Norway, the past 4 weeks is a
suitable period. In Britain, the last 7 days suffice. It has been
shown that in working populations those who claim their last 7
days were atypically heavy tend to be reporting a trivial
difference (Chick et al. 1981b). However, in hospital samples,
patients whose life leading up to admission was far from normal
should be asked to detail a "typical" week. If they do not have a
typical week, a "typical heavy week" is the next best measure.
Informants, such as spouse, have not been shown to improve
the accuracy of self-reported consumption. However, several
blood tests may be abnormal in regular drinkers and return to
normal, with a roughly logarithmic decline over 2-3 weeks,
when drinking ceases. Mean red-cell volume (MCV) and y-GT
are the cheapest and most commonly available of the existing
tests, though they lack power. Chick et al. (1981a) describe
their use as indicators of heavy drinking in working men. Fifty
per cent of men who admit drinking over 450 g (56 units) a week
have a y-GT of >50 iu (false positives about 15%) and 23-32%
have a MCV of over 98 fl (false positives about 5%), after men
with other causes of increased values, such as taking anti¬
convulsants or specific physical disorder, have been excluded.
Raised MCV is commoner in heavy smokers and in men whose
pattern of drinking is sustained rather than episodic.
The false-positive rates, when self-reported consumption is the
criterion, are in part probably due to lying and minimizing. The
crucial study, of the risk of having a raised value on either of
these two tests in a population whose consumption is known
with certainty to be slight, has yet to be conducted.
Of the more expensive tests which have been proposed,
abnormal heterogeneity of transferrin is still being investigated
(Stibler et al. 1979) and the ratio of a-aminobutyric acid to
leucine is probably only useful in detecting alcoholic patients
who have drunk heavily and very recently (Chick et al. 1981c).
Phillips (1981) has measured alcohol content of a sweat patch
which collects for up to 10 days. The fact that drinking is being
monitored may alter habitual consumption, however, and
clearly a degree of co-operation is required.
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SCREENING FOR PROBLEM DRINKERS AMONG MEDICAL
INPATIENTS
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Royal Infirmary, Edinburgh 3, Scotland (U.K.)
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Summary
Among 275 patients aged between 18 and 65 admitted to general med¬
ical wards, 19.3 per cent were found to have a current alcohol-related prob¬
lem and/or previous treatment for alcoholism. 13.2 per cent were newly
identified cases, with men significantly outnumbering women. The house
physician's history referred to alcohol consumption in 32 of 34 new cases
but often underestimated consumption, adverse social problems and depen¬
dence symptoms. Laboratory markers were not sufficiently sensitive to be
used as screening tests on their own.
Introduction
Treatment of patients with established alcoholism is often unsatisfac¬
tory and the importance of early detection is currently being emphasized
[1]. Population screening has been advocated on the assumption that inter¬
vention will be more effective if cases are detected at an early stage. Alcohol-
related problems are common among general hospital inpatients [2, 3] and
this is one group for whom selective screening has been recommended [4].
The extent of the problem, however, means that treatment should be widely
available and easy to administer. Cases should also be readily identified
during their hospital admission, but there is evidence that in routine clinical
practice doctors fail to record the drinking habits of many of their patients [5].
We are conducting a study on medical wards to determine the effective¬
ness of brief intervention in newly-identified problem drinkers. The treat¬
ment consists of a counselling session of approximately one hour's duration
conducted by a nurse with training in the treatment of alcoholism; patients
are also given a booklet informing them of the health hazards of alcohol and
advising on safe levels of consumption and approaches to cutting down
Similar counselling in general practice has been shown to have a significant
effect in helping patients to stop smoking [6]. In this paper we report the
detection rate obtained during the first six-month period using a screening
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interview. We have also examined the ability of the house physician's history
and of two laboratory indices to detect the cases identified by our screening
interview.
Subjects and methods
We studied a consecutive series of patients aged 18 to 65 admitted for
at least 48 hours to one of four medical wards in the Royal Infirmary, Edin¬
burgh. The wards, two male and two female, covered a wide range of medical
specialties, including a service for gastroenterological and liver disease. There
were no admissions following attempted suicide as the hospital has a special
poisons treatment unit for these patients.
A structured interview (available from the authors) of proven inter-rater
reliability covering drinking habits, recent and previous medical history and
social background was administered by the research nurse. Patients were
excluded if they were of no fixed abode or if their mental state precluded a
reliable history. Those who had attended a psychiatric unit because of an
alcohol problem or who had been to four or more meetings of Alcoholics
Anonymous were deemed to have had previous treatment and were not inter¬
viewed further. Patients were identified as having a current alcohol problem
if they acquired two or more points according to the criteria listed in Table 1.
Two laboratory markers of alcohol consumption [7, 8] were examined.
Mean corpuscular volume (MCV) was measured in all patients; serum gamma
glutamyl transpeptidase (7GT) was measured in the identified cases only.
The adequacy of recording alcohol-related problems in the medical notes of
identified cases was assessed, the recorded drinking history being classified as
either "quantitative", "descriptive", or "no record".
Results
Of 275 patients interviewed, 53 (19.3%) had a current alcohol problem
or had received previous treatment for alcoholism. When the sexes were com¬
pared fewer females (11.1%) than males (27.1%) fell into one of these cate¬
gories (x2 = 11.35; p < 0.001). This distinction was accentuated when pa¬
tients who had received previous treatment were excluded. Only four new
cases were identified among the women (3.2%) whereas 30 new cases were
discovered among the men (22.7%). This information is summarized in
Table 2.
7GT was raised (>40 i.u./l) in 21 (62%) of the newly identified cases.
MCV was elevated (>98 fl) in nine (26%) of these cases and in six (32%) of
the 19 patients who had received treatment previously. Ten (4%) of the
remaining patients also had a raised MCV: in four there was an obvious patho¬
logical basis other than alcohol; two patients had admitted regular alcohol




Consumption* More than 12 units in a day on 10 or more 1
occasions in last year
More than 50 units in typical week 1
More than 12 units in 24 hours in typical week 1
Current medical Present illness potentially alcohol related 1
problem Present illness definitely alcohol related
Weight problem due to alcohol 1
Medical conditions in Peptic ulcer aggravated by drinking 1
past 2 years Liver disease 1
Accident due to drinking 1
Symptoms of depen¬ Restlessness 1
dence on alcohol Tremor 1
Morning drinking 1
Difficulty reducing consumption 1
Hallucinations 1
Seizure 1
Alcohol-related social Antisocial behaviour 1
problems in previous Problems at work (incl. absence) 1
2 years Domestic arguments 1
Violence 1
Family rupture, either threatened or actual 1
Financial 1
Police 1
*1 unit = 1 oz. of spirits, 1/2 pint of beer, or 1 glass of wine (i.e. approx. 8 g ethanol).
TABLE 2








(n = 135) 15 (11.1%) 11 4/124 (3.2%)
Males
(n = 140) 38 (27.1%) 8 30/132 (22.7%)
Total
(n=275) 53 (19.3%) 19 34/256 (13.3%)
the other four subsequent information strongly suggested excessive drinking.
Patients with liver disease were more likely to be problem drinkers (x2 =
10.55; p < 0.01) but otherwise there was no association between case iden¬
tification and medical diagnosis.
The medical notes referred to alcohol consumption in 32 of the 34
newly identified cases (Table 3). However, the quantity consumed as noted
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TABLE 3
Drinking history of newly identified cases as recorded in medical notes
Record of Recorded adverse Recorded with¬
consumption consequences drawal symptoms
(n = 34) (n = 29) (71 = 21)
Quantitative 25 — —
Descriptive 7 12 5
No record 2 17 16
by the house physician was often considerably less than that uncovered by
the detailed interview. In the 25 patients for whom a quantitative record was
noted the mean weekly consumption recorded was 51.9 units while the
equivalent figure identified by the interview was 72.9 units. There was also
an underestimation of adverse consequences of drinking and of symptoms of
physical dependence.
Discussion
Reported rates of alcoholism among general hospital inpatients have
ranged from nine to 55 per cent [2], but direct comparisons between studies
cannot be made because of varying sampling methods and diagnostic criteria.
Our study differs from most others in not including cases of attempted sui¬
cide and patients of no fixed abode, groups known to contain a high propor¬
tion of problem drinkers. Yet 19.3 per cent of our sample had a current
alcohol-related problem or previous treatment for alcoholism, 13.2 per cent
being newly identified cases. The greater prevalence among men is in keeping
with previous reports but we were surprised to detect only four new cases of
problem drinking among female patients. Women may be reluctant to admit
their alcohol consumption because of the greater stigma attached to problem
drinking among females and our questionnaire may have favoured the detec¬
tion of males because several questions pertaining to work were included.
However, among the patients with alcohol problems, a greater proportion of
female patients reported previous treatment for alcoholism (x2 = 12.78 \P <
0.001); so these factors cannot entirely explain the low detection rate. In
any case, to be suitable for treatment patients have to be prepared to acknow¬
ledge their problem. If they remain undetected after a detailed interview
they are not likely to benefit from counselling.
One third of our newly identified cases had a normal 7GT and three-
quarters had a normal MCV. These findings support recent evidence that
laboratory markers lack sensitivity as screening tests [ 7 ]. Many cases are
detected by clinical interview, but are missed by blood tests. It is therefore
encouraging that the house physicians' notes referred to the drinking histories
in all but two of those cases we identified. The fact that this study was known
359
to be in progress may have alerted house physicians to look for alcohol prob¬
lems with greater suspicion than usual. Also alcoholism is commoner in Scot¬
land than in England, so it is possible that Edinburgh doctors are more aware
of alcohol as an aetiological factor in illness than their London counterparts
[5]. However, although our junior doctors are well-placed to identify prob¬
lem drinkers at an early stage they underestimate consumption and miss
important complications of drinking. More attention might be given to tak¬
ing an accurate drinking history and this could be incorporated in routine
clinical practice, especially in men. The alternative is a formal screening inter¬
view by a special worker. However, the value of either procedure depends on
whether intervention is effective. We will report on this in a larger sample in
the future.
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Summary
One hundred and sixty-one male medical inpatients were identified as problem drinkers according to criteria
previously defined. This paper describes the pattern of their drinking and the associated medical and
psychosocial problems. Over half had been admitted with an illness not typically related to alcohol and a
similar proportion reported levels of consumption which have previously been considered safe. Classical
symptoms of dependence were uncommon but specific enquiry revealed a broad range ofsocial problems related
to alcohol. Recognition of this profile is necessary ifproblem drinkers are to be identified at an early stage and to
benefit from counselling.
Introduction
Medical inpatients are known to have a high
prevalence of alcohol problems. Reported rates vary
widely according to the diagnostic criteria used and
the nature of the hospital studied1 but British figures
show an impressive consistency with regard to male
inpatients, indicating that just over a quarter have a
current or previous alcohol problem.2"4 The rates for
women are lower and more variable, reflecting both
women's lower consumption and greater reluctance
to admit to alcohol problems. Several reports have
described patients with advanced complications,
particularly liver disease, and have stressed the need
for earlier detection.7"' Saunders et al.10 interviewed
156 patients with newly-diagnosed alcoholic liver
Correspondence address: Dr Geoffrey Lloyd, Department of
Psychiatry, Royal Free Hospital, Hampstead, London NW3 2QG,
U.K.
disease. Thirty-five per cent claimed they had never
been advised to reduce or stop drinking before their
presentation with liver disease and only 22% had
been referred to a hospital clinic for specific
management of an alcohol problem. The failure to
detect alcoholism at an earlier stage in its evolution
has been attributed to doctors' neglect to ask the
appropriate questions about drinking habits." It has
become apparent that many patients who are
drinking to excess are admitted to a general hospital
for an illness not classically related to alcohol abuse
and their drinking will not be detected unless
specific enquiries are made. Several alcohol-related
illnesses develop insidiously over many years, dur¬
ing which time they remain asymptomatic. Screen¬
ing and early detection have been advocated on the
assumption that intervention will give the patient an
opportunity to modify his drinking habits before
irreversible physical complications have developed.
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We have conducted a study on medical inpatients
to identify early problem drinkers who had at least a
minimum of social support and - to evaluate the
effectiveness of nurse counselling on their subse¬
quent alcohol-related problems. Those with previ¬
ous treatment for alcoholism were excluded because
we wished to define the characteristics of patients
identified at an earlier stage than is usually the case.
We have already reported on the effectiveness of
counselling in this group.12 In this paper we describe
the pattern of drinking and the medical and
psychosocial characteristics of a cohort of newly-
identified male problem drinkers.
Subject and Methods
We studied patients aged 18 to 65 who had been
admitted to one of four medical wards for at least 48
hours. The wards covered a broad range of medical
specialities but there were no admissions following
attempted suicide because it is the hospital's policy
to treat these patients in a special unit.
Patients were excluded at the outset if they were
of no fixed abode, if they were terminally ill, if their
mental state precluded a reliable history or if they
had already been referred to the psychiatry depart¬
ment. A nurse with experience in the treatment of
alcoholism carried out a structured interview whose
reliability had been established during a pilot study.
Details of consumption were obtained by complet¬
ing a drinking diary for the week prior to admission
to hospital (or a 'typical' week if the previous week
was atypical for any reason). The total weekly
consumption and the maximum daily consumption
during a typical week were recorded in units of
alcohol (1 unit=8 g alcohol). Symptoms of depen¬
dence, social problems related to alcohol, previous
medical history, family and social background were
recorded in a standardized manner. The main
current medical diagnosis was noted in each case
and classified according to its apparent relationship
to alcohol. Definitely alcohol-related illnesses in¬
clude cirrhosis, alcoholic hepatitis, delirium tre¬
mens, Wernicke's encephalopathy and alcoholic
cardiomyopathy. Potentially alcohol-related ill¬
nesses included upper gastro-intestinal disorders,
gout, unspecified liver disease, and unexplained
peripheral neuropathy.
Patients were identified as problem drinkers if
they acquired two or more points according to our
previously defined criteria12 which are shown in
Table 1. To be included in the study, they also had
to satisfy two of the following criteria: currently
employed or employed for 6 of past 12 months;
married; has a 'confidant' or close friend; lives with
at least one other person. Those who satisfied these
criteria completed the 60 item General Health
Questionnaire.13 Mean cell volume (MCV) and
gamma glutamyl transpeptidase (gamma GT) were
measured as laboratory markers of alcohol con¬
sumption.
During the first 6 months of screening 27% of
men and 11% of women were identified as having a
current alcohol problem or had received previous
treatment for alcoholism.6 When those with previ¬
ous treatment were excluded 23% of men and 3% of
women were regarded as newly identified problem
drinkers; in view of the low yield among women the
study was subsequently confined to male patients.
Results
The screening interview showed that 731 men
eligible for inclusion were admitted during the
course of the study of whom 161 (22%) met our
diagnostic criteria. The mean age of the problem
drinkers (42.4 years; SD 12.5) was significantly
lower than the mean for the other 570 patients (48.6
years; SD 12.3) (P=31.7;p<.0001) and the mean
MCV was significantly higher (92.8 fi; SD 6.0
versus 89.2 fi; SD 7.4); (F=31.7; /X.0001). In
15% of the problem drinkers and 6% of the other
patients the MCV was above 98 fl. The gamma GT
was above 40 i.u./l in 52% of problem drinkers but
was not routinely measured in the others.
Alcohol Consumption, Withdrawal Symptoms and
Social Problems
One hundred and forty-one of the problem drinkers
(87.6%) had drunk alcohol during the 7 days before
admission. The remaining 20 reported that they
would normally have had a drink but had not
because of illness or some other factor. One hundred
and fifty-two (94.4%) reported that they normally
drank alcohol more than once weekly; 67 (41.6%)
drank every day. Heavy drinking on a single
occasion was common, with 126 (78.3%) admitting
that they had consumed more than 14 units of
alcohol (7 pints of beer or its equivalent) in 24
hours on at least 10 occasions during the previous
year. Forty-one (25.5%) admitted drinking more
than 28 units in 24 hours on at least 10 occasions
during the previous year. The mean consumption
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Table 1. Criteria for Inclusion as a Problem Drinker
Points
Consumption
More than 14 units* in a day
on 10 or more occasions in
last year
More than 50 units in typical week





problem Present illness definitely
alcohol-related
Weight problem due to alcohol
Medical problems




in past 2 years
Peptic ulcer aggravated by drinking
Liver disease due to alcohol
Accident due to drinking
Antisocial behaviour
Problems at work (inc. absence)
Domestic arguments
Violence






Difficulty in reducing consumption 1
Restlessness without alcohol 1
Tremor (more than 1 day per week) 1
Morning relief drinking (more than
1 day per week) 1
Hallucinations 1
Withdrawal seizure 1
*1 umt= 1 oz of 40% spirits, J pint of beer, 1 glass of wine, etc. (i.e. approx.
8 g ethanol).
during a typical week was 68.3 units (SD 43.3) and
the mean maximum daily consumption in a typical
week was 19.7 units (SD 10.8). Of the 570 patients
who did not satisfy our criteria for problem drinkers
352 drank regularly, at least once weekly, and their
consumption figures were also recorded. The mean
weekly consumption of these non-problem drinkers
was 16.3 units (SD 11.3; mode 12 units) and the
mean maximum daily consumption in a typical week
was 7.1 units (SD 4.5; mode 6 units). Figures 1 and
2 show the distribution of weekly and maximum
daily consumption figures for both the problem
drinkers and non-problem drinking group.
It can be seen that consumption was distributed
continuously, with no evidence of bimodality. The
groups overlap to some extent and a substantial
proportion of the problem drinkers reported levels
of consumption which have previously been re¬
garded as safe. Indeed 50% of the problem drinkers
reported a typical weekly consumption within the
limit of 56 units suggested by the Royal College of
Psychiatrists.14 The criterion which separated the
problem drinkers from non-problem drinkers with
the lowest number of mis-classified cases was a
weekly consumption above 39 units. Only 5% of
non-problem drinkers were drinking above this level
although 25% of the problem drinkers reported that
they drank 39 units or less. When similar calcula¬
tions were carried out on the maximum daily
consumption figures the equivalent criterion which
separated the two groups was a consumption of over
13 units. Seven per cent of non-problem drinkers
reported a maximum daily consumption above this
figure while 24% of the problem drinkers claimed 13
units or less.
Symptoms of dependence during the previous 2
years were reported by less than half the group.
Seventeen per cent had experienced difficulty
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Figure 1. Mean weekly consumption: n = 161 ■ Problem
drinkers; n=352 □ Non-problem drinkers.
reducing consumption, 12% reported restlessness or
irritability if they did not have a drink and 9%
reported regular morning relief drinking. With¬
drawal fits and hallucinations were reported by 5%
and 3% respectively. Social problems related to
alcohol were commoner; 25% reported domestic
arguments, 19% reported difficulty preventing
drunkenness and 17% had been absent from work
because of alcohol.
To determine whether consumption was related
to dependence symptoms and social problems the
problem drinkers were divided into three groups
according to their mean weekly consumption: 0-40
units; 41-80 units and 81 or more units. Those in
the highest consumption category were more likely
to have experienced severe tremulousness
(p<.001), otherwise there were no differences
between the groups with regard to dependence
symptoms. The high consumption group were more
likely to report difficulty preventing drunkenness
(p<.05), family rupture (j><.025) and a family
history of alcoholism among first degree relatives
(/><•01). They were also more likely to be divorced,
separated or widowed (p<.01). Weekly consump¬
tion was significantly correlated with MCV
(r=0.25; p<.001) but not with gamma GT.
Associations with maximum daily consumption
were calculated by dividing the problem drinkers
into two groups: those with a maximum daily
consumption of 1 to 15 units and those with a
maximum daily consumption of 16 or more units.
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Figure 2. Mean maximum daily consumption in typical
week. rt = 161 ■ Problem drinkers; n = 352 □ Non-
problem drinkers.
The groups did not differ with regard to any of the
dependence symptoms. The higher consumption
group were more likely to have had absences from
work (p<.025), less likely to be in a technical,
managerial or professional job (/><.025) and less
likely to be responsible for other people at work
(p<.025). Maximum daily consumption correlated
weakly with MCV (r=0.13); (j><.002) but not
gamma GT.
Medical Illness
The medical diagnostic categories of the problem
drinkers are shown in Table 2 with the diagnoses of
the other patients given for comparison. The groups
differed significantly (J><.001) with regard to the
distribution of diagnostic categories. The problem
drinking group contained proportionately more
patients with liver, upper gastro-intestinal and
respiratory disorders and fewer with cardiovascular
disorders. We did not, however, record smoking
habits which may have accounted for some of these
differences. In 43 of the problem drinkers (26.7%)
the medical illness was considered to be definitely
alcohol-related; in 30 (18.6%) it was potentially
alcohol-related while in 88 (54.6%) it was definitely
not alcohol-related. Fifty (31.1%) considered them¬
selves to have a weight problem due to alcohol.
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Table 2. Medical Diagnostic Categories in Problem Drinkers and Others (percentages
in brackets)
Problem drinkers Other patients
(»= 161) (* = 570)
Myocardial infarction 28 (17.4) 117 (20.5)
Other cardiovascular disorders 22 (13.7) 156 (27.4)
Liver disorders 18 (11.2) 18 (3.2)
Upper gastrointestinal disorders 35 (21.7) 68 (11.9)
Lower gastrointestinal disorders 6 (3.7) 23 (4.0)
Respiratory disorders 18 (11.2) 41 (7.2)
Peripheral neuropathy 8 (5.0) 21 (3.7)
Cerebrovascular disorders 5 (3.1) 26 (4.6)
Renal and urogenital 10 (6.2) 43 (7.5)
Locomotor ■ — 6 (3.7) 20 (3.5)
Blood disorder 1 (0.6) 7 (1-2)
Metabolic 3 (1.9) 23 (4.0)
Psychiatric 1 (0.6) 4 (0.7)
No diagnosis 0 (0.0) 3 (0.5)
Table 3. Comparison ofProblem Drinkers whose Illness was Alcohol-related with those whose Illness was not
Alcohol-related (numbers in brackets)
Alcohol-related Not-alcohol related
Mean SD N Mean SD N F P
MCV (fl) 94.5 6.6 (70) 91.5 5.0 (88) 10.70 0.0013
Gamma GT
(Lu./1) 236.9 459.0 (68) 68.2 109.5 (85) 10.73 0.0013
Age (years) 41.5 12.6 (73) 43.2 12.4 (88) 0.75 NS
Weekly
consumption
(units) 69.4 41.1 (73) 67.5 45.3 (88) 0.076 NS
Maximum daily
consumption
(units) 18.8 10.1 (73) 20.4 11.4 (88) 0.867 NS
During the previous 2 years, 27 (16.8%) had
experienced peptic ulcer symptoms aggravated by
alcohol, 39 (24.2%) had had alcohol-related liver
disease and 11 (6.8%) had had an accident related to
drinking.
Comparisons were made between problem drink¬
ers whose current illness was definitely or poten¬
tially related to alcohol and those whose illness was
definitely not alcohol-related. Those with an alco¬
hol-related illness were more likely to have experi¬
enced severe tremulousness (p<.05) but otherwise
there were no differences between the groups on any
other dependence symptom or social problem. From
Table 3 it can be seen that the alcohol-related illness
group had higher values for MCV and gamma GT.
The groups were similar with regard to their
reported weekly consumption and maximum daily
consumption.
Psychiatric Morbidity
The 60 item GHQ was completed by 155 problem
drinkers. Fifty-five (35%) had a score above 11, this
being the recommended cut-off point to identify
probable psychiatric morbidity. When the scores on
the 30 item version were derived from the larger
version 48 (31%) obtained a score above 4. Scores
on both versions correlated significantly with total
social problem score (GHQ 60, r— 0.20; p<.01;
GHQ 30, r=0.18; p<.015) and with the total
alcohol dependence score (GHQ 60, r=0.31;
p<.001; GHQ 30, r=0.26; p<.001). There were
no significant associations between GHQ scores and
weekly or maximum daily consumption.
Discussion
Physicians and general practitioners are well placed
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to identify patients with alcohol problems and to
advise them to modify their drinking habits or to
refer for specialist treatment. But early recognition
requires that patients are asked about a broad
spectrum of problems. The criteria used in this
study included not only data on consumption,
dependence symptoms and physical ill-health but
also a wide range of social problems related to
alcohol.
Previous studies,4-15 like our own, have relied
partly on consumption figures to identify problem
drinkers. However there is no generally accepted
level of consumption below which drinking can be
considered entirely safe. A recent survey" demon¬
strated a wide variation of opinion even among
those who are considered expert in this field and a
report from the Royal College of Psychiatrists14
suggested that an intake equivalent to 56 units
weekly would constitute a reasonable guideline for
the upper limit of safe drinking. This may be a
serious over-estimation. Fifty per cent of our
problem drinkers reported weekly consumption
levels within this figure, but nevertheless qualified
for inclusion when other factors were taken into
account. Consumption may be under-reported even
when information is recorded in a standardized
manner by a person experienced in the assessment
of alcohol problems. It is also possible that some of
our identified patients had been drinking more
heavily in the past but had reduced their consump¬
tion in the wake of declining health or financial
difficulties. There was some overlap in reported
consumption between the problem drinkers and
those who drank regularly but did not report
problems and who therefore did not qualify for our
trial of counselling. The best separation between the
groups was achieved at a level of 39 units weekly. It
was unlikely in this medical inpatient population
that anybody drinking above this level would not
have alcohol-related problems. Only 5% of the non-
problem drinkers were drinking more than this but
it must be emphasized that 25% of the problem
drinkers reported a weekly consumption of 39 units
or less. Weekly consumption was one of the criteria
we used to define problem drinkers but the figure
we used was over 50 units. It is clear that many
patients had problems related to alcohol even
though they reported consumption below our stipu¬
lated level. In this context it is interesting that
general practitioners tend to recommend a much
lower limit for healthy drinking, the mean figure
reported in a recent study being 18 units per week
for men."
Classical symptoms of dependence were uncom¬
mon in our patients and their prevalence was
intermediate between that observed in a community
sample of drinkers and that seen in patients
attending a psychiatric hospital clinic for alcohol
problems.18 This finding confirms other work show¬
ing that classical symptoms of dependence develop
relatively late in a drinking career.18 Although it is
important to enquire about dependence, a doctor
should not be misled into believing that alcohol
problems are absent if a patient does not report such
symptoms.
Over half our patients had been admitted to
hospital for an illness which was not related to
alcohol, an observation which is similar to that
described by other writers.5'15 Patients whose illness
was not alcohol-related reported levels of consump¬
tion which were just as high as those whose illness
was related to alcohol but the latter group had
significantly higher values for mean corpuscular
volume and gamma glutamyl transpeptidase. These
findings support the view that some individuals
might have an enhanced tissue susceptibility to the
harmful effects of alcohol. Physicians have realized
for a long time that the duration of heavy drinking
necessary to cause physical damage varies greatly
between individuals. Attention has been directed to
other risk factors, including genetic markers, and
there is evidence that various HLA antigens are
important aetiological factors as far as alcohol liver
disease is concerned."
We used the General Health Questionnaire to
obtain an estimation of the level of psychiatric
morbidity in view of previous claims that many
patients with advanced physical complications from
alcohol have a primary psychiatric illness which
might have led to the development of heavy
drinking. Using the recommended cut-off points we
found a prevalence of 35% with the 60-item version
and 31% with the 30-item version. These are
considerably lower than the figures reported from a
group of patients with liver disease20 but similar to
estimates of psychiatric morbidity in other groups of
physically ill patients assessed using a standardized
psychiatric interview.21'25 The patients studied by
Ewusi-Mensah et al.x probably had more advanced
disease than the majority of patients in our study
and we believe that the higher prevalence of
psychiatric morbidity observed in other studies is
likely to have been due to the physical and social
consequences of alcohol abuse rather than an
aetiological factor in the development of heavy
drinking.
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Conclusions 6.
This report describes a wide profile of alcohol-
related problems in a group of medical patients ?
identified at an earlier stage than is usual in clinical
practice. Our observations show that problem drink¬
ing can occur in the absence of admitted symptoms 8.
of dependence and at levels of admitted consump¬
tion lower than those which are generally considered 9
harmful. The patient may not be in hospital
primarily because of a classically alcohol-related
illness and is not especially likely to admit to
psychiatric symptoms. In nearly half the cases there
will be no elevation of MCV or gamma GT. 10
However an enquiry into the recent consumption
pattern during a typical week and areas of health
and social functioning commonly affected by alco¬
hol may reveal whether his drinking is causing
problems. At this early stage we have shown that a
nurse offering brief counselling can have a thera- 12.
peutic effect,12 making it all the more important that
medical and nursing staff should be familiar with
the profile of problems. 13
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MEDICAL ADMISSIONS IN MEN:
THE RISK AMONG DRINKERS
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Summary Information on alcohol consumption was
elicited by the same method from men in a
general population survey and from male medical inpatients
in a hospital serving that population. A measure of risk
controlling for age, the logarithm of the odds ratio, showed
that for liver disorders, upper gastrointestinal disorders,
myocardial infarction, other cardiovascular disorders, and
respiratory disorders, rising consumption of alcohol was
related to increased risk of hospital admission relative to
abstention. The risk of admission for the remaining
heterogeneous category of disorders was lower than that for
abstention, perhaps reflecting the effect ofchronic illness on
drinking habits, and also suggesting that the link between
alcohol consumption and medical diagnoses is not simply
due to greater frankness about drinking in hospital
inpatients.
introduction
Aware of the toll of harm from alcohol, the medical
profession in Britain has suggested levels for what might
constitute safe alcohol consumption. Estimates for men have
varied from 56 units per week (80 g ethanol per day)1 to 18
units per week.2 (A unit of alcohol has come to mean 8-9 g
ethanol, equivalent to half a pint ofbeer, a single measure of
spirits, a glass of table wine.) Such estimates have to be
qualified by the pattern of drinking and by whether the
subject is likely to be involved in any skilled or dangerous
activity—for example, driving.
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Data on the relative risks of physical illness associated
with different consumption levels have become available
only recently. Longitudinal studies noting drinking habits at
entry to the study have found alcohol consumption to be
associated with excess mortality; the level at which the
association becomes significant is about 30-40 units per
week. The strength of the association is reduced if smoking
is taken into account." Cross-sectional studies to determine
morbidity risks for certain illnesses compare consumption
reported by patients who have the disorder with that
reported by general population controls. Using this method
Pequignot and his colleagues found that the relative risk of
ascitic cirrhosis was raised at levels ofconsumption as low as
16-31 units per week, the relative risk in this consumption
category being three times that of abstainers.7 This widely
quoted study has probably led to some of the more
conservative estimates of safe limits. However, a systematic
bias towards more frank reporting in one group than the
other would affect the relative risk. In particular, relative risk
would appear to increase at lower levels if the hospital
patient tended to admit more of his drinking than a subject
interviewed in a general population survey. The fear that the
hospital staff might disapprove of his drinking might be
offset by the importance of being honest when health is in
question, an incentive that a control subject in a general
population survey does not have.
Our study was designed to compare reported alcohol
consumption in male medical inpatients with that reported
by a community sample, and to determine the relation
between alcohol consumption and various medical
diagnostic categories by means of the odds ratio, a measure
of association approximately equivalent to relative risk. In
an attempt to assess whether being a hospital patient itself
increases the readiness to admit alcohol consumption, the
study reports on a group of patients with miscellaneous
disorders in which there is no prior reason to suppose that
alcohol has an aetiological role.
subjects and methods
In 1978-79 a representative sample of homes in the Edinburgh
area was drawn from the electoral register and individuals selected
at random from these homes were approached.8 738 men aged
18-65 years were thus sampled. 21 % refused to be interviewed and
7 % could not be contacted, leaving 532 men who were interviewed.
Consumption data were elicited in a standard manner by trained
interviewers, who asked the subject to recall his activities in the
previous 7 days and in particular his drinking, which was recorded
in detail in units of alcohol.
In 1980, 1274 consecutively admitted men aged 18-65 years in
medical wards in the Royal Infirmary, Edinburgh, were screened in
connection with a study ofcounselling for newly identified problem
drinkers. This study and the characteristics of the patients have
been described elsewhere.910 No self-poisoning patients were
treated in the wards we sampled. We excluded men discharged
within 48 h of admission, those of no fixed address, those with
terminal illnesses or too ill to give an interview, men who were
known from their admission case-notes to have had previous
treatment for alcohol problems, and men already referred in the
course of their stay to the psychiatric department. Consumption
data were elicited by the same method as used in the general
population study: patients were asked to describe their
consumption in the 7 days before admission. If that had been an
abnormal week they described a "typical" week. The principal and
secondary diagnoses made by the treating physician were noted. A
patient with two diagnoses in different diagnostic categories was
given a separate entry in the tables of results for each diagnosis. A
category of heterogeneous disorders included all diagnoses not
covered by the other categories; a small number of alcohol-related
diagnoses, such as delirium tremens, alcoholic fits, or neuropathy,
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TABlE i—percentage of men in different categories by age
17- 30 yr 31- 50 yr 51- 65 yr
Patients Survey Patients Survey Patients Survey
— (n = 100) (n= 180) (n = 270) (n = 215) (n = 354) (n= 137)
Abstainers* 5 2 4 2 6 7
< weekly 15 13 19 13 23 20
1 -5 units/wk 3 16 8 22 12 20
6-10 units/wk 11 11 9 16 8 15
11-20 units/wk 15 19 19 19 18 18
21-50 units/wk 30 27 21 20 20 12
^51 units/wk 18 13 17 8 9 7
Known problem
drinkers f 3 3 3
MEAN ± SE IN REGULAR DRINKERS (DRINKING AT LEAST WEEKLY)
Maximum daily con¬
sumption (units) 141 ±10 120 ±0-7 11-5 ±0-6tj 8-3 ±0-5 9-6 ±0 61 6-4 ±0-6
Weekly consumption
(units) 34-9 ±3-9 27-6 ±21 36 3 ±2-6* 18-8 ±15 26-7 ±2-4 18 8±2-1
*No alcohol for at least 1 yr excluding (in patients) those who stopped because ofproblems.
|Had treatment for alcohol problems in the past, or stopped drinking for more than 1 yr
because of harm. Not known for survey subjects.
^Significantly greater than controls' mean (p <0 01)
are not included in that category or in the report, since we wanted
the category to represent disorders in which there was no prior
reason to implicate alcohol. Thus, data are given here on 724
patient-diagnoses.
To assess the association of alcohol consumption with each
diagnosis the odds ratio was used as a measure of risk;11 the ratio of
cases to controls (ie, survey subjects) among those drinking at a
given level is compared with the ratio of cases to controls among
abstainers. Logistic linear analysis was carried out, allowing a
separate assessment as independent variables of age and
consumption, and their interactions. This method allows tests of
significance and of whether the relations found are linear or non¬
linear.
To avoid veiling a possible association between alcohol
consumption and disease, we omitted from the abstainer category
(and from the whole analysis) patients who said they had stopped
drinking because alcohol had caused them illness or because of a
drinking problem. Only 1 abstainer in the survey population who
gave ill-health as his reason for having become an abstainer.
RESULTS
Table I shows the distribution of drinking in patients and
the general population sample. Mean consumption and
consumption on the heaviest day in those who drank at least
weekly tended to be greater in patients than men in the
population sample, especially in the older age groups.
TABLE II—ODDS RATIOS RELATIVE TO ABSTENTION FOR
INCREASING LEVELS OF ALCOHOL CONSUMPTION
Liver
Upper
GI MI Respiratory CVD Other
n 37 110 143 73 188 169
Alcohol consumption
( Variate: units/wk;
model 3) 103 1-02
Alcohol consumption
(category; model 1)
0 in prevous wk 0-73 1 18 3-01 402 3-06 1-38
1—5 units/wk 0-92 041 104 0-85 0-42 0-32
6—10 units/wk 0-99 0-76 1-21 0-71 1-63 0-45
11-20 units/wk 1-30 0-89 1-93 2-63. 1 85 0-75
21-50 units/wk 2-16 101 2-19 417 3-04 0-80
^51 units/wk 8-13 3-10 3 18 4-32 2-22 0-85
GI = gastrointestinal; MI = myocardial infarction; CVD = cardiovascular
disease except MI.
Table II shows the risk associated with increasing alcohol
consumption for the various diagnostic categories we used
and table III the logarithm of the risk. The risk is expressed
relative to the risk for abstainers (no alcohol in the past year
or more); thus, the risk for abstainers is 1 (log = 0). Age
has been controlled. Data on the category of lower
gastrointestinal disorders are omitted because of the small
number (26) in that category. The association with alcohol
was significant and positive in all categories except the
heterogeneous category. The risk ofa hospital admission rose
with increasing consumption. However, for heterogeneous
diagnoses, though there was a significant association
between alcohol consumption and being a patient in that
category, the risk was lower through the range of those
drinking in the past week than for abstainers.
The log-linear analysis did not reveal any significant age
by alcohol consumption interactions.
The relation between illness and alcohol consumption
was adequately fitted by a linear term only for liver disorders
and upper gastrointestinal disorders (see figure). For liver
disorders, there were (non-significant) deviations from
linearity with estimates indicating a risk lower than that of
abstainers at consumption of less than 11 units per week
(figure). For upper gastrointestinal disorders, reduced risk
was found at consumption levels between 1 and 21 units per
week, with the risk becoming steeply positive about that
level (figure).
Linearity could not be shown in the data relating alcohol
consumption to the other diagnostic categories used. For
table iii—logarithms of odds ratios relative to abstention for increasing levels of alcohol consumption
(and standard errors)
Liver Upper GI MI Respiratory CVD Other
n 37 110 143 73 188 169
Alcohol consumption (variate:
unitsjwk; model 3) 0-033 (0-006) 0-020 (0-004)
Alcohol consumption (category;
model 1)
0 in previous wk — 0 313 (1 255) 0-166(0-536) 1-101 (0-507) 1-391 (0-801) 1-117(0-472) 0-319(0-410)
1—5 units/wk -0-079 (1-151) -0-899 (0-579) 0-040 (0-518) -0-160(0-875) -0-870 (0-553) -1-138 (0-454)
6 — 10 units/wk -0-012(1-186) -0-268(0-588) 0-193 (0-541) -0-344(0-951) 0-487 (0-493) -0-796 (0-458)
11 — 20 units/wk 0-262(1-131) . —0 111 (0 531) 0-659(0-508) 0-967 (0-801) 0-614 (0-476) -0-283 (0-415)
21—50 units/wk 0-772(1-102) 0-014(0-531) 0-785 (0-521) 1-429 (0-785) 1-113(0-468) 0-223 (0-411)
^51 units/wk 2-096(1-080) 1-131 (0-528) 1-157 (0-555) 1-463 (0-823) 0-796 (0-532) -0-160(0-454)
P* <0-001 <0 001 <0-02 <0-001 <0-001 <0-001
*Of consumption/diagnosis relation with age controlled; difference between residual deviances of models fitted, first with alcohol and age both as factors, then
with age alone (referred to chi-square with 6 degrees of freedom).
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disease (B), and myocardial infarction (C).
myocardial infarction all log odds-ratio estimates (tables II
and III) were positive compared with the abstainers (figure).
DISCUSSION
Most of the patients who drank reported a weekly
consumption of over 10 units, so we cannot make firm
statements about the relations between disease and alcohol
consumption below 10 units per week. However, there was
an increased risk of disease associated with the lowest
category of drinking (less than weekly) in all categories
except liver disorders; it was particularly high for
myocardial infarction, other cardiovascular disorders, and
respiratory disorders. There are several likely reasons why
the numbers ofpatients in this lowest consumption category
may be inflated. Consumption in this category could range
from just 1 drink in the previous year up to several drinks
once a fortnight. It is likely that in the hospital sample this
group included men who had been advised or thought it
wise to drink very little because of their illness. Also, illness
prevents people from going out, and most drinking by
Scottish men is done outside the home. The chronically ill
perhaps find that alcohol disagrees with them, or they
cannot afford to drink.
One objection to the case/control design we and
Pequignot et al7 used is that hospital cases might be more
frank about their drinking than general population subjects.
The finding of a reduced risk associated with alcohol
consumption in the category of heterogeneous diagnoses
(arising out of a lower than expected number of patients
admitting drinking at all levels—except that of less than
weekly drinking) suggests that being a patient in hospital is
not by itself associated with higher admitted consumption.
The odds ratio we used is roughly equivalent to relative
risk, and we can therefore compare our findings for liver
disorders with those of Pequignot et al.7 They found for
cirrhosis that the relative risk rose exponentially, each gram
of alcohol per day increasing the log risk by 0 01473.
Converting their measure to ours (9 g = 1 unit) their model
coefficient becomes 00436/unit/week, comparable and
within 2 SE ofour finding for our category of liver disease of
0-033 for the increase in log risk for 1 unit per week.
The finding that upper gastrointestinal disorders are
strongly associated only with consumption of 21 units per
week or more accords with clinical experience; the more
common disorders included in this category—acute
gastritis, pancreatitis, and acute upper gastrointestinal
bleeding—are all linked to heavy session drinking.
It is not surprising that respiratory disorders are linked
with alcohol consumption in this study. Chest illness is a
major cause of death in alcoholics.12 Heavy drinking and
smoking are, of course, linked. For myocardial infarction
too, we do not have data to control for smoking. General
population cohort studies313 and a case-control study14 have
found that those who consume low amounts of alcohol are
less likely to be admitted to hospital or to die from
myocardial infarction than abstainers. Heavy drinking,
however, is associated with an increased risk. Among
patients diagnosed alcoholic the mortality from ischaemic
heart disease12 and risk ofhospital admission for myocardial
infarction are raised.15 An association between ischaemic
heart disease and heavy drinking has been found in
some3-516-17 but not other1819 cohort studies. The U-shaped
curve for myocardial infarction (figure) presents less than
weekly consumption as the high-risk consumption pattern
in our study. However, this consumption category probably
included patients who were drinking rarely because they had
a chronic illness. We did not find that drinking in the
moderate range (1-20 units per week) was associated with a
risk of myocardial infarction less than that of abstainers.
However, subjects abstinent for health reasons had been
systematically removed from our abstainer group in the
hospital sample. In other research on this topic, that has not
always been possible. Previous cohort studies have also
found a link between alcohol consumption and increased
mortality from other cardiovascular diseases, particularly
stroke. We found positive odds ratios in our category of
other cardiovascular disease at the level 6-10 units and
above.
If we had included subjects treated for alcohol-related
problems and abstainers who had stopped drinking because
alcohol caused them trouble or illness, the links found
between alcohol and disease would have been even stronger
than those reported. We have found a link between hospital
admission for medical diagnoses and a personal history of
heavy drinking. We can only suggest, not conclude, that
alcohol itself is having a pathological effect. The lifestyle of
the drinker, particularly his smoking habits, must be
considered. We are unable to validate any of the safe limits
proposed by others. Thresholds did not emerge from our
data, but for each of the alcohol-associated diagnostic
categories increased risk was present at 21-50 units per
week. Thus, our work supports the Royal College of
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Psychiatrists' recommendation of 21 units per week20 as the
upper end of the almost certainly safe zone of consumption.
We must move away from the notion that alcohol is a safe
drug except for those few unfortunates who become
"addicts". The graded increase in risk of social and personal
harm as consumption rises21 is paralleled by the increasing
risk of bodily harm.
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Admissions to an acute male orthopaedic ward (n = 369) were
asked about their accident, their alcohol consumption, and
alcohol-related problems in the past 2 years. Comparing their
consumption with that of males from a community survey
revealed an increased risk of orthopaedic admission in
drinkers consuming 21 units of alcohol/week or over, relative
to drinkers consuming less than 21 units/week, in the age
group 31-50 years. In all, 34% of the sample met a criterion
for problem drinking based on self-reported alcohol con¬
sumption and/or medical and social problems associated
with alcohol. In 13%, alcohol was viewed by the patient as
having contributed to the accident, and in 19% according to
the interviewer's perception of whom 76% were classifiable
as problem drinkers. Twenty-six men said the accident had
made them think about changing their drinking habits.
Detection of problem drinking in orthopaedic male admis¬
sions is possible and could be usefully linked to a counselling
service.
* Present appointment: Social Worker, Community Mental
Health Team, Midlothian
Correspondence to: J Chick, Department of Psychiatry,
University of Edinburgh, Royal Edinburgh Hospital,
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Acute ethanol intoxication and traumatic injury are
clearly related (1-6). The role of chronic drinking prob¬
lems and alcohol-related injury requires further study
(7). Waller (8) found a much higher incidence of cirrhosis
and previous arrest for drunken driving in traffic acci¬
dent fatalities associated with blood alcohol levels in
excess of 150 mg/100 ml when compared with victims
with no measurable blood alcohol. Although psychiatric
interviews with persons convicted for drunken driving
suggest that three-quarters reveal a history of problem
drinking, such interviews have tended to be rather
unstructured and in such studies no comparison group
has been interviewed (9).
In a more recent study of 3658 drunken drivers,
Gjerde (10) reported that only 8% reported daily drink¬
ing, 82% denied daily drinking and another 10% gave no
information about drinking frequency. Measurements of
serum gamma glutamyl-transferase (GGT) activities in a
random sample of each of the three groups, however,
suggested a high level of chronic alcohol ingestion in
those who denied daily drinking as well as those who
admitted daily drinking.
In the study reported here we administered a stan¬
dardised interview to patients admitted to the ortho¬
paedic wards of the Royal Infirmary of Edinburgh after
an accident severe enough to result in significant ortho¬
paedic trauma. Our aim was to define the frequency with
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which problem drinkers are admitted to such a service,
and calculate the extra risk that a drinker exceeding 'safe'
limits takes of having an acute orthopaedic admission.
Subjects and methods
For the period September to November 1987, 400
consecutive male admissions to the acute orthopaedic
service at the Royal Infirmary, Edinburgh, were
approached for their consent to be interviewed 'for a
study about patterns of drinking and accidents'. Patients
who were discharged before being seen were either
approached at the fracture follow-up clinic, or at home.
There were seven readmissions during the study period.
Of the remaining 393, six refused (one because of
language difficulty), 11 were too ill or confused to be
interviewed, seven were discharged early and could not
be seen because of a false address or distance. This gave a
coverage of 94%.
The instrument used to detect problem drinking
comprises questions of high face validity on recent
consumption, occasional heavy ('binge') drinking, and
alcohol-related problems in the past 2 years in the areas
of health, social relationships, the law, work, and depen¬
dence on alcohol (Fig. 1) (11,12).
Consumption
Over 14 units" in a day on 10 or more occasions in past year.
Over 50 units in typical week.
Over 12 units in 24 h in typical week.
Current medical problems
Current illness potentially related to alcohol.
Current illness definitely related to alcohol.
Weight problem due to alcohol.
Medical problems in past 2 years
Peptic ulcer aggravated by drinking.
Liver disease due to alcohol.
Accident due to drinking.
Social problems in past 2 years
Antisocial behaviour.
Problems at work (including absence).
Domestic arguments.
Violence.
Family rupture (threatened or actual).
Financial.
Police.
Dependence on alcohol in past 2 years
Difficulty in reducing consumption.
Restlessness without alcohol.
Tremor (over 1 day a week).
Morning relief drinking (over 1 day a week).
Hallucinations.
Withdrawal seizure.
Patients scored one point for presence of any variable except
presence of illness definitely due to alcohol, which scored two
points. Problem drinking defined as two or more points.
* 1 unit = 57 g (1 oz) of 40% (by volume) spirits; 13.7 ml (half pint)
of 3.6% (by volume) beer; one glass of wine, etc—that is, roughly,
8 g ethanol.
Figure 1. Criteria for problem drinking.
Regular drinkers (patients who drank at least weekly
or who had occasional days of very heavy drinking) were
asked in detail about the previous 7 days' drinking, or if
that had been atypical about a typical week or typical
heavy week. 'Problem drinkers' were defined as men who
admitted to two or more of the items in Fig. 1. The
interviewer made a judgement about whether, in her
view, alcohol had contributed to the accident, and, if
alcohol had been implicated, the patient was asked 'has
this led you to consider changing your drinking habits?'
A general population survey in the Edinburgh area had
been conducted 8 years earlier, using the same measures
of alcohol consumption (13,14). National surveys had
shown no change in consumption patterns in men during
that interval (15). This enabled a calculation of the
relative risk (odds ratio) (76) of incurring an orthopaedic
admission when admitted consumption exceeds the 'safe
zone' of admitted alcohol consumption as now recom¬
mended (21 units per week) (77), compared to consump¬
tion within that zone.
Results
In the age group 31-50 years, there is an excess of heavy
drinkers among patients, a significantly elevated mean
consumption among regular drinkers, and the relative
risk of having an orthopaedic admission at consumption
over 21 units/week is 1.79 (95% confidence limits 1.05,
3.03). These associations are not evident in other age
groups (Table I).
'Regular drinkers' comprised 71% (n = 263) and these
were the men who were interviewed in more depth
(Table II). This revealed an incident which led the
interviewer to conclude that alcohol had been the main
cause in 71 cases, that is, 19% of the whole sample. Other
common 'causes' of accident as classified by the inter¬
viewer, in the regular drinkers, were sports injuries
(19%), injuries at work (23%), and deliberate self-injury
(12%).
Of the 71 individuals for whom the interviewer
thought alcohol had contributed to the accident, 54
(76%) met the problem drinker criteria. Forty-nine men
(13%) themselves said alcohol contributed to the acci¬
dent. Of these, 41 (84%) met the problem drinker
criteria. In the whole cohort, irrespective of whether the
accident was deemed attributable to alcohol, 34% of men >
met the problem drinker criteria". Previous alcohol-
related accidents (reported by 21%), arguments due to
drinking with friends or family (reported by 40%), and
other social problems commonly contributed to the
problem drinker criteria being met in this sample.
Problem drinking was commonest in the 31-50 years age
group (39%) and in the 17-30 years age group (44%).
Twenty-six men said their accident had led them to
think about changing their drinking habits; that is, one-
half of those who considered alcohol contributed to the
accident (one-third of those in whom the interviewer
considered alcohol to have played a part in the accident).
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Table I. Alcohol consumption in patients and general population
(a) Percentage of men in different age categories
17-30 years 31-50 years 51-65 years
Patients Survey Patients Survey Patients Survey
n= 190 n = 180 n = 89 n = 215 n = 47 n=137
Abstainers
or less than weekly 24 15 21 15 32 27
1-10 units
per week 14 25 19 38 21 33
-11—20 units
per week 22 19 19 19 19 18
21-50 units
per week 29 27 26 20 17 12
>51 units
per week 10 13 15 8 9 7
(b) Mean consumption in regular drinkers (drinking at least weekly)
n— 144 n= 155 n=71 n= 183 n = 29 n = 99
Units/week 31.06 27.60 38.18 18.80 28.59 18.80
SE 3.73 2.10 6.56 1.50 6.26 2.10
SE (difference) 4.20 4.73 5.13
t 0.82 (NS) 4.9 (PcO.001) 1.91 (P< 0.10)
(c) Odds ratio for orthopaedic admission in regular drinkers for consumption of 21
units!week and over relative to consumption below 21 units!week (with confidence limits)
0.84 (0.44, 1.5) 1.79 (1.05, 3.03) 0.57 (0.28, 1.2)
Discussion and conclusions
In the 30-50 years age group, consuming 21 units of
alcohol a week or over increased the relative risk of an
orthopaedic admission. Perhaps the frequency of sport¬
ing injuries, plus the likelihood that sportsmen drink less
than their peers, reduces the proportionate contribution
of alcohol to orthopaedic injury in younger men.
However, among orthopaedic admissions, some young
problem drinkers can undoubtedly be identified.
This study was conducted away from the seasons of the
year when British consumption of alcohol peaks.
Table II. Prevalence of problem drinking
Population interviewed n = 369
'Regular' drinkers 71%
'Problem' drinkers 34%
Patient thought alcohol contributed 13%
to accident
Interviewer thought alcohol contributed 19%
to accident
— % 'problem' drinkers 76%
Accident led patient to consider 7%
changing drinking habits
Together with the probable under-reporting of consump¬
tion in such a study due to fear of medical disapproval or
jeopardising insurance claims, this suggests that our
estimate that 19% of admissions were alcohol-related is
likely to be low rather than high if extrapolated to an
annual figure.
Serum gamma glutamyl transferase tests in drink
driving offenders show that many are regular heavy
drinkers, rather than occasional drinkers who have been
detected by chance (18). The same applies to the men in
this study whose accident was contributed to by alcohol:
76% could be classified as problem drinkers according to
their self-reported consumption in the previous year and
previous alcohol-related problems. Only 1 in 4 is a man
whose drinking has not regularly been excessive or at
times problematic.
Besides individuals who admitted an alcohol-related
accident, the simple, brief interview used here reveals
other problem drinkers. One-third of all subjects met
criteria for problem drinking, a higher rate than the
27.1% obtained in medical wards in the same hospital
(11).
One-third of those in whom alcohol was deemed to
have contributed to their accident said that this had led
them to consider changing their drinking habits.
However, it is clear from the degree of co-operation
obtained in this hospital sample that many acute male
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orthopaedic admissions are at least prepared to discuss
their drinking and the problems it causes.
In a 3 month period, simple questioning revealed 26
patients who said their accident had led them to think
about changing their drinking habits, and a further 28
were identified as problem drinkers according to their
self reports. An offer of counselling about alcohol reduc¬
tion may well be taken up by such men. A study in the
USA showed that trauma patients with established alco¬
holism can be recruited into alcoholism treatment,
especially if the family are involved (19). In controlled
studies, counselling has been shown to have a detectable
effect in excessive drinkers detected in orthopaedic and
surgical wards in a New Zealand hospital (20), medical
wards in Edinburgh (12) and in UK general practice (21).
It would be worthwhile to establish brief counselling
aimed at safer drinking in an orthopaedic service.
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Assessor's comment
The results presented by Dr Chick et al. give further
useful insight into the accident risks taken by heavy
drinkers. The paper contains useful discussion of the age
distribution of those most at risk, and speculates on the
causes of injury. Presumably by reason of the available
sample size, little is said that relates directly to road
traffic accidents; it may therefore be appropriate to quote
some results of a recent study carried out over a 2-year
period at the John Radcliffe Hospital, Oxford, under
contract to TRRL. Of 515 road casualties treated as
inpatients, and on the basis of breath tests carried out in
the accident and emergency department, over 20% were
known to have been drinking alcohol, while over 14%
were over the legal limit for driving (35 ugl 100 ml
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BrAC). However, consideration of all road casualties who
attended the accident and emergency department (the
majority of whom had less severe injuries not requiring
further hospital treatment) indicated rather lower
evidence of alcohol involvement—14% had been drink¬
ing, 8.4% over 35 //g/100 ml BrAC. Within this group,
however, the incidence of heavy drinking was much
greater among pedestrian casualties, the proportion hav¬
ing a Breath Alcohol Concentration in excess of 35 pg/
100 ml BrAC being 27%. Considering again casualties
among all road users, the age group found to have been
drinking most heavily were those in their late thirties—a
result which compares well with Dr Chick's results.
This Study will be published shortly as a Research
Report (RR311) of the Transport and Road Research
Laboratory, Crowthorne, Berks.
J T Everest
Trauma and Road Research Laboratory
Crowthorne, Berkshire
Notes on books
Atlas of Ear, Nose and Throat Pathology by L
Michaels. 119 pages, illustrated. Kluwer Academic
Publishers, Dordrecht. 1990. £80. isbn 07923 8934 4
An atlas designed as a bench manual for pathologists who
report biopsies taken from the deeper recesses of the ear, nose
and throat. There is extensive supporting text; otolaryngolo¬
gists should find much of great value within its pages.
Outpatient Anesthesia edited by Paul F White. 520
pages, illustrated. Churchill Livingstone, New York.
1990. £47.50. isbn 0 443 08437 8
This volume reflects the greater use of day case surgery in
North American practice as compared to that in the UK. It is a
book written largely by anaesthetists, but has emphasis on
organisation and economic factors which take up the first 100
pages. Later chapters deal with surgical considerations, nursing
matters, different patient groups and different anaesthetic
techniques. Complications, including pain, are discussed and
the final chapter is devoted to controversial issues. There are 28
contributors, 26 from various centres in the USA, one from
Helsinki and one from Melbourne.
Anaesthesia edited by R D Miller. 2 Volumes. 3rd
edition. 2420 pages, illustrated. Churchill Livingstone,
New York. 1990. £115. isbn 0 443 08594 3
This large and popular American-based textbook has been
completely revamped to enable the 3rd edition to reflect the
increased knowledge in the subject that has accumulated since
the first edition in 1980. There is thus greater emphasis on
monitoring, and the increasing importance on legal and econo¬
mic issues. Special chapters have been devoted to autotransfu-
sion, haemodilution, patient-controlled analgesia and epidural
narcotics, with a special focus on postoperative analgesia.
Surgeons will be interested in these chapters and in those
devoted to operating room management and environmental
hazards. There are comprehensive chapters on cardiovascular,
hepatic, renal, cerebral, and neuromuscular physiology, all of
which would provide useful reading for both surgical and
anaesthetic disciplines.
The chapter on anaesthetic risk and the anaesthetic impli¬
cations of concurrent diseases should be read by practising
surgeons as well as anaesthetists. The former includes discus¬
sion and such questions as: 'Does anaesthetic risk depend on
who administers the anaesthesia?'! while the chapter on the
latter is a wide-ranging and helpful account which should be
read by all medical practitioners involved with surgical and
anaesthetic management.
In the second volume the section on Perioperative Fluid
Therapy and Resuscitation of the Newborn will appeal to both
disciplines, as will the chapter on Outpatient Anaesthesia. The
section on Critical Care Medicine includes interesting chapters
on Nutrition and Cardiopulmonary Resuscitation.
In summary, this large, multi-author, well-referenced book
should be one of the main texts available for reference in all
major medical centres.
The Story of Thoracic Surgery—Milestones and
Pioneers by Andreas P Naef. 157 pages, illustrated.
Hogrefe & Huber Publishers, Toronto. 1990. $19.80
isbn 3 456 81809 4
The development of surgery of the lung, oesophagus and heart
is traced in this well-illustrated, easy-to-read book written by a
distinguished Swiss cardiothoracic surgeon. The development
of open heart surgery is particularly well covered as Dr Naef
himself participated and knew personally most of the pioneers
in this field. There is a useful bibliography giving important
references. The volume can be recommended as a good
introduction for the general reader.
Counselling the Coronary Patient and Partner by David
R Thompson. 121 pages, paperback. Scutari Press,
Harrow. £11.95. isbm 1 71364 42 6
The author provides evidence that a programme of inhospital
counselling reduces anxiety and depression and increases know¬
ledge and satisfaction in patients with coronary artery disease
and also their partners. Proposals are made for a change in
customary practice and recommendations are given for the
direction of future research.
Addiction (1994) 89, 1613-1617
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Trends in alcoholism among male doctors in
Scotland
DALE HARRISON & JONATHAN CHICK
Royal Edinburgh Hospital, Momingside Park, Edinburgh EH10 5HF, UK
Abstract
Alcohol abuse within the medical profession has long been an issue of concern. Recently, the General Medical
Council reported that half of the doctors reported for health difficulties liable to affect professional competence
were found to have an alcohol problem. This paper examines how rates of alcoholism among male doctors in
Scotland have changed over the last three decades. Admission and discharge rates for doctors to psychiatric
inpatient beds with diagnoses of alcoholism are compared with non-medical professions, for the years
1963-87. The results, assessed in the light of changing Standardized Mortality Rales for liver cirrhosis for
the medical profession, suggest that doctors as a group remain at a higher risk of alcoholism compared to other
professionals, but that this increased risk appears to be largely accounted for by a cohort of heavy-drinking
doctors over the age of 45 years.
Introduction
The 1990 Annual Report of the General Medical
Council states that half of the doctors reported
for health difficulties liable to affect professional
competence were found to have an alcohol
problem. Explanations as to why doctors
may be heavy drinkers have been plentiful.
Doctors' incomes being above the national
average make alcohol relatively cheap for
them. Strong peer pressure on medical students
and doctors may encourage heavy drinking.
Many doctors work relatively free of close
supervision and so can conceal their drinking
more easily.1 Social expectations, availability
of alcohol and tolerance among the profession
have also been blamed.2 The British Medical
Association note that high stress in the medical
profession may contribute to alcohol problems.3
Murray1 compared alcoholism among male
Correspondence to: Dr D. Harrison, St David's Hospital,
Carmarthen, Dyfcd, Wales, UK.
doctors in Scotland with other social class
1 controls by investigating first admissions
to and discharges from Scottish psychiatric
inpatient beds for diagnoses of alcoholism.
For the period 1963-72 the rates were found
to be over two-and-a-half times higher among
doctors. Over half of all psychiatric hospital¬
izations of male doctors between the ages
of 45 and 54 years were attributed to alco¬
holism.
The Standardized Mortality Rate (SMR) for
deaths from cirrhosis of the liver in England and
Wales from 1970-72 showed doctors to have
three times the rate of the "average worker".4
However, the SMR has recently fallen from 350
in 1962 and 311 in 1970-72, to 172 in 1979-80
and 115 in 1982-83.5
The present study investigates whether this fall
in SMR might indicate a decline in alcoholism
among doctors. Two recent studies indicate that
the rate of alcoholism in the medical profession
may be becoming closer to that of the general
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population. Alcoholism rates among doctors in
the United States are reported to be little differ¬
ent now from that of the general population.6
Alcohol consumption among British male medi¬
cal students showed little difference from that of
the. general population when matched for age.7
The present study compares data on first admis¬
sions to and discharges from Scottish psychiatric
hospitals with diagnoses of alcoholism from
1973-87, with data from 1963-72 from Mur¬
ray's earlier study. The Scottish Health Service
(unlike the Service in England) routinely col¬
lected information on the occupation of patients
(until 1987), which allows for a comparison be¬
tween rates among doctors and other pro¬
fessional groups.
Methods
The study population included all social class 1
males, medical and non-medical, resident in
Scotland. The numbers of first admissions to
Scottish psychiatric inpatient beds for male doc¬
tors aged 25 years and over were obtained for the
International Classification of Diseases (ICD 9)
diagnoses of Alcoholic Psychosis (ICD 291) and
Alcohol Dependence Syndrome (ICD 303). In
this study the term alcoholism is used to refer to
both these diagnoses.
The data from Murray's study1 included first
admissions and not total admissions to hospital.
To allow a direct comparison of rates obtained
from that study first admissions, rather than total
admissions, were included in the present study.
It is possible that over the study period the
average number of repeat admissions required
for treatment has changed. Data on total admis¬
sions, therefore, gives a less clear indication of
trends of alcoholism. Admissions to private insti¬
tutions were not examined but for the period
under study, 1973-87, private care for alco¬
holism was not the custom in Scotland.
Admissions and discharge data, like cirrhosis
mortality, are-only.indicators, not absolute mea¬
sures, of rates of alcoholism. For the present
comparison over time and between occupations,
they are an adequate marker, because although
patterns of inpatient vs. outpatient treatment
may have changed over time there is no reason to
believe that these have changed differently for
different occupational groups. Outpatient at¬
tendance data by diagnosis was not available.
Female doctors were excluded from the study,
as a potential inaccuracy arises from the record¬
ing of the occupation of a married woman as that
of her husband.
Information was obtained for the 15 years
from 1973-87. (Murray's study examined figures
from 1963-72.) Identical data on non-medical
social class 1 (NMSC 1) males aged 25 years
and over were obtained for the same period to
provide a control of similar social and economic
level.
The numbers and age distribution of all male
doctors in Scotland aged over 25 years were
obtained from the General Medical Practitioners
Census and the Medical and Dental Census for
the years covering the period under study. The
numbers and age distribution of social class 1
males in Scotland over the age of 25 years were
obtained from the 1971 and 1981 Census
figures.8'9 Social class 1 category consisted of the
professional occupations. Their numbers and
age distribution over the period of study were
calculated assuming population changes to be
distributed equally over these years and the same
trends projected to 1987.
Results
First admissions
During the 15 years studied from 1973-87 a
total of 131 male doctors and 413 non-medical
social class 1 (NMSC 1) males aged 25 years
and over were admitted for the first time to
Scottish psychiatric inpatient beds with a pri¬
mary diagnosis of Alcoholic Psychosis or Alcohol
Dependence Syndrome. This represents a mean
annual first admission rate for alcoholism of 142
per 100 000 for doctors and 41 per 100 000 for
NMSC1 controls. This difference is statistically
significant (z value 13.6, p< 0.01).
Figure 1 shows the age-specific first admission
rates for alcoholism. The rates are virtually
the same for both doctors and other social
class 1 controls under the age of 45 years. From
45 years onwards there is a dramatic increase
in rates for doctors, whereas the increase for
other social class 1 professionals is much less
marked. The rate for doctors becomes approxi¬
mately three times the rate of other social class 1
males over this age. In Murray's study the first
admissions were not analysed according to age
groups, so a comparison between the present
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Figure 1. Age-specific first admission rales /or alcoholism per 100 000 population.
:V.
7All discharges
^During the 15 years 1973-87 there were 359
^discharges of male doctors and 1450 discharges
% of non-medical social class 1 males aged 25 years
and over with a primary diagnosis of alcoholism.
These figures account for 20% of the total dis¬
charges for male doctors and 25% of the total
discharges for other social class 1 males from
inpatient psychiatric beds in Scotland.
Figure 2 shows the age-specific discharge rates
for alcoholism. The discharge rates for 1973-87,
as with the first admission rates, dramatically
increase for doctors more than 45 years old. The
discharge rates for other social class 1 males
increase only slightly at this age. The results of
Murray's study for years 1963-72 are shown.
Here there is a peak in discharge rates at age
45-54 years. Results form 1973-87 show no
peak; rates continue to increase after 54 years
old. The 1963-72 figures show that, of the total
218 discharges of male doctors between the ages
of 45-54 years, 127 (58%) were due to alco¬
holism. In the present study the 1973-87 figures
show the proportion to be lower; of the total 426
discharges, 121 (28%) were due to alcoholism.
This proportion rises slightly in the older age
group (55-64 years); of the total 351 discharges,
117 (31%) were due to alcoholism.
Discussion
The first admission rate for alcoholism from
1963-72 was 165 per 100 000 for doctors and
60 per 100 000 for other social class 1 males.
The figures for 1973-87 of 142 per 100 000 for
doctors and 41 per 100 000 for non-medical
social class 1 males suggest that male doctors
remain a high risk group for alcoholism. If any¬
thing, their relative risk appears higher, 2.7 times
higher among doctors compared with other so¬
cial class 1 professionals in the 1963-72 period,
rising to 3.5 times higher for the 1973-87 pe¬
riod.
When age-specific rates are examined, the
higher risk of alcoholism is only true for doctors
aged 45 years and over. Doctors younger than 45
years have similar admission rates to other social
class 1 professionals (Fig. 1). This is consistent
with the finding that the fall in the SMR for
cirrhosis of the liver in doctors has been chiefly
in the younger age-band. The most recent age
specific data available for Britain (1979-80 and
1982-83) show an SMR for liver cirrhosis of 208
for ages 55-64 (significantly different from 100
at the 95% confidence level), but an SMR of 40
for ages 35-44 and 25 for ages 45-54 (admit¬
tedly based on small numbers).5
It is possible that the cirrhosis mortality data
and our Scottish data represent a cohort effect:
that doctors practising in the 1960s were drink¬
ing more than average for their age group in
social class 1 and continued into the next two
decades, while the subsequent generation did
not. The 1963-72 figures for psychiatric dis¬
charges for alcoholism show a peak of discharge
rates for doctors aged 45-54 years. In the 1973-
87 figures admission and discharge rates con¬
tinue to rise in the over-54-year age-groups,
suggesting an excess of older alcoholic doctors.
The doctors aged 45-54 years in the 1963-72
period are now in these older age groups.











Figure 2. Age-specific discharge rales for alcoholism per 100 000 population.
younger doctors becoming aware of the risk of
long-term alcohol abuse. This explanation is
supported by the finding that the drinking habits
of male medical students in the 1980s were in
line with their non-medical contemporaries.7 A
precedent has been set with the change in doc¬
tors' smoking habits. Education about the risk of
bronchial carcinoma resulted in decreased smok¬
ing and a subsequent SMR for lung cancer
among doctors much lower than the general
population.10 The increased emphasis on the
dangers of alcohol and the widespread effect it
has on health has hopefully contributed to an
increased awareness among doctors of their per¬
sonal consumption. In contrast to this, during
the period studied, per capita alcohol consump¬
tion in the United Kingdom (separate figures for
Scotland are not available) was increasing, apart
from a slight dip in 1980-82, until 1987."
It can also be asked whether the improved
SMR for cirrhosis in doctors has been in part
because of improved outcome of alcoholism in
the profession. Noble et al.12 have put forward
readier access to treatment as a possible expla¬
nation for falling cirrhosis mortality in the USA
during a time when consumption did not fall.
The Scottish data presented here show that de¬
spite a slight increase in the relative risk of
admission for alcoholism compared to other so¬
cial class 1 males, the number of discharges did
not rise: for the years 1963-77 there was an
average of 27 discharges per annum and for
1973-87, 24 per annum. The proportion of total
psychiatric discharges (all diagnoses) attributable
to alcoholism also fell for male doctors in the
past 25 years, from 40% for the 1963-72 period
to 31% for the 1973-87 period. These data may
indicate a reduction in repeat admissions
reflecting improved procedures within the pro¬
fession13 and a growing support network.14
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Mental health, alcohol
and drugs: constructing a
neighbourhood profile
A coherent, practical and explicit local approach is required to assess the
needs that individuals and the wider community have with respect to
mental health problems. A community psychiatric nurse (CPN), general
practitioner and psychiatrist together applied four approaches within a
council estate of 670 homes in Edinburgh. Data were collected by rapid
participatory appraisal, postal survey, analyses of routinely available small
area statistics and collation of practice-held information. Different
methods yielded complementary' insights into the needs of individuals,
their carers and the wider community with respect to mental health,
alcohol and drugs problems, and into current and potential service
provision in the community, primary and secondary care. The neighbour¬
hood profile built up by integrating different perspectives, utilizing
quantitative and qualitative data, was more reliable and informative than
concentrating time and effort on one method alone. Many residents and
community workers were concerned at the high concentration of people
with mental health problems who lived in the area. A change in housing
policy was considered to be the most useful intervention. CPNs in primary
care should have specific skills and apply interventions of proven
efficiency, but may also have a valuable role as part of an expanded
primary health care team, doing work which is currently undertaken by
less appropriately trained (and frequently more costly) members.
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General practitioners in an increas¬
ingly primary care-led NHS are
becoming more involved in the
process of defining and measuring
health needs, considering how these
needs might best be met, and
monitoring some aspects of the
performance of providers. In Eng¬
land the "Health of the Nation" set as
a key target "to improve significantly
the health and social functioning of
mentally ill people" [l]. The Scottish
Needs Assessment Programme has
estimated that 30% of the adult
population of Scotland suffer from a
mental health problem at some point
in their lives, and that nine out of 10
mentally ill patients are treated in
general practice [2], If mental health
needs could be assessed in primary
care, targeted health promotion and
support in the community could be
given for people with mental illness.
Commissioning of health ser¬
vices led by primary care requires
consideration of social services, edu¬
cation, employment and housing
since all these affect mental health
status [31. Much work has been done
to assess mental health needs using
single methods such as surveys of
mental health status [4], practice-
based data [51 or data based on
hospital attendances and admissions.
Community-based studies are rare [61.
Little has been done to bring to¬
gether these approaches to create an
overall picture and to examine which
approaches are most informative for
which purposes with respect to
mental health. Slade concluded that
no single mental health assessment
instrument integrates user and pro¬
fessional perspectives of need, and
that methods should be developed
to take account of both user and
medical views [71. Shanks advocated
a multi-method approach for health
needs assessment generally in pri¬
mary care [81.
The setting of our study was a
post-war council estate, Dumbie-
dykes, of 670 households in central
Edinburgh. It is served mainly, but
by no means exclusively [91, by the
general practice where the study was
based. Four complementary ap¬
proaches to assessing general health
and health service needs had pre¬
viously been applied within the
same neighbourhood [10]. Each
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method had yielded particular infor¬
mation. At the suggestion of a local
psychiatrist, a community psychiatric
nurse (CPN) was recmited, based in
the local practice for 1 year, and the
same four methods were reapplied
this time focused on mental health,
alcohol and drugs. The methods
were applied simply, such as might
reasonably be carried out by an
individual general practice in order
to inform the commissioning of
mental health services and also to




Information was obtained concern¬
ing the 538 adult residents of Dum-
biedykes registered with the practice
using the following methods.
• A random sample of 100 medical
records of adults was analysed.
The following marker conditions
were noted: drug abuse, alcohol
abuse, schizophrenia, other psy¬
choses, dementia, anxiety and
depression.
• The general practitioners were
presented with a list of the
residents of Dumbiedykes who
were registered at the practice.
They were asked to indicate
which patients had problems
relating to mental health (cover¬
ing all aspects from mild anxiety
to psychotic episodes), alcohol
and drugs.
The practice register of drug
addicts was examined for past
or present residents in Dumbie¬
dykes.
Doctors, district nurse, health
visitor, practice nurse, practice
manager and receptionists were
informally interviewed about
their perceptions concerning
mental health, alcohol and drugs
in Dumbiedykes.
Rapid participatory appraisal
A rapid participatory appraisal was
carried out to gain insight into the
community's own perspectives of its
priority needs. A CPN temporarily
based in the practice, a local GP and
a local psychiatrist collated data from
three sources:
• existing documents about the
neighbourhood;
• interviews with a range of infor¬
mants;
• direct observations made in the
neighbourhood and within
homes.
A profile was built using in¬
formation collected on 10 aspects of
the community. These were brought
together to form an information
pyramid (Fig. 1), which was adapted
to include specific blocks for mental
health, alcohol and drug problems
and their related services.
The validity of this approach
depends on the concept of triangula-
tion, with data collected from one
source being validated or rejected by
checking it with data from at least
two other sources. Key informants,
selected for their potential knowl¬
edge about the issues under study,
included people with professional
knowledge about the community,
community leaders and people
who were centrally placed because
of their work (see Appendix 1).
Twenty-six residents of Dumbie¬
dykes were selected to represent
various age groups, mental health,
alcohol and drug problems. A semi-
structured interviewing schedule was
devised and piloted on residents and
(with minor alterations) on local
professionals and workers. Partici¬
pants were interviewed in their
homes or at work by the CPN, and
occasionally in groups. The most
"information-rich" informants were
interviewed first. Data were ex¬
tracted from the questionnaires using
a thematic analysis where answers
relevant to the different information
blocks were grouped together. Sub¬

























FIG. 1. Information pyramid for rapid participatory appraisal.
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members of the community were set
up to discuss and allot priority to the
problems identified and to explore
potential interventions. The process
took the CPN 3 months, spending
15 hours/week.
Routinely available small area
statistics
Edinburgh Health Care NHS Trust
provided hospital-based morbidity
information (out-patient attendances
and admissions) collected by the
PSYMON data system relating to the
19 postcodes for Dumbiedykes (pop¬
ulation 1185), residents of South East
Locality of Edinburgh in which
Dumbiedykes is situated (population
117 000), and for the city of
Edinburgh (population 402 670) for
comparison. Census data on
demography were available.
Postal survey
A postal survey had been carried out
in 1993 on all residents of Dumbie¬
dykes registered at the study practice
(435 of the 993 adult residents of
Dumbiedykes), with a response rate
of 62% [to]. A mixture of lay concepts
and medical diagnoses had been
used. It covered the following areas:
• chronic illness;
• acute illnesses;
• health status: the Nottingham
Health Profile, a standard multi¬
dimensional measure based on
lay concepts to assess both func¬
tional and emotional distress
using six subscales;
• use of health services over 6
months: perceived need for cur¬
rent and potential services;
• social and demographic charac¬
teristics of the respondents.
Thus postal survey information was
available for comparison with data
from other sources.
Results
General findings from the rapid
participatory appraisal
Community composition, organiza¬
tions and capacity. There was a
relatively stable elderly population.
Their pride in their home environ¬
ment was matched only by a grow¬
ing sense of unease towards the
"incomers" to Dumbiedykes, some
of whom they perceived as bringing
with them alcohol and drug pro¬
blems, and general antisocial and
sometimes criminal behaviour. Their
feeling was that they, as a stable
community, were expected to cope
with (and care for) incomers with
problems, difficulties and needs, and
they were unable to do this. Resi¬
dents did not have many relatives
living nearby. There was little sense
of community identity. People felt
unsafe, especially at night.
Environmental, socio-economic and
disease profile. Many informants
complained about dampness, poor
windows and inadequate heating in
the houses. Action had been under¬
taken by individuals, residents
committees and their political re¬
presentatives, but the Housing De¬
partment Maintenance Programme
was perceived to be ineffective. A
high unemployment rate (26%
among males) plus a growing num¬
ber of elderly people receiving basic
pensions indicated that there were
people with financial difficulties.
Numerous comments about pigeon
dirt and dog fouling all combined to
suggest an area where people had
little pride in where they lived.
There were hints of violence, and
of feeling unsafe. A small number of
incidents were spoken about, and
house breaking was increasingly
common, where valuables and ta¬
blets were stolen. Drugs users were
frequently blamed. Graffiti relating
to a specific drug addict had been
sprayed on the side of a house.
Most residents knew the location of
the local social work office, but few
had had knowledge of what com¬
munity education could offer.
Health and social policy. All key
informants were positive towards the
concept of care in the community,
but all felt a need for better planning.
The notion of quality care required
money, and capable personnel in the
community to provide a co-ordi¬
nated, well-resourced community
care programme, distributed so that
services did not depend unfairly on
where the individual lives. But while
increased support in the community
was desired, greater possibility of
relevant and regular employment
was regarded as a high priority to
improve the lot of those with mental
health problems. Informants consid¬
ered that mental health services
should become more community
focused. They suggested that small,
specialist, residential units might be
needed, dependent on the severity
of the individual's problem, but the
primary focus of care should be at
home.
Mental health
Practice-held data. The random
sample of 100 medical records re¬
vealed the current or previous diag¬
noses shown in Table I. Thus a
psychosocial problem had been re¬
corded in 51 of 100 records. How¬
ever, the GPs could only actively
identify 80 (15%) out of 538 patients
as having the problems in Table I.
Routinely available small area
statistics. Table II lists the diagnoses
of new out-patient contacts (1991—
1994) seen at the psychiatric hospital
serving the area, by place of resi¬
dence. The total contact rate for
Dumbiedykes was three times that
of the locality (South East Edinburgh)
of which it is part. Organic psychosis,
schizophrenia, other psychoses and
neurotic conditions were all more
common in Dumbiedykes residents.
Neurotic conditions were responsi¬
ble for most contacts for both areas.
Table III lists the frequency of
admission diagnoses of patients by
place of residence for 1991-1994.
TABLE I. Current or previous mental
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TABLE n. Diagnosis of new out-patient contacts (1991-1994) by place of residence
Dumbiedykes residents SE locality residents Edinburgh residents
n Rate/1000/year n Rate/lOOO/year n Rate/lOOO/year
Organic psychoses 17 3.6 991 2.1 3756 2.3
Schizophrenia 14 3.0 601 1.3 1702 1.1
Other psychosis 11 2.3 702 1.5 2038 1.3
Neurotic conditions 84 17.8 4069 8.7 13217 8.2
Alcohol abuse/dependence 33 7.0 1171 2.4 3479 2.2
Drug abuse/dependence 26 5.5 563 1.2 1656 1.0
Learning difficulties 0 0 105 0.2 255 0.2
Total episodes 246 52.1 8103 17.3 25848 16.0
TABLE Hi. Ercquncy of admission diagnosis of patients for 4 year period (1991-1994) by place of residence
Dumbiedykes residents SE locality residents Edinburgh residents
n Rate/1000/year n Rate/lOOO/year n Rate/1000/year
Organic psychoses 20 4.2 1009 2.1 3662 2.3
Schizophrenia 37 7.8 635 1.3 1683 1.0
Other psychosis 29 6.1 787 1.6 2431 1.5
Neurotic conditions 7 1.5 807 1.7 2263 1.4
Alcohol abuse/dependence 24 5.1 379 0.78 1157 0.72
Drug abuse/dependence 2 0.4 65 0.13 173 0.11
Total episodes 119 25.2 3692 7.6 11369 7.1
Episodes of non-organic psychoses
occurred at five times the rate for
Dumbiedykes than the locality. Psy¬
chotic episodes accounted for most
admissions for both areas, especially
from Dumbiedykes. The figures
were relatively steady from 1991 to
1994. Census data revealed many
indicators of social disadvantage and
potential stresses: high unemploy¬
ment rate (26%, compared with 11%
in Lothian), owned housing 20%
(66% in Lothian) and 47 lone parents
bringing up 70 children. Twenty per
cent of residents, compared with
12% of Lothian, suffered from a
limiting long-term illness.
Rapid participatory appraisal. There
was a perceived increase of people
with mental health, drugs and social
problems being ''moved into Dum¬
biedykes", and that these same
people were receiving little medical
or social support. There were a large
number of isolated individuals, both
elderly and young. Mental health,
alcohol and drug problems were
perceived as breaking up relation¬
ships, causing financial difficulties,
crime and violence, and further
depression and anxiety. Within this
spiral, incidents have frightened and
antagonized neighbours, leading to a
lack of tolerance and increasing
separation and isolation between
individuals with mental health pro¬
blems and their neighbours. The GP
was perceived as being a key figure
in providing a service for those
people with mental health problems,
either as a means of access to more
specialized help, or in actually pro¬
viding the treatment and support.
The emergence of a local community
psychiatric day service for the south¬
east of Edinburgh was welcomed by
those working in this field, but after 1
year it was still unknown to most
residents. The psychiatric hospital
serving Dumbiedykes invoked
strong feelings. Clients, relatives
and other key infor-mants had per¬
ceived a pressure on almost all
aspects of the hospital service lead¬
ing to frustration, disillusionment and
anger, and uncer-tainty as to where
to channel these emotions. Consulta¬
tions appeared rushed. The constant
activities of staff, the changes of
personnel and an allocated keywor-
ker system added to delay when a
client requested help. Quick dis¬
charges were possible, but quick
admissions were not so easily ar¬
ranged. A local social worker re¬
ported inadequate arrangements for
the transferring of patients from the
hospital to the community, and a
general lack of resources. There
were many calls for mental health
workers to be available and acces¬
sible in the community. The reduc¬
tion in size of the large psychiatric
institution was welcomed, but the
need to create smaller residential
units was also stressed. Inaccessibil¬
ity and inflexibility were causing
concern. Both clients and workers
had experienced difficulties in con¬
tacting the appropriate service:
"mental illness doesn't stop at 5
o'clock". Some service providers for
those with mental health problems
had themselves found difficulties
with inter-agency communication,
leading to the thought that a "one-
door" approach, where different
service providers were based in the
same premises, could' provide a
more efficient and ultimately a more
effective approach to care in the
community.
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Postal survey. In the postal survey,
18% of the total respondents (rising
to 26% of females age 44—60 years)
complained of anxiety, depression or
"bad nerves". In the preceding 6
months, 28% had had difficulty
sleeping and 16% claimed to have
taken tranquillizers, antidepressants,
or sleeping tablets in that period. The
Nottingham Health Profile results
showed that residents aged 16-44
scored highly on the emotional
reaction and social isolation sub-
scales. Seventy-two per cent of
respondents indicated that advice
about coping with stress would be
helpful, and 63% had a perceived
need for advice about benefits. A
helpline was suggested.
Drug abuse
Practice-held data. The GPs re¬
ported they prescribed for a number
of drug users in Dumbiedykes who
tended to join and leave the practice
list with a high turnover. Drug users
frequently failed to utilize support
offered by statutory and voluntary
agencies, and sought to be certified
unfit for work. Domestic violence
and unplanned pregnancies oc¬
curred. Injecting in these users had
become less common in the past half
decade, but several children had
been treated for needle stick injuries.
Some drug addicts considered that
moving out of the area was a
solution for their drug problems,
while others were evicted due to
non-payment of rent.
Routinely available small area
statistics. The admission rate for drug
dependence for Dumbiedykes was
three times greater than Edinburgh
(Table II). The new out-patient con¬
tact rate was four times greater
(Table III).
Rapid participatory appraisal
findings. Drug addiction tended to
be seen as a desire by younger
people to escape from reality. A
wide variety of drugs were being
used: cannabis, methadone, ecstasy,
dihydrocodeine, diazepam and te-
mazepam. Neighbours complained
about incidents of violence, intimida¬
tion, burglaries, noise disturbance
and an influx of unwelcome non¬
residents visiting the drug users. In
general, informants reported favour¬
ably on the community services for
drug problems and their collabora¬
tion with GPs. Residents considered
that the benefits of prescribing
methadone probably improved the
quality of life for the addicts and the
community in which they lived. A
need was identified for more support
for young people at "street level",
and the provision of more appro¬
priate residential places.
Postal survey. Six per cent of re¬
spondents indicated they wanted
help or advice about illegal drugs,
and 26% wanted advice about HIV
infection.
Alcohol problems
Practice-held data. From the 100
medical records examined, alcohol
abuse was identified in five cases.
Only seven patients were identified
as having alcohol problems from the
list of Dumbiedykes residents. How¬
ever, practice-based staff commen¬
ted on the amount of disturbance
which a relatively small group of
individuals can cause. The only shop
on the estate sold alcoholic bev¬
erages but not low-alcohol beer.
Routinely available small area sta¬
tistics. Alcohol dependence was re¬
sponsible for three times more out¬
patient new contacts and six times
more admissions from Dumbiedykes
than would be expected in compar¬
ison with locality data (Tables II and
III).
Rapid participatory appraisal. The
closure of the local pub had made
little difference to the perceived
problems related to excessive drink¬
ing. Groups noted were men in their
forties and fifties, younger people,
and women drinkers. Dumbiedykes
was not an area where drinkers were
seen, although empty cans and
bottles were visible in some public
areas. Drinking was done in isola¬
tion, or in "drinking dens". These
heavy drinking sessions were seen
as causing damage to individuals'
health and were detrimental to com¬
munity cohesion.
Alcoholics Anonymous was the ser¬
vice most commonly recognized.
Two other voluntary agencies, the
city's NHS alcohol problems clinic
and the GP and CPN were also
mentioned. There was a mixed
response as to whether or not this
help was sufficient. An increase in
detoxification facilities, either home-
based support or residential places,
was proposed, and again the theme
of accessibility to the services was
highlighted.
Postal survey. Thirty-two per cent of
respondents to the survey indicated
that they would value help or advice
about reducing their alcohol intake.
Interventions suggested by key
informants to address mental health,
alcohol and drug issues in the
community
The residents suggested the follow¬
ing: nursery provision in the com¬
munity room; home visiting of the
isolated; help for unemployment and
financial problems; improved shop¬
ping; development of a community
centre such as a cafe "drop-in";
improved liaison among health and
other workers; and a change in
allocation procedures for council
housing. Local workers suggested:
improved access to care, perhaps
provided by a single allocation pro¬
cedure; improved communication
channels between residents, GPs,
social workers, CPNs, the housing
department, community projects,
community education and commu¬
nity centres; recruitment of more
CPNs; and increased resources for
the community facilities. A number
of these suggestions were facilitated
by the CPN and the GP in the second




Rapid participatory appraisal encour¬
aged a broad multi-disciplinary ap¬
proach to assessing health need. The
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role of selected users, community
leaders and workers in prioritizing
and planning care was developed. A
neighbourhood profile was gener¬
ated which detailed broad needs,
available resources and suggestions
for change. The process in itself
facilitated change in that, for exam¬
ple, a drop-in club for the socially
isolated was commenced during the
period of the study.
The postal survey yielded de¬
tailed information about perceived
mental health status, and perceived
need for existing and potential ser¬
vices for both users and non-users.
Census statistics indicated a high
frequency of socio-economic risk
indicators for psychiatric problems
and allowed comparison with regio¬
nal norms. Hospital statistics re¬
vealed a high usage of out-patient
and in-patient facilities. In the prac¬
tice data, there was considerable
evidence of mental health problems
in medical records, and GPs could
remember many such patients from
memory. For alcohol problems, there
appeared to be an under-identifica-
tion in the practice data compared
with the postal survey. Due to the
small numbers involved and as no
generalization from this very local
study was sensible, no quantitative
analyses of the findings were made.
The statistics were used descriptively
alongside more qualitative data.
Community profiling
In developing countries a number of
formal assessment procedures have
been developed to profile commu¬
nities and to assess the needs, wants,
demands and resources in a com¬
munity. These procedures seek opti¬
mal methods of obtaining infor¬
mation about a community while
including some type of community
involvement in the information-gath¬
ering process. Health visitors have
community profiling skills, but due
to lack of time and lack of homo¬
geneous practice areas have gener¬
ally been unable to do this work.
Profiling communities utilizing infor¬
mation from different sources may
form a basis for needs-led purchas¬
ing with considerable public input,
as is currently being advocated by
the NHS Management Executive [11].
Role of the community psychiatric
nurse in health needs assessment
This study has explored the role of a
practice-based CPN in the assess¬
ment of the needs of individuals,
their families, and the communities
in which they live. With knowledge
of services gained in community
profiling, the CPN can initially assess
patients with mental health problems
and refer to various appropriate
agencies, whether specifically for
mental health problems or not.
Practice-based CPNs may also be
able to support primary health
care teams by providing primary
mental health care where the public
perceive it is under-provided.
Implications
1) Practical strategies for assessing
local mental health needs are
required.
2) Possible methods may utilize:
• practice-held data;
• routinely available local sta¬
tistics;
• rapid participatory appraisal;
• postal surveys.
3) A method mix may yield more
information than one method
alone.
4) Many locally important mental
health needs cannot be met by
health services alone.
Conclusion
Caution must be exercised when
using only a single method to assess
need. Practice data may understate
the prevalence of disease in the
community. Postal surveys may not
be returned by mentally ill respon¬
dents. Rapid participatory appraisal
will not yield statistics for service
planning. Results are likely to be
more widely relevant and accurate if
data from different sources are built
up to describe mental health needs.
A locally appropriate method mix
could utilize data from various
sources according to ease of access,
potential utility and possible re¬
sources, to paint a detailed picture.
Similar methods could be used for
larger neighbourhoods within local¬
ities, or for localities within districts
for larger scale planning.
By adopting a comprehensive
approach to mental health appraisal,
this study provided broad informa¬
tion about the needs of people with
mental health problems and of their
relatives, neighbours and the com¬
munity in which they live. Many
significant social and environmental
as well as medical needs were
identified, implying that mental
health services alone cannot meet
the needs of the mentally ill. A
change in housing policy was the
intervention that most residents re¬
quested, to limit the large number of
incomers who had mental health
problems. GPs, CPNs and psychia¬
trists can be involved together in
identifying mental health needs. Re¬
latively inexpensive methods such as
used here are applicable.
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• People with a combination of the
above problems—four residents.
• Elderly people—four residents.
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Short Communication
Evidence Suggesting Increasing Health Damage in Scotland Related to Alcohol
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Abstract
General hospitals in Scotland have experienced a
steep rise in discharge rates for alcohol-related
diagnoses. This cannot fully be explained by changes
in drinking in the general population, a cohort of
heavy drinkers, changes in diagnostic practice, or
the closure of beds in psychiatric hospitals.
Moreover, there has been an increase in deaths from
alcoholic liver disease, not easily explained by
change in diagnostic practice or a putative cohort of
polysubstance abusers with viral hepatitis. Changes
in society such as greater income disparity and
greater social isolation may contribute and have not
been off-set by improvements in availability or
outcome of treatment.
Objective
There was a rise in discharges for alcohol dependence
and alcoholic psychoses in Scottish general hospitals
from 1980 to 1988. Discharges from general hospitals,
and deaths, from alcoholic liver disease also rose.' This
paper examines the continuation of these trends up till
1995, occurring in the already overstretched acute
services, and examines possible explanations.
Data presented
(a) Population consumption of alcohol
Per capita consumption of alcohol estimated from UK
Excise Duty rose from 1945. A peak of 10.00 litres of
alcohol/adult/year was reached in 1980. From 1981-94
annual per capita consumption plateaued (minimum
8.93 litres in 1983, maximum 9.72 litres in 1988).
Excise data are not published for Scotland separately but
self reported consumption data are available for
Scotland two-yearly.2 Rates of men reporting weekly
consumption above 21 units have remained on a plateau
and for women reporting above 14 units have only
increased slightly. (One unit is 8g ethanol.) The
proportion of the population drinking above these
levels, sometimes called the 'limits of sensible drinking'
(men >21 units/week; women >14 units/week) were for
men 27% in 1986 and 24.2% in 1994 and for women
7% in 1986 and 8.9% in 1994.* However, a continuous
telephone interview survey over the period 1988 to 1995
of 34,247 Edinburgh and Glasgow residents aged
18-60,3 which inter alia touched on self-reported
consumption of alcohol, found there had been an
increase in the rates of people reporting heavy drinking
on occasion. This was defined as '5 or more drinks' in
a session, and its occurrence increased significantly in
both men ( by 4.9%) and women (by 6.5%) during the
years 1988 to 1995.
(b) Morbidity4
Figure 2 shows that, for the diagnosis alcohol related
liver disorder, discharges from general hospitals, for
males and females, rose from 1983 to 1995 continuing
the trend noted by Findlay.1 Discharges from general
hospitals for alcoholic psychosis, alcohol dependence
and alcohol misuse likewise rose during this period, for
both genders (Figure 1).
On the other hand, admissions to psychiatric hospital for
alcoholic psychosis and alcohol dependence decreased
*These were the 'upper limits' used during the 1980s, in
connection with the term 'sensible drinking' and endorsed in
1995 by the Royal Colleges of Psychiatrists, of Physicians and
of General Practitioners.21 In 1995 a Government
Interdepartmental Working Group22 stated that for men regular
drinking of up to between 3 and 4 units per day and for women
up to between 2 and 3 units per day represented a 'sensible
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Figure 1. Discharges from Scottish General Hospitals (per 100,000 Population) 1983-1995.
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Figure 2. Alcohol Related Liver Damage: Total Number of Deaths;
General Hospital Discharges/100,000.
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Figure 3. Admissions/100,000 to Psychiatric Hospitals for Alcoholic Psychosis or Dependence.
somewhat in males and remained fairly stable in females
(Figure 3). (The coding system used for these, and other
data below, was the International Classification of
Diseases, 9th edition—ICD-9; 1995 data are
provisional; the accuracy of the Scottish Morbidity
Record (SMR) is regularly reviewed5 and is impressive.)
(c) Mortality6
Deaths certified as due to alcohol-related liver disorder
rose from 1983 to 1995 (Figure 2), also continuing the
trend noted by Findlay.1
Possible explanations
Is the rise in problems due to a rise in per capita
consumption? It is well grounded in 50 years' of
studies in many societies that a rise in per capita
consumption is often associated with a rise in health
problems related to alcohol.7 However, the rising rates
of alcohol related mortality and morbidity shown in the
Figures 1 and 2 have occurred during a period whenper
capita consumption was apparently on a plateau.
Mortality from alcoholic cirrhosis has usually risen
when per capita consumption rises, but sometimes with
a lag.8 A lag might explain why Scottish rates of alcohol-
related disorders continued to rise in the 1980s after
general population alcohol consumption had stabilised.
However, such lags have tended to last less than a
decade, so it might be expected that a plateau in health
damage from alcohol would have been reached by the
1990s. On the contrary, Figures 1 and 2 show a rise
continuing into the 1990s.
Threshold for admission may have fallen. The
threshold for emergency admission to general hospitals
in the UK seems have fallen in the past decade.9 This
may explain in part the rise in discharge rates that have
occurred for a number of diagnoses. Heart disease is an
example: discharges for heart disease rose from
1,093/100,000 in 1985 to 1,630/100,000 in 1994-5."
However, the rise in general hospital discharges for
alcohol-related disorders has been even steeper than that
for heart disease. The fact that, at least for alcohol-
related liver disorder, deaths have also risen argues
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against the rise in discharges being merely a lower
threshold resulting in milder cases being admitted, or
the same cases being more frequently readmitted.
Closure ofpsychiatric beds may have diverted alcohol-
related admissions to general hospitals. The fall in
male admissions to psychiatric hospitals for alcohol-
related conditions (Figure 3) may indeed result from a
combination of planned bed closures plus greater
confidence (hopefully not misplaced) in out-patient
treatments. However, the reduction in psychiatric
admissions is far less than the increase seen in general
hospital activity. It appears unlikely, therefore, that the
rise of alcohol problems seen in general hospitals is
accounted for merely by a shift in practice, from
admitting to a psychiatric hospital to a general hospital
instead, although this may have been occurring in some
regions. Furthermore, there has been no fall in female
alcohol-related psychiatric admissions.
Diagnosticpractices may have changed. Doctors may
have relaxed their criteria for diagnosing alcohol
disorders. This seems unlikely to be the full explanation
of the increasing indices because:
(a) if doctors had begun to use the appellation
'alcohol' more freely for liver disorders or their
alcohol detection methods had improved, then
there would have been a redistribution ofcodings.
That is, that the amount that 'alcohol-related liver
disorders' rates rose would be the amount that
rates for 'liver disorders—alcohol not specified'
would fall. However, discharge rates for 'liver
disorders—alcohol not specified' have been
increasing rather than falling (from 1990 to 1994:
33.0 to 43.7/100,000(m), 17.4 to
22.7/100,000(f));4
(b) total deaths from chronic liver disease and
cirrhosis have increased proportionate to the
increase in deaths from alcohol-related liver
disorder, rather than staying level6 which would
have been expected if the rise in alcohol deaths
had been due to redistribution of codes;
(c) discharge rates for 'suggestive' diagnoses,
alcohol not mentioned, are also increasing e.g.
acute pancreatitis (from 1990 to 1994—5: 46 to
62/100,000(m), 34 to 59/100,000(f)).4 This adds
further support to the argument that the rise in
rates of alcohol-related disorders is real and not
merely an artefact of coding;
(d) doctors' thresholds for coding alcohol disorders
seem still to be high: in 1995 an audit in ten wards
of a Scottish general hospital found that in 46
records of patients treated for alcohol
withdrawal, the discharge diagnoses mentioned
alcohol in only seven (D. MacKenzie, personal
communication);
(e) there have been no legal changes in Scotland to
stimulate change in doctors' death certification.
In the past decade in England and Wales,
coroners' rules changed to make it more
acceptable for alcohol to be mentioned on death
certificates. There was reason to believe it had
often been deliberately omitted, since previously
it would lead to a coroner's enquiry.10 This had
not been the case in Scotland, which was
sometimes given as an explanation of the higher
Scottish recorded alcoholic liver disease
mortality. While the Scottish procurators fiscal
may have followed the English coroners in trying
to ensure relevant recording of alcohol (albeit
without there having been any legal artefact), the
fact remains as stated already that records show
an increase in total liver disease deaths, and not
just the proportion coded as alcohol-related.
The rise in alcohol-related liver deaths may be due to
increased drug abuse. Intravenous drug misuse
increased 1970-1985." It is possible that in this period
some people destined to misuse alcohol had a period
using drugs during which they contracted viral hepatitis.
This could lead to higher rates of liver deaths in the
heavy drinking population, which, if they had been
drinking heavily prior to death might lead to their death
certificate including alcohol misuse as a secondary
cause of death. Antibodies to hepatitis C virus are
frequently found in alcoholics with liver disease, and
such antibody formation is related to the severity of liver
damage.12 According to the coding procedures of the
Registrar General such deaths would be coded as
'alcohol related liver disorder'. Against this as a
significant explanation of the rise in alcohol-related
liver deaths are the following points:
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(a) the increases in liver deaths are in all age groups,
arguing against a cohort effect;
(b) there has been no rise in North American liver
mortality13, 14 following a similar period of
increasing intravenous drug misuse;
(c) the rises in non-liver alcohol discharges are not
explained.
There may have been a generation with many heavy
drinkers. Perhaps there has been a specific cohort of
people starting off as heavy drinkers in the 1970s and
developing disorders in middle age, which could cause
an elevation in indices, but a transient one. If so, as time
passed we would see a rise in heavy drinkers in the age-
band 45-65 with a change to less heavy drinking in the
younger age bands. The General Household Survey
data2 do not show this for Scotland (though England and
Wales data are suggestive and more years could perhaps
reveal such a cohort effect). Also against a cohort effect
is the fact that alcoholic liver deaths have increased in
all ages.
There may be more people in recent years drinking in a
risky pattern. The liver is probably affected more by
regular heavy drinking, than heavy sessional drinking.
The only sequential population data available for
Scotland on patterns ofdrinking are the recent telephone
survey results for Glasgow and Edinburgh,3 but if
anything these would suggest that it is heavy sessional
drinking rather than regular drinking that has increased.
This study was not principally aimed at specifying
alcohol consumption and its results need replicating.
The rising rates of many other types of general hospital
'non-liver' alcohol related admissions (e.g.trauma, with
'alcohol misuse') would implicate heavy session
drinking rather than daily drinking. We do not seem to
have an explanation thus far for the rise in alcohol-
related liver mortality and morbidity shown in Figure 2.
Could per capita consumption have remained stable,
but with a greater dispersion of drinking as the years
passed: more light, fewer moderate, and more heavy
drinkers (be it heavy sessional or heavy regular)? The
General Household Survey does not show this, but
surveys are insensitive at the heavy end
(underestimating drinking compared to sales/excise
data).7 The explanation for the rise in recorded damage
of all types therefore seems unlikely to be due to
changing patterns or dispersion, but to more heavy
drinkers.
Scottish alcoholism treatment services might have
become less effective. Rates for liver deaths in
Scotland have not followed the USA and Canada, where
liver mortality fell in this period despite stable per
capita consumption. Noble etal." concluded that better
treatments for cirrhosis could not explain all of the fall,
but showed that the period corresponded with a
burgeoning of alcohol treatment services and affiliation
to Alcoholics Anonymous.13-14 During the past decade,
some specialist alcohol treatment units have closed or
been reduced in resource, though community services
have grown. For the services that exist there has been
no audit published which shows that they follow those
approaches which have been demonstrated in
randomised controlled studies to be effective. There is
no data to show that treatment outcome is either getting
worse, or that it is improving. A study which showed
that the suicide rate in hospital-treated alcoholics in
Scotland had decreased referred to 1974-83, the decade
period prior to that discussed in this paper." Doctors in
Scotland, with the exception of an older cohort, have
had a declining re-admission rate for alcohol
dependence compared to other professions which could
indicate improved outcome.16 However, these findings
are based on small numbers and are merely relative to
other professions.
Comment
While increasing national consumption explained the
post-war rise in alcohol problems, there is now a period
of rising harm no longer driven by the increasingly
liberal attitudes to drinking and fall in real price, which
were influences in the 1960s and 1970s.7 It is possible
that surveys have been too insensitive to detect a
growing number of problematic drinkers, and that these
drinkers are also masked in national alcohol sales
figures. A reason for the rise in their numbers might be
because, in an era of relatively low real price and high
availability of alcohol, other social changes have had an
influence. Increasing disparity in income has been put
forward as one social factor affecting health in the UK
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and in Scotland17 although there has been no link yet
investigated between income disparity and problematic
drinking. Another social change is increasing relative
social isolation, as indicated by falling marriage rate and
rising divorce rate6 (the UK has the highest divorce rate
in Europe6), rising rates of one person households18 and
doubling of the rate of lone parent families.18 It appears
to be increasingly easy in our society for women to leave
their partners. Living alone and being divorced or
separated are known to be related to regular and heavy
drinking in Scotland" as in other cultures e.g.20 The
putative continuing rise in problematic drinking in the
last decade appears not to have been offset by
improvements in the availability or outcome of
treatment.
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Abstract
Seven hundred and thirty one men admitted to medical
wards were interviewed to identify problem drinkers
who had not received previous treatment for alcoholism
and who had some social support. One hundred and
sixty one met the diagnostic criteria; 156 agreed to a
follow up interview and were allocated to one of two
groups. One group received a session of counselling
about their drinking habits from a nurse while the
other received only routine medical care. Both groups
reported a reduction in alcohol consumption when
interviewed 12 months later, but the counselled group
had a significantly better outcome than the control
group.
It is concluded that systematic screening for alcohol
consumption and related problems should become a
routine part of medical assessment and that advice on
drinking habits is effective if given before irreversible
physical or psychosocial problems have developed.
problem, however, requires thai the ideal treatment should be
brief and readily available.
We report a study carried out in medical wards to determine
the effectiveness of brief intervention in problem drinkers who
had not received previous treatment and had at least some
social support, which is an important influence on the outcome




Treatment of patients with alcohol problems is ofien un¬
satisfactory because many of them have developed advanced
physical, psychiatric, or social complications before they
present for medical help. Earlier detection has been recom¬
mended on the assumption that intervention will be more
effective at an earlier stage in the illness,1 but this has not yet
been widely tested. Problems related 10 alcohol are common
among inpatients in general hospitals,' 3 and people subse¬
quently identified as alcoholics have an excess of medical
admissions for a wide range of conditions.' The extent of the
• • ' ■ - - "." » ~ ■ V\ - ' j
We studied a consecutive scries of men aged 18-65 admitted for at
least 48 hours to one of four male medical wards covering a wide
range of specialties. The study was confined to men because the
first six months of screening indicated a very low proportion of newly
identified cases among women.®
Patients were excluded at the outset if they were of no fixed abode,
their mental state precluded a reliable history, they were terminally
ill, or they had already been referred to the department of psy¬
chiatry. A structured interview of proved interrater reliability
was then given by a nurse with experience in treating alcoholism;
this interview covered consumption, dependence, problems related to
alcohol, recent and distant medical history, and social background.
Patients were identified as problem drinkers if they acquired two or
more points according to ibe criteria listed in the figure.
Patients were included in the study only if they met at least two
of the following criteria: currently employed or employed for six of
the past 12 months; married; had a "confidant" or close friend; or
lived with at least one other person.
RANDOMISATION AND INTERVENTION
Alcohol Problems Clinic, Royal Edinburgh Hospital, Edinburgh
EH 10 5HD
Patients who satisfied the above criteria were asked to participate
in the study, which, they were told, was concerned with the relation
between their health and drinking habits; they were also informed
that they would be interviewed again 12 months later. Allocation
was made to one of two groups: control and treatment. A compromise
had to be made to the traditional method of random allocation of
patients in a clinical trial. We wished to avoid a control patient
being in the bed adjacent to a patient in the treatment group. Each
ward therefore "alternated every two or three months between being
a source of controls and patients in the treatment group. This had.ri,-.
the disadvantage that before the assessment interview began theT^
nurse knew whether the patient, if recruited to the study, would be
/ Viyi i-L-'.i**-1, ' h 'V- -
in the treatment group or not, but she endeavoured to keep the
assessment procedure standardised. Patients in the treatment group
received further counselling from the nurse. The session lasted up to
60 minutes, during which the nurse gave the patient a specially
prepared booklet and engaged him in a discussion on his lifestyle and
health, which helped him to weigh up the drawbacks of his pattern
of drinking and to come to a decision about his future consumption.
The objective was to help the patient towards problem free drinking,
though abstinence was the agreed goal for some. Controls received
no advice; no comment was made about the content of the screening
interview. The physician in charge, however, may have advised the
patient to modify his alcohol consumption, according to his normal
practice. Mean cell volume and y-glutamyltranspeptidase activity
w:ere measured in all cases as laboratory markers of alcohol con¬
sumption.
FOLLOW UP
Patients were approached again after one year. The interviewer
was a senior nurse with experience of interviewing about alcoholism.
He was unaware of the design of the study. The follow up interview
included questions about general health and experience of problems
related to alcohol (figure) in the 12 months since leaving hospital,
and questions about alcohol consumption were repeated. Blood was
Consumption
Over 14 units* in a day on 10 or more occasions in past year
Over 50 units in typical week
Over 12 units in 24 hours in typical week
Problems related to alcohol
Current medical problems
Present illness potentially related to alcohol
Present illness definitely related to alcohol
Weight problem due to alcohol
Medical problems in past tioo years
Peptic ulcer aggravated by drinking
Liver disease due to alcohol
Accident due to drinking
Social problems in past ttoo years
Antisocial behaviour
Problems at work (including absence)
Domestic arguments
Violence
Family rupture (threatened or actual)
Financial
Police
Dependence on alcohol in past two years
Difficulty in reducing consumption
Restlessness without alcohol
Tremor (over one day a week)
Morning relief drinking (over one day a week)
Hallucinations
Withdrawal seizure
Criteria for inclusion as a problem drinker. Patients scored one point For
presence of any variable except for t presence of illness definitely due to
alcohol, which scored two points.
*1 unit==57 g (1 oz) of 40% (by volume) spirits; 13-7 ml (half pint) of
3^6% (by yolume) beer; one glass of wine, etc—that is, roughly, 8 g ethanol.
."-'Vp -ti. ... ^ ^ ** ...Oj-tFp- .. .....£$1 " '
taken to measure mean cell volume and y-glutamyhranspeptidase
activity.
During the year the patient might have received treatment for
his alcohol problem from his general practitioner, from a hospital
doctor, or at a treatment agency listed in the advice booklet. The
interviewer did not ask about this as the information might have
biased his observations.
DEFINING OUTCOME CATEGORIES
Patients were thought to be definitely improved if they reported no
problems related to alcohol in the year to follow up. If the patient
reported no problems at either interview he was considered to be
improved if his consumption had fallen by 50",', or more. In both
cases improvement had to be supported by results of blood tests or
a relative's report. If these criteria were not satisfied patients were
regarded as not definitely improved.
y-Gluiamykranspeptidase activity supported self reported im¬
provement if it was 40 1U/1 or below at intake and remained at that
concentration, or if it had been above 40 IU/1 and subsequently fell
by at Ieast5"0"o. Adean cell volume supported self reported improve¬
ment if it was 96 fl or below at intake and remained at that level, or
if it had been above 96 fl and subsequently fell by at least 2 fl.
Results
A total of 731 men eligible for inclusion were admitted during
. the study, of whom 161 met our diagnostic criteria. One hundred and
fifty six agreed to a follow up interview, and 78 were allocated to
each of the two groups. Control and treatment groups did not differ
with regard to age, marital state, level of social support, occupational
state, medical diagnosis, mean alcohol consumption in the week
before admission, or mean cell volume and y-glutamyltranspeptidase
activity (table I). Symptoms of physical dependence were uncommon
and did not differ between the two groups. The groups differed,
-however, with regard to the total mean problem score, which was
higher in the group given counselling than in the controls (p = 0-014).
When patients were divided into those who did apd those who did
not admit to problems related to alcohol at intake the two groups
were still matched on medical, sociodemographic, and dependence
items and blood tests.
We interviewed 133 patients after one year. Data on f-glutamyl-
transpeptidase activity and mean cell volume were available at both
interviews in 124 cases. Three patients had died during the inter¬
vening period, and 20 could not be contacted or refused to be seen.
This indicated poor outcome' and applied to more controls than
patients given counselling.
Table I shows measures of outcome, from which it can be seen
that both groups significantly reduced their mean weekly alcohol
consumption. Patients who had been counselled did not reduce
their consumption more than the controls, but 44 (64%) of these
patients claimed that they had reduced their consumption by at
least 50%, compared with 31 (48%,) of the controls (p = 007). The
patients given counselling showed significant improvements in their
score for problems related to alcohol and y-glutamyltranspeptidase
activity. Because they had a higher mean problem score at intake,
however, the change in problem score was calculated as a percentage
of the initial value. This showed a greater mean fall (41%,) for the
patients given counselling than the controls (14%,',) (p = 0-03). At
intake 23 (30%„) of the patients given counselling and 30 (39%;,) of
the controls did not acknowledge any problems, whereas at follow up
the numbers were 40 (58%-k) and 33 (52%), respectively.
A significant difference between the groups was found when global
categories of outcome were examined. Of the 124 interviewed for
. whom complete blood tests were available, 34 (52°.(,) of those given
counselling and 20 (34%;,) of the controls were categorised as definitely
improved (p = 0-038) (table II). Thirteen (19%) of the patients given
-yi&r&i
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counselling (n = 78) 1 8 4 34" 31"
Controls (ri ■= 78) 2 12 5 20 39
fc. 'Patients given counselling r controls: /■ - 4 26, p = 0 038.
counselling and 15 (23";,) of ibe controls were admitted to hospital
during the follow up period; four (6"„) and 11 (17",,), respectively,
were admitted for eight days or more.
Discussion
Many patients showed a substantial improvement during the
12 months after the index admission to hospital. The experience
of being ill, advice from various doctors treating them, and
increases in the price of alcohol" may all have had a beneficial
effect.- There may also have been a "regression to the mean"
effect:.some patients were admitted with illnesses related to
alcohol after a period of heavy drinking, and it is to be expected
that at an arbitrary point in the future the consumption and
associated problems of such patients would be reduced. Never¬
theless, those who received additional counselling achieved a
significantly greater improvement than those who received only
routine medical care.
In defining outcome we gave precedence to improvements in
self reported problems related to alcohol over improvements in
self reported consumption because we believe that it is harder
for a man to prevaricate about whether he has lost a job through
drinking, for example, than about how much he drank in the
previous week or in a typical week. Furthermore, our strategy
of treatment was aimed at helping men achieve problem free
drinking and not necessarily complete abstinence.
Our groups were not matched for the number of alcohol
related problems at intake, though they were matched on every
other variable at intake that we measured. We believe that this
lack of matching can only have occurred by chance. In view of
the' difference in alcohol related problems we specified definite
improvement as complete freedom from problems at follow up.
This might have weighted our analysis against finding an
967
effect of counselling because it would be harder for patients with
several problems related to alcohol (of whom there were more
in the counselling group) to become completely free of them
than for patients with few problems.
The effectiveness of treatment for established alcoholics
continues to be a matter of debate. A controlled study of inter¬
vention in early cases has yielded promising results8; even
self help booklets, such as Drinking Problems: Information and
Advice for the Individual, Family and Friendsf have proved
successful.11 The effect of treatment may well persist if brief
intervention is repeated at intervals." Our study shows how.
important early detection is, and our results are sufficiently
encouraging for us to recommend that similar studies should
be conducted in other general hospitals with inpatients or out¬
patients. Patients may be especially receptive to counselling
when recovering from a medical illness. Screening for alcohol
problems should become a routine part of nursing assessment
and the medical history so that advice can be given before
irreversible physical or psychosocial problems have developed.
We thank the patients for their cooperation; the medical and
nursing staff of the Royal Infirmary; the Scottish Home and Health
Department, which funded the siudv; and Sally Anderson, Valerie
Walker, and especially Terry Anderson for his perseverance in the
follow up.
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Secondary Prevention of Alcoholism and the Centres
D'Hygiene Alimentaire
Jonathan Chick
Royal Edinburgh Hospital, Edinburgh EH10 5HF
Summary
France has invested in a mode of secondary prevention for alcoholism, the Centres d'Hygiene Alimentaire (C.H.A.). Early problem
drinkers detected in industry, general hospitals, by social services, and drinking/driving offenders are referredfor assessment and advice.
The approach is medical. Among drinking/driving offenders in Soissons, a majority attend the C.H.A. and a majority ofattenders return
forfollow-up. A randomized, controlled outcome study has not been performed, but the results of the Soissons C.H.A. are promising, as
are some early results in two other projects.
The secondary prevention of alcoholism - detecting and
intervening in the early case so as to prevent the
development of addiction or serious social or physical
harm — has been advocated in several policy documents
[1, 2]. Although research on early detection has been
widely published [e.g. 3], there is little yet in the
literature on early intervention except in the drinking/
driving area, where to date programmes have not de¬
monstrated unequivocal success [4],
In France, considerable resources have been allo¬
cated to a programme of secondary prevention - the
Centres d'Hygiene Alimentaire - but it is hard to find
any objective evaluation of this investment.
The development of the Centres d'Hygiene
Alimentaire
For 20 years before his death in 1979, Dr P.-M. Le Go
developed a method for detecting early alcoholism and
intervening. He worked in the French Railways where in
1957, 23 per cent of the many hundreds of workers
screened by physical examination had been diagnosed as
'third degree alcoholics'. In 1965 only four per cent were
so diagnosed [5], He felt that this could be attributed to
his intervention though it is not known whether recruit¬
ment policies altered during this period.
His approach to the excessive drinker was to edu¬
cate him about the adverse effects of excessive drinking,
and set this in the context of his daily diet. Unlike the
classic alcohol programmes in French clinics, moderate
drinking rather than abstinence was advised. The doctor
reviewed his patient at intervals, giving practical advice
and providing feedback about improvements - or de¬
terioration - in general health. Emphasis was on the
physical signs of excessive drinking — complexion, colour
of the tongue; tremor of the tongue, mouth and hands;
size and consistency of the liver. Blood tests, mean cell
volume and gamma glutamyl transpeptidase, have since
been added to the assessment. In France, where daily
drinking is common, these blood tests correlate more
highly with consumption [6] than has sometimes been
the case further north in Europe [7].
Modelling themselves on the work of Le Go, some
140 Centres d'Hygiene Alimentaire (C.H.A.) have been
created throughout France. The euphemistic appellation
is an acknowledgement that heavy drinkers do not wish
to be seen as alcoholics and need not be forced to.
Typically, a C.H.A. has a receptionist (the key figure in
ensuring that the initial contact is friendly and informal),
a nurse, perhaps a dietician and/or a social worker, and
general practitioners or general physicians with an in¬
terest in the field give several sessions per week.
The typical consultation takes less than 30 minutes;
is concerned almost exclusively with present medical and
to some extent social and psychological problems; sets
short term drinking goals for reduction of drinking; gives
practical advice on managing life with less alcohol and
probably includes a brief medical examination. The
patient may see the nurse for an informal chat prior to
the doctor's consultation. The offices may be in a health
centre, in down-town premises in a shopping area or
perhaps next to the gastrointestinal unit in a general
hospital.
Many C.H.A. have moved away from preventive
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work to meet the pressure of the needs of established
alcoholics. My impression, after visiting 11 rather diffe¬
rent C.H.A., is that some stafTfind it easier to respond to
the sick alcoholic than to win over the individual who is
the target of preventive medicine and rightly or wrongly
feel it is effort better spent. Thus, some C.H.A. have
become out-patient alcoholism treatment centres. For
example, in a C.H.A. in down-town Marseilles, 72 per
cent of cases in 1981 could be classed as already depen¬
dent on alcohol. Nevertheless, some still concentrate on
their original goal. At Soissons, for example, a small
town 60 miles north-east of Paris, less than half the
clients were, even on the loosest criteria, termed alcohol
dependent.
Babor and colleagues [8] have commented on the
paucity of evidence that the C.H.A.s are effective in
preventing or retarding the development of alcoholism.
This paper presents data from the Soissons C.H.A. (the
'model' centre) that I collected in an attempt to find
evidence that might go towards answering whether a
C.H.A. can claim to be effective.
Recruitment of cases to the C.H.A.
The C.H.A. based in a general hospital, for example in
an office suite adjacent to the Gastroenterology Depart¬
ment, receives a high proportion of its referrals from
hospital physicians, such as patients with upper gas¬
trointestinal symptoms, liver abnormalities, a first attack
of pancreatitis. However, as Table 1 shows, there is one
source of clients which many C.H.A. have in common —
those referred by the Direction Departmentale des
Affairs Sanitaries et Sociales (DDASS).
Drinking/driving referrals
All the drinkers referred by the DDASS have been
charged by the police for driving while intoxicated.
There is a procedure in many regions whereby, since
1978, the Prefecture refers such individuals to the C.H.A.
In Soissons since 1978 my analysis shows that 76 per
cent of such offenders are seen at the C.H.A. (some
non-attenders are individuals who were only temporarily
in the area and reside far away; others decline the
invitation). At other C.H.A. I studied, for example Nice
and Marseilles, the estimated percentage is much lower,
between 20 and 50 per cent attending. The initial
approach to clients in Soissons is made by the C.H.A.
not the Prefecture as in some other areas. In these areas
individuals fear that the appointment is to enable the
licensing authorities to label them as chronic alcoholics
and ban them permanently from driving. However, in
Soissons, the letter from the C.H.A. to the individual is
carefully worded so as not to be threatening. The Prefect
in Soissons at a special commission for reviewing driving
licences notes whether or not individuals have taken up
the invitation to attend the C.H.A. and may persuade
them to do so. A further factor which may explain why
the Soissons Centre has a greater attendance is that
evening and Saturday morning consultations are avail¬
able.
The C.H.A. has no officla role in deciding when or if
a driving licence is returned. However, every individual
has to report to the commission before his licence is
returned. In Soissons, where relations between the
Prefecture and the driving licence medical authorities are
good, the opinion of the C.H.A. may be sought. There is
no law specifying what level ofdaily drinking is permissi¬
ble amongst people who hold driving licences nor what
degree of liver abnormality is allowable. But even if there
was, it would not extricate the C.H.A. doctor from the
ethical dilemma of being asked to divulge information
about a patient, which may not be in the patient's best
interest. The C.H.A. doctor has the same ethical obliga-
Table 1 Source of referrals to three C.H.A. services in 1981
Department de Toulouse Nice:
l'Aisne (hospital-based) Hopital
(community-based) Cimiez
DDAS (drinking/driving offenders) 50% 40% 37%
Medical commission for driving licences 15% 1% 0%
Family doctor 2% 6% 5%
Industrial doctor 3% 6% 1%
General hospital 9% 45% 52%
Social services 8% 5% 1%
Other, including self-referral 3% 5% 2%
Total number of clients 818 146 111
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ions to his patients as any other doctor whose patients
onsult him freely. There is no law compelling the
rinking/driving offender to attend the C.H.A. nor is
tere a law compelling the C.H.A. doctor to give in-
jrmation to the Prefect or the commission on driving
cences. The C.H.A. doctors respect their patients'
ights.
because they did not wish to continue, ofwhom four were
known to be well. Four cases (1%) had died, one
possibly of an alcohol-related cause. This yields an
impressive 'improvement rate', but no independent eva¬
luation has been made. Unfortunately it appears to be
impossible easily to obtain accurate official data on
recidivism rates for drinking/driving offences per se.
10 most driving offenders only attend once, for
xample out of curiosity or to please the authorities?
n some C.H.A. the majority of drinking-driving offen-
ers attend once, as a formality and do not return,
lowever, in Soissons, from 1978 to 31 July 1982, out of
11 cases, nine cases only attended once. All others
ttended on two or more occasions. In the cohort
:cruited in the 2 years to December 1980, out of 181
ases, 57 (31%) had made eight or more visits in the
eriod from 1978 to the end of 1981. Presumably these
idividuals see a purpose in attending the clinic. Perhaps
)me of them keep relapsing and have to attend because
ley are doing badly? This may be true for some but
lany appear to have a satisfactory outcome. Of the 302
rinking driving cases recruited from 1978 to July 1982,
41 were still being followed at the end of that period,
'he state of these individuals, based on information
iven at the periodic visits supplemented by objective
riteria such as blood tests and the relatively objective
riteria of physical examination as coded according to
le 'Grid' method of Le Go [9], was as follows: 113
17%) 'abstinent or drinking without problems'; 70
13%) 'improved'; 9 (3%) unchanged; beginning treat-
lent 49 (16%). Assessment of outcome also takes into
ccount information gleaned by the staff from their
idely-based community contacts (Soissons is a small
immunity of 30,000). Fifty-seven cases had been dis-
larged, 29 (9%) as 'satisfactory', 15 (5%) because they
ad been referred on or had left the district; 14 (5%)
Are the people who attend truly at high risk for
alcoholism?
Without a lengthy follow-up of an untreated group of
drinking/driving offenders, we cannot answer this. In¬
deed, I do not know of such a follow-up in the interna¬
tional literature. But it is probable that the group seen
contain many individuals at risk.
First, as Table 2 shows, both in Nice and in
Soissons, three-quarters of attenders are either already
damaged or are in the excessive drinking range (the
classification used in Table 2 is based on the Grid
method of Le Go, which depends largely on physical
signs and has been compared with liver indices of
alcoholism [9]).
Second, it is not the case that the C.H.A. fail to
harvest the serious cxases. Attenders have the same age
range and the same range of blood alcohols at the time of
olfence as those who do not attend (Table 3). (It seems
likely that an individual who drives at a blood alcohol
level above 2 g/1 has an elevated tolerance to alcohol and
is a regular heavy drinker.) Heavy drinkers do not
specially avoid attending.
Discussion
The descriptive data presented here refer mainly to only
one, albeit the major, type of recruit seen at the C.H.A.,
namely the drinking/driver offender. It is, incidentally,
the type of recruit that many C.H.A. staff least prefer to
able 2 Classification of attenders at two C.H.A. referred for driving while intoxicated*
Occasional Excessive drinkers Verging on Dependent
drinkers probably drinking dependent already




















Classification according to Le Go [5] made by treating physician.
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Table 3 Age and blood alcohol level at time of offence of individuals referred for driving while intoxicated to
Soissons C.H.A. (Jan. 1978-July 1982): attenders v. non-attenders.
Age Blood alcohol g/1
20 20-30 30-40 40+ .80-1.00 1-2 2-3 3+
Attended C.H.A. 32 132 73 74 5 124 122 29
n = 311 (10%) (42%) (23%) (24%) (2%) (40%) (39%) (9%)
Did not attend C.H.A. 23 44 20 23 0 50 35 14
n = 99 (12%) (44%) (20%) (23%) (0%) (50%) (35%) (14%)
deal with. The data relate only to one C.H.A. and are
uncontrolled. One can conclude no more than that the
cases recruited are likely to be truly at risk and the
treatment results are promising. One must not disparage
the efforts of the C.H.A.: no-one, to my knowledge, has
yet designed a treatment outcome study in drinking/
driving offenders that could give information of value to
the worker interested in preventing deterioration in the
health and well-being of excessive drinkers.
Recidivism rates, which are not of interest to the
health worker, have generally been the only outcome
criterion in evaluations of treatment programmes for
drinking/driving offenders [4]. In such evaluations ran¬
domization to treatment versus no treatment has been
extremely difficult to arrange for administrative reasons.
It seems unlikely that a design can be conceived where a
control group accede to researchers wishing to collect
detailed baseline and follow-up information on the
group's medical and social state, drinking habits and
problems. Clayton and colleagues (10), for example,
obtained a research interview in only 36 per cent of 284
such offenders whom they approached.
There is greater hope of evaluating secondary pre¬
vention in a population who have come to medical
attention already - visiting a family doctor or hospital -
or even in the general population as Kristenson and
colleagues have done in Malmo [11]. The Malmo study
invited middle-aged men from the general population to
a medical screening. Men whose self-reported drinking
was heavy and where this was confirmed by elevated
gamma glutamyl transpeptidase (GGT) were allocated
to either (a) roughly three-monthly counselling and
feedback about GGT levels, or (b) no intervention.
About a quarter of the intervention group dropped out of
treatment. In the first 5 years after intake to this study,
the intervention group appears to have had a lower
mortality, fewer sickness days and fewer days in hospital.
In Edinburgh, male 'early problem drinkers' identified
in general medical wards were allocated either to a
counselling session with a nurse accompanied by a
booklet, or no intervention. Here also, independent
follow-up using objective criteria has begun to show
better outcome in the treated than the control group [12,
13].
The possibilities for secondary prevention at this
stage seem promising. However, if enthusiasm for secon¬
dary prevention is to be allowed to divert attention and
resources away from the care of the established alcoholic
or the imperatives of primary prevention, then it is
necessary for the effectiveness of secondary prevention
programmes to be properly established.
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BRAIN WATER IN CHRONIC ALCOHOUC PATIENTS
MEASURED BY MAGNETIC RESONANCE IMAGING
Sir,—In magnetic resonance imaging (MRI) the T^ relaxation
time is related to the state of water in the tissue.1 The T| value,
measured in milliseconds, increases as the proportion of free to
bound water increases. MRI is therefore a potentially valuable
technique in the study ofbrain water during withdrawal ofalcohol
in chronic alcoholic patients. It has been used previously in such a
study2 which suggested that there was "decreased free water during
intoxication and an increase in brain water during alcohol
withdrawal", a somewhat surprising result that the authors
admitted was "at variance with current clinical practice which
emphasises the role ofdehydration in the syndrome and encourages
fluid replacement". We have repeated the study in a larger group of
patients, since the result could have implications for the treatment
of alcoholism.
The subjects were 9 chronic alcoholic patients (7 male, 2 female,
aged 29-60 years, mean 46) voluntarily admitted to hospital for
detoxification. They had been drinking at least 130 g ethanol per
day (mean 180 g per day) before admission and had a 5-15 year
history of alcoholism. None was clinically malnourished, or had
physical disorders other than raised liver enzymes in serum. Over
the first 5 days each patient received a normal diet, intramuscular
vitamin B supplement, and decreasing doses ofchlordiazepoxide. 9
normal controls, sex and age matched (range 26-62 years, mean 45),
were chosen from hospital staff; their alcohol consumption ranged
from total abstinence to the equivalent of 80 g ethanol per week.
Measurements were performed using a 0-08T resistive MRI
system.3 All patients were investigated on two occasions, at 24 hand
at 7-21 days after cessation of alcohol consumption; controls were
investigated once. Measurements ofT, were made from a calculated
T, image of a 12 mm thick transverse section 10 mm above the
maximum diameter ofthe lateral ventricles. To define the T, in grey
and white matter in the frontal, parietal, and occipital regions small
regions of interest were defined—for grey matter 20 mm2 and for
white 69 mm2—and the mean ofsimilar regions in the left and right
hemisphere was noted. In addition the Ti value over the whole
brain, excluding the cerebrospinal fluid (CSF), was measured. The
precision of Tj estimation was estimated from four repeated
measurements on 3 normal volunteers over a period of a month. The
T, precision of white matter was 2 • 8%, grey matter 4 • 9%, and the
whole brain, excluding CSF, 2 • 6%.
At 24 h Tj over whole brain was higher in alcoholic patients than
in controls (see figure). It then falls over the next 7 to 21 days The
change in T| in the whole brain in alcoholic patients correlated with
the time between abstinence and the second measurement










Tj values over whole brain of individual patients at 24 h and at 7-21
days after withdrawal of alcohol compared with age-matched
normal controls.
Mean± 1SE is shown.
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in grey matter was 10*1 ms (SE = 6*9 ms) whereas the decrease in
white matter was only 0*6 ms (SE=4-0 ms). The decrease in Ti in
grey matter correlated with the duration of abstinence (r= - 0-76,
p<0 -05). Though the decreases in Tj over whole brain and in grey
matter in alcoholic patients were not significantly different from
zero, the reduction is significantly different (p<0-05) from the
increase previously reported by Besson et al.2
The preliminary results of this study suggest that chronic
alcoholic patients have a higher T, value in the brain than do normal
controls. This raised Tj probably reflects an increase in free water
within the brain. During withdrawal from alcohol the T| drops,
probably because of a decrease in the brain water content. Our
findings contradict those ofBesson et al2 but are consistent with the
generally accepted hypothesis that the brain becomes excessively
hydrated during chronic alcohol consumption and that abstinence
results in dehydration of the brain.
We intend to determine in more detail the differences between T,
in alcoholic patients and normal volunteers, whether the
subsequent reduction in T, is significant, and if so whether it
returns to normal values with prolonged abstinence. A larger
number of patients will enable the apparent difference in response
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Brain hydration during alcohol withdrawal in alcoholics
measured by magnetic resonance imaging
M.A. Smith, J.D. Chick*, H.M. Engleman, D.M. Kean, A.J. Mander, R.H.B. Douglas
and J.J.K. Best
NMR Imaging Unit, University of Edinburgh, Royal Infirmary, Edinburgh and Department of Psychiatry, University of
Edinburgh, Royal Edinburgh Hospital, Edinburgh (U.K.)
(Received October 28th 1987)
Twenty-seven patients had a first Magnetic Resonance Imaging (MRI) scan 1 — 3 days after stopping drinking and a second
approximately 2 weeks later with no change in whole brain T, or Tt in selected brain areas. Six patients whose first scan was
over 36 h after the last drink underwent an increase in whole brain Tl in the interval to the second scan. The later the first scan
was performed the greater was the increase in Tv These results are compatible with a very early fall in brain water
immediately on cessation of drinking (perhaps due to a rebound increase of vasopressin activity) with a return to 'baseline'
after two weeks. A third scan after discharge from hospital in 23 individuals who had abstained from alcohol or drank very
little did not reveal any further significant change in brain T,.
Key words: brain hydration; alcohol withdrawal; magnetic resonance imaging
Introduction
Water retention within the brain has been
postulated as a contributant to some of the
clinical features of alcohol withdrawal in
chronic alcoholics [1]. In magnetic resonance
imaging (MRI), Tx relaxation time is related to
the state of water in the tissue [2]. The Tx value,
measured in milliseconds (ms) increases as the
proportion of free to bound water within the
tissue increases. In vivo T values have been
shown to correlate with the level of brain water
[3 — 5] and so may enable a study of brain water
during withdrawal of alcohol in chronic
alcoholics.
MRI was first used for the investigation of
chronic alcoholics by Besson and colleagues [6],
These authors suggested that brain water is
diminished during intoxication and increased
during alcohol withdrawal. Acute intoxication
in occasional drinkers results in a fall in whole
brain Tv compatible with the dehydration
*To whom correspondence should be sent.
which follows acute intake of alcohol [7].
Eisenhoffer and colleagues [1] suggest that
such an effect, if chronic, might result on
alcohol withdrawal in a rebound increase of
vasopressin activity, followed by a return to
baseline.
It was therefore hypothesised that whole
brain T1 in alcoholics would be seen to fall from
the level at 24 — 48 h following cessation of
drinking to a lower level ('baseline') some 2
weeks later. We were unable to perform T
measurements in the present study in
intoxicated alcoholics immediately prior to
admission and thus unable to study the early
part of the postulated pattern of changes (that
is, the putative rise in brain water and T ).
Patients and Methods
Chronic alcoholic patients who were about to
be voluntarily admitted as inpatients for
detoxification to the Alcohol Problems Clinic,
Royal Edinburgh Hospital, were fully informed
about the study and invited to participate.
0376-8716/88/$03.50 ©1988 Elsevier Scientific Publishers Ireland Ltd.
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Twenty-seven patients (18 men, 9 women), were
admitted to this study. Their mean age was 44
years (range 26 — 63, S.E.M. 5.2). They were to
be scanned within 48 h of admission (day 1) and
again approximately on day 15. However, the
timing of scans varied according to the
availability of the scanner and the
requirements of the patients' participation in
the ward programme.
In connection with a separate study [8] of
cognitive impairment and MRI parameters,
results of a scan performed at approximately
day 15 were available in a further 42 patients.
These patients had not been scanned at or near
admission.
Patients had been drinking at least 130 g
ethanol/day before admission and had a 5 —15
year history of alcoholism. No patients were
included if they had a history of drug abuse, or
were clinically malnourished, or had physical
disorders other than raised serum liver
enzymes. Over the first 5 days each patient
received a normal diet, intramuscular multi¬
vitamin supplements and decreasing doses of
chlordiazepoxide to control withdrawal
symptoms.
Our procedures for measuring whole brain
Tj and Tx in regions of interest in the brain
have been described [9]. The inter-operator
reliability of our Tl measurements has been
reported [8]. Differences in T1 values between





DAY 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
N 1 19 43022171314 17 2 10 13105333
Fig. 1. Whole Brain T, measurements with means according to length of time since last drink.
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Table I. Mean change in Tx from Scan 1 to Scan 2 (A = Tx (Scan 2) - Tx (Scan 1)).
All subjects Scan 1 within 36 h
of last drink




1.83 ± 9.46 - 0.39 ± 2.04 8.50 ± 3.77
A Frontal
Grey
0.50 ± 17.51 -1.833 ± 4.26 7.50 ± 6.08
A Parietal
White
0.83 ± 9.17 -0.39 ±2.12 4.50 ± 3.90
A Parietal
Grey
-6.75 ± 22.21 -11.17 ± 5.09 6.50 ± 8.17
A Whole brain 0.75 ± 8.89 7-H001+1001 8.33* ± 2.04
n 24 18 6
♦Significantly greater (P = 0.012) than in those whose first scan was within 36 h of last drink.
compared using Student's t-test. Changes in Ti
in individual patients were assessed using a
paired Student's t-test.
Results
Three patients were unavailable for their
second scan. The mean whole brain T1 at the
first scan in the 24 patients who had a second
scan was 314 ms (range 283 — 338, S.E. 2.71). At
the second scan the mean T1 was also 314 ms
(range 283 — 334, S.E. 2.69). Tx measurements in
small areas of interest likewise showed no
significant change between scans. Figure 1
illustrates all our available data on whole brain
Tj in the withdrawal period. It includes the
subjects on whom only the first scan was done,
and subjects from our other study scanned only
at day 15 approximately. No trend suggestive
of a fall in whole brain Ti is visible.
Lest the hypothesised fall in Tx had been
early and had been followed by an early 'return
to baseline', an analysis of the change in T1
between the first and second scan was made,
comparing those patients who had their first
scan within 36 h of the last drink to those whose
first scan was later. The 18 patients scanned
within 36 h had their second scan at a mean of
13.6 days later (range 9 — 16 days, S.E. 0.43) and
the six whose first scan was up to 48 h later had
their second scan at a mean interval of 12.3
days since the first (range 9 — 16, S.E. 1.15).
This interval was not significantly different (P
= 0.33).
In those whose first scan had been within 36 h
of the last drink, the difference between
whole brain Tx on the first and second scans
was insignificant (mean difference — 1.78 ms —
a fall — range -15 — +9, S.E. 2.01). A
significant increase occurred, however, in those
whose first scan had been up to 48 h later (mean
8.33 ms, range +2— + 14, S.E. 2.04; t = 4.08,
d.f. 5 P < 0.01). The difference between the
changes in these two groups of patients,
(between those scanned within 36 h of
admission and those scanned later), is
Table II. Correlation of TIME OF SCAN 1 (post admission) with CHANGE IN T( from Scan 1 to Scan 2.
P-values(* — P< 0.01)m = 24
A WB A FW A PW AFG A PG
TIME OF
SCAN 1 0.4048* 0.2434* 0.1080* 0.4076* 0.4242*
28
significant (t = 2.73, d.f. 22, P = 0.012) (Table
I). The trend was visible but not significant in
each of the Tl measurements made in areas of
interest. The later the first scan was performed
after the last drink, the greater the change
between the first and second scans, as shown
by the correlation coefficients given in Table II.
In case our timing of the scans had resulted
in our missing any later changes in Tv another
comparison was made. Four patients had the
second scan on the 9th or 10th day and 20
patients beyond the 10th day. There was no
significant difference when these groups were
compared in the mean change between the first
and second scans (2.25 ms, S.E. 5.28, range — 11
— + 13 and 0.45 ms, range - 15 — + 14, S.E.
1.97, respectively; t = 0.36, d.f. 22, P = 0.72).
We had some further data after patients had
been discharged from the 2-week ward
programme. Seventeen patients from the
present study had a further scan 2 months after
discharge. There was also a scan at that point in
38 patients in the collateral study already
mentioned. The difficulty in using this data is
that we were not always certain whether or not
an individual had continued to abstain from
alcohol during that period. We examined the Ti
values in 23 individuals who had been scanned
at about day 15 and had a repeat scan at a mean
of 102 days and who as far as we could tell had
abstained during that period or drunk very
little. No significant change in T1 in any of the
regions of interest or in the whole brain was
noted. However, the trend in these apparent
abstainers in all our T1 measures was for a
slight increase, but with considerable
individual variation (for example, the mean
increase in whole brain Tl was 2.39 ms, range
- 11 — +19, S.E. 1.55 ms, n = 23).
Discussion and Conclusions
The only possible way in which our data
would support the notion that there is a fall in
brain water following withdrawal from alcohol
is using the sparse data comparing the changes
in those scanned within 36 h of the last drink with
those whose first scan was later. Our data would
support a fall in T1 between 36 h and 84 h, with
a subsequent return to 'baseline' during the
next 10 days approximately. It would have to
be postulated, however, that individual
differences in 'baseline' Tl prevented this from
emerging in the data on the whole sample as
illustrated in Fig. 1.
Our data do not uphold the provisional result
which we obtained on our first 9 patients [9]. In
that paper, we reported a fall in whole brain T1
which correlated positively with the length of
abstinence prior to the second scan. In our
present sample, the correlation between
change in whole brain 71, and interval to the
second scan was insignificant ( — 0.09). Neither
were there significant correlations between the
change in Tx in the areas of interest and
interval to the second scan.
Further studies should comprise daily
measurements beginning on the day prior to
admission, when the patient is still drinking,
and continuing for 2 weeks.
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The relationship of cerebral atrophy and T1 in
alcoholics: an MRI study
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There was a significant correlation between two measures of cerebral atrophy (the ventricle to brain ratio and the relative
cerebral volume) and Tl in 19 detoxified alcoholics. This provides further evidence that Tl is a marker of structural damage in
alcoholics although the partial volume effect of CSF may contribute to this finding. This has implications for studies comparing
alcoholics to normal controls and suggests that better ways of excluding CSF need to be found.
Key words: alcohol; cerebral atrophy; magnetic resonance imaging
Introduction
In magnetic resonance imaging (MRI) the Tx
relaxation time is related to the state of the
water in the tissue [1]. The T1 time increases as
the proportion of free to bound water within
the tissue increases. Raised Tt times have been
shown in alcoholics [2], which decrease tran¬
siently during the first 48 h of detoxification [3],
but show little change after 6 months absti¬
nence. Hospitalised Korsakoff's patients still
have significantly raised Tx times after 5 years
[4].
Despite these changes the exact physiologi¬
cal basis of the raised T1 time is still unknown.
It could be caused by an increase in intra- or
extracellular water content of the tissue or by a
«• change in the ordered structure of water
around macromolecules, perhaps related to
changes in phospholipids [5]. Indeed its relative
stability suggests a permanent structural
change. T1 times show a significant correlation
with age [6] and this provides further evidence
that structural change is a factor since brain
water levels do not change appreciably after
the age of 20 [7].
Interpretation is theoretically confounded
by the presence of CSF which has a high Ty If it
was not successfully excluded during measure¬
ment it could cause a spurious increase in Tl
Because alcoholics suffer cerebral atrophy [8],
and therefore have proportionally more CSF
present in an MRI scan, this might contribute
to the differences between patients and
controls.
This study was undertaken to examine the
relationship between cerebral atrophy and Tv
and to determine the effects of CSF.
Method
Nineteen alcoholics (15 males), mean age 46.2
± 9.3 years (range 32 — 63), who had been absti¬
nent for a median of 4 days (range 3 days to 2
years), had an MRI scan using a 0.08T resistive
system. A transverse 71, scan was obtained 10
cm above the maximum diameter of the lateral
ventricles. Ten contiguous proton density
serial coronal scans were also obtained. All sec¬
tions were 12 mm thick with a pixel size of 2
mm2. Measurement of mean Tx of the entire
area of the transverse section (the grey and
0376-8716/89/$03.50 © 1989 Elsevier Scientific Publishers Ireland Ltd.
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white matter together but not the CSF) was
made. The area of each hemisphere to be sam¬
pled was delineated separately using an irregu¬
lar region of interest; a cursor was used to draw
the boundary of the area to be measured
directly onto the image of the section as it was
displayed on the monitor. The mean Tx within
the region of interest was calculated and dis¬
played. CSF has a high Tx, and is white on the
coloured display. It is therefore possible to try
to exclude sulcal CSF by ensuring that it is not
included within the boundary of the area to be
sampled. Therefore an estimate of Tx for brain
tissue in the entire section ('whole brain Tx')
was obtained.
The relative Cortical Volume (rCV) was also
estimated from the transverse Tx image. The
area of brain tissue was divided by the intra¬
cranial area, identified by the MRI silent skull
(which appears black on the coloured display).
The Ventricle to Brain Ratio (VBR) was
measured from the serial coronal scans which
were available for 16 patients (13 males). Two
areas were measured on each scan and summed;
the intracranial area (ICR) bounded by the
superior edge of the cerebellum and the skull;
and the ventricular area (VA), again easily iden¬
tified because the proton density image high¬
lights the CSF, since it is red against the yellow
background of the brain tissue. The VBR is
then given by VA/(ICR - VA). These measure¬
ments were made blind to the Tx results and
the areas to be measured were identified with
the help of a radiologist.
In order to assess whether our method
excluded the partial volume effect of CSF, a
histogram of the Tx results was produced. This
estimated the percentage of pixels within each
of 17 Tx bands between 250 — 1000 ms. All
results were given ± standard deviation.
Results
A significant correlation existed between
rCV and age (r = - 0.65, df 17, P = 0.002) and
that for VBR and age just failed to reach
significance (r = 0.48, df 14, P = 0.06). Hence
the technique of partial correlation, holding age
constant, has been used in the data analysis [9].
Table I. An example of the distribution of whole brain Tl
values in the transverse MRI section.
r, (ms) Volume (%)
0-249 2
250 - 297 8




486 - 532 7







862 - 908 2
909 - 955 1
956 - 999 7
The mean Tx was 381 ± 15 ms, the mean
VBR was 4.0 ± 1.5 and the mean rCV was 80 ±
7%. The measures of cerebral atrophy were
significantly correlated with each other (r =
0.47, df 13, P = 0.03), and both were signif¬
icantly correlated with Tx (r = 0.62, df 13, P <
0.02, and r = -0.57, df 16, P < 0.02,
respectively).
Table I shows an example of the distribution
of Tx values for one of the patients. If partial
volume effects had been totally excluded a
clear discontinuity between brain tissue (Tx
approx. 200 — 400 ms) and CSF (Tx >700 ms)
would be expected. There was no discontinuity
for this and four other patients in the study.
Discussion
The significant correlation between Tx and
the measures of cerebral atrophy is at vari¬
ance with our previous report using linear
measures of cerebral atrophy [2]. However, this
is probably explained by the evidence from CT
studies that have shown that area measure¬
ments are more accurate [8]. Two explanations
for this relationship seem plausible: (1) An
effect on some intracellular structures that
increased their Tx into the range 400 — 700 ms
and simultaneously caused atrophy or cell
shrinkage. This would imply that the associa¬
tion was indirect and due to the severity of alco-
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holism. (2) Measurement artefact caused by the
'partial volume' effect of CSF. Although
obvious CSF was excluded during the measure¬
ment process, the imaged tissue slice is 12 mm
thick and a sulcus may therefore occur just
below the surface which is not obvious to the
investigator but which will affect the Tv This is
more likely to occur in alcoholics because they
have atrophied brains with increased sulcal
widths and ventricle to brain ratios [8]. The lack
of a discontinuity in the T1 results for some of
the patients could be interpreted to mean that
the partial volume effect has not been excluded.
Nevertheless we believe that this is unlikely to
be a major confounding factor since 75—80% of
the tissue at the level being measured is white
and not likely to be substantially influenced by
CSF. In addition, Christie et al. [4] in their
study that included control subjects, patients
with Alzheimer-type dementia and Korsakoffs
patients hospitalised for over 5 years found
that the latter had significantly raised Tx val¬
ues which were approximately 4% higher than
those of the Alzheimer's patients, whose values
in turn were no different to the controls. They
argued that this finding was unlikely to be a
measurement artefact of cortical atrophy since
it was identical in the two patient groups.
There is evidence of structural change
affecting in rats. Greentree et al. [10] have
used ethanol-tolerant rats to study the relation¬
ship of Tj, water content and phospholipid (PL)
composition. Different classes of PL are
distributed asymetrically within biological
membrane bilayers. Phosphatidylethanolamine
(PE), phosphatidylserine (PS) and phosphatidyl-
inositol (PI) composition determine the degree
of order in the inner lipid layer and therefore
influence the degree of structure in intracellu¬
lar water close to the cell membrane and hence
the T1 time. They found a reduction in T1 time
in the cortex while tissue water content
remained unaffected. Increased proportions of
saturated fatty acids and a reduction in the
proportion of long chain, polyunsaturated fatty
acids were detected in the PE fraction. This
suggested to the authors that MRI changes in
alcoholics could be attributable to altered
membrane composition and structure which in
turn influenced the nature of intracellular
water. However, there is currently no
explanation why phospholipid changes, which
are thought to increase the rigidity of cell
membranes with chronic exposure to alcohol
[10], should lead to an increase, rather than a
decrease in T1 in patients [2]. Similarly, the
increase in fluidity of cell membranes in
response to acute ingestion of alcohol would be
expected to increase T1 but the opposite has
been shown in volunteers [11]. The interpreta¬
tion of the Tx changes is therefore problemati¬
cal although it has been known for over 40
years that the brains of alcoholics at post mor¬
tem are oedematous [12,13] and this would lead
to an increase in Tv It is of course entirely pos¬
sible that a structural effect other than that
known to occur in lipids could be responsible
for these results.
The findings of this study support the
hypothesis that Tx is a marker of structural
change in alcoholics, but future work must find
effective methods of excluding the effect of
CSF from the field of measurement. By choos¬
ing appropriate pulse sequences it should be
possible to obtain a CSF map and estimate its
Tx. This could perhaps be used to obtain a Tl
image corrected for the presence of CSF.
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Magnetic Resonance Imaging of the Brain in Alcoholics:
Cerebral Atrophy, Lifetime Alcohol Consumption, and
Cognitive Deficits
J. D. Chick, M. A. Smith, H. M. Engleman, D. M. Kean, A. J. Mander, R. H. B. Douglas, and J. J. K. Best
Magnetic resonance imaging of the brain in 69 detoxified alcoholics
revealed that relaxation time (Tn) in whole brain and in grey matter
and parietal white matter was greater than in age-matched controls.
In 48 patients, data on cognitive function and lifetime alcohol con¬
sumption were available. With age-controlled, lifetime consumption,
and impairment on performance in the cognitive test (a Category
Sorting Test) correlated positively with T, in whole brain and in
selected regions. Impairment in the cognitive test correlated with
increased T, in whole brain and white matter independently of cere¬
bral atrophy. Alcohol consumption patterns in the following 6 months
were unrelated to changes in T,. The excess water implied by the
elevated Tn values may be intra- or extracellular. It is uncertain
whether or not T, elevation in alcoholics is a marker of neuronal
damage. T, elevation appears to be a marker of one type of alcohol-
related cognitive impairment.
"C^XCESSIVE DRINKING is associated with impaired
1' cognition.' There is evidence in some drinkers that a
defect in cognition predates the heavy drinking.2 However,
improvements in cognition occur in some alcoholics who
become abstinent.1,3 Also indicators of predrinking intel¬
ligence such as early academic attainment and retained
verbal skills suggest that the excessive drinking is at least
as much a cause of certain types of cognitive impairment
as a consequence thereof.1,2
Brain shrinkage is also well established,4,5 and modest
correlations between measures of shrinkage (especially
central shrinkage) and cognitive impairment have been
found.13 The cause of this shrinkage is unknown. How¬
ever, the cerebellar atrophy of alcoholism is due at least
in part to neuronal death.6 Neuronal death may contribute
to the cerebral shrinkage of the alcoholic, a possibility that
was raised over 80 years ago.7 Animal studies have shown
that ethanol consumption can cause nerve cell dysfunction
and death.8"11
A potential marker of nerve cell death in alcoholic
patients is, of course, the shrinkage visible in computer
tomographic (CT) scans. However, a search for another
marker seems justified since the correlations between cog-
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nitive impairment indices and CT measurements is, as
mentioned, modest at best. An alternative marker might
be provided by magnetic resonance imaging (MRI) of the
brain. Furthermore, the observation that the histology of
neuronal death may show oedemalous cells12 suggests a
particular importance for MRI.
In magnetic resonance imaging of living tissue the pa¬
rameter known as 7j relaxation time is related to the state
of water in the tissue.13 The 7j value, measured in milli¬
seconds, increases as the proportion of free to bound water
within the tissue increases. MRI scanning of brain in the
intact patient before neurosurgery has shown that in vivo
7j measurements predict the degree of brain hydration.14
Besson et al.15 were the first to report brain 7j measure¬
ments in a small group of alcoholics but reported only on
change in the phase immediately after cessation of alcohol
intake.
The present study had four hypotheses: (a) that the
detoxified alcoholic brain some 2 weeks after the last drink
would be overhydrated compared to age and sex matched
non-alcoholics; (b) that in detoxified alcoholics the degree
of overhydration in the brain would be related to the total
lifetime consumption of alcohol; (c) that this overhydra¬
tion would predict cognitive impairment; (d) that ex¬
tended abstinence in the posttreatment phase would be
associated with reduction of overhydration and improve¬
ment in cognitive functioning.
SUBJECTS AND METHODS
Alcoholic patients admitted for detoxification to the Alcohol Problems
Clinic at the Royal Edinburgh Hospital were fully informed about the
purpose and procedures of the study and invited to participate. Signed
consent was obtained. The project was approved by the appropriate
Ethics of Research Committee.
Hypothesis 1
Sixty-nine patients (46 males. 23 females) were scanned at the end of
detoxification—a mean interval of 14 days after the last alcoholic drink.
These 69 patients had a minimum of 5 years of recent heavy drinking.
Their mean age was 44 years (range, 22-70; se, 1.16). None had the
clinical features of Wernicke-Korsakoff syndrome, had a history of drug
abuse, were clinically malnourished, or had physical disorders other than
raised serum liver enzymes. They had all been drinking at least 130 g of
ethanol per day during drinking episodes. In Britain, a "standard drink,"
i.e., a half pint of beer, a glass of wine, or a single measure of spirits,
contains 8-9 g ethanol. They spanned the range of socioeconomic
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backgrounds, and though half were unemployed none were without a
fixed address.
Hypotheses 2, 3, and 4
A subgroup of 48 of the above patients (32 males 16 females) was
invited to have cognitive testing and to attend for repeat MRI scans and
cognitive testing at 6 months, (though in the event only 26 patients kept
the following appointments for both scans and testing). These patients
were selected on the basis of their willingness and likely ability to attend
for further testing. Their mean age was 44 years (range, 22-70; se, 1.36).
They had mean red cell volumes ranging from 88 to 111 fl (mean, 98.9;
se, 0.98; n = 42) and serum y-glutamyl transpeptidase (GGT) values
ranging from 5 to 1000 units (median, 100; mean, 217; se, 42; n = 43).
The consumption pattern of this group was studied in more detail. They
were asked to give anchor dates throughout their adult lives and com¬
mencing with the year in which they first drank alcohol, to reconstruct
their typical pattern of drinking month by month during each of the
succeeding years. The method is based on that of Skinner and Sheu.16
Thus an estimate was obtained of cumulative total lifetime alcohol
consumption. Inter-rater reliability of this method in 10 patients whose
responses were rated by two independent assessors showed an average
agreement between assessors of 87%. (Taking the past year's consump¬
tion enabled some of the relationships of interest to be analyzed using a
recent, rather than a lifetime consumption measure. However, to reduce
the total number of tests of significance made, it was decided to concen¬
trate on our cumulative lifetime measure of consumption).
Normal MRI values were available from a group (n = 26) recruited
from hospital staff and patients' relatives. Their usual alcohol consump¬
tion ranged from nil to 80 g ethanol per week. Their ages ranged from
23 to 74 years with a mean of 42 years, and a similar distribution to that
of the patients. The ratio of women to men in the normal sample was
14 males to 12 females, that is, a higher proportion of women than in
the patients. However a two-tailed I test of the differences in the females
and males of the control group found that there were no significant
differences in their whole brain T, measurements (p = 0.88) so the
differences in the proportions of the sexes in the control and the alcoholic
samples are not considered to be of importance. They may have been of
slightly higher mean socioeconomic status than the patients but this was
not thought likely to bias the results, though no study of MRI and
socioeconomic status has to our knowledge been reported.
Our index of cognitive function was the microcomputer-administered
Maudsley Category Sorting Test.1718 This provides a measure of abstract
reasoning ability and rigidity of thought processes and it is of interest
because rigidity of thinking in alcoholics is a major impediment in the
psychological treatment of the condition. The subject is required to
deduce the categorization system being used by the computer program
and to shift his or her set when the program changes. The program offers
six different methods and the number of times out of six in which the
subject correctly arrives at the solution is counted (CATEGORIES). The
number of trials needed to achieve that number of correct solutions is
counted (80K18). ihe total number of errors made is summed (ER¬
RORS). The number of perseverative errors (errors repeated despite
feedback from, the program) is totalled (PERSEVERATIONS) We have
concentrated on the Category Sorting Test because it has been shown
that deficits in this type of function correlate well with C t parameters of
atrophy,19 and are common to both older and younger alcoholics whereas
impairments on tests of memory and general intellect tend to be seen
only in older patients.1
Alcohol consumption in the follow-up period was estimated from the
clinic treatment records, and interviews with the patient conducted by a
research assistant at 3 months and 6 months. This information was
corroborated where possible by an additional interview with a relative
and by changes in the serum GGT in those patients who had an elevation
ofthis marker" at intake to the study. For some patients only a qualitative
report on consumption was available. Patients were categorized as follows
for each of the 3-month period: total abstinence; "intermediate" drinking
(1-40 g per day); "heavy" drinking (over 40 g per day).
MRI measurements were performed using a 0.08 Tesla-resistive MRI
system.21 Three or four transverse sections were obtained through the
brain centered to the maximum diameter of the lateral ventricles. The
slice thickness was 12 mm and pixel size was 2x2 mm. An interleaved
saturation recover,' and inversion recovery pulse sequence, with a repe
tition time of 1000 ms for both and a time from inversion of 200 ms for
the latter, was used to obtain a calculated 7j map of each section.
Measurements of the patient's brain T, wore made from a section
approximately 10 mm above the maximum diameter of the lateral
ventricles. The T, in grey and white mattor in tho frontal and parietal
regions was measured from the T, map using small regions of interest
generated by the computer. Different size regions of interest were used
for grey matter (20 mm2) and for white matter (69 mm2) and the mean
of similar regions in the left and right hemisphere was noted. Larger
irregular regions of interest were also moasurod to attain mean T, values
of each cerebral hemisphere. To achiovo this an electronic cursor was
used to delineate tho border ofeach hemisphere directly on the computer
reconstructed image of tho brain as displayod on tho monitor. Obviouc
areas of CSF (which have a very high I) and appear white on the
coloured image) were avoided. As a further precaution to exclude CSF,
the computer was programmed to display the mean 7j for each hemi
sphere only for values within the range 60 - 600 ms. An example of a T,
map in a patient including the regions of interest used for analysis is
shown in Fig. 1.
The precision of the 7j measurements was estimated from four
repeated measurements on three normal volunteers over a period of a
month. The T, precision of white matter was 2.8%, grey matter was
4.9%, and the whole brain 2.6%.22 The poorer precision of tho measure
ments of grey matter arc duo to tho fact that it is generally of small
volume and adjacent to CSF resulting in partial volume errors. In
addition smaller regions of interest are used resulting in a larger error.
The interoperator variation of our T, measurements was assessed in two
independent operators in 20 sections from five different patients. The
percentage differences between rates were: whole brain 1.9%; frontal,
occipital, and parietal white matter 2.5%; temporal white matter 5.2%;
grey matter (all areas) 5.5%. All ratings were blind to the clinical state of
the patient, consumption measures, and cognitive test ccorec. However,
control scans were identified as such, and dates of all scans were also
known to the raters. 7", maps were analyzed by three operators; results
from the same patient wore always analyzed by the same operator.
Atrophy Measurements
Commonly used indices of cerebral atrophy23 were made by caliper
measurement on MRI scans: (a) Third ventricle, widest diameter; (b)
Fig. 1. An example of an MRI scan in a patient indicating region of interest
marker.
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The Ventricular Index, the distance between the choroid plexuses divided
by the maximum width between the frontal horns; (c) The Iluckmann
Index, the sum of the maximum and minimum widths of the frontal
horns; and (d) The mean width offour cortical sulci was measured on a
slice 16 mm above tho upper limit of the lateral ventricles, choosing the
two widest sulci on each side.
As an attempt at assessing the reliability of these measures in our
hands, we checked the correlations between the indices of internal
atrophy. The Huckmann index correlated r = 0.33 (p < 0.05) with the
ventricular index and r = 0.47 (p < 0.01) with "3rd ventricle" (n = 46).
Differences in T, values within groups of patients at different times
were compared using Student's t test. Changes in T, were assessed using
a paired Student's t test. The relationship between changes in T, values,
drinking and changes in cognitive function were assessed using linear
regression analysis. Partial correlation analysis was used to investigate
the relationship between cognitive function and 7", value and cognitive
function and previous drinking history to control for the effect of age
and atrophy.
RESULTS
The Tx values obtained from the patients at 2 weeks
and 6 months are given in Table 1 with the results from
normal controls for comparison. The most pronounced
differences between normals and alcoholic patients are
seen in the whole brain and in grey matter Ti values.
Relationship between Tit Age, and Alcohol Consumption
In the subgroup studied intensively the mean lifetime
drinking total was 775 x 103 g (se, 104 x 103; range, 71
X 103—3329 x 103). The 7", values at the time of the first
scan correlated positively with the patient's age, signifi¬
cantly so in frontal white matter (r = 0.49, p < 0.01) and
in posterior white matter (r = 0.41 ,p< 0.05). Eliminating
the effect of age using partial correlation, a significant
positive correlation was found between whole brain 7? in
the detoxified patient and the patient's cumulative total
life's consumption r = 0.36, (p < 0.01). (The past year's
consumption, which not unexpectedly correlated signifi¬
cantly with lifetime consumption, correlated positively
with parietal white matter 7) but not significantly with
whole brain 1\). (n = 47).
Relationship between T, and Cognitive Impairment
In the alcoholics given cognitive testing^ impairment in
each of the scores on the Category Sorting Test was related
to an increase in 7) in all regions of the brain. The findings
are shown in Table 2. The effect of age has been controlled
for. Correlations of each of the test measures with whole
brain 7) and with frontal white 7) were significant at
either the 99% or 95% levels. The relationships remained
significant when the sexes were examined separately. Both
lifetime consumption and past year's consumption corre¬
lated significantly with each of the test measures with age
controlled.
Role ofAtrophy
Table 3 shows that internal atrophy as measured by the
Huckmann index appears to be associated with increased
T\ in white matter, and with impairment in the number
of categories achieved in the sorting test. However, by
chance, in the 36 correlations shown in Table 3, two
would be significant at the 5% level.
There is little evidence of a relationship between other
measures of atrophy and either 7) values or cognitive test
impairment. However, the correlation of 0.26 between
sulcal width and 7) in frontal grey matter is probably
meaningful in that when patients are divided about the
median for sulcal width, the 7) (frontal grey) is 10 points
higher for those with sulcal width above the median than
for those below the median (t = 3.3, p < 0.01). This
supports the possibility that CSF in the subarachnoid
space, increased in cortical atrophy, might tend to increase
Ti measurements in grey matter.
Can atrophy account for the relationships shown in
Table 2 between 7) increase and cognitive impairment?
Table 1. Mean ± se (Range) of T, in Whole Brain and Regions of Interest and in the Whole Sample of Alcoholics at a Mean of 15.0 Days after Admission
Timing
Whole brain Frontal white Parietal white Frontal grey Parietal grey (days after admission)
Control group (n = 26) 306 ± 1.69 268 ± 1.58 269 ± 1.97 341 ± 2.09 334 ± 1.50
(290-324) (252-283) (248-296) (326-371) (310-351)
Patients—whole sample (n = 69) 321 ± 1.67* 265 ± 1.49 276 ±1.45 367 ± 2.28* 360 ± 1.76* 15.0 ±0.06
(283-383) (230-326) (230-326) (314-400) (321-392) (6-24)
Patients—subgroup with cognitive 325 ±1.81* 266 + 1.93 277 ± 1.81T 373 ± 2.41* 361 ± 2.25 15.7 ± 0.8
test (n = 48) (304-383) (230-326) (230-326) (315-400) (326-392) (6-24)
Patients—subgroup attending for
follow-up (n = 26)
First scan 322 ± 1.74* 265 ± 1.89 276 ± 1.62 372 ± 2.99* 366 ± 2.90* 14.0 ± 0.9
(304-383) (249-284) (256-288) (336-400) (335-392) (6-23)
Follow-up scan
< 40 g ethanol per day 324 ±1.31* 266 ± 1.88 280 ± 2.71t 373 ±4.17* 365 ± 296*
(312-333) (254-285) (262-301) (349-406) (348-390) J 192 ± 4.0
> 40 g ethanol per day 330 ± 5.55* 270 ± 3.84 277 ±3.18 374 ± 4.31* 363 ± 4.04 | (147-258)
(311-378) (251-298) (258-293) (346-393) (342-392)
* Patients greater than controls, p < 0.01; *p < 0.05.
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Table 2. Age Controlled Correlation Coefficients of 7, Values and Estimated Lifetime Consumption with Scores on Components of the Category Sorting Test in
Alcoholics at a Mean of 15.7 Days after Admission (*p<0.01; fp<0.05). (Impairment Results in a Lower Score on Categories, and a Higher Score on Sorts, Errors, and
Perseverations).
Category Sorting Test scores [mean Lifetime
± se (range)] Whole brain Frontal white Parietal white Frontal grey Parietal grey drinking total
Categories 5.42 ± 0.16 -0.44* -0.50* -0.42* —0.24f -0.17 -0.31f
(37-136)
Sorts 60.90 ± 3.42 0.33T 0.261" 0.19 0.21 0.14 0.37'
(37-136)
Errors 21.00 ± 3.02 0.38T 0.34+ 0.30T 0.23 0.20 0.40*
(1-90)
Persevera¬ 6.33 ± 1.25 0.41* 0.34t 0.29' 0.21 0.25 0.40'
tions (0-35) n = 48 n = 48 n = 48 n = 48 coIIc n = 47
Table 3. Age-controlled Correlation Coefficients of Atrophy Indices,!, Values, and
Cognitive Test Scores (n = 46)
Huckmann Ventricular Third V Sulcal width
T,
Frontal white 0.33* 0.27 0.14 0.09
Frontal grey -0.13 0.04 -0.09 0.26
Parietal white 0.391" -0.10 0.26 0.23
Parietal grey 0.10 -0.15 0.06 0.12
Whole brain 0.03 -0.04 -0.01 0.06
Categories -0.30* 0.02 -0.21 -0.09
Sorts 0.16 -0.01 0.04 0.03
Error total 0.15 -0.01 0.06 0.07
Perseverations 0.11 -0.01 0.00 0.08
*p < 0.05; fp<0.01
Table 4. Correlation Coefficients of 7, Values (White Matter and Whole Brain)
with Cognitive Test Scores, Controlling for Age and Huckmann Index (n = 46)
Whole brain Frontal white Parietal white
Categories -0.43* -0.55* -0.44
Sorts 0.32f 0.40* 0.30t
Errors 0.36f 0.47* 0.40*
Perseverations 0.38* 0.46* 0.40*
*p < 0.05; Tp < 0.01
Table 5. Correlation Coefficients of 7, Values in Whole Brain and Grey Matter
with Cognitive Test Scores, Controlling for Sulcal Width and Age (n = 46)
Whole brain Frontal grey Parietal grey
Categories -0.43* -0.21 -0.20
Sorts 0.33t 0.20 0.17
Errors 0.37t 0.21 0.23
Perseverations 0.40* 0.19 0.27
*p < 0.05; fp< 0.01.
Table 4 shows that internal atrophy did not account for
the relationship between raised 7j in white matter and
cognitive impairment. Table 2 showed, as already men¬
tioned, correlations in the expected direction though in
general not significant between 7j in grey matter and
cognitive impairment. Table 5 shows little alteration in
the size of these correlations when cortical atrophy as
measured by sulcal width is controlled for. 7j in whole
brain also remains significantly related to cognitive im¬
pairment despite the possible confounding effect of atro¬
phy.
The relative lack of importance of atrophy in this study
may partly reflect our measurements. We used indices
previously used in CT scans, and by comparison MRI
scans lack definition. Our measurements were made by
caliper rather than by computer.
Changes in T, and Cognitive Function in Relation to
Degree ofAbstinence
There were 26 patients who reattended for the repeat
scan and on whom we had data on consumption ofalcohol
in the interval (Table 1).
Whether or not patients were deemed to have resumed
drinking heavily, the trend was for whole brain 7j to rise
slightly over the 6-month period. Whole brain 7j meas¬
urements at 6 months in those 15 patients who had been
abstinent or who had drunk on average less than 40 g of
ethanol per day had risen by a mean of 2.33 ms (range,
-11 to 29; se, 2.87) (see also Fig. 2). The mean serum
GGT of this group was within the normal range (21 IU/
liter, n = 14). In those 11 patients who had drunk more
than 40 g per day on average during the 6-month period
the mean rise in whole brain T\ was 6.27 ms (range, —15
to 60; se, 5.94) (see also Fig. 2). This was not a significantly
greater mean rise (p = 0.56) than in those drinking less
than 40 g/day. The mean serum GGT of this group was
elevated (178 IU/liter, n = 10). The two patients with the
highest 7j values at follow-up were in this group. They
were men who had severe long-standing dependence on
alcohol for many years and were once again drinking in
excess of a bottle of spirits per day (280 g ethanol per day)
up to the time of the scan.
There were only nine patients in whom we could be
sure that abstinence or near abstinence had been achieved
for the whole of the 6-month period. The mean change in
whole brain 7j in these patients was —0.78 ms (range, —11
to 10; se 2.85). Figure 2 illustrates the pattern of whole
brain 7j changes in individual subjects from the initial
scan to the 6-month scan showing abstainers, "interme¬
diate" and "heavy" drinkers separately. Analysis of vari¬
ance to compare the changes in Tt values in whole brain
and regions of interest over the 6-month period across
these three groups defined by increasing posttreatment
consumption did not reveal a significant trend for any of
the 7j measurements (frontal white, F = 1.65, p = 0.21;
frontal grey F = 1.06, p = 0.36; parietal white, F = 1.92,
p = 0.17; parietal grey, F = 0.26, p = 0.77; whole brain,
F = 0.67, p = 0.52; in each test df= 2/23).
There were 25 patients who repeated the Category Sort¬
ing Test in a sober state at the time of the 6-month scan.
The mean changes in these individuals' scores were: CAT-


















Fig. 2. Whole brain 7, measurements, separately
for those patients who abstained, drank 40 g
ethanol per day or less, and who drank over 40
g ethanol per day, to illustrate change between
scan at 2 weeks after admission and at approxi¬
mately 6 months later.
EGORIES, +0.44 (range, —1 to +3; se, 0.17); SORTS,
-5.2 (range, -44 to +18; se, 3.4); ERRORS, -5.2 (range,
-32 to +16; se, 2.5); PERSEVERATIONS, -0.8 (range,
-15 to +7; se, 1.0). However despite this trend towards
amelioration, no significant correlations were found be¬
tween these changes and changes in 7,.
DISCUSSION
The findings of a laised whole brain 7) in newly detox¬
ified patients and of a significant relationship between 7,
measurements and both cognitive impairment and the
possible cause of that impairment, total lifetime consump¬
tion, suggest that 7, measurements have both potential
clinical utility and a neuropathological significance. Cog¬
nitive deficits were also linked to increased Tt in white
matter, but not grey matter. The finding that is not cor¬
roborative is the lack of difference between controls and
patients in frontal white matter 7), given that cognitive
deficits appeared to relate to that measure. Grey matter
7, measures', while they did distinguish alcoholics from
controls did not relate (significantly) to cognitive impair¬
ment. This raises the question that our 7) findings are
artefacts due to cerebral atrophy (which would be expected
to affect grey rather than white matter 7, measurements).
However, the only 7, measurement which we made which
was significantly related to atrophy was that in frontal grey
matter. Thus, while noting that frontal white matter T\
measurements did not distinguish alcoholics from con¬
trols, we feel we have found a relationship between Tx in
whole brain and in white matter that relates to alcohol
consumption and to cognitive impairment, and that this
is independent of atrophy. We note that Harper et al.4
have stressed that it is loss of white matter, rather than
grey matter, which is most important in alcoholics.




time consumption1 16 but its reliability remains in some
doubt. Although we have little confidence in the absolute
accuracy of the estimates, the rank ordering that the
method yields is possibly more reliable. This is supported
by our finding a correlation of this estimate with 7, values,
and with cognitive test scores (Table 2). Measures of more
recent consumption might be thought to be more reliable.
However, while more reliable because the memory is
fresher, patients' recent consumption often poorly reflects
longer standing patterns of diinking: for example, the
patient coming to a clinic has often been trying recently
to abstain for periods; or, he has presented for treatment
because of one or two especially heavy recent binges. Thus
in the general working population, where patterns of
drinking are fairly stable over time, a marker such as the
serum GGT may correlate well with a measure of recent
drinking20; while in patients admitted to clinics no appar¬
ent relationship is found.24
In the "Subjects and Methods" section we explained
some of the reasons for our choice of the Category Sorting
Test. In addition, its microcomputer-assisted administra¬
tion makes it an inexpensive and convenient test to per¬
form and reduces tester-induced bias; it tests a psycholog¬
ical function ol clinical relevance; previous (unpublished)
work in some 150 patients had led us to conclude that
among a range of tests it was sensitive to increasing severity
of alcoholism. It is not a widely used test in the literature,
but it is closely based on the better known Wisconsin Card
Sorting Test.25 Category Sorting Tests are believed to
reflect frontal lobe functioning.17-25 It is notable therefore
that the largest correlations between test scores and 7, in
the region of interest measurements were found in frontal
tissue. Unfortunately, over a period of 6 months, we
believe that a subject who had mastered the test could
later recall his method of doing it and so we hesitate to
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interpret changes in scores in this test during the follow-
up period.
The associations which have been found by other au¬
thors between CT changes and cognitive tests suggest that
it is central atrophy (i.e., loss of white matter), rather than
cortical atrophy (loss of grey matter) which best predicts
cognitive impairment, albeit only explaining less than 20%
of the variance in cognitive performance overall.3 Central
changes appear to regress less quickly with abstinence than
cortical changes.3 Thus, our failure to find significant
correlation between 7) in grey matter and cognitive im¬
pairment is consistent with Bergman3 and also Ron.1
Only slightly over half of the patients invited for a 6-
month scan attended, despite repeated arrangements being
made in some cases. Only very occasionally did the patient
give as a reason that he or she found the enclosed space
of the scanner unpleasant. Nonattenders were mostly pa¬
tients who had resumed drinking and wished to break off
contact with the clinic. It is difficult to obtain reliable
information on drinking in the follow-up phase without,
for example, incorporating at the outset specific monitor¬
ing by relatives, or urine, blood, or sweat testing at frequent
intervals. It would be premature to conclude that our lack
of T\ reduction in our small number of supposedly absti¬
nent patients indicates that elevated values are permanent
in the established alcoholic. However, other follow-up
studies of abstinent alcoholics have failed to show im¬
provements in cognitive function26 and the classic alcohol-
related deficit, KorsakofFs syndrome, is marked by per¬
sisting permanent alterations in brain cells and persisting
cognitive impairment despite abstinence. On the other
hand, cortical shrinkage as identified by cerebral tomog¬
raphy sometimes resolves with abstinence.3 Also, cerebral
perfusion, diminished in the newly detoxified alcoholic by
comparison to controls, appears to improve with absti¬
nence.27
A number of neuropathological processes may occur
simultaneously in the alcoholic. An increase in the meas¬
ured 7) is a inaiker of overhydration or oedema of either
intra- or extracellular tissue. It remains speculative
whether an elevated 7) is a marker of damaged neurones.
Christie et al.28 have shown that frontal and parietal grey
and white matter 7", values are not elevated in patients
with presenile Alzheimer-type dementia when compared
to age-matched controls whereas patients with Korsakoff
psychosis, abstinent for 1-14 years, (mean, 5 years), have
raised cortical T} values when compared to age-matched
normal controls and to frontal grey and white matter in
patients with Alzheimer's disease. (Christie et al. were able
to distinguish increased 7) measurements from atrophy
in this study of dementia, supporting our conclusion in
the present study that our findings are independent of
atrophy). Measurements of 7), like cortical atrophy, in¬
crease with age as also found in a previous study29 as well
of the present study.
In conclusion we believe we have shown that MRI Tt
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measurements, especially in white matter, are elevated in
alcoholics proportionate to their cumulative alcohol in¬
take and to the degree of impairment on a Category
Sorting Test of cognitive function. These findings are
analogous to those of ageing. The precise location of the
extra water which is presumed to underly this change, and
its cause, is unknown. Potentially, MRI 7", is of clinical
value as a marker of alcohol-related brain damage.
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COMPARISON OF TWO BENZODIAZEPINES IN THE TREATMENT
OF ALCOHOL WITHDRAWAL: EFFECTS ON SYMPTOMS AND
COGNITIVE RECOVERY
BRUCE RITSON and JONATHAN CHICK
Royal Edinburgh Hospital, Edinburgh, EH10 5HF (U.K.)
(Received July 15th, 1986)
SUMMARY
Forty newly admitted alcohol dependent patients were randomly alio
cated to equivalent 6 day regimes of cither lorazcpam or diazepam, to com
pare involvement in physical, emotional and cognitive state during the first
8 days in hospital. Diazepam provided a more comfortable withdrawal pc
riod and was associated with slightly better cognitive functioning on the
eighth day.
Key words: Alcohol withdrawal — Treatment — Diazepam — Lorazepam
INTRODUCTION
The abstinence syndrome amongst patients suffering from alcohol depen
dence is characterised by well known physical signs of tremor, restlessness,
insomnia and increased central nervous system excitability with, on occa
sions, epileptic fits. Anxiety is also a significant component of this syn¬
drome. Tranquilisors arc commonly prescribed to alleviate these symptoms.
The present study aimed to contrast the efficacy of two benzodiazepines, di
azepam (Valium®) and lorazepam (Ativan®). Both drugs are widely used,
but it was felt that lorazepam, because of the absence of active metabolites,
might be associated with quicker recovery of cognitive functioning than di
azepam for a given degree of control of withdrawal symptoms. Cognitive im¬
pairment experienced during the early stages of treatment for alcohol
dependence may woll diminish a patient's capacity to enter into psychologi
cal treatment, by impairing recall, by rendering thinking inflexible and by
retarding new learning.
0376-8716/86/$03.50
© Elsevier Scientific Publishers Ireland Ltd.




New patients who were alcohol-dependent requiring withdrawal medica¬
tion and had been admitted to the Alcohol Problems Clinic were invited to
participate in the study. Specifically excluded were patients who had cur¬
rent active hepatocellular pathology, grossly disordered hepatic or renal
function, were known to be sensitive to benzodiazepines, were psychotic or
suffered from epilepsy, or had a history of withdrawal fits or psychosis, drug
abuse or recent sedative usage.
Forty patients were enrolled in the trial. Identical tablets containing
either lorazepam 1 mg or diazepam 5 mg were supplied in numbered bottles.
Numbers were allocated at random and the trial was therefore double-blind.
The patients were also given vitamin supplements according to the usual
routine of the clinic. The basic regime of the two drugs is shown in Table I.
Where clinically indicated medication was increased or reduced at the insti¬
gation of one or other author, the aim being to provide control of with¬
drawal symptoms without undesirable sedation. Such alterations were,
however, kept to a minimum.
On the day of admission patients were given a physical and mental state
assessment and measures made of their past drinking pattern and degree of
alcohol dependence [1]. They were also assessed using the Bexley Maudsley
Automated Psychological Screening and Bexley Maudsley Category Sorting
Test on a number of cognitive tests administered by microcomputer [2,3].
Psychomotor accuracy was assessed by finger tapping and the peg board
tests [4].
At the same time of each day throughout the trial patients completed a
visual analogue scale giving a rating in millimetres of their self-perceived
anxiety and depression. They also completed a 5-point scale estimating their
craving for alcohol. Nurses rated the patients' clinical state after the
TABLE I
SCHEDULE OF DRUG ADMINISTRATION
Time (h) Lorazepam Diazepam
mg mg
0800 1200 1800 2000 0800 1200 1800 2000
Day
1 Admit 2 2 2 Admit 10 10 10
2 21- 10 5- 10
3 1 -2 5 5- 10
4 1-1 5 5 --5
5 1-- 5 - -5
6 - --1 ---5
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method described by Gross et al. [5], On the eighth hospital day the patient
was reassessed physically and psychiatrically, and cognitive and psycho¬
motor accuracy tests were repeated, and a version of the Mill Hill vocabu¬
lary scale administered.
We have used the Ackers' automated testing in a context which is possi¬
bly novel and also outside the authors' intentions. Published work refers to
their use in already detoxified-alcoholics. The validity of each of the tests
was not our concern — in non-detoxified patients the validity of these tests
is unknown. We were only interested in change within a given patient. We
required tests that would be convenient to administer and attractive to our
subjects, and microcomputer administration was, therefore, ideal in this pro¬
ject.
RESULTS
Forty patients were recruited to the study, 20 in each drug group. In both
groups there were 14 men and 6 women. The average age in the lorazepam
group was 47.1 years (range 33-60) and in the diazepam group was 41.7
years (range 20-74). There was no significant difference between the two
groups in physical condition, degree of alcohol dependence, the presence of
concomitant anxiety state, depression or severity of withdrawal symptoms
at the time of admission. Both groups reported drinking similar amounts of
alcohol during the week preceding admission. (Blood ethanol concentration
on admission was measured in 29 patients and within these patients there
was no significant tendency for one group to have a higher mean.) Blood
tests on admission, including mean cell volume and gamma glutamyl
transpeptidase did not indicate that either group contained a predominance
of more severely affected patients. Mill Hill vocabulary score on day 8 did
not reveal a difference in verbal intelligence between the groups.
One patient from the lorazepam group was withdrawn because her symp¬
toms were not controlled. The mean number of capsules consumed by the
lorazepam group was 22.8 (S.D. 3.4) and by the diazepam group 23.0 (S.D.
3.5).
TABLE II
AVERAGE SELF-RATED MOOD DURING THE 7-DAY PERIOD
Drug N Anxiety Depression Craving
Median Range Median Range Mean S.D.
Interquartile Interquartile
Lorazepam 19 42* 23-56 33** 22-51 34 20




Self-reported anxiety, depression and craving was expressed as the aver¬
age of each patient's scores over 7 days. These findings are summarised in
Table II omitting two patients in the diazepam group whose daily ratings
were incomplete.
Patients in the lorazepam group reported significantly more depression
(P < 0.01) and anxiety (P < 0.05). There was no significant difference in
craving experienced.
The patients' daily clinical state assessed on 18 variables showed that
withdrawal symptoms were significantly less evident with diazepam
(P < 0.05) (Table III). The mean daily pulse rate was significantly (P < 0.05)
higher with lorazepam (mean 94 S.D. 10) than diazepam (mean 85 S.D. 9). A
grand mal seizure occurred in one patient in the lorazepam group, on day 8.
All patients improved on the finger tapping test during the week. No sig¬
nificant difference was evident between the drug groups.
The principal changes on automated cognitive testing are summarised in
Table IV (full details available on request). Three patients in the lorazepam
group did not take the second test and 1 patient in the lorazepam group did
not complete the first test — all 4 were excluded from further analysis.
In the capacity to make right/left discrimination elicited by the 'Little
Men' test there was a significant improvement in the percentages correct in
the diazepam group (P < 0.05) and no significant change with lorazepam.
There was a highly significant reduction (P < 0.001) in both groups in the
reaction time in the symbol digit test with no significant change in the num¬
ber of mistakes. In Visuo-spatial analysis there was a significant (P < 0.01)
increase in the diazepam group only, mainly attributable to a lower starting
value. There was a significant reduction in the number of mistakes
(P < 0.01) and the reaction time (P < 0.05) for both groups in the verbal
memory forced choice lists.
In most of the parameters of the Maudsley Category Sorting Test there
was a significant improvement. Neither the pattern nor the degree of im¬
provement distinguished the groups.
It is of note that in this group of severely addicted patients blood ethanol
level at admission did not significantly relate to performance on any of the
cognitive tests, though higher levels impaired psychomotor accuracy mea¬
sured by the tapping test.
TABLE III
MEAN OF CLINICAL STATE RATINGS OVER 7 DAYS
P < 0.05, I-test.
Drug N Mean S.D. Range
Lorazepam 19 15.6 8.4 3-40
Diazepam 18 9.4 5.3 2-22
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TABLE IV
RESULTS ON BEXLEY MAUDSLEY AUTOMATED TESTING AT START AND FINISH OF
TREATMENT
Significance of the change: *P < 0.05, **P < 0.01.
Lorazepam N = 15 Diazepam N = 20
Mean Range Mean Range
Test 1 Visual Spatial Ability
('Little men' test)
Percentage correct
Start 82.5 (55-100) 79.4 (53-100)
Finish 85.1 (47-100) 86.3 (59-100)
Change 2.6 (-19-36) 6.9* TTCO1CMH1
Reaction time (s)
Start 3.4 (1-6) 3.6 (2-7)
Finish 3.1 (1-6) 3.2 (2-7)
Change 0.3 (2-3) -0.4* (-2-2)
Test 2 Symbol Digit
Start 2.9 (2-7) 2.4 (2—4)
Finish 2.2 (1-5) 1.9 (1-3)
Change -0.7 (-2-0.1)** -0.5 (-2-0.4)**
Test 3 Visuo-spatial Analysis
Start 11.2 (9-12) 10.4 (6-12)
Finish 11.3 (9-12) 11.4 (9-12)
Change 0.1 (-1-3) 1.0** (-1-6)
Number correct (4 different)
Start 11.0 (8-12) 11.2 (9-12)
Finish 11.8 (11-12) 11.2 (8-12)
Change 0.8 (0-3)** 0 (-4-3)
Test 4 Verbal Memory forced choice
Start 28.6 (14-36) 32.4 (24-35)
Finish 32.8 (17-36) 32.1 (29-36)
Change 4.2 (-2-20) 1.7 (-1-8)
Maudsley Category Sorting Test
(number of categories achieved)
Start 4.5 (3-6) 3.8 (0-6)
Finish 5.1 (2-6) 4.8 (2-6)
Change 0.6* (-1-3) 1.0** (-1-5)
DISCUSSION
As anticipated both groups improved physically and mentally during the
withdrawal phase. The patients receiving diazepam had a significantly more
comfortable withdrawal phase and in some respects showed-a more rapid im¬
provement in cognitive skills as measured on the test battery.
One possible explanation for this observed difference may be that the ex¬
tended half-lives of diazepam and its active metabolites gives a smoother
control of symptoms. With the shorter acting tranquiliser break-through
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symptoms of the abstinence syndrome were more evident, a phenomenon
mentioned by Cohn [6]. It may be argued that a different more frequent
dosage regime might have suited lorazepam better, but it is hard to see any
clinical advantage in such a change.
Solomon et al.[7] compared lorazepam and chlordiazepoxide in predomi¬
nantly black male patients and found no significant difference in severity of
withdrawal phenomena, though 2 of the lorazepam group and apparently
none of the chlordiazepoxide group had seizures. These authors make the
point that hepatic conjugates of lorazepam, unlike those of diazepam and
chlordiazepoxide, are excreted in the urine, and suggest that liver disease
has little or no effect on lorazepam pharmacokinetics. We agree that it may
therefore be the drug of choice for alcoholics with severe liver damage.
ACKNOWLEDGEMENTS
We are grateful to Wyeth for their support and their help with statistical
analysis; also to the nursing staff of the Alcohol Problems Clinic and Mrs I.
Cansdale for her technical assistance.
REFERENCES
1 J. Chick, Br. J. Addict., 75 (1980) 175.
2 C. Acker W.L. Acker and G.K. Shaw, Alcohol Alcoholism, 19 (1984) 223.
3 W.L. Acker and C. Acker, Bexley Maudsley Automated Psychological Screening and Bexley
Maudsley Category Sorting Test, Oxford, NFER — Nelson, 1982.
4 M.O. Lezak, Neuropsychological Assessment, New York, Oxford University Press, 1976.
5 M.M. Gross et al., Q. J. Stud. Alcohol, 32 (1975) 611.
6 J.B. Cohn, Long and short-acting benzodiazepines, in: Benzodiazepines Divided, M.R. Trimble
(Ed.), Wiley & Sons, London, 1983.
7 J. Solomon, L.A. Rouck and H.H. Koepke, Clin. Therap., 6 (1983) 52.
Alcohol & Alcoholism Vol. 32, No. 1, pp. 79-84, 1997
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Abstract — An interview was obtained with 212 patients who had, at a point 12 months previously,
been in contact with an alcohol problems clinic. Quality of life (SF-36) was measured and for the
preceding 6 months the cost of health and social service resource use was estimated, together with the
total abstinent (or controlled drinking) days accrued. Alcohol related health, personal and social
problems experienced during that period were elicited using a brief 11-item questionnaire, the Alcohol
Related Problems Questionnaire (ARPQ). The estimate of costs correlated more strongly with the ARPQ
score (r = —0.32, P = 0.0001) than with abstinent days (r = 0.03, n.s.) or controlled drinking months
(r = —0.21, P = 0.002). The lack of relation of total abstinent days to cost is partly because abstainers
tended to use considerable alcohol problems clinic resources. ARPQ scores indicating more problems
were associated with lower quality of life. The ARPQ can serve as a proxy for resource use and quality of
life in alcoholism treatment.
INTRODUCTION
For some clients and for therapists in some
situations, abstinence is the chief goal of treatment
for alcohol problems. For other therapists and
clients, reduction or cessation of problems related
to alcohol is the chief goal, though it is often the
case that abstinence or reduction in consumption,
or at least reduction of the frequency of heavy
drinking, is the route to achieve that.
Self-reports of drinking in people who are
dependent on alcohol are sometimes at variance
with data from interviews with relatives, alcohol
analysis in breath or urine, and blood test markers
such as mean cell volume and serum gamma-
glutamyl transferase (Fuller et al., 1988; Keso and
Salaspuro, 1989). It is possible that measures of
alcohol related problems may be more valid than
measures of consumption. It is presumably as easy
to lie about an occurrence such as an injury or a
conflict at work as about the quantity of alcohol
consumed. But recall may be better about a
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specific event than how much alcohol was
taken.
Although including information from relatives
or other collaterals may improve reliability of
consumption data (Midanik, 1988), this may not
apply to data on alcohol related problems. For
example, during follow-up after treatment,
Loethan and Khavari (1990) found that patients
identified more alcohol related problems than
collaterals. Outcome measured in terms of prob¬
lems that may have social and medical costs are,
of course, not only relevant to patients and their
families but also, perhaps more than changes in
alcohol consumption, to purchasers of health and
social services.
This paper reports data from a 1-year follow-up
study which among other goals attempted to find a
convenient proxy measure for health and other
resource costs. We compared the traditional out¬
come measure in alcohol treatment studies, al¬
cohol consumption data, with a measure of
problems, the Alcohol Related Problems Ques¬
tionnaire (ARPQ). As well as cost, another
dimension of social and personal relevance is
quality of life, and we tested ARPQ as an indicator
© 1997 Medical Council on Alcoholism
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Table 1. Alcohol Related Problems Questionnaire (ARPQ) items
Yes No
1. Has the patient been in hospital (or casualty department) related to drinking? 1 2
2. Has he/she retched or vomited in the morning connected with drinking the day before? 1 2
3. Has he/she had diarrhoea connected with heavy drinking? 1 2
4. Has he/she been in an accident, (partly) due to alcohol, which came to medical attention or should have? 1 2
5. Has the patient been depressed due to drinking? 1 2
6. Has the patient tried to harm him/herself, deliberately taking an overdose? 1 2
7. Complete section (a) or (b)
(a) The patient has had a job in the past month.
Has he/she been off sick or absent from work due to drinking?
or Has he/she had any trouble? (e.g. warning about lateness or performance)
or Has he/she been dismissed from work (due to drinking)
(b) The patient has had no job in the past month.
(i) Has he/she been unable to fulfil a commitment? 1 2
8. Have there been arguments at home about drinking in the past month? 1 2
(If he/she has no home, explore living arrangements and family contacts and include any arguments with friends
or general public arising out of his/her drinking)
9. In the past month, have there been any times when the patient has become so violently angry that he/she hit 1 2
someone in the family, flat etc.
(Living alone — include violence to others, including general public)
10. Complete section (a) or (b)
(a) The patient is married
(i) Has had arguments which led to his/her partner threatening to leave, or created such an unpleasant
atmosphere that he/she thought of leaving
(b) The patient is not married
(ii) Has had arguments which led to friends and relatives threatening to leave, or led them to ask the patient to 1 2
leave, or created such an unpleasant atmosphere that the patient thought of leaving
11. Trouble with police — police involved because of his/her drinking (not necessarily leading to charge) 1 2
TOTAL SCORE:




The cohort of the Study of Socio-Economic
Consequences and Costs of Alcoholism and its
Treatment (SECCAT) is described in a recently
published paper (McKenna et al., 1996). It
comprised all those patients diagnosed on DSM-
III-R criteria (American Psychiatric Association,
1987) as alcohol dependent (« = 447), alcohol
abusers (n = 125), alcohol intoxicated (n = 10)
and four patients with an alcohol problem in
whom DSM-III-R diagnosis was not specified. All
subjects had been in contact with an alcohol
problems clinic (APC) at a point 12 months
previously and gave a home address within the
region. Following a protocol described by
McKenna et al. (1996), an invitation for interview
was posted to 586 patients and 212 were
interviewed, of whom 55 (26%) were female,
and 102 (48%) were still in contact, even if
occasionally, with the clinic. Currently, 97 (46%)
were living alone, 51 (24%) were in full-time
employment and 57 (27%) gave their marital
status as married. Their mean age was 48 (range
21-70).
The ARPQ
A scale used in a previous outcome study
(Chick et al., 1988) and modified following
further experience (Chick et al., 1991), the
ARPQ (Table 1), consists of 11 questions on
physical and mental health, problems at work (if
unemployed, failure to keep to commitments) and
at home (if living alone problems with acquain¬
tances or others), and police trouble. It is
completed by the interviewer. The total score
ranges from 11 to 22, a higher score indicating a
better outcome, that is, fewer problems, for
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Fig. 1. SF-36 dimensions (mean scores) by ARPQ score
example 'Tried to harm him/herself deliberately
taking an overdose': 'yes' would be scored as 1
point, 'no' as 2 points. The time frame used for
this study was the 6 months prior to the interview
(Table 1).
The SF-36
The SF-36 is an easily administered, psycho-
metrically sound, short measure of subjective
health status according to eight dimensions:
physical functioning, social functioning, role
limitations due to physical problems, role limita¬
tions due to emotional problems, general mental
health; energy/vitality, bodily pain, and general
health perceptions. A score is derived for each
dimension of between 0 (poor health) and 100
(good health). The time frame used was either
the present, or the past 1 month, depending on
the question. Analysis of SF-36 data in our
study followed the users' manual (Ware et al.,
1992). Our internal validation of the instrument
in this population showed acceptable validity
on all dimensions (M. McKenna et al., unpub¬
lished).
Indicators of alcohol consumption
In addition to the commonly used proxy for
alcohol consumption, the total of abstinent days,
we used an additional measure, controlled drink¬
ing months. This was defined as the total of
completed months when drinking occurred but in a
controlled way, defined as less than an average of
5 units (45 g ethanol) per day for men and 3 units
(27 g ethanol) for women with no days on which
consumption exceeded 8 units (72 g) for men and
6 units (54 g) for women.
Resource use
Hospital and general practice records supple¬
mented information from patients about the
following, which were each costed: APC: number
of individual or group sessions, number of home
visits from APC staff, number of inpatient stays;
GP: visits to or from the GP, to or from the
practice nurse; other: number of counselling
sessions at voluntary agencies, weeks in residen¬
tial treatment units (social work or non-statutory),
general hospital outpatient visits or inpatient stays,
visits to casualty departments, and cost of drugs
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Table 2. Correlation matrix of total cost, abstinent days, controlled drinking months and ARPQ score
Total cost Abstinent days Controlled drinking months ARPQ score
Total cost
r 1.0000 0.0344 -0.2147 -0.3245
P 0.0 0.2334 0.0020 0.0001
n 212 212 212 212
Abstinent days
r 0.0344 1.0000 0.4870 0.5488
P 0.2334 0.0 0.0001 0.0001
rt 212 212 212 212
Controlled drinking months
r -0.2147 0.4870 1.0000 0.5209
P 0.0020 0.0001 0.0 0.0001
n 212 212 212 212
ARPQ score
r -0.3245 0.5488 0.5209 1.0000
P 0.0001 0.0001 0.0001 0.0
n 212 212 212 212
prescribed. (The basis of these resource use
estimates is described by McKenna et al., 1996.)
Costs incurred in work accidents or absenteeism,




Spearman correlation coefficients were calcu¬
lated to ascertain which clinical parameters were
the best proxies for cost, that is, cost of total health
service contacts. First, alcohol consumption mea¬
sures were examined. The link was fairly weak:
abstinent days r = 0.03 (n.s.), controlled drinking
months r = —0.21 (P = 0.002). A stronger corre¬
lation was observed with ARPQ score: r = —0.32,
P = 0.0001) (more problems associated with more
cost). Table 2 is the matrix of correlations between
these predictor variables.
Table 3 shows the fall in mean resource use
costs by quartiles of the ARPQ distribution. There
was no a priori reason to expect that alcohol abuse
would differ from dependence when the relation¬
ship between ARPQ and cost was examined — a
problem is a problem, whether caused by a
dependent or non-dependent pattern of drinking
— and so it was decided not to pursue such sub-
analyses.
Scattergrams were examined to clarify the
relationship between ARPQ and cost. The dis¬
tribution is indeed somewhat scattered despite the
significant overall correlation. Outliers are: (a)
individuals who had ARPQ scores of 22 (i.e. free
of problems) but who had used resources reg¬
ularly, perhaps to help them stay sober or recover
from relapses before going on to develop prob¬
lems: (b) some individuals with low ARPQ scores
(i.e. many problems accrued) who had managed or
chosen to keep away from the health services.
Relation ofARPQ to SF-36
Figure 1 shows SF-36 scores with the improve¬
ment in the scores by quartiles of the ARPQ
distributions. There is a steep gradient in the
values on all dimensions, and with the exception
of 'pain', the gradient is entirely consistent in
direction for each quartile. SF-36 scores are very
high (indicating good quality of life) among those
who report no alcohol related problems, and are in
fact higher than UK SF-36 norms for the general
population, for all dimensions, except 'role
physical' (see Brazier et al., 1992; Jenkinson et
al., 1993).
DISCUSSION
To examine further the relationship between
ARPQ and costs, a post-hoc search for a
suppressor variable was made using multiple
regression, regressing total costs against abstinent
days, controlled drinking months, age and ARPQ,
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Table 3. Comparison of average total cost of health service use (£) by score on Alcohol Related Problems Questionnaire
(ARPQ)
ARPQ ARPQ ARPQ ARPQ
1-16 17-18 19-20 21-22






Costs are in £ and given by quartiles of the ARPQ.
APC = alcohol problems clinic; GP = general practitioners.
with the following as dummy variables: sex,
marital status, living circumstances, housing
situation and employment status. Backward elim¬
ination (and stepwise elimination) were con¬
ducted. Of these variables, all except controlled
drinking months met the criteria of statistical
significance. However, a suppressor variable
could not be identified.
The lack of relation of total abstinent days to
cost is partly because some patients achieving
lengthy abstinent periods used considerable APC
resources, and this has been discussed in a recent
paper (McKenna et al., 1996).
There are some contexts where 'at risk'
drinking is the target of treatment, for drinkers
who have not developed problems, or not yet, for
example, as identified in screening or opportun¬
istic interview in general practice (Wallace et al.,
1988). A measure of 'problems' would not
necessarily be a proxy for resource costs in that
setting. The present study has looked at costs in
the same period for which the ARPQ was
completed. It would be important to examine the
sensitivity of the ARPQ in a prospective study, to
see whether ARPQ scores for the past 6 months
would also predict future costs.
ARPQ scores and total cost are not strictly
independent variables, because the questionnaire
has one item about attending a hospital or casualty
department. While this point diminishes the value
of ARPQ as an independent construct, its practical
value as a proxy for costs is not diminished. It
would seem a useful outcome measure for service
use, particularly because it is also a marker for
quality of life.






measures of alcohol-related problems, the Alcohol
Problems Questionnaire (Drummond, 1990) and
the Addiction Severity Index (McLellan et al.,
1992) would perform in the same way, although
they are more data-hungry than the ARPQ. All are
considerably less elaborate to use than collecting
data on costs, or even using the SF-36, which,
although easy for patients to complete, does not
generate immediate figures for the clinician to use.
Whilst in a formal evaluation of one treatment
versus another, it would be justified to use the
methods of McKenna et al. (1996) and the SF-36,
in audit or in routine practice the ARPQ can be
recommended as a simple, convenient tool.
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Advice Versus Extended Treatment for
Alcoholism: a controlled study
JONATHAN CHICK, BRUCE RITSON, JENNI CONNAUGHTON,
ALEX STEWART
Royal Edinburgh Hospital, Edinburgh EH10 5HF, United Kingdom.
Summary
One hundred and fifty-two attenders at an alcohol problems clinic were randomly allocated to one session of
advice or extended in or outpatient treatment. Two years later, the group who were offered extended treatment
werefunctioning better, in that over theyearprior to the independently conductedfollow-up interview they had
accumulated less harm from their drinking than those only treated briefly. Abstinence was not, however, more
common in patients offered extended treatment. In the group of94 patients given advice only, no advantage in
amplifying the session of advice could be demonstrated.
Introduction
In alcoholism treatment clinics, when two treat¬
ments of differing intensity have been compared,
the less intensive has usually proved as effective as
the more intensive (e.g. Ritson,' Edwards & Gu¬
thrie,2 Edwards et al.3). Exceptions have been few
(e.g. Azrin,4 Chaney & O'Leary5). There may be
some patients for whom an authoritative, concen¬
trated, unequivocal session of advice may be effec¬
tive, and have a greater impact than involvement in
a drawn-out, complex alcoholism treatment pro¬
gramme.
Only in screening projects with less severe
problem drinkers has it been ethical or practical to
have a truly untreated control group.6'7 The closest
a controlled study has come to random allocation to
no treatment in the setting of an alcoholism
treatment clinic has been the London 'advice versus
treatment' 1 year follow-up study in 100 married
male alcoholics by Edwards et al.3. We report here a
further comparison of brief versus extended treat¬
ment, and within brief treatment a comparison of
very brief advice with more comprehensive advice
such as that offered to the minimal treatment group
in the London study. Our sample includes women
and single people as well and thus is more represen¬




The study, which was approved by the local ethics
committee, was conducted at the sole specialized
alcohol problems treatment service for Edinburgh, a
city of 500,000, and its surrounding area. Referrals
come mainly from general practitioners, but some
patients refer themselves or come via social workers
or hospital specialists. All patients are asked to
attend their initial appointment accompanied by a
close friend or relative.
With the aim of obtaining a sample as representa¬
tive as possible of the patients we see at our routine
clinics, during a 12-month period in 1980/81 every
second new patient was approached. Patients were
asked to participate in a study into how they fared
after contact with our clinic. They were asked if
they would agree to a friend or relative being
contacted every 3 months for information about
159
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how they are getting on, and to an interview with us
in 2 years. During the year of recruitment, four out
of five patients approached named an informant and
agreed to follow-up; those who had no-one close
enough to fulfill the role, and the few who refused,
were not taken into the study. Auxiliary addresses
such as those of other relatives were noted for both
patients and informants.
Excluded at the outset were patients who: were
diagnosed as not having an alcohol problem; exhibi¬
ted physical violence to family members; were
mothers in charge of children under 11 years old;
had cirrhosis or clinically evident brain damage; had
a major medical or psychiatric disorder other than
alcoholism; were suicidal; presented as emergencies
requiring immediate medical intervention; had been
seen at our clinic within the past 6 months; or lived
more than 20 miles away. One man who was totally
unwilling to discuss his drinking was also omitted.
The sample obtained differed from the remainder
of patients seen in that period and not recruited to
the study in that it contained a lower proportion of
socially isolated individuals (two-thirds of our
sample were married or cohabiting compared to half
of the non-recruited patients) and a lower propor¬
tion of women (1 in 5 as opposed to 1 in 4).
The Randomization
After the patient and informant assessment inter¬
viewing and testing were complete, random assign¬
ment to treatment group was made, stratified by
severity of alcohol dependence (high/low) and
marital status (whether or not married or cohabit¬
ing). (For this purpose a clinical judgement of
severity of dependence was made based on signs at
examination, e.g. tremor, tolerance to a high blood
alcohol level, and reports of early morning tremor
and relief drinking.) Randomization was by drawing
the top envelope from one of four piles of closed
envelopes according to the patient's level of depen¬
dence and marital status. The procedure was pre¬
designed so that the ratio of 'advice-only' to
'extended' interventions would be 3:2, and within
the 'advice' group half would be given 'simple'
advice and half 'amplified' advice. The final num¬
bers were: advice-only n= 96 (simple advice w=41;
amplified advice n = 55); extended treatment n = 58.
The Nature of the Treatment Interventions
Simple advice was standardized and lasted no
longer than 5 min. In the presence of the informant,
the patient was told "You have an alcohol problem.
The only treatment is to stop drinking". It was
emphasized that the responsibility for this lay in the
patient's hands.
Amplified advice was essentially the same but the
psychiatrist was allowed 30-60 min during which he
or she attempted to enhance the motivation of the
patient by encouraging the patient and informant to
reflect on the reasons why a radical change in
drinking was necessary and discuss how that might
be achieved. This did not specifically follow the
method sometimes termed 'motivational interview¬
ing'. Strategies were suggested and patients encour¬
aged to see the positive aspects of life without
alcohol. For married couples, advice was sometimes
given on how the cohesiveness of the marriage could
be improved.
'Extended' treatment consisted of the above advice
given on the first day, but with the offer of further
help according to the patient's needs, including
detoxification, further appointments or inpatient or
day-patient attendance at our 2-4 week milieu- and
group-therapy based treatment programme. Group
work, as well as aiming to educate the patient about
alcohol problems and reduce denial and rationaliza¬
tion, used the techniques of social skills training to
help patients identify situations when relapse was
likely and develop better strategies for coping with
these. Counselling tended to be either non-directive
or cognitive in style. The inpatient programme was
oriented towards abstinence, but for younger and
less severely dependent subjects in outpatient treat¬
ment, retraining with a view to controlled drinking
was occasionally the goal. Most patients including
all those admitted were informed about Alcoholics
Anonymous and the benefits of regular attendance.
Deterrent drugs such as disulfiram were seldom
prescribed. Thus extended treatment had much in
common with other British alcoholism treatment
programmes of the day, except perhaps for its
shorter length of inpatient stay.8 For patients who
declined further treatment, the offer of treatment
was kept open.
Follow-up Procedures and 'Safety Net'
At 3-monthly intervals one from a team of five
research social workers interviewed the informant
about his or her own well-being and that of the
patient. The social worker knew the treatment to
which the patient had been allocated. For 'advice'
patients, she kept the interview strictly to the
structured research schedule and the typical inter-
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view lasted 30 min. The workers were rotated so
that the informants of 'advice' patients were less
likely to build up a therapeutic relationship with the
research staff, a possibility that Edwards et al}
discussed in relation to the monthly social work
visits in their study.
The purpose of the social work visits was to act as
a safety net so that patients or families in serious
difficulties could be reassessed by a psychiatrist. In
some instances we found deterioration to be so
severe that we felt ethically bound to urge intensive
treatment. In this way 20 'advice' patients (21%)
were deemed to have failed in the advice-only
condition and will be referred to as 'failures of
advice' (F/A). These 20 were taken out of the study
and offered treatment at a mean of 33 weeks, 10 in
the first 6 months and 10 between 6 and 18 months.
The reasons for our intervening were: suicidal
behaviour (3); repeated haematemeses (1); worsen¬
ing antisocial behaviour causing severe family strain
or risk to spouse (5); risk of harm to children (3);
suspected developing Korsakov's syndrome (1);
imminent dismissal from job (2); paranoid syn¬
drome (1); repeated severe withdrawal syndromes
with fits or hallucinations (4).
Measures Used
Intake and follow-up interviews included a Scale of
Alcohol-related Problems. This was compiled both
of items asked of the patient (a sub-scale of nine
items about alcohol-related physical and mental
symptoms, and a sub-scale of fourteen items about
alcohol-related social problems in the areas of
money, job, the law, marriage) and items based on
the work of the London group3 asked of the
informant alone (a subscale of 12 items to do with
disagreeable behaviour in the family ascribed by the
informant to drinking, such as restlessness at night,
poor personal hygiene, not taking part in family life,
picking quarrels, violence, fear in the children,
possessiveness). Heavy binges (a bottle, 750 ml, of
spirits or equivalent in 24 h) scored points according
to frequency. Positive response to some items
yielded a score of more than one point depending on
severity. For example, threatened rupture of mar¬
riage scored one point, and actual separation scored
two. Each item was asked with respect to the past
month, and to the past year. As a way of dealing
with the issue of non-applicability of certain items
to certain subjects (e.g. unmarried subjects cannot
score on an item on marriage-rupture, the unem¬
ployed cannot be absent from work) sub-scale
scores were converted to percentage scores, with the
denominator being the number of possible items.
The total problem score was the sum of the sub-
scale scores.
Estimates of Alcohol Consumption were based on
accounts, checked against relatives' views, of what
the patient said he or she had drunk in the 7 days
leading up to the interview, or if that had not been
typical, in a typical week. This was elicited by going
over each day in that week and asking the patient to
recall his activities, the money he had spent, the
company he had been in, and the quantities and type
of beverage consumed. Conversion to grams of
ethanol was made. The number of days of absti¬
nence in the past month, and in the past year, was
estimated by asking the subject to recall such
periods.
Dependence on Alcohol was measured from re¬
sponses to four items previously reported on9
concerning restlessness without a drink, frequency
of tremor, severity of tremor and frequency of
morning relief drinking. The time frame was the
past 3 months. Possible scores ranged from 0 to 16.
Blood Tests: measurements were made at intake
and follow up of serum gamma glutamyl transpepti¬
dase (GGT), which has an association with heavy
drinking.10
An enquiry was made of the process of making
the decision to attend the clinic, and of previous
help obtained.
Assessment of Outcome
Follow-up was aided by our attempts to keep in
touch with the informant during the 2-year period.
The informant was the cohabitee/spouse in 67% of
the sample. At the 2-year point an experienced
psychiatric nurse not associated with the treatment
team conducted a structured interview usually at the
clinic with the patient and the informant always
seen separately. The interview contained the ques¬
tions that had been asked at intake, this time with
reference to the past 12 months and past 1 month.
Where patient and informant differed in their
replies, guided by her clinical experience she
adjusted her rating of the patient's responses taking
into account the views of the informant whom she
interviewed later in general resulting in her record¬
ing the more pessimistic of the two responses.
Strenuous and successful efforts were made to keep
this nurse blind to the treatment group of the patient
and she was not told that the design involved a
comparison of different treatments. Where informa-
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tion about a subject was deficient and/or no contact
could be made (16 cases), a search was made of
records of local hospitals and enquiries made to
general practitioners.
As shown in Table 2, seven patients had died and
the cause of death was obtained for each. Two F/A
patients died, each approximately 6 months after
being offered intensive treatment. Follow-up infor¬
mation was available on 84 (87.5%) of the brief
group and 53 (91.6%) of the extended group. In one
'advice' patient (case 145) who refused to be
interviewed at the 2-year point we had detailed
information from relatives in regular contact with
the patient and confirmatory evidence from general
practitioners. Since all reports were that his condi¬
tion was worse than at intake, he was given a
problem score at outcome equal to his intake score
so that he could be included in the analysis.
When the 2-year assessment was complete, a
psychiatrist saw each patient and where appropriate
offered further treatment.
Analysis. Analysis of variance was conducted to
compare the scores on continuous variables. In
analysing differences in scores on the scale of
alcohol-related problems and serum GGT, since
these variables yielded skewed distributions the
non-parametric Mann Whitney U test was also




Our three groups did not differ significantly in their
previous treatment experience, or on any socio-
demographic, clinical or drinking variable (Table
1), except the following. Patients given the 'ex¬
tended' intervention had a significantly higher
serum GGT (mean 138 i.u./l) than patients given
advice only (17=2097,Z= — .296,p = 0.02). Within
the group of patients given advice only, the
difference in serum GGT between those receiving
'simple' advice (mean 93 i.u./l) and those receiving
'amplified' advice (mean 59 i.u./l) was not signifi¬
cant (17=967, Z= — 0.766, p=0.44). The 'ex¬
tended' group had been abstinent for less days in the
month before the intake interview than the com¬
bined 'advice' patients (7.9 days as against 11.3
days, p=0.02, 2-tailed). 'Advice' patients were
more likely to have been referred as a result of a
crisis, than patients allocated to extended treatment.
Treatment Received
For the 58 patients offered extended care, the
treatment received was as follows. Fifty-six at¬
tended at least one further outpatient appointment,
of whom 32 (55%) attended at least 10 appoint¬
ments. Of the married patients, being seen with the
spouse present was common: 32 of the 39 married or
cohabiting patients (82%) had at least three joint
meetings. Thirty-two (55%) had inpatient treat¬
ment with seven (12%) having one or more
readmissions. The average total time as an inpatient
among those admitted was 19 days. Fourteen
patients also had a period attending the main
programme as a day patient; for some this was in
addition to an inpatient stay. In the initial phase a
specific AA referral was made in seven patients and
disulfiram or calcium carbimide was prescribed in
11 patients. Only one patient became a regular
attender at AA. Two became faithful adherents of
the Council on Alcoholism. Six continued in regular
contact with their general practitioner. One received
frequent counselling from another source. Some
patients were still being seen occasionally as out¬
patients at our clinic into the second year.
At some point in the 2 years 'social drinking' was
agreed by the therapist, albeit sometimes reluctantly
and perhaps only for a short experimental period, in
28 (48%) of the patients offered extended care.
Counselling was given on how to prevent this social
drinking getting out of control. At the time of intake
to the study 33 (57%) had said they did not wish to
stop drinking completely.
Although patients allocated to 'advice only' were
not referred to other agencies, six (6%) were known
through our contacts with informants to be attend¬
ing Alcoholics Anonymous regularly. Two (2%)
were regular attenders at the local Council on
Alcoholism and two patients were admitted to a
general psychiatric hospital elsewhere in the region.
Four obtained regular help from other sources
(hypnotherapist, company doctor, health visitor at
child's nursery, priest). During the 2-year period, 18
'advice' patients had regular contact (10 or more
visits) with their general practitioners.
Outcome: combined 'advice' groups versus 'extended
treatment'
In describing the patients at the 2-year point, we
retain F/A cases in their original 'advice' category.
All 3 'advice' patients who eventually died of
alcohol-related causes were offered full treatment
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Table 1. Characteristics at Intake
Advice Extended
only treatment
Simple advice Amplified advice
n = 41 n = 54 n=58
Males (%) 78 70 84
Females (%) 22 30 16
Age mean±SD 42 ± 11.5 38 ± 11.6 41 ±10.8
Previous help (any agency) (%) 68 66 64
SE Status (%)
Professional 2 7 7
Managerial 5 7 14
Technical 24 19 17
Skilled Manual 27 37 33
Unskilled Manual 39 30 28
Unclarified 2 0 2
Currently employed (%) 54 63 58
Serum GGT i.u./l mean±SD 93 ± 103 59 ±50 138 ±185
Married or cohabiting (%) 56 72 69
Achieved 2 + months of abstinence in past
year (%) 15 31 25
Attendance instigated because of a
crisis (%) 63 77 44
Previous attempts to cut down (%) 77 85 91
Sees self as having drink problem (%) 93 84 97
'Full' social support (%)
(see Ettore8) 51 67 64
Dependence Score
Low 0-3 (%) 12 27 32
High 10-16 (%) 63 50 49
Clinical diagnosis severe dependence (%) 68 65 53
Consumption in past week or typical week
<1000 g (%) 39 48 34
1000-1600 g (%) 22 28 26
>1600 g (%) 39 24 40
Alcohol-related offences since aged 18
(one or more) (%) 54 48 52
Alcohol-related problems scale (past I year)
Total (mean and SD) 45 ±13 46 ± 16 44± 15
Physical/Mental symptoms: few (0-3) (%) 12 20 12
very many (8-15) (%) 44 41 31
Disagreeable behaviour to family:
little (0-25) (%) 29 30 31
Much (51-100) (%) 24 24 19
Social problems: little (0-25) (%) 27 22 31
much (51-100) (%) 34 37 28
during the course of their deterioration though only
two accepted it.
Outcome by Categories
Table 2 categorizes cases according to the findings
based on the responses received by the nurse at the
2-year follow-up interview. Trouble-free drinking
is defined as drinking of any quantity, but without
incurring any of the alcohol-related problems on our
scale. Total abstainers included two patients who
each admitted one drink on one occasion. Abstainers
also had to have a normal serum GGT. Abstension
or drinking completely without problems for the full
year or more prior to the follow-up was not
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Table 3. Summary of Outcome in Patients Reassessed at 2 Years
No alcohol-related problems Continuing problems**
for at least preceding month
Advice only n = 82 32* (39%) 50(61%)
Extended treatment n—52 30 (58%) 22 (44%)
p = 0.053
*Includes 3 of the 20 cases who took up treatment offered after serious relapses.
**Includes deaths from alcohol-related causes.
group than either of the 'advice' sub-groups. 'Short-
term successes' were cases who were problem-free
for the past 1 to 12 months. Table 3 collapses the
data of Table 2 to show outcome categorized only in
terms of whether or not the patient has been
trouble-free (either drinking or abstinent) for a
minimum of the past month. Those dead of alcohol-
related causes are grouped with the poor-outcome
group. Those on whom no information was avail¬
able, or who died of non-alcohol related causes are
omitted. In the good outcome group there are
slightly more 'extended' patients (58% of 52) than
'advice' patients (39% of 82) (Chi-square with
Yates correction 3.74 d.f. l,p=0.053).
Duration of Satisfactory Outcome in Short-term
Successes
We did not attempt to obtain from patients exact
dates of alcohol related problems, but asked them to
specify only whether the problem had occurred
within the past month or only within the past year.
To reconstruct how long patients had been prob¬
lem-free working back during the year, we only had
two measures: (i) We asked when the last occasion
was that the patient had had any alcohol. Of the
'extended' patients 14% had been abstinent for at
least 3 months, and 12% for 6 months, compared to
17% and 13% in the 'advice' patients, (ii) We had
some incomplete information from the social-
workers' contacts with informants in the second
year. The social worker was not blind to the
treatment given. Out of 37 short term successes,
there were data on 29 at the 24-month informant
interview. This revealed that 12 of 14 'advice'
patients had been problem-free for at least the
preceding 3 months, and 10 of 15 'extended'
patients. The 21-month interview offered data on
23 of these short-term successes. This showed that
10 of 12 'advice' cases were problem-free for at least
6 months whereas only 6 of 11 'extended' cases
could be so classified. There is too much missing
data to allow conclusions to be drawn. The numbers
are anyhow small and the slight trend indicating that
short-term successes in the 'advice' group had been
doing well for longer did not reach significance (chi-
square) at either point.
So far, in presenting data on the strict criterion of
whether the patient is problem-free, or abstinent, it
seems that extended treatment at best contributes to
only short periods of recovery.
One-Year Scores on Alcohol-related Problems
At intake, the mean total score of alcohol-related
problems experienced in the preceding year on our
scale was not significantly different for patients
offered extended treatment (43.8, w = 58; SD 15.0)
and 'advice' patients (45.2, n = 96; SD 14.8). In
calculating follow-up scores using the one-year
window, patients who died during the study of a
definitely alcohol-related cause were given a follow-
up problem score equal to the highest follow up
problem score in the sample. We found that patients
offered extended treatment had a lower mean
problem score at follow-up (22.5, n = 52; SD 19.8,
95% confidence interval 17.0-28.0) than 'advice'
patients (34.3, n = 82; SD 27.1, 95% confidence
interval 28.3-40.3) (F= 7.32, p= 0.008, 2-tailed).
In order to control for problem score at intake, a
Mann Whitney U test was performed comparing the
groups on the difference between intake and follow-
up problem scores. The group offered extended
treatment was superior to the 'advice' group when
compared in this way (17=1653; Z= — 2.190;
p—0.0285, 2-tailed, «=134). If patients dying of
alcohol-related causes are not included, the differ¬
ence between the groups remains significant
((7=1576; Z=-1.988; p=0.0469, 2-tailed,
n = 129).
This difference between intake and outcome
problem scores was correlated with each of the
variables which at intake had significantly differen¬
tiated 'extended' from 'advice' patients. Only the
number of abstinent days in the month preceding
the intake interview correlated significantly
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(r=0.17, n — 134, p=0.025). Therefore, an analysis
of covariance was performed to test whether, with
that variable controlled, a significantly greater fall in
the problem score was still found in the 'extended'
group. This was confirmed: F (explained) 4.85, d.f.
2/131,/>=0.009. To explore which areas accounted
for the greatest improvement in the problem score
in patients offered extended treatment, changes in
individual items were examined. Looking at the
outcome data (one-year window), a 'symptom'
could be scored as now present where it had not
been present at intake; still present but no worse; no
longer present, or less severe; neither present at
intake nor at follow-up. Grouping the last two
categories together to represent good outcome, chi-
square tests were performed on 21 individual
problem items or combinations of related items.
There was no item where patients offered extended
treatment tended to have improved less than those
only given advice, though there was little difference
between the groups in alcohol-related physical
symptoms, trouble at work or absenteeism, and
police trouble. Significantly greater improvement
was found in the patients offered extended treat¬
ment in their behaviour in the family (or with the
people they lived with). They had improved more in
the following: joining in family activities
(p = 0.027), threatened violence (p=0.009), break¬
ing or damaging things (p=0.028), jealousy
and possessiveness (p=0.032), causing fear and
anxiety in the children (p = 0.0027), being noisy and
disturbing at night (J> = 0.07). Commensurate with
this, there was a trend favouring 'extended'
patients in the item on threatened or actual mari¬
tal/cohabiting break-up (J><0.2). There was a
trend for greater improvement also in the item on
'trouble with your nerves due to drinking'
(p=0.07).
In terms of alcohol consumption Table 4 shows
that there was a trend for those who received
extended treatment to have been drinking at a lower
consumption bracket in the 7 days before the
follow-up interview; and to have been less likely to
have had 20 or more days in the preceding year
drinking more than a bottle of spirits per day or
equivalent (200 g ethanol). Neither trend reached
significance. In both groups 87% of patients reduced
the frequency of such binges. No trend was visible
when 'extended' and 'advice' patients were com¬
pared in the number of abstinent days achieved in
the past year. The number of abstinent days was
increased in 73% of the 'extended' patients and in
67% of the 'advice' patients.
In terms of social stability, there was a general
decline over the 2 years, which was similar in all
treatment categories (Table 5).
Table 4. Problems and Consumption al the 2-year follow-up
Advice only Extended treatment
Simple advice Amplified advice
Alcohol-related problem
scale (past 1 year) 36.4 ±27.8 32.8 ±26.8 22.5 ±19.1
(Mean and SD) (* = 34) (* = 48) (* = 52)
Past 7 days' drinking
(g ethanol)
<500 g (%) 56 61 71
500-1000 g (%) 29 25 13
>1000 g (%) 15 14 16
(* = 27) (* = 44) (* = 49)
Frequency of drinking over
200 g ethanol per day (past year)
never (%) 52 41 54
1-20 days (%) 10 22 18
>20 days (%) 38 37 28
(* = 29) (* = 46) (* = 50)
Abstinence (past year)
Less than 2 months (%) 70 54 59
2-6 months (%) 17 24 25
>6 months (%) 13 22 16
oCOIIR (* = 46) (* = 49)
"Extended group significantly less than combined advice groups (p = 0.008).
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Serum GGT. There were 65 'advice' patients and
41 patients offered extended treatment in whom
intake and follow-up measures of this enzyme were
available. Serum GGT had decreased below the
intake measurement, i.e. improved, in 24 (59%) of
the 'extended' patients and 36 (55%) of the 'advice'
patients. However, the mean remained higher, as it
had been at intake, in the 'extended' patients (mean
127 i.u./l, SD 194,95% C.I. 67-187, «=42) than in
patients given amplified advice (mean 83 i.u./l, SD
160, 95% C.I. 34-132, « = 43) or patients given
simple advice (mean 93 i.u./l, SD 139, 95% C.I.
34-150, w = 24).
Comparison of'Simple' Versus 'Amplified' Advice
Collapsing the data in Table 2 and including
alcohol-related deaths with 'continuing problems'
reveals that abstinence or trouble-free drinking for
at least a month was noted in 11 (32%) of those
given simple advice and 21 (44%) of those given
amplified advice (percentages expressed as a per¬
centage of those on whom information available).
This trend in favour of amplified advice is not
significant (chi-square 1.09, d.f. l,p>0.1). There is
also a trend in favour of amplified advice when
marital stability is examined (Table 5) but this also
is non-significant (chi-square 3.04, d.f. 1,
0.1 </><0.05).
The mean past year's problem score at follow-up
for 'amplified' patients was 32.8 (SD 26.8, 95% C.I.
25.1-40.5, » = 48) and for 'simple' patients 36.4
(SD 27.8, 95% C.I. 16.9—44.9, «=34). The mean
fall in the problem score total between the intake
and outcome assessments did not distinguish signifi¬
cantly between these two groups either when those
dying of alcohol-related causes were included
(U= 784; Z=-0.306; p=0.760, 2-tailed, « = 82)
or excluded (I/-711, rr--0.179, />-0.858, 2
tailed, n = 79).
Problem-free drinking. Although Table 2 shows
11 individuals who continued to drink some alcohol
in the year to follow-up and achieved this with no
apparent problems, five had an elevated serum
GGT at follow-up (of whom two relapsed into
problematic drinking in the year following), and one
refused to give a blood sample (and also subse¬
quently relapsed).
Failure of Advice Cases. These cases differed at
intake from the remainder of the sample in that
proportionately more were female (half) and in that
on average they had had more previous treatment.
Seventeen of the 20 took up the treatment offered
though with varying levels of perseverance. Two
had an excellent outcome and a further three were
clinically definitely improved. As mentioned, two
died, despite being offered more help.
Help Acknowledged in Good Outcome 'Advice' Cases
Of the 16 'advice' patients who abstained or were
free of troubles for the year to follow-up, one had
received considerable help from a psychiatrist
elsewhere and also from AA. Two others had
attended AA. There were none who had sought
regular help from the Council on Alcoholism. Two
laid great store by the help, even though it was brief,
at their intake interview. Two others were F/A
patients given treatment with disulfiram, ingestion
being supervised in one by the clinic as part of an
agreement between himself and his employer.
Discussion
In terms of what is known of the predictors of
outcome in alcoholicm, our randomization gave us
apparently well matched groups.
The need to take out the 'advice' group patients
who were doing very badly, and offer therapy raises
the question of whether they should be left out of
Table 5. Employment and Marital Status of Patients in Whom Complete Follow-up Information Was
Available
Advice only Extended treatment
Simple advice Amplified advice
Employed at intake n 19 30 32
% still employed at 2 years 74 70 75
Living with spouse or cohabitee
at intake n 24 38 39
% still living with spouse or
cohabitee at 2 years 58 79 69
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the final analysis. To leave them out, removes from
the 'advice' group some of its poorest prognosis
cases. To keep them in, possibly weights the results
against finding a positive effect of treatment. We
chose to leave them in.
We believe that the follow-up interviewer re¬
mained blind to the treatment group of the patient.
We did not assess after each patient whether or not
she had guessed the group, because we tried, and
succeeded until the end of the study, to keep her
ignorant of the design itself.
There was a trend which did not quite reach
significance suggesting that at the point of follow-up
a higher percentage of the patients offered extended
treatment were in a state of remission. Much of this
comprises short-term abstinence, of the type shown
in the Rand Report" often to be temporary.
However, the data on accumulated problems in the
longer one-year window demonstrates that extended
treatment can result in a more sustained overall
lessening of problems if not complete abstinence.
This positive result in favour of treatment has been
found in a population slightly weighted towards
men, and towards married patients, in comparison
to our total clinic population.
While the reduction in problems reached statisti¬
cal significance, the accompanying trend towards
less consumption of alcohol in the patients offered
extended treatment did not. While a larger sample
may have demonstrated a clearer reduction in
consumption in that group, it may be that they were
simply achieving a less hazardous style of drinking
particularly as far as the family and spouse are
concerned.
Only four patients offered extended treatment
were readmitted during the year leading to follow-
up, and each spent on average 20 days in hospital. If
that occurred it counted in the score of alcohol-
related problems. Thus, the lower aggregate prob¬
lem scores at follow-up in the 'extended' group were
not due to institutionally enforced sobriety.
It is likely that we had more complete admission
by patients and their families of relapses and the
ensuing problems in the patients offered extended
treatment than in 'advice-only' patients, simply
because we had maintained contact with so many of
the patients during the follow-up period: it would be
less easy for them to deny problems. This also
weighs against finding a result in favour of extended
treatment.
Our conclusion that extended treatment contri¬
buted to an overall lessening of harm hinges on our
scale of alcohol-related problems. The items were
not novel. Most had been used either in the London
study,3 or our previous clinical work7 and survey
work in heavy drinking occupational subcultures
(Chick et al.1") and are of known reliability.
However, this compilation was new and concurrent
validation of the scale has not been attempted.
Nevertheless, the face validity of the individual
items is not in doubt. Furthermore, when improve¬
ments in individual items were examined there was
the expected concordance among individual items in
the domain of behaviour in the family related to
drinking. We cannot ourselves conceive of how a
property of our scale could lead to a biased result in
favour of the extended treatment group.
In the London study,3 10 of the 46 'advice'
patients had an admission, albeit usually short, to a
psychiatric hospital during the year of the follow-up
compared to only two of our 96 'advice' patients.
Some of our 'advice' patients undoubtedly received
other help, indeed 5 of the 15 who attained stable
abstinence attributed their recovery to the help they
had sought. However, as a group our minimally
treated patients probably received less help overall
than the 'advice only' group in the London study.
This could have contributed to our obtaining a
result showing an effect of extended treatment while
the London study did not.
Despite its undoubted link with heavy drinking10
the serum GGT in British alcoholism clinic samples
correlates poorly with admitted consumption and
other indices of severity.12'13 In these samples, as in
ours, there are bout drinkers whose consumption
patterns fluctuate greatly. In this study we are
dealing mainly with a population whose behaviour
in response to alcohol rather than their tissue
response is the presenting problem. Thus, we do not
feel the lack of clear advantage in terms of
improvement of serum GGT in the 'extended'
group should detract from the indication that those
patients had a somewhat better outcome. Of course,
it would be desirable to have a marker of outcome
that was purely objective. Without it, there remains
the possibility that the patients offered extended
treatment and their families minimized their reports
of problems more than 'advice' patients because
they wanted to please the clinic staff.
Some of the 'extended' group were still receiving
outpatient support at the time of the follow-up
interview. We cannot say whether the results for the
'extended' group might gradually worsen towards
that of the 'advice' group if that support was
withdrawn. We are aware of how short a period 2
years is in the span of a severe drinking problem.
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For the 20 'advice' patients who were doing so
badly as to necessitate removal from their study
group, we cannot know what the fate would have
been if they had been left untreated. It is worth
repeating, however, that with treatment two had an
excellent outcome. Substantial improvement was
noted in a further three.
We have not addressed the question of compli¬
ance. There were, of course, patients offered
extended treatment who did not take it. In the first 6
months of the study 16 of 47 patients offered
extended treatment in whom the therapist was able
to make a rating of compliance were said to be
cooperating poorly with treatment. In 19, denial of
their alcohol problem was rated as 'moderate' or
'marked'. However, it is our philosophy that dealing
with denial and enhancing motivation are key
ingredients of treatment.
The social work follow-up of all subjects may
have had a therapeutic effect on the drinker via the
family. This would have diminished the magnitude
of the advantage of extended treatment.
Our finding that greater improvement resulted
from extended than brief treatment supports the
tentative conclusion of Emrick.14 Emrick pooled the
findings of several studies where the outcome of
patients given treatment was compared with that of
patients given none or only minimal treatment. He
found that of 634 patients given no treatment or
minimal treatment, 42% improved, whereas of 1774
who received more than minimal treatment 65%
improved. However, in general these studies had not
randomly allocated patients to the different treat¬
ment categories nor attempted to match patients on
important prognostic characteristics. Nevertheless,
it suggested that treatment was offering some
advantage.
The Possible Value of the Advice-only Treatment
The finding that amplified advice was not more
effective than simple advice suggests that in the
study of Edwards et al.3 that important ingredient
was the unequivocal diagnosis and the injunction to
abstain rather than the additional advice given with
the London brief treatment. Or, indeed, the key
factor may be the decision of the patient to do
something about his drinking reflected in his coming
for the appointment and whatever brief advice is
given makes little difference. The assessment proce¬
dure was impressive and lengthy, involving compu¬
terized testing of cognitive function (to be reported
separately). This may have enhanced the power of
the advice-only treatment. We cannot say what the
effect of our advice, either simple or amplified,
would be in another setting, or with less attention
paid to taking a detailed personal, medical and
marital history. That 12 (12.5%) of 96 patients who
received only advice were stable abstainers 2 years
later should not be ignored. In the absence of a no-
treatment control we cannot know whether this is
merely the 'spontaneous remission rate'.
We will write elsewhere about the predictors of
outcome and the matching of different types of
patient to different intensities of treatment. We will
also treat separately the question of whether our
results lend support to the notion that a return to
controlled, problem-free drinking is possible in such
patients.
Conclusion
Extended treatment offered an overall lessening of
the harm which accrues to problem drinkers, their
families and society in the course of time. Extended
treatment did not increase the likelihood of a patient
achieving stable abstinence, or stable problem-free
drinking, beyond that which could result from much
briefer treatment. Nor did it improve the likelihood
that a patient would remain in employment or in
marriage. Larger samples in future studies may yield
clearer results.
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To assess the efficacy of supervised disulfiram as an adjunct to out-patient treatment of
alcoholics, a randomised, partially blind, six-month follow-up study was conducted in which
126 patients received 200 mg disulfiram or 100mg vitamin C under the supervision of a
nominated informant. In the opinion of the (blinded) independent assessor, patients on
disulfiram increased average total abstinent days by 100 and patients on vitamin C by 69,
thus enhancing by one-third this measure of treatment outcome. Mean weekly alcohol
consumption was reduced by 162 units with disulfiram, compared with 105 units with vitamin
C, and the disulfiram patients reduced their total six-month alcohol consumption by 2572
units compared with an average reduction of 1448 units in the vitamin C group. Serum
gamma-GT showed a mean fall of 21 IU/I in patients on disulfiram but rose by a mean of 13 IU/I
with vitamin C. Unwanted effects in the disulfiram group led to a dose reduction in seven
patients and to treatment withdrawal in four (and in one vitamin C patient). Two-thirds of
the disulfiram group asked to continue the treatment at the end of the study. There were
no medically serious adverse reactions.
Disulfiram (Antabuse) is an agent which inhibits
metabolism of alcohol, resulting in the unpleasant
symptoms (flushing, headache, nausea, dizziness,
tachycardia) of the disulfiram-alcohol reaction.
Although it has been available for many years as an
adjunct to counselling in the treatment of chronic
alcoholism, and despite a dearth of therapies for this
condition (Vaillant, 1983), disulfiram is not commonly
prescribed in the UK owing partly to concern that
the agent may cause hepatic damage (Peachey &
Naranjo, 1983; Peachey, 1988). In addition, the early
literature provided poor evidence of the efficacy of
disulfiram, but these studies often lacked adequate
controls (Bourne et al, 1966; Edwards & Dill, 1974;
Bigelow et al, 1976) or supervision of patient
compliance (Fuller & Roth, 1979). Compliance with
the disulfiram regime, found to be as low as 20%
in a study in the USA (Fuller et al, 1986), can be
improved with supervision by the spouse or clinic
(Gerrein et al, 1972; Robichaud et al, 1979; Azrin
et al, 1982; Sereny et al, 1986).
We report here the first UK controlled study
of supervised disulfiram as an adjunct to out¬
patient treatment of alcoholics, in which safety and
acceptability were assessed in addition to the effect
of the treatment on alcohol consumption and
related problems.
Method
One hundred and twenty-six subjects entered the trial from
among patients of either sex, aged 18-67 years, attending
seven alcoholism treatment centres. Only patients who had
already relapsed after previous therapy or other support
were invited to participate, since we felt the memory of
previous failure would aid their compliance with the study
treatment. Pregnant women were excluded, as were subjects
with cardiac disease, psychosis, or habitual drug abuse,
and those showing abnormally high levels of serum
bilirubin, aspartate aminotransferase (AST) or alanine
aminotransferase (ALT).
The protocol was approved by local hospital ethical
review committees. All patients gave their written, informed
consent to receive one tablet a day of disulfiram (200 mg,
dispersed in water) or vitamin C (100 mg) for six months
under supervision, and an informant was nominated,
usually the spouse (occasionally another relative, colleague,
or a member of the clinic staff, with whom they had contact
at least once a week). Treatments were randomly placed
against lists of numbers, supplied to the pharmacist at the
various centres, who then allocated the numbers sequentially
to patients entering the trial.
For ethical reasons the treatment codes were broken after
allocation so that a thorough explanation of the use of
disulfiram and the associated risks of drinking, to include
written information and a pocket warning card, could be
given to the patients and families concerned. If left blind,
patients might have been tempted to test whether or not
drinking could trigger a reaction.
The vitamin C group was included to control for the
effects of receiving supervised medication and out-patient
counselling, and patients were told this; if they asked further
they were told that vitamin C was chosen for the control
medication because alcoholics may have vitamin deficiencies,
of which this is one.
Medication was usually supervised daily by the informant;
where the informant was not the spouse the dose on a day
when the informant and patient did not meet was either
given the day before or given to take unsupervised at home.
The informant was encouraged to telephone the clinic if
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the patient refused the medication or lost touch, so that
advice could be offered. No written contract, however, was
involved, and no sanctions were invoked if the patient
ceased taking the medication.
Patients were either already in, or were offered, a range
of out-patient and community counselling and support,
which varied between centres. A few patients were offered
day-patient places. Marital therapy, relaxation therapy,
attendance at Alcoholics Anonymous (AA), vitamin B
supplements, and supportive group therapy were also used
by some patients.
At intake, the clinican conducted a physical examination
of the patient, which included blood tests, and took a
medical and psychiatric history. During treatment the
clinician monitored compliance (checking with the informant)
and drug safety at each visit, recording any unusual
symptoms reported by the patient, and reviewed patient
progress at the end of the six-month trial. Blood tests
(haematology and biochemistry, including liver function
tests and blood alcohol, plus serum gamma-glutamyl
transferase (GT) and mean red cell volume (MCV) as
markers of regular alcohol consumption (Chick et al, 1981))
were repeated after one, three and six months of treatment.
Each centre appointed as an independent assessor to
obtain follow-up data someone with previous experience
with alcoholics: medical practitioners, nurses, or trained
research interviewers. They were to stay blind to the
medication received. Patients and informants were reminded
at each contact not to give any information which could
reveal the medication.
The assessor saw patient and informant at intake and
again, separately, at weeks 2 and 4, and thereafter monthly
until the final interview at six months. Interview questions
concerned alcohol consumption, alcohol dependence (the
Severity of Alcohol Dependence Questionnaire (SADQ)
(Stockwell ct al, 1983)) and 13 alcohol related health and
social problems (Chick et al, 1988), all with reference to
the period since the last visit (or the previous six months
for the first and final visits).
'Typical week's consumption' was according to a retro¬
spective diary of a typical week during which the patient
drank. In addition, at each interview the assessor obtained
an estimate of total consumption in the previous four weeks.
These were aggregated in the analysis to give 'total units
consumed in past six months'. At intake the assessor had
obtained an estimate of the prior six months' consumption,
with anchor dates to aid memory. Informants' information
was included, and was evaluated by the assessor in making
a judgement, because patients are known to report less
consumption than informants (Fuller et al, 1988).
Statistical analysis
All data were used, on an 'intention-to-treat' basis,
irrespective of patient compliance, attempts having been
made to follow up all patients. Categorical data were analysed
using Fisher's exact test for 2x2 tables and Pearson's x2
test for larger tables. Otherwise, the Mack Skilling'c test
(Mack & Skillings, 1980), taking account of the weighting at
different centres, was used to test for significant treatment
differences. Laboratory blood data were analysed by fitting
an additive linear model of centre and treatment effects and
using a f-test to compare treatments (Searle, 1971).
Where possible, differences from pre-treatment were
analysed. All tests were two-tailed with a significance level
of 5%.
Results
The two groups of patients commencing treatment (64 on
disulfiram, 62 on vitamin C) had similar demographic and
social backgrounds. The overall mean age was 43 years
(range 18-67); 84% were male, 65% were unemployed, and
46% lived with a spouse or other cohabitee. The commonest
illness suffered was gastrointestinal disease (21 % of patients),
of which 85% was alcohol-related. Two-thirds of the disulfiram
group and half the vitamin C group had had in-patient treat¬
ment for alcoholism. Informants were mainly spouses (41 %)
or members of the clinic staff (33%).
Fifty-seven patients (28 on disulfiram, 29 on vitamin C)
did not adhere to their allocated treatment, 45 through
failure to keep appointments or by withdrawing consent.
Follow-up interviews were not obtained in 20% (15 disulfiram
patients, 14 vitamin C patients). Both initial and final blood
samples were available in only 57%, because at follow-up
some patients were interviewed by telephone, and at intake
and follow-up some samples were not analysable because
of delay or damage.
Four patients on disulfiram and one on vitamin C were
withdrawn with adverse reactions: two of the former owing
to allergic skin rash, one with suspected neuropathy, and one
with dizziness and nausea, while the patient on vitamin C
was admitted suffering left hemiparesis. A further two
withdrawals from the vitamin C group were due to increasing
problems with drinking. (Four of the patients on vitamin C
who withdrew their consent did so because they wanted to
take disulfiram; in addition, three initial recruits had
withdrawn as soon as they heard they had been assigned to
vitamin C and were thus excluded from the trial population.)
Unusual symptoms were reported equally in the two
groups (e.g. depression: 4 disulfiram, 5 vitamin C patients;
nausea: 2 disulfiram, 2 vitamin C patients) except for
headache (11 disulfiram, 5 vitamin C patients), fatigue (12
diculfiram, 6 vitamin C patients), and skin rash (4 disulfiram
patients only). Seven patients on disulfiram had their dose
reduced because of side-effects. Disulfiram-alcohol reactions
were reported on 29 occasions, but none led to a reduction
of dose. Five patients had their disulfiram dose increased
because the alcohol reaction was mild or absent, and one
such patient refused to have the dose increased. There were
no abnormalities of liver function during treatment.
Treatment effects are summarised in Tables 1-4. Both
treatment groups achieved a reduction in alcohol con¬
sumption which by most estimates was greater with
disulfiram, the treatment difference reaching statistical
significance for values at 6 months (Table 1). However, at
the final assessment the number of days since the last drink
and alcohol consumption in the last month of the study
revealed no significant treatment difference (Table 3).
The mean (s.d.) SADQ score at intake was similar in the
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Table 2
Blood test markers: comparison of changes from intake
after treatment (means (s.d.) )
Table 4
Final opinions of ability to control drinking















-34 i -74 to -7)
0.02
Week Disulfiram {nI Vitamin C (n)
2 0.76 (2.49) (58) 1.64 (3.34X53)
4 0.76 (3.07) (55) 2.09 (3.78I (47)*
8 1.63 (4.76X49) 4.36 (8.44) (45)
12 2.47 (5.71X45) 2.67 (5.14) (43)
16 3.12 (6.76X40) 2.82 (6.79) (38)
20 1.76 (5.68X37) 3.65 (7.27) (34)
Total 7.77 (11.40) (35) 17.91 (31.52) (34)
96.6 (5.8) (57) 97.8 (5.8I (52)
-3.0 (5.1) (31) -2.6 (4.5) (33)
-0.4 (-2.8 to 2.1)
0.78
51 (72) (57)
+ 13 (83) (38)
(n = 63), mean change with treatment - 8.3 (15.8) (n = 35);
vitamin C: 33.1 (13.3) (n = 59), mean change with treatment
— 10.8 (16.9) (n = 39)). Mean (s.d.) problem score reduced
more in the disulfiram group (intake: 6.30 (2.59) (n = 56),
mean change with treatment - 4.00 (3.21) (n = 43 ) than in
the vitamin C group (intake: 5.96 (2.25) {n = 54), mean
change with treatment -2.91 (3.02) (n = 45)), but this
difference was not significant (P=0.06).
Table 4 shows the opinions of the various participants
at the end of the trial regarding the ability of the patients
to control their drinking, by which was meant reduction
or cessation of their excessive drinking and its problems.
Patients, informants and clinicians all thought the disulfiram
group to have significantly better control (mostly moderate/
full) than the patients on vitamin C, half of whom
showed no change. In the opinion of the assessors,
however, the patients on vitamin C attained a similar
improvement in their control of drinking to those treated
with disulfiram.
At the end of the trial two-thirds of the patients on
disulfiram wanted to continue treatment, compared with
only one-quarter of those on vitamin C (P< 0.001).
At the end of the study the identity of the test treatment
was guessed correctly by the independent assessor for 65%
of those followed up. This was not measured at any of the
earlier assessments.
Table 3
Number of days since last visit on which alcohol was
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For the ethical reasons already stated each patient's
allocated treatment was known to all but the indepen¬
dent assessor. However, a double-blind design might
not necessarily reduce the problems of interpretation,
because of the tendency shown in a recent double-
blind cross-over study of calcium carbimide (Peachey
et al, 1989) in which 78% of patients thought they
were taking active drug at all times. This compromises
the chance of showing the deterrent effect of the
drug, depending as it does partly on instruction and
belief that an alcohol-reaction could occur. The
correct test of the drug is a test of the 'package',
which includes emphasising the alcohol-reaction to
the active group.
Although by the end of the study assessors were
guessing the correct medication better than chance,
the two measures for which their ratings significantly
differed between the groups were scores summated
(by computer) of ratings made over the six months,
that is, abstinent days and units consumed. In general
there was little discrepancy in the six-month summated
scores between the results as perceived by patient,
informant and assessor, but despite having guessed
accurately in some cases the assessors considered
those on vitamin C to have achieved the same
control of drinking as the disulfiram group. The
explanation for this is not clear, but perhaps it
slightly reduces the concern that bias influenced the
assessors' ratings.
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Estimates of alcohol consumption over the six-
month trial generally showed significant differences
in favour of disulfiram. There was little difference
in the final rating of 'number of days since last
drink', however, suggesting that some patients were
perhaps using disulfiram to practise occasional
limited drinking. By the end of the study there was no
statistical difference in the last month's consumption,
and this, together with the narrowing of the estimate
of days since last drink (Table 3), could indicate a
waning of the treatment effect.
Rating of alcohol-related problems (violent epi¬
sodes, time off work, police involvement, etc.) is less
open to bias but it takes longer for changes in the
frequency of these relatively rare events to become
apparent. The patients on disulfiram none the less
showed a strong trend towards a greater reduction
in total problem score than the vitamin C group,
falling just short of statistical significance. SADQ
scores in both groups improved somewhat. The
SADQ allocates a score for maximum sessional
consumption and some patients on disulfiram did
have relapses though perhaps less frequently than
those on vitamin C. It also allocates points for
'imagining your symptoms if you had a heavy
drinking session', and patients in our study, even
though abstinent, would score on these items since
they still regarded themselves as 'dependent'. The
SADQ is perhaps not a good measure of outcome
over six months.
Blood test markers of alcohol consumption, par¬
ticularly the more rapidly affected serum gamma-GT,
are not open to bias and it is important that the
disulfiram group showed a significantly greater
improvement here. Blood tests for both intake and
follow-up were available in only 57% of cases but
the patient drop-out rate was similar for both
treatment groups.
No previous study has used blood tests as markers
of outcome, although supervised disulfiram has been
studied, with promising results (Heather, 1989). Our
own methods of supervision did not use such a strict
'contract' as some of the successful reports in the
American literature (Azrin et al, 1982; Keane et al,
1984; O'Farrell & Bayog, 1986). We also used a lower
dose than in some of the American studies. In the
study by Fuller et al (1986), unsupervised disulfiram
(250 mg daily) plus counselling was associated with
a reduction in the number of days on which alcohol
was consumed, corroborated by relatives or friends.
However, this was demonstrated only in the one-
third of patients who provided all seven assessment
interviews, and could not be seen in the remainder.
It may be that supervision is necessary to the success
of disulfiram treatment.
Treatment practices varied in the different centres
involved, and some centres appeared to have slightly
better results than others. Even so, we suspect that
our method was something some general practitioners
could profitably arrange, with the spouse or practice
nurse supervising treatment.
There were no medically serious disulfiram-alcohol
reactions, and at the dose used in the study some
patients did not experience a reaction after drinking.
Concerns about hepatic toxicity were not borne out.
Disulfiram can, though, cause allergic skin reactions
and it is still to be recommended that patients taking
the drug have medical follow-up.
In conclusion, we found that supervised disulfiram
plus counselling enhanced treatment outcome in
alcoholics. A few patients developed skin rash,
headache or tiredness but there was no disturbance
of liver function. Disulfiram is a popular form
of treatment among some alcoholic patients and
their relatives.
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Abstract Disulfiram is known to cause hepatitis, which is sometimes fatal. The best
estimate of the frequency of disulfiram-induced fatal hepatitis is 1 case in 30 000
patients treated/year. Its appears to be more common in patients given disulfiram
for the treatment of nickel sensitivity. Frequent blood testing for liver function is
probably not necessary, but patients taking disulfiram should be in regular contact
with a physician.
There are rare reports of psychosis and confusional states in conjunction with
disulfiram treatment and peripheral neuropathy and optic neuritis have been re¬
ported; these effects are dose-related. Psychiatric complications appear to be
more common with the use of disulfiram in India than in Western countries. Of
the less serious adverse effects, tiredness, headache and sleepiness are the most
common.
Deaths from the disulfiram-alcohol (ethanol) interaction have not been re¬
ported in recent years, possibly because the dosages used are lower than those
used 40 years ago, and patients with cardiac disease are now excluded from
29
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treatment. There is no evidence to suggest that disulfiram causes cancer. Of note,
there are drug interactions with compounds that utilise the cytochrome P450
enzyme system.
Disulfiram can be viewed as a drug with a moderate record of adverse effects.
Alcohol dependence, for which it can be a helpful treatment, is associated with
a high morbidity and mortality.
Alcohol (ethanol) dependence is a potentially
fatal disorder, which often does not respond to
medical or psychiatric intervention. Randomised
controlled trials of disulfiram have shown that,
when patients agree to involve a third party to assist
their compliance, this deterrent approach can im¬
prove the outcome of treatment.[1] Since disulfiram
was first prescribed for alcohol dependence in
1947, there have been concerns about its safety,
namely the risks of the disulfiram-alcohol reaction
and the risk of toxic effects of the compound on the
nervous system and on the liver.
1. Search Procedure
The sources used in the following review were
literature searches on Medline (publications from
1966; date of search, early 1998) and the Adis
International comprehensive inhouse database;
certain specific enquiries to the manufacturer;
correspondence with the author of 1 paper; and
manual searches from 1966 back to 1950 of Quar¬
terly Journal of Studies on Alcohol, British Medi¬
cal Journal, and the Journal of the American Med¬
ical Association. No exclusion criterion based on
study methodology was applied: many papers were
individual case reports, although weight was given
to reports where re-exposure to disulfiram had rep¬
licated the adverse effect. Where a finding has been
replicated in successive publications only the study
or studies where the finding was most robust have
been cited, or a relevant review paper.
2. Hepatotoxicity
The world literature of the last 40 years contains
30 reports of patients with hepatitis related to di¬
sulfiram. National Drug Adverse event registers
would suggest there are also cases not written up
and published. At the recommended dosage level,
hepatotoxicity has been noted to occur as rapidly
as 13 days after commencing the drug, and after a
total dose of as low as 4.5g prescribed at 250
mg/dayJ21 Sometimes the hepatitis has resolved on
stopping the drug, but at other times a fulminant
course has ensued. In some reversible cases, the
causal relationship has been demonstrated by a
challenge e.g. Morris et aid31, Bartle et al.14' Al¬
though people with alcoholism clearly have a high
prevalence of liver disorders related to other
causes, many of the cases of disulfiram-related
hepatitis have occurred in patients who had normal
liver function tests on commencing the medication.
Hepatotoxicity has also been described in patients
without alcoholism (disulfiram is sometimes pre¬
scribed for nickel sensitivity).'51
2.1 Frequency
Denmark is probably the country in the world
where, per capita, the most disulfiram is pre¬
scribed.161 Reports to the Danish Committee on Ad¬
verse Drug Reactions from 1978 to 1987 of all
drug-induced hepatic injury revealed that 35
(2.9%) of the 1188 reports were linked to disul¬
firam, as were 5 (10%) of 52 drug-induced hepatitis
fatalities.I7'
However, the most important frequency esti¬
mate is of the risk per prescription of disulfiram.
There is only 1 such published estimate, also from
Denmark. Spontaneous reports of adverse drug re¬
actions to disulfiram treatment were examined for
the period 1968 to 1991 ,[81 There were 11 fatal liver
reactions reported in 22 years. Using drug sales
figures to estimate the number of patients taking
disulfiram to be 15 000 per year, the reported risk
of dying of hepatotoxicity caused by disulfiram can
© Adis International Limited. All rights reserved. Drug Safety 1999 May; 20 (5)
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be calculated to be 1 : 30 000 patients per year.
Some of these were patients receiving disulfiram
as treatment for nickel sensitivity, and it appears
from 1 uncontrolled study191 that the risk of liver
disorders linked to disulfiram is vastly greater in
these patients than in people with alcoholism, hep¬
atitis occurring in 8% of such patients (nickel in
the body is mobilised by disulfiram and can be de¬
posited in the liver).
2.2 Timing
In the Danish data,181 disulfiram-related hepati¬
tis had commenced between 16 and 120 days after
starting treatment, with a peak frequency at 60
days. However, in 1 case, a woman who had com¬
menced taking disulfiram in excess of the pre¬
scribed dosage (she took 1.5 to 2 g/day) developed
jaundice within 5 days.'10'
2.3 Mechanism
When liver function is monitored during disul¬
firam treatment, abnormalities in liver enzyme lev¬
els may occur but can often be attributed to re¬
sumption of drinking. There is 1 report which has
shown more liver enzyme level elevations in pa¬
tients taking disulfiram than in patients in the same
programme who did not receive the drug (the Tri-
Services Alcoholism Recovery Project study).1"!
Allocation to disulfiram or no disulfiram was not
random in the study. The clinic offered disulfiram
250 mg/day to all patients, but some were excluded
for various reasons including any abnormal liver
function test. Compliance was monitored. Patients
were inpatients throughout the study period and
were screened for use of alcohol at random by
breath and urine alcohol tests. At 4 weeks into the
study, the level of 1 or more transaminase had be¬
come elevated in 30% of patients taking disulfiram
and in 11% of control patients. The levels of 2 or
more transaminases were elevated in 9% of pa¬
tients taking disulfiram. Two patients taking disul¬
firam, compared with none of the control individ¬
uals, had an elevation of ALT levels greater than 3
times the upper limit of normal, which is the level
at which in other drug hypersensitivities the risk of
hepatitis is significant.
Two studies where there was random allocation
to disulfiram or a placebo have been published that
give follow-up liver function test data. Iber et al.1'21
followed 453 male patients for 1 year. In both stud¬
ies abnormalities in liver function tests did not oc¬
cur more frequently in the disulfiram patients than
in control participants.I12"3! In only 1 of these 2
studies1'31 was compliance with medication over 6
months ensured by supervision. In that study, liver
enzymes levels showed an on average improve¬
ment in the disulfiram group but a deterioration
(associated with more frequent alcoholic relapse)
in the control participants.
Two reports provide long term data on hepato-
toxicity from studies that did not include a control
group. Borup et al.1141 reported data from 93 pa¬
tients who had taken disulfiram for 1 year super¬
vised by the clinic at a dosage of 600 to 800mg
twice weekly. No patient developed liver function
abnormalities. In a series of 43 patients receiving
supervised disulfiram treatment in dosages up to 1
g/day (mean 363 mg/day) for a mean of 7.6
months, Brewer1'51 reported that all patients who
had abnormal liver function tests at the start of
treatment showed improvement. Nine patients
were taking 500 mg/day or more and in none of
these patients was there even a slight elevation of
previously normal liver function tests. In a study
of 50 male inpatients randomised to receive either
placebo, disulfiram 250 mg/day or disulfiram 500
mg/day no differences in liver function tests
emerged.1'61
In a 12-week follow-up study of 57 men with
alcoholism, some of whom had elevated transami¬
nase levels and serological evidence of hepatitis C
virus infection at commencement of disulfiram
therapy, 1 patient showed an elevation of transam¬
inase levels attributable to disulfiram, without clin¬
ical complications.1'71
It seems from the Tri-Services Project1"1 that
under some circumstances disulfiram is associated
with an increase in liver transaminase levels, but
the weight of evidence is that clinical hepatitis is
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rare. There is no evidence that a pre-existing liver
disorder increases the risk of disulfiram hepatotox¬
icity."81 In most of the reported cases of patients
with hepatitis the patients had normal liver func¬
tion tests at the start of treatment. A fatal outcome
was more likely when the drug was continued for
some days after jaundice had been noticed."01 Hep¬
atitis may be due to accumulation of toxic metabo¬
lites"01 or in some cases due to the expression of
autoantibodies directed against specific cyto¬
chrome P450 enzymes."91
2.4 Monitoring
There have been several attempts in the litera¬
ture to specify when liver function in blood tests
should be checked. In some treatment centres it
became routine practice to assess liver function be¬
fore and at frequent intervals during treatment with
disulfiram (e.g. Wright et al.1"1). A recent single
case report, where liver function testing at day 16
produced normal results, but jaundice had devel¬
oped by day 42, led to another call for 2-weekly
testing of all patients receiving disulfiram.1201
However, the onset of the hepatitis is usually very
rapid, and so even frequent testing may not detect
it. In addition, abnormal enzymes levels are com¬
monly caused by a resumption of alcohol ingestion
which might lead to unnecessary withdrawal of the
drug. Thus, it can be argued that frequent blood test
monitoring is unlikely to be productive, especially
given the rarity of severe hepatotoxicity.12"
In my view, informing the patient, the patient's
relatives and the family practitioner, of the 1 in 30 000
risk of fatal hepatotoxicity, emphasising detection
of jaundice usually preceded by fever, so that the
drug is stopped when adverse effects are noticed,
is probably an equally efficient way to prevent fatal
hepatitis and still allow many patients to benefit
from disulfiram treatment.
Brewer and Hardt1221 recommend that patients
should be asked about nickel sensitivity before
starting treatment with disulfiram and that liver
function tests should be measured near the time of
starting therapy (not necessarily in advance) and
again after about 1 month.
In summary, hepatitis is very rarely a conse¬
quence of disulfiram use. Abnormal liver enzymes
levels caused by alcohol use need not be a contra¬
indication to the use of disulfiram. Indeed, when
the patient is helped to achieve abstinence by tak¬
ing disulfiram such abnormalities will probably re¬
solve. However, patients should be informed about
even very rare risks associated with drug therapy.
Medical supervision of patients taking disulfiram
should continue for as long as the patient uses it
and should be at least monthly for the first 6
months. There is no compelling evidence to sup¬
port repeated liver function testing as a way of pre¬
venting serious hepatotoxicity.
3. CNS Adverse Effects
3.1 Confusional States/Psychosis
There are occasional reports from Europe and
North America of disulfiram-linked psychosis or a
confusional state (beginning with fatigue and for-
getfulness, rarely proceeding to ataxia or stupor).
These reports were commoner in the early days of
disulfiram therapy when higher dosages than are
commonly used today (500 mg/day or more) were
routinely prescribed. This potentially serious ad¬
verse effect may be more frequent in some coun¬
tries than others. While only 4% of adverse drug
reactions reported for disulfiram in a Danish
database were psychiatric,181 the WHO database
when examined by Enghusen Poulsen et al.181
showed that 13% of disulfiram adverse effects
were psychiatric.
Two papers from India, Krishna Murthy and
Praveenlal1231 and Krishna Murthy,1241 have de¬
scribed higher rates of disulfiram-induced psycho¬
sis arising de novo than other papers, with the effect
starting 2 to 3 weeks after commencing treatment
with disulfiram. Symptoms included overactivity,
overtalkativeness, paranoid delusions, insomnia
and auditory hallucinations. Symptoms usually
completely resolved after withdrawal of disulfiram
and sometimes after a short course of treatment
with an antipsychotic drug. In 1 series, 6 cases of
disulfiram-induced psychosis occurred in 52 pa-
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tients,'23' and in the second series there were 5
cases of disulfiram-induced psychosis among 53
patients.'241 In all patients the dosage of disulfiram
was 250mg twice daily. Another paper from In¬
dia'25' described a series of 38 patients of whom 1
developed a confusional state while receiving di¬
sulfiram at a dosage of 250 mg/day. The adverse
effect resolved and then recurred on each of 2 re-
exposures.
The reason for the apparently high rates in India
is unknown. One possibility is that the bioavaila¬
bility of disulfiram manufactured locally may be
different from the compound available in Europe
and North America. Two cases of psychosis asso¬
ciated with disulfiram have been reported in Cau¬
casian patients; however, the psychosis seemed to
result from an interaction between cannabis and
disulfiram.'26'27] The Indian papers do not mention
concomitant cannabis, which is widely available in
that country; however, Krishna Murthy (personal
communication) states that cannabis use was not
suspected in the patients in his reports.
In a North American series of 243 patients
treated with disulfiram 250 mg/day, 5 patients had
'an organic brain syndrome' (which was not well
defined in the paper).'28' In patients with alcohol¬
ism, psychiatric disturbances can be caused by
drinking alcohol and can occur because of co¬
existing psychiatric disorders. Therefore, only a
controlled study can provide a realistic estimate of
the prevalence of unwanted psychiatric effects
with disulfiram. In a follow-up study of 612 male
North American patients randomised for 1 year to
either disulfiram 250 mg/day, disulfiram 1 mg/day
or placebo, the incidence of psychiatric complica¬
tions was 2.4% in the disulfiram-treated groups,
and the incidence was not significantly different
between the groups.'29' No psychotic illness was
diagnosed. This was a treatment outcome study,
and previous psychotic illness had been an exclu¬
sion criterion. Thus, if disulfiram causes psychosis
by precipitating a pre-existing illness, this would
explain the absence of any psychotic adverse ef¬
fects in this and in other placebo-controlled studies
(e.g. Chick et al.'13') where no psychiatric compli¬
cations have been noted.
There has been 1 report of catatonia attributed
to disulfiram therapy and this adverse effect is
therefore presumably very rare.'30'
In the data sheet for disulfiram, previous psy¬
chosis is an exclusion for the use of this agent.
However, alcohol misuse in schizophrenia can be
very harmful to the patient and, lacking another
effective treatment, clinicians weighing up the
risks and benefits of treatment have sometimes rec¬
ommended disulfiram in this context.'31' A wide-
reaching review of all aspects of disulfiram use in
patients with alcohol dependence and other psychi¬
atric disorders that also looked at potential drug
interactions, concluded that the rate of serious un¬
wanted psychiatric effects was extremely low at
recommended disulfiram dosages of 200 to 250
mg/day.'32'
The reason for a possibly higher rate of psycho¬
sis in India needs further examination.
3.2 Other Serious CNS Syndromes
A case report was published about a man who
took disulfiram 250 mg/day for 30 years, and ex¬
perienced a gradual decline thereafter in memory
and performance IQ tests; this decline partially re¬
covered on stopping the drug.'33' Peripheral neu¬
ropathy was also noted to have occurred. A posi¬
tron emission tomography study,'34' which showed
reduced cerebral metabolic rate for glucose in pa¬
tients with alcoholism taking disulfiram compared
with those not taking disulfiram, found no differ¬
ences between the groups with respect to neuro¬
psychological performance. No adjustments were
made for differences in severity or duration of pa¬
tients' heavy drinking in this study.'34' There are no
published randomised controlled studies which
have compared cognitive performance changes
over the course of disulfiram use.
That very large doses of disulfiram might dam¬
age the basal ganglia is illustrated in 3 case reports
by Laplane et al.'35' In 1 case report, a patient who
took an overdose of 75 disulfiram 500mg tablets,
developed parkinsonian symptoms and low den-
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sity lesions of the basal ganglia, but made a full
recovery. The second case was a young man who
took disulfiram 1 g/day for 8 weeks, and his par¬
kinsonian symptoms had not completely resolved
at 19 months. The third case was a male patient who
had taken disulfiram 500 mg/day for 'several
months' and poor cognitive performance and apa¬
thy were attributed 12 years later by his family to
the period of treatment with the drug. It must be
emphasised that such reports are very rare.
4. Neuropathy
The earliest onset of neuropathy in a patient tak¬
ing disulfiram was 10 days.1361 Most reports place
the onset of symptoms as several months after com¬
mencing treatment and the peak time in the Danish
data'8' was 1 year. The rate of disulfiram-induced
neuropathy in that study can be estimated from the
sales figures quoted for the reporting period of 22
years as about 1 in 15 000 patient years. Except in
1 patient, who was taking disulfiram 250 mg/day
for 30 years,1241 the dosage in patients developing
peripheral neuropathy has been 500 mg/day or
more. Sometimes patients developing neuropathy
have been taking other medications. For example,
in 1 report the patient took the sedatives ethchlor-
vynol and triclofos (trichloroethyl phosphate),
which are substituted alcohols.1371 Only 2 patients
have developed neuropathy at our Edinburgh clinic
after 18 years of treating several hundred patients.
These 2 patients were also taking amitryptiline and
both patients had on their own initiative been tak¬
ing disulfiram 500 mg/day or more because at a
dosage of 200 mg/day the alcohol-disulfiram reac¬
tion was insufficient to be a deterrent.
Systematic investigations of nerve function
have found delayed nerve conduction without clin¬
ical signs of symptoms in patients taking disul¬
firam 250 mg/day but not at a dosage of 125
mg/day. Abnormalities develop during the first 3 to
6 months and seem not to have onset thereafter
(reviewed by Enghusen Poulsen181 and Dupuy et
al.t381).
The clinical presentation of disulfiram-induced
neuropathy is usually a slow onset; however, acute
onset over 24 hours has been described.!391 Recov¬
ery may be complete or partial, with residual symp¬
toms such as foot drop or paraesthesia.
4.1 Pathology
Carbon disulphide is a metabolite of disulfiram
and industrial exposure to this agent has caused
neuropathy with axonal degeneration.1371 The pa¬
thology, as well as the clinical presentation of di¬
sulfiram-induced neuropathy, also resembles that
seen in alcohol-induced neuropathy.
Since 1953, some 11 cases of optic neuropathy,
apparently always reversible, have been de¬
scribed.1381
In summary, 50 years of disulfiram use has es¬
tablished that neuropathy is a risk when higher dos¬
ages of disulfiram are administered, but this ad¬
verse effect is rare and reversible if detected early.
Alerting the patient, even to rare risks, is advisable,
and medical monitoring of patients is required.
5. Less Serious Adverse Effects
In controlled studies, the adverse effects which
occur more frequently in disulfiram recipients than
in control patients are tiredness, headache and
sleepiness. Some patients' spouses report an un¬
pleasant odour on the patient's breath. This is
sometimes described as a garlic smell. However, in
my experience usually the spouses state that they
prefer to have a partner who is abstinent and has
garlic-smelling breath than one who is drinking
and has stale alcohol on the breath.
Skin complaints with disulfiram are rare. How¬
ever, rashes, pruritus and exfoliative dermatitis
have all been described in association with disul¬
firam. Although these skin complaints have been
described as occurring after 1 year of treatment
they tend to occur in the first 2 weeks of treatment.
Early rashes sometimes clear without the need for
treatment or discontinuation of disulfiram; dis¬
placement of nickel could perhaps explain the oc¬
currence of skin complaints in some cases (dis¬
cussed by Enghusen Poulsen et al.181).
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6. The Disulfiram-Alcohol Interaction
Many patients taking disulfiram 200 to 250
mg/day risk experiencing the disulfiram-alcohol
interaction by deliberately ingesting some alcohol.
The severity of the reaction at these dosages varies
from a slight flush to a distressing state of nausea,
headache, dizziness and tightness in the chest. Very
rarely, when larger amounts of disulfiram have
been taken, the reaction has been fatal. These fatal
cases, which only appear in the literature in the first
10 years following disulfiram's introduction, were
examined in detail at the time. The patient de¬
scribed in the report by Becker and Sugarman'40'
had been given 5g of disulfiram over 4 days and
was then given loz of whisky (i.e. about 15g of
alcohol). He experienced a hypotensive collapse,
followed by 4 hours' recovery with some treat¬
ment. The patient then died suddenly of acute right
heart failure. His coronary arteries showed some
atherosclerosis but he had had a prior normal elec¬
trocardiogram (ECG) and exercise test. One of the
cases investigated by Jacobsen'41' died some hours
after the reaction had apparently been at its worst.
In the days when patients were given a 'test' reac¬
tion, ECG studies showed that most patients devel¬
oped some ECG changes during the reaction, usu¬
ally prolongation of the QT interval. Hypotension
is clearly a dangerous aspect of the disulfiram-al¬
cohol reaction. However, hypertension has been
described in a patient who also developed broncho-
spasm (he took 300ml of 4.1% lager after 6 days
treatment with disulfiram 200 mg/day).'42'
The hypotension associated with the disulfiram-
alcohol reaction is greater in older patients,'431 per¬
haps because the elderly have less cardiovascular
tolerance to the toxic reaction. The hypotensive re¬
action is related to the level of acetaldehyde found
in the blood during the reaction. It might be sup¬
posed that when liver function is poor, less acetal¬
dehyde might be produced and therefore the disul¬
firam-alcohol reaction might be less in patients
with liver disease. However, in a detailed study in
13 patients, variations in liver function did not help
to explain the marked variations found in the se¬
verity of the disulfiram-alcohol reaction.'43'
There have been no reports of death due to the
disulfiram-alcohol interaction in recent years.'44'
This may be due to less reporting, but is perhaps
more likely to be due to more cautious dosage and
patient selection than in the early years of use.
Because of the potentially fatal outcome of a
disulfiram-alcohol reaction in a patient with heart
disease or a patient taking hypotensive medication,
disulfiram should normally not be offered to such
patients. This restriction would apply absolutely in
a patient with heart disease who was still in the
chaotic stage of alcohol dependence where there is
mood disturbance and a risk that the patient might
consume alcohol while taking disulfiram.
7. Intentional Overdosage
Patients with alcoholism are at high risk of drug
overdose. Disulfiram overdose with or without the
ingestion of alcohol has occurred on numerous oc¬
casions. Serious results seem to be very rare. Acase
of acute fulminant polyneuropathy following si¬
multaneous ingestion of alcohol and a high dose of
disulfiram has been described in by Rothrock et
al.'45' and a case of basal ganglia damage has al¬
ready been mentioned in section 3.2.'35'
Disulfiram should not be given to a suicidal pa¬
tient. Despite this caveat, there are patients with
alcoholism who take medication overdoses when
they are intoxicated and in practice the use of di¬
sulfiram can significantly help patients not to drink
and thereby reduces or stops this behaviour which
is costly to the patient and to health service re¬
sources.
8. Drug Interactions
Drugs utilising the cytochrome P450 enzyme
system in their oxidative breakdown will show
augmented plasma concentrations and longer elim¬
ination half-lives if the patient is taking disulfiram.
This has been demonstrated for amitryptiline,
imipramine, warfarin and phenytoin and will apply
to other agents such as, for example, benzo¬
diazepines such as chlordiazepoxide and diaze¬
pam, though not lorazepam and oxazepam.'46' A
case of delirium with concomitant administration
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of phenytoin and disulfiram has been described.1471
An interaction with omeprazole has been reported
that resulted in confusion with catatonia, and this
was effect was reproduced at a second supervised
re-exposure to the two drugs.148!
Regarding a possible interaction with paraceta¬
mol (acetaminophen), a review of 2 studies in rats
and 1 in humans suggest that there is no hazardous
reaction.181 Paracetamol overdose is especially poi¬
sonous in overdose in patients with alcoholism and
theoretically disulfiram might reduce its toxic ef¬
fect on the liver.
9. Cancer
A long-term, Swedish follow-up study found
that 14 out of 24 individuals who had died of neo¬
plasm (mainly lung) had received disulfiram treat¬
ment, while among the other 142 deaths only 47
had received disulfiram.1491 This association with
lung cancer was almost certainly spurious: the pa¬
tients with more severe alcoholism in that sample
had received disulfiram, and I believe would also
have been the heavier smokers. An earlier Cana¬
dian mortality study found lung cancer deaths to be
lower in those treated with disulfiram.1501 There is
therefore no evidence that disulfiram causes cancer.
10. Overall Conclusions
Alcohol dependence is associated with high
rates of minor symptoms, numerous serious pathol¬
ogies and an age-related mortality risk 3 times that
of the general population. It is to be expected that
a drug used in the treatment of alcoholism might
become a suspect cause of some of the adverse con¬
sequences of alcoholism, and careful disentangling
of causal and noncausal association is needed, as
for example in the case of cancer and disulfiram.
However, disulfiram can cause fatal hepatitis, al¬
beit very rarely, and can cause neuropsychiatric
and skin complications. Taken together, these
amount to a frequency of 1 case per 200 to 2000
patients per year.181 Serious hepatotoxicity and
neuropathy probably occur at less than 1 case per
10 000 patients per year. This does not place disul¬
firam among the high risk category for adverse
drug reactions.
There is no unanimity among authors or manu¬
facturers on what monitoring should be in place for
early detection of the adverse effects of disulfiram.
It has been recommended that greater vigilance is
needed in female than male patients1381 and the
probable dose relationship for neurological ad¬
verse drug reactions should dictate greater vigi¬
lance whenever the dosage exceeds 250 mg/day.
Clearly, all patients taking disulfiram should seen
regularly by a physician at a minimum time inter¬
val of every 2 weeks for the first 2 months and
monthly thereafter. Patients should be advised that
there are some serious rare adverse effects associ¬
ated with disulfiram treatment and to report any
unexplained symptoms immediately. They can also
be told that disulfiram can be a very helpful aid in
recovery from alcoholism.
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ABSTRACT
Aims To evaluate the ability of a hand-held breath analyser, the Zenalyser® (Zenics Medical), to identify alcohol-
dependent patients receiving disulfiram therapy and to assess the sensitivity and specificity of the instrument at
different lime intervals posl-disulliram dosing. Design Breath samples were taken from two groups of alcohol-
dependent patients, one group on a daily disulliram regimen and one group receiving no disulfiram. The breath sam¬
ples were analysed for the combined concentration of carbon disulphide and acetone produced from the metabolism of
disulfiram. From these data, two reference ranges were prepared and used for sensitivity and specificity assessments.
Setting Breath samples for the reference ranges were obtained from patients at Shelton Hospital. Shrewsbury. Breath
samples used to assess the sensitivity and specificity of the instrument were obtained from patients at the Edinburgh
Alcohol Problems Clinic. Participants Twenty in-patients from Shelton Hospital receiving a daily 200 mg disulfiram
regimen and 20 in-patients receiving no disulfiram. At the Edinburgh Clinic, 54 patients taking a thrice-weekly dis¬
ulliram regimen and 22 patients not on disulfiram. Measurements A total of 489 breath samples from Shelton
Hospital and 391 breath samples from the Edinburgh Clinic were analysed for the combined concentrations of carbon
disulphide and acetone. Findings The breath analyser produced results that distinguished between the disulliram-
treated and untreated groups (P < 0.001). At 1 day post-dose, the sensitivity was 100% and the specificity was 100%.
At 2 and .3 days post-dose, the sensitivities and specificities were 84.6% and 100% and 88.2% and 100%, respectively.
Conclusion The breath analyser can improve the assessment of the compliance status of patients receiving a daily
dose regimen of disulliram. but is less useful for this purpose if disulliram is taken on a thrice-weekly regimen.
Keywords Antabuse, breath test, compliance, disulliram. Zenalyser*.
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INTRODUCTION
Disulfiram has been used as a treatment for alcohol depen¬
dence for more than 50 years 11 ]. The action of disulfiram
is mediated through the production of a metabolite, S-
methyl N.N-dielhyldithiocarbamate sulphoxide [2,3],
which inhibits aldehyde dehydrogenase activity. The rapid
increase in blood levels of acelaldehydeproducedif alcohol
is consumed causes unpleasant systemic reactions, the
severity of which are related to the dose of disulfiram [41.
In addition to its role as a deterrent 15], disulfiram is
now recognized to have other benefits. There are sugges¬
tions in trials that it may be effective as an adjunct to the
anti-craving medication acamprosale [6,7]. It is thought
to have anti-craving properties of its own 18], In random¬
ized. open trials in alcohol-dependent men who have fam¬
ily support, it has been found to be superior to both
naltrexone and acamprosate in preventing relapse |9.10|.
Disulliram has also emerged as a promising treatment for
cocaine addiction [11-13], These studies found that the
benefits of disulfiram combined with cognitive behav¬
ioural treatment were most pronounced for patients who
were not alcohol-dependent. The conclusion was that dis¬
ulfiram. together with cognitive behavioural therapy, was
an effective treatment for the general population of
cocaine-dependent patients, disulfiram apparently exert¬
ing its effect directly on cocaine use rather than through
reducing concurrent alcohol consumption.
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A problem associated with disulfiram therapy in all
its applications is the patients' compliance [14,15].
Using riboflavin labelling of tablets and urine testing, a
US study found that only 20% of patients treated with
disulfiram were fully compliant |16|. A similar picture
emerged in a Danish study [17J. However, controlled
research has shown that when disuliiram is supervised it
is an effective treatment for alcohol-dependent patients
[18-21],
There is no reliable method in routine use to assess
compliance in patients who are unsupervised. In an
attempt to address this a non-invasive breath test has




Forty patients attending the Drug and Alcohol Unit at
Shelton Hospital, Shrewsbury, who had previously been
diagnosed as alcohol-dependent and who had given
informed consent, were asked to blow into a breath
analyser lilted with a disposable mouthpiece. Twenty
in-patients were treated with the following supervised
disulfiram regimen—loading dose, day 1, 800 mg: day 2,
600 mg; day 3, 400 mg: followed by daily maintenance
doses of 200 mg. The time elapse between administration
of disulfiram and the taking of breath samples ranged
from approximately 1 hour and thereafter at intervals
throughout the morning, afternoon and evening up to
16 hours post-dose. Multiple breath samples were
obtained from a further 20 alcohol-dependent patients
who were not receiving disuliiram treatment. The age.
gender, ethnic origin, body mass index and smoker/non-
smoker details were recorded for each patient.
A total of 489 breath test results were used in this
study. A mean breath result was calculated for each
patient. Comparison between groups was made using
generalized linear models (GLM) with robust standard
errors to allow for clustering.
Breath samples were obtained and analysed by the
hand-held breath analyser for the combined concentra¬
tion of carbon disulphide. a known metabolite of disul¬
iiram [22], and acetone, which is known to increase
signiiicantly in patients treated with disulfiram [231.
The method of analysis used to determine the com¬
bined carbon disulphide and acetone concentrations in
the breath was photoionization detection. The concentra¬
tions in breath of carbon disulphide and acetone rise and
fall rapidly after each dose. For example, carbon disul¬
phide reaches peak plasma concentrations 5-6 hours
after dosing and has a breath elimination half-life of 13.3
hours [24].
The results of the 489 breath tests provided the data
from which two reference ranges were established, one
for patients known to be on a daily dose of 200 mg of dis¬
ulfiram and one for patients not on disuliiram treatment.
These ranges are suggested as a guide for the expected
lest results for patients who are compliant with
maintenance daily disuliiram treatment. Their sensitivity
and specificity were tested in Study 2.
In order to compare the method of photoionization
used in the breath analyser with a long-established
method, namely gas chromatography mass spectroscopy
(GCMS). it was decided to conduct a small study to see if
there was a statistically acceptable comparison between
the two analytical systems. Twenty samples of breath,
taken using the BioVOC™ sampler [25], were obtained
from a separate group of 11 supervised alcohol-depen¬
dent patients on a daily maintenance dose of 200 mg of
disulflram and from six alcohol-dependent patients not
on disuliiram. All patients attended the Shelton Clinic.
These breath samples were sent to the Health and Safety
Laboratory, a World Health Organization collaborating
centre, for independent analysis by GCMS. A generalized
linear model (with robust standard errors) was used to
assess the difference between those who had had their
breath analysed by photoionizalion (population 1) and
those who had had their breath analysed by GCMS
(population 2).
Study 2
Seventy-six patients attending the Alcohol Problems
Clinic in Edinburgh who had given informed consent
were asked to provide breath samples. Fifty-lour patients
were receiving a supervised disulliram regimen (meaning
that the drug was taken dispersed in 50 ml of water under
the view of a nurse) consisting of: Monday, 400 mg;
Wednesday, 400 mg; Friday. 600 mg; the remainder, 22.
were not receiving disulfiram therapy. Patients were to be
in 'steady state', having either received their loading dose
or to have been on the supervised regimen and taking dis¬
uliiram for at least the previous week.
Breath samples were taken from groups of these
patients at post-dose intervals of 72 hours (day 3). 48
hours (day 2) and 24 hours (day 1). The two gases, car¬
bon disulphide and acetone, produced in breath as a
result of disuliiram therapy, rise and fall rapidly after each
dose. The prolonged time intervals of 3 and 2 days post-
dose therefore presented the opportunity to test the
breath analyser to the limits of detectable disulfiram
breath metabolites.
The investigator conducting the breath-testing proce¬
dures in Edinburgh did not know which patients were on
disuliiram treatment and which were not. Breath test
results were recorded for each coded patient and data
were sent to Shelton Hospital where, on the basis of the
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breath test results alone, the Edinburgh patients were cat¬
egorized as either on disulliram treatment or not on dis-
ulfiram treatment. The reports were then returned to the
Edinburgh clinic for comparison with the known disul-
iiram status of each patient to calculate the sensitivity
and specificity of the breath analyser for the 3-day, 2-day
and 1-day time intervals.
RESULTS
Study 1
Figure 1 shows that in 489 breath tests obtained from
alcohol-dependent patients, combined carbon disul-
phide/acetone breath concentrations were significantly
higher in the 20 patients who were on a 200-mg daily
maintenance dose of disulfiram than the 20 who were
not receiving disulliram treatment.
The reference range for patients on disulliram treat¬
ment was 374-518 nmol/1, with a mean value of
446 nmol/1. The reference range for patients not on dis¬
ulfiram treatment was 2 7-40 nmol/1, with a mean value
of 33 nmol/1. Those who were on disulliram had a breath
test result 358 nmol/1 higher for every nmol/1 for those
not on disulfiram [P< 0.001, 95% confidence interval
(CI) 284-351 nmol/1].
No Disulfiram Disulfiram
Table 1 summarizes the separate patient groups used
to compare data from the two analytical methods, photo-
ionization and GCMS.
Results of the breath samples that were analysed for
carbon disulphide and acetone are given in Table 2 and
the data compared in box-plots in Fig. 2. There was no
significant difference between the methods (P = 0.47).
Study 2
Breath sample data taken from patients attending the
Alcohol Problems Clinic in Edinburgh are given in
Tables 3 and 4.
A total of 13 patients should have been excluded from
the study, according to the protocol, for the following rea¬
sons: three patients were known to the investigator who
was therefore no longer 'blind', three patients had only
just completed their loading doses and were not yet on
maintenance treatment and seven patients had not com¬
plied with their prescribed disulliram dose regimen dur¬
ing the previous week, so were not at a steady-state. The
main analysis has excluded the data for these patients
Photoionisation, No Disulfiram Photoionisation, Disulfiram
GCMS, No Disulfiram GCMS, Disulfiram
Figure I Box-plot showing medians, quartiles and range of breath
concentrations (nmol/1), analysed by photoionization, in alcohol-
dependent patients receiving no disulfiram (n = 20) versus patients
receiving a 200-mg daily dose of disulfiram (n = 20) at Shelton
Hospital
Table 1 Patient groups used to compare data from photoioniza¬
tion and GCMS analyses.
No disulfiimn (11) Disulfiram (11) Total (a) Method of analysis
Figure 2 Box-plots comparing photoionization and GCMS data
showing medians, quartiles and range of breath concentrations
(nmol/1) in alcohol-dependent patients receiving no disulfiram and
patients receiving 200 mg daily doses of disulfiram at Shelton
Hospital
Table 2 Mean results of breath samples from patients on a 200-
mg daily disulfiram regimen comparing photoionization detec¬
tion (n = 20) versus gas chromatography mass spectroscopy
(n = 11) to measure combined concentrations of carbon disul¬
phide and acetone (l' = 0.47).
Lowerliinit Upper
(based limit (based














Photoionization detection 446 374 518
Gas chromatography/ 431 344 519
mass spectroscopy
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Table J Sensitivity and specificity of the breath analyser instru¬
ment at different time intervals post-disulfiram dose (all patient
analysis). One day post-dose is the intended operating condition
of the instrument.
No. of days No. Sensitivity Specificity
post-dose tested (%) (%)
3 22d 88.0 100
17c
2 2()d 80.0 100
2c
1 12d 100 100
3c
d = patients on disuifirarn: c = controls: patients not on disulfiram.
('per protocol' analysis). However, all patients were
included in the 'all patient' analysis shown in Table 3.
The mean breath test result of the Edinburgh patients
on thrice-weekly disulliram doses were significantly
lower. 121 nmol/1. compared to those of the Shelton
patients. 446 nmol/1, on daily disulfiram doses. This was
a reflection of the different steady-state levels between the
two different regimens employed. The known half-life
periods of disulfiram and its metabolites |24| would pre¬
dict this observation. Consequently, Edinburgh patient
results that were above the Shelton Clinic 'no disulliram'
reference range of 40 nmol/1 (Fig. 1) were scored as pos¬
itive for disulfiram. This method of assessment produced
no false positives (specificity of 100% for 3-day, 2-day and
1-day intervals). However, there were two false negatives
at the 3-day and 2-day intervals (sensitivities 88.2% and
84.6%, respectively, for the per protocol sample). Sensi¬
tivity at an interval of 1 day was 100%.
DISCUSSION
The results of the first part of this study indicate that the
breath analyser is able to distinguish unequivocally
between patients who are compliant, with a daily regimen
of 200 mg of disulfiram from those alcohol-dependent
patients who are not on disulfiram therapy. This result
was replicated in Study 2 for the 1-day interval. (The
exclusion of patients who were found not to meet protocol
definitions did not affect the results materially; in partic¬
ular, the sensitivity and specificity at 1-day intervals
remained at 100%: see Table 3.)
The urine riboflavin test, that has been used as a
method to assess compliance with disulfiram. has been
reported to have a sensitivity and specificity of 86% and
82%. respectively, when the test was performed by medi¬
cal personnel and 82% and 94%, respectively, when per¬
formed by paramedical personnel [26]. A further study
using a urinary riboflavin tracer found the inter-rater
reliability of the test to range from 73% to 95%
Table 4 Sensitivity and specificity of the breath analyser instru¬
ment at different time intervals post-disulfiram dose (per proto¬
col analysis).
No. of days No. Sensitivity Specificity
post-dose tested (%) (%)
3 15d 88.2 100
17c
2 lid 84.6 100
2c
1 12d 100 100
3c
d = patients on disulfiram; c = controls; patients not on disulfiram.
(mean = 88%) agreement between two judges [27]. The
breath analyser is more sensitive and more specific than
the riboflavin test; it produces results more rapidly and is
more hygienic than the urinary riboflavin test procedure.
fn Study 2 (Table 4), two false negatives were identi¬
fied after a time interval of 3 days post-disulfiram ttnd two
false negatives after 2 days post-disulfiram. it is possible
that there were no measurable metabolites present in the
patients' breath after the elapse of these lime periods, par¬
ticularly on consideration thai the breath elimination
half-life of carbon disulphide is only 13.3 hours [24J.
Alternatively or additionally the individuals may have
been fast metabolizers. The latter possibility is supported
by the observation that there is a wide inter-individual
variation of plasma levels of disulfiram and its metabolites
[28].
There were no false positive results. At 1 day post-dose
the sensitivity was 100% and the specificity was 100%.
One day post-dose is the intended operating condition of
the breath analyser and, because of the rapid decline in
detectable breath metabolites, patients on a daily dose
regimen who miss one or more daily doses might produce
results that indicate non-compliance with a prescribed
daily 200-mg dose regimen.
It is important not only to be able to assess the patient
who is non-compliant objectively but also, and far more
importantly, to have a breath test that identifies the gen¬
uinely compliant patient who is at last able to demon¬
strate and confirm to the clinician that they are indeed
adhering to their prescribed therapy. This provides helpful
and important information to the clinician and also pro¬
vides the patient with the opportunity to have their com¬
pliance verified.
The breath test is expected to improve compliance
because patients on prescribed disulfiram therapy would
have no excuse for not recording a positive breath test.
Patients who realize that they are to be tested are
expected to show a more positive attitude towards adher¬
ence to disulfiram therapy.
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The breath test can be administered at the discretion
of the clinician. The test can be performed at a convenient
venue for the patient: for example, at the clinic, the local
pharmacy, the work-place or at home. The test interval
could be chosen by the clinician with a telephone call or
e-mail message to the patient for testing on a chosen date.
Once informed of this random monitoring strategy,
it would be difficult for the patient to modify the dose
regimen.
The breath analyser approach to compliance monitor¬
ing has potential applications, particularly in the vital
role of objectively assessing alcohol-dependent individu¬
als at risk with their jobs. There are opportunities to mon¬
itor expensively trained people who. by the nature of their
addiction, could jeopardize the lives of others if they are
not abstinent from alcohol.
For example, individuals from backgrounds such as
medicine, transport and the armed forces whose non¬
compliance and subsequent alcohol consumption could
prove hazardous to others, notwithstanding the expen¬
sive costs incurred during the periods when they are
excluded from their professional work because drinking is
still suspected. The breath analyser incorporates an elec¬
tronic data-logging device that enables daily, weekly or
monthly sets of data to be recorded and downloaded by
the clinician for computer review. Expensively trained
individuals who need to be monitored on a daily basis
over long-term periods could be provided with the instru¬
ment for self-testing over the required time. These data
could be monitored daily and as long as compliance levels
were maintained, the expensively trained individual
could be engaged in full employment.
A further application of objective disulflram compli¬
ance monitoring could be made in keeping offenders con¬
victed of alcohol-related crimes out of prison. Supervised
disulflram has already been recommended as an effective
option in this respect [29,30], Disulflram treatment, as
an alternative to serving a custodial sentence, could
potentially reduce the serious problem of overcrowding in
prisons and bring about major cost-savings for the prison
service. Similarly, courts require high quality informa¬
tion in child-care cases when making decisions about
returning a child to the care of a parent with alcohol
dependence. The breath analyser provides information
that can assist clinicians in monitoring high-risk situa¬
tions. Because it increases the degree of certainty regard¬
ing a patient's compliance with treatment, any serious
restrictions (for example, loss of employment or removal
of a child from a parent) can be considered with more
confidence.
The ability of the instrument to identify rapidly those
patients on and those not on disulfiram therapy coupled
with an analytical performance comparable to an estab¬
lished GCMS method suggests that this non-invasive
monitoring system would provide an important and use¬
ful tool in the management of alcohol dependent patients.
It has yet to be established whether a patient could test
positive (i.e. compliant) on the basis of taking one large
dose, on the day of testing or the day before, and deceive
the tester. A further study will examine this. The effect of
introducing the breath analyser to monitor compliance
could be made by comparing standard supervised and
daily unsupervised disulfiram, and this will be a useful
subject for a further study.
The true potential of objectively monitoring disulflram
treatment with confidence may now bring about oppor¬
tunities that have not been possible since the introduc¬
tion of disuliiram more than 50 years ago.
CONCLUSION
The hand-held breath analyser can, within 10 seconds,
distinguish between patients who are compliant with a
daily maintenance dose of disulflram and those who. for
whatever reason, are not compliant. It may enable the
more effective use of disulflram in those patients so
treated.
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Abstract — The opioid antagonist, naltrexone, is reported, in single centre studies, to improve the clinical outcome of individuals with
alcohol dependence participating in outpatient psychosocial programmes. This is the first multicentre controlled study to evaluate the
efficacy and safety of naltrexone as adjunctive treatment for alcohol dependence or abuse. Patients who met criteria for alcohol depend¬
ence (n = 169) or alcohol abuse (n = 6) were randomly assigned to receive double-blind oral naltrexone 50 mg daily (n = 90) or placebo
(« = 85) for 12 weeks as an adjunct to psychosocial treatment. The primary efficacy variable was time to first episode of heavy drinking;
secondary efficacy assessments included time to first drink, alcohol consumption, craving, and changes in the serum biological markers
gamma-glutamyl transferase (GGT), and aspartate and alanine aminotransferases. Compliance was assessed by tablet counts and, in the
naltrexone-treated group, by measurement of urinary concentrations of 6-P-naltrexol. Forty-nine (58%) patients randomized to placebo
and 53 (59%) randomized to naltrexone did not complete the study. In intention-to-treat analyses, there was no difference between
groups on measures of drinking. The median reduction from baseline of serum GGT (P < 0.05) and the reductions in alcohol craving
(Obsessive and Compulsive Drinking Scale: OCDS) were greater in the naltrexone group (P < 0.05), from approximately half-way
through the study. Of 70 patients (35 placebo; 35 naltrexone) who met an a priori definition of compliance (80% tablet consumption,
attendance at all follow-up appointments), those allocated to naltrexone reported consuming half the amount of alcohol (P < 0.05), had
greater median reduction in serum GGT activity (P < 0.05), and greater reduction in alcohol craving (OCDS total score: P < 0.05; Obses¬
sive subscale score: P < 0.05), compared to patients in the placebo group. Use of naltrexone raised no safety concerns. Naltrexone is
effective in treating alcohol dependence/abuse in conjunction with psychosocial therapy, in patients who comply with treatment.
INTRODUCTION
Psychosocial treatment programmes for alcoholism have only
limited success and pharmacotherapy may help to prevent early
relapse. Preclinical and clinical findings support the hypo¬
thesis that alcohol stimulates endorphin activity and reduces
deficiencies in endogenous opioid transmission [reviewed by
Froehlich and Li (1993) and Volpicelli et al. (1995a)].
The orally administered opioid antagonist, naltrexone, was
shown in randomized, double-blind, placebo-controlled clin¬
ical trials to reduce the relapse rate of individuals with alcohol
dependence participating in outpatient psychosocial pro¬
grammes (O'Malley et al., 1992; Volpicelli et al., 1992) with
moderate effect sizes of 0.42 and 0.60 respectively (Volpicelli
et al., 1995c). Further studies have replicated this (Volpicelli
et al., 1997; Anton et al., 1999). Another opioid antagonist,
nalmefene, appears to have a similar action in the treatment of
alcohol dependence (Mason et al., 1994, 1999).
This paper reports the first multicentre study, and the largest
study to date, of naltrexone's efficacy and safety in alcohol de¬
pendence and abuse and differs from previous studies in offering
generally less intensive psychosocial support, which varied
between centres, thus perhaps better reflecting routine clinical
practice.
"Author to whom correspondence should be addressed at: Department of
Psychiatry, Edinburgh University, Royal Edinburgh Hospital, Edinburgh
EH10 5HF, UK.
PATIENTS AND METHODS
The study was conducted over a 13-month period at six sites
in the UK, which were five alcohol treatment units and one
academic department of hepatology with a special interest in
alcohol-related illness.
Patient selection
Men and women, aged 18-65 years, who met DSM-III-R
(American Psychiatric Association, 1987) criteria for alcohol
dependence or alcohol abuse were eligible for the study.
Patients had to be abstinent from alcohol for 5-30 days before
entry into the study and enrolled in, or about to enter, an out¬
patient alcohol rehabilitation treatment programme or routine
out-patient follow-up. Patients were excluded if they had psy¬
chiatric conditions requiring medication, polysubstance abuse,
serum aspartate (AST) or alanine aminotransferase (ALT)
activities greater than three times the upper reference range, a
total serum bilirubin concentration greater than twice the upper
reference range, or significant physical illnesses such as, for
example, ischaemic heart disease, chronic obstructive airways
disease or insulin-dependent diabetes mellitus. Patients using
opioids in any form, other opioid antagonists, disulfiram,
acamprosate, lithium salts, antidepressants, antipsychotics or
benzodiazepines except as a bedtime hypnotic, were also ex¬
cluded. All patients provided written informed consent. The
study was conducted in accordance with world-wide standards
for Good Clinical Practice (GCPs) and conformed to accept¬
able ethical standards as outlined by local requirements and
the Declaration of Helsinki.
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Randomization and treatment
Patients with alcohol dependence or abuse were randomized
to receive either naltrexone 50 mg or a placebo preparation,
identical in appearance, once daily for up to 12 weeks in ad¬
dition to psychosocial treatment. Randomization was stratified
according to diagnosis based on DSM-III-R criteria (alcohol
dependence or alcohol abuse) with equal assignment of placebo
and naltrexone in each stratum. Each study centre entered the
trial patients into its usual psychosocial treatment programme;
the type and amount of treatment provided was not subject to
protocol constraints. Patients were free to attend alternative
facilities, such as Alcoholics Anonymous or other support
groups. At the point of giving consent, patients were informed
that naltrexone had been shown in previous studies in alcohol¬
ism treatment centres to reduce craving for alcohol and alcohol
consumption. After screening and enrolment visits, patients
returned for study visits every 2 weeks during the 12-week
treatment period.
Assessments
The primary goal of each patient's treatment was to support
abstinence from alcohol and to reduce the likelihood of
relapse to heavy drinking. The primary efficacy variable was
the time to first episode of heavy drinking, as assessed by the
Time-Line Follow-Back (TLFB) method (Sobell and Sobell,
1992). An episode of heavy drinking was defined as five drinks
on a single occasion for men and four drinks for women. (One
'drink' is defined as that amount of beverage containing 13 g
ethanol, corresponding to the USA tradition, which was used
in this study to permit comparison with the previous naltrexone
trials, rather than the UK unit system where 1 'unit' is that
amount containing 8 g ethanol.) This was chosen as the pri¬
mary efficacy variable, first, because it has clinical meaning,
in that it is heavy drinking which causes problems, and, second,
because it was the outcome variable used in the two previous
studies (O'Malley et al., 1992; Volpicelli et al., 1992). Second¬
ary effectiveness measures included time to first drink, overall
alcohol consumption, number of abstinent days, craving as
measured by the Obsessive-Compulsive Drinking Scale
(OCDS; Anton et al., 1995, 1996), a physician rating of global
severity ('need for treatment') from an abbreviated version of
the Addiction Severity Index (aASI; McLellan et al., 1991),
and changes in serum gamma-glutamyl transferase (GGT),
ALT and AST (Rosalki and Rau, 1972; Chick et al., 1981;
Salaspuro, 1986). Urine was collected at each visit. Safety was
assessed by observed or volunteered adverse clinical events
(ACE) and laboratory test results. All clinical laboratory
determinations were performed by a central laboratory. (The
markers carbohydrate-deficient transferrin and mean red
corpuscular volume were not used.) The above measurements
were made at baseline and repeated at 2, 4, 6, 8, 10 and
12 weeks.
Compliance with medication was assessed by counting
returned tablets. For the naltrexone group, compliance was
also assessed by identification of the presence in urine of
6-p-naltrexol, a metabolite of naltrexone with a half-life of
14-18 h (Cone et al., 1974). Urinary 6-p-naltrexol concen¬
tration of 1 pg/ml was set as the limit for detecting those who
actually took their dose during the preceding 24 h (Pieniaszek
et al., 1996). No comparable biological marker of placebo
compliance was used.
Statistical analysis
Based on the assumption that 50% of patients treated with
placebo relapse to heavy drinking, compared to 25% of patients
treated with naltrexone during a 12-week period, 75 patients
per treatment arm were needed to obtain 80% power when
testing at the 5% significance level. All statistical analyses were
performed using the Statistical Analysis System package,
version 6.08 (SAS Institute, Cary, NC, USA). A result was
deemed statistically significant when the statistical test
yielded a two-tailed probability (P-value) of <0.05. Baseline
was defined as the last observation obtained prior to initiation
of study medication. Endpoint was defined as the last obser¬
vation available during the 12-week treatment period for each
patient.
Survival analysis methods (Kaplan-Meier estimates and
log-rank test) were used to analyse the time-to-event variables.
For continuous variables, differences in means between groups
were tested using an analysis of variance model (ANOVA).
Changes from baseline were tested within each treatment
group using a paired r-test. Biochemical test results were not
normally distributed, so median changes from baseline were
compared between treatment groups using the Kruskal-Wallis
test. Discrete variables were compared between treatments using
X2-test or Fisher's exact test. Adverse clinical events were
classified and summarized according to World Health Organ¬
ization Adverse Reaction Terms (WHOART; WHO, 1992)
Initial analyses were carried out on an intention-to-treat
basis, including all patients who received at least one dose of
study medication. Drop-outs were assigned to the heavy-
drinking category. The analysis plans detailed in the study pro¬
tocol identified a priori that compliance with study medication
would be used to identify subgroups of patients for further an¬
alyses. For these analyses, a patient was considered compliant
if at least 80% of the scheduled medication was consumed, as
documented on the basis of tablet counts, and all appointments
had been attended.
RESULTS
Of the 175 patients entering the trial, 85 were randomized
to receive placebo and 90 to receive naltrexone (Fig. 1). No
significant differences between the naltrexone and placebo
groups were observed for any baseline variable (Table 1).
Overall, patients tended to lack social support: only 40% were
married or in a permanent relationship, 26% lived alone and
only 27% were in full-time employment. During the week
prior to study entry, the mean attendance at an intervention
session or a 12-step meeting was 3.1 (±5.5) times for the
naltrexone group and 2.4 (±3.2) times for the placebo group.
Forty-nine (58%) patients randomized to placebo (P) and
53 (59%) randomized to naltrexone (ntx) discontinued the
study before the end of the 12-week treatment period because
of: adverse clinical events (P 11, ntx 13), protocol violations
including starting other medicines (P 12, ntx 18), withdrawal
of consent (P 9, ntx 3), poor compliance (P 1, ntx 2) and loss
to follow-up (P 16, ntx 17).
Of the 73 patients (P 36, ntx 37) who completed the study,
70 (P 35, ntx 35) attended all follow-up appointments
and showed 80% compliance based on tablet counts. In this
completed and compliant subgroup, patients randomized
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Completed study
n = 36 (42%)
Attended all appointments
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Attended all appointments
and took >80% of tablets
n = 35 (41%)
to naltrexone or placebo were still matched with respect to
demographic and baseline characteristics (Table 1).
Analysis of urinary concentrations of 6-p-naltrexol revealed
that naltrexone patients who discontinued the trial during the
first 6 weeks of the study had substantially higher rates of non¬
compliance with study medication than those who remained in
treatment for more than 6 weeks. Thus, for example, at the
2-week visits, 78 urine specimens were tested and 40% of
those who completed 6 or more weeks in the study were com¬
pliant with their naltrexone medication, compared to only 5%
of those who subsequently dropped out before the 6th week.
Efficacy results: intention-to-treat analyses
Alcohol consumption. Alcohol consumption data for
patients who received at least one dose of randomized study
medication were available for 164 patients (79 placebo
and 85 naltrexone) for some or all of the 12-week study
period. Overall, no significant differences between treatments
were observed in the time to first heavy drinking episode or
the time to first drink (Fig. 2). Complete abstinence for the
entire study period was achieved by 19% of placebo patients
and 18% of naltrexone patients. The number of drinks
consumed during the last 4 weeks of the study was lower in
the naltrexone group (mean ± SEM: 49 ± 12.0) than in the
placebo group (mean ± SEM: 86 ± 15.4) but this difference
was not significant.
Biochemical markers. In the 76 patients for whom more
than baseline biochemical test results were available, sig¬
nificant decreases in serum GGT activities were observed in
both treatment groups at all time points. In these patients, there
had been no difference at baseline in median serum GGT, AST
or ALT activities between the treatment groups. The median
reduction in serum GGT activity for the naltrexone group
was significantly greater than in the placebo group at week 8
(P < 0.05). Reductions in serum AST and ALT activities did
not discriminate between the groups (data not shown).
Craving. Significant mean decreases from baseline in total
OCDS score were observed at all time points in the naltrexone
group, compared to a significant decrease from baseline
only at week 6 for the placebo group. The reduction in total
OCDS score in the naltrexone group was significantly greater
(P < 0.05) than in the placebo group at weeks 10 and 12.
Physician's global assessment. The alcohol component of
the aASI assesses the patient's 'need for treatment for alco¬
holism' as a global measure of severity. A significantly greater
percentage of patients in the naltrexone group than in the
placebo group (64% versus 45%; P < 0.05) were characterized
as 'needing less treatment' at week 12, than at baseline.
Table 1. Demographic and alcohol history
All patients Completed and compliant
Placebo Naltrexone Placebo Naltrexone
Variable (n = 85) (n = 90) (n = 35) (n = 35)
Age (years; mean ± SD) 43.9 ± 9.7 43.1 ± 8.3 43.9 ± 11.0 43.9 ± 8.0
Gender: male (%) 66 (78) 65 (72) 27 (77) 27 (77)
Length of drinking (years; mean ± SD) 25.9 ± 10.6 22.9 ± 8.7 25.4 ± 10.8 22.2 ± 8.8
Average intake (drinks/day)a 10.3 ± 7.5 10.1 ±9.1 9.2 ± 5.0 11.4 ± 12.3
(mean ± SD)
Abstinence before study initiation 11(0-30) 10 (0-30) 11 (0-30) 11 (3-29)
(days; median, range)b
DSM-III-R criterion: alcohol dependence (%) 82 (97) 87 (97) 35 (100) 34 (97)
Alcohol abuse (%) 3(4) 3(3) 0 1 (3)
Serum GGT (U/l; median) 36 45 54 52
(reference range 7-64)
Serum ALT (U/l; median) 24 26 26 28
(reference range 8-48)
Serum AST (U/l; median) 22 22 34 27
(reference range 6-37)
Not married/cohabiting (%) 52 (59) 53 (59) 18 (52) 16(49)
Living alone (%) 26 (31) 20 (22) 8 (23) 6(17)
Employed full time (%) 18 (21) 29 (32) 9(26) 13 (37)
■'During the 90 days preceding the first day of the study, based on the Time-Line Follow-Back method.
bThe actual range differs from that specified in the protocol (5 to 30) because of protocol violations.
ALT, alanine aminotransferase; AST, serum aspartate; GGT, gamma-glutamyl transferase.
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Fig. 4. Mean alcohol consumption during periods between assessments:
completed and compliant patients.
Bars show means + SE. +P < 0.05.
Efficacy results: completed and compliant patients
Alcohol consumption. In the completed and compliant sub¬
group, there was no significant advantage of naltrexone over
placebo in time to first episode of heavy drinking or time to first
drink (Fig. 3). The naltrexone patients consumed, on average,
half the total amount of alcohol consumed by placebo patients,
during weeks 4-8 (P < 0.05) and cumulatively over the whole
study (P < 0.05) (Fig. 4). The number of non-abstinent days
accruing in each of the 4-week periods is shown in Fig. 5.
There was a trend suggesting that naltrexone patients had
fewer non-abstinent days (i.e. more days of abstinence) than
placebo patients but this did not reach significance.
Fig. 5. Mean number of non-abstinent days during periods between
assessments: completed and compliant patients.
Bars show mean + SE. The differences are not significant.
Baseline Week 4 Week 8 Week 12 End-point
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Fig. 6. Median, and median change from baseline, in serum gamma-
glutamyl transferase (GGT) activities (U/l): completed and compliant
patients.
* Statistically significant change from baseline P < 0.05; +statistically
significant difference between groups P < 0.05.'Endpoinf is the last
result available for each patient.
Biochemical markers. The median decrease in serum GGT
activity in the naltrexone group was greater than that in the
placebo group at all time points (P < 0.05) (Fig. 6). Median
reductions in serum GGT activity ranging from 19 to 25 U/l
were observed for the naltrexone group throughout the study
period, compared to median reductions ranging from 5 to
8 U/l in the placebo group. Significant decreases from baseline
in serum GGT activity were observed at all time points for the
naltrexone group and at weeks 4 and 8 for the placebo group.
A similar trend which reached significance at 12 weeks, of
a greater median reduction in the naltrexone patients than
NALTREXONE IN THE TREATMENT OF ALCOHOL DEPENDENCE 591
placebo patients, was seen for serum AST, but not for serum
ALT, activities (data not shown).
Craving. There were significant mean decreases from
baseline in total OCDS scores in the naltrexone group at all
visits. No significant mean changes from baseline in total
OCDS scores were observed in the placebo group. Significant
between-group differences in total score favouring naltrexone
were observed at all time points, except week 6 and over
the whole 12-week study period (P < 0.01) (Fig. 7). Because
there is a component of the total score which measures alcohol
consumption itself, a separate analysis of the scale without the
consumption items, the obsessive subscale, was conducted.
There was a significantly greater reduction in the obsessive
subscale in the naltrexone patients than the placebo patients
over the 12-week period (P < 0.01) (Fig. 7).
Physician's global assessment. Global benefit of naltrexone
was observed in the alcohol component of the aASI: a signifi¬
cantly greater percentage of patients in the naltrexone group
than in the placebo group (69% versus 43%; P < 0.05) were
characterized as 'needing less treatment' at week 12 than at
baseline.
Safety
Safety results were based on data for all patients who
received at least one dose of study medication (P n = 83; ntx
n = 90). The most frequently reported adverse clinical event
was headache (P 51%, ntx 44%) (Table 2). Significant differ¬
ences between treatments were observed for the incidences of
nausea, pain, dyspepsia and anorexia. Dyspepsia occurred
more frequently in the placebo group than in the naltrexone
group. Nausea, pain and anorexia occurred more frequently
in the naltrexone group. Although events classified by the
non-specific WHOART term 'pain' occurred more often in
the naltrexone group, incidences of other 'pains' such as
Table 2. New-onset adverse clinical events with an incidence of >10%: all patients
Placebo Naltrexone
Adverse clinical event n (%) n (%)
Total no. of patients evaluated' 78 85
Total no. of patients with an ACE 71 (91) 81 (95)
Headache 40 (51) 37 (44)
Upper respiratory tract infection 17 (22) 29 (34)
Nausea 13 (17) 27b (32)
Insomnia 15 (19) 14 (16)
Vomiting 11 (14) 15 (18)
Depression 13 (17) 13 (15)
Somnolence 7 (9) 15 (18)
Dizziness 11 (14) 10 (12)
Diarrhoea 9 (12) 11 (13)
Anorexia 1 (1) 8b (9)
Abdominal pain 9 (12) 11 (13)
Arthralgia 12 (15) 8 (9)
Anxiety 7 (9) 12 (14)
Fatigue 9 (12) 10 (12)
Back pain 10 (13) 9 (ID
Pain 3 (4) 13b (15)
Coughing 3 (4) 9 (11)
Dyspepsia 9 (12) 2b (2)
'Excludes patients who withdrew before adverse clinical events could be reported.
bSignificant difference between treatment groups, P < 0.05. In addition to the events in this table, the incidence of anorexia was significantly higher in
the naltrexone group than the placebo group (9% vs 1%).
ACE, adverse clinical events.
14 T
Placebo (n = 35)
Total score
—H— Naltrexone (n = 35)
Total score
—A— Placebo (n = 35)
Obsessional scale






Fig. 7. Mean Obsessive-Compulsive Drinking Scale (OCDS) total score
and obsessive subscale score: completed and compliant patients.
LP <0.01.
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headache, back pain, abdominal pain, and arthralgia were
comparable in the two groups.
Eleven (14%) placebo patients and 13 (15%) naltrexone
patients discontinued the study because of adverse clinical
events, the most common being nausea. One placebo patient
discontinued the study because of deteriorating liver function
presumed to be alcohol-related. There were no deaths during
the study. No scale of depressive symptoms was used in this
study. Depression did not emerge as commoner in patients
taking naltrexone.
DISCUSSION
An attrition rate in excess of 50% within the first month
of treatment for alcohol is common (Stark, 1992). The dis¬
continuation rate in the present study was higher than in the
previously published naltrexone trials. High discontinuation
rates have been a feature of multicentre alcoholism treatment
studies in the UK (e.g. Chick et al., 1992, 2000).
As in many currently published controlled trials, no attempt
was made to assess whether the blindness of patients or staff
to the treatment allocated had been maintained (Moncrieff and
Drummond, 1998). In the present study, the comparability of
the incidence of side-effects makes it unlikely that side-effects
would have significantly disturbed the blindness.
The analyses of the completed and compliant subpopulation
in this study were performed to elucidate more clearly the
treatment effects of naltrexone in patients motivated to stay in
treatment and to comply with study medication, the rationale
being that naltrexone will only benefit patients who take it.
In the subgroup defined by full attendance and tablet count,
greater reduction in total alcohol consumption reported by
the naltrexone patients was corroborated by improvements in
serum GGT activities, improvements in physicians' global
rating of alcoholism severity, and by greater reduction in
craving.
However, a statistically significant advantage in the primary
efficacy variable, time to first heavy drinking episode, was not
seen, although there was a trend in favour of naltrexone. Thus,
the study has not replicated the results of the previous clinical
trials. One possible explanation could be that the psychosocial
treatment offered at these six UK sites was in general much
less intensive and was not specified, compared to that offered
in previous studies. (This was not intended in the design, but
resulted from the real-life National Health Service environ¬
ment of the research.) In samples of patients where few are
likely to sustain complete abstinence, structured coping skills
training possibly interacts with the use of naltrexone to help
prevent major relapse. This is suggested in the studies of
O'Malley et al. (1992) and Anton et al. (1999) and the pre¬
liminary report of a Swedish study (Balldin et al., 1997), and
the nalmefene study of Mason et al. (1999). It could, however,
also be argued from this UK study that, at least in compliant
patients, some benefits from naltrexone can be seen with
varied and non-intensive psychosocial treatment.
Our findings with respect to compliance are similar to those
seen previously in studies in the USA. O'Brien et al. (1996)
found that the size of the naltrexone treatment effect among
compliant patients was substantially greater than that in the
less compliant. In a different outpatient population, Volpicelli
1 et al.
et al. (1997) found large naltrexone treatment effects for
highly compliant subjects, but no naltrexone effect for the less
compliant.
Mechanism of action
Our result, that in compliant patients naltrexone helped
reduce alcohol intake, without an unequivocal reduction in
number of drinking days, would be consistent with the hypo¬
thesis that naltrexone reduces the loss of control which
some dependent drinkers experience when they start to drink
(Volpicelli et al., 1995b) or that naltrexone reduces the amount
consumed by reducing the euphoric effect or inducing an
aversive effect of drinking alcohol (e.g. Swift et al., 1994;
Davidson et al., 1999). Although all patients recruited to the
study had been advised to abstain, less than 20% did so. Many
of the therapists at the centres where the studies were carried
out would have been prepared to continue working towards a
modified goal of 'safer drinking' with some patients who gave
up aiming for total abstinence, and perhaps naltrexone helped
here.
Craving appeared to be reduced by naltrexone, and yet
abstinence was not enhanced. At first, this appears to be a dis¬
crepancy. However, craving may result from heavy drinking
as well as being a stimulus to start drinking. Patients taking
naltrexone drank less heavily and this could be a partial ex¬
planation of why they reported less craving.
In summary, efficacy, as defined in the protocol's primary
measures, was not demonstrated in the whole study popu¬
lation. In those patients who complied with medication and
attended appointments, naltrexone over a period of 3 months
helped patients reduce their alcohol consumption, reduced their
perceptions of craving and improved their global recovery
as assessed by their physician, and was accompanied by a
reduction in serum markers of alcohol consumption.
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Abstract — A 6-month randomized controlled study of acamprosate versus placebo in preventing relapse following withdrawal from
alcohol was undertaken in 20 centres throughout the UK. Patients diagnosed as alcohol dependent and detoxified within tho preceding
5 weeks were randomly assigned to treatment with either acamprosate (A) 666 mg three times/day or identical placebo (P). A total of
664 patients were screened; 581 were entered into the treatment phase. One-third were episodic drinkers, 84% were male, 44% were
unmarried and 48% were unemployed. Medication was first taken on average 24 days after the start of detoxification; 32% of patients
had already relapsed by this time. The 6-month study period was completed by 35% of patients; adverse events led to withdrawal of a
further 14% (A) and 9% (P) respectively. Compliance was poor in that, by the end of the second week, only 57% of patients were
judged to be taking at least 90% of their tablets. The mean total of abstinent days achieved was 77 (A) and 81 (P). Complete abstinence
for 6 months was achieved by 12% (A) and 11% (P); drinking remained within controlled limits in a further 3% (A) and 6% (P). An
effect of acamprosate on consumption was not seen when subgroups, including those defined by the Lesch typology, were analysed
separately. However, the mean percentage reduction in craving for alcohol measured on a visual analogue scale was greater in the
acamprosate, than placebo, patients at week 2 and week 4 (P < 0.001) and the mean decrease in the Hamilton Anxiety score at the 4th
week was greater in the acamprosate than placebo patients (P = 0.017). In comparison with other published trials of acamprosate,
patients started study medication after a longer time following detoxification, had more often recommenced drinking before medication
was started and had a higher drop-out rate, and this might have contributed to the lack of a treatment effect in this study.
INTRODUCTION
The rapidity of relapse in alcohol-dependent patients who
have sought assistance to withdraw from alcohol is a cause for
concern. Admissions of patients diagnosed as alcohol-
dependent is placing an increasing burden on acute medical
services (Chick, 1997). Advances in understanding the neuro¬
pharmacology of alcohol dependence and the rapid reinstate¬
ment of the syndrome after abstinence have supported hopes
that pharmacotherapy may aid recovery (Chick and Erickson,
1996).
There is evidence that acamprosate, calcium acetyl homo-
taurinate, can lengthen time to relapse, reduce drinking days,
and increase the percentage attaining complete abstinence
among alcohol-dependent patients who have accepted treat¬
ment for their condition (see e.g. Sass et al., 1996; Whitworth
et al., 1996; Geerlings et al., 1997; Pelc et al., 1997; Poldrugo,
1997). Homotaurinate is a naturally occurring structural
analogue of y-aminobutyric acid (GABA); acamprosate is a
synthetic derivative. This compound crosses the blood-brain
barrier, modulates GABA transmission (Daoust et al., 1992),
decreases postsynaptic potentials in the neocortex, perhaps by
affecting excitatory amino acid (/V-me thy I -D -aspartate: NMDA)
receptors (Zeise et al., 1993), and diminishes voluntary alcohol
intake in alcohol-preferring rats (Boismare et al., 1984;
Le Magnen et al., 1987a; Gewiss et al., 1991). Evidence by
Lamblin et al. (1993), Rassnick et al. (1992) and other studies
reviewed by Tsai et al. (1995) implicates glutamate neuro¬
transmission, and NMDA modulation thereof, in the GABA
system in alcohol-seeking behaviour. Tsai et al. (1998)
assessed glutamatergic neurotransmission and oxidative status
*Author to whom correspondence should be addressed.
in alcohol-dependent patients after acute alcohol withdrawal
and 4 weeks later and found persistent abnormalities in
cerebrospinal fluid. Littleton (1995) has proposed that one of
acamprosate's actions, mediated by its effects on calcium
channels as well as on the NMDA receptors in the glutamate
system, is to suppress conditioned alcohol withdrawal craving.
Acamprosate administration to animals does not give rise to
a dependence syndrome (Grant and Woolverton, 1989), nor
does it exacerbate either acute or chronic ethanol toxicity in
rats (Le Magnen, 19871?). When alcohol-dependent patients
who have been abstinent while taking acamprosate cease
taking the drug they do not experience a rebound of craving or
alcohol misuse (Whitworth et al., 1996). The drug thus has no
abuse potential.
This paper reports the results of the first study into the
safety and efficacy of acamprosate in a sample of patients
attending specialized treatment centres in the UK. Its design
differed in some respects from previously reported trials,
including its use of a diary card on which patients were to
record on a daily basis any alcohol consumed instead of rely¬
ing on memory at assessment visits. Some preliminary data




This work was undertaken in 20 UK clinics during 1991—
1993 as a 6-month randomized controlled study of acamprosate
versus an identically presented placebo. The clinics were
connected with psychiatric services and a general hospital,
including both teaching hospitals and district general
hospitals. It was intended that the medication would be used
I 76
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as an adjunct, not an alternative, to the clinic's usual psycho¬
social out-patient treatment programme. No check on blind¬
ness of patients or assessors was made; in other ways this
study design followed criteria recommended by Moncrieff and
Drummond (1998) and the Plinius Maior Society (1994).
A recruitment examination and assessment was conducted
within 5 weeks of the end of detoxification (defined as at least
5 days of abstinence). Detoxification may have been carried
out on an in-patient or an out-patient basis. The length of this
'pre-baseline period', up to 5 weeks, was chosen, because
some patients to be recruited would be undergoing in-patient
treatment of about 4 weeks duration. There was then a 'wash¬
out' period of 1 week, during which patients had to be free
of benzodiazepines and were instructed not to drink alcohol.
Patients were then reassessed and, using randomization in
blocks of eight, allocated to treatment with either active
medication, acamprosate 1998 mg (two tablets of 333 mg each
three times per day), or identically presented placebo (also
two tablets three times per day). Assessments were made after
1 week on medication, then at 2-weekly intervals, and later at
4-weekly intervals for a total of 24 weeks. Medication was
stopped and patients then reassessed 4 weeks later to monitor
the effects of the abrupt withdrawal of the study medication.
In all, 11 assessments were planned (see Fig. 1).
During the study, the protocol was amended to allow reduc¬
tion of the dosage to four tablets per day if gastrointestinal
side-effects were distressing. The study was approved by the
local Ethics of Research Committee at each UKMAS centre.
Treatment for detoxification when on medication during
the study, even if hospital admission were required, was not a
reason for withdrawal from the study, nor was the prescription
of benzodiazepines for periods up to 7 days. Admission to
hospital for reasons other than alcohol withdrawal was re¬
garded as a serious adverse event and led to withdrawal from
the study. Benzodiazepines were not permitted for other pur¬
poses, but the urine checks made did not systematically
include a check for these or other drugs.
Inclusion and exclusion criteria
Patients were included if they were 18-65 years of age,
weighed >60 kg (later modified to 50 kg), fulfilled criteria for
alcohol dependence (DSM-III; American Psychiatric Association,
1980), had at least a 12-month history of alcohol dependence,
had undertaken withdrawal from alcohol during the preceding
5 weeks, had been abstinent for at least 5 days before enrol¬
ment to the study and gave written informed consent.
Patients were excluded if they were receiving disulfiram or
calcium carbimide, drugs known to induce hepatic enzymes
with the exception of oral contraceptives, or tranquillizers on
a regular basis. Patients were also excluded if they had abused
drugs in the previous 12 months, had serious medical or psy¬
chiatric disorders, or were pregnant or at risk of becoming
pregnant. During the study any patient given drugs known
to induce hepatic enzymes or psychotropic medication, apart
from hypnotics, were withdrawn from the study.
Baseline measures
At baseline, a drinking history was obtained, and the follow¬
ing scales completed: the SADQ (Stockwell et al., 1983) in
which a score of 30 suggests severe dependence (range 0-60),
the MAST (Selzer, 1971) in which a score of 5 indicates
'alcoholic' (range 0-52) and the CAGE (Ewing, 1984) in which
a score of 2 indicates a probable alcohol problem (range 0—4).
Safety monitoring
Tolerance of the drug, concomitant diseases, concurrent
medications, and vital signs were recorded at every visit;
physical examination including ECG was conducted before
and after the study, and blood samples for measurement of
haematological and biochemical variables (analysed at a
centralized laboratory) were taken at entry and after 1 month,
3 months and at the end of the medication period. At the
visit immediately prior to starting medication, and at 1, 3 and
6 months, the clinician rated the Hamilton Anxiety and the
Pre-Baseline Baseline
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Fig. 1. UK Multicentre Acamprosate Study plan.
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Hamilton Depression scales (Hamilton, 1959, 1967 respect¬
ively).
Outcome variables
Indicators of alcohol consumption. At each assessment,
breath alcohol was checked using an alcolmeter (Lion Labora¬
tories, Ty Verlon, Cardiff, UK); the patients rated their degree
of craving on a visual analogue scale 100 mm long [no desire for
alcohol (0 mm) to uncontrollable desire for alcohol (100 mm)];
a record card (Fig. 2) was issued on which patients were asked
to note on a daily basis whether or not they drank and how
much, and the previous period's card was collected. At
1 month, 3 months and 6 months, mean red blood corpuscular
volume (MCV) and serum y-glutamyl transferase (GGT)
activity (Chick et al., 1981), and also serum aspartate amino¬
transferase (AST) activity and urinary ethanol concentration
were all assessed. At the end of the study, the Alcohol-Related
Problems Questionnaire (Patience et al., 1997) was admin¬
istered; this contains eleven questions about problems in
relationships with friends or family, or the areas of health,
work or the law. Attempts were made to contact patients who
did not attend by telephone and letter, in order to obtain
missing data.
At completion of the study, each patient was asked to rate
how effective his or her 'control' in abstaining from alcohol
had been during the study. Each investigator was asked to rate
in a similar way their patients' success in 'control'.
Compliance. Returned tablets were counted. Failure to attend
or to return the tablet bottle even at a subsequent visit, was
recorded as 'no data'. Some patients were permitted to reduce
their daily dosage if they suffered unwanted side-effects. This
was taken into account when assessing compliance.
DATE
Have you had any alcoholic drink
today ? (Yes or No)
How was your sleep last night ?
(see scale below)
How many units of alcohol have you
had today in total ? (see scale below)
How was your appetite today ?
(see scale below)
How was your mood today ?
(see scale below)
MEDICATION
How many study tablets have you
taken today (No. of tablets)
Please complete this card every evening until your next visit to the hospital. Notes/Comments:
Please use a black pen.
Units of Alcohol Sleep/Appetite/Mood Scores
half pint beer 1 unit 0 poor
1 moderate
half pint cider = 1 unit 2 good
1 glass of wine = 1 unit 3 excellent
1 measure of spirits = 1 unit Please put the appropriate number in
1 bottle of spirits = 30 units the box to record your score.
Fig. 2. Monthly daily record card.
Typology categorization. A retrospective categorization of
the patients enrolled in the Edinburgh and London centres was
undertaken using the Lesch typology algorithm, which has
been used to predict response to acamprosate (Lesch and
Walter, 1996). Patients were traced through contact addresses,
hospital and primary care National Health Service Records,
and the Register of Deaths. The data necessary to classify a
patient were obtained at interview by a psychologist from the
Lesch clinical group, supplemented if necessary from clinical
records, and the research database. Classification was based
on a computer-held algorithm. Analysis was made of outcome
in relation to typology.
Analysis
Power. For the primary efficacy variable of abstinence for
6 months, based on previous reports of an expected placebo
response of 25% and an expected response to acamprosate of
40% (Lhuintre et al., 1985), a sample of 512 would have a
95% power of detecting a difference between treated and
untreated patients using a 5% significance level and a two-
tailed test.
Efficacy. Following the intention to treat (ITT) principle,
any randomized patient who took at least one dose of study
medication was entered into the analysis. It was assumed that
all patients who terminated treatment before the end of the
study, including those experiencing adverse events, were
treatment failures. Primary efficacy variables were pre-defined
as: duration of continuous abstinence; duration of continuous
abstinence or controlled drinking. Abstinence was defined as:
diary card available and no reported drinking and negative
breath and/or urine alcohol levels. Controlled drinking was
defined as mean daily self-reported consumption of 5 units or
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below (men) or 3 units or below (women) and no single day
exceeding 8 units (men) or 6 units (women). A unit was that
amount of beverage containing 8 g of ethanol. Secondary
outcome variables were cumulative abstinence duration, and
craving for alcohol.
Compliant subgroup. A subgroup of more compliant
patients was identified post hoc as those who (1) met inclusion
criteria; (2) did not take any prohibited medication during the
first 14 days on study medication; (3) attended at least one of
the scheduled visits in the first 2 weeks after starting medi¬
cation; (4) took at least 50% of study medication according to
tablet counts during the first 14 days. Excluded from this
subgroup were 24 patients who had not met the initial inclu¬
sion criteria, but which had not been identified at the outset.
To examine predictors of outcome, subgroups were created
according to ratings on certain baseline characteristics (e.g.
gender) and the proportions of good responders in the two
treatment groups were compared either using %2 or two-tailed
Fisher's exact probability tests, as appropriate. Multiple
regression analysis was used to examine the significance of
these relationships.
RESULTS
Recruitment to the study
An unspecified number of patients was considered or
approached without formal evaluation of eligibility. Staff were
asked later about their reasons for pre-recruitment exclusion;
the commonest were medical or psychiatric unfitness, patient's
refusal, or patient requesting disulfiram. A total of 664 patients
were formally examined for eligibility to enter the study. Of
these, 83 did not go forward to randomization. These 83 com¬
prised: 24 lost to follow-up between assessment and randomiza¬
tion, 40 failed to meet inclusion criteria, three showed worsening
of their condition, 10 changed their minds about taking
medication or otherwise withdrew co-operation, and in the
remaining six no reason for exclusion was specified.
Thus 581 patients were randomized and included in the ITT
sample.
Baseline data
At the point of randomization, the acamprosate (A) and
placebo (P) groups were well matched on the following
variables: age (A 42.8, P 43.8 years), gender (A 87% male, P 80%
male), marital status (unmarried: A 43%, P 45%), and employ¬
ment status (unemployed: A 51%, P 46%); pattern of drinking
('episodic': one-third of each group); mean SADQ score
(A 34, P 33), CAGE [a score of 4 in 76% (A) and 74% (P)]
and MAST [mean score 38(A), 37(P)], including being
matched for those items in MAST with an antisocial com¬
ponent (involved in fights, been arrested, trouble with police,
drunk driving), blood MCV (A 98.3, P 98.2 fl), serum GGT
(A 122 U/l, P 108 U/l, n.s.); mean craving at baseline (A 24 mm,
P 22 mm, not significant).
The groups were not matched on: prior weekly alcohol con¬
sumption (A 188 units/week, P 168 units/week, P = 0.022); place
of detoxification (home not hospital: A 55%, P 45%, P = 0.020).
The mean interval between the beginning of detoxification
and start of study medication was 24 days (A), 25 days (P).
However, in 158 patients (27%) (A 74, P 84) this was between
29 and 42 days and in 34 patients (6%) (A 18, P 16) between
43 and 56 days. Patients for whom there was more than 5 weeks
between the beginning of detoxification and randomization
should not have been included according to the protocol; how¬
ever, some were randomized and therefore are included in the
analysis except when stated. Some patients (168) drank alcohol
in the 7-day 'wash-out' period between the assessment intake
interview and the start of study medication. This was con¬
trolled drinking in 13% (A) and 16% (P), and uncontrolled
drinking in 15% (A), 14% (P), with no data available in 3% of
patients in each group.
Attendance
There were no statistically significant differences in
attendance between the treatment groups at any time point in
the study. At the mid-point of the study (84 days) 51% of the
acamprosate group and 54% of the placebo group attended;
this fell to 35% (A) and 37% (P) by the 24th week. Only 203
patients completed the study [A: 100 (35%), P: 103 (35%)].
The commonest reasons for early withdrawal were: lost to
follow-up (A 23%, P 25%), adverse events (A 14%, P 9%),
condition worsened (A 7%, P 9%), refused medication (A 11%,
P 8%), and 'non-compliance' (i.e. missing many appointments)
(A 6%, P 9%). A major effort to contact all patients was made
1 month after the end of the medication phase; 486 were
interviewed. A summary of patient retention in the study is
shown Fig. 3.
Fig. 3. Retention in the study.
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Fig. 4. Survival curve for complete abstinence (n = 581). d, days.
Efficacy
Continuous abstinence: survival analysis. The survival curve
for complete abstinence is shown in Fig. 4. At randomization
to study medication, 32% of patients had already relapsed. No
significant differences emerged at any visit in the proportion
of patients abstinent, nor in the proportion drinking in a
controlled way, between study groups. Continuous abstinence
for the 24 weeks was achieved by 12% (A) and 11% (P). A
further 3% (A) and 6% (P) drank some alcohol but without
meeting criteria for our definition of 'uncontrolled'.
Cumulative abstinence duration (CAD). CAD is the totalled
number of abstinent days recorded on all diary cards for the
period between first study medication and end of medication.
CAD did not differ between treatment groups: 77 days (A) and
81 days (P) (P = 0.492).
'Control' and craving. Of the 203 patients still in contact at
the end of the study, who answered the question 'how effective
they perceived their 'control' in abstaining from alcohol
during the study', 70% (A) and 73% (P) stated 'good' or
'excellent'. In this group of compliant patients, investigators
were also positive about the patient's response to treatment,
rating 84% (A) and 82% (P) as 'success'.
The mean decrease in craving was significantly greater in
the acamprosate group after 2 weeks of treatment (P < 0.001)
and after 4 weeks (P < 0.001) and there was a trend at 1 week
(P = 0.079) and 12 weeks (P = 0.069). One month after the
end of the medication phase, the mean decrease in craving was
greater in the acamprosate-treated patients than in those
receiving placebo (P = 0.022, n = 486) (Fig. 5).
The scores on the Alcohol-Related Problems Questionnaire
medication phase improved during the medication phase
between intake and 6 months by the same amount, a mean of
3.8 points, in both groups.
between treatment groups in either mean values at any of the
time points or in the percentage change in values from base¬
line. The proportion of patients attending at each visit with an
elevated serum GGT (>50 U/l) did not differ between treat¬
ment groups. At visit 1, 50% of patients had elevated serum
GGT activities and at the end of the medication phase 29%
had raised activities. The proportions of patients having an
increased blood MCV (>97 fl) at baseline were 56% (A) and
49% (P). There was no difference between the groups at any
visit. At visit 10, increased blood MCV was detected in 35%
(A) and 36% (P). For patients completing the study in whom
complete data on blood tests were available, the mean GGT
corroborated self-reported drinking as recorded in the diary
cards (Fig. 6).
Secondary effects
Hamilton Anxiety and Depression scores. At baseline, the
means and SD for the Hamilton Anxiety scores were: mean
9.8 ±8.1 (A) and 9.6 ± 7.9 (P). The mean decrease after 4
weeks was greater in the acamprosate group (2.6 ± 7.7) than
in the placebo group (1.0 ± 5.4) (P - 0.017). A trend in the
same direction was still visible at 3 months (P = 0.076), but
was no longer apparent at the end of treatment. A significant
Blood tests
Laboratory test results improved throughout the study in both Fig. 5. Alcohol craving: mean difference from baseline on visual analogue
treatment groups; no significant differences were observed scale (mm); **P < 0.01. d, days; mo, months.
• Placebo
x Acamprosate
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Duration of study (weeks)
Fig. 6. y Glutamyl transferase (GGT) changes by drinking classification at 2<\ weeks: patients completing the study with all blood samples available
(;n = 210 for each point); *P < 0.05, **P < 0.01, ***P < 0.001.
difference was, however, again noted at 1 month post treat¬
ment (P - 0.014). Improvements in the Hamilton Depression
ratings were noted overall, without differences between the
treatment groups.
Safety and tolerability
The most frequently reported adverse events were head¬
ache, diarrhoea, nausea and vomiting. The protocol permitted
a reduction in the luLd daily dose fiom 6 lo 4 tablets/day if
gastrointestinal symptoms were distressing and this was done
in 11.4% of the acamprosate group and 9.2% of the placebo
group. Serious adverse events were reported in 83 patients
(29%) in the placebo group and 93 (28%) in the acamprosate
group. Hospital admission occurred for detoxification in 14
patients (2%): for an alcohol related disorder in six patients
(1%) and a non-alcohol related disorder in nine (1.5%). Two
patients ingested large quantities of the active drug in a
deliberate overdose, the larger overdose being approximately
128 of the 333 mg tablets, but did not suffer harmful effects.
No changes which could be attributed to the drug occurred
in body weight, electrocardiography, haematology or bio¬
chemistry test results.
Compliance
By the end of the first 2 weeks of receiving medication,
57% of patients in each group were talcing at least 90% of their
tablets. This gradually reduced until the end of the 6-month
medication phase, when 27% (A) and 28% (P) met this
criterion. A separate analysis of those patients attending and
compliant with medication was not conducted. It would have
been a small subset and a separate analysis could not be
justified.
SUB-GROUP ANALYSES
Sub-groups according to certain baseline characteristics
The groups were not matched at baseline with respect to
where they were detoxified (Table 1). However, this did not
have an influence on outcome: of the 290 patients detoxified in
hospital, 16.9% achieved 6 months of abstinence or controlled
drinking, compared to 14.8% of the 291 patients detoxified at
home. There was no significant difference in outcome in
relation to gender: 21.8% of the 96 women attained 6 months
of complete abstinence or controlled drinking, compared to
14.6% of the 485 men. Being abstinent in the 'wash-out' week
before starting study medication, not unexpectedly, predicted,
indeed was a necessary condition for, abstinence duiing the
whole treatment period. No patient who drank in the wash-out
week attained complete abstinence. However, three patients
(one A, two P) who drank in the wash-out week succeeded in
not losing control of drinking during the 6-month treatment
period. There was a non-significant trend for those who had
had a longer abstinent period between detoxification and start
ing the study to remain abstinent throughout the study. This is
to be expected: patients able to abstain for a month tend to stay
abstinent for longer. Baseline craving predicted outcome, with
only five of the 106 patients (4.7%) with high craving (>50 cm
on the visual analogue scale) achioving controlled drinking or
abstinence for 6 months.
When outcome by treatment group was examined in sub¬
groups defined according to the predictor variables in Table 1
(namely: gender; place where detoxified; drinking pattern in
baseline week; severity of baseline craving; interval till start of
medication) no interaction with acamprosate emerged. Multiple
regression analyses including these five variables did not iden¬
tify an acamprosate effect. This was the finding when either
continuous abstinence, or continuous abstinence/controlled
drinking, were used as outcome criteria. Although baseline
previous weekly consumption had been higher in the acam¬
prosate group, when added to this multiple regression analysis,
an acamprosate treatment effect did not emerge. (The slightly
higher baseline consumption in the acamprosate group may
have reflected the slightly greater proportion of males.)
Compliant subgroup
A sub-group was defined excluding early non-compliance
with medication in the first two weeks and those patients
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Table 1. Baseline characteristics of patients. Abstinence at every visit: rates for various subgroups
Characteristic
Acamprosate Placebo
Abstinent n % Abstinent n %
Sex
Male 24 252 9.5 25 233 10.7
Female 6 37 16.2 7 59 11.7
Place where the patient was detoxified
Home 12 158 7.6 13 132 9.8
Hospital 18 130 13.8 19 160 11.9
Days between detoxification and commencing study medication
0-14 4 61 6.6 1 67 1.5
15-28 15 135 11.1 16 124 12.9
29^12 8 74 10.8 15 84 17.9
43-56 3 18 16.7 0 16 0.0
Drinking pattern in week between recruitment and commencing study medication
Abstinent 29 199 14.6 30 194 15.5
Controlled 0 32 0.0 0 41 0.0
Uncontrolled 0 41 0.0 1 41 2.4
Missing data 1 17 5.9 1 16 6.3



























Total population, n = 581.
randomized but who had been ineligible on inclusion criteria.
This group consisted of 378 patients (A 194, P 184). In terms
of their baseline characteristics, these groups were slightly
unbalanced in that the patients receiving placebo were more
likely to be female (P 22.3%, A 13.4%, P = 0.024). They
were, however, balanced for place of detoxification as well as
on all other baseline characteristics. Within this subgroup,
there were no differences between those receiving
acamprosate and those receiving placebo on any of the out¬
come criteria, except for craving at weeks 2 and 4 which was
lower in the acamprosate group (P = 0.045 and 0.050
respectively).
There were no significant interactions between treatment
group and any of the baseline factors singled out as likely
predictors of outcome (gender, previous weekly consumption,
place where detoxified, interval to starting medication,
drinking between enrolment and commencing medication, and
baseline craving). In the 78 patients who started study medi¬
cation within 14 days of the stait of detoxification, four (5%)
sustained abstinence, and all were in the acamprosate group
(P = 0.052).
Post-medication assessment
At a minimum of 1 month after stopping medication, 385
patients were assessed. Of these, 203 had completed the study
(A 100; P 103) and they tended to be seen at or near to the
1 -month point post-treatment; others had withdrawn early for
various reasons and hence tended to be seen at a relatively
later point than the completers. The proportion of patients
abstinent 1 month after medication ended was slightly
higher than at the last visit on medication. This was because
some patients who had relapsed and terminated before the end
of the study were now abstinent. There was no evidence of
sudden relapse in drinking when the medication was
discontinued.
Centre differences and psychosocial treatments offered
Analysis of outcomes by centre did not suggest that
acamprosate was more effective in some centres than others,
but the numbers analysed were small, and the data by centre
are not presented here.
Data weie available on the psychosocial treatments offered
at the 16 centres which contributed most patients to the study.
Nine were specialized alcohol problem clinics, five were
addiction centres, one was a general psychiatric setting and
one a general medical setting which contributed 72 patients.
Day-patient facilities were available in 11 centres. All but two
centres reported that a typical in-patient stay, if indicated,
would be less than 4 weeks, with two centres specifying less
than 2 weeks. Cognitive-behavioural group therapy was
offered at 13 centres, and out-patient support groups at nine
centres. Eight offered 'educational groups'. Only five offered
marital therapy, and five social skills training. Only two
centres had on-site meetings of Alcoholics Anonymous (AA),
but 14 centres used AA as a resource. The amount of other
treatment taken up by patients in the study period was not
documented at the time. However, later estimates revealed
that, at seven centres, less than 20% of the patients attended
appointments outside the research visits, whereas at five
centres more than 75% did so. When asked to compare their
clinical impression of patients they had recruited to the study,
nine centres said that patients recruited had been 'typical', but
six said they had been 'less severe' than typical patients.
Typology
An attempt was made to trace all 149 patients randomized
into the study at the two main centres. Two patients were too
cognitively disabled to give an interview, 10 refused, 29 were
untraceable and 32 had died. An interview was obtained and a
classification made in 76. The two Lesch types tending to be
responsive to acamprosate in the Austrian study of Lesch and
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Walter (1996), Types I and II, accounted for 25% and 18% of
the sample interviewed respectively. Types III and IV, which in
the Austrian study tended to be non-responsive to acamprosate,
accounted for 15% and 42%. 'Types' were equally distributed
between the two treatment groups; 17 Type I and II patients
leeeived die placebo while 16 leeeived acamprosate. There
was no trend suggesting that these Type I and II patients had a
better outcome in one treatment group rather than another.
DISCUSSION
In terms of abstinence for the duration of study, the success
of this patient population was low, at ~11%. Analysing data on
the whole population, no evidence of an effect of acamprosate
on drinking in the 6 months following detoxification was
found. This is not explained by effects of those baseline
characteristics which were imbalanced between the groups,
namely gender, place of detoxification and mean previous
weekly alcohol consumption.
The craving rating at weeks 2, 4 and at the month after
medication ceased was lower in patients treated with the active
drug.
The findings of this study differ from those of previously
published randomized controlled trials (Table 2), all of which
have shown that acamprosate improves self-reported abstinence
rates in recently abstinent alcoholics, over periods varying from
3 to 12 months of medication, with two exceptions: Roussaux
etal. (1996), and Lhuintre etal. (1990) who did not report con¬
sumption data. Not all studies reported corroborative advantages
in objective markers of alcohol consumption, such as serum
GGT activity. There are a number of possible explanations for
these contrasting findings.
Patient characteristics
Severity of condition or resistance to treatment may have
been greater in the UK patient population, than in some other
samples. Thus, in the study of Paille et al. (1995), half of the
patients treated were receiving treatment for their alcohol prob¬
lem for the first time. While previous treatment experience
was not recorded in the UKMAS sample, it is believed that
more than 50% had a history of treatment failure. Where
details have been published, it appears that patients' social
supports in the positive studies were greater than in UKMAS.
Thus, in the study of Sass et al. (1996), 26% were unemployed,
and in the study of Paille et al. (1995), 21% were unemployed,
compared to 48% in UKMAS. [In the other negative study
(Roussaux et al., 1996) 60% were unemployed and only 20%
married, resembling the low social support of the UKMAS
sample.]
Response to the MAST questionnaire is sometimes used as
an index of severity of alcoholism. However, great caution must
be used when comparing MAST scores between cultures, and
between samples with differing proportions of men and
women, because some items depend on the interaction
between the drinker and society. For example, 5 MAST points
can be scored for attending AA, but the availability of AA
varies between countries; similarly, several points can be
scored for legal infringements, but the rate of police activity
towards drinkers also varies between societies and in relation
to gender. However, the UKMAS sample scored a mean of
37, similar to the Ladewig et al. (1993) sample (mean 38), but
higher than those of Whitworth et al. (1996) (mean 32) and
Poldrugo (1997) (mean 27). The other studies did not use
MAST.
Within our population, therefore, we proceeded to examine
whether groups of different seventy, defined on baseline MAST
or consumption, had a greater or lesser response to acamprosate.
However, no such interaction was found. The UKMAS sample
may have contained a higher proportion of patients with
personality disorder than the other studies. No specific meas¬
ure was used in any study, but there are certain MAST items
relating to social disorder, police trouble and violence, which,
to illustrate this point, we have calculated as a separate index.
The mean score on these 'sociopathic' items in the UKMAS
patients was 6.5 (SD 2.7, max. score 11), but these data are not
available for other studies.
As regards typology, the Austrian study (Whitworth et al.,
1996) contained 39% of non-responding patient types, Types
III and IV (Lesch and Walter 1996). If the two UKMAS
centres are representative of patients from other centres, then
the UKMAS sample contained a higher proportion (57%) of
Type III and IV than at least one of the studies from con¬
tinental Europe. However, there was no trend in the limited
data obtained to suggest that Type I and II patients had relapsed
less if receiving acamprosate than if receiving placebo.
Pattern ofdrinking
One-third of our patients drank episodically rather than
continuously. Few data on patterns of drinking are given in
the other trials of acamprosate. However, in the study of
Whitworth et al. (1996), 18% were episodic drinkers and
Poldrugo (1997) reported that, in his Italian study, 86% of
patients drank on 7 days per week. At this juncture, there are
insufficient data to state whether an acamprosate response is
more likely in continuous than episodic drinkers.
Diary card
Using such a card, which the patient had to return in person,
may introduce stricter criteria for monitoring alcohol con¬
sumption than employed in some of the previously reported
studies. Perversely, it could encourage less accurate overall
recording of consumption if the assessors did not also use
careful questioning and their clinical sense. We have no way
of assessing either of these possibilities, though we can state
that the objective marker, serum GGT activity, correlated well
with our diary card measures and did not reveal any advantage
to the acamprosate group.
Timing of the medication
The mean interval between the last drink and the start of
medication was 25 days and, in some patients who were ran¬
domized and given medication, was over the 5 weeks specified
in the protocol. The range of intervals in the other studies was
shorter (Table 2). The effect of acamprosate in the German and
Austrian studies was most prominent in the first 30 days. In the
UKMAS study, only 78 (13%) of the patients began study
medication within 14 days of the start of detoxification, and of
the four patients who achieved complete abstinence all were in
the acamprosate group, a difference which, however, failed to
reach significance (P = 0.052). Altogether, 35% of patients
had relapsed before starting medication. In some of the
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published studies (e.g. Besson el al., 1998), patients were
withdrawn from the study before medication was started if
they were drinking on the day of commencement.
If the calcium channel abnormalities or NMDA receptor
changes in the recovering alcohol-dependent patient are most
marked in the immediate weeks after the last drink, then it may
be that, if acamprosate is to be effective, it should be started as
soon after detoxification as possible, or even during detoxification.
There was a very early relapse in our UKMAS sample: 155
(27%) drank in the first 7 days after detoxification, that is, the
week between evaluation and randomization during which
they were on no medication, and no data are available for a
further 33 patients, suggesting that these individuals had
already been lost to follow-up and were probably drinking. If
acamprosate could prevent this early relapse in, say, half of
these patients, then the difference in overall total abstinence
rates could have been 16%. In retrospect, if patients had been
given a placebo preparation during that period they might have
been less likely to drink.
Location ofwithdrawal treatment
Approximately 50% of patients entering the UKMAS study
were detoxified as outpatients. This contrasts with other
studies, in which home detoxification was uncommon. Even
in the study of Paille etal. (1995), only 20% had not been hos¬
pitalized for detoxification. It is difficult to see why this should
influence the efficacy of acamprosate; it may however indicate
that UKMAS patients had slightly lower motivation/were not
willing to come into hospital; or it may reflect the relatively
low intensity of the UKMAS clinic approaches compared
to approaches in the centres taking part in some of the other
studies; or that, compared to those in the other studies,
UKMAS patients tended to be less severely dependent, which
was also mentioned by six UKMAS centres.
Type ofpsychosocial treatments offered
Descriptions of the psychosocial treatments offered in the
other studies are sparse. However, it should be noted that, in
UK centres, relatively few were offering those psychosocial
therapies which are perhaps of most proven value, such as
12-step facilitation leading to regular attendance at AA
meetings, marital therapy, social skills training (Miller et al.,
1995; Project Match, 1997). Attendance at AA was more
common in the German study, in that, during the first month,
25% of patients went to at least one meeting and by the end of
the 12 months, 14% were still attending. The figures for the
present UK study are not exact, but it is believed that there was
much less AA attendance.
Drop-outs
In all the other studies, even those of 12-month duration,
completion rates were better than in UKMAS. This may
reflect higher rates of patients with personality disorder or
lack of social resources, or reflect that with some exceptions
the UK centres tended to offer a less intensive approach.
Loss to follow-up is a major problem when interpreting
results of treatment outcome in alcohol-dependent samples
when studies extend over many months. All the studies
described here, including UKMAS, reported results analysed
using 'the intention to treat' principle, which classifies
patients who drop out as treatment failures, and does not risk
sub-group analyses where original matching between the
groups may be lost. It takes no account of whether or not those
patients remaining in the study actually complied with treatment.
Many consider the 'intention to treat' analysis to be the only
correct approach in analysing treatment outcome. Never¬
theless, one other analysis was carried out here, of the sample
defined as those who had not violated the protocol in any way
and who complied for the first 2 weeks, taking at least 50% of
their medication according to tablet count. However, no evi¬
dence of a trend towards an effect of acamprosate on outcome
was revealed.
Was the sample too small to show a treatment difference?
The effect size in the other studies has been at least the 15%
allowed for when the power calculations for the UKMAS
study were made: at first sight, the UK result seems unlikely
to be due to a lack of statistical power. However, the power
calculation had assumed that all patients would be abstinent at
the start of the treatment period. The fact that 155 patients
were no longer abstinent at the start of treatment would have
reduced the statistical power of the study.
By chance, a negative study has occurred
As the number of controlled studies of apparently successful
treatments increases, the proportion of studies which fail to
show an effect may also increase. This may be due to vari¬
ations in the application of the treatment, characteristics of the
sample or treatment setting, or perhaps chance. For example,
Morris and Beck (1974) reviewed all the randomized con¬
trolled studies of tricyclic antidepressant drugs which had
been published up to 1 January 1973. Out of 93 studies,
tricyclic antidepressants were more effective than placebo in
61 studies, no difference was found in 32 studies, and there
were no studies where placebo was more effective than
tricyclic drug. Despite the many negative studies, tricyclic
antidepressants became accepted as a valuable therapy for
depression. It remains to be seen what will be the eventual
proportion of positive to negative studies for acamprosate.
GENERAL CONCLUSIONS AND COMMENTS
The weight of results of the other studies reported to date lead
to the conclusion that acamprosate is a helpful adjunct to
conventional outpatient treatment after detoxification, approxi
mately doubling the number of patients achieving continuous
abstinence, and increasing by some 30-40% the cumulative
total of days abstinent. This UK study does not support these
findings. Contributing to an explanation of this negative result
may be loss of statistical power due to a higher drop-out rate
and relapse into drinking before starting the drug, but also a
background of less intensive treatment in general, although the
amount and type of preceding and collateral psychosocial
and/or pharmacological treatment which best facilitates
response to acamprosate has yet to be specified.
From the other studies it is, of course, clear that not all
patients respond. The characteristics of responders have yet
to be defined. Perhaps the delta (continuous) rather than the
gamma (episodic) alcoholic might respond better (Jellinek,
1960), and our UK sample probably had a much higher
proportion (33%) of episodic drinkers than other centres,
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particularly the wine-drinking centres of Italy, Austria, France
and Southern Germany. Lesch and Walter (1996) showed that
a more classical, primary type of alcoholic, rather than the
alcoholic with other psychiatric or organic disorder or many
social problems, is more likely to benefit from acamprosate.
Specification of the optimal patient characteristics and optimal
accompanying psychosocial treatments is required so that
acamprosate can be used to its best advantage.
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Does acamprosate improve reduction of drinking as well as aiding
abstinence?
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The study aimed to discover whether acamprosate reduces the severity of relapse for those patients
undergoing abstinence-orientated treatment who are unable to abstain completely. Data on patients'
alcohol consumption from 15 placebo-controlled treatment studies (n = 3309) were examined to test
whether, at a given time point, patients who have taken one or more drinks since the last assessment
Crelapsers', n = 1010) take alcohol on fewer days, report lower average number of drinks per day, and
consume less alcohol in total with acamprosate compared to placebo. These studies had varying duration (90
days, 180 days and 360 days). There were four dates that were common to some studies (days 30, 90,180 and
360). Among relapsers, acamprosate was significantly associated with less quantity (Q) and frequency (F) of
drinking compared to placebo in each of the four follow-up periods (p < 0.001). The differences were most
marked for the product Q x F (overall weekly consumption). For each period, there were fewer who were
drinking an average of five or more drinks per day in the acamprosate compared to the placebo groups.
Acamprosate helps reduce the severity of relapse in patients undergoing abstinence-orientated treatment.
Key words: acamprosate, alcohol consumption, binge drinking, controlled drinking, lapse, outcome, relapse, treatment
Introduction
Acamprosate has been shown in many individual trials, systematic
reviews (Garbutt et al., 1999; Mason and Ownby, 2000) and meta¬
analyses (Kranzler and Van Kirk, 2001; Slattery et al., 2003), to
help sustain continuous abstinence in detoxified alcohol dependent
patients during the whole duration of the trial. These studies have
also shown that acamprosate is associated with more total days of
abstinence than placebo.
Tempesta et al. (2000) reported a placebo-controlled trial of
acamprosate in 246 detoxified alcohol dependent patients, which
showed that, at a given time point, those who had taken one or
more drinks since the last assessment drank less frequently and a
lesser amount of alcohol if they were in the acamprosate-treated
group rather than the plaoeho-freafed group Although the
mechanism may be different, the phenomenon has been shown for
naltrexone. Thus, newly detoxified patients, who resumed
drinking, consumed less alcohol if treated with naltrexone than if
treated with placebo (O'Malley et al., 1992; Volpicelli et al., 1995;
Anton et al., 1999; Chick et al., 2000a). Volpicelli et al. (1995)
hypothesized that naltrexone reduces the loss of control that some
dependent drinkers experience when they start to drink. This has
received some support in laboratory studies, which suggest that a
possible mechanism might be that naltrexone reduces the euphoric
effect or induces an aversive effect of drinking alcohol (Swift et
tl., 1994; Davidson et al., 1999).
This study examined the hypothesis that acamprosate helps to
prevent a lapse becoming a relapse. The specific predictions to be
tested were that, at any given time point, patients who have taken
one or more drinks since the last assessment will (i) have taken
alcohol on fewer days; (ii) report lower average drinks per day;
(iii) consume less alcohol in total; and (iv) will be less likely to
have consumed five or more drinks/day ('uncontrolled drinkers')
in the acamprosate group compared to placebo.
Materials and methods
Of the double-blind controlled studies of the efficacy of
acamprosate in enhancing abstinence for detoxified patients, 15
were found from which usable data on alcohol consumption were
available. These studies had varying duration. Two studies had a
duration of 90 days (Roussaux et al., 1996; Pelc et al., 1997). Eight
studies lasted 180 days (Pelc et al., 1992; Ladewig et al., 1993;
Geerling et al., 1997; Poldrugo, 1997; Chick et al., 2000b; Tempesta
et al., 2000; Gual and Lehert, 2001; Borg, 2003). Five studies
lasted 360 days (Paille et al., 1995; Sass etal., 1996; Whitworth et
al., 1996; Barrias etal., 1997; Besson etal., 1998) (Table 1).
Follow-up assessments were not planned at the same time from
baseline in each study although, depending on the overall length of
the study, there were four common dates (days 30, 90, 180 and
360).
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Table 1 Description of the trials
Study Country Plac (n) Acamp (n) Total (n) Treatment duration (months)
Pelc el al. (1997)a Belgium/France 62 126 188 3
Poldrugo (1997)a Italy 124 122 246 6
Chick et al. (2000b) U.K. 292 289 581 6
Tempesta et al. (2000P Italy 166 164 330 6
Gual and Lehert (200 l)a Spain 147 141 288 6
Whitworth et al. (1996)a Austria 224 224 448 12
Barrias et al. (1997)a Portugal 152 150 302 12
Sass et al. (1996) Germany 136 136 272 12
Geerlings et al. (1997)3 Benelux 134 128 262 6
Paille et al. (1995) France 177 361 538 12
Ladewig et al. (1993J2 Switzerland 32 29 61 6
Besson et al. (1998)a Switzerland 55 55 110 12
Pelc et al. (1992F Belgium 47 55 102 6
Borg (2003F Swede.1 5 5 10 6
Rousseaux et al. (1996F Belgium 64 63 127 6
n. Number of patients; Plac, placebo-treated patients; Acamp, acamprosate-treated patients. Study medication was dose adjusted according to following
regimen; patients below 60 kg body weight receiving 1332 mg and those above 60 kg received 1998 mg acamprosate or matching placebo. Categories
were used to collect consumption data.
The method of collecting consumption data at the assessment
points varied from study to study. In some studies, patients were
asked to complete a daily card that was used as a basis for arriving
at the most accurate figures for that period. In other studies, mean
consumption for the last period was derived solely from the
patient's interview with the investigator, sometimes with
information from relatives.
Drinking since last assessment was recorded at each
examination in terms of abstinence, average quantity per drinking
day and frequency of drinking. For each period, the patient was
classified as abstainer, relapser, or 'missing' (not attending the
examination).
Depending on the study, the average daily consumption of
alcohol was documented either as the estimated mean number of
drinks/week, or by categories (never, less than five drinks, between
five and 10 drinks, and more than 10 drinks). A 'drink' contained
10-12 g ethanol except in the UK study (Chick et al., 2000b)
where a unit was 8-9 g, a small difference that was ignored for the
present purposes because of the lack of significant Study-treatment
interactions. Weekly frequency of drinking was documented as
number of days on which drinking occurred, or using four
categories from none to 'daily'.
The population of interest in this paper comprised relapsers (i.e.
patients who took at least one drink in at least one period). Non-
attenders, for whom detailed consumption data are missing, were
not included in the analysis.
Statistical analysis
Because some of the studies used categories to collect consumption
data, we used medians (and interquartiles) instead of arithmetic
means (and SDs) to estimate daily quantities and frequencies of
consumption. Three measurements of alcohol consumption could
thus be calculated and comparisons made between the two
treatment groups: median drinks per drinking day (Quantity),
median number of drinking days per week (Frequency), and the
weekly Total Consumption defined as the product Q x F. In
addition, for each study period, we determined the percentage of
relapsers with a consumption of an average of five drinks or more
per day ('uncontrolled drinkers').
As more than one study is involved, a meta-analytic estimation
was necessary. This was calculated on an Individual Patient Data
(IPD) basis (i.e. data on individuals, not on treatment groups, were
entered). Because the categorical aspect of data collection may
lead to departures from usual normality and homoscedasticity
assumptions, the assessment of the difference between the two
groups was carried out with a non-orthogonal analysis of variance
(ANOVA) on ranks considering the Treatment (fixed factor), the
Study (random factor), and the interaction between Treatment and
Study. For each period, we compared the percentage of
uncontrolled drinkers (a 5 drinks/day) between treatment groups
using the simple random model of DerSimonian and Laird (1986).
Statistical analysis was performed using the SAS statistical
software package (version 6.02 for Windows) (SAS Institute,
Cary, NC, USA).
Results
The numbers of relapsers, abstainers, and missing patients for each
study and for each period are shown in Table 2.
Quantity, frequency and total consumption for
relapsers
The three measurements of alcohol consumption, estimated across
studies by their observed medians, remain similar over the four
examined periods, within each treatment group (Table 3). On
averaging the relative difference (acamprosate - placebo)/placebo
over the four periods, we found a relative decrease of 29.40%
(Quantities), 27.8% (Frequencies) and 50.23% in the Total
Consumption estimate.
The p-values associated with the analysis of variance cannot be
considered as confirmatory, given the repetition of the tests. Also,
these p-values cannot be compared between periods because
different sample sizes are involved. The Treatment effect is
overwhelmingly significant for all measurements in all periods,
consumption under acamprosate appearing to be reduced compared
with the placebo. A linear correlation of r = 0.74 was observed
between Quantity and Frequency, for all the periods together.
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ble 2 Percentages of patients missing, relapsed and abstinent within each treatment group for the four periods
Day 30 Day 90 Day 180 Day 360
Plac Acamp Plac Acamp Plac Acamp Plac Acamp
c et al. (1997) 0.022 0.008








bstinent 47 67 26 48 - - - -
Idrugo (1997) 0.019 0.051
39
0.035
lissing 29 19 52 61 47 - _
elapse 12 6 8 7 6 5 - -
bstinent 59 75 40 55 32 48 - -
ick et al. (2000b) 0.304 0.692 0.875
[issing 26 28 46 49 63 65 - -
elapse 34 38 26 24 19 18 - _
bstinent 41 35 29 27 18 17 - _





2 18 16 27 24 _ _
elapse 39 29 34 25 28 18 - -
bstinent 56 68 48 59 45 58 _ _
al and Lehert (2001) 0.342 0.351 0.331
[issing 7 6 26 19 35 27 - _
elapse 24 17 20 19 16 16 - -
bstinent 69 77 54 62 50 57 - _
litworth et al. (1996) 0.319 0.035 0.041 0.043
[issing 17 13 38 31 51 48 63 59
elapse 20 17 24 19 22 16 16 11
bstinent 63 70 38 50 26 36 21 30
Tias etal. (1997) 0.028 0.004 0.125 0.029
[issing 2 2 11 11 24 27 43 39
elapse 30 17 42 25 39 28 31 22
bstinent 68 81 47 65 37 45 26 39
:s et al. (1996) 0.140 0.010 0.003 0.002
issing 15 12 38 24 52 35 60 43
elapse 22 15 18 15 19 17 18 15
bstinent 63 74 44 62 29 49 22 42
erlings et al. (1997) 0.490 0.127 0.057
issing 15 15 50 43 69 59 - -
elapse 40 33 28 23 18 16 - -
bstinent 46 52 22 34 13 25 _ —
lie etal. (1995) 0.069 0.155 0.007 0.002
issing 8 7 23 19 46 33 64 49
elapse 36 26 37 33 24 26 17 20
bstinent 56 66 40 48 30 42 19 31
iewig etal. (1993) 0.031 0.396 0.184
issing 13 10 19 14 31 31 - -
elapse 47 17 56 45 47 28 - -
bstinent 41 72 25 41 22 41 _ -
>son et al. (1998) 0.019 0.081 0.010 0.141
issing 9 7 33 27 44 49 65 65
elapse 44 20 35 20 40 16 20 9
bstinent 47 73 33 53 16 35 15 25
c etal. (1992) 0.068 0.202 0.012
issing 28 13 55 38 79 56 - -
elapse 30 24 17 20 13 11 - -
bstinent 43 64 28 42 9 33 _ -
:g (2003) 1.000 1.000 0.497
issing 0 0 0 0 0 0 - -
elapse 20 20 20 20 20 40 - -
bstinent 80 80 80 80 80 60 — _
jssaux etal. (1996) 0.916 0.874
issing 22 19 28 30 - - - -
elapse 27 29 39 41 - - - -
bstinent 52 52 33 29 - - _ _
studies 0.000 0.000 0.000 0.000
issing 15 12 34 28 49 42 59 50
elapse 30 24 28 24 22 19 20 17
bstinent 55 . 64 38 48 29 39 21 33
each cell, p (chi-square test) is provided at the top of the cell.
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Table 3 Median estimates of consumption and assessment of Treatment, and Treatment by Study, effect significances
Period
Quantities (Q) Frequencies (F) QxF
Placebo Acamp P Placebo Acamp P Placebo Acamp P
D30 5.76 4.22 0.006 3.52 2.93 0.101 20.27 12.36 <0.001
2.51,27.58 1.94, 9.10 (0.015) 2.25,5.35 2.06,5.26 (0.201) 15.1,26.5 7.4, 18.5 (0.062)
D90 4.83 3.76 0.005 3.75 2.75 0.027 18.11 11.14 < 0.001
2.28,9.47 1.55,8.44 (0.099) 1.73,5.34 1.35,4.92 (0.084) 12.4, 24.4 5.3,17.5 (0.091)
D180 5.19 3.52 0.004 3.22 2.64 0.005 16.03 10.05 < 0.001
2.63,9.87 K43,6.94 (0.435) 1.83,5.61 1.27,4.71 (0.522) 10.3,22.7 5.2, 12.4 (0.17)
D360 5.12 3.25 0.074 4.17 2.5 0.245 21.35 8.12 < 0.001
2.36, 8.92 0.93,6.73 (0.922) 1.89, 6.06 0.94,4.83 (0.880) 16.2,26.2 5.1, 12.3 (0.15)
For each period and treatment Group, Median (first row) and Interquartiles (second row) are shown, p-values of main Treatment effect are in the first row.
p-values of the corresponding interaction Treatment-with-Study are beneath (in parentheses).
Concerning the interaction Study-Treatment (i.e. whether or not
acamprosate has a greater effect on these measurements in
relapsers in some studies than in others), no difference was found
in 11 out of 12 tests performed. However, the Study effect (not
shown) was always highly significant, indicating that some studies
showed better overall outcome than others.
The observed median consumptions were similar across studies
for each treatment group. Thus a pooled estimate based on the four
periods is reasonable. In averaging the relative differences for each
period, the pooled relative difference between consumption
Frequency under acamprosate (Ca) and placebo (Cp), (Ca -
Cp)/Cp> is -26.7%, whereas the analogous relative difference for
Quantity is -25.8%.
Finally, the observed proportions of uncontrolled drinkers for
each period were found to be similar (Table 4). The difference
between treatment groups, adjusted for Study, was from -11 % until
-14%, with a mean estimated difference of-12.5%. As the studied
sample decreases in time, the precision of the estimation (measured
by 95% confidence interval) decreases. The treatment effect
remained significant and, except for day 30, the heterogeneity of
the difference between studies was not suspected. Moreover, the
observed power for the three first periods range from 0.89-0.956.
Thus, in light of the observed differences, this test was reasonably
powered with respect to clinically significant differences.
Discussion
The principal finding of this analysis is that those patients who
relapsed and who were taking acamprosate drank less than those
relapsers taking placebo. In relapsers, a significant effect of
acamprosate in reducing either quantity (g), or frequency (F) or
both was seen for each of the four follow-up periods (p < 0.001).
The differences were most marked for the product Q x F (Total
Consumption). The difference in consumption was of the order of
10 additional drinks per week in the placebo-treated relapsers. If
relapse is defined as drinking five or more drinks per day on
average ('uncontrolled drinkers'), the result also favours
acamprosate.
Limitations
A first possible limitation, in common with any alcoholism
treatment outcome study using self-reported consumption, is the
reliability of the consumption data. However, in research studies,
self-reported data are shown to be consistent with blood
investigations (Fine et al., 1978; Babor et al., 2000) and
independent informants (Hesselbrock et al., 1983; Chermack et al.,
1998; Babor et al., 2000).
Another possible limitation of our analysis is the lack of
precision of the consumption estimates in those studies which used
categories for the mean reported number of drinks per drinking day
and mean number of drinking days per week. Using categories
instead of values, on the one hand, increases residual variance, but
is not expected to bias consumption estimates under general
conditions of a unimodal, not markedly skewed, distribution
(Elderton and Johnson, 1969; Sahai and Misra, 1992). Thus, these
estimates, although less efficient, are not biased. In addition, we
estimated the central tendency of consumption by using medians,
on the one hand, and percentage of patients drinking five or more
drinks, on the other.
Another criticism might be that a mean estimated consumptior
cannot differentiate a uniformly distributed consumption in time
from a discontinuous, erratic, or occasional consumption, whicf
could indeed be of interest. Aiming for this greater accuracy
researchers have sometimes used more complex procedures: diarj
cards completed daily by the patient, supposedly prospectively
Table 4 'Uncontrolled drinking': meta-analytic estimate of difference of proportion of patients drinking on average five or more drinks
per day (random model)
Period Placebo, % Acamp, % Adj Diff Treat Homog Power Sample size
D30 53% 41% -13 (-19, -8) < 0.001 < 0.001 0.956 983
D90 48% 36% -11 (-19,-8) 0.002 0.224 0.936 927
D180 51% 32% -14 (-22,-6) 0.001 0.475 0.890 651
D360 51% 33% -11 (-23,0) 0.056 0.475 0.469 244
Columns 2 and 3 (Placebo, % and Acamp, %) are the unadjusted percentages of patients drinking on average five or more drinks per day. Fourth column
(Adj Diff) is the meta-analytic estimate of the difference in proportions with 95% confidence interval. Treat and Homog are the tests of significance for
Treatment effect and Heterogeneity. Power is the observed power, and last column is the sample size.
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and Time Line Follow Back where patient and investigator attempt
to reconstruct, in detail, drinking day by day. Although these
procedures might increase accuracy, they might be criticized as
departing widely from normal clinical practice, and therefore
artificially having an additional effect on the outcome, possibly
even introducing a bias on the measured difference between the
two groups.
Finally, these results were obtained from patients who attend
assessments. This has several implications. First, our estimate is
not generalizable to all the relapsers but only to those in touch with
the clinic. Second, because it was necessary to examine the results
for each period, several analyses were carried out, and the sample
sizes are different because the number of missing patients increases
at each period. Thus, conclusions are essentially based on the
estimated effect size, and test significances are only indicated as
safeguards and do not constitute the most important information.
We cannot guarantee excluding a global experiment-wise type 1
error, nor a comparability between the p-values at every period,
because the sample sizes are not identical.
The treatment effect
The effect of the acamprosate is modest, with an estimated 29.4%
reduction in quantity and 27.8% in frequency. However, the
difference is larger when considering the effect on total
consumption (estimated reduction of 50.20%). When looking at the
proportion of uncontrolled drinkers, an estimated difference of
13% was found. As the Study-Treatment interaction effects were
essentially non-significant, we conclude that there is only a small
difference, if any, between the treatment effect in different studies.
Thus, to the extent that the reliability of the data is accepted, we
conclude that a prescription of acamprosate was associated with a
reduction in the quantity and frequency of consumption which
followed a lapse. Furthermore, because we did not find a sig¬
nificant interaction between Study and Treatment, this finding can
be generalized to different sites and different practice conditions.
An analogous effect has been shown in rodents made
'dependent' on ethanol. When re-exposed to ethanol after a period
of abstinence, reinstatement of drinking is attenuated by pre-dosing
with acamprosate (Spanagel et al., 1996). There is no ready
neuropharmacological explanation for this, nor for our result
obtained from patients. Acamprosate was believed to act by
facilitating inhibitory neurotransmission (mediated by taurine or,
more likely by y-aminobuiyric acid) (Dahchour and De Wilte,
2000) and by modulating the activity of voltage-dependent calcium
channels (Al-Qatari and Littleton, 1998). Recent consensus is that
the mechanism of action of acamprosate for its effect on alcohol
consumption is attenuation of excitatory glutamatergic neurotrans¬
mission in the brain, leading to changes in the reinforcing efficacy
of alcohol (Littleton, 1995; Koob et al., 2002).
With any subgroup analysis, because the original matching
following randomization may be lost, there is the chance that a
confounding factor may become implicated. However, it is hard to
conceive why some characteristic of the subgroup, Relapsers,
should predispose them to benefit from acamprosate, other than
their tendency to relapse, which was the object of our study.
Implications for clinical practice
As for most treatments, especially for a condition of such
heterogeneous aetiology as alcohol dependence, all patients do not
necessarily respond. Thus for acamprosate, when patients continue
to repeat the relapse cycle with unremitting severity, acamprosate
prescription should cease and another treatment approach be
attempted. However, until that point, a relapse should not be taken,
on its own and without re-evaluation, as a reason for stopping
acamprosate.
We do not know whether the patients who relapsed in these
studies continued to take study medication after starting to drink.
However, protocols did not instruct them to stop medication. Thus,
we do not know whether the benefit of being in the acamprosate
group was because they had taken acamprosate before relapse, or
because they continued taking it during the relapse. However, on
the basis of this analysis and current knowledge, and because there
is no known adverse interaction between ingested alcohol and
ingested acamprosate, the advice to patients should be that, if they
relapse, they should continue taking the medication. Definitive
answers will only be provided by a study in which patients who
relapse are randomly allocated to continue acamprosate or
switched to placebo.
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Abstract
Patients with a diagnosis of alcohol dependence, detoxified and abstinent for 10-30 days, were randomly allocated to placebo or the
serotonin reuptake inhibitor, fluvoxamine (up to 300 mg per day), plus counselling and support.
In the intention to treat sample of 193, there was a trend for the fluvoxamine group to do worso than the placebo group on the primary
outcome criteria: abstinence; and relapse defined as drinking >5 units on an occasion and >4 such occasions in a week, or > 12 units on an
occasion (1 unit = 9 g ethanol).
When typology of alcoholism was assigned by scores on the Tridimensional Personality Questionnaire, Types 1 and II had similar rates of
survival without relapse on placebo (PLC I: 19.3%,n = 135; PLC 11: 18.2%, n = 110), but on fluvoxamine Type II did worse than Type I (FLU
I: 13.7%, n = 131; FLU II: 6.14%, rt = 111) (P < 0.01). When typology was assigned on the basic of age of onset of alcohol problems (£ or
> age 25), early-onset patients in the fluvoxamine group relapsed more frequently than late-onset patients in that group (no longer significant
after adjustment for gender), as did those who commenced regular drinking before age 25 (both with and without adjustment for gender). One
explanation for our finding could be that impulsivity in early-onset or Type II patients may be accentuated by serotonin enhancement.
© 2003 Elsevier Ireland Ltd. All rights reserved.
Keywords: Alcohol dependence; Outcome; Treatment; Fluvoxamine; SSRl; Typology; Age of onset
1. Introduction
Serotonin neurotransmission may mediate alcohol-seeking
behaviour in animals (Le et ah, 1996; Gerald and Higley,
2002). Low levels of serotonin metabolites in the cere¬
brospinal fluid were noted in detoxified alcohol dependent
patients and in alcohol dependent patients who commit
suicide (Roy et ah, 1987). Evidence suggesting a more
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fax: +44-131-537-6866.
E-mail address: jchick@compuserve.com (J. Chick).
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Scholz, Karnten; Prof. T. Silverstone, London; Dr. R. Thomas, Cardiff;
Dr. C. Uehlinger, Neufchatel; Dr. J. Waterhouse, Dumfries.
general serotonergic abnormality in alcoholics came from
studies showing significantly reduced serotonin uptake into
platelets from these subjects (Kent et ah, 1985), a finding
which has been associated especially with those in whom
alcohol problems develop early (reviews: Hill et ah, 1999;
Johnson, 2000).
General practitioners often prescribe serotonergic drugs
to patients whose main diagnosis is alcohol dependence.
One-fifth of new patients referred to a Scottish alcohol
problems clinic in 1999 were already taking an antide¬
pressant prescribed by their general practitioner, usually a
specific serotonin re-uptake inhibitor (SSRI) (unpublished
report, University of Edinburgh). However, the efficacy of
SSRIs in preventing relapse in alcohol-dependent patients is
equivocal (see reviews by Lejoyeux, 1996; Pettinati, 1996;
Garbutt et ah, 1999 and Pettinati et ah, 2000a); and two
0376-8716/$ - see front matter © 2003 Elsevier Ireland Ltd. All rights reserved.
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sertraline studies published subsequently, namely, Co-kunol
et al. (2002) reported a small, transient effect in 59
non-depressed patients, and Gual et al. (2003) reported no
effect in 83 depressed patients. The possibility has been
raised by Pettinati et al. (2000b), in a study in which ser¬
traline was compared to placebo, that 'Type B' patients
(early onset of alcohol dependence, with prominent social
problems) (Babor et al., 1992) are a group that do not ben¬
efit from SSRIs, and Kranzler et al. (1996) published data
suggesting that the SSRI fluoxetine might actually reduce
the treatment gains of cognitive behavioural therapy and
increase the risk of relapse compared to placebo in Type B
patients. Johnson (2000) explored one explanation for this.
Fluvoxamine is a monocyclic SSRI registered worldwide
for the treatment of depression and obsessive-compulsive
disorder; the therapeutic dose range is 100-300 mg per day.
The study reported here, on the efficacy of fluvoxamine in
preventing relapse in alcohol dependence, was conceived
and executed from 1990 to 1994. Its negative result, though
available in 1994, has not been published. However, con¬
cerned about the bias which can develop in the medical lit¬
erature if negative results are not published (Garattini and
Liberati, 2000), and questioning whether SSRIs may even
be harmful to some alcohol dependent patients (Kranzler
et al., 1996), we have returned to our data.
This study had three primary aims: to test fluvoxamine's
efficacy in reducing relapse in newly detoxified alcohol de¬
pendent patients; to examine fluvoxamine's efficacy, relative
to placebo, in alleviating symptoms of depression and anxi¬
ety associated with abstinence in alcohol dependence; and to
investigate fluvoxamine's safety in the long-term treatment
of alcohol dependence. A secondary aim, formulated a pri¬
ori, was to examine the interaction between pharmacother¬
apy, outcome, and type of patient defined either according
to age of onset regular drinking or of problem drinking,
or to the typology of Cloninger (1987a,c). (Limitations to
the clinical validity of the original Cloninger typology have
since been published (Marcus, 1997; Cloninger, 1999) with
classifications which include dimensions of alcohol use and
frequency of negative consequences appearing more useful
(e.g. Carpenter and Hasin, 2001).)
Reports on characteristics of our study sample and their
prognosis have appeared (Meszaros et al., 1996, 1999). Re¬
lapse in this sample was predicted by high trait anxiety, and
the traits of high novelty seeking and low harm avoidance
implying exploratory excitability, impulsiveness, extrava¬
gance, disorderliness and uninhibited optimism (Willinger
et al., 2002).
2. Materials and methods
The design was a one-year, prospective, randomised,
placebo-controlled, multicentre study in parallel groups.
Ten sites in the United Kingdom, Eire, Austria and Switzer¬
land participated. The site principal investigators were se¬
nior psychiatrists experienced in the treatment of alcoholic
patients. Local Committees granted ethical approval.
Patients (of either gender, aged 21 and over) were to have
a DSM-III-R diagnosis of alcohol dependence (American
Psychiatric Association, 1987) at randomisation, and to have
been detoxified and abstinent for 10—30 days.
The sample size was calculated on the basis of "the pro¬
portions of patients assessed as relapsed to uncontrolled
drinking". For these calculations, two analyses were pro¬
posed: an analysis of those patients completing the study ei¬
ther by receiving treatment for 1 year, or by dropping-out as
a result of relapsing to uncontrolled drinking (the group of
"completers"); and an analysis of "the group of all patients"
defined as those patients receiving double-blind treatment
and providing drug efficacy data—in which all drop-outs
were to be regarded as treatment failures. For both analy¬
ses the following assumptions were made: that the range of
non-completers would be between 10 and 50%; that the re¬
lapse rate on placebo would be between 30 and 70%; and
that a clinically relevant benefit would be a 50% reduction
in relapse rates.
On the basis of these assumptions the numbers of patients
per group to be enrolled for an 80% power, 2-tailed, was cal¬
culated to be between 43 and 748 depending upon relapse
rates, completer rates and choice of group to analyse. How¬
ever, it was noted that 250 patients per group would suffice
if drop-out rates (not due to relapse) did not exceed 50%, the
relapse rate on placebo was at least 50%, and the group of
all patients was analysed. These assumptions were thought
not unreasonable (Pickens et al., 1985; Welte et al., 1983).
The following criteria led to exclusion from participation:
failure to give signed consent; pregnancy; breast feeding; not
wishing to aim for total abstinence; suicidal thoughts; previ¬
ous schizophrenia; mania; seizure disorder; amnesic disor¬
der; dementia; dependence on psychoactive drugs other than
alcohol; clinically important medical illness; use of disul-
firam in the 10 days preceding allocation to double-blind
treatment; receiving monoamine-oxidase inhibitor or lithium
with 10 days of allocation to double blind treatment; previ¬
ous drug allergies; currently in remission from alcohol de¬
pendence.
Randomisation after meeting inclusion and exclusion cri¬
teria was within centres, in blocks of eight, four patients
per block to each treatment. At randomisation, patients were
given the next sequential number at that centre, and received
the trial supplies for that patient number. The randomisa¬
tion code was provided by the department of statistics and
data management at Solvay-Duphar B.V. It was maintained
in a locked file, and access by monitors or other staff was
not possible until after the study database had been locked.
Per patient emergency disclosure envelopes were provided
to the investigators and to the pharmacies responsible for
the storage and dispensing of trials supplies. If an envelope
was opened, the investigator had to note the date and rea¬
son in the case report form. Such an action automatically
terminated the study for that patient.
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2./. Dose selection
The literature available at the point of design of this study
suggested that the effect of SSRIs on drinking was seen at
relatively high doses, at or above the antidepressant dose. For
example, fluoxetine is an effective antidepressant at 20 mg
per day while the anti-alcohol effect was seen at 60 mg per
day but not at 40 mg (Naranjo et al., 1988).
The choice was made for this study of a fluvoxamine dose
of 100-300 mg per day, with the intention to give doses at
the higher end of this range if well tolerated. The Company
literature had shown that lluvoxamine was effective as an
antidepressant at around lOOmg per day in most people.
Fluvoxamine (50 mg) and placebo were supplied in in¬
distinguishable yellow enteric-coated tablets, in numbered
containers for dispensing, according to a randomisation
schedule held centrally and by the clinic pharmacist. Nei¬
ther the investigator, their staff, nor the patients were aware
of the treatment allocation. No attempt was made to assess
how accurately the patient or investigator could guess to
which group the patient had been allocated.
2.2. Efficacy measures
The following measures were listed in the protocol as
primary efficacy variables:
• the proportion of patients abstinent since the last assess¬
ment (with missing values in LOCF analysis (last obser¬
vation carried forward) replaced by 'not abstinent');
• the proportion of patients not relapsing to uncontrolled
drinking since baseline (assessed only at Weeks 12 and
52), defined as 5 or more units on an occasion and 4 or
more such occasions in a week, or 12 or more units on
an occasion (a unit contained 9g ethanol i.e. as either: a
half-pint of beer, or one glass of wine (11% by volume), or
one measure of spirits (40% by volume)); missing values
in LOCF analysis were replaced by 'relapsed';
• alcohol dependence severity index (based on the sum of
the symptoms listed in DSM-1II-R criteria) (missing val¬
ues in LOCF analysis replaced by baseline value);
• the proportion of days not drinking since last assessment
(missing values in LOCF analysis replaced by baseline
value for proportion of typical heavy drinking week prior
to detoxification).
2.3. Supportive efficacy variables were
• serum gamma glutamyl transferase (GGT);
• clinical global index (CGI) severity of illness score
(National Institute of Mental Health, 1976) (missing val¬
ues in LOCF analysis replaced by last known on-drug
score);
• Hamilton depression scale (HAMD) (Hamilton, 1960):
total score and depressed mood score;
• STAI-Y state anxiety score (Spielberger, 1983).
The following informative measurements were made at
intake:
SADQ scale of severity of alcohol dependence (Stockwell
et al., 1983) (the dependence severity described above was
preferred as an outcome measure to SADQ), the TPQ per¬
sonality scale (Cloninger, 1987b); answers to the questions
'age at which patient started drinking regularly?' and 'age
when drinking became a problem?' (the interview being
conducted, and the age entered, by experienced clinicians,
mostly psychiatrists); and at intake and at follow-up: mean
red cell volume (MCV), breath alcohol, average amount of
alcohol consumed per week, visual analogue scale of alcohol
craving, ARPQ (the Alcohol-Related Problems Question¬
naire on health, family, work, legal adverse consequences:
Patience et al., 1997) and proportion of patients not satisfy¬
ing DSM-III-R criteria for alcohol dependence.
To improve the accuracy of data collected, monitors vis¬
ited each study site regularly, and checked investigators'
case report forms against raw data including patients' hospi¬
tal case records where appropriate, all subjects having given
prior consent to this. The computer database was constructed
using a procedure which called for double entry of case re¬
port form data, and which had inbuilt checks for erroneous
data entry.
2.4. Statistical testing
The data from the contributing centres were to be com¬
bined. An all-patient sample was to be used for safety and
tolerance analysis and an intention to treat (ITT) sample
for efficacy analysis (defined in Fig. 1). Tests were to be
two-sided and conducted at the 5% level of significance. No
formal adjustments were to be made for multiple testing,
though this was to be taken into account before interpreting
results should a number of comparisons reached statistical
significance.
The TPQ score was to be used according to the Type
I/II dichotomy defined by Cloninger (1987a,b,c) in which
TPQ score = (Harm avoidance score + Reward-dependence
score — Novelty-seeking score) and Type I are patients who
exhibit high TPQ sores, while Type II have scores in the
opposite direction. The median TPQ score in this study was
to be used to differentiate the sample into two types, with
those scoring above the median being classed as Type I and
those below the median as Type II.
Concordance between the typologies was assessed using
Goodman and Kruksal's gamma (http://www2.chass.ncsu.
edu/garson/pa765/assocordinal.htm#gamma).
It was specified in the protocol that for each primary effi¬
cacy variable an analysis of covariance would be conducted
for the Week 52 (LOCF) data, with the covariates being bi¬
nary indicators: gender, TPQ type and age at onset of regu¬
lar drinking and of problem drinking—before age 25 versus
at/after age 25.
Continuous data were analysed by r-tests and paramet¬
ric analysis of variance. Binary data were analysed by
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Fig. 1. Recruitment, randomisation and retention.
chi-square tests and binary logistic regression when co-
variates were included. Ordinal data were analysed by
ordinal logistic regression. Assumptions underlying these
procedures were checked appropriately and alternative
methods considered when assumptions were violated. In
particular, the Wilcoxon rank sum test was used when
the r-test proved invalid in a particular situation. Multiple
logistic regression analysis was employed to examine in¬




The outpatient psychosocial treatment usually offered at
each clinic was available to all patients in the study. This
varied between centres, but tended to be individual or group
therapy according to the precepts of cognitive-behavioural
therapy. Patients would often have been advised to at¬
tend meetings of Alcoholics Anonymous. The amount of
psychosocial treatment received by each subject was not
recorded.
2.5.2. Medication
Disulfiram was not permitted. All additional psychoactive
medications were forbidden, with the exception of night se¬
dation and medication, if required at some point in the study,
for alcohol detoxification. Night sedation, prescribed for as
short a period and as infrequently as possible was permitted
as follows: either chloral hydrate up to 2 g or temazepam
up to 20 mg taken 30 min before retiring. Electro-convulsive
therapy was forbidden.
If a patient relapsed to dependent drinking and required
detoxification, double-blind treatment was suspended and
the centre's own typical detoxification regimen was used.
Double-blind therapy could be restarted after completion of
detoxification and resumption of abstinence.
2.6. Assessments
Patients were assessed, usually by the same rater at each
occasion, after detoxification on the day of randomisa¬
tion, and after 2, 4, 6, 8, 12, 16, 24, 32, 40 and 52 weeks
of treatment. The scheduled end of the study was Week
52. To allow for flexibility in scheduling appointments,
individual patients could receive their final evaluation
up to two weeks early or late. They would still be con¬
sidered to have completed the study, provided that they
had also received double-blind medication until this final
assessment.
2.7. Withdrawals
Should a patient permanently discontinue medication, or
be instructed to discontinue study medication before the end
of Week 52, he or she was to be considered a premature
withdrawal.
Within the first eight weeks, any patient who missed 14
consecutive or 21 cumulative days of double-blind drug was
to be withdrawn from the study for non-compliance. The
underlying reason for non-compliance was considered when
deciding upon the 'reason for termination'. Likewise, the
reason for permanently stopping study medication was noted
on the withdrawal form, according to predefined categories.
Some patients continuing into the later weeks of the study
missed doses of medication for longer periods of time and
continued in the study. Such patients could continue, pro¬
vided that:
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• study medication had not been missed for four or more
consecutive weeks, medication was retitrated, according
to the time off drug,
• the dates of and reason for the drug holiday were docu¬
mented,
• and every effort was made to perform assessments on
schedule.
Should a patient's condition worsen or should a major
depressive episode emerge, the investigator had to decide
a course of treatment in the patient's best interest. Options
included: (1) increase study medication, (2) add concurrent
therapy or (3) discontinue study medication and consider
alternative therapy. Premature termination could be due to
'relapse to uncontrolled drinking after an adequate trial of
study medication (six tablets daily for at least 4 weeks)'; or
to 'uncontrolled drinking requiring a medical intervention
prohibited by the protocol'.
2.8. Initiation of medication
Patients were instructed to take one tablet during the first
3 days, then two tablets up to Day 7 and three tablets during
the second week all at bedtime. After Week 2, the dose could
be adjusted, if the patient was not suffering dose-limiting
symptoms, according to response. The maximum permitted
dose was six tablets per day. For dosages in excess of three
tablets, the dose was divided to twice daily. Records of dis¬
pensed and returned medication were maintained.
Table 1
Demographic and baseline clinical data, all-patient sample
Fluvoxamine Placebo
Age
Males N= 183 N = 183
Mean (S.D.) 41.6(10.0) 42.4(10.0)
Range 21-67 19-72
Females N = 61 N = 66
Mean (S.D.) 42.4 (10.4) 41.7 (7.8)
Range 21-68 25-61
Age at start of regular drinking
Mean (S.D.) 21.5 (8.3) 21.8 (7.6)
Range (median) 12-65 (18) 12-50 (18)
Age at start of problem drinking
Mean (S.D.) 31.3(10.9) 31.5(9.8)
Range (median) 14-66 (30) 15-65 (30)
Current pattern
Heavy drinking most days 65% 69%
Episodes interspersed with 5% 6%
abstinence
Mixed
Number of units in typical week's
recent heavy drinking: mean
(S.D.)
Number of days drank in typical
week: mean (S.D.)




SADQ: mean (S.D.) 32.0 (14.4) 32.2 (12.8)
GGT u/1: mean (S.D.) (median) 77 (98) (45) 81 (165) (40)
30% 24%
182 (117) 174 (118)
6.3 (1.4) 6.1 (1.5)
3. Results
3.1. Recruitment and retention
Fig. 1 shows that out of 521 patients who entered the
trial 493 took at least one dose of trial drug and contributed
at least some efficacy data (ITT sample). From the UK,
331 patients were entered, from Austria 120, from Eire 48
and from Switzerland 22. In age, gender and severity of
dependence (Table 1) they are typical of patients treated
at specialised alcoholism treatment centres. At entry, there
were no differences that reached statistical significance in
the characteristics measured of patients allocated to the two
treatment groups.
Fewer patients on fluvoxamine (flu) (28%) than on
placebo (pla) (45%) completed the study. Table 2 shows
the reasons for the higher numbers of drop-outs on flu¬
voxamine: ineffectiveness, intercurrent illness and adverse
experiences (clinical details in Table 4). The mean duration
of double-blind treatment was 173 days (S.D. 143, range
2-388, median 131) on lluvoxamine and 231 days (S.D.
144, range 1-399, median 280) on placebo.
Doses were to be titrated to the highest dose allowed
by the protocol (six tablets per day). After the sixth week,
of patients still taking medication, about twice the number
on placebo than on fluvoxamine were receiving the full six
tablets.
Efficacy by Week 2, 76% (flu) and 72% (pla) were still
abstinent but by Week 12 (LOCF) these proportions had
fallen to 42% (flu) and 46% (pla), and by Week 52 (LOCF)
to 29% (flu) and 29% (pla). Clearly, there are no differences
between the treatment groups on outcome measured as com¬
plete abstinence (Table 3).
Fig. 2 shows a trend towards less relapse to uncontrolled
drinking in the placebo group than the fluvoxamine group
at Week 12 in the LOCF analysis, but the difference is not
statistically significant (P = 0.18; Table 3).
Table 2
Reasons for withdrawal (numbers of cases) (total sample n = 492)
Fluvoxamine Placebo
Adverse experiences 34 11
Ineffectiveness 39 23
Intercurrent illness 13 7
Lost to follow-up 53 5)
Non-drug related 24 27
Protocol violation 5 4
Death other than suicide 1 1
Attempted suicide 3 8
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Table 3







Days not drinking since
last assessment
(a) LOCF
Week 12 Fluvoxamine (N = 243) 42% 54% 2.9 69%
Placebo (N = 249) 46% 60% 2.5 77%
P-value 0.40 0.18 0.029 0.009
Week 52 Fluvoxamine (N — 243) 29% 36% 3.6 56%
Placebo (N = 249) 29% 36% 3.5 62%
P-value 0.94 0.47 0.42 0.13
(b) Observed cases
Week 12 Fluvoxamine (/V = 151) 50% 64% 2.5 83%
Placebo (N = 192) 54% 69% 2.0 87%
P-value 0.46 0.38 0.087 0.081
Week 52 Fluvoxamine (N = 75) 55% 55% 2.4 88%
Placebo (TV = 117) 63% 63% 2.3 88%
P-value 0.24 0.24 0.75 0.99
In the LOCF analysis, at Week 12 the percentage of days
not drinking since the last assessment and the mean depen¬
dence severity was significantly more favourable for the
placebo group. In the observed cases analysis (i.e. including
only those on whom an assessment was made), there were
non-significant trends (P < 0.10) at Week 12 for these two
measures in favour of placebo. There were no statistically
significant differences between the two treatment groups at
the Week 52 endpoint for any of the four primary efficacy
variables.
3.2. Supportive efficacy variables
CGI: observed case analyses showed no difference be¬
tween treatment groups on the score change from Day 1 for
CGI at any assessment point. However, there were hints that
the outcome may be slightly less favourable on fluvoxamine
than on placebo in the CGI severity score change (P < 0.10)
at Weeks 12 and 52 on LOCF analyses. This was not found
at Week 24 LOCF.
HAMD total score: scores were low at baseline (mean 10,
range 0-41) and fell in both groups during treatment, with
no statistically significant treatment-related effects.
HAMD depressed mood item. No significant differences
between treatment groups were found.
STAI-YI: in general, no treatment related effects were
present. At one time point (Week 24) on one analysis
(number of patients with a 12-point fall from baseline),





baseline week 12 week 52
Fig. 2. Proportion of patients not relapsing to uncontrolled drinking since baseline: ITT sample, analysis based on last observation carried forward (LOCF)
(n = 492).
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3.3. Informative variables
Breath alcohol: at two time-points, fluvoxamine-treated
patients were found to have higher mean breath alcohol lev¬
els than placebo treated patients; Week 12, P — 0.012 and
Week 32, P — 0.023. The converse never occurred.
ARPQ: at three out of eight time-points on which total
alcohol-related problems were scored, fluvoxamine-treated
patients were rated as having more problems than patients
on placebo (Week 4, P — 0.064; Week 16, P = 0.006;
Week 40, P = 0.042).
GGT: no treatment-related effects were found.
Craving: no treatment-related effects were found.
3.4. Covariates affecting efficacy results
No sub-group analysis was made of patients who had
the higher depression scores at intake. The finding that the
fluvoxamine group did not benefit in terms of HAMD scores
more than placebo suggests that such a post hoc analysis
would not have been fruitful.
3.5. Typology by TPQ score
Table 5 shows data on relapse by typology and by treat¬
ment group, with all missing values deemed 'relapse'. Types
I and II, categorised according to TPQ scores (Cloninger),
had similar rates of survival over 52 weeks without relapse
on placebo (PLC I: 19.3%, n = 135; PLC II: 18.2%, n =
110), but on fluvoxamine Type II did worse than Type I
(FLU I: 13.7%, n = 131; FLU II: 6.1%, n = 114) (log rank
test, P = 0.0006). (This effect was visible already at Week
12 (log rank test, P — 0.0007); data not shown.) The corol¬
lary of this is that Type II patients did worse on fluvoxamine
than on placebo. This was not the case for Type I patients,
whose outcome was about the same on either drug. The data
for Week 52 are shown in Table 4.
3.6. Typologies by ages of onset
There were 243 subjects who reported starting regular
drinking below age 25, and of these 130 also had their
first problems before that age, concordance between these
parameters being low (gamma = 0.067; where there is
Table 4
Percentages of patients at Week 52 who had not relapsed (all patient
sample) alcoholism typology according to TPQ
Fluvoxamine (At = 260) Placebo (At = 260)
Type 1 Type 11 Type I Type 11
At = 131 At =114 At = 135 At = 110
13.7% 6.14% 19.3% 18.2%
Chi-square test: P = 0.0172. Log rank test: P = 0.000602.
complete concordance, gamma = 0.5). There was also little
concordance between TPQ score (high/low) and start of reg¬
ular drinking (below/at or after 25 years) (gamma = 0.094)
and age of onset of problems (below/at or after 25 years)
(gamma = 0.057).
Age of start of regular drinking was a slightly stronger
predictor of relapse by 52 weeks (P — 0.0224) than age of
onset of problems (P = 0.0537). The predictive effect was
greatest for relapse in first 16 weeks: for age of start of regu¬
lar drinking, P — 0.0048, and for age of onset of problems,
P = 0.0438. If adjustment is made for gender as an addi¬
tional explanatory variable, age of regular drinking below
25 still predicts both relapse by 52 weeks (P = 0.0299) and
relapse by 16 weeks (P = 0.0056).
Males tended more often than females to report an onset
of regular drinking and of problems before age 25. Gender
affected subjects' response to treatment, males responding
better to placebo than fluvoxamine which was an interaction
that was not seen for females (log rank test, P = 0.0052;
Week-52 data). Therefore, the interaction between age of on¬
set typology and treatment was examined adjusted for gen¬
der. Adjusted for gender, onset of problems before age 25
did not predict poor response to fluvoxamine (log rank test,
p = 0.143) though numbers in some cells being small may
have affected accuracy. Unadjusted for gender, interaction
with treatment was significant (log rank test, P = 0.002),
with onset of problems before age 25 indicating poorer re¬
sponse to fluvoxamine.
For age of start of regular drinking, adjusting for gender
does not significantly reduce the interaction: fluvoxamine
patients are still more likely to have relapsed at 52 weeks
than placebo patients (P = 0.01 17) (Table 5). When males
only are examined, the interaction between age of start of
regular drinking, and treatment group, is still significant
(P = 0.0124).
Table 5
Multiple logistic regression: relation between treatment group, age of start of regular drinking and gender (all patient sample)
Estimate Standard error Z-value Pr (>[Z])
Intercept 2.018 0.131 6.746 9.4 x 10"lla
Treatment group -0.666 0.264 -2.520 0.0117h
Age of start of regular drinking <25 years -0.345 0.570 -0.605 0.5450
Gender -0.005 0.309 -0.017 0.9862
Interaction: gender x start of regular drinking <25 years 1.498 0.710 2.111 0.0348b
a Highly significant.
b Significant.
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Table 6
Adverse events reported by at least two patients in the fluvoxamine-treated
group and reported at least twice as often as patients on placebo
Adverse experience Number of reports: Number of reports:
fluvoxamine placebo
Asthenia 5 1









Manic reaction 3 0




Adverse events Table 6 shows the adverse experiences
that occurred more often in the fluvoxamine than the placebo
group. Asthenia, abdominal pain, diarrhoea, nausea, agita¬
tion and tremor are typical of a selective serotonin reuptake
inhibitor. The frequencies of these events are typical of stud¬
ies with fluvoxamine at this dosage in other indications. It is
notable that suicide attempts occurred in eight of the placebo
patients but only in three of the fluvoxamine group.
Two deaths occurred during the study. A 63-year-old male
placebo-treated patient died suddenly, after only 7 days in the
study. One fluvoxamine-treated patient (a 54-year-old male)
died following a massive haematemesis from oesophageal
varices after 31 days of treatment. Oesophageal varices are
a long-term consequence of alcoholic liver cirrhosis. The
investigator on site did not attribute this death to the study
drug.
4. Discussion
This study shows no evidence that fluvoxamine helps pre¬
vent relapse in detoxified, abstinent, alcoholics. On the con¬
trary, fluvoxamine was associated with worse outcome than
placebo for early-onset drinkers, or Type II on the basis
of their TPQ scores. If the outcome overall was no differ¬
ent for fluvoxamine than for placebo, and a worse outcome
was seen with fluvoxamine than for Type II, why did the
data not show a 'balancing' advantage for fluvoxamine in
Type I? The reason, we suggest, is that although the over¬
all result showed that outcome for fluvoxamine was not
significantly different from the outcome for placebo, there
was nevertheless a trend towards a worse overall outcome
for fluvoxamine—attributable to the harmful effect (which
reached significance) in Type II patients.
There was a high drop-out, especially in fluvoxamine-
treated patients, and thus for analysis a procedure that
permits missing values to be entered was necessary. LOCF
analysis is such a method. On LOCF analysis, at Week
12, fluvoxamine-treated patients appear to be drinking on
more days, and appear to have a worse dependence severity
score. Observed cases analyses only showed a trend towards
that effect which suggests that perhaps the apparent differ¬
ences between the two treatment groups can be accounted
for by the adoption of the "worst-case" LOCF analyses.
Three explanations will be considered for the three-way
association between being in the fluvoxamine group,
dropping-out of the study and drinking more with more
problems.
First, in the LOCF analyses, drop-outs were allocated
baseline DSM-III-R alcoholism dependence severity derived
index scores, and were assumed to be drinking. There were
more drop-outs on fluvoxamine, so fluvoxamine seems to
have a negative effect as an artefact of entering LOCF values.
Frequent drop-out on fluvoxamine was noted by Kranzler
et al. (1993), who aborted a placebo-controlled study of flu¬
voxamine in alcoholism because 6 out of 10 subjects given
fluvoxamine withdrew due to side effects (nausea, headache
and sedation) and 2 out of 10 due to return to heavy drink¬
ing, compared to one placebo-treated patient who with¬
drew due to return to heavy drinking and none due to side
effects.
A second explanation is that perhaps subjects on fluvox¬
amine drank more as a result of dropping-out, albeit due to
their intolerance of the drug, because they did not continue
to benefit from other aspects of the treatment offered at the
clinic.
Third, perhaps SSRIs by themselves increase the risk
of drinking in some patients. This could be due to
adverse-effects. Many of the symptoms reported in excess
on fluvoxamine resemble alcohol withdrawal symptoms
(diarrhoea, nausea, anxiety, agitation, insomnia, tremor).
Patients are used to self-medicating themselves to reduce
withdrawal symptoms. Or it could be due to an action of an
SSRI which increases, in some patients, the likelihood of
relapse. For example, anecdotally, patients being treated for
depressive or anxiety disorders sometimes report feeling
more carefree and optimistic, even more ready to take risks.
Indeed, this may be one explanation for the success of the
SSRIs in obsessional patients crippled by over-cautiousness.
The patient who is newly abstinent from alcohol may do
best if he is very cautious and does not take risks especially
with alcohol. Poor prognosis in our sample was predicted
by risk-taking, and impulsive traits (Willinger et al., 2002)
and conceivably this could be exacerbated by an SSRI.
4.1. Typology analysis
Our result replicates that of Kranzler et al. (1996) who
found that random allocation to fluoxetine rather than
placebo impaired drinking outcome of 'Type B' alcoholics
(who are in part defined as early onset). The result also
recalls that of Pettinati et al. (2000a), who found that
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sertraline, while benefiting Type A alcoholics, had no effect
in Type B patients. There was variation between sites in our
study in the psychosocial intervention received by the sub¬
jects, which could theoretically have been a confounder, but
the fact that the above two studies which used manualised
therapies found a similar typology relationship supports the
typology construct we report here.
One explanation for our finding is that impulsivity in Type
B patients, instead of being reduced by serotonin enhance¬
ment as previous authors suggested, may be worsened. An¬
other could be that early onset regular drinkers or Type II
subjects (cf. Type 'B') patients are more prone to drink to
reduce the side effects of these drugs such as agitation or
insomnia.
In the only other published completed randomised con¬
trolled study of fiuvoxamine in preventing relapse in alcohol
dependent patients (Angelone et al., 1998), fiuvoxamine
(I50mg per day) was associated with nearly twice the
abstinence rate over 16 weeks as the no-tablets control
group. That was a single-blind study. Note that in this study
the fiuvoxamine group had a relatively high proportion of
women (40%) and tended to be 'late onset patients' (mean
age 44.8 years, mean duration of alcohol dependence 107
months).
A possibly relevant finding with the SSRI citalopram has
been reported by Berggren et al. (2001). They found that
alcohol-dependent patients who had low or no prolactin
response to fenfluramine (a measure of central serotonergic
function), tended to have a worse drinking outcome than
patients with a more normal prolactin response. Deficient
serotonergic responsivity is one feature of early onset al¬
coholism (Roy et al., 1987; Fils-Aime et al.. 1996). It is
possible that a serotonin antagonist is a more appropri¬
ate medication, if one is to be offered, for a Type II or
early-onset patient (Johnson, 2000).
5. Conclusion
Systematic reviews find that serotonergic medications
probably only benefit alcoholics who have a definite de¬
pressive illness or anxiety disorder (Garbutt et al., 1999).
Our fiuvoxamine study adds to other data suggesting that,
unless there is an over-riding clinical reason such as spe¬
cific psychiatric co-morbidity, caution should be exercised
in the use of SSRIs in patients whose regular drinking com¬
menced before age 25 or who report problems from their
drinking before age 25.
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Antidepressant treatment and the risk of fatal and ^
non-fatal self harm in first episode depression: nested
case-control study
Carlos Martinez, Stephan Rietbrock, Lesley Wise, Deborah Ashby,Jonathan Chick,Jane Moseley,
itephen Evans, David Gunnell
Abstract
Objective To compare die risk of non-fatal self harm
ind suicide in patients taking selective serotonin
euptake inhibitors (SSRIs) with that of patients
aking tricyclic antidepressants, as well as between
Efferent SSRIs and different tricyclic antidepressants,
lesign Nested case-control study.
Jetting Primary care in the United Kingdom,
'articipants 146 095 individuals with a first
irescription of an antidepressant for depression,
dain outcome measures Suicide and non-fatal self
tarm.
Results 1968 cases of non-fatal self harm and 69
uicides occurred. The overall adjusted odds ratio of
ion-fatal self harm was 0.99 (95% confidence interval
186 to 1.14) and that of suicide 0.57 (0.26 to 1.25) in
leople prescribed SSRIs compared with those
irescribed tricyclic antidepressants. We found little
vidence that associations differed over time since
tarting or stopping treatment We found some
vidence that risks of non-fatal self harm in people
irescribed SSRIs compared with those prescribed
ricyclic antidepressants differed by age group
interaction P = 0.02). The adjusted odds ratio of
ion-fatal self harm for people prescribed SSRIs
ompared with users of tricylic antidepressants for
hose aged 18 or younger was 1.59 (1.01 to 2.50), but
to association was apparent in other age groups. No
uicides occurred in those aged 18 or younger
urrently or recendy prescribed tricyclic
ntidepressants or SSRIs.
Conclusion We found no evidence that the risk of
uicide or non-fatal self harm in adults prescribed
ISRIs was greater than in those prescribed tricyclic
ntidepressants. We found some weak evidence of an
acreased risk of non-fatal self harm for current SSRI
ise among those aged 18 or younger. However,
(referential prescribing of SSRIs to patients at higher
isk of suicidal behaviour cannot be ruled out
ntroduction
lata in adults have not consistently shown any
ffluence on suicide or self harm from use of selective
erotonin reuptake inhibitor (SSRI) antidepressants.1
tandomised controlled trials in young people,
lowever, indicate that they may increase the risk ofsui-
idal thoughts and self harm in those aged under 19.2 5
The most comprehensive studies of suicidal behav-
nur are based on data from the General Practice
Lesearch Database.4 5 The first found some evidence of
n increased risk of suicide among people prescribed
uoxetine,4 but the drug's safety in overdose may have
I'd to selective prescription to people at risk of self
iarm. The other study found no notable differences
between a range of antidepressants and risk of fatal or
non-fatal suicidal behaviour.5 However, the study was
not restricted to patients treated for depression and
examined only four antidepressants.
We report a nested case-control study, based on the
General Practice Research Database, of patients with a
new diagnosis of depression who were prescribed anti¬
depressants for the first time between 1995 and 2001.
We compared the risk of non-fatal self harm and




Our cohort comprised patients aged 10 to 90 years
with a first recorded prescription for antidepressants
between 1 January 1995 and 31 December 2001.
Members of the cohort were required to have contrib¬
uted a minimum of 365 days to the database before
their first recorded prescription for antidepressants
and to have received a diagnosis of depression in the
180 days before or 90 days after entry to the cohort
The date of the first prescription of antidepressants
defined entry to tire cohort Follow up ended with the
earliest of either an episode of suicidal behaviour, the
end of the first treatment episode, the end date of the
study, or when the patient left the practice.
We identified depression by a set of Read and
Oxford Medical Information System (OXMIS) medical
terms indicative of depression, bipolar disorder, or dys¬
thymic disorder. We classed severity of depression as
mild, moderate, or severe (see b'mj.com). We catego¬
rised antidepressants into three classes: tricyclic and
related antidepressants, SSRIs, and other antidepres¬
sants (see bmj.com).
We studied two outcomes, non-fatal self harm and
suicide, using the relevant medical terms, review of the
patient's free text notes, and death certificates when
available (around 60% of cases).
We selected a random sample of up to 20 controls
for each case from the cohort, matching for sex, year of
birth within one year, and duration of cohort member¬
ship. We derived the duration ofprescriptions from the
quantity of drug prescribed and the daily dose plus an
additional seven day washout period (see bmj.com).
Data analysis
We classified the cases and controls as currently or pre¬
viously exposed to an SSRI, tricyclic antidepressant, or
Editorial by Cipriani
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Table 1 Characteristics of study cohort according to first antidepressant class prescribed. Values are numbers (percentages) unless
otherwise indicated




(n=4863) Total (n=146 095)
Age in years:
10-18 3830 (4) 1316 (3) 141 (3) 5287 (4)
19-30 23 561 (26) 10 145 (20) 1086 (22) 34 792 (24)
31-45 31 541 (35) 15 431 (30) 1548 (32) 48 520 (33)
46-60 18 310 (20) 11 506 (23) 989 (20) 30 805 (21)
61-75 7949 (9) 7538 (15) 605 (12) 16 092 (11)
76-89 5212 (6) 4893 (10) 494 (10) 10 599 (7)
Women 58 444 (65) 33 399 (66) 2924 (60) 94 767 (65)




0.67 (0.57-1.03) 0.65 (0.57-1.02) 0.65 (0.57-1.02) 0.66 (0.57-1.03)
Severity of depression:
Mild 60 537 (67) 36 893 (72) 3306 (68) 100 736 (69)
Moderate 26 710 (30) 12 116 (24) 1329 (27) 40 155 (27)
Severe 3156 (3) 1820 (4) 228 (5) 5204 (4)
Referral to psychiatrist or
psychologist*
721 (1) 211 (0) 75 (2) 1007 (1)
History of self harmf 479 (1) 201 (0) 33 (1) 713 (<1)
Concomitant conditions:
Diagnosis of, or therapy for,
anxiety and panic disorders
21 501 (24) 11 209 (22) 1476 (30) 34 186 (23)
Schizophrenia 101 (0) 97 (0) 10 (0) 208 (0)
Antipsychotic therapy 2947 (3) 1916 (4) 252 (5) 5115 (4)
Drug misuse 61 (0) 45 (0) 3 (0) 109 (0)
Alcohol misuse 2408 (3) 1269 (2) 184 (4) 3861 (3)
"In year previous to index day.
tlncludes drug overdose, poisoning, self laceration, and other non-fatal suicidal attempts before entry to cohort.
other antidepressant, or co-exposed to more than one
antidepressant, according to the exposure status on the
index day (day of self harm or suicide or equivalent
control day). We standardised the incidence rates to the
UK populadon in 2001.
We assessed risks associated with "current exposure"
by using multivariable conditional logistic regression
controlling for a range of possible confounding factors
(see bmj.com). We investigated whether risk varied in
relation to duration of current use of antidepressants,
time since stopping treatment, and age at entry to the
cohort (10-18, 19-30, and >30). We stratified by the
duration of exposure (days) to antidepressants and time
since discontinuation. In all comparisons, we compared
SSRI monotherapy with tricylic antidepressant mono¬
therapy for the same duration of exposure.
Results
Our cohort included 146 095 patients with a first pre¬
scription for an antidepressant for depression, contrib¬
uting 62 224 person years of follow (see bmj.com).
Almost twice as many women as men received antide¬
pressants. SSRIs were the most commonly prescribed
antidepressants. People prescribed SSRIs tended to be
younger, with a more frequent history of self harm and
referral to psychiatrists than those prescribed tricyclic
antidepressants (table 1).
The strongest predictors of non-fatal self harm
were a history of self harm, referral to a psychiatrist,
alcohol misuse, and drug misuse. The strongest predic¬
tors for suicide were a history of non-fatal self harm,
antipsychotic therapy, number of antidepressants
prescribed in the previous year, alcohol misuse, and
referral to a psychiatrist
Over the study period, 1968 people had a record
episode of non-fatal self harm: 1344 were exposed
antidepressant medication at the time, and 624 fi
stopped treatment before the episode. Drug overdc
accounted for most episodes of non-fatal self ha
(81%). The incidence rate ofnon-fatal self harm, stai
ardised by age and sex, per 100 000 person years
follow up among people prescribed antidepressa
was 2894 (95% confidence interval 2618 to 3170). 1
rate per 100 000 person years for men was 2834 (25
to 3089) and for women was 2952 (2471 to 3432).
Overall, 69 suicides took place (56 men,
women); 36 of those people were taking antidepr
sants at the time of death. The overall standardi:
incidence rate for suicide was 62 (40 to 85) per 100 C
person years; in men this was 117 (72 to 163) and
women 9(1 to 18).
The adjusted odds ratio for non-fatal self ha
among SSRI users compared with users of tricyi
antidepressants was 0.99 (0.86 to 1.14). We found
evidence that the risk "of non-fatal self harm var
among the different individual SSRIs or tricy
antidepressants (P = 0.35 and P = 0.69, respectivi
and no evidence of an increased risk of suicide assc
ated with use of SSRIs compared with tricyclic anti
pressants (odds ratio 0.57, 0.26 to 1.25; table 2).
We found borderline evidence that the risk of m
fatal selfharm (P for interaction = 0.05), but not suic
(P for interaction = 0.73), differed between the differ
antidepressant categories in relation to time sh
starting therapy. This association showed no cl
pattern.
We found evidence of a difference in risk
non-fatal self harm for current SSRI users compa
with current users of tricyclic antidepressants
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Table 2 Risk of non-fatal self harm and completed suicide in people prescribed SSRIs, other antidepressants, or exposed to more
than one antidepressant compared with people prescribed tricylic antidepressants and among specific SSRIs compared with paroxetine
and specific tricyclic antidepressants compared with dothiepin (all ages)
Non-tatal self harm Completed suicides
Controls
Cases (n=19 Crude odds ratio Adjusted odds ratio* Cases Controls Crude odds ratio Adjusted odds ratio*
Exposure (n=1344) 953) (95% CI) (95% CI) (n=36) (n=664) (95% CI) (95% CI)
Any current use of
tricylic
antidepressant
319 4901 1 1 15 201 1 1
Any current use of
SSRIs
854 13 636 0.97 (0.85 to 1.12) 0.99 (0.86 to 1.14) 17 406 0.59 (0.28 to 1.27) 0.57 (0.26 to 1.25)
Other
antidepressants
86 894 1.30 (1.01 to 1.68) 0.99 (0.76 to 1.29) 3 28 1.51 (0.39 to 5.85) 0.80 (0.16 to 4.06)
Co-exposuret 85 522 2.55 (1.96 to 3.31) 1.53 (1.15 to 2.04) 1 29 - -
Specific SSRIs:
Paroxetine 289 4209 1 1 8 135 1 1
Citalopram 128 1915 1.03 (0.83 to 1.29) 1.01 (0.80 to 1.26) 2 5 - -
Fluoxetine 304 5239 0.88 (0.74 to 1.04) 0.94 (0.79 to 1.11) 6 159 0.60 (0.20 to 1.81) 0.42 (0.13 to 1.39)
Fluvoxamine 42 810 0.74 (0.52 to 1.03) 0.73 (0.52 to 1.04) 0 29 - -
Sertraline 91 1463 0.92 (0.72 to 1.17) 0.86 (0.67 to 1.10) 1 33 - -
Specific tricyclic antidepressants:
Dothiepin 136 2334 1 1 7 102 1 1
Amitriptyline 66 926 1.21 (0.89 to 1.65) 1.18 (0.86 to 1.61) 2 31 - -
Lofepramine 68 1096 1.11 (0.82 to 1.50) 1.08 (0.79 to 1.47) 4 47 1.12 (0.30 to 4.20) 0.94 (0.24 to 3.61)
Other tricylic
antidepressant
49 545 1.43 (1.01 to 2.02) 1.19 (0.83 to 1.69) 2 21 " -
"Adjusted for severity of depression; time depression was diagnosed in relation to start of therapy; referral to psychiatrist or psychologist before index day; history
of sell harm; diagnosis of, or treatment for, anxiety or panic disorder; schizophrenia; antipsychotic drugs; drug misuse; and alcohol misuse.
tAny exposure to more than one antidepressant of same class or different classes.
relation to age (P for interaction = 0.02), with an
increased risk associated with SSRI use among those
aged 18 or younger, but not in 19 to 30 year olds or
those older than 30 (table 3).
hi people aged 18 or younger, we found no
evidence ofany difference in risk ofnon-fatal selfharm
between individual tricyclic antidepressants, but
among SSRIs (figure), the greatest risk was in relation
to paroxetine use.
The risk of non-fatal self harm or suicide did not
seem to differ between or within antidepressant classes
according to the time since stopping treatment (see
bmj.com).
Discussion
In patients with newly diagnosed depression treated
with antidepressants for the first time, we have found
no evidence that the risk of suicide or non-fatal self
harm in people currently prescribed SSRIs is higher
than in those prescribed tricyclic antidepressants.
We found no strong evidence of variability in the
risk of non-fatal self harm between substances or
between drug classes associated with time since
starting or stopping antidepressant therapy. However,
in patients aged 18 or younger, we found the risk of
non-fatal self harm was higher in people prescribed
SSRIs than with tricyclic antidepressants. In this age
group, we found a weak indication that the risk of non¬
fatal self harm among users of the SSRIs studied is
highest in those who used paroxetine. These findings
are in keeping with those ofJick et al.5
Limitations
SSRIs are relatively non-toxic in overdose; it is possible
that they were selectively given to individuals at higher
risk of overdose and that SSRI overdose did not result
in presentation to hospital or general practice.
Table 3 Risk of non-fatal self harm in people prescribed SSRIs compared with tricyclic antidepressants in relation to age
Non-fatal self harm
Exposure Cases (n=1344) Controls (n=19 953) Crude odds ratio (95% CI) Adjusted odds ratio* (95% CI)
10-18 yearsf:
Any current use of tricyclic antidepressants 24 493 1 1
Any current use of SSRIs 168 2148 1.73 (1.10 to 2.72) 1.59 (1.01 to 2.50)
19-30 years:
Any current use of tricyclic antidepressants 106 1687 1 1
Any current use of SSRIs 312 5013 1.00 (0.79 to 1.27) 1.04 (0.82 to 1.32)
>30 years:
Any current use of tricyclic antidepressants 189 2721 1 1
Any current use of SSRIs 374 6475 0.83 (0.69 to 1.01) 0.86 (0.71 to 1.04)
Participants exposed to more than one antidepressant or prescribed non-SSRI, non-tricyclic antidepressants (see table 2) were included in models but, for
presentational purposes, data are not given in table.
•Adjusted for severity of depression; time depression was diagnosed in relation to start of therapy; referral to psychiatrist or psychologist before index day; history
of self harm; diagnosis of, or treatment for, anxiety or panic disorder; schizophrenia; antipsychotic drugs; drug misuse, and alcohol misuse,
tlncludes nine cases of non-fatal self harm and 86 controls exposed to SSRIs, and no cases and t8 controls exposed to tricyclic antidepressants among patients
aged 10 to 14 years.
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Previous self harm is an important predictor of further
self harm and suicide. The prevalence of recorded past
self harm among study members who harmed
themselves (< 5%) is considerably lower than reported
among case series of people who harmed themselves
(50%)6 and completed suicides (30% to 47%),7 which
indicates the possibility of residual confounding if
non-fatal self harm is recorded differentially for SSRIs
compared with tricyclic antidepressants. Three other
limitadons are worth noting. Firsdy, we assumed
prescribing to be a marker for exposure, but not all
prescriptions are dispensed, and some of those
dispensed are not taken. Secondly, it is possible that
some associations may be chance findings. Thirdly, we
did not deal with the question of whether people
treated with SSRIs are at greater risk of self harm than
those with equivalent morbidity who do not receive
treatment. We have assessed risk only relative to people
receiving tricyclic antidepressants.
Representativeness of the study
The suicide rate in our study (62 per 100 000 patient
years) was higher than in the general population (9 per
100 000 people). The incidence of non-fatal self harm
was seven times higher than that of around
400/100 000 in 1995 reported in Oxford.8 The ratio of
cases of non-fatal to fatal self harm (approximately
30:1) in our study approximates to the ratio of the esti¬
mated number of hospital presenting episodes of self
harm (n= 142 000)8 and suicides in the general popu¬
lation of England and Wales (n = 5000).9
Potential biases
Our findings for people younger than 19 are
consistent with the results from randomised controlled
trials,2 3 but they may have resulted from confounding
by indication. For example, patients with personality
disorders and adjustment disorders may be given a
diagnosis of depression in primary care and be
prescribed SSRIs.
Strengths of the study
The main strengths are the large sample size, detailed
exposure data, and confounder information. Our study
covered 1995 to 2001 and patients with a first
prescription of antidepressants in this period. Further¬






Risk of non-fatal self harm in patients aged 10-18 currently exposed
to citalopram, fluoxetine, fluvoxamine, and sertraline compared with
paroxetine
What is already known on this topic
Selective serotonin reuptake inhibitors (SSRIs) are
the most commonly prescribed class of
antidepressant
Evidence from recent clinical trials shows that
SSRIs may increase the risk of self harm and
suicidal thoughts in children and adolescents
Previous studies of the risk of suicide in adults
have been restricted to the four most frequently
prescribed antidepressants and have lacked
statistical power to identify whether risks differ in
children compared to adults
What this study adds
Risks of self harm and suicide were no different in
adults prescribed SSRIs compared with those
prescribed tricyclic antidepressants.
Children and adolescents prescribed SSRIs
seemed possibly to be at increased risk of self
harm compared with those prescribed tricyclic
antidepressants
No children taking antidepressants in this study
committed suicide
The absence of excess risk of self harm in adult
users of SSRIs may be interpreted as reassuring
evidence of their safety or that any adverse or
protective effects of SSRIs are no different from
those seen with other antidepressants.
non-fatal self harm and suicides gives us considerab
more power than previous studies.
We have endeavoured to control as closely as poss
ble for factors that may be associated both with the ri:
of suicidal behaviour and the choice of antidepressar
Conclusion
As prescribing to adults accounts for over 95% of ani
depressant use in the United Kingdom, our findir
that SSRIs and tricyclic antidepressants have a simil;
risk profile with respect to suicide and non-fatal sc
harm is reassuring. It is possible, however, that at
adverse or protective effects are common to all class<
of antidepressants. Further research, based on lan
randomised trials, should assess the long term ar
short term risk and benefits of antidepressants ar
compare these with non-pharmacological therapi
for depression in adults.
Paroxetine Citalopram Fluoxetine Fluvoxamine Sertraline
Specific selective serotonin reuptake inhibitor
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Subfecundity and neonatal mortality: longitudinal study
within the Danish national birth cohort
Olga Basso,Jorn Olsen
Treatment for infertility correlates with adverse out¬
comes in pregnancy, especially in singleton deliveries.1 A
long time to pregnancy (subfecundity) also correlates
with adverse outcomes,2"1 but few studies evaluating
treatment take subfecundity into consideration. We
explored the association between time to pregnancy and
neonatal death in the Danish national birth cohort
Participants, methods, and results
We identified 27 624 firstborn singleton babies, born
alive from the 24th week of gestation between March
1998 and December 2001, whose mothers were
enrolled in the Danish national birth cohort.4 5
Mothers had been interviewed during pregnancy (50%
by the 16th completed week and 95% by the 25th) and
asked about pregnancy planning and other factors.
Women who reported having planned or partly
planned their pregnancy were asked how long it had
taken them to conceive. If the answer was six months or
longer, they were further asked whether they had
received infertility treatment We excluded 402 women
reporting infertility treatment after less than one year
of trying and 11 women with missing data on smoking.
We analysed 27 329 births (with 66 deaths within 28
days of life (0-24%)). Age at death was recorded in the
Danish birth registry.
We grouped women into five categories: up to two
months of waiting time (reference); 3-12 months; >12
months, no infertility treatment; >12 months, treatment
reported; and non-planners (including part planners).
We examined the association between these categories
and neonatal death through logistic regression, adjust¬
ing for mother's age, body mass index, smoking, and
social class, the latter derived from the mother'sjob title.4
The risk of neonatal death increased with
increasing time to pregnancy (table). Death between
the 29th and the 365th day of life was not related to
time to pregnancy (data not shown).





















Neonatal deaths (per 1000 births) as a function of time to pregnancy and treatment and crude and adjusted logistic regressions
Time to pregnancy or treatment Deaths/births (per 1000) Crude odds ratio (95% CI) Adjusted odds ratio* (95% CI)
<3 months 13/8361 (1.55) 1.00 1.00
3-12 months 22/7944 (2.77) 1.78 (0.90 to 3.54) 1.76 (0.89 to 3.50)
>12 months 18/4142 (4.35) 2.80 (1.37 to 5.73) 2.82 (1.35 to 5.90)
No treatment reported 11/2104 (5.23) 3.38 (1.51 to 7.54) 3.32 (1.47 to 7.53)
Treatment reported 7/2038 (3.03) 2.21 (0.88 to 5.55) 2.32 (0.86 to 5.80)
Unplanned or partly planned 13/6882 (1.89) 1.22 (0.56 to 2.62) 1.14 (0.52 to 2.49)
"Adjusted for mother's age at delivery (<26 years, 26-30, 31-35, >36), smoking from conception to time of interview (no/yes), pre-pregnancy body mass index (<20,
20-24.9, 25-29.9, >30, missing), and social class (low, middle, high, missing). All covariates except age were self reported. When social class or body mass index
were missing (4.8%), we included a separate category in the variable.
BMJ VOLUME 330 19 FEBRUARY 2005 bmj.com 393
Eur J Clin Pharmacol (2004) 60: 221-224
DOI 10.1007/s00228-004-0748-x
PHARMACOEPIDEMIOLOGY AND PRESCRIPTION
D. N. Bateman ■ J. Chick • A. M. Good
C. A. Kelly ■ G. Masterton
Are selective serotonin re-uptake inhibitors associated with
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Abstract Objective: To investigate likelihood of self-
harm by overdose with antidepressant drugs of different
types by examining hospital admission data and poisons
inquiries and relating them to prescribing.
Design: Retrospective analysis of prospectively collected
data on overdose admissions, poisons inquiries and
prescribing of antidepressants in Edinburgh and Scot¬
land.
Setting: Poisons treatment unit of the Royal Infirmary
of Edinburgh and its surrounding catchment for over¬
dose cases and Scotland for poisons inquiries.
Participants: All patients admitted to the Royal Infir¬
mary of Edinburgh between 1 January 2000 and 31
December 2002 with an overdose involving an antide¬
pressant.
Main outcome measures: Overdose admissions (patients)
in relation to prescribing in Edinburgh and poisons
inquiries in relation to prescription rates in Scotland.
Results: There were 1656 admissions involving 1343
patients. The likelihood of admission for an individual
patient in relation to volume of prescribing (likelihood
ratio: 95%CI) in the catchment was somewhat smaller
for amitriptyline (0.83:0.74-0.92) and sertraline
(0.79:0.63-0.99), and somewhat greater for mirtazapine
(1.99:1.57-2.51), trazadone (1.30:1.09-1.54) and venla-
faxine (1.33:1.13-1.55). For poisons inquiries in Scot¬
land, the excess for venlafaxine and mirtazapine was
confirmed and likelihood of an inquiry lowest for
selective serotonin re-uptake inhibitors (SSRIs).
D. N. Bateman (E3) ■ A. M. Good • C. A. Kelly
Scottish Poisons Information Bureau (NPIS Edinburgh),
Royal Infirmary of Edinburgh, 51 Little France Crescent,





Department of Psychological Medicine,
Royal Infirmary of Edinburgh, EH 16 4SA Edinburgh, Scotland
J. Chick
Royal Edinburgh Hospital, EH 10 5HF Edinburgh, Scotland
Conclusions: There was no evidence of an excess likeli¬
hood of presentation with overdose with SSRIs, and the
likelihood was reduced with sertraline. There was a
small excess of both admissions and poisons inquiries
for mirtazapine and venlafaxine. This is a concern in
view of the increased toxicity of venlafaxine in overdose
in comparison with SSRIs.
Keywords Selective serotonin re-uptake inhibitors •
Self-harm • Antidepressant
Introduction
Antidepressants developed over the past 40 years have
revolutionised the management of depression. Patients
with depression are at risk of suicide and self-harm.
There has been concern that antidepressant drugs
themselves may increase the risk of self-injury and sui¬
cide. Furthermore, there have been suggestions that such
effects may be more likely with some drugs than others,
particularly with respect to selective serotonin re-uptake
inhibitors (SSRIs).
In 1990, some case histories were published suggest¬
ing that fluoxetine might increase suicidality in some
patients [1], A UK study in 1995-1996 suggested an
excess risk of self-harm in association with SSRI pre¬
scribing [2], but overdose patterns change with time [3,
4], The current position is confused as three recent pa¬
pers illustrate. Hall et al. (2003) [5] have suggested from
Australian mortality data that a reduction in suicides
among the elderly may be linked to increased prescribing
of SSRIs. Khan et al. (2003) [6] examined the USA Food
and Drug Administration (FDA) summary reports of
the controlled clinical trials for nine modern FDA-
approved antidepressants. Of 48,277 depressed patients
participating in the trials, 77 committed suicide. Based
on patient-exposure years, their analysis could not
support an overall difference in completed suicide risk
between antidepressants and placebo-treated depressed
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subjects, or between SSRIs and either other antide¬
pressants or placebo suicide rates. The authors pointed
out that patients recruited to such trials tend not to be
suicidal at entry and are mild to moderately, rather than
severely, depressed. Healy (2003) [7] considered that
SSRIs increase suicide risk, particularly in vulnerable
patients.
The issue was heightened in the UK in June 2003 with
an announcement by the CSM recommending paroxe¬
tine not to be prescribed to treat depression in young
people up to the age of 18 years, and attributing an
excess risk (relative risk 1.5 to 3.2) of suicidal behaviour
to the drug [8]. The manufacturer, at about the same
time, added to the Undesirable Effects section of the
Summary of Product Characteristics for paroxetine that,
in their paediatric clinical trials, "self-harm, suicidal
thoughts and attempted suicide" were among those ad¬
verse events which had occurred "at a rate of at least
twice that of placebo" [9].
If SSRIs were associated in the adult population with
an increased risk of self-harm in comparison with other
antidepressants, then an excess likelihood of hospital
admission arising from drug overdose might occur. In an
attempt to address this issue, we have examined patterns
of admission to our poisons treatment unit in Edinburgh
of patients with self-harm who consumed antidepressants
as part of their overdose. We have compared these with
rates of prescribing in our catchment area. We have also
examined Scottish inquiries to our poisons information
systems and compared these with national prescribing in
Scotland. We have used these measures to investigate
potential differences between antidepressant classes and
individual SSRIs in Edinburgh and across Scotland.
Methods
Hospital admission data were available from the Poisons
Unit at the Royal Infirmary of Edinburgh. This manages
all cases of deliberate self-harm presenting to hospital in
the City of Edinburgh and surrounding region of East
and Mid Lothian (population ~700,000). There is a
100% admission policy, reviews of which indicate
80-90% of cases are actually admitted. We excluded
patients from other sources. All patients admitted under
our care are recorded in a central hospital database.
Anonymised data on admissions for the three calendar
years 2000 to 2002 in which an antidepressant was taken
as part of an overdose were obtained. Information on
age, gender and antidepressant drugs ingested was
extracted. A number of patients, 204, were admitted
more than once: the analysis was confined to individual
patients admitted with ingestion of individual antide¬
pressants, rather than total admissions. Patients
admitted on separate occasions with different antide¬
pressant ingestions were counted under both drugs. We
have also compared the frequency of recurrent admis¬
sions involving the same antidepressant in the same
patient to assess any influence on repetitive self-harm.
The Lothian Health Board provided prescribing data
(prescription items) for the years in question for Lothian
general practitioners in our catchment, i.e. excluding
West Lothian. Prescribing records do not link to indi¬
vidual patients, but document overall frequency of pre¬
scription items for individual drugs. Similar data were
also available to us for the whole of Scotland from the
Information and Statistics Division of the Scottish
Common Services Agency. Data on defined daily doses
is not available to us, but in Scotland prescriptions are
most often for 1 month's supply of drugs. There is no
suggestion in the prescribing data that this varies with
newer antidepressants.
We compared admission rates to prescribing rates for
antidepressants to derive likelihood ratios for individual
antidepressants relative to the average for all antide¬
pressants. For SSRIs, we also compared individual
agents against the rest of the group. Finally, we exam¬
ined the numbers of patients who re-present with an
overdose involving the same drug as on a previous
occasion within this 3-year period.
Separately, we examined poisons inquiries relating to
overdoses with the three main classes of antidepressants
received by our Poisons Information Service, BNF
sections 4.3.1 tricyclics, 4.3.3 SSRIs and 4.3.4 others
(flupenthixol, mirtazapine, nefazadone, reboxetine,
tryptophan and venlafaxine) [10], These were obtained
in two ways: from telephone inquiries and accesses
to our web-based poisons information database,
TOXBASE [11], Numbers of telephone inquiries are
much lower than those to TOXBASE, which is the
first-line information source for Scottish hospitals, and
we concentrate on TOXBASE accesses in our analysis.
Since these originate from the whole of Scotland, we
have used national prescribing data to investigate the




There were 1656 admissions involving 1343 patients (471
male, 872 female) during the years 2000-2002. As a
whole, there was no age difference between those using
SSRIs (median 31 years) and those using antidepres¬
sants (median 33 years).
Table 1 shows rates of admission for patients for
individual antidepressants, as well as rates of prescribing
and likelihood ratios with 95% confidence intervals.
Trazodone, mirtazapine and venlafaxine have a likeli¬
hood ratio significantly greater than one, indicating a
greater risk of presentation. Amitriptyline, doxepin,
imipramine and sertraline have likelihood ratios signifi¬
cantly less than one, indicating a lower rate of presen¬
tation.
Rates of presentation with SSRIs, other than sertra¬
line, were not statistically significantly different from the
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average. In the catchment area, prescribing numbers and
overdose rates with fluoxetine and paroxetine were
remarkably similar (Table 1), while amitriptyline re¬
mained the most frequently prescribed antidepressant.
Re-presentation rates
Of the 270 patients who had taken paroxetine during
their first presentation in this period, 51 re-presented
with an overdose including the same drug on one or
more subsequent occasions (18.9%). Of the 454 patients
who took other SSRIs, 76 re-presented with the same
drug (16.7%). There is no statistical difference in these
percentages. Some of these patients also re-presented on
other occasions with overdoses not including SSRIs. We
cannot be sure whether they were still taking SSRIs
therapeutically, and we have excluded these admissions
from our analysis.
Poisons information inquiries
During the period 2000-2002, there were 1550 telephone
inquiries and 13,417 TOXBASE accesses to information
on antidepressants in the categories of interest. There
was a close relationship between the numbers of
telephone and TOXBASE accesses for antidepressants
(R2 = 0.9674). TOXBASE accesses were significantly
lower for SSRIs than the other groups, but more likely
for the category "other antidepressants" than for
tricyclics and SSRIs (Table 2). Mirtazapine and venla-
faxine accounted for 84% (1980 of 2355) of TOXBASE
accesses and 88.5% (385,121 of 434,788) of prescription
items for "other antidepressants".
Discussion
Studies of this type have inherent weaknesses. Patients
may not actually be taking on a regular basis the drug
they ingest in overdose and, in some cases, the drug may
not be prescribed for them. We have not recorded data
on patients receiving antidepressants who have taken an
overdose not involving them, nor included patients who
presented only with other types of deliberate self-harm
but we have included patients whose self-poisoning was
judged to be accidental. However, these factors should
not produce systematic biases such that comparisons
among drugs are invalid.
This study reflects experience in the largest clinical
unit of its kind in the UK. The methods we have used
address exposure (as reflected by prescribing volume),
and risk (as admission numbers) and poisons inquiries.
Table 1 Numbers of patients
admitted to the Royal Infirmary
of Edinburgh (2000-2002) with
an overdose involving an
individual antidepressant, and
numbers of prescription items
in its catchment area; shown
with likelihood ratios for this
association and their 95%
confidence intervals (note:
likelihood ratio = 1 represents
the overall average)
Antidepressant Overdose Lothian Likelihood 95% Confidence
patients prescriptions ratio interval
Tricyclics
Amitriptyline 268 177,283 0.83 0.74-0.92
Clomipramine 29 13,993 1.13 0.79-1.62
Dothiepin 63 31,722 1.08 0.85-1.38
Doxepin 4 13,038 0.17 0.07-0.43
Imipramine 12 13,807 0.47 0.27-0.83
Lofepramine 29 19,170 0.83 0.58-1.18
Trazodone 120 50,341 1.30 1.09-1.54
SSRIs
Citalopram 125 65,983 1.09 0.98-1.21
Fluoxetine 270 135,044 1.03 0.93-1.15
Paroxetine 270 158,278 0.93 0.84-1.04
Sertraline 68 46,998 0.79 0.63-0.99
Others
Mirtazapine 66 18,151 1.99 1.57-2.51
Nefazodone 16 7196 1.21 0.75-1.96
Reboxetine 8 4718 1.16 0.59-2.29
Venlafaxine 140 81,320 1.33 1.13-1.55
Table 2 Numbers of TOXBASE accesses and prescriptions for the land. The likelihood ratios for the association are shown with 95%
major antidepressant groups ("others" are flupenthixol, mirtaza- confidence interval. Mirtazapine and venlafaxine are also shown
pine, reboxetine, tryptophan and venlafaxine) prescribed in Scot- separately
Agent TOXBASE accesses Prescriptions Likelihood ratio 95% Confidence interval
TCA 4606 1,111,145 0.99 0.96-1.01
SSRI 6456 1,660,511 0.93 0.91-0.94
Others 2355 434,788 1.29 1.20-1.34
Mirtazapine 561 93,854 1.42 1.31-1.54
Venlafaxine 1419 291,267 1.16 1.10-1.22
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Since the referral pattern and admission protocols in this
single-centre service have remained stable, the approach
we have used allows comparison of different drugs in a
defined population as demonstrated before when
examining changes in prescribing behaviour and
overdose patterns for antipsychotics [12],
Our data from Edinburgh show a lower risk of
admission for amitriptyline. While this finding might be
confounded by the use of this drug in the management
of chronic pain, it is also likely to reflect a natural
cautiousness in the prescribing of tricyclic antidepres¬
sants to patients deemed at high risk of self-harm, which
is encouraging given the considerably greater toxicity in
overdose associated with this group [13, 14],
Crucially we have found no evidence of either
increased risk involving the SSRIs as a group or par¬
oxetine individually—indeed sertraline was associated
with a reduced risk of admission. Furthermore, we
found no evidence of a greater risk of recurrence
involving SSRIs. In contrast, overdose rates for mirt-
azapine, trazadone and venlafaxine were significantly
higher than average. Worryingly, both in our clinical
experience [15] and in that reported from national
mortality statistics [13], venlafaxine appears to be
associated with significantly more toxicity in overdose
than other newer antidepressants. The differences we
have found are small in absolute terms and do not
necessarily indicate an effect on self-harm behaviour.
Inquiries to poisons information services are markers
of clinical activity in managing acute overdose. We have
previously shown for antipsychotics that the number of
TOXBASE accesses is generally related to prescribing
volume [12]. In this study, the relationship between
accesses and prescription numbers was the same for
tricyclics and SSRIs but significantly greater for "other
antidepressants", principally mirtazapine and venlafax¬
ine. This finding may confirm that the presentation rates
for venlafaxine and mirtazapine are indeed greater,
although there are other explanations, notably that
doctors are less familiar with the effects of these drugs in
overdose.
In conclusion, our data show that presentations to
hospital involving an overdose of antidepressant drugs
was not more likely than expected when SSRIs had been
taken in relation to SSRI prescribing rates, and indeed
was significantly less than expected for sertraline along
with amitriptyline, imipramine and doxepin. However,
admissions involving venlafaxine and mirtazepine were
significantly more frequent than would be expected from
the prescribing rates. This finding is a concern, given
evidence of venlafaxine's greater toxicity in overdose,
and the potential for patients to be switched from the
SSRIs in general and paroxetine in particular in
response to the current health scare about the drug and
its class.
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Abstract — The SECCAT survey assessed the Socio-Economic Costs and Consequences of Alcoholism
Treatment. Basic demographic and health service resource use data (for a previous 6-month period) were
obtained for a cohort of 586 eligible patients who had had treatment at the Alcohol Problems Clinic
(APC) in Edinburgh. The cohort was 75% male with a mean age of 46.0 years. Seventy-six per cent had
an initial diagnosis of alcohol dependence and 21% alcohol abuse. Use of health services was highly
variable. Thirty-six per cent agreed to be interviewed to provide data on their level of abstinence, on
resource use, on quality of life (SF-36), on socio-economic characteristics and key adverse events. These
212 individuals had similar age and sex ratios to the full cohort, but alcohol abusers were under-
represented. Nineteen patients reported no days of abstinence and 41 were abstinent over the whole 6-
month period. Patients experienced a much poorer quality of life than a normal population in terms of all
dimensions of the SF-36. The average total health care costs of the interviewed patients were £1134 of
which 38% were related to treatment at the APC. Analysis suggests that alcohol-dependent patients make
substantially more costly use of resources than abusers and experience a much poorer quality of life. No
clear relationship of cost to degree of abstinence has been found. There is a clear and consistent
relationship of SF-36 scores and drinking behaviour.
INTRODUCTION
The 1991 Health Survey for England suggests that
7% of men and 5% of women can be classified as
problem drinkers [Office of Population Censuses
and Surveys (OPCS), 1993]. It is widely reported
that individuals with alcohol problems are a
diverse group, from a wide range of social
backgrounds, and that types of alcoholism vary
considerably. Appropriate care often means indi¬
vidually tailored 'packages' of care, which to be
effective need to be client-led, taking into account
what is acceptable to the patient at a given time.
Alcohol and alcoholism impose significant costs
on the National Health Service (NHS). It has been
estimated that in 1989 the cost of sickness absence
associated with alcohol consumption was £779
million (Maynard, 1989). However, little is known
about the overall magnitude of such costs, and
even less about the social circumstances, quality
of life and health service resource use of specific
categories of patients. As a result, little is known
about the potential cost-effectiveness of interven¬
tions aimed at this patient group, and there is a
considerable problem to produce accurate cost and
cost-effectiveness data given such a diversity of
service provision (Godfrey, 1994).
This paper presents the findings of the SECCAT
survey to assess the Socio-Economic Costs and
Consequences of Alcoholism and its Treatment.
The survey provides evidence of the socio¬
economic characteristics of a group of patients
who had been treated for alcohol problems, their
levels of abstinence, quality of life, key adverse
events that they have suffered and the costs of
providing health care and support to them. All the
patients had had contact with the Alcohol Prob¬
lems Clinic (APC) at the Royal Edinburgh
Hospital (Lothian), chosen for its representative
approach to the treatment of alcoholism. Service
provision was available on an inpatient and
outpatient basis and was directed at both the
alcohol-dependent patient and those with milder♦Author to whom correspondence should be addressed.
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forms of medical need, and ranged from intensive
supportive therapy with individual counselling to a
programme of detoxification with group therapy
lasting 3 weeks, for a range of alcohol-related
problems. Additional measures, such as super¬
vised disulfiram therapy and antidepressants, were
advocated as the need arose, and patients were
encouraged to make contact with Alcoholics
Anonymous and other voluntary agencies.
The paper first outlines the methods of data
collection and costing used, and then describes the
socio-economic circumstances of the full cohort. It
then describes the limited socio-economic and the
health service resource use data for the cohort as a
whole, and the much fuller data available for those
patients who agreed to be interviewed. Finally it
presents two important sub-group analyses com¬
paring patients in different diagnostic classifica¬
tions and by levels of abstinence.
METHODS
The study surveyed a cohort of patients who had
had contact with the APC. Referrals to the APC
came chiefly from general practitioners (GPs).
Other sources of referral included general psy¬
chiatrists, general hospitals, self-referrals and
referrals from the courts, voluntary bodies and
social work services. Ethical approval was sought
and approved for the methods to be used in the
survey. A case register was used to identify 685
patients who have been in contact with the APC
during 1992. Case notes of these patients were
checked to ensure that they satisfied the inclusion
criteria for the survey: namely, that the patients
had an alcohol problem and had been in contact
with the APC for treatment at a point 12 months
previously. Patients were excluded if they were of
no fixed abode or had an address outside the
Lothian Region. In total, 85 patients from the
database were found to be ineligible. The remain¬
ing 600 patients were entered into the study and
allocated a survey number. If the case notes
indicated that the patient was in current contact
with APC, their keyworker confirmed their most
recent contact. In addition, the keyworker was
asked if there was any reason why a patient should
not be approached for the survey.
Patients were then written to and invited to
return a reply-paid card stating whether or not they
wished to take part in the survey. If no reply was
received within 2 weeks, a further letter was sent.
If after 2 weeks there was still no response, the
patients' addresses were checked with their
general practitioner. If the address was incorrect
the patient was written to at their new address. For
patients who were no longer in contact with the
general practitioner (GP) recorded in their hospital
notes, the name and address of their new GP along
with their new address were obtained from
primary care administration. These patients were
then reapproached as above. If, following these
procedures, patients did not reply, or declined to
be interviewed and for patients who had died
during the past 6-month retrospective time-frame,
then the baseline information on the patient was
completed in the case-record file (CRF) using data
from the hospital case-record and additional
information about NHS resource use from a
questionnaire sent to the GP.
Patients who agreed to take part were then
invited to attend a single interview, at which the
CRF was completed. In addition, a questionnaire
was sent to the patient's GP to confirm details of
medical history, medication and to obtain infor¬
mation on NHS resource use. The process
provided for all patients basic demographic data,
clinical diagnosis (at time of initial contact) and
information on some items of resource use. For
patients who agreed to be interviewed, social
circumstance, drinking behaviour in the previous 6
months, use of NHS resources including pre¬
scribed drugs, and the incidence of a variety of
events relating to employment, the legal system
and accidents was collected. During the interview,
patients completed the UK version of the SF-36
health status questionnaire (Brazier et al., 1992).
The SF-36 measures health status according to
eight dimensions: physical functioning; social
functioning; role limitations due to physical prob¬
lems; role limitations due to emotional problems;
general mental health; energy/vitality; bodily pain;
and general health perceptions. A score is derived
for each dimension of between 0 (for poor health)
and 100 (good health). Comparative norms from a
survey of a UK population are available (Jenkin-
son et al., 1993). In addition, the Alcohol Related
Problems Questionnaire (ARPQ) (Chick et al.,
1988, 1991) was completed. The results of the
ARPQ will be presented in a separate paper
(Patience et al., 1997).
Recruitment and interview of the patients took
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Table 1. Unit cost and components of total cost
Component Items Unit costs (£) Source
APC costs Individual counselling session 36.25 Netten (1994)
Group counselling session 3.65 Netten (1994)
In-patient stay at APC 1422.30* A T Edinburgh
Home visit by APC staff 22.00f en (1994)
GP costs Visit to GP 7.62 Netten (1994)
Visit to practice nurse 3.83 Netten (1994)
Visit from GP 22.00 Netten (1994)
Visit from practice nurse 7.89 Netten (1994)
Other costs Non-APC counselling sessions 3.65 Netten (1994)
Week in residential units 275.00} 1
Outpatients visits 29.50 1 National Health Service in
Non-APC inpatient day 200.00 [ Scotland (1993)
Visit to A&E 57.00 J
Drugs costs Specific drugs prescribed Specific cost BNF; MIMS
APC = Alcohol Problems Clinic, Royal Edinburgh Hospital: A&E = Accident and Emergency department; BNF =
British National Formulary (1994); MIMS = Monthly Index of Medical Specialities (1994).
*Average of the two programmes offered at the Unit (2 weeks).
•fCosted as equivalent to GP home visit.
JMid-point of range of Edinburgh residential units.
place over 1 year, each month dealing with those
who had been in contact 12 months previously. Of
the 600 patients allocated a survey number, 212
agreed to be interviewed; 59 declined to be
interviewed; 18 had died during the relevant
period; 297 did not respond; 14 were eventually
found to be ineligible. Thus for the purpose of
subsequent analysis the full cohort is 586 (600
minus 14) patients. Data were collected for the 6-
month period immediately prior to the interview
date. For those not interviewed, the period was
taken as 6 months prior to their being allocated an
interview number. Where data were sought and
obtained from more than one source (e.g. the
patient and his GP), a predetermination was made
for each item on the basis of an a priori likelihood
of accuracy as to which source would be used in
the analysis. For example, the GP was taken as the
preferred source of data on medications.
For each individual, a total cost of health
service contacts during the 6-month period was
calculated. This calculation applied standard unit
costs to the number of each type of contact for
each individual, to estimate four component costs
and the total cost. The make-up of the four
components and the principal unit costs are
summarized in Table 1. All drug prescriptions
have been costed for the full 6-month period using
prices from Monthly Index of Medical Specialities
(June 1994) or British National Formulary (March
1994). Rather than making subjective decisions
about causality, all health service resource use
(including prescribed drugs), whether or not
obviously related to their alcohol problem was
costed.
RESULTS
Characteristics of the full cohort
The cohort consisted of 586 individuals and its
demographic characteristics are shown in Table 2.
The group is 74% male, has a mean age of 46.0
years and the most common diagnosis is alcohol
dependence (DSM-I1I-R, 303.90) [DSM Classifi¬
cation of the American Psychiatric Association
(1987)]. The cohort had had a mean (SD) length of
contact with the APC of 4.48 (5.56) years. The
median length of contact was 2.11 years, with an
interquartile range of 0.57-6.16 years. The longest
period of contact was nearly 30 years. Data on
some aspects of health service resource use, in the
6-month survey period, is available for the full
cohort from routine records. This is presented in
Table 3. A wide range of usage is observed within
the group, with some striking maximum values.
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Mean (SD) cohort age 46.0(10.8)
Range 20-82
Disease classification (DSM III-R)
Alcohol intoxication (303.00) 10
Alcohol dependence (303.90) 447
Alcohol abuse (305.00) 125
Missing data 4
APC contact
Mean (SD) length of contact in years 4.48 (5.66)
Median length of contact in years 2.11
























APC = Alcohol Problems Clinic.
Table 3. Health service resource use: full cohort (586 individuals)
Number of contacts
Resources
Total number of Total number of
responses non-zero responses Mean
Median (90%
central range) Minimum Maximum
Individual sessions at APC 580 i 74 1.87 0(0-6) 0 31
Group sessions at APC 582 62 2.28 0(0-2) 0 150
Home visits by APC staff 582 20 0.18 0(0-0) 0 22
IP admissions at the APC 582 54 0.11 0(0-0) 0 2
Visits to GP 558 477 4.94 4 (0-10) 0 59
Visits to GP (alcohol related) 551 322 2.71 1 (0-7) 0 50
Visits to a practice nurse 551 72 0.40 0(0-1) 0 51
Hospital OP visits (except APC) 547 167 0.75 0(0-2) 0 28
Visits to A&E 551 124 0.37 0(0-1) 0 12
IP admissions to a hospital or
clinic (except APC) 551 92 0.24 0(0-1) 0 5
APC = Alcohol Problems Clinic; A&E = Accident and Emergency department; IP = inpatient; OP = outpatient;
GP = general practitioner.
An APC inpatient stay was recorded only for 54
patients (<10% of the cohort) with no patient
being treated more than twice as an APC inpatient,
but over the 6-month period at least one individual
attended the APC for individual counselling 31
times and another attended 150 group sessions, i.e.
more than five sessions per week. One patient
made 59 visits to a GP. Two individuals made 12
visits each to accident and emergency depart¬
ments.
A comparison can be made with data for 1992
for the population of Great Britain as a whole
(OPCS. 1993). Nationally, the average number of
contacts with a GP per 6-month period would only
be ~2.5, approximately half that observed in this
cohort. It would also appear that the rate of
inpatient stays of this cohort is considerably higher
than that of the population as a whole which had
an average of only 0.06 inpatient stays per
6-month period.
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Table 4. Health services resource use: comparison of interviewed and non-interviewed groups
Interviewed patients Non-interviewed patients
(212 individuals)* (374 individuals)t
Resources mean (SD) mean (SD)
Individuals sessions at APCJ 3.8 (5.92) 0.76 (2.86)
Group session at APCj: 5.93 (19.7) 0.2 (1.52)
IP admissions at the APC 0.18 (0.45) 0.06 (0.13)
Visits to CP 5.59 (4.76) 4.54 (5.40)
Hospital OP visits (except APOJ 1.01 (2.42) 0.57 (1.52)
Visits to A&E 0.36 (0.79) 0.38 (1.21)
Inpatient admissions to a hospital or clinic (except APC) 0.28 (0.62) 0.22 (0.69)
'Due to missing data, observations for specific items range from 208 to 212.
tDue to missing data, observations for specific items range from 337 to 374.
JDifference statistically significant (Ps 0.05): calculated using the Wilcoxon rank sum test.
For abbreviations see Table 3.
These f igures for the full cohort clearly indicate
the higher use of health service resources made on
average by alcoholics who have had recent contact
with a clinic. However, they do not provide any
indication as to which sub-groups make greater or
lesser demands.
Characteristics of the interviewed group
The interviewed group of 212 individuals
represented 36% of the full cohort. The sex ratios
and ages of those interviewed (Table 2) reflect
well those of the group as a whole, but alcohol
abusers are under-represented, as are those who
have not maintained contact with the APC.
Table 4 compares the use of those health service
resources for which data were available from the
APC routine data or from a questionnaire to CPs,
of the interviewed group and the non-interviewed
group. The interviewed group made significantly
greater use of APC services, of visits to their GPs,
and outpatient visits to hospital.
Column 1 of Table 6 shows that the mean (SD)
costs of health care in the 6-month period for
interviewed patients totalled £1134 (£1809), of
which only 38% were costs at the APC.
The number of abstinent days has been used as
an outcome measure in clinical trials and serves as
a proxy for alcohol consumption. Interviewed
patients were asked if there had been a period in
the last 6 months when they had been completely
abstinent and, if so, were helped to calculate the
total number of abstinent days using the time-line
follow back method (Sobell et al., 1980). Forty-
one patients were abstinent over the whole period.
Nineteen patients had no days of complete
abstinence. A graphical presentation of individual
patient values for the number of abstinent days is
shown in Fig. 1.
Figure 2 compares the subjective health status,
as measured by the SF-36, of those interviewed
with that of the UK population norms. These
patients experience a much poorer health status on
all dimensions than a normal population. (This
effect is unchanged by age standardizing the
comparison.)
Data were also obtained at the interview
relating to the socio-economic circumstances and
to the incidence of certain adverse events. Twenty-
five per cent of the interviewed group were single
or widowed, 27% married, 42% divorced or
separated. Forty-five per cent were living alone,
and 36% were in owner occupied accommodation.
Only 26% were in full or part-time employment,
whilst 37% were permanently sick/disablcd or
prematurely retired due to ill health. Comparison
with data for Great Britain indicates that the
proportion living alone is very high (national
figure of 14% of the adult population) as is the
proportion not in employment, where nationally
~77% of men and ~66% of women of working
age might be expected to be employed (OPCS,
1994).
Those who were employed had, as a result of
their alcohol problem, missed a mean (SD) of 10.2
(33.2) days of work with their employer's
agreement and a mean (SD) of 6.8 (12.9) days
where absence was not planned. There was a high
incidence of legal events in the 6-month period: 23
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Fig. 2. SF-36: comparison of SECCAT data with UK norms.
individuals had been arrested at least once, 13 had More than 20% of the group had had an accident
been disqualified from driving, and 12 had been at home, compared with the rate of 2^4% which
divorced or divorce proceedings were underway, earlier national data from the 1989 General
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SF-36 Dimensions
lAbuse ■Dependence
Fig. 3. SF-36: comparison of mean scores for DSM-III-R categories of 'alcohol abuse' and 'alcohol dependence'.
Household Survey suggests would be normal
(OPCS, 1991). Thirteen per cent of those inter¬
viewed had been involved in accidents as
pedestrians. Seventeen per cent of those working
had had an accident at work. Thirteen per cent had
taken an overdose or tried to harm themselves.
(Despite these overall high incidence rates, the
small absolute numbers prevent meaningful sub¬
group analysis of these data.)
Sub-group comparisons
Given the diversity of the groups, it was judged
important to see whether resource use of quality of
life varied according to diagnostic classification or
to the degree of abstinence achieved in the 6-
month period.
Diagnostic classification: abuse vs dependence.
The comparison between diagnostic classifications
relates to 209 individuals: the majority (180) were
classed as alcohol-dependent (DSM III-R,
303.90), and 29 classified as alcohol abusers
(305.00). The remaining three patients in the
interviewed group had a clinical diagnosis of
alcohol intoxication (DSM III-R, 303.00) and
form too small a group for comparison.
Table 5 shows the mean number of health
service contacts made by the two groups for each
resource category. In most cases, alcohol-depen¬
dent patients average a higher number of health
service contacts than alcohol abusers, although
this is only statistically significant for inpatient
visits (P ^ 0.05). For GP/practice nurse visits,
abusers made more use than alcohol-dependent
patients (P ^ 0.05). Table 6 shows the generally
higher use of services made by alcohol-dependent
patients, reflected in a higher average cost for this
group. The difference is striking with average total
health service costs of dependent drinkers almost
double that of the non-dependent drinkers.
In terms of the SF-36, alcohol abusers score
higher on every dimension than the alcohol-
dependent group (Fig. 3). Dependent alcoholics
exhibit very low scores on the 'role mental' and
'role physical' dimensions. Clearly individuals
diagnosed as alcohol-dependent have a signifi¬
cantly lower subjective health status than alcohol
abusers.
The usefulness of the clinical distinction
between abuse and dependence has been ques¬
tioned (Shuckit et al., 1985). After following a
group of alcoholics distinguished by DSM cate¬
gorization for 1 year, the diagnostic criteria did not
support different prognostic implications. The
distinction is, however, important from an eco-
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Fig. 4. SF-36: comparison of SECCAT mean scores for quartiles ordered by number of abstinent days.
nomic perspective. Alcohol-dependent patients
impose significantly higher costs on the NHS
and suffer much poorer health status.
Abstinent and non-abstinent drinkers. Table 5
also shows the resource use data for patients
divided into quartiles according to their level of
abstinence, as measured by the reported number of
abstinent days in the 6-month period. This shows
that the most abstinent group made significantly
less use of emergency care, either in calling out
their GPs or visiting Accident and Emergency. For
other resource use, the picture is less clear, though
there is a tendency for the middle quartiles to
make greater use of services than the least or most
abstinent groups. This tendency is confirmed in
Table 6, which clearly shows that, whilst patients
in quartiles 1 and 4 have similar mean total health
service costs (£783 and £862 respectively), the
costs of quartiles 2 and 3 are very much higher
(£1443 and £1446 respectively). If the data are
categorized slightly differently, separating out
those 41 individuals who were completely absti¬
nent (instead of quartile 1) and those 19
individuals who were never abstinent (instead of
quartile 4) a similar pattern emerges, with the two
extreme groups having very similar total costs of
£735 (SD £1237) and £745 (SD £1828) respec¬
tively. Within the total costs, the one component
that is statistically significantly different is that of
the APC costs. APC costs are lowest for those who
were completely abstinent or who were not at all
abstinent during the 6-month period.
Univariate analysis of the relationship between
abstinence days and total cost produced a positive
but non-significant rank correlation coefficient
(0.03, Spearman's rho). A plot of the relationship
emphasized the absence of a linear relationship.
While the plot was suggestive of a curvilinear
relationship (with individuals at both extremes of
the abstinence days distribution consuming simi¬
larly low levels of resources and those in the
middle of the distribution consuming a greater
number) a one-way analysis of variance was
unable to detect such a relationship (t = 0.324,
df = 1, P = 0.75). In summary, as most observa¬
tions were clustered along the *-axis, it appears
likely that whatever the number of abstinent days
achieved, most patients incurred a similarly low
level of costs.
Multivariate regression analyses looked at the
relationship between average total cost as the
dependent variable against the number of abstinent
days and the number of controlled drinking
months. The age of individuals was also included
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as an independent variable and dummy variables
were included for sex and disease classification.
The number of abstinent days was positively
related to total cost and significant (/ = 2.62,
df = 1, P = 0.034), whilst there was a negative and
significant relationship between controlled drink¬
ing months and total cost (t = 1.17, df = 1,
P = 0.002). Age was also negatively related to
average total cost and this was significant
(t = 3.75, df = 1, P - 0.046). The model explains,
however, only 5% of the variation in the data
(adjusted R2 = 0.056).
Figure 4 compares the SF-36 scores according
to levels of abstinence. There is a great difference
in subjective health status, and a clear and
consistent gradient on each of the dimensions.
The sub-group comparison reveals a very striking
difference in subjective health status with the
abstinent group enjoying broadly normal health
status levels.
DISCUSSION
This study sought very detailed information on
drinking behaviour, health service resource use,
quality of life and key events from interviews with
patients who had been in previous contact with an
alcohol problems clinic. Given the nature of the
patient population, the low interview response rate
of 36% was expected, and the comparison of the
resource use data for the respondents with
equivalent data for the full cohort shows again,
not surprisingly, that the interviewed group is
biased towards those with greatest clinic and
health service contact, although the age-sex
breakdowns are similar. The interviewed group
under-represented patients with a diagnosis of
alcohol abuse.
The design of the study attempted to strike an
effective balance between the ideal and the
attainable. A long-term cohort study prospectively
following the course of intervention and subse¬
quent outcomes for new patients would obviously
have been preferable, rather than this cross-
sectional retrospective review of those who have
had previous contacts with the APC. But the
former would have required a very long, expen¬
sive and intrusive study, which itself might have
impacted on patient outcomes and behaviour. If
such a study were in future to be seriously
contemplated, the current data would provide a
basis for determining necessary sample size and
duration. Within this retrospective approach, it
would have been attractive to obtain data on
resource use over a longer-period (for example 1
year), but research on patient recollection of
hospitalization indicates that memory begins to
deteriorate rapidly after ~ 10 months (National
Center for Health Statistics, 1965).
Despite the necessary design limitations, the
interviews produced clear evidence of high rates
of adverse socio-economic events and accidents,
and striking data on the overall poor quality of life
of patients, as measured by all dimensions of the
SF-36 and its consistent relationship to abstinent
days. The relationship of levels of abstinence and
costs is more complex with both extremes of high
and low abstinence associated with lower costs
than those in between. Generally the diagnostic
distinction between alcohol dependence and al¬
cohol abuse appeared important. Alcohol-depen¬
dent patients made greater use of health service
resources. Their health service costs as calculated
here are on average double those incurred by
abusing patients. There is also a clear distinction
between the health status of dependent and
abusing patients. As is customary in such studies,
the estimates of cost incorporate average costs for
the units of health care resources recorded on a
patient-specific basis (Drummond et al., 1987). No
data were available on, for example, variation in
length of counselling sessions. Allowing for such
differences might well have slightly increased the
between-patient variation in total cost.
Two implications may perhaps be drawn. First,
alcohol dependence may be of greater significance
than abuse in generating costs to the health service
and imposing on the quality of life of patients.
Studies of the natural history of the disease have
shown that a progression from abuse to depen¬
dence occurs (Ojesjo, 1981). This emphasizes the
costs that could be avoided in preventing the
progression from abuse to dependence, and the
need for effective therapies to achieve this.
Second, whilst more effective treatment or support
facilities for alcoholic patients may be unlikely to
have a dramatic effect on the total health service
costs of these patients in the short term, there
would appear to be substantial scope for improv¬
ing their quality of life, and reducing adverse
socio-economics through achieving better control
of their drinking. Longer-term follow-up might
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confirm the finding of Holder and Blose (1992)
that the cost of care for abstainers does decrease
over time.
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1 EXECUTIVE SUMMARY
1.1 Background
1. The 1998 Scottish Health Survey included questions
to estimate the scale of alcohol dependence in Scotland.
It recorded that 10% of male drinkers and 3 - 4% of
female drinkers replied affirmatively to one or more of
three questions designed collectively to identify alcohol
dependence. All three questions were answered
affirmatively by 1% of male drinkers but less than 0.5%
of female drinkers.
2. Untreated alcohol dependence results in levels of
drinking which substantially increase the risk of stroke,
cirrhosis of the liver, brain damage and several forms of
cancer and are associated with increased mortality.
3. Following initial detoxification of people with alcohol
dependence, a longer-term programme of treatment is
required to prevent relapse into heavy drinking and
dependence. A number of different psychosocial and
pharmacological interventions are available to prevent
relapse. These are the focus of this Health Technology
Assessment.
4. The Plan for Action on Alcohol Problems was
published in January 2002 (Scottish Advisory Committee
on Alcohol Misuse (SACAM), 2002) and covers a wide
range of social, economic and clinical aspects of the
misuse of alcohol in Scotland, including chronic heavy
drinking. This Health Technology Assessment provides
policy makers, planners and those working in the field of
prevention of relapse in alcohol dependence with
information required to implement a part of the plan.
Local Alcohol Action Teams should take account of this
advice when preparing the local strategies to be
published in April 2003, that are required by the Plan
for Action.
5. People with established alcohol dependence are likely
to require treatment mainly within Tier 3 (for people
with more complex needs) or Tier 4 (for people with
highly specialised needs) of the Scottish Executive's
Alcohol Problems Support and Treatment Framework.
Thus, this Health Technology Assessment will be of
primary interest to those concerned with these specialist
tiers. However, aspects of prevention of relapse may
happen in Tier 1 (services for the whole community) or
Tier 2 (local services that identify and respond to people
with alcohol problems). In 2003, the Scottish
Intercollegiate Guidelines Network (SIGN) will publish a
guideline on the management of harmful drinking and
alcohol dependence in primary care.
6. There is no single definition of alcohol dependence
used by clinical trial investigators, although certain basic
features tend to be shared. Rigid adherence to any
single criterion would have forced many studies to be
discarded and so in this Health Technology Assessment,
when possible, the pragmatic criterion that any process
of detoxification had been undergone was preferred.
1.2 Objectives of this Health Technology Assessment
The objectives of this Health Technology Assessment
were to answer the following questions:
1. Which treatment or combination of treatments
(pharmacological and psychosocial) will yield the
maximum maintenance of recovery amongst the
population of those with alcohol dependence who have
undergone detoxification?
2. What is the most effective and efficient approach to
delivering the individual interventions (or combination
of interventions) taking into account the different risk
groups, locations, durations of treatment, etc?
1.3 Health Technology Assessment evidence
1. This Health Technology Assessment used systematic
literature searching to identify evidence published in
scientific literature. It also used evidence submitted by
professional groups, patient groups, manufacturers,
other interested parties and experts and commissioned
primary research with patients to elicit their views and
preferences.
2. For clinical effectiveness, a number of comprehensive
reviews of treatment for alcohol problems and reviews
of specific interventions were consulted. Studies
particularly relevant to people with alcohol dependence
were extracted from these reviews. Additional relevant
studies were identified and an analysis was carried out to
estimate the effects of treatment in a form suitable for
input to the Health Technology Board for Scotland
economic model.
3. The patient issues component used published
scientific literature, materials from Alcoholics
Anonymous, and a qualitative study of patient attitudes
commissioned by the Health Technology Board for
Scotland.
4. The economic evaluation critically appraised the
economic models contained in the literature. The Health
Technology Board for Scotland developed a simple,
transparent model to combine the clinical effectiveness
and epidemiology data with the costs of therapies and
diseases in order to inform the cost effectiveness
estimates of four psychosocial and three
pharmacological therapies to prevent relapse in people
who are alcohol dependent.
5. The current provision of services for prevention of
relapse in alcohol dependence in Scotland was assessed
by two postal surveys. One of these was targeted at
National Health Service specialist services and the other
at non-National Health Service providers.
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1.4 Clinical effectiveness
1. A number of psychosocial interventions were found to
be of value in preventing relapse in alcohol dependence.
The total combined success rates, in terms of abstinence
or controlled drinking at the trial end (varying between
six months and beyond one year), in trials of those
psychosocial treatments judged effective, was 42% for
patients in the intervention groups and 26% for those
receiving control treatments. In common with clinical
trials in many other areas of medicine, these may
overestimate the absolute benefits attainable in everyday
clinical practice.
2. The Health Technology Board for Scotland
meta-analysis suggested similar, statistically significant,
beneficial effect sizes for four types of psychosocial
treatment. The odds ratios for abstinence or controlled
drinking at the end of the clinical trial compared with
patients offered control treatments were: Behavioural
Self-Control Training (odds ratio=1.75, 95% confidence
interval 1.02, 3.02); Motivational Enhancement Therapy
(odds ratio=1.88, 95% confidence interval 1.28, 2.77);
Marital/Family Therapy (odds ratio=1.94, 95%
confidence interval 1.37, 2.73); and Coping/Social Skills
Training (odds ratio=2.11, 95% confidence interval
1.53, 3.92).
3. Behavioural Self-Control Training showed benefit
when compared with control interventions. However,
the only trial which focused on the unique defining
features of Behavioural Self-Control Training and
controlled for the more general features of Cognitive
Behavioural Therapy did not show a benefit. Thus, there
is no proof of superiority over other Cognitive
Behavioural Therapy based approaches.
4. There is mixed evidence for Motivational
Enhancement Therapy. It shows efficacy over ineffective
controls. However, it was slightly less effective than
Alcoholics Anonymous based treatment in outpatients in
Project MATCH. This may be due to the short course of
treatment given. It is suggested that Motivational
Enhancement Therapy might be provided first, if such a
relatively low intensity approach has not already failed,
and more intensive therapy then given if necessary.
5. Although Marital/Family Therapy has shown a
beneficial effect it should be recognised that this
approach is only usually feasible in those with relatives
willing to invest substantial effort in the treatment and
with the consent of the patient. Thus, it is an option for
treatment of only some patients. An exception to this is
the Community Reinforcement Approach, which has
been shown to be effective when a contractual element
with non-family members has been tested.
6. Trials of Brief Interventions have failed to show any
benefit in patients with established alcohol dependence.
7. Acamprosate and naltrexone are pharmacological
treatments intended to reduce relapse. The meta-analysis
suggested statistically significant beneficial effects for
both treatments: acamprosate (odds ratio=1.73, 95%
confidence interval 1.36, 2.20); and naltrexone (odds
ratio=1.46, 95% confidence interval 1.12, 1.90). The
combined success rates, in terms of abstinence or
controlled drinking at the trial end (varying between
three months and one year), in trials of these treatments
was 34% for treated patients and 25% for those
receiving placebo treatments. These may overestimate
absolute benefits attainable in clinical practice.
8. Disulfiram, which causes unpleasant symptoms when
taken with alcohol, was found to be ineffective if taken
without supervision to ensure compliance. One good
clinical trial and some substantiating evidence supports
the use of supervised oral disulfiram.
9. All the evidence for effectiveness of pharmacological
treatments is obtained from studies in which they were
adjuncts to 'counselling'. Thus, the psychosocial
treatment should preferably be organised prior to
starting medication.
10. Within a specialist unit, protocols should be available
for all treatment options to ensure standardised and
consistent treatment. These protocols should be closely
based on methods that have proven effective in
clinical trials.
11. Evidence suggests that practical help with problems
such as housing, debt and claiming benefits is likely to
contribute to control of alcohol problems. Thus, close
liaison with local authority services such as social work
and housing and groups able to deliver such help
is essential.
12. Encouragement to attend Alcoholics Anonymous
meetings has been shown to have benefit. Explanation
of the aims and philosophy of Alcoholics Anonymous
during treatment will allow patients to make an
informed choice. For benefit to be obtained from
Alcoholics Anonymous, as with other psychosocial
treatment approaches, people with alcohol dependence
should not be pressurised to attend.
1 3. The effectiveness of interventions for prevention of
relapse delivered by the Councils on Alcohol, and some
other non-statutory services, has not been tested in
clinical studies. Where counsellors are practising
treatments that have been shown to be effective in
other settings there is likely to be benefit.
1.5 Patient issues
1. Method of treatment, treatment awareness and
access, involvement in choice of treatment and follow
up were identified as key patient issues.
2. It is important that both the person who is alcohol
dependent and his or her doctor understand and agree
the purpose of treatment and review this understanding.
3. In reply to the Health Technology Board for Scotland
survey, only 36% of National Health Service specialist
services carrying out psychosocial interventions
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indicated that they had patient information sheets or
leaflets for any of these interventions. It is recommended
that such information should be available for all
interventions.
4. A qualitative study has been undertaken for the
Health Technology Board for Scotland, to explore
patients' treatment preferences and also to elicit factors
which were felt to prevent relapse to drinking. The aim
was to describe the experiences and preferences of
individuals for pharmacological or psychosocial
interventions, or a combination of both, for the
treatment for alcohol dependence. This was achieved
by undertaking in-depth one-to-one interviews with
45 patients in three Trusts in NHSScotland.
5. Issues to emerge from this qualitative research
include:
• participation in residential or day case relapse services
may currently depend on the way services are
structured locally, rather than patient choice
• lack of understanding of terms such as Cognitive
Behavioural Therapy and Motivational Enhancement
Therapy need to be recognised in communication
with service users
• participants valued activities such as coping skills
training, assertiveness training, anger management,
stress/anxiety management, relaxation exercises and
rehearsing difficult situations within a safe environment
• views about pharmacological interventions differed
greatly. Some people identified a role for acamprosate
in providing confidence about not being tempted to
drink, while others doubted whether acamprosate
reduced the sense of craving. However, those who felt
the benefits were convinced.
• most people who had no experience of taking
disulfiram said this was because they would not trust
themselves not to drink while taking it
• all who took these pharmacological interventions
believed that the pharmacological and psychosocial
interventions were complementary
• women who had experienced 'women only' group
work had a preference for women only groups, but
conversely men may have a preference for mixed sex
group work
• individual therapy sessions may be valued for the
depth of work they enable
• flexibility of times and venues was valued
• a Helpline number given to people when they were
discharged from inpatient treatment in one Trust
was valued
• all participants in this sample of National Health
Service attenders recognised that Alcoholics
Anonymous works well for many people, but most of
them felt that it was not suitable for them
• awareness of services other than Alcoholics
Anonymous may be low and may require
better promotion.
6. Additionally, the study, the literature and consultation
comments indicate that awareness of different services
and treatments may be low among health professionals
and service users and require better promotion and
discussion to identify treatment preferences. A shared
understanding and mutual agreement regarding the
purpose of treatment is important between a person
who is alcohol dependent and his or her doctor.
7. Letters from services users of residential 12-step
settings tended to emphasise the benefits of residential
treatment and Alcoholics Anonymous.
8. It is clear from the results of clinical studies that all
interventions are of limited effectiveness. It is therefore
worth providing a range of options of proven efficacy.
Treatment should be individualised taking account of
patients' expectations, needs and wishes with the
understanding that these needs may change and the
treatment plan should adapt to this.
1.6 Economic evaluation
1. The economic evaluation compared the costs and
consequences of seven therapies in comparison to a
standard care package. The relevant outcomes were
disease states, these being alcohol dependence,
alcoholic psychosis (including alcohol-related brain
damage), liver cirrhosis, epilepsy, chronic pancreatitis,
cancer, stroke and death.
2. For each therapy, the costs and consequences for
1000 patients complying with the therapy were
modelled and compared with the costs and
consequences for 1000 patients receiving a standard
care package. This involved:
• defining and costing each intervention
• applying the clinical effectiveness odds ratio for the
intervention to the epidemiology for the cohort, to
calculate the number of patients likely to be in the
various disease states
• calculating the costs to NHSScotland of the
disease states
• calculating an incremental cost or saving per
additional abstinent patient.
3. The results show that each of the four psychosocial
interventions (Coping/Social Skills Training, Behavioural
Self-Control Training, Motivational Enhancement
Therapy and Marital/Family Therapy) and acamprosate
produce net savings per incremental abstinent patient.
This means that the cost of the intervention is less than
the savings it affords to NHSScotland. These savings
arise because the improved abstinence rate results in a
lower incidence of diseases, thereby saving inpatient
hospital stays and other disease-related costs.
4. Naltrexone and unsupervised oral disulfiram have a
net cost per abstinent patient but are judged to be cost
effective in comparison to standard care. Sensitivity
analysis shows that the ranking of therapies is robust.
5. A limitation of the model is the absence of data on
relapse rates beyond the relatively short trial periods.
There are also concerns about generalising from trials to
treating patients in a Scottish setting. Further research
and evidence is therefore needed to give more definitive
estimates of the long-term effectiveness of all the
therapies in a Scottish setting.
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1.7 Organisational issues
1. Randomised controlled trials testing matters related to
the organisation of specialist alcohol services are scarce.
Thus, recommendations with regard to organisational
issues also take account of clinical expert judgement,
economic evaluation, patients' needs and preferences,
surveys of existing services and relevant policy
documents.
2. Alcohol dependence is a relapsing condition and the
need for ongoing treatment, even after a number of
unsuccessful interventions, should be recognised.
3. Alcohol services are highly suited to 'joint working', as
recommended by the joint Futures Group, involving
specialist mental health and social work addiction
services and non-statutory agencies with joint resourcing
and management of community care services.
4. Certain subgroups such as young people, the
homeless and those with comorbid mental health
problems, have special service needs and providers
should ensure that the service is accessible to all and
responsive to differences in users' needs.
5. NHS specialist alcohol services should be
multidisciplinary community (and day hospital) based
services with the option of specialist inpatient/residential
care. Consolidation of services may be necessary to
allow for a concentration of expertise and resources for
inpatient services for example.
6. Specialist services must make themselves aware of
mutual help (Alcoholics Anonymous) and non-statutory
agencies operating in their area and coordinate their
approach, making this information available to
individuals within their care. Informing patients about
Alcoholics Anonymous and non-statutory agencies
should be part of the overall strategy for prevention
of relapse.
7. In specialist settings it will usually be the case that
abstinence will be the goal for severe dependence,
where controlled use is rarely sustainable and especially
when there is evidence of alcohol-related organ
damage. Controlled use of alcohol may be an
appropriate treatment goal for those with less severe
alcohol problems. If controlled use or harm minimisation
is the considered preferred goal of the individual,
there must still be options for intervention e.g.
referral to a non-statutory agency or outpatient
motivational sessions.
8. The National Health Service survey identified gaps in
the core provision of services for inpatient/residential
facilities and for staffing. In addition to the core services,
it is good practice for specialist services to make
arrangements for continuing care of service users. For
example, service users value follow up, such as a phone
call, when they miss appointments.
9. An improved information collection system is
required. Information and Statistics Division is currently
developing the National Alcohol and Information
Resource for use by those who plan and provide
services. Local services should liaise with Information
and Statistics Division regarding methods of recording
and collecting information.
10. A regularly updated comprehensive directory of
alcohol services including residential treatment would be
beneficial. This should be useable by all participating
agencies and where available provide accurate outcome
data as well as a greater understanding of progress
through the treatment system.
11. The financial implications of implementing the
recommendations presented in the organisational and
patient issues sections of this Assessment Report amount
to £2.5 million per annum.
1.8 Discussion
1. This Assessment Report addresses the problems of
prevention of relapse in people who are alcohol
dependent and have undergone detoxification and are
newly abstinent.
2. The focus of this Assessment Report is the service
delivered by NHS specialist staff and the evidence
reviewed is largely drawn from studies carried out in a
specialist setting. Extrapolation from any of the Health
Technology Assessment conclusions to other settings
should be undertaken with caution. Advice on
management of alcohol problems by primary care
professionals is available from the Scottish Intercollegiate
Guidelines Network (SIGN).
3. This Health Technology Assessment views alcohol
dependence from a health perspective. However, no
effective service can ignore the societal aspects of
drinking alcohol. The existence of a spectrum of
drinking from the socially acceptable, and even
encouraged, to the socially unacceptable and dangerous
necessitates an unbiased self-assessment by the person
before treatment will even be sought. Thus, judgmental
attitudes concerning alcohol dependence may delay
some people in seeking help. In consequence, weight
has been given in this Health Technology Assessment to
perceptions of service users and the message that any
alcohol treatment service must be approachable cannot
be emphasised too highly.
4. The long-term health consequences of harmful
drinking have been reviewed using sources drawn from
published literature. This analysis revealed the extensive
damage caused to the health of people who drink
beyond defined limits. The increased risk of several types
of cancer, liver disease, brain damage and of death from
many causes show clearly the importance of identifying
and effectively treating alcohol dependence at an
early stage.
5. The quality of evidence regarding effectiveness of
interventions is not high. Most studies of psychosocial
interventions are performed by skilled enthusiasts.
Furthermore they generally involve small, and
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necessarily unblinded, trials. The assumption that other
specialists can consistently achieve similar results in
everyday practice is not obviously justifiable. Hence,
very stringent criteria have been imposed in the
cost-effectiveness analyses to test the robustness of the
Health Technology Assessment conclusions on this point.
Similar remarks apply to acamprosate and naltrexone
which show unexpected variations in efficacy
between studies.
6. The concern that it might be difficult to reproduce in
clinical practice the effectiveness seen in clinical trials
has led to several conclusions with respect to the
importance of therapist training, access to expert
psychological advice and the existence of robust quality
assurance measures. It is stressed that the complex
nature of psychosocial interventions and the important
role of therapist qualities in their delivery make these
measures an essential element in ensuring a consistent
and effective service.
1.9 Recommendations
1. Behavioural Self-Control Training, Motivational
Enhancement Therapy, Marital/Family Therapy and
Coping/Social Skills Training are clinically and
cost-effective psychosocial interventions and are
recommended treatment options for the prevention
of relapse in alcohol dependence.
2. Brief Interventions are not recommended, as trials in
people with alcohol dependence have failed to show
any benefit. However, the Scottish Intercollegiate
Guideline Network (SIGN) will recommend Brief
Interventions for hazardous drinkers (a less severely
affected group than those who are considered to be
alcohol dependent).
3. Other psychosocial interventions are not
recommended as their clinical effectiveness is unproven.
4. Acamprosate and supervised oral disulfiram are
treatment options recommended as adjuncts to
psychosocial interventions. Naltrexone does not have a
Marketing Authorisation for the treatment of alcohol
dependence in the United Kingdom and is not
recommended for routine use in NHSScotland.
5. Alcohol services should aim to reduce the delay
between detoxification and interventions for the
prevention of relapse. This would be facilitated by
joint working between specialist mental health
services, primary care, social work addiction services
and non-statutory agencies, as recommended by the
joint Futures Group.
6. Acamprosate or supervised oral disulfiram should
usually be initiated by a specialist service. The specialist
service will: ensure that the patient meets the criteria for
suitability; ensure the assessment of the motivation and
ability of the patient to use the medication correctly;
monitor efficacy; and ensure that adjunctive
psychosocial treatment is organised. Usage should be in
accordance with the Summary of Product
Characteristics, and should also be reviewed regularly
during the first 12 weeks after initiation of treatment,
at which stage transfer of prescribing to the general
practitioner may be appropriate, even though specialist
care may continue (shared care).
7. Introduction to Alcoholics Anonymous and
non-statutory agencies such as local Councils on
Alcohol (Alcohol Focus Scotland) should be part of
the overall strategy of specialist NHS services for the
prevention of relapse. As with other psychosocial
treatments, attendance is most likely to be beneficial
if it is an informed voluntary decision.
8. People who are alcohol dependent should be
informed about treatment choices. Their needs,
preferences and social circumstances should be
considered. As a result, the choice of interventions
should be a shared decision between the health
professional and the patient.
9. NHS specialist services should contact people who
drop out of treatment programmes and offer them
another appointment.
10. Health professionals should provide patient
information, including leaflets, which should be used to
support discussion between health professionals and
patients about the most appropriate treatment option.
11. Written information about the range of available
services should be readily accessible to people with
alcohol problems, their families, carers and to health
professionals, especially general practitioners. Alternative
formats such as cartoons or audio-visual material should
be used to support discussions with people who have
low reading skills or poor concentration. Alcohol Action
Teams could coordinate information requirements.
12. A regularly updated comprehensive directory
of alcohol services and accommodation should be
developed for the benefit of NHSScotland staff,
patients and their families, friends and carers.
13. Shorter, less intensive interventions (such as
Motivational Enhancement Therapy) might be provided
first, following the principle of 'stepped' care, if the
history suggests that such a relatively low intensity
approach has not already failed. Non-response will
indicate the need to move to more intensive treatment.
14. Recurrent relapse should not be a barrier to
re-referral. If a particular intervention is unsuccessful for
an individual, it is important to recognise that other
treatments may be more suitable and that further
options should be explored.
15. Core services should provide the full spectrum of
treatment options, including access to beds for NHS
inpatient or private/non-statutory residential treatment.
This might be achieved economically by sharing of
services across Trusts and Boards provided that access is
carefully considered.
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16. To ensure equity of access for the heterogeneous
group of people with alcohol dependence, the provision
and standard of alcohol services should be consistent
throughout NHSScotland.
17. Specialist NHS services should make provision for
the continuing care of each individual.
18. Certain subgroups of people with alcohol
dependence such as those in rural communities, young
people, the homeless, those with comorbid mental
health problems and those in the criminal justice system
can encounter unique difficulties in accessing specialist
services. Providers should make reasonable efforts to
ensure that the needs of every alcohol-dependent
person can be accommodated somewhere within the
spectrum of service provision.
19. Providers should develop services for the relatives,
carers and dependants of people with alcohol
dependence.
20. Joint training of staff from NHS and non-statutory
services is recommended to help ensure that all staff are
trained to uniform standards and equipped with the
necessary skills to deliver the recommended
interventions.
21. Interventions should be carried out in accordance
with standardised protocols by staff trained to agreed
national standards.
22. Measures should be in place to ensure that
psychosocial treatments are delivered to consistently
high standards over time. The delivery of these
interventions should be as similar as possible to that
which has been shown effective in clinical trials. As these
have involved delivery by clinical psychologists, the skills
of such professionals should be used at least in
supervision of treatment delivery and in training in
methods of delivery.
23. The Plan for Action (Scottish Advisory Committee on
Alcohol Misuse, 2002) requires each Alcohol Action
Team to draw up, publish by April 2003, and
subsequently implement, a local strategy covering at
least three years. These strategies should take account of
these recommendations.
24. An improved information collection system is
required to ensure that the requirements of these
recommendations are fulfilled. Development of the
National Alcohol and Information Resource (NAIR),
currently being undertaken by the Information and
Statistics Division, should take these requirements into
account.
25. In order to assess the long-term clinical course of
alcohol dependence following treatment in Scotland,
measurement of simple, verifiable outcomes such as
further detoxification over a period of, for example, five
years would prove useful. Long-term treatment success
rates in terms of abstinence or controlled drinking
should be reported.
26. More research is needed regarding the benefits of
different settings for psychosocial interventions in order
to determine the most effective and efficient approach
to delivering the interventions. It has not been
established whether group therapy is more effective
than individual therapy, or whether an inpatient,
outpatient or day unit setting is most conducive to
treatment success. It is unclear if there is a correlation
between the effectiveness of interventions and the
length, frequency or intensity of treatment. In particular,
the impact on effectiveness of multiple psychosocial
treatments for one individual is not established.
27. Acamprosate (and naltrexone) have given unusually
variable results in clinical trials in specialist settings, with
some trials having shown no treatment effect. Possible
explanations have been suggested but these require
corroboration by prospective studies. Given the
variability of effect even in specialist settings, any
extrapolation to use in primary care requires new clinical
trial evidence of effectiveness.
28. A trial of supervised oral disulfiram has shown a
convincing reduction in drinking while on the drug but
no study has demonstrated that this results in an
increased likelihood of ongoing abstinence or controlled
drinking. Such a study is needed to inform clinical
practice.
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Abstract — Background: End-stage alcoholic liver disease (ALD) is a common indication for liver transplantation. Outcomes may be
limited by return to harmful drinking. Previous studies have identified few predictors of drinking relapse. Aim: This study examined
novel postulated predictors of relapse to drinking. Method: The case notes of all patients transplanted for ALD at the Royal Prince
Alfred Hospital from 1987-2004 were reviewed. Pre-transplant characteristics were rated by a psychiatrist independent of the transplant
team, blind to the outcome. Outcomes were rated by a second independent alcohol treatment specialist also blind to the pre-transplant
ratings. Results: Of 100 patients, 6 died before discharge from hospital, 4 had <6 months follow-up, 18 relapsed to harmful drinking, 10
drank below harmful levels, and 62 remained abstinent after a mean of 5.6 years follow-up. Univariate analyses identified six potential
pre-transplant predictors of return to harmful drinking. These were a diagnosis of mental illness (of which all cases were of depression),
the lack of a stable partner, grams per day consumed in the years before assessment for transplant, reliance on 'family or friends' for
post-transplant support, tobacco consumption at time of assessment, and lack of insight into the alcohol aetiology. Duration of pre-
transplant abstinence and social class by occupation did not predict relapse. A multivariate model based on the above characteristics
correctly predicted 89% of the outcomes. Conclusion: A model based on readily defined behaviours and psychosocial factors predicted
relapse to harmful drinking after transplant for ALD. This model may improve assessment and post-transplant management of patients
with advanced ALD.
Alcoholic liver disease (ALD) is a common cause of cirrhosis
of the liver and is also a common indication for liver trans¬
plantation. Following early uncertainty, it is now widely
accepted that the overall clinical outcomes of liver trans¬
plantation for carefully selected patients with ALD are similar
to those of other forms of liver disease (Lucey et al., 1992;
Haber et al., 1999; Bjornsson et al., 2005). However, relapse
after transplant to harmful use of alcohol remains a concern
and can lead to significant problems. Up to 40% of those
receiving a liver transplant will return to consuming alcohol
(Bird et al., 1990; Lucey et al., 1997; Gish et al., 2001;
Pageaux et al., 2003; Lim and Keeffe, 2004). Up to 20% drink
heavily (Pageaux et al., 2003; Lim and Keeffe, 2004), which
can lead to recurrent ALD (Pageaux et al., 2003), graft failure
due to non-compliance with immunosuppression treatment
and other serious alcohol-related harms including death
(Cuadrado et al., 2005).
Orthotopic liver transplantation is a highly resource inten¬
sive treatment with access typically limited by availability of
suitable donor livers. The identification of those patients likely
to experience the maximum sustained benefit is very impor¬
tant. Specific and objective selection criteria have been sought
without success to date. A minimal period of 6 months pre-
transplant abstinence from alcohol is an objective measure
widely adopted as it provides adequate time to demonstrate
cessation of alcohol use and also provides the opportunity
for many patients to recover adequately so as to no longer
♦Author to whom correspondence should be addressed at: Drug Health
Services, Royal Prince Alfred Hospital, Missenden Road, Camperdown,
NSW 2050, Australia. Tel.: +61 2 9515 6419; Fax: +61 2 9515 8970;
E-mail: phaber@mail.usyd.edu.au
require transplantation. However, this 'six month rule' has
been criticized as being arbitrary and the pre-transplantation
duration of abstinence is a poor predictor of outcome
(Weinrieb et al., 2000; Neuberger et al., 2002; Lim and
Keeffe, 2004). Lucey et al. (1992) proposed that four factors
defined risk of post-transplant relapse to heavy drinking
(insight, stable partner, stable housing, stable employment).
Subsequent research from several groups has shown that
pre-transplant assessment does not predict the minority who
return to heavy drinking after successful transplantation
(Lucey et al., 1997; Mackie et al., 2001; Bjornsson et al.,
2005). However, DiMartini et al. (2001) reports predictive
data in a study of 36 patients surviving transplantation
for ALD. Post-transplant use of any alcohol was significantly
associated with prior non-alcohol substance use, presence of a
first-degree relative with alcoholism, prior alcohol rehabilita¬
tion but not with prior psychiatric history. Diagnosis
of alcohol dependence by an addiction psychiatrist was the
only pre-transplant factor assessed, which predicted return to
harmful drinking (Smyth et al., personal communication).
The relevance of factors associated with relapse in
addictions outside the transplant context remains unclear.
Prognostic factors of interest include insight, presence of
psychiatric comorbidity, stability of relationships, housing
and employment, maintenance of abstinence while physically
well enough to drink, and expansion of social role with absti¬
nence. Rather than any consumption of any alcohol, the
outcome variable of interest was harmful alcohol consumption
as the latter is of greater clinical significance. The aim of this
study was to test the value of these parameters as predictors
of relapse to harmful drinking after liver transplantation
for ALD.
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METHODS
The study protocol was approved by the Ethics Review Com¬
mittee of Central Sydney Area Health Service (RPA Zone).
The Australian National Liver Transplant Unit is based at
Royal Prince Alfred Hospital and maintains a prospective
database of all liver transplants, which includes the underlying
aetiology for liver disease. The standardized pre-operative
checklist did not include the specific questions we wished to
look at, covering medical and demographic items. Accord¬
ingly, the notes of all patients who received a liver transplant
with a record of alcoholic cirrhosis as either the primary or
secondary diagnosis were reviewed.
From study of the literature, consultation with the transplant
team, including the liaison psychiatrist and the substance mis¬
use specialist who had interviewed a proportion of the
patients, a list was prepared of candidate predictors of post-
transplant drug and alcohol misuse, which was refined to
include only the items for which the pre-transplant assessment
and medical records would provide data. Some pre-transplant
variables of possible interest were not included because data
were not consistently recorded, e.g. alcohol rehabilitation
experience and family history of alcoholism.
A psychiatrist (M.K.) who was blind to the post-transplant
outcome examined the pre-transplant hospital notes for all
information recorded of relevance to the candidate predictors
of outcome (Table 1). All patients had had a discussion with
the transplant team about their alcohol use, and the need for
life-long abstinence from that point was routinely stressed.
Only when it was noted specifically that motivation or insight
was a concern was that patient given a negative score for that
binary variable. Where there had been no mention of concern,
the patient was rated by M.K. as 'positive'. A senior alcohol
specialist (J.C.), who was blind to the pre-transplant ratings,
examined the post-transplant notes to rate outcome. Neither
had met the patients or had any role in the treatment of the
patients, nor in the transplant unit. In two instances where
post-transplant data were equivocal, further information was
obtained from an outside specialist who had treated the patient
since the transplant.
As a measure of inter-rater reliability, the assessments made
on eight patients by a third rater (M.H.) were compared with
the ratings made by M.K. and J.C.
Outcome variables
Our primary outcome variable was the incidence of return to
harmful drinking. The definition of harmful drinking was
drinking with recorded medical or social harm, or drinking
above 140 g ethanol/week. 'Harm' included evidence of ongo¬
ing abnormal liver tests consistent with alcohol, which could
not be accounted for by other factors despite investigations
and careful consideration of organ rejection and medication.
None of the case records includes results of breathalyser tests,
or blood or urine ethanol. In our analysis, those who drank
below harmful limits are included with the abstainers. Any
record or evidence of post-transplant drinking was noted.
Statistical analysis
Univariate tests of significance between the two outcome
groups were conducted using cross-tabulations and Chi-
squared tests for categorical variables (continuity corrected).
Tablel. The predictor variables
Addiction variables
• Grams per day of alcohol when drinking (in the pre-transplant
assessment years)
• Number of days abstinent before transplant
• 1CD 10 diagnosis of dependence present or not: diagnosis recorded in the
records, or any history of withdrawal symptoms, including an
alcohol-related seizure
• Insight into cause of liver failure—did the patient believe the cause
was alcohol?
• Motivation to stop drinking as assessed by addictions specialist or others
• Any drug misuse and amount per day
• Ever injected
• Tobacco use (cigarettes per day at time of final transplant assessement)
Psychosocial variables
• Housing stability—more than 2 years in current address
• Committed cohabiting spouse or partner
• Family or friends named as primary support, as stated by the patient
• Previous employment (coded as professional, blue collar, or unemployed)
• Diagnosis of any mental illness: a pragmatic definition based on any
record made by the physician of a diagnosis and specific treatment for
that illness
• Post-alcohol lifestyle. This was registered as illness lifestyle—i.e. no
other meaningful occupation such as return to work or home activities or
voluntary work during the period of abstinence prior to liver failure and
transplantation
Assessment factors
• Early or late assessment—due to medical condition of patient—
assessment may not have included consultation with addictions or
psychiatry specialist
• Consensus of opinion—did every consultant involved offer the clear
opinion to go ahead with transplant or were doubts raised
with appropriate attention to small cell sizes. Mann-Whitney
(/-tests were used for continuous variables. Stepwise logistic
regression analysis (forward conditional) was conducted to
identify significant predictors to harmful drinking. The Statis¬
tical Package for the Social Sciences (SPSS Version 13 for
Windows, Chicago, IL) was used for all analyses.
RESULTS
There were 100 patients between 1987 and 2004 who received
liver transplants for ALD alone or with a diagnosis of chronic
viral hepatitis. Three patients were transplanted twice, owing
to complications unrelated to substance misuse, making a total
of 103 such transplants. The numbers of patients transplanted
for ALD increased as the years went by. Between 1987 and
1990, there were only 3; from 1991 to 1994, 14; from 1995
to 1998,26; from 1999 to 2002,30; and from 2003 to 2004,30.
Six died at or soon after the transplant, and four had less
than 6 months of follow-up at the time of the ratings and
were not included in the study. Of the remaining 90, 18
(20%) relapsed to harmful drinking and another 10 drank
below harmful levels up to the date of the study (total drinkers
28, 31%; Fig. 1). Of the 26 patients who had ever used illicit
drugs prior to transplant, 22 of whom had injected, 10 (38%)
resumed illicit drug use post-transplant, and 2 (9.1%) resumed
injecting. Of those who consumed illicit drugs post-transplant
four were also harmful drinkers and six were abstainers from
alcohol. Of the abstainers and non-harmful drinkers, 67 were
male (81%); of the 18 harmful drinkers, 15 were male (83%).
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Fig. 1. Overview of study results.







Fig. 2. Cumulative survival to time to first record of harmful drinking following transplant (days).
The time to a record in the casenotes of harmful drinking
post-transplant varied from 60 days to over 10 years (Fig. 2).
Fifty percent of relapses were recorded within the first 2 years.
The mean duration of follow-up was 5.6 years, suggesting
the duration of follow-up was sufficient to detect most
relapse events. Relapse to harmful drinking emerged as very
serious for several patients. One patient had a drink drive
offence, another's drinking led to his partner leaving, one
patient developed life-threatening alcoholic pancreatitis, and
one man died on the waiting list for a second transplant liver
having once again developed ALD.
Inter-rater reliability
In all eight cases there was complete agreement between raters
on all pre-transplant and outcome variables.
Univariate analysis
The characteristics of interest as possible predictors of relapse
among these 90 patients are shown in Table 2. A series of uni¬
variate tests, showed that tobacco consumption at the time of
assessment, the presence of mental illness diagnosis prior to
transplant, lack of a stable partnership, and tobacco consump¬
tion were significantly associated with post-transplant harmful
drinking. In addition, there were a number of variables
approaching significance. These were a lack of insight into
alcohol as the main aetiology of liver failure, lack of a mean¬
ingful abstinent lifestyle, unstable housing, grams per day of
alcohol consumed when drinking in the years before the
assessment for transplant, late referral for transplant assess¬
ment, and a lack of consensus concerning suitability amongst
the transplant team. The presence of stated family or friend
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Table 2. Univariate analysis of pre-transplant risk factors for harmful alcohol consumption post-transplant
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None/not harmful drinking Harmful drinkers
Pre transplant variable li to N= 18 Significance P-value"
Alcoholic cirrhosis—primary diagnosis n (%) 44(61%) 7 (40%) 0.089
Age at transplant mean (SD) (median) 50.8 (7.2) (50.5) 47.5 (5.8) (48.5) 0.101
Days from transplant to outcome assessment mean (SD) (range) 2022 (1689)(143-6302) 2195 (963) (635-1175) 0.246
Addiction behaviours
Ethanol per day fg; mean (SD)] 135 (67) 188 (109) 0.077
No. of days abstinent before transplant mean (SD) (range) 686 (680)(120-3650) 697(642)(60-2190) 0.940
Abstinent <1 year pre-transplant n (%) 22 (30%) 7 (39%) 0.499
ICD 10 diagnosis of dependence n (%) 19 (26%) 6 (33%) 0.556
Insight: poor n (%) 17 (24%) 9 (50%) 0.055
Motivation: doubtful 11 (%) 12(17%) 6 (33%) 0.114
Any drug misuse n (%) 19 (26%) 7 (39%) 0.295
Ever injected n (%) 15 (21%) 7 (39%) 0.111
Tobacco use per day (median) (range) 1 (0-60) 10 (0-50) 0.026
Psychosocial
Housing unstable n (%) 10(14%) 6 (33%) 0.054
No partner n (%) 16 (22%) 9 (50%) 0.019
No family/friend support n {%) 14(19%) 1 (6%) 0.157
Previous occupation 0.669
Blue collar n (%) 49 (69%) 11 (61%)
Professional n (%) 18(25%) 5 (28%)
Unemployed n (%) 4(6%) 2(11%)
No 'post-alcohol lifestyle' n (%) 36 (50%) 13 (72%) 0.053
Previous diagnosis mental illness n (%) 3 (4%) 4(22%) 0.011
Transplant assessment factors
Late assessment 4 (5.6%) 4 (22.2%) 0.079
Consensus—doubt 10(14.%) 6 (33.%) 0.054
Continuity correction used for 2 x 2 tables.
Table 3. Final regression model
95% confidence intervals for Exp [i
Variables entered in final model Coefficient p Standard error P-value for use in model Odds ratio Lower Upper
Grams per day alcohol 0.009 0.005 0.059 1.009 1.000 1.018
Mental illness 2.005 1.026 0.051 7.424 0.993 55.485
Partner -2.611 0.823 0.002 0.073 0.015 0.368
Family/friends 3.669 1.444 0.011 39.16 2.314 663.792
Cigarettes/day 0.061 0.025 0.016 1.063 1.012 1.116
Insight -1.770 0.754 0.019 0.170 0.039 0.748
Constant -4.079 1.681 0.015 0.017
support correlated with harmful drinking outcome
(see Discussion).
Multivariate analysis
A stepwise logistic regression analysis showed that a model
based on six pre-operative predictor variables accounted for
52% of the variance in outcome (P < 0.0001). All the
hypothesized predictor variables were significant and were
included in the following order (Table 3):
(i) grams per day alcohol before assessment for
transplant;
(ii) mental illness diagnosis;
(iii) stable relationship;
(iv) family or friends support;
(v) tobacco use per day;
(vi) insight into alcohol aetiology.
The multivariate model correctly classified the outcome of
89% of patients (Table 4). Ten of the twelve who the model




Observed drinking drinking % correct
Abstinent/not harmful drinking 69 2 97.2
Harmful drinking 8 10 55.6
Overall percentage 88.8
predicted would return to harmful drinking did so, indicat¬
ing that the positive predictive value was 83%. Two were
incorrectly predicted to return to harmful drinking. Of the
77 cases where the model predicted no return to heavy drink¬
ing, 8 cases relapsed indicating that the negative predictive
value was 90%.
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DISCUSSION
This study has demonstrated that pre-transplant assessment of
patients with ALD is able to identify patients at particular risk
of returning to harmful consumption of alcohol post-
transplant. The predictors of outcome were those that could
be defined by the transplant hepatologist without specialist
skills in addiction medicine, or psychiatry. A comprehensive
structured assessment battery was not in place in the service
studied; a role for routine use of such batteries is not yet estab¬
lished. The model predicted the presence or absence of relapse
in 89% of cases. There is evidence that relapse to alcohol use
adversely impacts on survival. The findings of this study
should be replicated in a different transplant population before
being incorporated into transplant assessment protocols. Addi¬
tionally, prospective identification of the group at greatest risk
of post-transplant substance use problems creates the opportu¬
nity for additional intervention to prevent relapse and its
associated adverse clinical events.
Strengths and limitations
The strengths of the study design are that we had independent
blind raters who assessed clinically relevant outcomes with a
relatively large sample size for a single centre study. The study
looked strictly at recorded material and was not influenced by
any knowledge or personal involvement in any clinical care.
The outcome ratings were done by an expert in alcohol prob¬
lems with experience in detecting alcohol abuse using all clini¬
cal indicators. Harmful drinking, not 'any drinking' was used
as the outcome of interest; this is a more clinically relevant
outcome measure. It avoids making assumptions of whether
low-level drinking may or may not lead to later harm, although
it may be noted that only one-third of post-transplant drinking
was rated as 'non-harmful'. The focus for this study was the
clinical records made by clinicians performing routine care,
yielding a measure of clinically significant relapse. This may
have been less sensitive than any self-reported alcohol con¬
sumption, but was likely to be more specific by focussing on
clinically important use of alcohol. It did not include sub¬
clinical alcohol consumption and thus reduced 'noise' in the
data. Self-reports of consumption, unreliable in many con¬
texts, may be especially unreliable when, as in a transplant
unit, the patient had given a vow to abstain. However it is
possible that relying only on case records will miss some cases
of return to heavy drinking, which have not aroused clinical
suspicion, despite frequent close monitoring by the transplant
and community teams of both clinical and laboratory parame¬
ters, and regular communication between transplant clinicians
and the patients carers.
Similarly, the date of recording of harmful drinking does not
necessarily indicate the date harmful drinking commenced,
because it may have been hidden for some time. Nonetheless,
it is striking that the majority of relapses occurred early, and
therefore interventions even only in the first post-transplant
year would be likely to help reduce the total relapse rate. How¬
ever, as almost half the relapses occurred after the first 2 years,
close monitoring of an at risk group should be sustained
long term.
The model
Our findings indicate that if each patient is assessed and given
a score according to these variables it is possible to predict
with a fair reliability the patients who are vulnerable to a
return to harmful drinking. It is important to validate these
findings in a different transplant population before applying
the model more widely. This study has also shown that no sin¬
gle predictor, when used on its own, predicted relapse with any
reliability. The diagnosis of mental illness, the lack of a stable
partner, and tobacco use were individually significant; how¬
ever, the increase in relapse risk was modest. The illnesses
recorded were, in the event, all cases of depression of varying
severity, all with previous treatment. However, depression is a
condition that can respond to psychiatric treatment, and relapses
can be prevented, if treatment is available and accepted. These
findings do not suggest that a history of depressive illness
should be an exclusion from transplant, but an indication for
specific assessment and outpatient monitoring.
Entry to the transplant waiting list is based on consensus
decision from a weekly meeting of transplant clinicians. The
clinical opinion of transplant psychiatrist and substance
misuse physician is included in this process. The present sta¬
tistically significant findings have emerged despite the possi¬
bility that the more extreme scorers on these parameters
would already have been excluded from transplantation, thus
biasing the study against identifying predictive factors. This
helps to support the validity of the identified factors. Even
though these findings are statistically impressive, it is impor¬
tant to place them in the appropriate clinical context. The
transplant team would not wish to refuse transplantation on
the basis of a wrong prediction that the candidate will return
to harmful drinking. This would have occurred on 2 of 12
occasions based on a model using these predictors. Indeed, 8
of 18 relapses occurred in those predicted to be at low risk
according to our model. Moreover, many relapses were not
life threatening. Once identified, most patients responded to
further interventions and reduced their drinking.
Comments on individual predictors
The finding that average consumption in grams per day during
heavy drinking periods during the years before the assessment
for transplant correlates positively with the risk of relapse may
say something important about the recording of alcohol con¬
sumption data. Studies that have found that pre-transplant con¬
sumption was not a predictor of relapse may have used weekly
consumption or some other averaging method, which blurred
the importance of heavy session drinking as a predictor of
harm (Miller et al., 2005).
Unlike in the Edinburgh follow-up study (Smyth et al., per¬
sonal communication), the presence or absence of a diagnosis
of previous alcohol dependence was not often stated in the
notes. The reason may be that relatively few patients receive
assessment by an addictions specialist so more of those who
relapsed may have met the criteria for dependence than we
have shown. Previous studies have found that a significant
number of patients transplanted for ALD never met criteria
for dependence (Lucey et al., 1992).
Looking further at the factors that contributed to our predic¬
tor model, we suggest that the evaluation of insight into cause
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of illness and motivation to change may be valuable for every
candidate during the pre-transplant assessment. The level of
insight described in this study is relatively modest and future
research might evaluate this in greater detail to include insight
into personal limitations and treatment needs. This should
also, ideally, be a time for planning long-term support and
an illness-free and addiction-free lifestyle.
The stated presence of family and friend support correlated
with return to drinking, which seems counter-intuitive. One
explanation is as follows. The pre-transplant patient is asked
to name a support network and if he/she does not have a
cohabiting partner, may identify 'family or friend support'.
A number of patients named former spouses who agreed to
give specific support for a limited time period—for example,
the acute post-operative period. The same applied to parental
or other family support where a patient planned to move tem¬
porarily into a family or friends' home during the early recov¬
ery period. However, this is also the time that they are least
likely to resume drinking. The years after the acute illness
has passed are likely to be more risky (Fig. 2) and in some
of the cases where 'family and friends' support' had been
named, perhaps the least supported.
It was noteworthy that pre-transplant tobacco use was a pre¬
dictor of post-transplant alcohol use. This association might
reflect the presence of a greater tendency to substance misuse
in general. In our centre, transplant candidates are strongly
encouraged to stop smoking in view of the association with a
range of adverse events post-transplant including post¬
operative respiratory complications, vascular complications
(Pungpapong et al., 2002), and osteoporosis (McCaughan and
Feller, 1994). It is not surprising that those who continue to
smoke against advice may be at risk of other therapeutic non-
adherence. Post-transplant smoking has recently been shown to
adversely impact on clinical outcomes (Dimartini etal., 2005).
Thus, smoking is both a marker of the risk of returning to alco¬
hol consumption and a significant clinical problem per se.
The duration of abstinence prior to transplantation was not a
predictor. Our transplant centre generally adopts the six-
month rule and accordingly only six cases were transplanted
with less than 6 months abstinence. Nonetheless, the finding
is consistent with other studies that have found that other fac¬
tors are more important predictors of outcome than the dura¬
tion of abstinence taken in isolation (Weinrieb et al., 2000).
Finally, we wish to underline that, in this sample, social class
measured by occupation did not predict outcome, either in
univariate analysis or after adjustment for other variables.
In conclusion, we have found that a multivariate model
based on four adverse factors (presence of documented mental
illness, level of alcohol consumption, continuing tobacco use,
and the need to rely on friends or family for support) and two
protective factors (presence of a cohabiting partner and insight
into the aetiological role of alcohol) was able to predict the
likelihood of relapse to harmful alcohol consumption after
liver transplantation for ALD in 89% of cases. Similar factors
are known to influence the prognosis of alcohol dependence
outside the transplant context (Neuberger et al., 2002), but
this is the first study to identify pre-transplant factors that
can predict return to harmful alcohol consumption after suc¬
cessful transplantation. The detailed psychosocial assessment
plays a role in predicting outcome after liver transplant for
ALD in terms of harmful drinking. The factors highlighted
in this report can be assessed by non-specialist staff, but asses¬
sment by an addictions specialist may also be valuable
because several of these factors may be amenable to change.
Additional research should be directed towards validating
these findings in other transplant populations, applying them
prospectively to enhance pre-transplant assessment and case
selection, and in designing pre-transplant and post-transplant
monitoring and intervention programmes to minimize the
relapse rates and attending harms to transplant patients and
the community.
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1.1 THE NEED FOR A GUIDELINE
Harmful drinking and alcohol dependence are common conditions which contribute considerably
to morbidity, mortality and burden to the NHS, as well as causing social harm:
■ in the Scottish population, at any one time 250,000 people report symptoms of mild alcohol
dependence, and 16,000 report moderate to severe symptoms'
■ deaths attributed to alcohol misuse more than doubled between 1990 and 1999 and they
continue to rise2
■ alcohol dependent patients consult their general practitioners (GPs) about twice as frequently
as other patients in a practice3 4
■ alcohol dependence and alcohol related diagnoses have been rising among patients discharged
from Scottish general hospitals2
■ Accident and Emergency (A&E) attendance surveys conducted in Glasgow5 and Edinburgh6'7
have noted a high burden to the A&E service of problems related to serious alcohol misuse
■ there is widespread variation in practice, interest, knowledge and experience in dealing with
alcohol dependence amongst healthcare professionals in primary care.8
1.2 DEFINITIONS
1.2.1 UNIT OF ALCOHOL
One "unit" in the UK usually means a beverage containing 8 gof ethanol, eg a half pint of 3.5%
beer or lager, or one 25 ml pub measure of spirits. A small (125 ml) glass of average strength
(12%) wine contains 1.5 units (see Annex 7 for a list of the alcohol content of a range of
beverages).
1.2.2 HAZARDOUS DRINKING
The term hazardous drinking is widely used. It is synonymous with "at-risk drinking" and can be
defined as the regular consumption of:
■ over 40 g of pure ethanol (5 units) per day for men
■ over 24 g of pure ethanol (3 units) per day for women.
These figures derive from population studies showing the relationship of self reported levels of
drinking to risk of harm. It is arbitrary which point on the risk curve is deemed to merit a
warning.913 Other authorities have quoted weekly recommended upper limits for alcohol
consumption of 21 units per week for men and 14 units per week for women.14
Consuming over 40 g/day alcohol on average doubles a man's risk for liver disease, raised blood
pressure, some cancers (for which smoking is a confounding factor) and violent death (because
some people who have this average alcohol consumption drink heavily on some days). For
women, over 24 g/day average alcohol consumption increases their risk for developing liver
disease and breast cancer.912These studies used self reported consumption figures.
The term hazardous drinking is also used loosely to cover those who have experienced minimal
as opposed to serious harm.
1.2.3 HARMFUL DRINKING
Harmful drinking is defined in the International Classification of Diseases (ICD-10) as a pattern
of drinking that causes damage to physical (eg to the liver) or mental health (eg episodes of
depression secondary to heavy consumption of alcohol).15 The diagnosis requires that actual
damage should have been caused to the mental or physical health of the user.
1
THE MANAGEMENT OF HARMFUL DRINKING AND ALCOHOL DEPENDENCE IN PRIMARY CARE
1.2.4 ALCOHOL DEPENDENCE
Alcohol dependence is defined as a cluster of physiological, behavioural, and cognitive phenomena
in which the use of alcohol takes on a much higher priority for a given individual than other
behaviours that previously had greater value.15 A central characteristic is the desire (often strong,
sometimes perceived as overpowering) to drink alcohol. Return to drinking after a period of
abstinence is often associated with rapid reappearance of the features of the syndrome (priming).
A definitive diagnosis of dependence should usually be made only if three or more of the following
have been present together at some time during the previous year:
■ a strong desire or sense of compulsion to take alcohol
■ difficulty in controlling drinking in terms of its onset, termination or level of use
■ a physiological withdrawal state when drinking has ceased or been reduced (eg tremor,
sweating, rapid heart rate, anxiety, insomnia, or less commonly seizures, disorientation or
hallucinations) or drinking to relieve or avoid withdrawal symptoms
■ evidence of tolerance, such that increased doses of alcohol are required in order to achieve
effects originally produced by lower doses (clear examples of this are found in drinkers who
may take daily doses sufficientto incapacitate or kill non-tolerant users)
■ progressive neglect of alternative pleasures or interests because of drinking and increased
amount of time necessary to obtain or take alcohol or to recover from its effects (salience of
drinking)
■ persisting with alcohol use despite awareness of overtly harmful consequences, such as harm
to the liver, depressive mood states consequent to periods of heavy drinking, or alcohol
related impairment of cognitive functioning.
1.3 POPULATION COVERED BY THE GUIDELINE
This guideline pertains to patients with alcohol dependence, hazardous or harmful drinking, in
primary care (general practice and community nursing) and among those attending, but not
admitted from, A&E Departments.
The guideline does not address some specific situations:
■ patients already in specialist care
■ patients admitted to general or psychiatric hospitals
■ driving
■ drinking related to vocational or professional issues eg for van drivers, surgeons or teachers
with alcohol problems
■ adolescents with an alcohol problem
■ child safety
■ the management of alcohol related organ damage
■ treatment of carers and family members of patients with an alcohol problem.
A health technology assessment has been performed by NHS Quality Improvement Scotland on
the prevention of relapse in alcohol dependence in specialist settings, which complements this
guideline (see Annex 8).
2
1 INTRODUCTION
1.4 STATEMENT OF INTENT
This guideline is not intended to be construed or to serve as a standard of medical care. Standards
of care are determined on the basis of all clinical data available for an individual case and are
subject to change as scientific knowledge and technology advance and patterns of care evolve.
These parameters of practice should be considered guidelines only. Adherence to them will not
ensure a successful outcome in every case, nor should they be construed as including all proper
methods of care or excluding other acceptable methods of care aimed at the same results. The
ultimate judgement regarding a particular clinical procedure or treatment plan must be made by
the doctor, following discussion of the options with the patient, in light of the diagnostic and
treatment choices available. It is advised however, that significant departures from the national
guideline or any local guidelines derived from it should be fully documented in the patient's
case notes at the time the relevant decision is taken.
1.5 REVIEW AND UPDATING
This guideline was issued in 2003 and will be considered for review as new evidence becomes
available. Any updates to the guideline in the interim period will be noted on the SIGN website:
www.sign.ac.uk
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2 Detection and assessment
2.1 CLINICAL HISTORY
There is evidence from clinical and epidemiological studies of a relationship between heavy
drinking and certain clinical presentations (injuries, physical and psychiatric illnesses, frequent
sickness absence) and social problems (see Annex 2). There are some signs at physical examination
recognised by experts as linked to heavy drinking, such as injuries (including in the elderly),
tremor of the hands and tongue, and excessive capillarisation of the facial skin and conjunctivae.'6'17
The exact association between these signs and actual heavy drinking has not been thoroughly
investigated.
Research suggests that most people are not offended by being asked about their alcohol
consumption and will give a reliable account if there is no sanction anticipated.'8-'9
Primary care workers should be alerted by certain presentations and physical signs, to the
possibility that alcohol is a contributing factor and should ask about alcohol consumption.
2.1.1 THE ACCURACY OF SELF ASSESSMENT
Although evidence is not consistent, patients in research projects tend to report consumption
that correlates with blood tests and is fairly close to that reported by their family.20 It is not
known if this is true for UK primary care consultations, where the GP may be perceived by the
patient as having several roles, and where fears of employment, legal or insurance consequences
affect what patients disclose to the GP.
Severely dependent drinkers may not want to admit a pattern of drinking, which they prefer to
continue, or feel they cannot alter. Shame or guilt may lead some drinkers to minimise their
reported consumption.2'
0 While most patients are factual about their drinking, the primary care team should recognise
that some will under-report their consumption at times.
2.2 SCREENING FOR ALCOHOL DEPENDENCE AND THOSE AT RISK
There is a large volume of good quality evidence indicating that appropriate screening helps the
detection and treatment of alcohol problems (see Annex 2 for a list ofalerts). This evidence has
consistently shown that screening using the Alcohol Use Disorders Identification Test (AUDIT)
is effective within primary care, A&E, pre-and antenatal settings. The AUDIT is more sensitive in
the detection of hazardous drinking than CAGE (attempts to Cut back on drinking, being Annoyed
at criticisms about drinking, feeling Guilty about drinking, and using alcohol as an Eye-opener;
positive answers to two or more = probable alcohol dependence), unless CAGE is supplemented
with questions on maximum daily and total weekly consumption (CAGE plus two).22'33
The scoring procedure for AUDIT can be difficult to memorise, and the questionnaire itself can
take five minutes to complete. Abbreviated versions of AUDIT are preferred by many primary
care workers, and accuracy is only slightly diminished. These include the Fast Alcohol Screening
Test (FAST; see Annex 3), which is a thirty second version of the AUDIT and the Paddington
Alcohol Test (PAT; see Annex 4).22-3' TWEAK and T-ACE are abbreviated screening tools found to




Abbreviated forms of AUDIT (eg FAST), or CAGE plus two consumption questions,
should be used in primary care when alcohol is a possible contributory factor.
In A&E, FAST or PAT should be used for people with an alcohol related injury.
TWEAK and T-ACE (or shortened versions of AUDIT) should be used in antenatal and
preconception consultations.
4
2 DETECTION AND ASSESSMENT
When a patient registers with a GP, a medical history is taken which includes questions on
alcohol consumption.34 A screening questionnaire at this point is a useful tool for identifying
hazardous drinking.
0 When new patients register with a GP they should be asked about weekly and maximum
daily alcohol consumption, or an appropriate screening tool should be used.
The screening and brief interventions algorithm shown in Box 1 in section 3.1 is based on the UK
Alcohol Forum guidelines for the management of alcohol problems in primary care and general
psychiatry35 and is a useful tool to aid decision making.
2.3 BIOLOGICAL MARKERS OF ALCOHOL PROBLEMS
2.3.1 MARKERS OF ALCOHOL PROBLEMS
Elevations in mean red blood cell volume (MCV), serum gamma glutamyl transferase (GGT) and
carbohydrate deficient transferrin (CDT) are markers of heavy drinking in preceding weeks. The
difficulty in assessing their accuracy as diagnostic tests has been that self reported consumption
is used as the "gold standard" but sometimes a biological marker may be more accurate than a
self report.36 38
False positive results occur with GGT and MCV due to other causes of elevation. False positive
MCV can occur as a result of vitamin B12 deficiency, folic acid deficiency, thyroid disease or
chronic liver disease. False positives with GGT are due to other causes of liver disease or enzyme
induction including some drugs. CDT is normal in mild to moderate liver disease. It may be
raised in severe liver disease, but otherwise gives few false positives. If elevated due to alcohol,
it remains elevated for several weeks after consumption has reduced. It will not detect a recent
relapse. CDT may be a more accurate marker of very recent (past two weeks') drinking than
GGT.39'40
As CDT measurement is not available within Scotland, it is recommended only when there is
clinical difficulty in interpreting a normal or an abnormal GGT or other liver test result. King's
College Hospital, London accept serum samples by post for CDT assay.
Biological tests are of less value than self reports for screening with the intention of intervention.
They have their greatest role where patients have a reason for minimising (or, less commonly,
exaggerating) their consumption, and in monitoring patients' progress in reducing their drinking.
Even though these tests have limited sensitivity and specificity, if elevated in a given patient,
they may help motivate a patient to reduce drinking and they are then useful in monitoring
change in consumption.
2.3.2 BLOOD ALCOHOL CONCENTRATION
Blood alcohol concentration (BAC), normally measured by reference to breath alcohol, can
contribute to screening41 and is valuable for monitoring patients during detoxification in the
community, as well as following progress thereafter. Breathalysers permit estimates to be made
of very recent alcohol consumption and are often used by specialist nurses in the community. A
breathalyser is a useful item of equipment in a Health Centre and in A&E.
Saliva alcohol tests also give a reliable estimate of BAC.42'43
Biological tests are useful when there is reason to believe that self reporting may be
inaccurate.
0 Biological tests are useful to motivate patients to review their drinking and to consider
change.
0 Biological tests should be used to monitor patients' progress in reducing their drinking.
0 A&E departments and health workers regularly dealing with alcohol problems in the
community should have access to a breathalyser.
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2.4 PRESENTATION IN CRISIS
Patients presenting in crisis may place the primary care team in difficult situations. There is no
evidence on how best to approach these encounters. This section discusses some possible common
sense solutions.
2.4.1 PATIENT IN CRISIS
Suicidal threats or demands for immediate but undefined "help" require assessment, preferably
within the surgery or by the out-of-hours service. Listening to the patient's concerns may help to
al leviate the pressure on the healthcare professional to take additional action. Immediate admission
is rarely indicated or possible but, if suicidal ideation persists it may be needed, in which case
referral to psychiatric services is appropriate.
2.4.2 DRUNK PATIENTS ON THE TELEPHONE, OR IN PERSON, EXPRESSING THREATS
Physically threatening behaviour should be dealt with by calling the police.44 Drunk patients
should be listened to politely and with courtesy, as showing frustration may inflame the situation.
The patient may respond to being listened to politely and may be gently encouraged to go home.
Drunk patients on the telephone can be disruptive to surgery function and also out-of-hours
services as they may block the line. Having given due consideration and advice on who to
contact when the patient is sober, it may be appropriate to terminate the call. At times, it may be
quicker to see these patients.
2.4.3 DOMESTIC ABUSE
The domestic violence/abuse liaison officers at police stations provide advice to victims of
domestic abuse and can put them in touch with support systems, whether or not they wish to
prosecute their partner. Sometimes the police arrest and charge the aggressor, even if the victim
will not give evidence. The victim may need to be removed to a place of safety such as a refuge.
2.4.4 ORGANIC BRAIN DAMAGE
Community management of patients with organic brain damage can be difficult. They often do
not attend appointments. The community nursing team may be able to offer advice and support
to the patient. A community care assessment by the social work department may be needed. If
drinking continues to be problematic, sometimes patients will agree to an arrangement with
their family or their social worker such that, at any one time, they only have access to small
amounts of their money.
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Brief interventions for hazardous and harmful
drinking
Within the literature, the terms "brief" and "minimal" interventions cover a range from one five
minute interaction to several 45 minute sessions. The major positive studies discussed in this
section typically consist of one interaction lasting between five and 20 minutes, sometimes with
one brief follow up contact.
The acronym FRAMES45 captures the essence of the interventions commonly tested under the
terms "brief intervention" and "motivational interviewing":
■ Feedback: about personal risk or impairment
■ Responsibility: emphasis on personal responsibility for change
■ Advice: to cut down or abstain if indicated because of severe dependence or harm
■ Menu: of alternative options for changing drinking pattern and, jointly with the patient,
setting a target; intermediate goals of reduction can be a start
■ Empathic interviewing: listening reflectively without cajoling or confronting; exploring with
patients the reasons for change as they see their situation
■ Self efficacy: an interviewing style which enhances peoples' belief in their ability to change.
This guideline uses "brief intervention" throughout to cover short duration interventions which
use the FRAMES style. The efficacy studies on brief interventions quoted have almost always
excluded alcohol dependent patients because they were deemed inappropriate for this intervention.
BRIEF INTERVENTIONS IN GENERAL PRACTICE
There is consistent evidence from a large number of studies that brief intervention in primary care
can reduce total alcohol consumption and episodes of binge drinking in hazardous drinkers, for
periods lasting up to a year. There is limited evidence that this effect may be sustained for longer
periods. All groups understudy reduced alcohol consumption, but those with brief interventions
did so to a greater extent than those in control groups. Very brief interventions (5-10 minutes)
may have a similar effect to extended interventions (20-45 minutes or several visits), although
the evidence is not consistent.46"57
Studies have varied in whether the intervention is given on the day of detection or later, without
revealing a preferred timing. Some successful studies have used a booster contact (a follow up
intervention at a later date).58'59
There is some evidence that the use of written media such as booklets or leaflets enhances the
efficacy of brief interventions.60
The optimum type of intervention is still to be defined. Sometimes "advice" is given, while at
other times the style of interaction epitomised in "motivational interviewing" has been used.
Additionally, the comparative value of opportunistic intervention, versus intervention after
population screening is not clear.
Data on follow up beyond one year are very limited.61 One study found that the effect had
disappeared at 10 years.62 Another found a continuing small effect at four years.63 A10-16 year
follow up of a sample recruited in a screening projectfound that intervening had reduced mortality,
but the original intervention comprised sessions repeated regularly over up to two years - much
more than a brief intervention.64
The evidence does notsupportthe use of brief interventions for more severely affected patients
seeking treatment.57 A brief intervention is effective at the point when the hazardous or harmful
drinker is newly identified (iean opportunistic encounter).54 This may be during attendance for a
related or even unrelated illness or injury, at health screening for employment or insurance
purposes, or at the time of registering with the practice (see Box 1).
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Box 1: Screening and brief interventions
ASSESS
elicit patient's concerns
how does alcohol fit in?
ELICIT AND RECORD
typical day's drinking
maximum in a day
alcohol related physical, emotional and social problems
CONSIDER
FAST or CAGE plus two consumption questions
MCV, GGT
DELIVER BRIEF INTERVENTION
discuss costs and benefits of drinking from patient's perspective
offer information about health risks
(patient may not be receptive on first consultation;
repeated interviews/reviews may be necessary)
IS THE PATIENT INTERESTED?
AGREE GOAL SOW SEEDS
REDUCTION ABSTINENCE*
Assisting goal of reduction
Elicit patient's concerns
Regular review to offer
encouragement
Monitor (see or telephone
patient; information from
family/GGT)
Reassess with patient the costs
and benefits of change
Assisting goal of abstinence
Enlist support of family and friends
Consider use of local alcohol services
Plan medically assisted withdrawal if indicated, at
home or in hospital
Recommend Alcoholics Anonymous, especially if
other support for abstinence is lacking
Consider specific pharmacotherapy: acamprosate
(reduces intensity of and response to cues and
triggers to drinking) and/or disulfiram (deterrent)
Initiate active intervention if other psychiatric
problems (depression/anxiety) persist >2 weeks
Monitor (see or telephone patient; information
from family/GGT)
* Absolute indications for
abstinence:
■ alcohol related organ damage
• severe dependence (eg
morning drinking to stop
the shakes or previous failed
attempts to control drinking)




■ social factors (eg legal,
employment, family)
Cased on the UK Alcohol Eoium guidelines for the management of alcohol problems in primary care and general psychiatry.3
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The effectiveness of brief interventions has been reported as number needed to treat (NNT) of 7-
9. That is between seven and nine patients will need to be given a brief intervention in order to j
achieve a reduction of drinking to within non hazardous levels in one patient.54'56'63
This compares favourably with treatment for other medical conditions (eg the use of statins to
prevent cardiovascular mortality following myocardial infarction over trial duration, NNT = 30-
9065 or the use of antihypertensive therapy to prevent a cardiovascular event within five years,
NNT = 40-125).66
In research studies of brief intervention, patients were recruited by screening all attenders at the
practice, or all those on the practice list. Of attenders screened, less than 5% met criteria and
entered the treatment arm.54-58'6770 Thus, at an NNT of eight, 1000 patients would need to be
screened for around six patients to show clear benefit. For this reason, primary care professionals
should rely on case detection based on clinical presentation, with judicious use of questionnaire
tools where there is suspicion, rather than the screening of whole populations.
3.1.1 TRAINING
Training healthcare providers in the use of structured interventions enhances the efficacy of brief
interventions.7'
Training practice nurses at health centres in screening and delivering brief interventions has the
potential for increasing the availability of these services, but more research is needed to verify
this.7'
There are well documented difficulties in disseminating research findings to primary care providers.
Research on implementing screening and brief alcohol intervention showed personal meetings to
effect most behaviour change in GPs, but ongoing telephone support to be the most cost effective
measure.72 74
Training is required in order to deliver effective brief interventions.
Training for GPs, practice nurses, community nurses and health visitors in the identification
A v of hazardous drinkers and delivery of a brief intervention should be available.
General Practitioners and other primary care health professionals should
opportunistically identify hazardous and harmful drinkers and deliver a brief
(10 minute) intervention.
The intervention should, whenever possible, relate to the patient's presenting problem
and should help the patient weigh up any benefits as perceived by the patient, versus
the disadvantages of the current drinking pattern.
3.2 BRIEF INTERVENTIONS IN THE ACCIDENT AND EMERGENCY SETTING
A few studies have been conducted of brief interventions to non-admitted A&E patients. One
involved the use of a routine follow up letter to patients advising attendance at alcohol counselling
services. The letter appeared to be useful in encouraging a significant minority of people to 1+
attend appropriate specialist services.75 The use of follow up correspondence may be a low cost
intervention which could produce positive results but more research is needed in this area.
Another study delivered an onsite intervention to adolescents presenting with alcohol problems
and showed a positive effect of a single intervention in this patient group.76 This study has 1"
limitations in its design and only applies to a limited subset of A&E attenders.
A third study compared standard care, motivational interviewing or motivational interviewing
plus a booster session 7-10 days later.59 This study recruited injured patients who screened
positive for harmful or hazardous drinking. At one year follow up, the "motivational interviewing
plus booster session" group reduced their alcohol related injuries by 30% more than those who 1 +
received standard care. There was no difference between standard care and a motivational interview
offered at the time without the booster session. The interventions were delivered by research staff
trained in motivational interviewing.
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In A&E departments where brief interventions are offered by busy A&E staff, uptake of such
interventions by patients may be very low.77
When conducted by specially trained and allocated staff offering and arranging follow up, brief
intervention can be beneficial. There is insufficient evidence however, to recommend routine
brief intervention alone in A&E.
13 Patients who screen positive for harmful drinking or alcohol dependence in A&E should
be encouraged to seek advice from their GP or given information on how to contact
another relevant agency.
3.3 BRIEF INTERVENTIONS IN THE ANTENATAL SETTING
Advice from the Health Education Board for Scotland (now NHS Health Scotland) is that light,
occasional drinking during pregnancy (one or two units once or twice a week) is not likely to do
any harm.78 Heavy drinking is associated with miscarriage, and sometimes with serious effects
on the baby's development.78 Some authorities recommend complete abstinence during
pregnancy (the US National Institute on Alcohol Abuse and Alcoholism:
http://www.niaaa.nih.gov/publications/brochure.htm).
Two studies have been identified which looked at brief interventions in the antenatal setting.
One study, in women of childbearingage identified by screening as "at-risk drinkers", compared
giving the patient a booklet without additional advice with two 15 minute physician consultations
that incorporated a workbook, a drinking agreement and drink diary cards. Both groups reduced
consumption with the physician intervention group reducing consumption to a greater extent.
Differences overall were significant but the magnitude of difference between groups was small.
Subjects who became pregnant however, showed the greatest reduction.53
A study of women receiving antenatal care compared an "alcohol consumption assessment only"
group with a brief intervention group. Both groups reduced their drinking during the rest of the
pregnancy, but differences in reductions by group were not statistically significant. Those who
received the brief intervention maintained higher rates of abstinence.79
j Routine antenatal care provides a useful opportunity to deliver a brief intervention for
stRAj reducing alcohol consumption.
3.4 EFFECTIVENESS OF MOTIVATIONAL INTERVIEWING
Motivational interviewing (a non-judgemental interviewing style which avoids confrontation,
helps the individual weigh up the pros and cons of change, and enhances self efficacy) is a style
which is helpful in brief interventions (see Annex 5).80 A systematic review showed that 1 +
motivational interviewing has a significant effect on reducing alcohol consumption in the primary
care setting.81 There is no evidence to support a confrontational style of interviewing.
■jS Motivational interviewing techniques should be considered when delivering brief
interventions for harmful drinking in primary care.





Detoxification refers to the planned withdrawal of alcohol. Alcohol withdrawal carries risks and
requires careful clinical management.
The choice of timing for a preplanned detoxification is important, in relation to the patient's
commitment and medium term plans. Detoxification should be seen as the first step towards
achieving abstinence.
4.2 PRIMARY CARE DETOXIFICATION VERSUS INPATIENT DETOXIFICATION
A comparison between community and inpatient detoxification of alcohol dependent patients
found no difference in the number of patients remaining sober six months later.82 At least three
out of four such patients can be detoxified successfully in the community.62 . „ +
No studies of outpatient detoxification using medication were identified where fits occurred but
studies had, appropriately, excluded patients with a history of withdrawal seizures or with
impending delirium.83
Home detoxification does notappearto have any clinical advantages but may offer cost savings.82*5 1 * +
There are too few reports to be able to show rare serious events and publication bias may contribute 1 +
to the current favouring of home detoxification as the first line. 2 '3
There is evidence that many patients prefer home detoxification.86 | 2*
Community detoxification is an effective and safe treatment for patients with mild to moderate
withdrawal symptoms. Personnel involved in detoxification may include CPs, community
psychiatric nurses, primary care nurses and community pharmacists. There are resource
implications, including the cost of a breathalyser.
0 Where community detoxification is offered, it should be delivered using protocols specifying
daily monitoring of breath alcohol level and withdrawal symptoms, and dosage adjustment.
0 Every CP practice (and out-of-hours service) would benefit from access to a breathalyser
for use in the acute situation and for follow up.
0 Intoxicated patients presenting in GP practices, out-of-hours services and A&E, requesting
detoxification should be advised to make a primary care appointment and be given written
information about available community agencies.
See Annex 6 for advice to give to patients who undergo home detoxification.
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4.2.1 SITUATIONS WHERE INPATIENT DETOXIFICATION WOULD BE ADVISED
The following list is based on expert opinion and comprises validated and best practice
contraindications to managing withdrawal at home:35
Hospital detoxification is advised if the patient:
■ is confused or has hallucinations
■ has a history of previously complicated withdrawal
■ has epilepsy or a history of fits87
■ is undernourished
■ has severe vomiting or diarrhoea
■ is at risk of suicide
■ has severe dependence coupled with unwillingness to be seen daily
■ has a previously failed home-assisted withdrawal
■ has uncontrollable withdrawal symptoms
■ has an acute physical or psychiatric illness
■ has multiple substance misuse
■ has a home environment unsupportive of abstinence.
0 If admission to hospital is unavailable or the patient refuses, specialist opinion should be
sought to aid risk assessment.
4.3 PHARMACOLOGICAL DETOXIFICATION
4.3.1 WHEN IS MEDICATION FOR WITHDRAWAL INAPPROPRIATE?
Cessation of drinking is unlikely to be complicated in milder dependence.35
Medication may not be necessary if:
■ the patient reports consumption is less than 15 units/day in men /10 units/day in women and
reports neither recent withdrawal symptoms nor recent drinking to prevent withdrawal
symptoms
■ the patient has no alcohol on breath test, and no withdrawal signs or symptoms.
Among periodic drinkers, whose last bout was less than one week long, medication is seldom
necessary unless drinking was extremely heavy (over 20 units/day).35 Patients need to be informed
of the likely symptoms if medication for withdrawal is not given. Annex 7 may be used to assist
in deciding whether medication for withdrawal and admission are necessary.
When medication to manage withdrawal is not needed, patients should be informed that
I at the start of detoxification they may feel nervous or anxious for several days, with
difficulty in going to sleep for several nights.
4.3.2 THE EFFICACY OF BENZODIAZEPINES IN DECREASING ALCOHOL WITHDRAWAL
SYMPTOMS
A body of evidence, based on randomised controlled trials (RCTs), has shown that benzodiazepines
are currently the best drug group for alcohol dependence detoxification. The studies are of variable
quality, with some reporting on small numbers of patients. Although the evidence is mostly
derived from inpatient studies, the conclusions are generalisable to primary care.8892
Benzodiazepines can cause temporary cognitive slowing and may interfere with learning and
planning.93 This, and the need to avoid benzodiazepine dependence, are reasons for keeping the
length of treatment to a maximum of seven days.
Benzodiazepines should be used in primary care to manage withdrawal symptoms in
1 alcohol detoxification, but for a maximum period of seven days.
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4.3.3 LONGACTING VERSUS SHORTACTING BENZODIAZEPINES
There is insufficient consistent evidence to makea recommendation about the use of longacting
versus shortacting benzodiazepines.88'9496
4.3.4 MISUSE OF BENZODIAZEPINES
All benzodiazepines have a potential for misuse, but diazepam is the benzodiazepine most
associated with misuse and alcohol related fatality.9798 If used in community detoxification,
diazepam requires supervision to avoid misuse.99 Chlordiazepoxide has a more gradual onset of
its psychotropic effects and therefore may be less toxic in overdose. These factors probably
contribute to chlordiazepoxide being less often misused and having less 'street' resale value.
; For patients managed in the community, chlordiazepoxide is the preferred benzodiazepine.
4.3.5 THE ROLE OF CLOMETHIAZOLE IN PRIMARY CARE ALCOHOL DETOXIFICATION
Although clomethiazole (former name chlormethiazole) is an effective treatment for alcohol
withdrawal, there are well documented fatal interactions with alcohol which render it unsafe to
use without close supervision.90'98''°°~'03
III Clomethiazole should not be used in alcohol detoxification in primary care.
4.3.6 DO ELDERLY PEOPLE REQUIRE DIFFERENT PHARMACOLOGICAL MANAGEMENT?
Physical illness sometimes increases the risk of delirium in the elderly, but otherwise there is no
difference between alcohol withdrawal symptoms in the elderly, or the amount of benzodiazepine
required for detoxification, as compared to younger patients.104''05 Nevertheless, the risk of
accumulation of a drug in the elderly patient needs to be considered.
I Provided attention is paid to any acute or chronic physical illness, elderly patients should
j be managed the same way as younger patients.
4.3.7 ANTIEPILEPTIC MEDICATION
There is insufficient evidence to support the use of antiepileptic medication as the sole treatment
for the management of alcohol withdrawal or in the prevention of alcohol withdrawal seizures.'06'107
; Antiepileptic medication should not be used as the sole medication for alcohol detoxification
pS|| in primary care.
0 People with a history of alcohol related seizures should be referred to specialist services
for detoxification management.
4.3.8 ANTIPSYCHOTIC DRUGS
Antipsychotic drugs have been shown to prevent delirium but increase the incidence of seizures.88
Antipsychotic drugs should not be used as first line treatment for alcohol detoxification.
0 Delusions and hallucinations due to alcohol withdrawal, which would indicate the need
for antipsychotic drugs, should be managed by specialist services.
4.3.9 SYMPTOM-TRIGGERED DOSING
Although there are studies of the efficacy of symptom-triggered dosing and/or loading dosing in
inpatients, there is no evidence regarding the use of these methods in primary care.92'108"0 Tapered
fixed dose benzodiazepine regimen is likely to be as effective in primary care.
0 Tapered fixed dose regimen of a benzodiazepine is recommended for primary care alcohol
detoxification, with daily monitoring whenever possible.
1
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4.4 THE ROLE OF VITAMIN SUPPLEMENTS IN DETOXIFICATION
There are very few high quality studies on which to base recommendations in this area. To do
such studies now would be inappropriate.
4.4.1 TREATMENT OF ACUTE WERNICKE-KORSAKOV SYNDROME
Detoxification may precipitate Wernicke's encephalopathy (see Box 2), which must be treated
urgently with parenteral thiamine.1" There is a very small risk of anaphylaxis with parenteral
vitamin supplementation. This is less likely with the intramuscular route. There has been one
case of anaphylaxis solely attributable to intramuscular Pabrinex since 1996.112
Box 2: Pointers to diagnosis of Wernicke-Korsakov syndrome
Signs of possible Wernicke-Korsakov syndrome in a patient undergoing detoxification
■ confusion




■ hypothermia and hypotension
■ coma
One RCT has examined the role of parenteral vitamin supplements in inpatient alcohol
detoxification using memory function as the outcome."3 This study was done in people who did
not have Wernicke-Korsakov symptoms.
Any patient who presents with unexplained neurological symptoms or signs during
detoxification should be referred for specialist assessment.
Patients with any sign of Wernicke-Korsakov syndrome should receive Pabrinex in a
setting with adequate resuscitation facilities. The treatment should be according to British
National Formulary (BNF) recommendations and should continue over several days, ideally
in an inpatient setting.
4.4.2 TREATMENT OF THOSE AT RISK OF WERNICKE-KORSAKOV SYNDROME
There is no published evidence and conflicting expert opinion on the treatment of malnourished
patients, and the specification and treatment of "at-risk" patients (those with diarrhoea, vomiting,
physical illness, weight loss, poor diet), with the majority of experts recommending parenteral
vitamin supplementation during detoxification.1"
For the malnourished patient in the community, intramuscular Pabrinex given in the GP surgery,
A&E department, outpatient clinic or day hospital is indicated if facilities for treating anaphylactic
reactions are available, such as in any setting where routine immunisations take place.
0 Patients detoxifying in the community should be given intramuscular Pabrinex (one pair
of ampoules daily for three days) if they present with features which put them at risk of
Wernicke-Korsakov syndrome.
4.4.3 ORAL SUPPLEMENTATION
No studies were identified that have looked at oral thiamine and its benefit to memory in either
the recovering alcoholic or those who continue to drink in general practice. Absorption is
diminished when patients continue to drink and should be given in divided doses to maximise
absorption. The B N F recommended dose for treatment of severe deficiency is 200-300 mg dai ly.114
0 Patients who have a chronic alcohol problem and whose diet may be deficient should be
given oral thiamine indefinitely.
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THE PREFERRED SETTING FOR TREATING DELIRIUM TREMENS
Delirium tremens is defined here as withdrawal symptoms complicated by disorientation,
hallucinations or delusions. Autonomic overactivity is a potentially fatal aspect of this condition.
A Clinical Resource and Audit Group (now part of NHS Quality Improvement Scotland)
good practice statement on delirium tremens recognises the serious medical aspects of
this syndrome and recommends that local protocols for admitting patients with delirium
tremens are used.87
Although the proportion of such patients seen by psychiatrists varies across Scotland, the majority
of cases are treated by the acute medical service. This is because there is often a coexisting
medical condition such as pancreatitis, pneumonia or other infection and there may be life
threatening complications.
I Local protocols for admitting patients with delirium tremens should be in place.
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5 Referral and follow up
5.1 WHO TO REFER, AND TO WHOM
Specialist treatments for alcohol problems are effective. A health technology assessment from
NHS Quality Improvement Scotland concluded that specialist services are effective for relapse
prevention if offering behavioural self control training, motivational enhancement therapy, family
therapy/community reinforcement approach and/or coping/communication skills training (see
Annex 8)."5
General Practitioners are able to manage more patients with alcohol related problems if they
perceive that they are working in a supportive environment which includes access to help with
difficult patients."6
Research aiming to predictwhich patients will do betterwith which type of specialist treatments
has given few leads. The GP's decision whereto refer a patient should be guided in large part by
the patient's choice. Some predictors however, have emerged: patients who are angry at the
initial assessment appear to do better, in the short term, if given motivational interviewing.n7'"8
Patients with psychiatric disorders ('dual diagnosis') tend to do better if referred to specialist
psychological or psychiatric services than to 12-step Alcoholics Anonymous (AA) groups."9
Patients referred to specialist care, who live or work in environments where there is a lot of
drinking and little support for abstinence, may do better in a service which offers consultations
which emphasise the 12-step AA approach, rather than specialised psychological therapy.
One underpowered study found no advantage to specialist treatment over general practice
management in the UK.'20 Two North American studies have shown that milder alcohol dependence
can sometimes be successfully managed without specialist care.'2"'22 However, brief primary
care intervention has usually excluded alcohol dependent patients who should, in general, be
referred for specialist care.
B Access to relapse prevention treatments of established efficacy should be facilitated foral ohol dependent pati ts.
5.1.1 PATIENTS WITH ALCOHOL RELATED PHYSICAL DISORDER
American studies have shown that for patients with alcohol related physical disorders, integrated
medical care and addiction treatment gives a better outcome than when the two services are
separate.'22-'23 If this is extrapolated to the NHS, it suggests that these are patients for whom
particularly good links between the alcohol agency and medical care should be nurtured or
where the treatment of the alcohol problem should be based as much as possible in primary care.
\ When the patient has an alcohol related physical disorder, the alcohol treatment agency
IH should have close links with the medical and primary care team.
5.1.2 STEPPED CARE
Stepped care124 (in a tiered treatment service2'125) occurs when treatment is chosen where possible
to match the patients' needs and wishes and cause least disruption to their family and their work.
More intensive treatment is only required if the outcome is unsatisfactory.
; The principles of stepped care should be followed for patients with alcohol problems
■ and dependence.
5.2 WAITING TIME TO REFERRAL
Two case control studies and one cohort study found that increased waiting times made attendance
at specialist clinics less likely.'26^'28 None found a link between delay in referral or waiting time
for assessment with ultimate outcome of treatment.
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5.3 MONITORING
Low intensity monitoring over the course of one to three years has been shown to reduce the
severity of relapses.'29-'30 This may be done by telephone or a brief appointment. In these studies, 1 *
benefit may have been partly due to earlier rereferral to specialist services.
■ Primary care teams should maintain contact over the long term with patients previouslytreated by specialist services for alcohol dependence.
5.4 EFFECTIVENESS OF LAY SERVICES
5.4.1 ALCOHOLICS ANONYMOUS
The health technology assessment from NHS Quality Improvement Scotland supports the
appropriate use of AA."5
Alcoholics Anonymous believes that alcohol dependence is a chronic and progressive illness 2„
without cure, for which total abstinence is the only solution. Alcoholics Anonymous is widely
available and entirely self-funding, but there is limited formal evidence of efficacy from randomised
studies. It is a network of support including advice for individuals in crisis. Their members are
willing to help primary care teams link patients with AA.
\ Alcohol dependent patients should be encouraged to attend Alcoholics Anonymous.
5.4.2 OTHER LAY AND NON-STATUTORY SERVICES
Motivational interviewing and coping skills training for relapse prevention have been shown to
be effective when delivered by psychologists.'3' Counselling by lay and non-statutory agencies is
available in most of Scotland (eg by Councils on Alcohol) but has not been evaluated in controlled 2*
studies.132 These agencies welcome referrals from NHS primary care. The evidence for efficacy of
client-centred counselling for alcohol dependence is conflicting. Less defined counselling and
education appear to be ineffective. Day care/drop-in centres are available in certain areas.
Blf patients are referred to a lay service, agencies where lay counsellors use motivationalinterviewing and coping skills training should be utilised.
5.5 EFFECTIVENESS OF MEDICATIONS TO PREVENT RELAPSE
The health technology assessment by NHS Quality Improvement Scotland included meta-analyses
of the efficacy and cost effectiveness of medications for relapse prevention and found evidence of
efficacy for disulfiram (supervised) and acamprosate."5 This was also the conclusion of a health
technology assessment by the Swedish Council on Technology Assessment in Health Care'06 and
a literature review for the Aberdeen Health Economics Research Unit.32
Other meta-analyses support these findings'33-'34 as does the joint guideline of the US Agency for
Healthcare Research and Quality/American Society of Addiction Medicine (2002). Acamprosate
is believed to act by modulating disturbance in the gamma-aminobutyric acid /glutamate system
associated with alcohol dependence, reducing the risk of relapse during the postwithdrawal
period. It is a safe drug with few unwanted side effects, and is not liable to misuse. Its value is
in the first months after detoxification. Acamprosate is not effective in all patients so its efficacy
should be assessed at regular appointments, and the drug withdrawn if there has not been a
major reduction in drinking. Where it appears to be effective, good practice suggests prescribing
for 6-12 months. The studies were conducted in specialist centres where psychosocial treatment
was offered. It is an assumption that, as long as there is a system of monitoring compliance and
efficacy, these data are applicable to primary care.
H Acamprosate is recommended in newly detoxified dependent patients as an adjunct topsychosocial interventions.
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0 Acamprosate will usually be initiated by a specialist service within a few days of successful
detoxification. If a specialist service is not available, the GP should offer acamprosate,
monitor its efficacy and provide links to local support organisations.
Disulfiram's function is to deter the patient from resuming drinking. Iftaken regularly there is an
unpleasant reaction when alcohol is consumed. It has unwanted effects in some patients, and
carries special warnings. The health technology assessment by NHS Quality Improvement Scotland
found some support for the use of supervised disulfiram and none for its non-supervised use. "5 2
If used, it should be offered for six months in the first instance, with regular review. Supervision
is agreed by the patient to increase the likelihood that the medication is taken even at times of
ambivalence.
s Supervised oral disulfiram may be used to prevent relapse but patients must be informed
) that this is a treatment requiring complete abstinence and be clear about the dangers of
\ taking alcohol with it.
0 Disulfiram supervision maybe undertaken by the spouse, healthcare or support worker, or
the workplace representative if appropriate.
Naltrexone, although supported by the above reports, and used by specialists in Scotland, is not
licensed in the UK for the treatment of alcohol dependence.
5.6 TREATING ALCOHOL DEPENDENCE AND ANXIETY OR DEPRESSION
In patients with an alcohol problem, there is good evidence that most anxiety and depression
resolves with standard treatment for alcohol dependence.'33'35"'38
For patients with panic disorder and social phobia, there is no consistent evidence of extra
benefit of cognitive behavioural therapy beyond the simultaneous treatment for the alcohol 1 ♦
problem.,39'140
In detoxified patients with definite depressive illness, antidepressants improve depressive
symptoms and in some studies drinking outcomes.133 '35"'38 The strongest effect is with fluoxetine,
although this treatment seems to reduce the beneficial effect of cognitive behavioural therapy in 1»
the type of patients characterised by early onset and prominent social problems."" Therefore
caution should be exercised in prescribing selective serotonin reuptake inhibitors (SSRIs) to patients
characterised by early onset of alcohol problems and antisocial behaviour.
There is insufficient evidence that antidepressants improve drinking outcomes in non-depressed
patients.
■jEf Patients with an alcohol problem and anxiety or depression should be treated for the
'
; alcohol problem first.
If depressive symptoms persist for more than two weeks following treatment for alcohol
^ dependence, consideration should be given to using an SSRI or referring for counselling
or special ist psychological treatment along with the relapse prevention treatment.
0 If severe anxiety symptoms persist for more than two weeks in abstinent patients,
consideration should be given to using an SSRI, or referring for specialist psychological
treatment along with the relapse prevention treatment.
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5.7 TREATING ALCOHOL DEPENDENCE WHEN OTHER PSYCHIATRIC ILLNESS IS
PRESENT
Patients with comorbid schizophrenia/schizoaffective disorder and substance misuse benefit from 1 +
motivational interviewing, cognitive behavioural therapy and family interventions aimed at 2 +
decreasing their dependence.'43146 These patients are best treated by specialist services. 4
Disulfiram may be used with caution in these patients bearing in mind drug interactions.'47 | 4
Patients with psychotic disorder and alcohol dependence should be encouraged to address
their alcohol use and may benefit from motivational, cognitive behavioural, family and
non-confrontational approaches.
0 Patients with psychoses should be referred for psychiatric advice.
5.8 EFFECTIVENESS OF ALTERNATIVE THERAPIES
Information on outcomes following use of alternative therapies was found only for acupuncture 1 *
and transcendental meditation. RCTs and systematic reviews have not demonstrated an effect for 1"
acupuncture in the treatment of alcohol dependence.'48 150 4
A review of transcendental meditation'5' (plus the accompanying erratum'52) reports that this
may be useful as an adjunctive treatment for people with an alcohol or drug dependence. The 4
studies included in this review were heterogeneous and patient selection criteria were not reported.
There is insufficient evidence to make any recommendations about the use of acupuncture,
transcendental meditation or other alternative therapies in treating patients with an alcohol
problem.
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6 Advising families
The drinker's family may seek advice on how they should intervene when the drinker is not
motivated to change. "Detaching with love" (one of the principles by which Al-Anon members
lessen the risk of harm to their own mental health resulting from living with a drinker), or simple
confrontation, are less likely to get the drinker to change or seek help than using an approach
based on community reinforcement and family training (CRAFT).153'154 Although not tested in
primary care, the method can be taughtto non-specialists.
CRAFT instructs the family or "committed significant other" to reinforce, by encouragement or
other rewards, any changes or statements that the drinker makes towards stopping or reducing the
drinking, and to do nothing to enable or reward drinking. The treating team lays down the
groundwork for rapid availability of outpatient treatment for the drinker in the event that he or
she opts to begin therapy. The family are prepared from the beginning to recognise and respond
safely to any potential for domestic violence during the introduction of what may be a new way
of reacting to the drinker and the drinking.
The family are helped to:
■ understand the nature of alcohol dependence
■ improve communication with the drinker
■ selectively apply or withdraw reinforcement, to amplify non-drinking
■ apply pressure without bickering or recrimination
» learn stress reduction and gain more reward in their own life
■ use effective methods and optimal times for proposing treatment entry to the drinker, such as
restricting key messages to moments of sobriety, and exploiting alcohol related crises
■ support the drinker through treatment.
The following recommendation has been extrapolated from the above trials.
§31 The primary care team should help family members to use behavioural methods which
will reinforce reduction of drinking and increase the likelihood that the drinker will seek
3 help.
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7 Information for discussion with patients and
carers
The following points were drawn up by the guideline development group to reflect the issues
likely to be of most concern to patients and carers. These points are provided for use by health
professionals when discussing alcohol problems with patients and in guiding the production of
locally produced patient information materials.
7.1 PATIENT FEARS AND PERCEPTIONS WHEN PRESENTING WITH AN ALCOHOL
PROBLEM
Research carried out by System Three Social Research,2 and the SIGN patient involvement project,
commissioned by the Scottish Executive, has identified recurrent themes of concern to patients
presenting with an alcohol problem.
There is a widespread acceptance that the GP is the most appropriate first point of contact once
a patient has decided to seek help. However, there are considerable fears or reservations associated
with seeking such help even where a good relationship exists with the GP. Such fears include:
■ the normal shyness or hesitancy associated with a condition perceived to be "shameful"
■ being labelled an "alcoholic"
■ jeopardising one's work by admitting to having an alcohol problem
■ being concerned that children may betaken into care
■ not being treated seriously or being told to "pull yourself together".
Other general points to emerge from the SIGN research and the literature:
■ continuity of personnel providing support is essential as establishing trust is very important
■ speed of referral is also very important as, once the difficult decision to seek help has been
made, it needs to be followed up quickly or this positive attitude may evaporate
■ there are wide differences in understanding of the terms "alcohol misuse", "alcohol problems"
and "alcoholic". A common usage is for alcohol misuse to mean "beginning to impinge on
normal life" and alcoholism to mean the above plus "a need or compulsion to drink" (see
section 1.2 for medical definitions)
■ there is confusion regarding what constitutes the standard unit of alcohol
■ patients may have heard of Alcoholics Anonymous but will rarely have any knowledge of its
methods or operations
■ there is widespread belief that there are substantial facilities for sufferers from drug abuse but
very little for those with alcohol problems.
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7.2 KEY MESSAGES FOR PATIENTS
Problems with alcohol are suffered by people in varying degrees, ranging from occasional excess
consumption to an addiction or dependence, which may affect the person and their whole
lifestyle. Patients often progress from mild misuse of alcohol to more extreme stages so it is
important to try to address any problem at an early stage, seeking medical assistance where
necessary.
7.2.1 EFFECTS ON THE PERSON
At a personal level alcohol misuse has many effects including:
■ anxiety, which often leads to a compounding of the problem
■ health problems caused by the alcohol consumption itself including liver and brain damage
and other serious conditions such as epilepsy and heart disease
■ consequential health problems caused by the effects of alcohol such as malnutrition, injuries
and gaps in memory
■ difficulties in sustaining employment.
7.2.2 EFFECTS ON THE FAMILY
Having a family member with an alcohol problem can seriously affect the family, where family
members and friends can become anxious, depressed or alienated.
Financial problems caused by the purchase of alcohol, coupled with reduced earnings potential
also impact on the family.
7.2.3 HELP AVAILABLE FROM THE PRIMARY CARE TEAM
The range of advice, treatment and referral available from the GP and the primary care team
includes:
■ initial discussion and support
■ advice regarding non-hazardous drinking levels and ways to reduce drinking
■ counselling and therapy for the individual
■ counselling and therapy for the family
■ treatment options including medication to relieve the physical effects of stopping drinking
and to help to reduce the incidence of drinking in the longer term
■ referral to a specialist nurse, often within the practice, for individual help
■ referral to another agency for clinical care with information about treatment options available
■ referral to a voluntary agency for lay counselling
■ link with a mutual help association such as Alcoholics Anonymous
■ longer term support and monitoring.
0 It should be stressed to patients that stopping or cutting down their drinking can only
result from their own decision to do so. Any treatment, from whatever source, can only be
an aid to taking this decision and following it through.
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7.3 ORGANISATIONS WHICH PROVIDE USEFUL INFORMATION
AL-ANON
Mansfield Park, Unit 6, 22 Mansfield Street
Glasgow, G11 5QP
24h telephone service: 0141 339 8884
Website: www.al-anonuk.org.uk
Support for families and friends of alcoholics
Alcoholics Anonymous
National helpline: 0845 76 97 555
Website: www.alcoholics-anonymous.co.uk
Alcohol Concern
Waterbridge House. 32-36 Loman Street
London, SE1 OEE
Tel: 020 7922 8667 (Information Team)
Email: info@alcoholconcern.org.uk
Website: www.alcoholconcern.org.uk
Provides information on a wide range of alcohol related subjects. Alcohol Concern does not
operate a helpline.
Alcohol Focus Scotland (formerly the Scottish Council on Alcohol)
2nd floor, 166 Buchanan Street
Glasgow, G1 2LW




Online program for reducing drinking
Website: www.downyourdrink.org.uk
National Alcohol Information Resource




Tel: 08454 24 24 24
Website: www.nhs24.com
NHS Health Scotland (formerly the Health Education Board for Scotland)
Woodburn House, Canaan Lane
Edinburgh, EH10 4SG
Tel: 0131 536 5500, Fax: 0131 536 5501
Website: www.hebs.org
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8 Implementation, audit and further research
8.1 LOCAL IMPLEMENTATION
Implementation of national clinical guidelines is the responsibility of local NHS organisations
and is an essential part of clinical governance. It is acknowledged that not every guideline can be
implemented immediately on publication, but mechanisms should be in place to ensure that the
care provided is reviewed against the guideline recommendations and the reasons for any differences
assessed and, where appropriate, addressed. These discussions should involve both clinical staff
and management. Local arrangements may then be made to implement the national guideline in
individual hospitals, units and practices, and to monitor compliance. This may be done by a
variety of means including patient-specific reminders, continuing education and training, and
clinical audit.
8.2 KEY POINTS FOR AUDIT
■ Are primary care workers opportunistically identifying people with an alcohol problem and
delivering appropriate brief interventions?
■ At new patient registration in general practice, what is the proportion of completed sections
on alcohol consumption?
■ Are staff delivering treatments such as motivational interviewing according to recognised
methodology?
■ Are there local protocols for alcohol withdrawal management in place and in use?
■ Does the practice have access to a breathalyser?
A brief instrument which has been used in audit of outcomes is the Alcohol Related Problems
Questionnaire.'55
8.3 RECOMMENDATIONS FOR RESEARCH
Further high quality research in a representative population group is needed to:
■ establish the effectiveness of routine brief intervention in the A&E setting
■ compare outcomes for in/outpatient detoxification
■ study the use of oral vitamin preparations in primary care, and whether subsequent Wernicke-
Korsakov syndrome, neuropathy or cerebellar damage is delayed/prevented
■ appraise alcohol policy initiatives in order to ascertain the cost effectiveness of such treatments,
and of "brief interventions"
■ simplify screening tools
■ study the efficacy of alternative therapies in treating patients with an alcohol problem.
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9 Development of the guideline
9.1 INTRODUCTION
SIGN is a collaborative network of clinicians, other healthcare professionals, and patient
organisations, funded by NHS Quality Improvement Scotland. SIGN guidelines are developed by
multidisciplinary groups of practising clinicians using a standard methodology based on a
systematic review of the evidence. Further details about SIGN and the guideline development
methodology are contained in "SIGN 50: A Guideline Developer's Handbook", available at
www.sign.ac.uk
9.2 THE GUIDELINE DEVELOPMENT GROUP
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the guideline development group. Further details are availablefrom theSIGN Executive. Guideline
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Executive.
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9.3 SYSTEMATIC LITERATURE REVIEW
The evidence base for this guideline was synthesised in accordance with SIGN methodology. A
systematic review of the literature was carried out using an explicit search strategy devised by a
SIGN Information Officer. Databases searched include Medline, Embase, Healthstar, Cinahl,
PsychlNFO, Alcohol and Alcoholism, and the Cochrane Library. The year range covered was
1995-2001. Internet searches were carried out on various websites including the New Zealand
Guidelines Programme, the UK Health Technology Assessment programme, the NIAAA Alcohol
and Alcohol Problems Science Database (ETOH), and the US National Guidelines Clearinghouse.
The Medline version of the main search strategies can be found on the SIGN website, in the
section covering supplementary guideline material. The main searches were supplemented by
material identified by individual members of the development group. All selected papers were
evaluated by two members of the group using standard SIGN methodological checklists before
conclusions were considered as evidence.
9.4 CONSULTATION AND PEER REVIEW
9.4.1 NATIONAL OPEN MEETING
A national open meeting is the main consultative phase of SIGN guideline development, at
which the guideline development group presents its draft recommendations for the first time.
The national open meeting for this guideline was held on 29 April 2002 and was attended by
around 150 representatives of all the key specialties relevant to the guideline. The draft guideline
was also available on the SIGN website for a limited period at this stage to allow those unable
to attend the meeting to contribute to the development of the guideline.
9.4.2 SPECIALIST REVIEW
The guideline was also reviewed in draft form by a panel of independent expert referees, who
were asked to comment primarily on the comprehensiveness and accuracy of interpretation of
the evidence base supporting the recommendations in the guideline. SIGN is very grateful to all
of these experts for their contribution to this guideline.
Dr Peter Anderson
Dr Alan Begg
Public Health Consultant, Nijmegen, The Netherlands
General Practitioner, Montrose
Lay Representative
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9.4.3 SIGN EDITORIAL GROUP
As a final quality control check, the guideline is reviewed by an Editorial Group comprising the
relevant specialty representatives on SIG N Council to ensure that the specialist reviewers' comments
have been addressed adequately and that any risk of bias in the guideline development process as
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Annex 1
Alcohol content of some beverages




Beers/lagers Barbican 0.02 440ml <0.01
Kaliber 0.05 Pint 0.03
Tennents LA 1.2 440ml 0.5
Mild/light beers (various brands) 3.1 Pint 1.8
Best bitter (various brands) 3.5 Pint 2.0
Skol 3.6 Pint 2.0
McEwans/Labatt 4.0 Pint 2.3
Guinness draff stout 4.1 Pint 2.3
Grolsch 5.0 440ml 2.2
Premium beer/lager (various brands) 5.0 Pint 2.8
Stella Artois 5.2 330ml 1.7
Lowenbrau Pils 6.0 440ml 2.6
Hofmeister Special 9.0 440ml 4.0
Kestral Super 9.5 440ml 4.2
Ciders/Perries Strongbow LA 0.9 330ml 0.3
Woodpecker 3.5 Pint 2.0
Strongbow 4.5 1000ml 4.5
Old English 5.5 Pint 3.1
Strongbow Super 8.0 Pint 4.5
Diamond White 8.2 275ml 2.3
Strong White Cider 8.4 1000ml 8.4
Spirit based drinks Hooch 4.7 330ml 1.6
with mixers WKD Original Vodka Blue or Iron Brew 5.5 330ml 1.8
(alcopops) Smirnoff Ice 5.5 275ml 1.5
Bacardi Breezer 5.4 275ml 1.5
Metz Snapps (Black, Still or Original) 5.4 275ml 1.5
Vodka Red Square (Barrs Irn Bru) 5.5 275ml 1.5
Aftershock 40.0 700ml 28.0
Vodka Hooch Lemon/Apple/Orange/Hoopers Hooch 4.7-5.1 330ml 1.6-1.7
Shooters (addition to Jelly Pots 15.0 47ml 0.7
main drink) Sidekick 20.0 30ml 0.6
Aftershock 40.0 30ml 1.2
Frostbite 50.0 30ml 1.5
Absinthe 75.0 30ml 2.3
Wines Various brands 9-14 750ml 6.8-10.5
A purchased glass of wine can vary from 125 to 250 ml and can contain 1.1-3.5 units per glass depending on % alcohol.
A small (125ml) glass of average strength (12%) wine contains 1.5 units.
Fortified Wines and Cinzano bianco/Buckfast 14.7 750ml 11.0
similar Croft Original Sherry 17.5 750ml 13.1
Cockburn's Port 20.0 750ml 15.0
Spirits Gordons Dry Gin/Smirnoff Vodka 37.5 700ml 26.3
Bacardi White Rum 37.5 700ml 26.3
Bells Whisky/Martell cognac brandy 40.0 700ml 28.0
Captain Morgan's dark rum 40.0 700ml 28.0
A purchased measure of spirit is 25 or 35 ml. A 25ml measure of 40% spirit contains 1 unit of alcohol.
Liqueurs Bailey's Irish Cream 17.0 350ml 6.0
Archers Peach Schnapps 23.0 700ml 16.0
Apricot Brandy/Creme de Menthe/Malibu 24.0 700ml 16.8
Pernod/Cointreau/Drambuie 40.0 700ml 28.0
Formula: the amount of alcohol (in units) = volume (in litres) x percentage alcohol
Note: there are 1,000 ml in 1 litre and 1 pint = 568 ml.
The information in this table has been adapted from three sources: the Medical Council on Alcoholism,14 Alcohol Focus




Clinical presentations where the role of alcohol
should be considered
Hazardous drinking and alcohol dependence present in many ways. The following presentations
should alert clinicians to the possibility that alcohol may be involved:
Social
■ marital disharmony and domestic violence
■ neglect of children
■ criminal behaviour such as driving offences, breach of the peace, shoplifting




■ repeated absenteeism, especially around weekends
■ impaired work performance and accidents
■ poor employment record
Psychiatric
■ amnesia, memory disorders and dementia




■ treatment resistance in other psychiatric illnesses and as a factor in relapse
■ repeated self harming
Physical
■ multiple acute presentations to A&E with trauma and head injury
■ dyspepsia, gastritis, haematemesis
■ diarrhoea and malabsorption
■ acute and chronic pancreatitis
■ liver abnormalities from deranged liver function tests, through hepatitis, to fatty liver and
cirrhosis
■ cardiac arrhythmias
■ hypertension and stroke
■ cardiomyopathy
■ peripheral neuropathy, cerebellar ataxia
■ impotence and problems with libido
■ withdrawal seizures and fits starting in middle age
■ falls and collapses in the elderly
■ blood dyscrasias such as low platelet count and white cell count (neutrophils)
■ acne rosacea, discoid eczema, psoriasis, multiple bruising
■ cancers of mouth, pharynx, larynx, oesophagus, breast and colon
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Annex 3
The Fast Alcohol Screening Test (FAST) for the
detection of probable hazardous drinking31
For the following questions please circle the answer which best applies.
1 drink = 1 unit = '/2 pint of beer or 1 glass of wine or 1 single spirits
1. MEN: How often do you have EIGHT or more drinks on one occasion?
WOMEN: How often do you have SIX or more drinks on one occasion?
Never Less than Monthly Weekly Daily or
monthly almost daily
Only ask Questions 2, 3 & 4 if the response to Question 1 is "Less than monthly" or "Monthly"
2. How often during the last year have you been unable to remember what happened the
night before because you had been drinking?
Never Less than Monthly Weekly Daily or
monthly almost daily
3. How often during the last year have you failed to do what was normally expected of you
because of drink?
Never Less than Monthly Weekly Daily or
monthly almost daily
4. In the last year has a relative or friend, or a doctor or other health worker been concerned
about your drinking or suggested you cut down?
No Yes, on Yes, on morethan one
occasion one occasion
Scoring is quick and can be completed with just a glance at the pattern of responses as follows:156
Stage 1
The first stage only involves question 1.
If the response to question 1 is never then the patient is not misusing alcohol.
If the response to question 1 is Weekly/Daily or Almost Daily then the patient is a hazardous,
harmful or dependent drinker. Over 50% of people will be classified usingjustthisonequestion.
Only consider Questions 2, 3 & 4 if the response to Question 1 is Less than monthly or Monthly.
Stage 2
If the response to Question 1 is Less than monthly or Monthly then each of the four questions
is scored 0 to 4. These are then added resulting in a total score between 0 and 16. The person
is misusing alcohol if the total score for all four questions is 3 or more.
Score Questions 1, 2 & 3 as follows: Score Question 4 as follows:
Never = 0 No = 0
Less than monthly = 1 Yes, on one occasion = 2
Monthly = 2 Yes, on more than one occasion - 4
Weekly = 3
Daily or almost daily = 4
In summary, score Questions 1, 2 & 3: 0,1,2,3,4. Score Question 4: 0,2,4
The minimum score is 0
The maximum score is 16




The one minute Paddington Alcohol Test (PAT)157
Please complete for ALL A&E PATIENTS where there is any INDICATION OF ALCOHOL MISUSE:
eg assault, head especially facial injury, fall, non-specific gastrointestinal problem, "unwell", fit,
blackout, collapse, insomnia, sweating, hypo/hyperglycaemia, palpitations, chest pain, gout,
rashes, depression, overdose; note REPEAT attendance (perhaps with unexplained symptoms) and
DELAYED attendance >4 hours (perhaps intoxicated at the time of "incident").
Remember the elderly presenting with: falls, confusion, incontinence and self neglect.
1. Quite a number of people have times when they drink more than usual; what is the most you
will drink in any one day?
N.B. Please note if home or pub measures. Units (1 unit - 8 grams alcohol) relating to pub measures, are
shown in brackets.
TYPE OF DRINK AMOUNT
Beer/Lager/Cider Pints (2) or Cans (1.5) = Units/day
Strong Beer/Lager/Cider Pints (5) or Cans (4)
Wine Glasses (1.5) or Bottles (9)
Fortified Wine (Sherry, Martini) Glasses (1) or Bottles (12)
Spirits (Gin, Whisky, Vodka) Singles (1) or Doubles (2) or Bottles (30)
2. If this is more than 8 units/day for a man, or 6 units/day for a woman, does this happen:
Once a week or more? YES: PAT + ve
or
Between once a month and once a week? YES: PAT + ve
or
Neither (ie once a month or less)? YES: PAT -ve (go to Question 3)
3. Do you feel your current attendance in A&E is related to alcohol?
YES: PAT +ve
NO: PAT -ve
ie PAT +ve if >8 units male or 6 units female more than once a month, and/or YES to
Question 3.
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Annex 5
Important elements of motivational interviewing
Adapted from Miller and Rollnick, 2002.158
Portraying empathy
■ use of open ended questions and avoiding premature closure
■ respect for individual differences
■ reflective listening so that patients sense you are trying to "get on their wavelength"
■ expressing interest/concern
■ acceptance that ambivalence is normal.
Developing discrepancy
■ patients are helped to see the gap between the drinking and its consequences and their own
goals/values - the gap between "where I see myself, and where I want to be"
m enhancing their awareness of consequences, perhaps adding feedback about medical symptoms
and test results: "How does this fit in?" "Would you like the medical research information on
this?"
■ weighing up the pros and cons of change and of not changing
■ progressing the interview so that patients present their own reasons for change.
Avoiding argument ("rolling with resistance")
■ resistance, if it occurs (such as arguing, denial, interrupting, ignoring) is not dealt with head-
on, but accepted as understandable, or sidestepped by shifting focus
■ labelling, such as "I think you have an alcohol problem" is unnecessary, and can lead to
counterproductive arguing.
Supporting self efficacy
■ encouraging the belief that change is possible
■ encouraging a collaborative approach (patients are the experts on how they think and feel,
and can choose from a menu of possibilities)
■ the patient is responsible for choosing and carrying out actions towards change.
Facilitating and reinforcing "self motivating statements"
■ recognising that alcohol has caused adverse consequences
■ expressing concern about effects of drinking
■ expressing the intention to change
■ being optimistic about change.




Advice to patients on withdrawing from alcohol
at home
1. If you have been chemically dependent on alcohol, stopping drinking causes you to get
tense, edgy, perhaps shaky or sweaty, and unable to sleep. There can be vomiting or
diarrhoea. This "rebound" of the nervous system can be severe. Medication controls the
symptoms while the body adjusts to being without alcohol. This usually takes three to
seven days from the time of your last alcoholic drink. If you don't take medication, the
symptoms would be worst in the first 48 hours, and then gradually disappear. This is why,
if you do take medication, the dose starts high and then reduces. If you have been
prescribed 10 mg tablets of chlordiazepoxide, use the table below to remind you when to
take the right number of tablets.
2. YOU HAVE AGREED NOT TO DRINK ALCOHOL. You may get thirsty. Drink fruit juices
and water but do not overdo it. You do not have to "flush" alcohol out of the body. More
than three litres of fluid could be too much. Don't drink more than three cups of coffee or
five cups of tea. These contain caffeine which disturbs sleep and causes nervousness.
3. AIM TO AVOID STRESS. The important task is not to give in to the urge to take alcohol.
Help yourself relax by going for a walk, listening to music, or taking a bath.
4. SLEEP. You may find that even with the capsules, or as they are reduced, your sleep is
disturbed. You need not worry about this - lack of sleep does not seriously harm you,
starting to drink again does. Your sleep pattern will return to normal in a month or so. It is
better not to take sleeping pills so that your natural sleep rhythm returns. Try going to bed
later. Take a bedtime snack or milky drink.
5. The capsules may make you drowsy so you must not drive or operate machinery. If
you get drowsy, miss out a dose.
6. MEALS. Even when you are not hungry, try to eat small amounts regularly. Your appetite
will return.
Number of chlordiazepoxide (10 mg) tablets to take and when to take them when
withdrawing from alcohol as an outpatient
First thing 12 noon 6 pm Bedtime
Day 1 - 3 3 3
Day 2 2 2 2 3
Day 3 2 1 1 2
Day 4 1 1 - 2
Day 5 - 1 - 1
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Annex 7
Assisting withdrawal from alcohol
Yes, if patient:
* is confused or has hallucinations
* has a history of previous complicated withdrawal
■ has epilepsy or history of fits
■ is undernourished
■ has severe vomiting or diarrhoea
■ is at risk of suicide
■ has severe dependence coupled with unwillingness
to be seen daily
■ has a previously failed home-assisted withdrawal
■ has uncontrollable withdrawal symptoms
* has an acute physical or psychiatric illness
■ has multiple substance misuse
* has a home environment unsupportive of abstinence
Is medication required?
Is admission necessary?
Advise the patient that he/
she may have mild anxiety/
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Psychosocial interventions
■ Behavioural Self Control Training (BSCT), Motivational Enhancement Therapy (MET), Marital/
Family Therapy and Coping/Social Skills Training are clinically and cost effective psychosocial
interventions and are recommended treatment options for the prevention of relapse in alcohol
dependence.
■ Brief Interventions are not recommended, as trials in alcohol dependent people have failed to
show any benefit. However, this guideline recommends Brief Interventions for
hazardous drinkers (a less severely affected group than those who are considered to be alcohol
dependent).
■ Other psychosocial interventions are not recommended as their clinical effectiveness is
unproven.
Pharmacological interventions
■ Acamprosate and supervised oral disulfiram are treatment options recommended as adjuncts
to psychosocial interventions. Naltrexone does not have a Marketing Authorisation for the
treatment of alcohol dependence in the UK and is not recommended for routine use in
NHSScotland.
Delivery of services
■ Alcohol services should aim to reduce the delay between detoxification and interventions for
the prevention of relapse. This would be facilitated by joint working between specialist
mental health services, primary care, social work addiction services and non-statutory agencies,
as recommended by the Joint Futures Croup.
■ Acamprosate or supervised oral disulfiram should usually be initiated by a specialist service.
The specialist service will: ensure that the patient meets the criteria for suitability; ensure the
assessment of the motivation and ability of the patient to use the medication correctly;
monitor efficacy; and ensure that adjunctive psychosocial treatment is organised. Usage should
be in accordance with the Summary of Product Characteristics and reviewed regularly during
the first 12 weeks after initiation of treatment, at which stage transfer of prescribing to the
general practitioner may be appropriate, even though specialist care may continue (shared
care).
■ Introduction to AA and non-statutory agencies such as local Councils on Alcohol (Alcohol
Focus Scotland) should be part of the overall strategy of specialist NHS services for the
prevention of relapse. As with other psychosocial treatments, attendance is most likely to be
beneficial if it is an informed voluntary decision.
■ People who are alcohol dependent should be informed about treatment choices. Their needs,
preferences and social circumstances should be considered. As a result, the choice of
interventions should be a shared decision between the health professional and the patient.
■ NHS specialist services should contact people who drop out of treatment programmes and
offer them another appointment.
Communication with patients
■ Health professionals should provide patient information, including leaflets, which should be
used to support discussion between health professionals and patients about the most appropriate
treatment option.
■ Written information about the range of available services should be readily accessible to
people with alcohol problems, their families, carers and to health professionals, especially
GPs. Alternative formats such as cartoons or audiovisual material should be used to support
discussions with people who have low reading skills or poor concentration. Alcohol Action
Teams could coordinate information requirements.
■ A regularly updated comprehensive directory of alcohol services and accommodation should
be developed for the benefit of NHSScotland staff, patients and their families, friends
and carers.
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Abbreviations
AA Alcoholics Anonymous
A&E Accident and Emergency
AUDIT Alcohol Use Disorders Identification Test
BAC Blood alcohol concentration
BNF British National Formulary
CAGE Attempts to Cut back on drinking, being Annoyed at criticisms about drinking,
feeling Guilty about drinking, and using alcohol as an Eye-opener
CDT Carbohydrate deficient transferrin
CRAFT Community reinforcement and family training
FAST Fast Alcohol Screening Test
GGT Serum gamma glutamyl transferase
CP General practitioner
ICD-10 International Classification of Diseases version 10
MCV Mean red blood cell volume
NNT Number needed to treat
PAT Paddington Alcohol Test
RCT Randomised controlled trial
SIGN Scottish Intercollegiate Guidelines Network
SSRI Selective serotonin reuptake inhibitor
T-ACE Tolerance, Annoyed by someone criticising your drinking, felt need to Cut
down, Eye-opener
TWEAK Tolerance to effects of alcohol, Worry about drinking, Eye -opener, Amnesia,
























Singleton N, Bumpstead R, O'Brien M, Lee A, Meltzer H. Psychiatric morbidity
among adults living in private households, 2000: the report ofa survey carried
out by Social Survey Division of the Office for National Statistics on behalf of
the Department of Health, the Scottish Executive and the National Assembly
forWales. London: The Stationery Office; 2001. [cited 11 Aug 2003]. Available
from url: http://www.statistics.gov.uk/downloads/theme%5Fhealth/
psychmorb.pdf
Scottish Executive Health Department. Plan for action on alcohol problems.
Edinburgh: The Department; 2002. [cited 11 Aug 2003]. Available from url:
http://www.scotland.gov.uk/health/alcoholproblems/docs/paap-00.asp
Buchan IC, Buckley EG, Deacon GL, Irvine R, Ryan MP. Problem drinkers and
their problems. J RColl Gen Pract 1981 ;31 (224): 151-3.
Anderson P. Managing alcohol problems in general practice. Br Med J (Clin
Res Ed) 1985;290(6485): 1873-5.
Greater Glasgow Health Board. Alcohol strategy consultation document.
Glasgow: The Board; 2000. [cited 11 Aug 2003]. Available from url: http://
www.show.scot.nhs.uk/gghb/PubsReps/strats/alcohol/
Graham L. The epidemiology of alcohol problems in Lothian [unpublished
report]. Edinburgh: Lothian Health; 1997.
HoltS, Stewart IC, Dixon JM, Elton RA, Taylor TV, Little K. Alcohol and the
emergency patient. Br Med J 1980;281(6241):638-40.
Deehan A, Templeton L, Taylor C, Drummond C, Strang J. How do general
practitioners manage alcohol-misusing patients? Results from a national survey
of GPs in England and Wales. Drug Alcohol Rev 1998;17(3):259-66.
Thakker KD. An overview of health risks and benefits of alcohol consumption.
Alcohol Clin Exp Res 1998;22(7Suppl):285S-98S.
Greenfield TK. Individual risk of alcohol related disease and problems. In:
Heather N, Peters TJ, Stockwell T, editors. International handbook of alcohol
dependence and problems. Chichester: Wiley; 2001. p.413-37.
Corrao G, Bagnardi V, Zambon A, Arico S. Exploring the dose-response
relationship between alcohol consumption and the risk of several alcohol-
related conditions: a meta-analysis. Addiction 1999;94(10):1551-73.
Edwards G. The individual's drinking and degree of risk. In: Edwards G,
Anderson P, BaborTF, Casswell S, Ferrence R, Giesbrecht N, etal., editors.
Alcohol policy and the public good. Oxford: Oxford University Press;
1994. p.41-74.
Anderson P, Cremona A, Paton A, Turner C, Wallace P. The risk of alcohol.
Addiction 1993;88(11): 1493-508.
Morgan MY, Ritson B. Alcohol and health: a handbook for students and
medical practitioners. 4th ed. London: Medical Council on Alcohol; 2003.
World Health Organization. International statistical classification of diseases
and related health problems. 10th ed. Geneva: The Organization; 1992.
Royal College of Physicians of London. Alcohol - can the N HS afford it? London:
The College; 2001.
HoltS, Skinner HA, Israel Y. Early identification of alcohol abuse: 2: Clinical
and laboratory indicators. Can Med Assoc J1981 ;124(10):! 279-94,99.
Wallace PG, Haines AP. General practitioner and health promotion: what
patients think. Br Med J (Clin Res Ed) 1984;289(6444):534-6.
Richmond R, Kehoe L, Heather N, Wodak A, Webster I. General practitioners'
promotion of healthy life styles: what patients think. Aust N Z J Public Health
1996;20(2): 195-200.
BaborTF, Steinberg K, Anton R, Del Boca F. Talk is cheap: measuring drinking
outcomes in clinical trials. J Stud Alcohol 2000;61 (1 ):55-63.
Rollnick S, Kinnersley P,StottN. Methods of helping patients with behaviour
change. BM] 1993;307(6897):188-90.
Bradley KA, Boyd-Wickizer], Powell SH, Burman ML. Alcohol screening
questionnaires in women: a critical review. JAMA 1998;280(2):166-71.
Fiellin DA, Reid MC, O'Connor PG. Screening foralcohol problems in primary
care: a systematic review. Arch Intern Med 2000;160(13): 1977-89.
Thorn B, Herring R,Judd A. Identifying alcohol-related harm in young drinkers:
the role of accident and emergency departments. Alcohol Alcohol
1999;34(6):910-5.
Russell M, MartierSS, Sokol RJ, Mudar P, Jacobson S, Jacobson J. Detecting risk
drinking during pregnancy: a comparison of four screening questionnaires.
Am J Public Health 1996;86(10): 1435-9.
ChangG, Wilkins-Haug L, Berman S, Goetz MA, Behr H, Hiley A. Alcohol use
and pregnancy: improving identification. ObstetGynecol 1998;91 (6):892T5.
Gordon AJ, Maisto SA, McNeil M, Kraemer KL, Conigliaro RL, Kelley ME, et
al. Three questions can detect hazardous drinkers. J Fam Pract
2001 ;50(4):313-20.
Aertgeerts B, Buntinx F, Ansoms S, Fevery J. Screening properties of
questionnaires and laboratory tests for the detection of alcohol abuse or
dependence in a general practice population. Br J Gen Pract
2001 ;51 (464):206-17.
Taj N, Devera-Sales A, Vinson DC. Screening for problem drinking: does a
single question work? J Fam Pract 1998;46(4):328-35.
30. Bradley KA, Bush KR, McDonell MB, Malone T, Fihn SD. Screening for
problem drinking: comparison of CAGE and AUDIT. Ambulatory Care Quality
Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. J
Gen Intern Med 1998;13(6):379-88.
31. Hodgson R, Alwyn T, John B, Thorn B, Smith A. The FAST Alcohol Screening
Test. Alcohol Alcohol 2002;37(1):61-6.
32. Ludbrook A, Godfrey C, Wyness L, ParrottS, Haw S, Napper M, etal. Effective
and cost-effective measures to reduce alcohol misuse in Scotland: a literature
review. Edinburgh: Scottish Executive; 2001. [cited 12 Aug 2003]. Available
from url: http://www.scotland.gov.uk/health/alcoholproblems/docs/lire-
OO.asp
33. Friedmann PD, Saitz R, Gogineni A, Zhang JX, Stein MD. Validation of the
screening strategy in the NIAAA "Physicians' Guide to Helping Patients with
Alcohol Problems". J Stud Alcohol 2001 ;62(2):234-8.
34. National Health Service in Scotland, Management Executive. The National
Health Service (General Medical Services) (Scotland) Regulations 1995.
Edinburgh: Scottish Office; 1995. [cited 3 Sep 2002]. Available from url: http:/
/www.show.scot.nhs.uk/publications/publications/GMSregulations.pdf
35. UK Alcohol Forum. Guidelines for the management of alcohol problems in
primary care and general psychiatry. London: The Forum; 2001. [cited 13
Aug 2003]. Available from url: http://www.ukalcoholforum.org/pages/
alcoholguidelineset.htm
36. ScoullerK,Conigrave KM,Macaskill P, Irwig L, Whitfield JB. Should we use
carbohydrate-deficient transferrin instead of gamma-glutamyltransferase for
detecting problem drinkers? A systematic review and metaanalysis. Clin Chem
2000;46(12): 1894-902.
37. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and
monitoring of hepatic injury. II. Recommendations for use of laboratory tests
in screening, diagnosis, and monitoring. Clin Chem 2000;46(12):2050-68.
38. Salaspuro M. Carbohydrate-deficient transferrin as compared to other markers
of alcoholism: a systematic review. Alcohol 1999;19(3):261 -71.
39. Anton RF, Stout RL, Roberts JS, Allen JP. The effect of drinking intensity and
frequency on serum carbohydrate-deficient transferrin and gamma-glutamyl
transferase levels in outpatient alcoholics. Alcohol Clin Exp Res
1998;22(7): 1456-62.
40. Conigrave KM, Degenhardt LJ, Whitfield JB, Saunders JB, HelanderA,Tabakoff
B, et al. CDT, GGT, and AST as markers of alcohol use: the WHO/ISBRA
collaborative project. Alcohol Clin Exp Res 2002;26(3):332-9.
41. RybGE, Soderstrom CA, KuferaJA, Dischinger PC, HoSM. Useof blood
alcohol concentration and laboratory tests to detect current alcohol
dependence in trauma center patients. J Trauma 1999;47(5):874-9.
42. Smolle KH, Hofmann G, Kaufmann P, Lueger A, BrunnerG. Q.E.D. Alcohol
test: a simple and quick method to detect ethanoI in saliva of patients in
emergency departments. Comparison with the conventional determination
in blood. Intensive Care Med 1999;25(5):492-5.
43. Bates ME, Martin CS. Immediate, quantitative estimation of blood alcohol
concentration from saliva. J Stud Alcohol 1997;58(5):531-8.
44. Department of Health. We don't have to take this: resource pack. London:
The Department; 2000. [cited 13 Aug 2003]. Available from url: http://
www.nhs.uk/zerotolerance/downloads/nhs_ztz.pdf
45. BienTH, Miller WR,Tonigan JS. Brief interventions for alcohol problems: a
review. Addiction 1993;88(3):315-35.
46. Kahan M, Wilson L, Becker L. Effectiveness of physician-based interventions
with problem drinkers: a review. CMAJ1995;152(6):851-9.
47. WilkAl, Jensen NM, HavighurstTC. Meta-analysis of randomized control
trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern
Med 1997;12(5):274-83.
48. Poikolainen K. Effectiveness of brief interventions to reduce alcohol intake in
primary health care populations: a meta-analysis. Prev Med
1999;28(5):503-9.
49. Aalto M, Saksanen R, Laine P, Forsstrom R, Raikaa M, Kiviluoto M, etal. Brief
intervention for female heavy drinkers in routine general practice: a 3-year
randomized, controlled study. Alcohol Clin Exp Res 2000;24(11 ):1680-6.
50. Aalto M, Seppa K, Mattila P, Mustonen H, Ruuth K, Hyvarinen H, etal. Brief
intervention for male heavy drinkers in routine general practice: a three-year
randomized controlled study. Alcohol Alcohol 2001 ;36(3):224-30.
51. Fleming MF,Manwell LB, Barry KL, Adams W, Stauffacher EA. Brief physician
advice foralcohol problems in older adults: a randomized community-based
trial. J Fam Pract 1999;48(5):378-84.
52. Maisto SA, Conigliaro J, McNeil M, Kraemer K, Conigliaro RL, Kelley ME.
Effects of two types of brief intervention and readiness to change on alcohol
use in hazardous drinkers. J Stud Alcohol 2001 ;62(5):605-14.
53. Manwell LB, Fleming MF, Mundt MP, Stauffacher EA, Barry KL. Treatment of
problem alcohol use in women of childbearing age: results of a brief
intervention trial. Alcohol Clin Exp Res 2000;24(10): 1517-24.
54. OckeneJK, Adams A, Hurley TG, Wheeler EV, HebertJR. Brief physician-and
nurse practitioner-delivered counseling for high-risk drinkers: does it work?
Arch Intern Med 1999; 159(18):2198-205.
55. Senft RA, Polen MR, Freeborn DK, Hoi I is JF. Brief intervention in a primary
care setting for hazardous drinkers. Am J Prev Med 1997; 13(6):464-70.
56. A cross-national trial of brief interventions with heavy drinkers. WHO Brief
Intervention Study Group. Am J Public Health 1996;86(7):948-55.
37





















Moyer A, Finney JW, Swearingen CE, Vergun P. Brief interventions foralcohol 82.
problems: a meta-analytic review of controlled investigations in treatment-
seeking and non-treatment-seeking populations. Addiction
2002;97(3):279-92.
Fleming MF, Barry KL,Manwell LB, Johnson K, London R. Brief physician 83.
advice for problem alcohol drinkers. A randomized controlled trial in
community-based primary care practices. JAMA 1997;277(13):1039-45. 84.
Longabaugh R,Woolard RE, NirenbergTD,Minugh AP, Becker B, Clifford
PR,etal. Evaluating the effects of a brief motivational intervention for injured 85.
drinkers in the emergency department. J Stud Alcohol 2001 ;62(6):806-16.
Mullen PD, Simons-Morton DG, Ramirez G, Frankowski RF, Green LW, 86.
Mains DA. A meta-analysis of trials evaluating patient education and counseling
for three groups of preventive health behaviors. Patient Educ Couns
1997;32(3): 157-73. 87.
WallerS, Naidoo B, Thorn B. Prevention and reduction of alcohol misuse:
evidence briefing. London: Health Development Agency; 2002. [cited 13
Aug 2003]. Available from url: http://194.83.94.67/niche_docs/ 88.
EB_DATABASE_CONTENT/HTML_database_content/EBBD-Alcohol.html
Wutzke SE, Conigrave KM, Saunders JB, Hall WD. The long-term effectiveness
of brief interventions for unsafe alcohol consumption: a 10-year follow-up.
Addiction 2002;97(6):665-75. 89.
Fleming MF, Mundt MP, French MT, Manwell LB, Stauffacher EA, Barry KL.
Brief physician advice for problem drinkers: long-term efficacy and benefit-
cost analysis. Alcohol Clin Exp Res 2002;26(1):36-43. 90.
Kristenson H, Osterling A, Nilsson JA, Lindgarde F. Prevention of alcohol-
related deaths in middle-aged heavy drinkers. Alcohol Clin Exp Res 91.
2002;26(4):478-84.
Scottish Intercollegiate Guidelines Network (SIGN). Secondary prevention of 92.
coronary heart disease following myocardial infarction. Edinburgh: SIGN;
2000. (SIGN publication no. 41). [cited 13 Aug 2003]. Available from url:
http://www.sign.ac.uk/guidelines/fulltext/41/index.htrnl 93.
Psaty BM, Smith NL,Siscovick DS, KoepsellTD, Weiss NS, HeckbertSR,etal.
Health outcomes associated with antihypertensive therapies used as first-line
agents. A systematic review and meta-analysis. JAMA 1997;277(9):739-45. 94.
Richmond R, Heather N, Wodak A, Kehoe L, Webster I. Controlled evaluation
of a general practice-based brief intervention for excessive drinking. Addiction 95.
1995;90(1): 119-32.
Wallace P, Cutler S, Haines A. Randomised controlled trial of general
practitioner intervention in patients with excessive alcohol consumption. BMJ 96.
1988;297(6649):663-8.
Anderson P, Scott E. The effect of general practitioners'advice to heavy drinking
men. Br J Addict 1992;8 7(6):891 -900. 97.
Scott E, Anderson P. Randomized controlled trial of general practitioner
intervention in women with excessive alcohol consumption. Drug Alcohol 98.
Rev 1990; 10(4):313-21.
Kaner E, Lock C, Heather N, McNamee P, Bond S. Promoting brief alcohol 99.
intervention by nurses in primary care: a cluster randomised controlled trial.
Patient Educ Couns. In press 2003.
Kaner EF, Lock CA, McAvoy BR, Heather N, Gilvarry E. A RCT of three training
and support strategies to encourage implementation of screening and brief 100.
alcohol intervention by general practitioners. BrJ Gen Pract 1999;49(446):699-
703.
Lock CA, Kaner EF, Heather N, McAvoy BR, Gilvarry E. A randomized trial of 101.
three marketing strategies to disseminate a screening and brief alcohol
intervention programme to general practitioners. 102.
Br J Gen Pract 1999;49(446):695-8.
Kaner EF, Wutzke S, Saunders JB, Powell A, Morawski J, Bouix JC. Impact of
alcohol education and training on general practitioners' diagnostic and 103.
management skills: findings from a World Health Organization collaborative
study. J Stud Alcohol 2001 ;62(5):621-7.
Batel P, Pessione F, BouvierAM, Rueff B. Prompting alcoholics to be referred
to an alcohol clinic: the effectiveness of a simple letter. Addiction 104.
1995;90(6):811-4.
Monti PM, Colby SM, Barnett NP, Spirito A, Rohsenow DJ, Myers M, et al. 105.
Brief intervention for harm reduction with alcohol-positive older adolescents
in a hospital emergency department. J Consult Clin Psychol
1999;67(6):989-94. 106.
Peters J, Brooker C, McCabe C, Short N. Problems encountered with
opportunistic screening foralcohol-related problems in patients attending an
accident and emergency department. Addiction 1998;93(4):589-94.
Health Education Board for Scotland. Alcohol - safe in pregnancy? The Board; 107.
2003. [cited 13 Aug 2003]. Available from url: http://www.hebs.scot.nhs.uk/
readysteadybaby/pregnancy/health.htm 108.
Chang G, Wilkins-Haug L, Berman S, Goetz MA. Brief intervention foralcohol
use in pregnancy: a randomized trial. Addiction 1999;94(10): 1499-508.
Rollnick S. Behaviourchange in practice: targeting individuals. IntJ Obes Relat 109.
Metab Disord 1996;20(Suppl 1):S22-6.
Dunn C, Deroo L, Rivara FP. The use of brief interventions adapted from
motivational interviewing across behavioural domains: a systematic review. 110.
Addiction 2001 ;96(12): 1725^2.
Hayashida M, Alterman Al, McLellan AT, O'Brien CP, Purtill JJ, Volpicelli JR,
et al. Comparative effectiveness and costs of inpatient and outpatient
detoxification of patients with mild-tomoderate alcohol withdrawal syndrome.
N Engl J Med 1989;320(6):358-65.
BennieC. A comparison of home detoxification and minimal intervention
strategies for problem drinkers. Alcohol Alcohol 1998;33(2): 157-63.
Klijnsma MP, Cameron ML, Burns TP, McGuigan SM. Out-patient alcohol
detoxification-outcome after 2 months. Alcohol Alcohol 1995;30(5):669-73.
Bartu A, Saunders W. Domiciliary detoxification: a cost effective alternative to
inpatient treatment. Aust J Adv Nurs 1994; 11 (4): 12-8.
Stockwell T, Bolt L, Milner I, Pugh P, Young I. Home detoxification for problem
drinkers: acceptability to clients, relatives, general practitioners and outcome
after 60 days. BrJ Addict 1990;85(1):61-70.
CRAG/SCOTMEG Working Group on Mental Illness. The management of
alcohol withdrawal and delirium tremens: a good practice statement. 2nd ed.
Edinburgh: Scottish Office; 1998.
Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A
meta-analysis and evidence-based practice guideline. American Society of
Addiction Medicine Working Group on Pharmacological Management of
Alcohol Withdrawal. JAMA 1997;278(2): 144-51.
Holbrook AM, CrowtherR, LotterA, Cheng C, King D. Meta-analysis of
benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ
1999; 160(5):649-55.
Williams D, McBride AJ. The drug treatment ofalcohol withdrawal symptoms:
a systematic review. Alcohol Alcohol 1998;33(2):103-15.
Moscowitz G, Chalmers TC, Sacks HS, Fagerstrom RH, Smith H Jr. Deficiencies
of clinical trials of alcohol withdrawal. Alcohol Clin Exp Res 1983;7(1):42-6.
Sellers EM, Naranjo CA, Harrison M, Devenyi P, Roach C, Sykora K. Diazepam
loading: simplified treatment of alcohol withdrawal. Clin Pharmacol Ther
1983;34(6):822-6.
British Medical Association, Royal Pharmaceutical Society of Great Britain.
British National Formulary. London: The Association, The Society; 2003. [cited
13 Aug 2003]. Available from url: http://www.bnf.org
Hill A, Williams D. Hazards associated with the use of benzodiazepines in
alcohol detoxification. J Subst Abuse Treat 1993;10(5):449-51.
Ritson B, Chick J. Comparison of two benzodiazepines in the treatment of
alcohol withdrawal: effects on symptoms and cognitive recovery. DrugAlcohol
Depend 1986;18(4):329-34.
MillerWC Jr, McCurdy L. A double-blind comparison of the efficacy and
safety of lorazepam and diazepam in the treatment of the acute alcohol
withdrawal syndrome. Clin Ther 1984;6(3):364-71.
Griffiths RR, Wolf B. Relative abuse liability of different benzodiazepines in
drug abusers. J Clin Psychopharmacol 1990;10(4):237-43.
Serfaty M, Masterton G. Fatal poisonings attributed to benzodiazepines in
Britain during the 1980s. BrJ Psychiatry 1993;163:386-93.
Information and Statistics Division. Drug misuse statistics Scotland 2001.
Edinburgh: The Division; 2002. [cited 14 Aug 2003]. Available from url:
http://www.drugmisuse.isdscotland.org/publications/abstracts/
drugstats2001.htm
Burroughs AK, Morgan MY, Sherlock S. Double-blind controlled trial of
bromocriptine, chlordiazepoxideand chlormethiazoleforalcohol withdrawal
symptoms. Alcohol Alcohol 1985;20(3):263-71.
Mclnnes GT. Chlormethiazole and alcohol: a lethal cocktail. Br Med J (Clin
Res Ed) 1987;294(6572):592.
Naik PC, Lawton J, Brownell LW. Comparing general practitionerand specialist
alcohol services in the management of alcohol withdrawal. Psychiatr Bull
2000;24(6):214-5.
AstraZeneca UK Limited. Heminevrin capsules. Electronic Medicines
Compendium; 2003. [cited 14 Aug 2003]. Available from url: http://
emc.medicines.org.uk/emc/industry
default.asp?page=displaydoc.asp&documentid = 175
Wetterling T, Driessen M, Kanitz RD, Junghanns K. The severity of alcohol
withdrawal is not age dependent. Alcohol Alcohol 2001;36(1):75-8.
Kraemer KL, MayoSmith MF, Calkins DR. Impact of age on the severity, course,
and complications of alcohol withdrawal. Arch Intern Med
1997;157(19):2234-41.
Berglund M, Andr£asson S, FranckJ, Fridell M, HSkanson I, Johansson B, et
al. Treatment of alcohol and drug abuse: an evidence-based review [Swedish].
Stockholm: The Swedish Council on Technology Assessment in
Health Care; 2001.
Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic
drugs: meta-analysis of controlled trials. Epilepsia 2001 ;42(4):515-24.
Saitz R, Mayo-Smith MF, Roberts MS, Redmond HA, Bernard DR, Calkins DR.
Individualized treatment for alcohol withdrawal. A randomized double-blind
controlled trial. JAMA 1994;272(7):519-23.
Jaeger TM, Lohr RH, Pankratz VS. Symptom-triggered therapy foralcohol
withdrawal syndrome in medical inpatients. Mayo Clin Proc
2001 ;76(7):695-701.
ManikantS,Tripathi BM, Chavan BS. Loading dose diazepam therapy for
alcohol withdrawal state. Indian J Med Res 1993;98:170-3.
38
REFERENCES
111. Thomson AD, Cook CC, Touquet R, Henry JA, Royal College of Physicians
London. The Royal College of Physicians report on alcohol: guidelines for
managing Wernicke's encephalopathy in the accident and Emergency
Department. Alcohol Alcohol 2002;37(6):513-21.
112. Committee on Safety of Medicines [personal communication]. 2002.
113. Ambrose ML, Bowden SC, Whelan G. Thiamin treatment and working
memory function of alcohol-dependent people: prelim inary findings. Alcohol
Clin Exp Res 2001 ;25(1): 112-6.
114. British Medical Association, Royal Pharmaceutical Society of Great Britain.
British National Formulary (BNF). London: The Association, The Society; 2003.
[cited 14 Aug 2003]. Available from url: http://www.bnf.org
115. Slattery J, Chick J, Cochrane M, Craig I, Godfrey C, Kohli H,etal. Prevention
of relapse in alcohol dependence. Glasgow: Health Technology Board for
Scotland; 2003. Health technology assessment report 3. [cited 14 Aug 2003].
Available from url: http://www.htbs.co.uk/docs/pdf/Alcohol%20Report.pdf
116. Deehan A, Marshall EJ,StrangJ. Tackling alcohol misuse: opportunities and
obstacles in primary care. Br J Gen Pract 1998;48(436): 1779-82.
117. Matching Alcoholism Treatments toClientGroup Heterogeneity: Project
MATCH posttreatment drinking outcomes. J Stud Alcohol 1997;58(1):7-29.
118. Project MATCH secondary a priori hypotheses. Project MATCH Research
Group. Addiction 1997;92(12): 1671-98.
119. Longabaugh R, Wirtz PW, Zweben A, Stout RL. Network supportfordrinking,
Alcoholics Anonymous and long-term matching effects. Addiction
1998;93(9): 1313-33.
120. Drummond DC, Thorn B, Brown C, Edwards G, Mullan MJ. Specialist versus
general practitioners treatment of problem drinkers. Lancet
1990;336(8270):915-8.
121. Sanchez-Craig M, Davila R, Cooper G. A self-help approach for high-risk
drinking: Effect of an initial assessment. J Consult Clin Psychol
1996;64(4):694-700.
122. WeisnerC, Mertens], Parthasarathy S, Moore C, Lu Y. Integrating primary
medical care with addiction treatment: a randomized controlled trial. JAMA
2001 ;286(14): 1715-23.
123. Samet JH, Freidmann P, Saitz R. Benefits of linking primary medical care and
substance abuse services: patient, provider, and societal perspectives. Arch
Intern Med 2001 ;161(1 ):85-91.
124. Sobell MB, Sobell LC. Stepped care as a heuristic approach to the treatment of
alcohol problems. J Consult Clin Psychol 2000;68(4):573-9.
125. Scottish Executive Health Department. Alcohol problems support and treatment
services framework. Edinburgh: The Department; 2002. [cited 14 Aug 2003].
Available from url: http://www.scotland.gov.uk/library5/health/apst-00.asp
126. Leigh G, Ogborne AC, Cleland P. Factors associated with patient dropout
from an outpatient alcoholism treatment service. J Stud Alcohol
1984;45(4):359-62.
127. Rees DW, Beech HR, Hore BD. Some factors associated with compliance in
the treatment of alcoholism. Alcohol Alcohol 1984;19(4):303-7.
128. Rees DW. Health beliefs and compliance with alcoholism treatment. J Stud
Alcohol 1985;46(6):517-24.
129. Hilton ME, Maisto SA, Conigliaro], McNiel M, Kraemer K, Kelley ME, et al.
Improving alcoholism treatment across the spectrum of services. Alcohol Clin
Exp Res 2001 ;25(1): 128-35.
130. Stout RL, Rubin A, Zwick W, Zywiak W, Bellino L. Optimizing the cost-
effectiveness of alcohol treatment: a rationale for extended case monitoring.
Addict Behav 1999;24(1):17-35.
131. MillerWR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical
trials for treatments for alcohol use disorders. Addiction 2002;97(3):265-77.
132. MartinusT, Anderson B,CarterH. Counsellingforalcohol problems inprimary
care in Forth Valley - an innovative approach? Health Bull (Edinb)
2001 ;59(3):158-62.
133. GarbuttJC, WestSL, Carey TS, Lohr KN, Crews FT. Pharmacological treatment
of alcohol dependence: a review of the evidence. JAMA
1999;281(14): 1318-25.
134. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcohol ism
treatment: a meta-analysis. Ale Clin Exp Res 2001 ;25(9):1335-41.
135. Pettinati HM, Volpicelli JR, LuckG, Kranzler HR, RukstalisMR, Cnaan A.
Double-blind clinical trial of sertraline treatment for alcohol dependence. J
Clin Psychopharmacol 2001 ;21 (2):143-53.
136. Roy-Byrne PP, Pages KP, Russo JE, Jaffe C, Blume AW, Kingsley E, et al.
Nefazodone treatment of major depression in alcohol-dependent patients: a
double-blind, placebo-controlled trial. J Clin Psychopharmacol
2000;20(2): 129-36.
137. Kabel Dl, Petty F. A placebo-controlled, double-blind study of fluoxetine in
severe alcohol dependence: adjunctive pharmacotherapy during and after
inpatient treatment. Alcohol Clin Exp Res 1996;20(4):780-4.
138. Kranzler HR, Modesto-Lowe V, Van Kirk J. Naltrexone vs. nefazodone for
treatment of alcohol dependence: A placebo-controlled trial.
Neuropsychopharmacology 2000;22(5):493-503.
139. Randall CL, Thomas S,Thevos AK. Concurrent alcohol ism and social anxiety
disorder: a first step toward developing effective treatments. Alcohol Clin Exp
Res 2001 ;25(2):210-20.
140. Bowen RC, D'Arcy C, Keegan D, Senthilselvan A. A controlled trial ofcognitive
behavioral treatment of panic in alcoholic inpatients with comorbid panic
disorder. Addict Behav 2000;25(4):593-7.
141. Kranzler HR, Burleson JA, Brown J, BaborTF. Fluoxetine treatment seems to
reduce the beneficial effects ofcognitive-behavioral therapy in type B alcoholics.
Alcohol Clin Exp Res 1996;20(9): 1534^11.
142. Reference removed.
143. Barrowclough C, Haddock G, Tamer N, Lewis SW, MoringJ, O'Brien R,etal.
Randomized controlled trial of motivational interviewing, cognitive behavior
therapy, and family intervention for patients with comorbid schizophrenia
and substance use disorders. Am J Psychiatry 2001 ;158(10):1706-13.
144. Drake RE, Mercer-McFadden C, Mueser KT, McHugo GJ, Bond GR. Review
of integrated mental health and substance abuse treatment for patients with
dual disorders. Schizophr Bull 1998;24(4):589-608.
145. McHugo GJ, Drake RE, TeagueGB,Xie H. Fidelity to assertive community
treatment and client outcomes in the New Hampshire dual disorders study.
Psych iatr Serv 1999;50(6):818-24.
146. Hellerstein DJ, Rosenthal RN, Miner CR. A prospective study of integrated
outpatient treatment for substance-abusing schizophrenic patients. Am J Addict
1995;4(1):33-42.
147. Larson EW, Olincy A, Rummans TA, Morse RM. Disulfiram treatment ofpatients
with both alcohol dependence and other psychiatric disorders: a review.
Alcohol Clin Exp Res 1992;16(1): 125-30.
148. Sapir-Weise R, Berglund M, Frank A, Kristenson H. Acupuncture in alcoholism
treatment: a randomized out-patient study. Alcohol Alcohol
1999;34(4):629-35.
149. Ter Riet G, Kleijnen J, Knipschild P. A meta-analysis of studies into the effect of
acupuncture on addiction. Br J Gen Pract 1990;40(338):379-82.
150. NIH Consensus Conference. Acupuncture. JAMA 1998;280(17): 1518-24.
151. AlexanderCN, Robinson P, Rainforth M. Treating and preventing alcohol,
nicotine, and drug abuse through transcendental meditation: A review and
statistical meta-analysis. Alcohol Treat Q 1994;11(1-2): 13-87.
152. AlexanderCN, Robinson P, Rainforth MV. Erratum: Treating and preventing
alcohol, nicotine, and drug abuse through transcendental meditation: A review
and statistical meta-analysis. Alcohol Treat Q1995;13(4):97.
153. BarberJG,Gilbertson R. An experimental study of brief unilateral intervention
for the partners of heavy drinkers. Res Soc Work Pract 1996;6(3):325-36.
154. MillerWR,Meyers RJ,Tonigan JS. Engaging the unmotivated in treatment for
alcohol problems: a comparison of three strategies for intervention through
family members. J Consult Clin Psychol 1999;67(5):688-97.
155. Patience D, Buxton M, Chick J, Howlett H, McKenna M, Ritson B. The SECCAT
Survey: II. The Alcohol Related Problems Questionnaire as a proxy for resource
costs and quality of life in alcoholism treatment. Study ofSocio-Economic
Consequences and Costs of Alcoholism and Treatment. Alcohol Alcohol
1997;32(1):79-84.
156. Health Development Agency, University of Wales College of Medicine.
Manual forthe FastAlcohol Screening Test (FAST). Fast screening for alcohol
problems. London: The Agency; 2002. [cited 15 Aug 2003]. Available from
url: http://www.hda-online.org.uk/documents/manual_fastalcohol.pdf
157. WrightS, Moran L, MeyrickM, O'Connor R, Touquet R. Intervention by an
alcohol health worker in an accident and emergency department. Alcohol
Alcohol 1998;33(6):651-6.
158. MillerWR, RollnickS. Motivational interviewing: preparing people for change.
2nded. London: Guilford Press; 2002.
39
